Clustering O 0 3.112381455139257e-05
of O 0 1.4805578985033208e-07
missense O 0 0.0005179928266443312
mutations O 0 4.439671465661377e-05
in O 0 1.44782035249591e-07
the O 0 2.330670577066485e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999980926513672
telangiectasia I-Disease 1 0.9999991655349731
gene O 0 5.645930286846124e-06
in O 0 1.6252105439207298e-08
a O 0 9.399221312378359e-08
sporadic B-Disease 0 6.744904385413975e-05
T I-Disease 0 0.10053154826164246
- I-Disease 0 0.05850447341799736
cell I-Disease 0 0.19654345512390137
leukaemia I-Disease 0 0.12517257034778595
. O 0 3.4208687793579884e-07

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999967813491821
telangiectasia I-Disease 1 0.9999996423721313
( O 0 0.004331785719841719
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999849796295166
T I-Disease 1 0.9999991655349731
) O 0 4.459974611847883e-09
is O 0 1.7825894094158912e-09
a O 0 2.4083645300265744e-08
recessive B-Disease 0 6.471959204645827e-05
multi I-Disease 0 2.3121829144656658e-05
- I-Disease 1 0.5544570684432983
system I-Disease 0 0.03301718458533287
disorder I-Disease 1 0.594085156917572
caused O 0 1.8818558089606086e-07
by O 0 3.6407086234646613e-09
mutations O 0 1.2296669638089952e-07
in O 0 1.0877625467031748e-09
the O 0 8.73186911665158e-10
ATM O 0 2.802638299215232e-08
gene O 0 1.5965083477453845e-08
at O 0 1.408413163872524e-09
11q22 O 0 7.379489375125559e-07
- O 0 2.4845926418493036e-06
q23 O 0 1.4295969776867423e-06
( O 0 3.087566868842373e-09
ref O 0 1.4894660580466734e-06
. O 0 2.9860727224217953e-09
3 O 0 8.578939336700842e-09
) O 0 9.871209627476674e-09
. O 0 8.556555286531875e-08

The O 0 5.900108135392657e-07
risk O 0 6.482547405539663e-07
of O 0 2.1103232938912697e-08
cancer B-Disease 0 2.032415068242699e-05
, O 0 1.5226319760586193e-08
especially O 0 4.425741906288749e-08
lymphoid B-Disease 0 1.48997469295864e-06
neoplasias I-Disease 0 2.3285287170438096e-05
, O 0 8.606243717679263e-09
is O 0 9.09812225557971e-09
substantially O 0 5.605214141723991e-07
elevated O 0 1.597167647560127e-05
in O 0 4.637058381717907e-08
A B-Disease 1 0.9999979734420776
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 1 0.9991878867149353
and O 0 1.0688158624816424e-07
has O 0 1.844034187570287e-07
long O 0 2.5041501316991344e-08
been O 0 1.0057347310521436e-07
associated O 0 2.2277513167523466e-08
with O 0 6.097344140698624e-08
chromosomal O 1 0.9999966621398926
instability O 1 0.9999198913574219
. O 0 4.66182336822385e-06

By O 0 1.0212946790488786e-06
analysing O 0 8.310695193358697e-06
tumour B-Disease 1 0.9999266862869263
DNA O 0 2.358942992941593e-06
from O 0 1.2052410625074117e-08
patients O 0 2.3799823622994154e-07
with O 0 4.61038718313489e-09
sporadic B-Disease 0 1.7464442862547003e-05
T I-Disease 0 0.00720972241833806
- I-Disease 0 0.0003422387526370585
cell I-Disease 0 0.003141883062198758
prolymphocytic I-Disease 0 0.06211228668689728
leukaemia I-Disease 0 0.15075603127479553
( O 0 3.607530629778921e-08
T B-Disease 0 1.6120136933750473e-05
- I-Disease 0 1.3225951988715678e-05
PLL I-Disease 0 8.839381189318374e-05
) O 0 6.918265960109693e-09
, O 0 1.1564141866315936e-09
a O 0 7.667965817859113e-09
rare O 0 1.300956569139089e-07
clonal B-Disease 0 1.9206963770557195e-06
malignancy I-Disease 0 9.440368557989132e-06
with O 0 3.2831890539597453e-09
similarities O 0 3.0607374412738864e-08
to O 0 1.090519763380371e-08
a O 0 4.5406093818201043e-07
mature B-Disease 0 1.2290049653529422e-06
T I-Disease 0 3.546302832546644e-05
- I-Disease 0 5.036527363699861e-05
cell I-Disease 0 0.0009071895619854331
leukaemia I-Disease 0 0.0025365755427628756
seen O 0 3.7764982607768616e-07
in O 0 7.525537526476e-09
A B-Disease 1 0.9974924325942993
- I-Disease 1 0.9983002543449402
T I-Disease 1 0.9999961853027344
, O 0 7.48750927925812e-09
we O 0 3.8257394474605633e-10
demonstrate O 0 2.628894435474649e-09
a O 0 2.311881130978577e-09
high O 0 6.450353584597224e-09
frequency O 0 2.4372742046807616e-08
of O 0 4.68289906851993e-10
ATM O 0 4.292924131732434e-07
mutations O 0 4.068764098974498e-07
in O 0 2.1169913821950104e-08
T B-Disease 0 0.00037743261782452464
- I-Disease 0 0.0002656395372468978
PLL I-Disease 0 0.0013859905302524567
. O 0 7.543596325376711e-07

In O 0 3.6893570154461486e-07
marked O 0 2.8947664532097406e-07
contrast O 0 1.0644072290233453e-07
to O 0 1.398834159616058e-09
the O 0 5.422620130701716e-10
ATM O 0 2.1874525657494814e-07
mutation O 0 3.0792679694968683e-07
pattern O 0 1.8019321146311995e-07
in O 0 1.8277125590770993e-08
A B-Disease 1 0.99998939037323
- I-Disease 1 0.9999712705612183
T I-Disease 1 0.9999992847442627
, O 0 6.385695083821474e-09
the O 0 1.865259752209525e-10
most O 0 9.66017377201922e-10
frequent O 0 1.1637075303383426e-08
nucleotide O 0 3.964870209927085e-09
changes O 0 2.7038475902685377e-09
in O 0 1.0559799701326256e-09
this O 0 1.1097399443826816e-08
leukaemia B-Disease 0 0.00372297503054142
were O 0 3.821878351573105e-07
missense O 0 0.0001382655609631911
mutations O 0 1.1568354238988832e-05
. O 0 3.00637935879422e-07

These O 0 2.8834477916461765e-07
clustered O 0 5.093628487884416e-07
in O 0 2.104493912469252e-09
the O 0 4.0514899768417934e-10
region O 0 1.716917275018659e-09
corresponding O 0 1.7851004008306859e-09
to O 0 7.27354620977394e-10
the O 0 4.5362075207222574e-10
kinase O 0 1.7307776545294473e-07
domain O 0 6.3056924126669855e-09
, O 0 7.767218535015274e-10
which O 0 9.777438858549203e-10
is O 0 7.973144922068798e-10
highly O 0 8.021131536750659e-10
conserved O 0 1.2043396280247975e-09
in O 0 2.445113000959509e-10
ATM O 0 3.2622544665628084e-08
- O 0 7.584042549524384e-08
related O 0 1.2886467448680605e-09
proteins O 0 4.3849518460703507e-10
in O 0 4.799238784158888e-10
mouse O 0 2.0999844707603188e-07
, O 0 1.2958017991948623e-09
yeast O 0 7.122795153691186e-08
and O 0 8.332742496008905e-09
Drosophila O 0 2.1856342868886713e-07
. O 0 7.740265317579542e-08

The O 0 3.1715865134174237e-07
resulting O 0 3.64165543942363e-07
amino O 0 4.095422312389019e-08
- O 0 1.973110528297184e-07
acid O 0 8.821099584110925e-08
substitutions O 0 1.2246879954602718e-08
are O 0 4.3932146809311234e-10
predicted O 0 1.1971763136386926e-08
to O 0 2.721786795945036e-09
interfere O 0 7.956107594964124e-08
with O 0 2.474551052955576e-08
ATP O 0 5.694906235476083e-07
binding O 0 1.0213228733846336e-06
or O 0 1.3286662436939878e-08
substrate O 0 3.379767804290168e-06
recognition O 0 2.540872401368688e-07
. O 0 2.309359672381106e-07

Two O 0 2.077323131288722e-07
of O 0 6.50311449135188e-09
seventeen O 0 2.686833227016905e-07
mutated O 0 4.060068476974266e-06
T B-Disease 0 1.894618799269665e-05
- I-Disease 0 6.759284133295296e-06
PLL I-Disease 0 0.00011699517926899716
samples O 0 3.644403534508456e-07
had O 0 1.195464278680447e-07
a O 0 2.53519090165355e-08
previously O 0 4.850654704569024e-07
reported O 0 4.3497126966940414e-07
A B-Disease 1 0.9971134662628174
- I-Disease 1 0.9998618364334106
T I-Disease 1 0.999998927116394
allele O 0 0.002426054095849395
. O 0 6.53891333968204e-07

In O 0 6.372229108819738e-07
contrast O 0 1.9003808802153799e-06
, O 0 5.775953049180771e-09
no O 0 9.812286982935348e-09
mutations O 0 6.227003268577391e-08
were O 0 5.593581597906905e-09
detected O 0 1.8060262618746492e-08
in O 0 3.9246969563144773e-10
the O 0 3.602150244752522e-10
p53 O 0 3.455499708593379e-08
gene O 0 1.330999754856066e-08
, O 0 8.384649086146112e-10
suggesting O 0 5.757737842060351e-09
that O 0 2.7724376128190897e-09
this O 0 1.66477978069679e-08
tumour B-Disease 1 0.9999929666519165
suppressor O 0 0.00010412947449367493
is O 0 3.337355991561708e-08
not O 0 6.4217635653562866e-09
frequently O 0 2.9603169693359632e-08
altered O 0 1.7583805345111614e-07
in O 0 4.400706021812084e-09
this O 0 5.811272885125618e-08
leukaemia B-Disease 0 0.003276009578257799
. O 0 2.6724330837168964e-07

Occasional O 0 8.254917338490486e-05
missense O 0 0.0008624507463537157
mutations O 0 1.6227892047027126e-05
in O 0 7.072757046699962e-09
ATM O 0 1.3509165341929474e-07
were O 0 5.1524320809903656e-08
also O 0 4.333002223688709e-08
found O 0 1.439346064557867e-08
in O 0 1.0181099519002146e-08
tumour B-Disease 1 0.9999986886978149
DNA O 0 3.6035467019246425e-06
from O 0 1.1413735734322472e-08
patients O 0 7.649657050023961e-07
with O 0 1.976936392367179e-09
B B-Disease 0 2.600760637960775e-07
- I-Disease 0 8.220175686801667e-07
cell I-Disease 0 1.1531718882906716e-05
non I-Disease 0 4.589552418110543e-07
- I-Disease 0 0.30243244767189026
Hodgkins I-Disease 1 0.9958810806274414
lymphomas I-Disease 1 0.9771664142608643
( O 0 1.8253608402574173e-08
B B-Disease 0 3.152762531044573e-07
- I-Disease 0 9.021150049193238e-07
NHL I-Disease 0 1.376499767502537e-07
) O 0 2.500149420825437e-09
and O 0 3.2867606414299644e-09
a O 0 6.00454299615194e-08
B B-Disease 0 9.717986131363432e-07
- I-Disease 0 3.995369752374245e-06
NHL I-Disease 0 2.256593916172278e-06
cell O 0 3.435224698478123e-06
line O 0 2.0060347196704242e-06
. O 0 1.2210870181661448e-07

The O 0 5.90390172305888e-08
evidence O 0 2.0632393571418106e-08
of O 0 1.5511697482040177e-10
a O 0 2.3881678856696453e-09
significant O 0 7.207551444565752e-09
proportion O 0 6.144202924218689e-09
of O 0 2.1623941526272006e-10
loss O 0 7.470651297580844e-08
- O 0 2.0093841612833785e-07
of O 0 1.7575322308616137e-09
- O 0 8.981706741906237e-06
function O 0 6.15457338426495e-08
mutations O 0 4.056071389868521e-08
and O 0 6.483591996619964e-10
a O 0 3.526717584634298e-09
complete O 0 5.980937523020202e-09
absence O 0 9.254096156041669e-09
of O 0 9.150042529215696e-11
the O 0 2.1830652563448183e-10
normal O 0 1.0565803787443429e-09
copy O 0 1.6998948915158962e-09
of O 0 3.921941590934175e-11
ATM O 0 4.9365724841266e-09
in O 0 3.265538395247347e-10
the O 0 6.694816367946999e-10
majority O 0 3.367658862885037e-08
of O 0 2.1162391838913663e-09
mutated O 0 0.002175453584641218
tumours B-Disease 1 0.9999842643737793
establishes O 0 9.401334182257415e-07
somatic O 0 7.720329904259415e-07
inactivation O 0 1.3414922932497575e-06
of O 0 4.505037454194394e-10
this O 0 4.73074857065825e-10
gene O 0 3.908272372399324e-09
in O 0 3.002736947976814e-10
the O 0 9.387514099401528e-10
pathogenesis O 0 7.939553370306385e-08
of O 0 2.0677923817657984e-09
sporadic B-Disease 0 2.9835360692231916e-05
T I-Disease 0 0.006127846892923117
- I-Disease 0 5.6811284594004974e-05
PLL I-Disease 0 0.0001323508331552148
and O 0 2.3334301602062624e-08
suggests O 0 6.3414535844685815e-09
that O 0 3.5466424241903383e-10
ATM O 0 1.8347259711504194e-08
acts O 0 9.800147360294886e-09
as O 0 5.625883758852979e-09
a O 0 7.924407441350922e-07
tumour B-Disease 1 0.9999967813491821
suppressor O 0 0.0109521159902215
. O 0 6.809814863117936e-07

As O 0 3.896473970144143e-07
constitutional O 0 1.2179468455997267e-07
DNA O 0 1.338949715545823e-07
was O 0 1.0190233723506026e-07
not O 0 3.2962530482905095e-09
available O 0 5.379384160342227e-10
, O 0 1.4659397307159594e-10
a O 0 6.172322652986395e-09
putative O 0 5.10616519022733e-06
hereditary O 1 0.9670526385307312
predisposition O 0 0.14776162803173065
to O 0 8.139591955114156e-06
T B-Disease 0 0.04679941385984421
- I-Disease 0 0.000408670399338007
PLL I-Disease 0 6.108127854531631e-05
will O 0 7.017344216819765e-08
require O 0 1.493580370492964e-08
further O 0 7.261268919478425e-09
investigation O 0 4.5850462981888995e-08
. O 0 1.1752598005898562e-08
. O 0 1.2032947438456176e-07

Myotonic B-Disease 1 0.9999973773956299
dystrophy I-Disease 1 0.9999996423721313
protein O 0 0.000650573696475476
kinase O 0 0.0001439970947103575
is O 0 2.264974874321979e-08
involved O 0 1.0997704968929156e-09
in O 0 1.2934035786837939e-10
the O 0 1.3032694368142472e-10
modulation O 0 3.4618459210378205e-08
of O 0 1.2267532822907157e-10
the O 0 1.0248935033985163e-09
Ca2 O 0 2.1812147679156624e-06
+ O 0 1.5709602507740783e-07
homeostasis O 0 7.72664975556836e-07
in O 0 1.3581733071532653e-08
skeletal O 0 0.0005396928172558546
muscle O 0 0.0005962889990769327
cells O 0 3.975761501351371e-06
. O 0 2.1170041009099805e-07

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
( O 1 0.9858124256134033
DM B-Disease 1 0.9999998807907104
) O 0 2.8552082653732214e-07
, O 0 2.077882088613592e-09
the O 0 2.74614275763696e-10
most O 0 9.536824663314292e-09
prevalent O 0 2.890500809371588e-06
muscular B-Disease 1 0.9996567964553833
disorder I-Disease 1 0.9923592209815979
in O 0 5.942148391113733e-07
adults O 0 1.4699159692099784e-05
, O 0 1.4917924673341076e-08
is O 0 3.5138612020091387e-08
caused O 0 6.602754751838802e-07
by O 0 1.219750345171633e-08
( O 0 3.2630744772887965e-09
CTG O 0 6.186681389408477e-07
) O 0 9.295647029894383e-10
n O 0 1.262566318160907e-08
- O 0 4.090457039751527e-08
repeat O 0 1.8504849208511587e-08
expansion O 0 1.3662634357203274e-09
in O 0 2.1311526154921268e-10
a O 0 1.0929638305512412e-09
gene O 0 3.1033366987287536e-09
encoding O 0 4.290760635683455e-09
a O 0 8.653186611695673e-09
protein O 0 1.528393767102898e-07
kinase O 0 1.5717405403847806e-05
( O 0 2.889376204961991e-08
DM B-Disease 1 0.9999979734420776
protein O 0 1.4193827155395411e-05
kinase O 0 1.1753104445233475e-05
; O 0 3.113767732543238e-08
DMPK O 0 2.5711790385685163e-06
) O 0 1.154866757779871e-09
and O 0 7.254371547915639e-10
involves O 0 7.947895119819748e-10
changes O 0 4.9338049201708145e-09
in O 0 1.1681146050435132e-09
cytoarchitecture O 0 1.6012602372939e-06
and O 0 3.169977347283748e-08
ion O 0 2.3009975848253816e-05
homeostasis O 0 0.0001194303622469306
. O 0 3.435659721162665e-07

To O 0 4.876629873251659e-07
obtain O 0 1.0047875775853754e-07
clues O 0 1.0387572046965943e-07
to O 0 2.308563118447182e-09
the O 0 4.686186994007357e-10
normal O 0 3.5571043888182885e-09
biological O 0 1.4516305935075025e-09
role O 0 5.617346032771309e-10
of O 0 2.4811083743081497e-10
DMPK O 0 1.338346351076325e-06
in O 0 1.447251651853776e-09
cellular O 0 4.1782925563893514e-08
ion O 0 6.220510044840921e-07
homeostasis O 0 2.3341972337220795e-06
, O 0 1.1114169584658384e-09
we O 0 3.6466138442214913e-10
have O 0 1.7706546229234732e-09
compared O 0 5.4885944678062515e-09
the O 0 7.593255468840709e-10
resting O 0 4.090512675247737e-07
[ O 0 1.5789833440749135e-08
Ca2 O 0 6.434382271436334e-08
+ O 0 1.6818836101606394e-08
] O 0 3.601767328831329e-09
i O 0 2.586691083550363e-09
, O 0 9.62594101650005e-11
the O 0 4.279967005804686e-11
amplitude O 0 1.0896173741059556e-08
and O 0 1.1805411093135376e-09
shape O 0 6.612898229008124e-09
of O 0 3.175947005384927e-10
depolarization O 0 2.0187228244594735e-07
- O 0 9.843442967394367e-06
induced O 0 0.0012210835702717304
Ca2 O 0 3.933521838916931e-06
+ O 0 1.1443396630284042e-07
transients O 0 3.954993417210062e-07
, O 0 5.619789078536996e-10
and O 0 1.3252986208467377e-10
the O 0 7.990923200917877e-11
content O 0 9.927660915565184e-10
of O 0 1.2454018372132225e-10
ATP O 0 3.139129134410723e-08
- O 0 3.1886912665868294e-07
driven O 0 3.9543218122162216e-07
ion O 0 1.8759087083708437e-07
pumps O 0 3.3501632401566894e-07
in O 0 2.345942107240262e-09
cultured O 0 1.4718169438765472e-07
skeletal O 0 1.798669109120965e-05
muscle O 0 2.5834194730123272e-06
cells O 0 1.5473652581476927e-08
of O 0 4.437689660186095e-10
wild O 0 5.3066044891636466e-09
- O 0 1.6560126141484943e-06
type O 0 2.602003405627329e-06
and O 0 2.452008551756535e-08
DMPK O 0 2.8659875169978477e-05
[ O 0 2.5818275517508482e-08
- O 0 1.1981035186181543e-06
/ O 0 6.003191970194166e-07
- O 0 5.681784841726767e-06
] O 0 7.083789341777447e-07
knockout O 0 0.0001094392646336928
mice O 0 0.0012345490977168083
. O 0 2.66730239673052e-07

In O 0 7.047254939607228e-07
vitro O 0 2.9511134016502183e-06
- O 0 1.2322723705437966e-05
differentiated O 0 3.26058329847001e-06
DMPK O 0 1.0266361641697586e-05
[ O 0 6.983562883533523e-08
- O 0 6.349044952003169e-07
/ O 0 3.6693492688755214e-07
- O 0 1.3769267752650194e-06
] O 0 7.846142580092419e-08
myotubes O 0 2.212967586956438e-07
exhibit O 0 2.7437110361461237e-08
a O 0 1.2844953545254612e-08
higher O 0 1.547707739746329e-08
resting O 0 3.5774573348135164e-07
[ O 0 1.782705894015635e-08
Ca2 O 0 1.387110586392737e-07
+ O 0 2.3907533730493924e-08
] O 0 4.08625977499355e-09
i O 0 3.2487599277430945e-09
than O 0 4.91529872359564e-10
do O 0 6.89444612511636e-10
wild O 0 1.9176478183169365e-09
- O 0 3.9340326907222334e-07
type O 0 8.98648579550354e-07
myotubes O 0 1.1486293942652992e-06
because O 0 1.145272099378758e-09
of O 0 4.235617759307253e-11
an O 0 7.12511272205063e-10
altered O 0 8.086502134574403e-08
open O 0 1.7837559207478648e-09
probability O 0 7.581417715840644e-10
of O 0 1.6428709781468598e-10
voltage O 0 3.194742384948768e-05
- O 0 1.228502355843375e-06
dependent O 0 4.873621151091356e-07
l O 0 3.59894073653777e-07
- O 0 3.7737152069894364e-07
type O 0 4.626351710612653e-07
Ca2 O 0 3.559292167665262e-07
+ O 0 3.3790861664328986e-08
and O 0 4.9885842123842394e-09
Na O 0 2.4039732693381666e-07
+ O 0 1.1819626877240808e-07
channels O 0 1.0661404559186849e-07
. O 0 4.8456936241336734e-08

The O 0 2.7801922897197073e-07
mutant O 0 2.36797268371447e-06
myotubes O 0 1.811536208151665e-06
exhibit O 0 9.935891398527019e-08
smaller O 0 1.6231195942850718e-08
and O 0 2.8545634744858717e-09
slower O 0 2.5002182724165323e-07
Ca2 O 0 3.748524704860756e-06
+ O 0 1.533908999817868e-07
responses O 0 1.9356624747501883e-08
upon O 0 5.3922075693435545e-09
triggering O 0 2.1194962229742487e-08
by O 0 1.674166139054023e-09
acetylcholine O 0 1.070239719069832e-07
or O 0 3.833871442537884e-09
high O 0 2.2109670538839055e-08
external O 0 6.984881224525452e-07
K O 0 1.2739934618366533e-06
+ O 0 3.24911525240168e-07
. O 0 6.086700921059673e-08

In O 0 3.5891994798475935e-07
addition O 0 2.350897432279453e-08
, O 0 1.712573749479418e-09
we O 0 2.9390587186206574e-10
observed O 0 6.924203432845388e-10
that O 0 2.027379236713145e-10
these O 0 5.360027421907887e-10
Ca2 O 0 2.781348484859336e-07
+ O 0 1.119329837706573e-07
transients O 0 1.0672955568225007e-06
partially O 0 3.7772440464323154e-07
result O 0 1.750279476908645e-09
from O 0 7.221166720139394e-11
an O 0 2.0453934379549565e-10
influx O 0 3.4154876704661774e-09
of O 0 2.907666885043625e-10
extracellular O 0 1.0799570127062452e-08
Ca2 O 0 2.1101145364355034e-07
+ O 0 1.0710643039146817e-08
through O 0 4.2511275055723274e-10
the O 0 6.434131005761401e-10
l O 0 1.999005547759225e-07
- O 0 6.926751439095824e-07
type O 0 1.3572897614722024e-06
Ca2 O 0 2.2559697754331864e-06
+ O 0 4.728092619643576e-07
channel O 0 6.83908979226544e-07
. O 0 9.875225259747822e-08

Neither O 0 5.6272779147548135e-06
the O 0 1.1815238565304753e-08
content O 0 1.4090103306330093e-08
nor O 0 5.773684197407647e-09
the O 0 1.328431809000108e-10
activity O 0 8.643878945946426e-10
of O 0 5.630024224601016e-10
Na O 0 9.09647752678211e-08
+ O 0 7.037262150788592e-08
/ O 0 4.013874388419936e-08
K O 0 5.742211683923415e-08
+ O 0 2.8957925835015885e-08
ATPase O 0 1.7243324634819146e-07
and O 0 8.487308633675639e-09
sarcoplasmic O 0 1.2869411420979304e-06
reticulum O 0 4.274762886780081e-06
Ca2 O 0 2.3776531179464655e-06
+ O 0 3.740058218681952e-07
- O 0 3.1263755317922914e-07
ATPase O 0 1.0792350622068625e-06
are O 0 8.350371949461532e-09
affected O 0 1.4092469413640174e-08
by O 0 1.4816124327410307e-08
DMPK O 0 5.6233740906463936e-05
absence O 0 8.133625328810012e-07
. O 0 1.8198271334313176e-07

In O 0 3.1687082469034067e-07
conclusion O 0 3.918253810297756e-08
, O 0 3.165504747215664e-09
our O 0 4.1430772701467333e-10
data O 0 8.262911466161427e-10
suggest O 0 1.7773406080223708e-09
that O 0 8.001298512638755e-10
DMPK O 0 4.40000349044567e-07
is O 0 1.2553785788682603e-09
involved O 0 3.023847006122793e-10
in O 0 1.2513212688247677e-10
modulating O 0 3.932029102315937e-08
the O 0 4.677506715289326e-10
initial O 0 3.940022530457554e-09
events O 0 3.1063021599386786e-10
of O 0 1.330861254533744e-10
excitation O 0 4.544248355387026e-08
- O 0 5.048546540820098e-07
contraction O 0 6.817405164838419e-07
coupling O 0 5.512222287507029e-07
in O 0 1.0942680539471894e-08
skeletal O 0 0.001361820031888783
muscle O 0 0.0003486989880912006
. O 0 7.860042927632094e-08
. O 0 9.003714041000421e-08

Constitutional O 0 0.00032808215473778546
RB1 O 0 0.008276034146547318
- O 0 0.00010157974611502141
gene O 0 6.09329163125949e-06
mutations O 0 5.29734643350821e-06
in O 0 3.132669590399928e-08
patients O 0 1.05676481325645e-05
with O 0 5.87026072196295e-08
isolated O 0 2.112055881298147e-05
unilateral B-Disease 0 0.0005151841905899346
retinoblastoma I-Disease 0 0.1414848119020462
. O 0 1.319354964834929e-06

In O 0 6.584707534784684e-07
most O 0 2.0076068096841482e-07
patients O 0 1.3336206166059128e-06
with O 0 9.98219906733766e-09
isolated O 0 1.240318056261458e-06
unilateral B-Disease 0 2.550144745327998e-05
retinoblastoma I-Disease 0 0.007703333627432585
, O 0 4.143349841001509e-08
tumor B-Disease 0 6.905111717969703e-07
development O 0 1.0183462961776968e-09
is O 0 2.363331530474966e-09
initiated O 0 4.9760879861082685e-09
by O 0 1.2054565123875705e-09
somatic O 0 7.088020481660351e-08
inactivation O 0 1.207928903568245e-06
of O 0 5.98757710079667e-10
both O 0 2.2572368418849464e-09
alleles O 0 1.1526623211466358e-08
of O 0 6.445418643252765e-10
the O 0 1.4096877443137146e-08
RB1 O 0 3.5030570870731026e-05
gene O 0 6.745406153640943e-07
. O 0 1.1563059842956136e-07

However O 0 2.8762046895280946e-06
, O 0 9.691700775249501e-09
some O 0 4.213960014265439e-10
of O 0 1.498475371564112e-10
these O 0 5.965670180074767e-09
patients O 0 2.0366187527542934e-06
can O 0 4.681242415927045e-08
transmit O 0 4.7449542762478814e-05
retinoblastoma B-Disease 0 0.0011286599328741431
predisposition O 0 0.0006573130376636982
to O 0 7.202359597613395e-08
their O 0 5.128919511321328e-08
offspring O 0 4.368437657831237e-06
. O 0 2.0178028137252113e-07

To O 0 1.7765458437679627e-07
determine O 0 4.07090610110572e-08
the O 0 1.007419481169336e-09
frequency O 0 1.187273568348246e-07
and O 0 3.2778331160443486e-09
nature O 0 3.058599817862273e-09
of O 0 2.555242684110226e-10
constitutional O 0 8.432625122622994e-07
RB1 O 0 6.82013196637854e-05
- O 0 7.699572392994014e-07
gene O 0 1.8249507149903366e-07
mutations O 0 2.4862160330485494e-07
in O 0 5.345226483655097e-09
patients O 0 2.5845824893622193e-06
with O 0 6.342530500802468e-09
isolated O 0 1.1214427786399028e-06
unilateral B-Disease 0 1.2294609405216761e-05
retinoblastoma I-Disease 0 6.737139483448118e-05
, O 0 3.604660792078107e-09
we O 0 7.214754904616427e-10
analyzed O 0 7.955073044740857e-09
DNA O 0 6.144624808968047e-09
from O 0 9.566442082942217e-10
peripheral O 0 5.130544309395191e-07
blood O 0 2.873113089663093e-07
and O 0 1.5862580582393093e-08
from O 0 2.361287165797421e-08
tumor B-Disease 0 0.00037291631451807916
tissue O 0 0.00012936053099110723
. O 0 4.767284451645537e-07

The O 0 1.7929312434716849e-07
analysis O 0 6.590362033875863e-08
of O 0 7.051595307672187e-09
tumors B-Disease 1 0.9996873140335083
from O 0 1.1897305363106625e-08
54 O 0 2.202818336627388e-07
( O 0 1.844820740615205e-09
71 O 0 1.8555165581801703e-07
% O 0 1.1636069885412326e-09
) O 0 1.242559249936548e-10
of O 0 3.490791267157789e-10
76 O 0 8.352985787496436e-07
informative O 0 8.337721055795555e-07
patients O 0 0.0016609872691333294
showed O 0 9.753974836712587e-07
loss O 0 3.409975946055965e-08
of O 0 2.3606960830591106e-09
constitutional O 0 2.9549004466389306e-05
heterozygosity O 0 0.15907710790634155
( O 0 2.5005567749758484e-07
LOH O 1 0.9915934801101685
) O 0 6.0396194712097895e-09
at O 0 6.425647125496425e-09
intragenic O 0 6.034317721059779e-06
loci O 0 1.3321523510967381e-06
. O 0 2.413469530893053e-07

Three O 0 4.1290752506029094e-07
of O 0 1.3835324885747013e-08
13 O 0 9.12819615450644e-08
uninformative O 0 0.00024638904142193496
patients O 0 0.0010343228932470083
had O 0 4.6204254999793193e-07
constitutional O 0 5.079623974779679e-07
deletions O 0 3.0247609174693935e-05
. O 0 1.1484091828606324e-06

For O 0 8.082167255452077e-07
39 O 0 1.0603450846247142e-06
randomly O 0 2.3713616315035324e-07
selected O 0 3.0343773005370167e-07
tumors B-Disease 1 0.9980999827384949
, O 0 8.814772023413298e-09
SSCP O 0 4.282466306904098e-06
, O 0 1.0964826380188697e-08
hetero O 0 5.067453457741067e-06
- O 0 1.2349195230854093e-06
duplex O 0 2.6169293050770648e-05
analysis O 0 1.2637830337780542e-08
, O 0 1.6663474766698272e-10
sequencing O 0 5.228108501675877e-10
, O 0 2.1533969052356383e-10
and O 0 8.145317753616155e-10
Southern O 0 3.502010015310475e-09
blot O 0 1.3866645531379618e-05
analysis O 0 3.1905267317000607e-09
were O 0 3.813332427604621e-10
used O 0 2.4918846985855225e-09
to O 0 1.4466726483419734e-08
identify O 0 7.044378662612871e-07
mutations O 0 1.7326020724794944e-06
. O 0 8.546605556603026e-08

Mutations O 0 0.0011037529911845922
were O 0 9.472016131439887e-07
detected O 0 3.9782767657925433e-07
in O 0 9.139342616037993e-09
21 O 0 5.74852379031654e-08
( O 0 3.754429211966226e-09
91 O 0 1.7935691687398503e-07
% O 0 1.4847744145285446e-09
) O 0 3.87192111706014e-10
of O 0 4.285762855715802e-09
23 O 0 0.0015919138677418232
tumors B-Disease 1 0.9999995231628418
with O 0 0.0003149581898469478
LOH O 1 0.9999938011169434
. O 0 3.423366251809057e-06

In O 0 8.234133588302939e-07
6 O 0 1.3772694273939123e-07
( O 0 5.383184564777821e-09
38 O 0 6.23605984628739e-08
% O 0 9.841539805321986e-10
) O 0 2.4205012993938624e-10
of O 0 1.365065283032152e-09
16 O 0 0.00022327006445266306
tumors B-Disease 1 0.9999998807907104
without O 0 1.609272112546023e-05
LOH O 1 0.9999393224716187
, O 0 5.63790392149599e-09
one O 0 2.9044922023047093e-09
mutation O 0 2.5620092714007114e-08
was O 0 4.861931657273999e-08
detected O 0 2.3627107381685164e-08
, O 0 5.462200691752628e-10
and O 0 1.0821854523612728e-09
in O 0 1.0457718024881046e-09
9 O 0 3.964318207039241e-09
( O 0 2.1779703041069354e-10
56 O 0 2.183150726864369e-08
% O 0 2.118087788494094e-10
) O 0 5.890833654209615e-11
of O 0 1.1975816172071774e-10
the O 0 9.83707877821871e-07
tumors B-Disease 1 1.0
without O 0 3.835867755697109e-05
LOH O 1 0.9999051094055176
, O 0 6.234012417394297e-09
both O 0 2.2446702274692143e-09
mutations O 0 5.3227349638973465e-08
were O 0 1.2664252757588201e-08
found O 0 7.569201443402562e-08
. O 0 1.1003903921391611e-07

Thus O 0 2.490601900717593e-06
, O 0 6.6663408126999e-09
a O 0 2.578514068929394e-09
total O 0 3.982413565584153e-10
of O 0 2.2682150602193474e-10
45 O 0 8.989141875304085e-09
mutations O 0 6.875988134424915e-08
were O 0 1.1448315184736657e-08
identified O 0 9.532935507650109e-08
in O 0 4.188945368355235e-08
tumors B-Disease 1 0.9999927282333374
of O 0 2.9126931977430104e-08
36 O 0 1.12605948743294e-05
patients O 0 5.993277227389626e-05
. O 0 1.9298569498005236e-07

Thirty O 0 8.932290256780107e-06
- O 0 1.9117455849482212e-06
nine O 0 1.9723271904581452e-08
of O 0 5.684125392591e-10
the O 0 1.2810986715905415e-09
mutations O 0 1.0798111560461621e-07
- O 0 2.0124832644796697e-07
including O 0 1.0361981495066175e-08
34 O 0 2.7236161770360923e-08
small O 0 2.025007272976609e-09
mutations O 0 1.3989473757192172e-07
, O 0 8.45492509338186e-10
2 O 0 1.561768825375509e-09
large O 0 1.4482208765542737e-09
structural O 0 2.2008309770171763e-06
alterations O 0 5.59793297725264e-05
, O 0 8.831331221870187e-09
and O 0 8.061888934207673e-09
hypermethylation O 0 1.2393966244417243e-05
in O 0 2.8426279996551784e-08
3 O 0 1.0096900950884447e-06
tumors O 1 0.9999926090240479
- O 0 1.9916422388632782e-05
were O 0 1.509536105004372e-07
not O 0 3.355129507554011e-09
detected O 0 1.0778148151757705e-08
in O 0 2.9674596113693497e-10
the O 0 3.9858633060774196e-10
corresponding O 0 2.0387895816043056e-08
peripheral O 0 2.90366278932197e-06
blood O 0 8.697003295310424e-07
DNA O 0 1.781878381734714e-06
. O 0 1.445553436951741e-07

In O 0 9.629624173612683e-07
6 O 0 1.1926276499707456e-07
( O 0 3.431014361510165e-09
17 O 0 2.3037255658664435e-08
% O 0 6.696603827016645e-10
) O 0 6.119191958697812e-11
of O 0 8.801088330345763e-11
the O 0 1.985105413382371e-09
36 O 0 1.9333565433043987e-06
patients O 0 2.833977077898453e-06
, O 0 8.054415467917408e-10
a O 0 1.8390915457189294e-08
mutation O 0 1.5557023402834602e-07
was O 0 7.543647484453686e-08
detected O 0 1.453421116792697e-08
in O 0 3.8629810461543457e-10
constitutional O 0 5.185657414585876e-08
DNA O 0 1.54417591602396e-07
, O 0 8.564220443929571e-10
and O 0 5.37513866749606e-10
1 O 0 1.4311922480469974e-10
of O 0 7.004243018915446e-11
these O 0 5.575651607081511e-10
mutations O 0 1.7866341295302846e-08
is O 0 1.1396283916553784e-09
known O 0 2.008405441955574e-09
to O 0 2.329951120927376e-09
be O 0 1.2765331902642174e-08
associated O 0 5.660477864211089e-09
with O 0 1.3051513647610591e-08
reduced O 0 5.707689979317365e-06
expressivity O 0 0.002940010279417038
. O 0 3.8421603676397353e-07

The O 0 1.367886568459653e-07
presence O 0 2.941989407645451e-08
of O 0 5.463482444234558e-10
a O 0 1.5385483109753295e-08
constitutional O 0 4.993765969629749e-07
mutation O 0 2.3838924789743032e-06
was O 0 3.8354832554432505e-07
not O 0 2.4885078442338227e-09
associated O 0 8.368671866598731e-10
with O 0 2.9155194924967986e-10
an O 0 2.348977679034192e-09
early O 0 3.67772869935834e-08
age O 0 3.009465388004173e-08
at O 0 4.2968455460368205e-09
treatment O 0 3.1242968816513894e-06
. O 0 1.698651885817526e-07

In O 0 7.115917242117575e-07
1 O 0 2.090722546199686e-07
patient O 0 2.91625656245742e-06
, O 0 8.169858567441679e-09
somatic O 0 5.392969910644752e-07
mosaicism O 0 0.00013975409092381597
was O 0 3.086184506173595e-06
demonstrated O 0 5.543146386344233e-08
by O 0 7.624181841414668e-10
molecular O 0 6.690172860146504e-09
analysis O 0 1.089454637615006e-09
of O 0 1.600103938237396e-10
DNA O 0 3.8942999935898115e-08
and O 0 3.6482159515571766e-09
RNA O 0 2.3501174339912723e-08
from O 0 5.913941336643802e-09
peripheral O 0 5.339326435205294e-06
blood O 0 4.232678747939644e-06
. O 0 2.7035713401346584e-07

In O 0 1.5702936480010976e-06
2 O 0 6.762351745237538e-07
patients O 0 2.6837524274014868e-06
without O 0 3.179833951705291e-09
a O 0 3.002762838377748e-08
detectable O 0 2.340465243833023e-06
mutation O 0 3.638659222815477e-07
in O 0 9.923009969270424e-09
peripheral O 0 1.2160335245425813e-05
blood O 0 6.288199074333534e-06
, O 0 2.6307315437179568e-08
mosaicism O 0 2.0326879166532308e-05
was O 0 1.1263238093306427e-06
suggested O 0 1.7421204034917537e-08
because O 0 7.39948324834927e-10
1 O 0 1.4162566952524713e-10
of O 0 1.2058376519519243e-10
the O 0 1.008023531312574e-08
patients O 0 0.0005473709898069501
showed O 0 0.002021406777203083
multifocal O 1 0.9999675750732422
tumors B-Disease 1 1.0
and O 0 5.549398451876186e-08
the O 0 1.0108224257621146e-09
other O 0 8.578427967975699e-10
later O 0 3.22316004996992e-08
developed O 0 1.0525103277814196e-07
bilateral B-Disease 0 3.154729597554251e-07
retinoblastoma I-Disease 0 0.007053604815155268
. O 0 1.0198648396908538e-06

In O 0 5.956258632977551e-07
conclusion O 0 7.077172625713501e-08
, O 0 2.945997223946506e-09
our O 0 1.0619951584800447e-09
results O 0 2.033561097292136e-09
emphasize O 0 5.654003487620685e-09
that O 0 8.993065181428506e-10
the O 0 4.702823686031365e-10
manifestation O 0 2.512340380178557e-08
and O 0 3.971545758929551e-09
transmissibility O 0 1.4466347408870206e-07
of O 0 3.8992981066243715e-10
retinoblastoma B-Disease 0 4.773121418111259e-07
depend O 0 1.3981760638159813e-08
on O 0 3.6687031190751895e-09
the O 0 5.439577677179841e-10
nature O 0 7.113543087911012e-10
of O 0 4.592636340672307e-11
the O 0 1.250338166336462e-10
first O 0 3.6756371279977884e-09
mutation O 0 1.2232872492745628e-08
, O 0 1.2128266446698177e-10
its O 0 9.152242852472625e-11
time O 0 3.512658219850806e-10
in O 0 1.2543271976639403e-10
development O 0 6.906195754163846e-11
, O 0 2.6407837028230574e-10
and O 0 2.2529818288763437e-10
the O 0 7.040353022791379e-11
number O 0 2.8128746554223483e-10
and O 0 6.661443618938279e-10
types O 0 6.599110702332212e-10
of O 0 8.292969089218616e-11
cells O 0 2.2767940865975334e-09
that O 0 1.712044728208184e-09
are O 0 1.5491746774287662e-09
affected O 0 1.1016122236640058e-08
. O 0 9.22980625261971e-09
. O 0 3.667809522767129e-08

Hereditary B-Disease 1 0.9999958276748657
deficiency I-Disease 1 0.9975597858428955
of I-Disease 0 5.92156013112799e-09
the I-Disease 0 1.5181884638337806e-09
fifth I-Disease 0 1.4828960281931813e-08
component I-Disease 0 8.68630856132313e-09
of I-Disease 0 3.755787902903762e-10
complement I-Disease 0 9.069326623034613e-09
in O 0 6.7515752988356326e-09
man O 0 1.3675641639565583e-05
. O 0 2.236131990684953e-07

I O 0 0.000442236807430163
. O 0 1.4852920685370918e-05

Clinical O 0 0.0021150086540728807
, O 0 8.061375069701171e-07
immunochemical O 0 2.275023507536389e-05
, O 0 2.088221151552716e-08
and O 0 1.4809908854829246e-08
family O 0 8.444956023367922e-08
studies O 0 2.7699600835262572e-08
. O 0 7.709236626851634e-08

The O 0 2.4903377493501466e-07
first O 0 3.1151103030424565e-08
recognized O 0 2.5080410637201567e-08
human O 0 2.0649045140430644e-08
kindred O 0 6.555636446137214e-06
with O 0 1.5975462019923725e-06
hereditary B-Disease 1 0.9999896287918091
deficiency I-Disease 0 0.027445007115602493
of I-Disease 0 6.968693955222705e-10
the I-Disease 0 9.216044594140271e-10
fifth I-Disease 0 3.715562968409358e-08
component I-Disease 0 1.106987479460031e-08
of I-Disease 0 7.664452406075384e-10
complement I-Disease 0 3.102870849147621e-08
( O 0 6.583901424050964e-09
C5 O 0 9.755146948009497e-07
) O 0 2.498766971115174e-09
is O 0 2.8400103602166382e-08
described O 0 1.869070615612145e-06
. O 0 1.8120721279046847e-07

The O 0 1.4450847629632335e-07
proband O 0 2.4524399577785516e-06
, O 0 3.1926206123245038e-09
a O 0 2.8083142478152467e-09
20 O 0 1.5737208203248088e-09
- O 0 4.2945288214468746e-08
year O 0 5.385310863914583e-09
- O 0 6.990932206463185e-07
old O 0 2.8822703370678937e-06
black O 0 9.327069392384146e-07
female O 0 2.394903276581317e-06
with O 0 2.732926304815919e-06
systemic B-Disease 1 0.9999998807907104
lupus I-Disease 1 0.9999996423721313
erythematosus I-Disease 1 0.9999996423721313
since O 0 5.8211277064401656e-05
age O 0 2.9377764576565824e-07
11 O 0 4.651530272070659e-09
, O 0 3.136691573146777e-09
lacked O 0 2.0617326299543492e-06
serum O 0 3.3309479476884007e-06
hemolytic O 0 2.376519660174381e-06
complement O 0 1.3491984418578795e-08
activity O 0 4.03679756288966e-09
, O 0 1.4075296483895272e-09
even O 0 8.307178056554676e-09
during O 0 1.0283662277288386e-07
remission O 0 2.742759306784137e-06
. O 0 1.6946196979006345e-07

C5 O 0 0.0025010874960571527
was O 0 7.103039934008848e-06
undetectable O 0 1.4747015484317672e-06
in O 0 1.3276529209349519e-08
her O 0 7.0013676634062e-08
serum O 0 9.253959376565035e-08
by O 0 1.682100903011019e-09
both O 0 3.6223115618128077e-09
immunodiffusion O 0 2.342644393138471e-06
and O 0 9.621952301586134e-08
hemolytic O 0 0.0006426959298551083
assays O 0 2.4396742446697317e-05
. O 0 3.888051480771537e-07

Other O 0 9.098334174950651e-08
complement O 0 3.6233636535598635e-08
components O 0 1.1529217580630302e-08
were O 0 2.678271382450248e-09
normal O 0 6.638097183042646e-09
during O 0 1.7087767645307395e-08
remission O 0 2.743235540947353e-07
of O 0 7.264053358824185e-09
lupus O 0 0.001284647616557777
, O 0 1.2036030838658007e-08
but O 0 4.567066369531858e-08
C1 O 0 2.786118784570135e-06
, O 0 9.860295691055398e-09
C4 O 0 4.3017763573516277e-07
, O 0 2.9871621620713995e-08
C2 O 0 1.257437361346092e-06
, O 0 4.266416997467104e-09
and O 0 1.2781119274052344e-08
C3 O 0 3.2373175145039568e-06
levels O 0 2.7176175976251216e-08
fell O 0 6.119971658335999e-07
during O 0 7.130298484980813e-08
exacerbations O 0 0.023100147023797035
. O 0 9.509433311905013e-07

A O 0 7.431564426951809e-06
younger O 0 6.56215433991747e-06
half O 0 1.5660060626032646e-07
- O 0 1.467223341933277e-06
sister O 0 2.597238335511065e-06
, O 0 5.085355248013457e-09
who O 0 3.883381438640754e-08
had O 0 6.511768191330702e-08
no O 0 3.350935884327555e-08
underlying O 0 6.3523248172714375e-06
disease O 0 3.3406029160687467e-06
, O 0 6.5524070613776075e-09
was O 0 1.2234654604981188e-06
also O 0 1.3082892103000177e-08
found O 0 2.03246752761288e-09
to O 0 4.520438690036599e-09
lack O 0 1.0004503536720222e-07
immunochemically O 0 0.0022328693885356188
detectable O 0 5.6282402510987595e-05
C5 O 0 2.5444169295951724e-05
. O 0 3.675036452932545e-07

By O 0 3.4670508739509387e-06
hemolytic O 0 0.0012148675741627812
assay O 0 1.7444803233956918e-05
, O 0 1.0049024723457478e-07
she O 0 1.33560320136894e-07
exhibited O 0 1.4172586304539436e-07
1 O 0 3.230691714151135e-09
- O 0 1.342655338021359e-07
2 O 0 1.2144204752928545e-08
% O 0 2.7348365239099337e-10
of O 0 3.620733227127637e-11
the O 0 8.212944768715147e-10
normal O 0 3.788940006188568e-08
serum O 0 5.216947442931996e-07
C5 O 0 2.8223800541127275e-07
level O 0 2.769208418129665e-09
and O 0 1.2260428228216824e-09
normal O 0 1.766175206086018e-09
concentrations O 0 5.330056840335828e-09
of O 0 8.393253453364835e-11
other O 0 4.613015247567631e-10
complement O 0 2.0596417016349733e-08
components O 0 3.223535429697222e-07
. O 0 9.130529576850677e-08

C5 O 0 0.0009898465359583497
levels O 0 3.03963389569617e-07
of O 0 1.691043860496677e-09
other O 0 1.1620722162319908e-09
family O 0 5.947605519196486e-09
members O 0 5.293530613847963e-10
were O 0 5.07897679469238e-09
either O 0 2.3292359152549125e-09
normal O 0 3.163585171606087e-09
or O 0 6.707738253730611e-10
approximately O 0 1.1456958715072574e-09
half O 0 6.159162957430908e-09
- O 0 2.8180875233374536e-07
normal O 0 2.1296999719311316e-08
, O 0 1.6204244612794128e-09
consistent O 0 2.1682694750779774e-08
with O 0 8.806940954286802e-09
autosomal O 0 0.00024356959329452366
codominant O 0 2.475173278071452e-05
inheritance O 0 1.472429005389131e-07
of O 0 4.533439457166111e-10
the O 0 3.4851646013578375e-09
gene O 0 1.9952051388827385e-06
determining O 0 2.2213367628864944e-05
C5 B-Disease 1 0.9999979734420776
deficiency I-Disease 1 0.9999980926513672
. O 0 5.201965905143879e-06

Normal O 0 0.00019505158707033843
hemolytic O 0 0.17109349370002747
titers O 0 0.0013381704920902848
were O 0 9.55075051933818e-07
restored O 0 4.768994585901964e-07
to O 0 3.779837953743481e-08
both O 0 3.5929940622736467e-07
homozygous O 0 0.07749935984611511
C5 B-Disease 1 0.9999924898147583
- I-Disease 1 0.999981164932251
deficient I-Disease 1 0.9999998807907104
( O 0 9.343432907371607e-07
C5D B-Disease 1 0.9999964237213135
) O 0 2.197882587040567e-08
sera O 0 8.803602469242833e-08
by O 0 1.4097730760553873e-09
addition O 0 7.797752443750028e-10
of O 0 4.529135400055395e-10
highly O 0 1.944788508012607e-08
purified O 0 2.534621330596565e-07
human O 0 1.0934944327800622e-07
C5 O 0 8.359238563571125e-06
. O 0 3.5241345130998525e-07

In O 0 6.00112002757669e-07
specific O 0 1.1446343251009239e-07
C5 O 0 9.383228643855546e-06
titrations O 0 8.456940850010142e-05
, O 0 1.6088028687022415e-08
however O 0 6.506998051492019e-09
, O 0 5.163534044783091e-10
it O 0 1.6204431130262265e-09
was O 0 2.42266139593994e-07
noted O 0 4.734018510532678e-09
that O 0 4.773766937304913e-10
when O 0 4.678720744166753e-10
limited O 0 8.273887130982871e-10
amounts O 0 5.091758126241075e-10
of O 0 2.3588808684138485e-10
C5 O 0 7.790059441958874e-08
were O 0 2.954020805745472e-09
assayed O 0 3.522148261936309e-08
in O 0 4.842030110197015e-10
the O 0 1.763373891350284e-10
presence O 0 1.1060119486927533e-09
of O 0 1.520569781199299e-10
low O 0 3.672170123536489e-08
dilutions O 0 7.78028663717123e-07
of O 0 2.010659194695563e-09
either O 0 4.555490988877864e-07
C5D B-Disease 1 0.9999972581863403
serum O 0 1.0855373147933278e-05
, O 0 2.2396198229301945e-09
curving O 0 8.445101684628753e-08
rather O 0 1.0950677697962874e-08
than O 0 3.6097038691451644e-09
linear O 0 4.337094949846687e-08
dose O 0 1.0667827154975384e-06
- O 0 3.591767665511725e-07
response O 0 9.276207890707155e-08
plots O 0 4.973699319066327e-08
were O 0 3.286536554014674e-08
consistently O 0 2.7027050464312197e-07
obtained O 0 5.926316770654694e-09
, O 0 6.782600592281085e-10
suggesting O 0 3.6900160704789187e-09
some O 0 1.0537829497891948e-09
inhibitory O 0 1.4233634715310473e-07
effect O 0 5.968256573396502e-07
. O 0 8.854661359691818e-08

Further O 0 3.1101405966182938e-06
studies O 0 4.257590902057018e-08
suggested O 0 2.3826046913200116e-08
that O 0 3.712557816726303e-09
low O 0 7.401776969118146e-08
dilutions O 0 3.2001262297853827e-06
of O 0 3.34795871026472e-08
C5D B-Disease 1 0.9999940395355225
serum O 0 1.8489944295652094e-06
contain O 0 1.484203249191296e-08
a O 0 7.505382981776165e-09
factor O 0 6.709290012452129e-09
( O 0 2.6118751605963553e-10
or O 0 5.736884856055724e-10
factors O 0 2.348959693421193e-09
) O 0 4.1728331900969806e-10
interfering O 0 6.831043286581462e-09
at O 0 5.109747069909076e-10
some O 0 1.9740038770255097e-10
step O 0 3.5235372397579567e-09
in O 0 6.297672383581698e-10
the O 0 1.3038667923126468e-09
hemolytic O 0 6.568415301444475e-06
assay O 0 3.412816909076355e-07
of O 0 5.460724317174481e-09
C5 O 0 1.5959867596393451e-06
, O 0 3.170912865613218e-09
rather O 0 3.899002898322124e-09
than O 0 3.5132092790490788e-09
a O 0 9.03079921954486e-09
true O 0 8.727099043426279e-08
C5 O 0 2.734670488280244e-06
inhibitor O 0 1.1594822808547178e-06
or O 0 7.876611363144548e-08
inactivator O 0 2.8428499717847444e-05
. O 0 3.563490054148133e-07

Of O 0 2.0699921776667907e-07
clinical O 0 1.6448595943074906e-06
interest O 0 2.8944560526156238e-08
are O 0 9.258894206887192e-10
( O 0 2.727699732751887e-10
a O 0 9.814776547045767e-09
) O 0 6.4336891369976e-10
the O 0 4.1495148983550223e-10
documentation O 0 1.7386017958642697e-08
of O 0 8.2454398864229e-09
membranous O 1 0.959031343460083
glomerulonephritis B-Disease 1 0.9999998807907104
, O 0 0.0014651783276349306
vasculitis B-Disease 1 0.9999995231628418
, O 0 3.6487092529569054e-06
and O 0 0.002916476223617792
arthritis B-Disease 1 1.0
in O 0 3.1854327176006336e-08
an O 0 1.361145240963424e-08
individual O 0 1.2919231018315713e-08
lacking O 0 2.7526857593329623e-07
C5 O 0 1.3840624433214543e-06
( O 0 4.4562312173646035e-10
and O 0 6.900023885592077e-10
its O 0 1.0395431182530501e-09
biologic O 0 1.3020637368299504e-07
functions O 0 1.1345748784918896e-09
) O 0 4.036680434360562e-10
, O 0 7.95449206503207e-10
and O 0 4.938399023046713e-09
( O 0 8.816213314943866e-10
b O 0 4.215746862712422e-09
) O 0 6.764432763928241e-11
a O 0 1.6155146109753105e-09
remarkable O 0 2.312283520211622e-08
propensity O 0 3.324632189105614e-06
to O 0 2.792529585349257e-06
bacterial B-Disease 1 0.999998927116394
infections I-Disease 1 1.0
in O 0 3.38013670386772e-08
the O 0 6.182479417304876e-09
proband O 0 4.357839770818828e-06
, O 0 1.2731332654780658e-09
even O 0 5.691176974131906e-10
during O 0 1.4042608187381234e-09
periods O 0 1.7960291032181885e-09
of O 0 2.1801689620293274e-10
low O 0 4.0883978869032944e-08
- O 0 9.130057492257038e-07
dose O 0 7.892610369708564e-07
or O 0 1.0761257440705663e-09
alternate O 0 1.1978936065304424e-08
- O 0 6.65889558604249e-07
day O 0 1.1507406583177726e-07
corticosteroid O 0 0.0036850469186902046
therapy O 0 4.065935354446992e-05
. O 0 1.8358713305133278e-07

Other O 0 8.318898636616723e-08
observations O 0 1.0136072603472712e-07
indicate O 0 3.2373243641359295e-08
that O 0 4.0884273744268285e-09
the O 0 9.391708744033167e-09
C5D B-Disease 1 0.9999920129776001
state O 0 5.837910599382212e-09
is O 0 9.831858660547255e-10
compatible O 0 2.4700228529184187e-09
with O 0 5.262895674817969e-10
normal O 0 4.5636592282960464e-09
coagulation O 0 1.3749511751370846e-08
function O 0 1.1323135762353331e-09
and O 0 4.3156359041951475e-10
the O 0 3.1590730031894054e-10
capacity O 0 5.153884430342259e-09
to O 0 4.365143357887291e-09
mount O 0 1.5200791381175804e-07
a O 0 5.012101382817491e-07
neutrophilic O 0 0.017034899443387985
leukocytosis O 0 0.0017867089482024312
during O 0 9.076959486264968e-07
pyogenic B-Disease 0 0.055099546909332275
infection I-Disease 0 0.001242317957803607
. O 0 5.509711087370306e-08
. O 0 1.597087617710713e-07

Susceptibility O 1 0.9994431138038635
to O 1 0.7340148091316223
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 5.2569139370461926e-05
twins O 0 2.49142376560485e-05
: O 0 8.030867637565109e-10
the O 0 1.6718677831040196e-10
role O 0 1.4622291155674816e-09
of O 0 2.3144211547254656e-10
genes O 0 8.956829944395395e-09
, O 0 3.900237466325507e-09
HLA O 0 2.6865204745263327e-06
, O 0 4.741962378318476e-09
and O 0 2.057139569799915e-09
the O 0 1.8465280415824736e-09
environment O 0 2.788971471545665e-07
. O 0 1.6078833198207576e-07

OBJECTIVE O 0 9.705746379040647e-06
To O 0 5.743329012375398e-08
determine O 0 1.638638558176808e-08
the O 0 1.2057186360436845e-09
relative O 0 1.9006289875278526e-08
effects O 0 3.599118514330257e-08
of O 0 6.569723653981896e-10
genetic O 0 1.226013495170264e-07
and O 0 1.1792566922963488e-08
environmental O 0 5.231515132209097e-08
factors O 0 9.066853046135748e-09
in O 0 1.758897916204205e-08
susceptibility O 1 0.998618483543396
to O 1 0.9974421262741089
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 1.3257775208330713e-05
AS B-Disease 1 0.9994072914123535
) O 0 9.894682762023876e-08
. O 0 1.8673588897399895e-07

METHODS O 0 2.0966293959645554e-05
Twins O 0 2.321269676031079e-05
with O 0 3.644462154284156e-08
AS B-Disease 1 0.8319681882858276
were O 0 5.4150905981487085e-08
identified O 0 1.0905799818772266e-08
from O 0 1.9577083010258178e-10
the O 0 9.629746999806343e-10
Royal O 0 1.1494149703139556e-06
National O 0 1.0071952161183617e-08
Hospital O 0 4.707343123300234e-06
for O 0 8.502867387960578e-08
Rheumatic B-Disease 1 0.9982789754867554
Diseases I-Disease 0 0.0001503858802607283
database O 0 4.738728023312433e-07
. O 0 1.584621145411802e-07

Clinical O 0 0.00039889090112410486
and O 0 9.134629408436012e-07
radiographic O 0 0.00010862768249353394
examinations O 0 2.725586512042355e-07
were O 0 1.4551547522501096e-08
performed O 0 1.7156086329350728e-08
to O 0 3.755990629628059e-09
establish O 0 2.7019578396902943e-07
diagnoses O 1 0.9169613122940063
, O 0 5.317509277347199e-08
and O 0 1.6562053133384325e-06
disease O 0 0.0004907427355647087
severity O 0 0.05048997700214386
was O 0 1.3293096344568767e-05
assessed O 0 3.0038169285262484e-08
using O 0 2.697496226389262e-09
a O 0 8.791499972460315e-09
combination O 0 3.0998126732129094e-08
of O 0 6.398517826688987e-10
validated O 0 3.0369074011105113e-07
scoring O 0 4.744325821093298e-08
systems O 0 1.8653582856131834e-07
. O 0 8.454626510001617e-08

HLA O 0 0.0022959928028285503
typing O 0 2.099722951243166e-05
for O 0 2.955142122118559e-07
HLA O 0 1.5079583135957364e-05
- O 0 6.668264632025966e-06
B27 O 0 3.2348791592085036e-06
, O 0 3.1421784285612375e-08
HLA O 0 1.3885550060876994e-06
- O 0 1.4472765315076686e-06
B60 O 0 9.28498423036217e-07
, O 0 4.812183540536807e-09
and O 0 1.0261048011273033e-08
HLA O 0 0.00010900911729549989
- O 0 0.019893690943717957
DR1 O 1 0.9997004270553589
was O 0 8.729959972697543e-07
performed O 0 6.607426605853561e-09
by O 0 1.2503741098068843e-10
polymerase O 0 1.578886887898534e-08
chain O 0 5.747427422875262e-08
reaction O 0 6.3581553355618325e-09
with O 0 1.2179358910291427e-10
sequence O 0 8.869578960180036e-10
- O 0 1.6742500719146847e-08
specific O 0 2.5806838888087213e-09
primers O 0 9.118701314037025e-07
, O 0 5.8098406086060095e-09
and O 0 3.2347982070746184e-09
zygosity O 0 7.041208505143004e-07
was O 0 9.217529850502615e-08
assessed O 0 2.17999662766033e-08
using O 0 2.4031519885170383e-08
microsatellite O 0 1.2411045645421837e-05
markers O 0 7.129181540221907e-06
. O 0 3.7119829698895046e-07

Genetic O 0 0.0002872462500818074
and O 0 3.266002863711037e-07
environmental O 0 3.415802396489198e-08
variance O 0 1.7611773373005235e-08
components O 0 4.99248002938657e-08
were O 0 2.8880924318741563e-08
assessed O 0 5.0838835363720136e-08
with O 0 1.420765172177596e-09
the O 0 1.3358262274110189e-09
program O 0 2.0550297019639174e-09
Mx O 0 5.7977441514367456e-08
, O 0 2.365052875763496e-10
using O 0 3.818587668291684e-10
data O 0 3.4885813682272726e-10
from O 0 4.104800527260366e-11
this O 0 1.1218653089839492e-10
and O 0 1.5422788601782145e-09
previous O 0 4.04192146419291e-09
studies O 0 7.551457792409622e-10
of O 0 1.778078795311444e-10
twins O 0 5.641305165227095e-07
with O 0 1.2112281844167683e-08
AS B-Disease 1 0.9869323372840881
. O 0 4.680666734202532e-07

RESULTS O 0 9.151134690910112e-06
Six O 0 8.608250112729365e-08
of O 0 4.329439029504556e-09
8 O 0 1.3357764316879184e-07
monozygotic O 0 2.769808634184301e-05
( O 0 5.0311754762333294e-08
MZ O 0 0.1852019727230072
) O 0 2.7503968880182583e-08
twin O 0 0.00020693009719252586
pairs O 0 9.682761969997955e-08
were O 0 5.3656782483813e-07
disease O 0 8.222637575272529e-07
concordant O 0 6.970800313865766e-06
, O 0 1.9034224862934934e-08
compared O 0 1.3007203314430171e-08
with O 0 6.107627736895438e-10
4 O 0 1.5978356415757844e-09
of O 0 3.422555017174034e-10
15 O 0 7.818188763053513e-09
B27 O 0 3.743633669728297e-07
- O 0 3.917031790479086e-06
positive O 0 1.8196398343661713e-07
dizygotic O 0 5.731334340453031e-07
( O 0 1.5340934078622581e-09
DZ O 0 8.62376168697665e-07
) O 0 3.6906708800188426e-09
twin O 0 5.85291491006501e-06
pairs O 0 3.9500243076417973e-08
( O 0 1.0857663657048988e-09
27 O 0 5.2822194618329377e-08
% O 0 8.584696842284245e-10
) O 0 2.0059161276453352e-10
and O 0 1.3343441906954467e-09
4 O 0 1.733065246867227e-09
of O 0 4.2508682684960775e-10
32 O 0 3.229233982438018e-07
DZ O 0 6.710561865475029e-05
twin O 0 6.340544496197253e-05
pairs O 0 1.1525303378334684e-08
overall O 0 1.33544215685788e-08
( O 0 7.930375245379651e-10
12 O 0 3.797547609707408e-09
. O 0 1.4927594715885562e-09
5 O 0 9.361038166844082e-09
% O 0 3.1949354273308472e-09
) O 0 7.123132750308514e-09
. O 0 1.1055594484332687e-07

Nonsignificant O 0 0.0002107658510794863
increases O 0 2.583892410257249e-06
in O 0 3.2628753032781788e-09
similarity O 0 2.1473208988709303e-08
with O 0 1.2695710038812535e-09
regard O 0 5.492731158796005e-09
to O 0 1.995545950705946e-08
age O 0 1.629782246936884e-07
at O 0 1.0384873405655526e-08
disease O 0 2.947583425338962e-06
onset O 0 4.888456714979839e-07
and O 0 4.470996017857942e-09
all O 0 5.1639945791714936e-11
of O 0 5.255369750489791e-11
the O 0 9.180644688910888e-09
disease O 0 7.667480531381443e-06
severity O 0 0.0006134069990366697
scores O 0 1.3474065951868397e-07
assessed O 0 7.190884332430869e-08
were O 0 1.244842628977949e-08
noted O 0 3.433491002624578e-08
in O 0 4.435993261608928e-08
disease O 0 6.176653550937772e-05
- O 0 0.051605064421892166
concordant O 1 0.8830010294914246
MZ O 1 0.9993564486503601
twins O 0 0.0003234596224501729
compared O 0 5.343221118891961e-07
with O 0 3.843259577251956e-08
concordant O 0 0.0003787743335124105
DZ O 0 0.010278449393808842
twins O 0 5.9741505538113415e-05
. O 0 5.48247555798298e-07

HLA O 0 0.02721254713833332
- O 0 0.0005671500111930072
B27 O 0 1.5537689250777476e-05
and O 0 7.03119766853888e-08
B60 O 0 3.7739491176580486e-07
were O 0 1.1716316805632232e-08
associated O 0 2.6063275981869083e-09
with O 0 9.961195202023987e-10
the O 0 1.617701528289217e-08
disease O 0 2.294492105647805e-06
in O 0 7.394266532401161e-09
probands O 0 1.3920385754317977e-05
, O 0 1.5469809877544094e-09
and O 0 3.8689387804602404e-10
the O 0 2.652525421531493e-10
rate O 0 4.8739998703695164e-09
of O 0 8.140021989788693e-10
disease O 0 2.619866279474081e-07
concordance O 0 4.906742105958983e-07
was O 0 1.3261668527775328e-06
significantly O 0 3.421776000323007e-07
increased O 0 9.328690708798604e-08
among O 0 1.251098069587897e-08
DZ O 0 2.5892062694765627e-05
twin O 0 9.909857908496633e-05
pairs O 0 1.0348925272296583e-08
in O 0 4.2911513231658205e-10
which O 0 3.472246046243299e-09
the O 0 2.171181678889411e-09
co O 0 2.5293961698480416e-06
- O 0 1.9569321011658758e-05
twin O 0 0.0010154639603570104
was O 0 4.618284776825021e-07
positive O 0 4.085916938123546e-09
for O 0 5.52211998350316e-10
both O 0 7.2623489444367806e-09
B27 O 0 1.5075421515575727e-06
and O 0 4.2275453893125814e-07
DR1 O 1 0.9350807070732117
. O 0 2.957755782517779e-07

Additive O 0 1.8252016161568463e-05
genetic O 0 5.834384410263738e-06
effects O 0 1.0794523177537485e-06
were O 0 4.8046747025409786e-08
estimated O 0 7.168204696483826e-09
to O 0 2.6569118016794846e-09
contribute O 0 4.55585791314661e-09
97 O 0 1.110879299659473e-08
% O 0 3.815427973563601e-10
of O 0 3.61147708960452e-11
the O 0 1.8388800482327383e-09
population O 0 1.7259276674508328e-08
variance O 0 1.2646178504382988e-07
. O 0 2.279503092950108e-07

CONCLUSION O 0 2.496161323506385e-05
Susceptibility O 0 0.006081281695514917
to O 0 7.030607207525463e-07
AS B-Disease 1 0.9879251718521118
is O 0 5.2895092750304684e-08
largely O 0 2.1417783102606336e-08
genetically O 0 9.442418047456158e-08
determined O 0 7.989362984517356e-07
, O 0 1.5897283489607617e-09
and O 0 8.683041508028566e-10
the O 0 4.425112498651629e-10
environmental O 0 1.8646035826463958e-08
trigger O 0 1.367213542380341e-07
for O 0 3.0992375332772326e-09
the O 0 2.1413944395476392e-08
disease O 0 2.933578798547387e-06
is O 0 1.6177571282582903e-08
probably O 0 3.3132585031125927e-07
ubiquitous O 0 9.287561510973319e-07
. O 0 1.7643284877522092e-07

HLA O 0 0.0109108816832304
- O 0 0.00013246925664134324
B27 O 0 6.661914994765539e-06
accounts O 0 2.7336295005397915e-08
for O 0 5.687465498560584e-10
a O 0 3.6193972263731666e-09
minority O 0 1.1419571066539902e-08
of O 0 2.9719896682545155e-11
the O 0 4.735641878639285e-10
overall O 0 7.917082456287972e-08
genetic O 0 2.1588705294561805e-06
susceptibility O 0 0.023437807336449623
to O 0 4.9643058446235955e-06
AS B-Disease 1 0.99994957447052
. O 0 2.1941102659184253e-06

Cell O 0 0.00011705990618793294
cycle O 0 7.559313417004887e-06
- O 0 1.1329576409480069e-05
dependent O 0 1.216188820762909e-06
colocalization O 0 1.9778553905780427e-06
of O 0 4.606818482244535e-09
BARD1 O 0 6.51870414003497e-06
and O 0 1.5349311155432588e-08
BRCA1 O 0 2.3194444054297492e-07
proteins O 0 9.540584988698697e-10
in O 0 9.337495221473091e-10
discrete O 0 1.1137905886471344e-07
nuclear O 0 3.1050734605742036e-07
domains O 0 3.90929642435367e-07
. O 0 2.878062730360398e-07

Germ O 0 0.0001488013076595962
- O 0 0.00025689665926620364
line O 0 3.842534169962164e-06
mutations O 0 1.152135240545249e-07
of O 0 4.2845019199155843e-10
the O 0 2.349085148622976e-09
BRCA1 O 0 1.6169601622095797e-06
gene O 0 1.6979360850655212e-07
predispose O 0 7.153645583457546e-06
women O 0 4.713038137538206e-08
to O 0 9.682277202216483e-09
early O 0 1.8546373325989407e-07
- O 0 0.33935803174972534
onset O 1 0.8119314908981323
breast B-Disease 1 0.999994158744812
and I-Disease 1 0.9999040365219116
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
by O 0 1.0720413001763518e-08
compromising O 0 1.4551359583947487e-07
the O 0 1.3377920993207226e-09
genes O 0 2.4636346296347256e-08
presumptive O 0 4.858713145949878e-05
function O 0 1.3325974990152645e-08
as O 0 5.334023445158209e-09
a O 0 1.0815301720867865e-07
tumor B-Disease 0 9.710706217447296e-05
suppressor O 0 0.00038525843410752714
. O 0 8.258757588919252e-07

Although O 0 2.0665220290538855e-06
the O 0 8.096823655989738e-09
biochemical O 0 1.7925533768448076e-07
properties O 0 2.8210337177370093e-08
of O 0 1.0086096402517342e-09
BRCA1 O 0 2.7524124561750796e-06
polypeptides O 0 4.143054752603348e-07
are O 0 5.53290790961114e-09
not O 0 8.777894855427348e-09
understood O 0 2.9138657708926985e-08
, O 0 3.9943112706275485e-10
their O 0 4.008629261864627e-10
expression O 0 1.619745404468631e-08
pattern O 0 7.909777366421622e-08
and O 0 3.594602615564213e-09
subcellular O 0 2.3905988655315014e-07
localization O 0 8.966268438825864e-08
suggest O 0 7.839930482589352e-09
a O 0 2.163608181504628e-09
role O 0 7.700943882582578e-09
in O 0 3.0045486099083973e-09
cell O 0 3.694715928759251e-07
- O 0 1.543635562484269e-06
cycle O 0 1.6061835594882723e-07
regulation O 0 3.0855733257340034e-07
. O 0 1.7436670418646827e-07

When O 0 2.511723323550541e-06
resting O 0 2.6233542484987993e-06
cells O 0 5.3994757109876446e-08
are O 0 1.034963115209564e-09
induced O 0 5.385384724831965e-07
to O 0 3.1476787398787565e-08
proliferate O 0 1.3749307470334315e-07
, O 0 1.4200064457625672e-09
the O 0 3.2657748727515923e-10
steady O 0 3.921416080743256e-08
- O 0 3.63448009466083e-08
state O 0 1.477660660498259e-09
levels O 0 2.437731960736045e-10
of O 0 5.0333757994902584e-11
BRCA1 O 0 5.1834721404020456e-08
increase O 0 3.787514746278475e-09
in O 0 4.0590858452205225e-10
late O 0 6.158376031351054e-09
G1 O 0 3.866925624151918e-07
and O 0 1.3284349176245769e-09
reach O 0 9.508630549603936e-10
a O 0 3.832664852154721e-09
maximum O 0 3.8167563332081045e-08
during O 0 1.7469984570084307e-08
S O 0 3.886281774612144e-06
phase O 0 1.8112271504833188e-07
. O 0 8.417698182938693e-08

Moreover O 0 8.89590592123568e-06
, O 0 6.937667507145306e-08
in O 0 7.217332953501909e-09
S O 0 2.0662737370003015e-06
phase O 0 1.0337330280663082e-07
cells O 0 1.1009467471012613e-07
, O 0 4.167871825444536e-09
BRCA1 O 0 2.0416582913185266e-07
polypeptides O 0 1.5640239325875882e-07
are O 0 3.3609837135628595e-09
hyperphosphorylated O 0 3.9769224713381846e-07
and O 0 3.0066009681917194e-09
accumulate O 0 2.031534585000827e-08
into O 0 1.6484494880231182e-09
discrete O 0 6.637972660428204e-08
subnuclear O 0 3.5381913221499417e-06
foci O 0 2.4781274987617508e-06
termed O 0 7.415214327011199e-07
" O 0 1.1248451414758165e-07
BRCA1 O 0 2.62604021372681e-06
nuclear O 0 3.044400500584743e-07
dots O 0 4.527224064077018e-06
. O 0 3.542103854670131e-07

" O 0 2.7350455638952553e-05
BRCA1 O 0 0.0007144285482354462
associates O 0 7.541541890532244e-06
in O 0 2.4531312092790358e-08
vivo O 0 5.154521431904868e-07
with O 0 3.2896456669817553e-09
a O 0 8.157467590308443e-08
structurally O 0 0.0002561629517003894
related O 0 1.7656515183261945e-07
protein O 0 9.887585292744916e-07
termed O 0 3.4349236557318363e-06
BARD1 O 0 0.00025257343077100813
. O 0 5.640799827233423e-07

Here O 0 6.836194756942859e-07
we O 0 1.1064090976731222e-08
show O 0 6.4317537962210736e-09
that O 0 2.5228735767157673e-10
the O 0 1.5770372507883934e-10
steady O 0 6.608311053923899e-08
- O 0 6.723075784975663e-08
state O 0 3.22054649615211e-09
levels O 0 5.930248514474101e-10
of O 0 1.0126938176924227e-10
BARD1 O 0 1.9479889488138724e-06
, O 0 1.1456565696121856e-09
unlike O 0 8.372758597552377e-10
those O 0 1.0308667114378167e-10
of O 0 9.555641000691395e-11
BRCA1 O 0 3.5603684978013916e-07
, O 0 2.37270803005174e-09
remain O 0 8.901275272421572e-09
relatively O 0 3.2200060395837227e-09
constant O 0 1.770230007025475e-08
during O 0 1.3711328961107938e-08
cell O 0 7.551981866527058e-07
cycle O 0 5.905067155254073e-07
progression O 0 1.6115043308673194e-06
. O 0 2.0420786484010023e-07

However O 0 4.145811544731259e-06
, O 0 3.370499257471238e-08
immunostaining O 0 1.8620218042997294e-06
revealed O 0 2.2844866975901823e-07
that O 0 1.0945290007668973e-08
BARD1 O 0 2.385047628195025e-05
resides O 0 3.6249127788323676e-07
within O 0 1.3534402487636044e-09
BRCA1 O 0 1.0651810811168616e-07
nuclear O 0 1.9311009680222924e-08
dots O 0 1.4138755943804426e-07
during O 0 1.2405429572481808e-08
S O 0 6.332421094157326e-07
phase O 0 3.5914022866734285e-09
of O 0 1.1113061859635565e-10
the O 0 3.150258109929638e-10
cell O 0 2.3719717745507296e-08
cycle O 0 7.936386658968786e-09
, O 0 2.631612150416629e-10
but O 0 3.680279414552956e-10
not O 0 3.780634694194873e-10
during O 0 4.5025205785975686e-10
the O 0 1.1823663159660214e-09
G1 O 0 1.7294191820838023e-06
phase O 0 1.7983150257805391e-07
. O 0 9.893795294146912e-08

Nevertheless O 0 3.706194183905609e-05
, O 0 5.5313073232809984e-08
BARD1 O 0 2.3120555852074176e-06
polypeptides O 0 4.142916338878422e-07
are O 0 2.6178714751523557e-09
found O 0 1.6237597932899916e-09
exclusively O 0 1.2936706150767918e-09
in O 0 9.493909824964675e-11
the O 0 7.900086140821827e-11
nuclear O 0 8.910087112568021e-10
fractions O 0 4.970336919818408e-10
of O 0 5.949256365322952e-11
both O 0 7.044601568750863e-10
G1 O 0 3.0030096809241513e-07
- O 0 3.413952924802288e-07
and O 0 2.7654728285142482e-08
S O 0 4.700412318925373e-06
- O 0 1.4975303201936185e-06
phase O 0 4.890680997959862e-07
cells O 0 5.466364427775261e-07
. O 0 9.562181446653994e-08

Therefore O 0 2.8425495202100137e-06
, O 0 4.025827138320892e-08
progression O 0 9.052359217776029e-08
to O 0 1.6324772644793484e-08
S O 0 1.2094067642465234e-05
phase O 0 4.168326839248948e-08
is O 0 8.033659959494344e-09
accompanied O 0 6.717651324095186e-09
by O 0 2.2025301027461808e-10
the O 0 1.7165169285959792e-10
aggregation O 0 7.239653765367393e-09
of O 0 4.668175290767351e-10
nuclear O 0 5.215952469939111e-08
BARD1 O 0 3.815668151219143e-06
polypeptides O 0 2.254742952345623e-07
into O 0 3.1679704193265934e-08
BRCA1 O 0 3.061913503188407e-06
nuclear O 0 3.6050687413080595e-07
dots O 0 5.3404774007503875e-06
. O 0 3.772250920519582e-07

This O 0 2.2379390429705381e-07
cell O 0 6.11181178555853e-07
cycle O 0 1.9479780632991606e-07
- O 0 4.642111548491812e-07
dependent O 0 1.0506089154205256e-07
colocalization O 0 3.231766356748267e-07
of O 0 1.8124369782768213e-09
BARD1 O 0 9.045676961250138e-06
and O 0 4.580675394549871e-08
BRCA1 O 0 6.897845423736726e-07
indicates O 0 6.818716702383654e-09
a O 0 2.8870885682152903e-09
role O 0 5.09651210123252e-09
for O 0 1.8926440414901435e-09
BARD1 O 0 3.1430790841113776e-05
in O 0 3.091381017839012e-08
BRCA1 O 0 1.3707631296711043e-05
- O 0 5.250936737866141e-06
mediated O 0 0.00015943186008371413
tumor B-Disease 0 0.0012111496180295944
suppression O 0 2.8099395876779454e-06
. O 0 8.213890509978228e-07

Ethnic O 0 7.868239663366694e-06
differences O 0 1.5452704928975436e-06
in O 0 1.9127721628819927e-08
the O 0 9.822754165611514e-09
HFE O 0 2.6178080588579178e-05
codon O 0 6.542163077938312e-07
282 O 0 1.017641920952883e-06
( O 0 6.728733126237785e-08
Cys O 0 0.0027754134498536587
/ O 0 1.8613081920193508e-05
Tyr O 0 2.7587313525145873e-05
) O 0 4.398475894618059e-08
polymorphism O 0 3.308761370135471e-05
. O 0 4.328112765961123e-07

Recent O 0 2.7386818146624137e-06
studies O 0 4.3122170723108866e-08
have O 0 1.9555232100287867e-08
shown O 0 1.431098723969626e-07
that O 0 4.7041659854585305e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 4.741159136756323e-05
HH B-Disease 1 0.8067925572395325
) O 0 4.371792261537166e-09
is O 0 8.983211507995748e-09
likely O 0 1.3469876591898355e-07
to O 0 1.7826241816010224e-08
be O 0 1.612457651845034e-07
caused O 0 5.020899607188767e-07
by O 0 1.8507204657680631e-09
homozygosity O 0 4.760288163652149e-07
for O 0 7.392345069412443e-10
a O 0 3.6069668141180955e-08
Cys282Tyr O 0 1.588854684086982e-05
mutation O 0 2.6387300522401347e-07
in O 0 1.4238603629479485e-09
the O 0 3.169443596462429e-09
HFE O 0 4.489586717681959e-05
gene O 0 4.044935337788047e-07
located O 0 7.105712285238042e-08
4 O 0 1.3822484845604777e-07
. O 0 1.6003671987618873e-07

5 O 0 8.856645763444249e-06
Mb O 0 3.540764009812847e-05
telomeric O 0 8.413022442255169e-05
to O 0 5.061108936388337e-07
HLA O 0 8.586224430473521e-05
- O 0 9.628093721403275e-06
A O 0 1.7588865830475697e-06
. O 0 3.5866398206962913e-07

Population O 0 1.5405926205858123e-06
studies O 0 7.038427174421713e-09
of O 0 3.319634012122208e-10
this O 0 1.3387646546902943e-09
polymorphism O 0 5.811577466374729e-06
are O 0 3.187448971431195e-09
facilitated O 0 9.168780401580534e-09
by O 0 6.83075374041664e-10
the O 0 2.475596672102398e-10
fact O 0 6.584287559618929e-10
that O 0 8.335409029669449e-10
the O 0 5.250163082060055e-10
Cys282Tyr O 0 2.3577824777021306e-06
mutation O 0 7.068471319371383e-08
creates O 0 1.0119282300991017e-08
a O 0 9.483964724665839e-09
Rsal O 0 1.3694480003323406e-06
restriction O 0 4.85028465391224e-07
site O 0 4.052905353546521e-07
. O 0 9.868841743809753e-08

We O 0 4.953467964696756e-07
have O 0 1.3313197655406839e-08
studied O 0 4.929703756317849e-09
the O 0 6.043914257958249e-10
codon O 0 6.327791624016754e-08
282 O 0 1.4769689471449965e-07
( O 0 4.4430468193468187e-08
Cys O 0 0.0009705015108920634
/ O 0 6.632905751757789e-06
Tyr O 0 8.077689017227385e-06
) O 0 6.599667923268271e-09
polymorphism O 0 1.4512100960928365e-06
in O 0 2.952466049421787e-09
different O 0 1.1658085607990643e-09
ethnic O 0 3.087421163172621e-08
groups O 0 3.757583044716739e-08
. O 0 7.470024598887903e-08

In O 0 4.6186281110749405e-07
agreement O 0 1.6667177860085758e-08
with O 0 2.007662480707495e-09
previous O 0 5.157060112281897e-09
observations O 0 1.8805653922981946e-08
the O 0 2.1761152879662404e-09
Tyr O 0 2.283864432683913e-06
allele O 0 4.042000796289358e-07
appeared O 0 1.150995316834269e-07
to O 0 1.1424706736207213e-09
be O 0 2.8608644342398293e-09
rare O 0 2.385100827950737e-08
or O 0 9.228644515246742e-09
absent O 0 1.2331241805441095e-07
in O 0 1.0658554039366663e-08
Asiatic O 0 8.908565973797522e-08
( O 0 3.613380705758118e-10
Indian O 0 1.597872278935597e-09
, O 0 1.1251659604027964e-09
Chinese O 0 1.7001445806741344e-09
) O 0 4.079096171949459e-09
populations O 0 3.2611346512112505e-08
. O 0 3.1600528416220186e-08

The O 0 3.257818548263458e-07
highest O 0 1.4241767587463983e-07
allele O 0 6.942736376913672e-07
frequency O 0 3.0254486205194553e-07
( O 0 1.2882731548202742e-09
7 O 0 7.3049433169103395e-09
. O 0 1.2059440113176834e-09
5 O 0 3.6294625083144183e-09
% O 0 7.541194890769987e-10
) O 0 2.6106150574634057e-10
was O 0 3.665487469106665e-08
found O 0 4.503476258577166e-09
in O 0 7.150902980868068e-09
Swedes O 0 0.0005422130925580859
. O 0 3.5668222153617535e-07

Saamis O 0 0.00041788819362409413
( O 0 4.444971182238078e-07
2 O 0 1.599828607368181e-07
% O 0 6.011645403702914e-09
) O 0 7.47372275178293e-10
and O 0 7.422994663386362e-09
Mordvinians O 0 1.0535461569816107e-06
( O 0 4.5725875863489307e-10
1 O 0 1.19501752937623e-09
. O 0 9.051833171902501e-10
8 O 0 2.8053053213739076e-09
% O 0 6.218309756000906e-10
) O 0 2.0743567974434995e-10
had O 0 2.958579443657072e-07
significantly O 0 3.9672022467129864e-07
lower O 0 5.8101868205540086e-08
frequencies O 0 3.1939990208229574e-08
of O 0 5.632784794151746e-10
the O 0 9.402445044770502e-09
Tyr O 0 5.9186804719502106e-05
allele O 0 8.32411660667276e-06
. O 0 2.484289041149168e-07

Comparisons O 0 1.5094948139449116e-05
with O 0 8.885571389782854e-08
allele O 0 1.589206817698141e-06
frequencies O 0 1.6577018868701998e-07
based O 0 1.4279188498278472e-08
on O 0 7.205396457266033e-08
prevalence O 0 3.6110184282733826e-06
estimates O 0 3.4183244679297786e-08
of O 0 2.425336598221861e-09
HH B-Disease 1 0.6380277872085571
showed O 0 1.7170648789033294e-05
some O 0 2.0934123323712583e-09
disagreements O 0 7.072341645653069e-08
with O 0 2.473200089170291e-09
the O 0 3.5447504931340745e-09
RFLP O 0 2.4698067136341706e-05
data O 0 1.1740141303562268e-08
, O 0 6.40376807137244e-10
particularly O 0 2.212645178190087e-09
in O 0 5.056301155548226e-09
Finns O 0 3.3859705581562594e-05
. O 0 1.9400228268295905e-07

The O 0 3.987974821484386e-07
newly O 0 4.64797665244987e-07
described O 0 1.2553454098451766e-06
HFE O 0 1.8276819901075214e-05
marker O 0 9.930829492077464e-07
provides O 0 5.613749909372245e-09
a O 0 2.0091026620150387e-09
new O 0 1.0074733269860303e-09
approach O 0 6.2521592347764e-09
to O 0 1.3130008191808429e-09
the O 0 3.529797842904969e-10
screening O 0 6.528031892827357e-09
of O 0 1.2123601011992946e-09
HH B-Disease 0 0.006627919618040323
as O 0 8.82249651112943e-08
well O 0 4.150506160982559e-09
as O 0 1.6651982015503108e-09
studies O 0 1.4757361999073737e-10
of O 0 1.574520895608611e-11
the O 0 1.809444816203154e-10
relationship O 0 1.715535824509118e-09
between O 0 7.713980010315424e-10
the O 0 1.0507989145480678e-08
HFE O 0 0.0008218728471547365
Tyr O 0 4.399908721097745e-05
allele O 0 1.086609017875162e-06
and O 0 5.355390797490145e-09
different O 0 1.782610681289043e-08
disorders O 0 0.0009280306403525174
including O 0 6.543506970047019e-06
cancer B-Disease 1 0.5372085571289062

Autosomal B-Disease 1 0.9998657703399658
dominant I-Disease 1 0.9991596937179565
neurohypophyseal I-Disease 1 0.9998971223831177
diabetes I-Disease 1 0.9999966621398926
insipidus I-Disease 1 0.9977566599845886
associated O 0 1.906303964460676e-06
with O 0 1.2577399566282566e-08
a O 0 6.039622348907869e-07
missense O 0 0.0002970564819406718
mutation O 0 3.9475198718719184e-06
encoding O 0 3.229554010886204e-07
Gly23 O 0 4.381401140562957e-06
- O 0 2.8499134714365937e-06
- O 0 2.0272076653782278e-05
> O 0 1.2383914054225897e-06
Val O 0 1.384662482450949e-05
in O 0 3.9784545435850305e-08
neurophysin O 0 2.3282269467017613e-05
II O 0 0.00013115206093061715
. O 0 3.5249345842203184e-07

Autosomal B-Disease 1 0.9997833371162415
dominant I-Disease 1 0.9988036155700684
neurohypophyseal I-Disease 1 0.9999111890792847
diabetes I-Disease 1 0.9999977350234985
insipidus I-Disease 1 0.9995792508125305
( O 0 7.974200002536236e-07
ADNDI B-Disease 0 0.00045333217713050544
) O 0 2.3827592343650394e-08
is O 0 2.034609636325513e-08
an O 0 1.6408486089858343e-06
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
caused O 0 0.0029956286307424307
by O 0 2.2514296915687737e-07
progressive O 0 0.1998441368341446
degeneration O 0 0.08287540823221207
of O 0 1.5325842817048851e-09
the O 0 6.44305009345203e-09
magnocellular O 0 9.675871979197836e-07
neurons O 0 6.866735446919847e-08
of O 0 1.5947961007345413e-10
the O 0 7.982701166753259e-10
hypothalamus O 0 1.1841571989634758e-07
leading O 0 1.4893189792530848e-08
to O 0 7.626948850258941e-09
decreased O 0 1.244214047346759e-07
ability O 0 9.825714464284374e-09
to O 0 4.8880295366871e-09
produce O 0 3.287013328190369e-08
the O 0 1.706705177184631e-08
hormone O 0 7.18139915534266e-07
arginine O 0 6.696175205433974e-07
vasopressin O 0 1.1200638709851773e-06
( O 0 6.301075661241384e-09
AVP O 0 1.9676097053888952e-06
) O 0 4.331572256432992e-08
. O 0 9.771556364057687e-08

Affected O 0 2.5747844119905494e-05
individuals O 0 1.5298344635539252e-07
are O 0 4.540875675473899e-09
not O 0 1.9953633412228555e-08
symptomatic O 0 5.219488230068237e-06
at O 0 1.1745359351778006e-08
birth O 0 2.988975040807418e-07
, O 0 3.0566522646324756e-09
but O 0 1.930972004515752e-08
usually O 0 3.661602931970265e-07
develop O 0 3.5841412682202645e-06
diabetes B-Disease 1 0.8143861889839172
insipidus I-Disease 0 0.0001159152525360696
at O 0 8.139249274563554e-09
1 O 0 1.1214043915686034e-08
- O 0 5.38431368113379e-06
6 O 0 1.6907503663787793e-07
yr O 0 3.662846438601264e-06
of O 0 3.259572389779919e-09
age O 0 8.782286897712765e-08
. O 0 3.9223515102548845e-08

The O 0 2.2417926004436595e-07
genetic O 0 6.361779014696367e-07
locus O 0 2.460930090819602e-07
of O 0 1.8293996317808592e-09
the O 0 2.9753064012538744e-08
disease O 0 2.423045771138277e-06
is O 0 1.1743209071823912e-08
the O 0 8.281264562981505e-09
AVP O 0 2.7947386115556583e-05
- O 0 0.0010806280188262463
neurophysin O 0 0.002488680649548769
II O 0 0.0005601387238129973
( O 0 4.113473117683952e-09
NPII O 0 1.731158590700943e-06
) O 0 1.3167074097708564e-09
gene O 0 7.6377943969419e-09
, O 0 9.43178979362358e-10
and O 0 5.360704768975211e-09
mutations O 0 1.505296722825733e-07
that O 0 3.203431120368805e-08
cause O 0 5.645944725074514e-07
ADNDI B-Disease 0 7.147774158511311e-05
have O 0 6.741052516190393e-08
been O 0 1.0044594489500014e-08
found O 0 1.3028003120751919e-09
in O 0 1.0206773620735632e-10
both O 0 1.8065136886402655e-10
the O 0 1.3073674087760168e-10
signal O 0 3.941993753642237e-08
peptide O 0 1.8228688558608042e-09
of O 0 5.808338879309538e-11
the O 0 5.643248091047326e-10
prepro O 0 1.0705230124585796e-06
- O 0 2.316624431841774e-06
AVP O 0 4.081973202119116e-06
- O 0 1.7211992826560163e-06
NPII O 0 1.7604571667106939e-06
precursor O 0 2.2605769700589917e-08
and O 0 4.287005861414173e-09
within O 0 2.6741060477064593e-09
NPII O 0 3.952119186578784e-06
itself O 0 3.4791165148817527e-07
. O 0 6.952794961989639e-08

An O 0 1.1131528481200803e-06
affected O 0 3.7858956147829304e-07
girl O 0 1.7622646737436298e-06
who O 0 9.075334617136832e-08
presented O 0 5.4263575854918145e-09
at O 0 2.532013487765994e-10
9 O 0 1.952090045165278e-09
months O 0 4.4229717666155466e-09
of O 0 1.9306166387789148e-10
age O 0 9.057156802327881e-09
and O 0 1.1913035002919514e-09
her O 0 5.2940411165991463e-08
similarly O 0 5.078601930108562e-07
affected O 0 3.116583968676423e-08
younger O 0 4.566164761854452e-07
brother O 0 3.195391684585047e-07
and O 0 1.836906626806467e-09
father O 0 6.774397576236879e-08
were O 0 1.1428934465484986e-09
all O 0 3.266894740838744e-11
found O 0 3.0822402963259776e-10
to O 0 1.023709561565056e-09
have O 0 8.354163583135232e-09
a O 0 4.697395894481815e-08
novel O 0 1.0878418379434152e-06
missense O 0 6.620461590500781e-06
mutation O 0 3.82461649905963e-07
( O 0 3.242105695022701e-09
G1758 O 0 7.838391979930748e-07
- O 0 7.660909432161134e-06
- O 0 8.065176371019334e-05
> O 0 7.783544901940331e-07
T O 0 6.768804041712428e-07
) O 0 7.180762651159966e-10
encoding O 0 2.492493322847622e-09
the O 0 2.012369437753847e-10
amino O 0 1.2016687644944568e-09
acid O 0 9.277318469003148e-09
substitution O 0 1.0718818721500156e-08
Gly23 O 0 1.4914630810380913e-06
- O 0 2.540051582400338e-06
- O 0 3.153214493067935e-05
> O 0 1.373970235363231e-06
Val O 0 1.5851284842938185e-05
within O 0 3.5785692631407073e-08
NPII O 0 3.0747964046895504e-05
. O 0 2.182801495109743e-07

The O 0 1.0812904065460316e-06
mutation O 0 1.3347133972274605e-05
was O 0 1.1350265367582324e-06
confirmed O 0 1.1107377417829412e-07
by O 0 9.517053811691767e-09
restriction O 0 3.4568847695481963e-07
endonuclease O 0 9.919056174112484e-05
analysis O 0 1.0796376272992347e-06
. O 0 2.8141610641796433e-07

A O 0 8.906694347388111e-06
T1 O 0 0.00013322054292075336
- O 0 5.339367362466874e-06
weighted O 0 3.776837047553272e-07
magnetic O 0 5.359171154850628e-06
resonance O 0 3.828495209745597e-06
imaging O 0 1.4458252053373144e-06
of O 0 1.7360858306503246e-09
the O 0 1.2330272802785203e-08
fathers O 0 8.05422075700335e-07
pituitary O 0 8.267630846603424e-07
gland O 0 4.7490607357758563e-07
demonstrates O 0 1.5710200784724293e-07
an O 0 1.9760248548550408e-08
attenuated O 0 7.215265213744715e-05
posterior O 0 1.3452175153361168e-05
pituitary O 0 5.186890120967291e-05
bright O 0 1.1800319953181315e-05
spot O 0 4.6642871893709525e-06
. O 0 4.978787160325737e-07

This O 0 5.832003466821334e-07
mutation O 0 1.3909238987253048e-05
may O 0 2.2196698523657687e-07
be O 0 1.1134200228468671e-09
valuable O 0 1.0587106746839936e-09
for O 0 5.962641491663589e-10
developing O 0 3.0387536931186787e-09
models O 0 4.4972551904720603e-08
of O 0 3.031072282055902e-09
dominantly B-Disease 0 0.004791004583239555
inherited I-Disease 1 0.8092393279075623
neurodegeneration I-Disease 1 0.9999997615814209
, O 0 1.3067903203989317e-08
as O 0 6.584375267237874e-10
the O 0 2.9387783873069395e-10
early O 0 4.938512265795225e-09
age O 0 2.6287840793060013e-09
of O 0 1.5115335372239969e-10
onset O 0 1.1542159938926488e-07
of O 0 1.5855531998454353e-08
symptoms O 0 0.008141271770000458
suggests O 0 1.7082227188325305e-08
that O 0 1.057505749635368e-09
this O 0 8.905992610053204e-10
mutation O 0 5.574104733341301e-08
may O 0 2.1084884949118532e-08
be O 0 2.7215896203358625e-09
particularly O 0 4.164844025211778e-09
deleterious O 0 4.34989090081217e-07
to O 0 1.1683824574504342e-08
the O 0 3.377293111839208e-09
magnocellular O 0 2.926687784565729e-06
neuron O 0 5.465741196530871e-06
. O 0 1.2364988144497602e-08
. O 0 7.701755322386816e-08

Frequent O 0 0.0002493575739208609
inactivation O 0 0.0006369476905092597
of O 0 4.902466912426462e-07
PTEN O 0 0.0022088258992880583
/ O 0 1.2377076018310618e-05
MMAC1 O 0 3.600999843911268e-05
in O 0 5.426406346487056e-07
primary O 0 0.39957526326179504
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 3.5210409805586096e-06

Sporadic B-Disease 1 0.9977779984474182
prostate I-Disease 1 0.9999939203262329
carcinoma I-Disease 1 1.0
is O 0 7.111270292625704e-07
the O 0 4.903521588772719e-09
most O 0 9.357396635323312e-09
common O 0 8.029957143662614e-08
male B-Disease 0 0.0006562515045516193
cancer I-Disease 0 1.8181008272222243e-06
in O 0 1.3985940183758316e-09
the O 0 1.5354839622006011e-09
Western O 0 5.606003217195621e-09
world O 0 1.788580061834466e-09
, O 0 6.297468102545167e-10
yet O 0 1.6192812646309562e-09
many O 0 4.2552867479672685e-11
of O 0 9.057453571881258e-12
the O 0 3.280663241067572e-11
major O 0 4.2770556540894233e-10
genetic O 0 2.7592752527283437e-09
events O 0 2.9252228417320225e-10
involved O 0 6.259744944614454e-10
in O 0 2.4969742939973116e-10
the O 0 5.541830327970843e-10
progression O 0 2.8124969020382196e-08
of O 0 2.1835981633966384e-10
this O 0 2.0080721530035817e-09
often O 0 1.1147654959131614e-06
fatal O 0 0.46151992678642273
cancer B-Disease 0 0.013890714384615421
remain O 0 9.388148924927009e-08
to O 0 1.5216535587114777e-08
be O 0 9.963294900217079e-08
elucidated O 0 2.345187203900423e-05
. O 0 2.439381887597847e-07

Numerous O 0 1.0027827556768898e-05
cytogenetic O 0 0.0009374959045089781
and O 0 2.655687865171785e-07
allelotype O 0 7.220457973744487e-06
studies O 0 1.912896152589383e-08
have O 0 1.570084862123622e-08
reported O 0 8.220883529475032e-08
frequent O 0 2.6720584855866036e-07
loss O 0 5.257944621916977e-07
of O 0 3.5915321827673097e-09
heterozygosity O 0 6.584220045624534e-06
on O 0 1.798327105007047e-07
chromosomal O 0 7.119177462300286e-05
arm O 0 1.4319453839561902e-05
10q O 0 4.074086064065341e-06
in O 0 1.204212054517484e-07
sporadic B-Disease 1 0.8035051226615906
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
. O 0 3.112713329755934e-06

Deletion O 0 0.0002919715188909322
mapping O 0 4.126880867261207e-06
studies O 0 1.5294013167022058e-07
have O 0 4.294340527621898e-08
unambiguously O 0 4.8263786993629765e-06
identified O 0 7.549908787041204e-08
a O 0 7.494310061417764e-09
region O 0 2.323148340366288e-09
of O 0 4.158944022503164e-10
chromosome O 0 1.3115230785842868e-06
10q23 O 0 1.271001792702009e-07
to O 0 2.5018667137999273e-09
be O 0 2.0136374789814226e-09
the O 0 8.271220930389234e-10
minimal O 0 1.562559930334828e-07
area O 0 1.2476760957724764e-08
of O 0 2.0859032279219036e-09
loss O 0 3.356797606102191e-06
. O 0 4.6490006866406475e-07

A O 0 5.711512130801566e-06
new O 0 3.9101615811887314e-07
tumor B-Disease 0 5.1214983614045195e-06
suppressor O 0 1.3299169950187206e-05
gene O 0 1.3272245951156947e-06
, O 0 5.9360711901490504e-08
PTEN O 0 0.00020964948635082692
/ O 0 1.922719775393489e-06
MMAC1 O 0 6.989856774453074e-05
, O 0 1.7080534320257357e-08
was O 0 1.7803823482154257e-07
isolated O 0 3.935645764840956e-08
recently O 0 2.1378399495119993e-08
at O 0 2.1596532895351572e-10
this O 0 2.170816304492007e-10
region O 0 7.798942047720914e-10
of O 0 1.5334139513711875e-10
chromosome O 0 4.2569740799081046e-07
10q23 O 0 1.4268439940678945e-07
and O 0 1.680359629219197e-09
found O 0 7.150053882298835e-10
to O 0 1.020975748389219e-09
be O 0 1.5599349589834333e-09
inactivated O 0 6.834969923374956e-08
by O 0 7.432213733338244e-10
mutation O 0 2.6072338954463703e-08
in O 0 9.443297699363029e-09
three O 0 4.287983392714523e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
cell O 0 0.0010561998933553696
lines O 0 2.1667065084329806e-05
. O 0 3.6141875625617104e-07

We O 0 5.3066441978444345e-06
screened O 0 5.6403026974294335e-05
80 O 0 8.605657967564184e-06
prostate B-Disease 1 0.9422651529312134
tumors I-Disease 1 0.9999940395355225
by O 0 3.2932884863612344e-08
microsatellite O 0 7.222317435662262e-06
analysis O 0 7.592306872084009e-08
and O 0 9.167835379741973e-09
found O 0 1.584857933778494e-08
chromosome O 0 4.4248307062844106e-07
10q23 O 0 8.441171672757264e-08
to O 0 2.0203545503250098e-09
be O 0 1.622471823559124e-09
deleted O 0 5.308580952601005e-08
in O 0 4.1313530374509355e-09
23 O 0 9.298491931986064e-08
cases O 0 1.559826472430359e-07
. O 0 2.2074071637234738e-07

We O 0 5.721275329051423e-07
then O 0 2.3133996052138173e-08
proceeded O 0 1.2387933345792135e-08
with O 0 2.388658715268832e-10
sequence O 0 4.810859488557639e-10
analysis O 0 2.4686841459953257e-10
of O 0 5.515443310399881e-11
the O 0 1.439070862474523e-09
entire O 0 3.631901890344125e-08
PTEN O 0 6.592239515157416e-05
/ O 0 6.684537083856412e-07
MMAC1 O 0 7.173984158725943e-06
coding O 0 4.945745217810327e-07
region O 0 3.0972774567317174e-08
and O 0 1.5302395794947188e-08
tested O 0 3.880249721532891e-08
for O 0 1.0900408353720081e-09
homozygous O 0 2.1971055730318767e-07
deletion O 0 5.992243501395933e-08
with O 0 9.949024937228046e-10
new O 0 3.92555277173301e-09
intragenic O 0 2.638164232848794e-06
markers O 0 2.3608623678228469e-07
in O 0 9.34804456065308e-10
these O 0 1.2725676068470193e-09
23 O 0 1.4503473089177987e-08
cases O 0 9.689113511512915e-09
with O 0 1.2486450096105273e-08
10q23 O 0 7.212021955638193e-06
loss O 0 4.1549844809196657e-07
of O 0 1.0319517684820312e-08
heterozygosity O 0 4.12729277741164e-05
. O 0 4.148301115947106e-07

The O 0 5.808148273445113e-08
identification O 0 2.216980554692327e-08
of O 0 1.7366048876699125e-10
the O 0 6.796638807315958e-10
second O 0 2.6542133824136727e-08
mutational O 0 5.59444970349432e-06
event O 0 3.359537004143931e-08
in O 0 3.3078038086387096e-09
10 O 0 3.134813519878321e-09
( O 0 1.404223293199891e-09
43 O 0 6.70048109441268e-07
% O 0 1.330487009454373e-08
) O 0 7.226385179137651e-08
tumors B-Disease 1 0.9999988079071045
establishes O 0 0.0002823378308676183
PTEN O 0 0.028371458873152733
/ O 0 5.211080065237184e-07
MMAC1 O 0 2.4280584511870984e-06
as O 0 3.827135053313668e-09
a O 0 6.28568663785245e-09
main O 0 1.1163976409989118e-08
inactivation O 0 1.051202730195655e-06
target O 0 9.922819899088609e-09
of O 0 3.360648703765179e-10
10q O 0 2.174059261506045e-07
loss O 0 7.104031141125233e-08
in O 0 2.327948855906925e-08
sporadic B-Disease 1 0.9913574457168579
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 1.9223588765271415e-07
. O 0 2.2429259161071968e-07

Risk O 0 9.820554259931669e-05
reversals O 0 2.3344029614236206e-05
in O 0 1.0746027356844934e-07
predictive O 0 3.531415359248058e-06
testing O 0 1.1226668448216515e-06
for O 0 1.2905311450595036e-06
Huntington B-Disease 1 0.9999923706054688
disease I-Disease 1 0.9999639987945557
. O 0 2.4612991182948463e-06

The O 0 4.887398219466377e-08
first O 0 1.9773445103510312e-08
predictive O 0 1.5774396899814747e-07
testing O 0 1.3444440583043615e-07
for O 0 4.770022314914968e-07
Huntington B-Disease 1 0.9999970197677612
disease I-Disease 1 0.9999909400939941
( O 0 2.375136354260121e-08
HD B-Disease 0 6.744506208633538e-06
) O 0 2.1273847128355783e-09
was O 0 2.312709881380215e-07
based O 0 1.868187382569886e-09
on O 0 7.327028983539208e-10
analysis O 0 5.382340129145291e-10
of O 0 1.0528040245150194e-10
linked O 0 7.802163537462548e-08
polymorphic O 0 9.509750498182257e-07
DNA O 0 1.2298123408527317e-07
markers O 0 8.452223454469276e-08
to O 0 3.408309634522766e-09
estimate O 0 3.483263899539679e-09
the O 0 2.3019181005778933e-10
likelihood O 0 2.117022557257542e-09
of O 0 1.5712156575808933e-10
inheriting O 0 2.7820426851121738e-08
the O 0 4.181392121438421e-09
mutation O 0 1.567302945204574e-07
for O 0 1.3449692914946354e-08
HD B-Disease 0 5.3261865105014294e-05
. O 0 2.284260176566022e-07

Limits O 0 9.90733269645716e-07
to O 0 2.8471587754097527e-08
accuracy O 0 5.165637873005835e-08
included O 0 3.2984919240419686e-09
recombination O 0 5.895290922097729e-09
between O 0 8.285179209366333e-10
the O 0 7.407588986652058e-10
DNA O 0 8.146786001361761e-08
markers O 0 3.1124113775149453e-07
and O 0 3.9586813826986145e-09
the O 0 1.6003611769122017e-09
mutation O 0 4.390346077798313e-07
, O 0 3.762357536629679e-09
pedigree O 0 4.122815369100863e-07
structure O 0 2.777578345103393e-08
, O 0 6.403743091354386e-10
and O 0 5.141284620258091e-10
whether O 0 1.857241138658594e-09
DNA O 0 9.355005659017479e-09
samples O 0 3.2174887198976876e-09
were O 0 1.2244630864799433e-09
available O 0 4.1127179439826023e-10
from O 0 4.2754080831208796e-10
family O 0 1.3102895657368663e-08
members O 0 6.454673684430645e-09
. O 0 2.9030259085516263e-08

With O 0 2.405736836408323e-07
direct O 0 1.0299091712795416e-07
tests O 0 2.9346420404863238e-08
for O 0 5.060505348097877e-10
the O 0 2.5582869156437482e-09
HD B-Disease 0 2.0551799025270157e-05
mutation O 0 6.556209797281554e-08
, O 0 7.564763815359754e-10
we O 0 4.038050727128706e-10
have O 0 1.1447042203016622e-09
assessed O 0 9.59953005974512e-09
the O 0 8.520652516885718e-10
accuracy O 0 3.140932136602714e-08
of O 0 3.6084907284461565e-10
results O 0 1.0473192979532087e-08
obtained O 0 2.814405597462155e-09
by O 0 3.83430814876462e-10
linkage O 0 4.113836027386242e-08
approaches O 0 1.0749692691547352e-08
when O 0 4.326220270911563e-09
requested O 0 2.328334192114312e-09
to O 0 1.06362296747875e-09
do O 0 1.6523655776978785e-09
so O 0 9.752015861508312e-10
by O 0 1.9473847534534627e-10
the O 0 6.577521860506863e-10
test O 0 4.1001587902655956e-08
individuals O 0 9.100395992334143e-09
. O 0 4.891828098152473e-08

For O 0 2.506702685423079e-07
six O 0 1.8415766689372504e-08
such O 0 9.905418707489844e-10
individuals O 0 8.370810711255672e-10
, O 0 8.601955814313555e-10
there O 0 1.4350743926527798e-09
was O 0 7.198060814062046e-08
significant O 0 1.13637739218575e-08
disparity O 0 6.114347428365363e-08
between O 0 1.0533849348348667e-09
the O 0 3.0621138957798166e-09
tests O 0 1.8973807414113253e-07
. O 0 6.101706873096191e-08

Three O 0 3.869511431275896e-07
went O 0 4.6317282453856023e-08
from O 0 4.976503098497176e-10
a O 0 1.986825992617014e-08
decreased O 0 4.210742758914421e-07
risk O 0 1.0749200640702838e-08
to O 0 1.8436845383718037e-09
an O 0 1.3217152705635726e-08
increased O 0 1.9907729438273236e-06
risk O 0 1.2475670985168108e-07
, O 0 1.2195404686110578e-09
while O 0 9.497754804854708e-10
in O 0 1.1786865927732038e-10
another O 0 1.2093160917103773e-09
three O 0 2.9110297505852145e-10
the O 0 1.7421660780669868e-09
risk O 0 4.876456927149775e-08
was O 0 6.301198141045461e-07
decreased O 0 8.934820243666763e-07
. O 0 7.805630986013057e-08

Knowledge O 0 1.1098669574494124e-06
of O 0 4.98245045221779e-09
the O 0 8.803980877658546e-10
potential O 0 2.3189203890439103e-09
reasons O 0 2.477992921967598e-09
for O 0 3.781550350634433e-10
these O 0 2.2918156261653166e-10
changes O 0 1.9404893247809696e-09
in O 0 1.1783813924637343e-09
results O 0 8.493753256288983e-09
and O 0 1.4313239482532936e-09
impact O 0 2.458498071788995e-09
of O 0 6.844548539053363e-11
these O 0 2.691389611175765e-10
risk O 0 2.6823816501320152e-09
reversals O 0 1.5605226622028567e-07
on O 0 5.408360692626957e-08
both O 0 5.005905379107389e-08
patients O 0 9.924392543325666e-07
and O 0 9.76282943376816e-10
the O 0 4.4580164559882007e-10
counseling O 0 3.217716093573131e-09
team O 0 2.0912881149026674e-10
can O 0 2.1017410034573913e-10
assist O 0 4.313528978450165e-10
in O 0 1.3748895077991818e-10
the O 0 6.300396315772616e-11
development O 0 4.0729503103520415e-11
of O 0 3.0422941943442083e-11
strategies O 0 7.128021506375148e-10
for O 0 2.763139439476703e-10
the O 0 1.361328827442776e-09
prevention O 0 1.4006049653403352e-08
and O 0 4.631169225888243e-09
, O 0 5.508948852650519e-10
where O 0 8.193933864752978e-10
necessary O 0 1.95082461296181e-09
, O 0 4.0120332056581276e-10
management O 0 1.494182971795155e-10
of O 0 2.198692616861564e-11
a O 0 6.053793466520574e-09
risk O 0 1.36644660031493e-08
reversal O 0 6.721101897255721e-08
in O 0 6.205134184256167e-10
any O 0 6.8827393784332e-10
predictive O 0 3.398917769459331e-08
testing O 0 7.693617298798472e-09
program O 0 7.515090216791975e-10
. O 0 8.702074616451227e-10
. O 0 1.9784271998446457e-08

A O 0 6.710189154546242e-06
novel O 0 3.2123327855515527e-06
common O 0 2.615442724618333e-07
missense O 0 1.902293115563225e-05
mutation O 0 1.3164265055820579e-06
G301C O 0 2.959115761314024e-07
in O 0 1.0906647807118475e-09
the O 0 9.536929024278606e-10
N O 0 1.7347779248666484e-06
- O 0 1.6171688912436366e-05
acetylgalactosamine O 0 0.00010289193596690893
- O 0 1.1084748621215113e-05
6 O 0 3.0098104275566584e-07
- O 0 4.465496022021398e-05
sulfate O 0 0.00011368683044565842
sulfatase O 0 8.803685886960011e-06
gene O 0 2.1745113087945356e-07
in O 0 3.9566224074860656e-08
mucopolysaccharidosis B-Disease 0 3.3396507205907255e-05
IVA I-Disease 0 0.00013544224202632904
. O 0 7.275842222043138e-07

Mucopolysaccharidosis B-Disease 1 0.5335643291473389
IVA I-Disease 1 0.9857354760169983
( O 0 0.000827670912258327
MPS B-Disease 1 0.9999978542327881
IVA I-Disease 1 0.9999803304672241
) O 0 8.247928917626268e-08
is O 0 4.1487748347890374e-08
an O 0 3.03241563415213e-07
autosomal B-Disease 1 0.9986518025398254
recessive I-Disease 1 0.9999097585678101
lysosomal I-Disease 1 0.9996887445449829
storage I-Disease 1 0.9982067346572876
disorder I-Disease 1 0.9997155070304871
caused O 0 7.67968776926864e-06
by O 0 1.7343392499924448e-08
a O 0 1.713332130748313e-05
genetic B-Disease 1 0.9999970197677612
defect I-Disease 1 0.9999964237213135
in O 0 1.4477097920462256e-07
N O 0 9.538130143482704e-06
- O 0 1.120472006732598e-05
acetylgalactosamine O 0 0.00031040149042382836
- O 0 7.933592132758349e-05
6 O 0 9.4567167252535e-07
- O 0 0.022737128660082817
sulfate O 0 0.08402987569570541
sulfatase O 0 4.467463804758154e-05
( O 0 1.161224272294703e-08
GALNS O 0 5.071204668638529e-06
) O 0 3.013721894262744e-08
. O 0 6.90971049266409e-08

In O 0 3.697708734762273e-07
previous O 0 5.874685271578528e-08
studies O 0 5.567981631315888e-09
, O 0 5.175543882351974e-10
we O 0 5.853852402815107e-10
have O 0 1.3500935924781743e-09
found O 0 1.5320640311955458e-09
two O 0 4.771746331400095e-10
common O 0 4.1173584541809305e-09
mutations O 0 5.47307301701494e-08
in O 0 3.1663682786842173e-09
Caucasians O 0 1.5366381944659224e-07
and O 0 6.791471829359352e-09
Japanese O 0 3.974745510504363e-08
, O 0 3.704889728339822e-09
respectively O 0 5.590000995425726e-08
. O 0 5.206350905950785e-08

To O 0 4.5839709628126e-07
characterize O 0 1.3264667586554424e-06
the O 0 1.7231974069886746e-08
mutational O 0 4.033479854115285e-05
spectrum O 0 1.0400781320640817e-06
in O 0 1.2099529156373023e-09
various O 0 4.692850552601158e-10
ethnic O 0 5.010927672799426e-09
groups O 0 1.0073888390138563e-09
, O 0 9.858166505338772e-10
mutations O 0 2.1094379576425126e-08
in O 0 4.4958958778096303e-10
the O 0 1.1095234730973402e-09
GALNS O 0 4.553902726911474e-06
gene O 0 5.057847118905556e-08
in O 0 8.34498958823815e-09
Colombian O 0 3.9322876546066254e-06
MPS B-Disease 1 0.9999977350234985
IVA I-Disease 1 0.9999988079071045
patients O 1 0.9624529480934143
were O 0 1.3501656326297962e-07
investigated O 0 1.1244569009249972e-07
, O 0 1.974942653859557e-09
and O 0 6.630302085142148e-09
genetic O 0 6.427978860301664e-08
backgrounds O 0 1.7123198858826072e-08
were O 0 5.877730746561838e-09
extensively O 0 1.3538514309630045e-08
analyzed O 0 1.791004677897945e-08
to O 0 1.907131785827687e-09
identify O 0 2.2015074208070473e-08
racial O 0 2.0310036319415303e-08
origin O 0 8.906981818768145e-09
, O 0 1.4462525621539157e-09
based O 0 1.1674863298338778e-09
on O 0 7.945670787989911e-09
mitochondrial O 0 1.7632195294936537e-06
DNA O 0 5.48010291367973e-07
( O 0 2.9013971225566593e-09
mtDNA O 0 9.639053644150408e-08
) O 0 6.718035461261707e-09
lineages O 0 1.1711428271610203e-07
. O 0 6.067274682663992e-08

Three O 0 1.1663349823720637e-06
novel O 0 3.0739884095964953e-06
missense O 0 4.0588925912743434e-05
mutations O 0 7.430826826748671e-06
never O 0 2.903993276959227e-07
identified O 0 2.9182929850435357e-08
previously O 0 1.2245243929953631e-08
in O 0 4.460704028375062e-10
other O 0 4.1448164345148086e-10
populations O 0 2.291663969700153e-09
and O 0 4.082193694188163e-09
found O 0 4.825069233049817e-09
in O 0 7.727896100817588e-10
16 O 0 1.0658954829878553e-09
out O 0 7.821853720280103e-10
of O 0 5.471815223145882e-10
19 O 0 4.4318660741282656e-08
Colombian O 0 7.228852609841852e-07
MPS B-Disease 1 0.9999619722366333
IVA I-Disease 1 0.9995201826095581
unrelated O 0 1.388099462928949e-06
alleles O 0 2.7028079330193577e-07
account O 0 5.354167598170534e-08
for O 0 9.499933284473627e-09
84 O 0 4.414558816279168e-07
. O 0 1.1384453557639063e-07

2 O 0 1.5603411611664342e-06
% O 0 2.2824476531013715e-08
of O 0 3.439215578993071e-10
the O 0 1.5114275386807208e-09
alleles O 0 5.384994850032854e-08
in O 0 2.4615667282290588e-09
this O 0 4.359202776527127e-09
study O 0 4.8408715258574375e-08
. O 0 1.0393497262839446e-07

The O 0 9.133305525210744e-07
G301C O 0 5.3763205869472586e-06
and O 0 3.746662358139474e-08
S162F O 0 1.2745208550768439e-06
mutations O 0 3.534599102295033e-07
account O 0 1.6306071159988278e-08
for O 0 5.531240798717363e-09
68 O 0 7.162425390561111e-07
. O 0 1.6661718404975545e-07

4 O 0 6.229989139683312e-06
% O 0 1.3161537992800731e-07
and O 0 1.4290550964801696e-08
10 O 0 3.384465685485338e-08
. O 0 8.800681428056123e-08

5 O 0 1.0009911193264998e-06
% O 0 4.991204249904513e-08
of O 0 1.4549208504632816e-09
mutations O 0 3.8599620211243746e-07
, O 0 6.563201093712223e-09
respectively O 0 3.2916180003894624e-08
, O 0 2.575741842036905e-09
whereas O 0 4.023783528595004e-09
the O 0 3.68363617386791e-10
remaining O 0 3.1410258838349137e-09
F69V O 0 2.8627653136936715e-06
is O 0 2.9554974023682234e-09
limited O 0 1.1016977330413624e-09
to O 0 5.294994998017444e-10
a O 0 1.9534580175673e-08
single O 0 5.630545274470933e-07
allele O 0 2.6302234346076148e-06
. O 0 1.1352275208764695e-07

The O 0 7.023108423709346e-07
skewed O 0 1.1411151717766188e-05
prevalence O 0 1.7100733202823903e-06
of O 0 1.264691351643421e-09
G301C O 0 2.1134334815542388e-07
in O 0 2.272577015460797e-09
only O 0 3.6015341819961577e-09
Colombian O 0 2.2540656630098965e-07
patients O 0 3.0655795853817835e-05
and O 0 2.976714164049099e-08
haplotype O 0 4.971534144715406e-05
analysis O 0 3.2615934397739466e-09
by O 0 5.915404832634863e-10
restriction O 0 7.042633143328203e-08
fragment O 0 7.890066626714543e-07
length O 0 1.5644594952846091e-07
polymorphisms O 0 1.1397685284464387e-07
in O 0 9.143488188811943e-10
the O 0 9.84773596002242e-10
GALNS O 0 4.664211701310705e-06
gene O 0 3.612874266423205e-08
suggest O 0 1.2343450705998293e-08
that O 0 3.067316178828605e-09
G301C O 0 1.3971208545626723e-07
originated O 0 2.665377918376066e-09
from O 0 9.629889247131374e-11
a O 0 3.815036730969723e-09
common O 0 1.555665996022526e-08
ancestor O 0 1.895886612146569e-07
. O 0 1.0855291776579179e-07

Investigation O 0 1.1670905450955615e-06
of O 0 5.4531055226902936e-09
the O 0 2.010712929489955e-09
genetic O 0 4.5104673773721515e-08
background O 0 4.623175797746626e-08
by O 0 2.5556730065545707e-09
means O 0 1.3862920811291701e-09
of O 0 2.6196131375222365e-10
mtDNA O 0 2.5340934683981686e-08
lineages O 0 5.861665375306302e-09
indicate O 0 6.1781411098138506e-09
that O 0 1.031541851936879e-09
all O 0 1.5776720208027228e-10
our O 0 1.4887928667661754e-09
patients O 0 8.08007243335851e-08
are O 0 1.996739579235296e-10
probably O 0 5.228499855292057e-09
of O 0 2.944557653261626e-10
native O 0 1.1817221867715944e-08
American O 0 1.3330378578757518e-07
descent O 0 7.832008850527927e-05

Low O 0 3.579453914426267e-05
frequency O 0 3.3603944302740274e-06
of O 0 1.3146854271894881e-08
BRCA1 O 0 1.2325414900260512e-05
germline O 0 7.260507118189707e-06
mutations O 0 3.5124755868309876e-06
in O 0 2.451190361796307e-08
45 O 0 1.0702351573854685e-06
German O 1 0.9980407357215881
breast B-Disease 1 0.9999985694885254
/ I-Disease 1 0.9999977350234985
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 4.028918283438543e-06
. O 0 3.9461770029447507e-07

In O 0 7.770707810550448e-08
this O 0 1.7119141659804882e-09
study O 0 1.797914261914002e-09
we O 0 6.33967267571478e-10
investigated O 0 3.4083701194731475e-08
45 O 0 1.1187300685833179e-07
German O 1 0.7743656635284424
breast B-Disease 1 0.9999935626983643
/ I-Disease 1 0.9999967813491821
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.1748254280519177e-07
for O 0 8.110332849753377e-09
germline O 0 5.072162821306847e-06
mutations O 0 8.587846878072014e-07
in O 0 3.769209389048456e-09
the O 0 2.1727776911006913e-08
BRCA1 O 0 2.0254685296094976e-05
gene O 0 2.3310115011554444e-06
. O 0 2.5808461145970796e-07

We O 0 1.1080373951699585e-06
identified O 0 3.346459322983719e-07
four O 0 1.1782157471884602e-08
germline O 0 1.0777047236842918e-06
mutations O 0 9.850390370047535e-07
in O 0 8.0609208197302e-09
three O 0 6.741141760358005e-07
breast B-Disease 1 0.9923322200775146
cancer I-Disease 0 0.0010409033857285976
families O 0 7.688864656074657e-09
and O 0 2.783591357413684e-09
in O 0 3.533100256802868e-09
one O 0 1.5286201232811436e-05
breast B-Disease 1 0.9999881982803345
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 5.108412324261735e-07
. O 0 8.051634914352235e-10
among O 0 1.6882037434662323e-10
these O 0 7.988758959909248e-11
were O 0 2.7683635384079253e-09
one O 0 1.2114499625681674e-08
frameshift O 0 0.00017766142264008522
mutation O 0 1.3820218214277702e-07
, O 0 1.308942509936628e-09
one O 0 5.410896175561675e-09
nonsense O 0 9.185059752780944e-07
mutation O 0 2.6953023279929766e-07
, O 0 8.734017953315742e-10
one O 0 8.295473197250658e-10
novel O 0 8.803112017119474e-09
splice O 0 2.6618363335728645e-07
site O 0 9.898552377762826e-08
mutation O 0 1.0973052866347643e-07
, O 0 1.0756373569620337e-09
and O 0 1.934768345535076e-09
one O 0 7.664664281037403e-08
missense O 0 7.682462455704808e-05
mutation O 0 5.625249286822509e-06
. O 0 1.773118327719203e-07

The O 0 7.225261242638226e-07
missense O 0 0.00018594489665701985
mutation O 0 3.058603033423424e-05
was O 0 6.64501499159087e-07
also O 0 1.639429392241709e-08
found O 0 7.788184319679203e-09
in O 0 3.4374729729336195e-09
2 O 0 1.0959038831970247e-07
. O 0 2.5788801849557785e-07

8 O 0 3.0602143397118198e-06
% O 0 1.947134187219035e-08
of O 0 1.8368601084617353e-10
the O 0 4.463717173663895e-10
general O 0 4.496189198732736e-09
population O 0 5.2217630219786315e-09
, O 0 7.689066050531324e-10
suggesting O 0 5.853006967981855e-09
that O 0 1.1365415275577107e-09
it O 0 1.7577467259499713e-09
is O 0 1.0740306422007961e-08
not O 0 3.8968715898590744e-07
disease O 0 1.8597378357299021e-06
associated O 0 1.7457303158607829e-07
. O 0 1.7828612897119456e-07

The O 0 4.954081873620453e-07
average O 0 5.177307116355223e-07
age O 0 4.3602199184533674e-08
of O 0 5.193117491586463e-09
disease O 0 4.960244950780179e-06
onset O 0 1.3472127875502338e-06
in O 0 2.720272895828657e-08
those O 0 1.3674164911492426e-08
families O 0 1.9547178098378026e-08
harbouring O 0 3.2587336136202794e-06
causative O 0 1.1662310498650186e-05
mutations O 0 4.894543508271454e-06
was O 0 2.859734422600013e-07
between O 0 1.092222490228778e-08
32 O 0 7.108151294232812e-07
. O 0 2.0733983774334774e-07

3 O 0 3.7864799651288195e-06
and O 0 2.2879730465774628e-07
37 O 0 1.53777000377886e-06
. O 0 1.4927108793472144e-07

4 O 0 3.3550916214153403e-06
years O 0 2.1426899365906138e-07
, O 0 6.749708347797423e-09
whereas O 0 8.017862818121557e-09
the O 0 9.69025526487144e-10
family O 0 1.601003063456119e-08
harbouring O 0 8.332285261758443e-08
the O 0 4.7211781151190735e-09
missense O 0 3.336896725159022e-06
mutation O 0 2.2386582543276745e-07
had O 0 1.805309857161319e-08
an O 0 1.153301676382057e-09
average O 0 1.7791119688581603e-08
age O 0 3.018863825587914e-09
of O 0 2.7834093363487966e-10
onset O 0 6.251851658589658e-08
of O 0 9.06503760944588e-09
51 O 0 7.210371222754475e-06
. O 0 3.946041715607862e-07

2 O 0 6.705641226290027e-06
years O 0 1.4426532288780436e-06
. O 0 4.796983148480649e-07

These O 0 3.59935938831768e-07
findings O 0 3.020789449692529e-07
show O 0 5.995524787749673e-08
that O 0 6.064264201910419e-09
BRCA1 O 0 6.109125365583168e-07
is O 0 7.402070067996647e-09
implicated O 0 2.7970362026508155e-08
in O 0 3.1468652683663834e-10
a O 0 1.4876204712521712e-09
small O 0 1.126729487488376e-09
fraction O 0 1.4877233667220935e-08
of O 0 6.050736800489176e-08
breast B-Disease 1 0.9999885559082031
/ I-Disease 1 0.9999973773956299
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 4.919130347502687e-08
suggesting O 0 1.130208282518197e-08
the O 0 3.360418054931813e-10
involvement O 0 4.565095856889911e-09
of O 0 5.252386303666867e-10
another O 0 2.62600480027686e-07
susceptibility O 0 0.02021147310733795
gene O 0 4.112278020329541e-06
( O 0 9.514987908687544e-08
s O 0 0.00011342111247358844
) O 0 9.735834964885726e-07

Paternal O 1 0.929414689540863
transmission O 0 0.03618950769305229
of O 0 1.3686118109035306e-05
congenital B-Disease 1 0.9999992847442627
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0009196803439408541

We O 0 9.102184890252829e-07
report O 0 5.2663150285070515e-08
a O 0 1.1568867641642555e-08
rare O 0 3.403614456942705e-08
case O 0 1.4839801565358357e-07
of O 0 4.846923218337906e-08
paternally O 1 0.8299556970596313
transmitted O 1 0.999931812286377
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.028289034962654114
DM B-Disease 1 0.9999998807907104
) O 0 2.0889674487989396e-06
. O 0 5.49497599422466e-07

The O 0 3.8400617086153943e-07
proband O 0 4.906451522401767e-06
is O 0 9.312386417548169e-09
a O 0 5.208294684422299e-09
23 O 0 1.255372072961336e-08
year O 0 2.1165622587915323e-09
old O 0 6.075740088817838e-07
, O 0 2.4425523292848084e-07
mentally B-Disease 1 0.9999997615814209
retarded I-Disease 1 0.9999998807907104
male O 0 0.02895721048116684
who O 0 0.0001255708048120141
suffers O 1 0.9997966885566711
severe O 1 0.9993767142295837
muscular B-Disease 1 0.999925971031189
weakness I-Disease 1 0.9855265617370605
. O 0 6.4595869844197296e-06

He O 0 7.253876447066432e-06
presented O 0 1.0372480119258398e-06
with O 0 9.595686378816026e-07
respiratory O 1 0.8612151145935059
and O 0 1.0235274885417311e-06
feeding O 0 3.291654593340354e-06
difficulties O 0 6.848200655440451e-07
at O 0 4.4037140156660826e-08
birth O 0 2.2950698621571064e-06
. O 0 5.004168315281277e-07

His O 0 1.0837312402145471e-05
two O 0 8.926218697524746e-07
sibs O 0 0.010399998165667057
suffer O 0 0.006373286712914705
from O 0 1.8156771375288372e-07
childhood O 0 8.605290349805728e-05
onset O 0 0.0999559536576271
DM B-Disease 1 0.9999994039535522
. O 0 0.00012375161168165505

Their O 0 3.3400439747310884e-07
late O 0 1.0798111560461621e-07
father O 0 1.821674686652841e-07
had O 0 1.487490841611816e-08
the O 0 2.9425026304430446e-10
adult O 0 1.9580911114758237e-08
type O 0 4.281043075593516e-08
of O 0 4.379888451921943e-09
DM B-Disease 1 1.0
, O 0 5.4114153158479894e-08
with O 0 2.3212658462057334e-09
onset O 0 1.452559814651977e-07
around O 0 1.196920607071661e-08
30 O 0 1.4052423225052735e-08
years O 0 1.999294774179816e-08
. O 0 3.967542383520595e-08

Only O 0 5.131390707902028e-07
six O 0 2.2882408856617076e-08
other O 0 4.79173811740452e-10
cases O 0 1.8492067876962892e-09
of O 0 1.2811817162727834e-09
paternal O 0 0.018383296206593513
transmission O 0 0.004056395031511784
of O 0 6.950792226234626e-07
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 1.0
have O 0 0.07647769898176193
been O 0 9.914251677400898e-06
reported O 0 5.669513143402583e-07
recently O 0 2.1150243867396057e-07
. O 0 8.76249259817996e-08

We O 0 2.8072454938410374e-07
review O 0 1.7197761437159897e-08
the O 0 1.3263310449929122e-09
sex O 0 1.3562913458997627e-08
related O 0 3.557395933384555e-09
effects O 0 1.1246949327414768e-07
on O 0 1.4006884612172144e-06
transmission O 0 0.0008658073493279517
of O 0 6.125617915131443e-07
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 1.0
. O 0 0.00041735649574548006

Decreased O 0 7.327321509364992e-05
fertility O 0 5.457123961605248e-07
of O 0 1.7687104003627496e-09
males O 0 3.022575612021683e-08
with O 0 8.68266525344552e-09
adult O 0 2.1305189875420183e-05
onset O 0 0.00012810001499019563
DM B-Disease 1 0.9999998807907104
and O 0 6.057480277377181e-07
contraction O 0 1.236553401895435e-07
of O 0 3.321939390232842e-10
the O 0 6.515216144364899e-10
repeat O 0 3.257367708897618e-08
upon O 0 9.351045271444036e-09
male O 0 2.8102883220526564e-07
transmission O 0 6.391741891320635e-08
contribute O 0 1.562311058300736e-09
to O 0 1.330049959058499e-09
the O 0 9.3822694058332e-10
almost O 0 1.0607445588561859e-08
absent O 0 3.1995107008242485e-08
occurrence O 0 7.231939047613878e-09
of O 0 6.280961861726553e-10
paternal O 0 5.854562914464623e-05
transmission O 0 7.670260674785823e-05
of O 0 5.335400032890902e-07
congenital B-Disease 1 0.999998927116394
DM I-Disease 1 1.0
. O 0 0.0005272648413665593

Also O 0 7.151197678467724e-07
the O 0 3.033385764794616e-09
fathers O 0 7.936840518141253e-09
of O 0 1.5693706056918444e-10
the O 0 1.3679218868745124e-09
reported O 0 4.4228815454516734e-07
congenitally O 0 0.0002951388305518776
affected O 0 1.3478872062933078e-07
children O 0 7.10847771756562e-08
showed O 0 2.300678971778325e-07
, O 0 9.105965426137175e-10
on O 0 8.948821239584959e-09
average O 0 4.254993157815079e-08
, O 0 1.874658872580426e-09
shorter O 0 2.3775118052071775e-07
CTG O 0 5.203283990340424e-07
repeat O 0 1.3122121345077176e-07
lengths O 0 3.1571613590131165e-07
and O 0 2.650877961585252e-09
hence O 0 5.541367809058784e-09
less O 0 2.9283517832823236e-08
severe O 0 0.2841300964355469
clinical O 0 0.2326880693435669
symptoms O 1 0.6917127370834351
than O 0 1.7023680243255512e-08
the O 0 5.69115776727358e-09
mothers O 0 1.1086994078368662e-07
of O 0 8.859231126479017e-10
children O 0 6.898805509081285e-07
with O 0 7.652271960978396e-06
congenital B-Disease 1 0.9999992847442627
DM I-Disease 1 1.0
. O 0 0.00042046993621625006

We O 0 3.7484960557776503e-07
conclude O 0 2.23103455709861e-07
that O 0 4.615334603386145e-08
paternal O 0 5.3649131587008014e-05
transmission O 0 2.277832754771225e-05
of O 0 2.727216781295283e-07
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 1.0
is O 0 0.0010250424966216087
rare O 0 9.809891707845964e-07
and O 0 4.752332216639843e-08
preferentially O 0 1.2604797348103602e-06
occurs O 0 2.6904258820792393e-09
with O 0 1.1919171205576617e-09
onset O 0 1.0014087337140154e-07
of O 0 1.3623036032583968e-08
DM B-Disease 1 0.9999994039535522
past O 0 4.765966252762155e-07
30 O 0 1.0275247319668779e-08
years O 0 2.0024844005206432e-09
in O 0 2.118774738990581e-10
the O 0 6.203619840050578e-10
father O 0 6.73961210395646e-07
. O 0 9.161961855852496e-09
. O 0 3.5396176656377065e-08

The O 0 2.4761620807112195e-06
RB1 O 0 0.00026307650841772556
gene O 0 1.866172738118621e-06
mutation O 0 1.3308432471603737e-06
in O 0 3.4841809437580196e-09
a O 0 4.0200266226975145e-08
child O 0 3.797893668888719e-06
with O 0 4.010364591522375e-06
ectopic B-Disease 1 0.999970555305481
intracranial I-Disease 1 0.9999878406524658
retinoblastoma I-Disease 1 0.9888274669647217
. O 0 6.637961632804945e-06

The O 0 8.848480774759082e-07
RB1 O 0 0.00018841493874788284
gene O 0 1.5192601949820528e-06
mutation O 0 2.2049846393201733e-06
was O 0 1.3352173766634223e-07
investigated O 0 2.3122703751710105e-08
in O 0 5.792343826804824e-10
a O 0 2.697662360162667e-08
child O 0 7.933050255815033e-06
with O 0 9.731490990816383e-07
ectopic B-Disease 1 0.9999526739120483
intracranial I-Disease 1 0.9999514818191528
retinoblastoma I-Disease 0 0.00012866855831816792
using O 0 6.769824523189527e-08
DNA O 0 1.2318147923906508e-07
obtained O 0 3.9891587810814144e-09
from O 0 1.6066238617273854e-10
both O 0 6.180235767594411e-10
the O 0 8.597821898881364e-10
pineal B-Disease 0 2.96681173495017e-06
and I-Disease 0 3.066428234888008e-06
retinal I-Disease 1 0.9986353516578674
tumours I-Disease 1 0.9999985694885254
of O 0 8.616295232855009e-09
the O 0 5.8479212583506524e-08
patient O 0 0.0002567306801211089
. O 0 3.785596049965534e-07

A O 0 2.8196111543365987e-06
nonsense O 0 1.1217251085327007e-05
mutation O 0 1.6870890249265358e-06
in O 0 1.496882973128777e-08
exon O 0 5.175924684408528e-07
17 O 0 6.397913665523447e-08
( O 0 1.1375457242834841e-09
codon O 0 1.2296593965288594e-08
556 O 0 8.830741471399506e-09
) O 0 3.1537150668725644e-10
of O 0 1.8428819581473022e-10
the O 0 7.391925738176042e-09
RB1 O 0 4.382716724649072e-06
gene O 0 3.273436277595465e-08
was O 0 2.0629324026799623e-08
found O 0 1.1542501399119942e-09
to O 0 1.612734612521649e-09
be O 0 7.603187412996704e-09
present O 0 2.8088069647935754e-09
homozygously O 0 4.944301963405451e-07
in O 0 8.335631629385887e-10
both O 0 8.581061972101622e-10
the O 0 3.211578336603793e-09
retinal B-Disease 0 0.00015810840704943985
and I-Disease 0 1.6982404815735208e-07
the I-Disease 0 1.400284901365012e-07
pineal I-Disease 0 0.012658653780817986
tumours I-Disease 1 0.9999963045120239
. O 0 1.165853404927475e-06

The O 0 1.3433776757665328e-07
same O 0 2.280959421341322e-08
mutation O 0 1.2536759186332347e-07
was O 0 2.7135152791402106e-08
present O 0 2.5964337346806587e-09
heterozygously O 0 3.1088902119336126e-07
in O 0 4.4591558223672223e-10
the O 0 1.2141783412022988e-10
DNA O 0 3.877909549032665e-09
from O 0 9.368620462746335e-11
the O 0 2.367255280688596e-10
constitutional O 0 1.4224522892902769e-08
cells O 0 1.7170940225241793e-09
of O 0 5.3402074429165225e-11
the O 0 9.589898875006497e-10
patient O 0 1.1570134574867552e-06
, O 0 1.0789558135826383e-09
proving O 0 1.9922676841588327e-08
it O 0 1.0665177629931577e-09
to O 0 6.221583803700526e-10
be O 0 8.82137751734291e-10
of O 0 1.093109713856677e-09
germline O 0 8.807261338006356e-07
origin O 0 4.918633322859023e-08
. O 0 5.220650578507957e-08

The O 0 1.4127650160844496e-07
initial O 0 1.700661869108444e-07
mutation O 0 2.7325305040903913e-07
was O 0 3.68417403251442e-08
shown O 0 6.016578346645929e-09
to O 0 1.860471110504136e-09
have O 0 3.685015403931402e-09
occurred O 0 4.55722259928848e-09
in O 0 4.855282842441966e-10
the O 0 4.748650805908028e-09
paternally O 0 9.505801244813483e-06
derived O 0 8.859913691594556e-07
RB1 O 0 4.423025529831648e-05
allele O 0 7.454746537405299e-06
. O 0 3.099860350630479e-07

The O 0 3.913481805284391e-07
mutation O 0 1.0658593510015635e-06
is O 0 3.7165961419560745e-09
in O 0 2.837522161680539e-10
an O 0 8.927234507183357e-10
area O 0 2.6516464579628973e-09
of O 0 6.7565286698823e-11
the O 0 2.633761264636547e-10
gene O 0 4.1880809931171825e-09
that O 0 6.208520364481274e-10
encodes O 0 2.921962005686396e-09
the O 0 1.6048781747990404e-10
protein O 0 4.120116248174099e-09
- O 0 1.0933734984064358e-07
binding O 0 1.1111403352970228e-07
region O 0 8.340343526924698e-09
known O 0 8.062734480063227e-09
as O 0 3.0564655251197337e-09
the O 0 9.666680789166548e-10
pocket O 0 0.0005179069121368229
region O 0 1.4453928720570275e-08
and O 0 5.814418724270354e-09
has O 0 3.774362866693082e-08
been O 0 1.3071693061306178e-08
detected O 0 1.1609806449541793e-08
in O 0 1.912664332470726e-10
other O 0 1.2177059360851672e-10
cases O 0 3.5005274234833905e-09
of O 0 1.8050094752197765e-09
retinoblastoma B-Disease 0 1.948124736372847e-05
. O 0 3.552651151039754e-08
. O 0 7.942734470134383e-08

Low O 0 6.762203702237457e-05
levels O 0 7.102188703811407e-08
of O 0 6.91129931063017e-10
beta O 0 3.3270521893058458e-09
hexosaminidase O 0 1.56314413857217e-07
A O 0 2.6249725948446212e-08
in O 0 4.072410408895166e-09
healthy O 0 4.4903984530719754e-08
individuals O 0 1.5968608657601635e-09
with O 0 1.4475973308947232e-08
apparent O 0 0.29497775435447693
deficiency O 0 0.00042818966903723776
of O 0 5.262614788392739e-10
this O 0 5.2782391790628935e-09
enzyme O 0 1.685191648448381e-07
. O 0 8.413669405626933e-08

Appreciable O 0 0.0001426138187525794
beta O 0 1.4992895103205228e-06
hexosaminidase O 0 1.1962553799094167e-05
A O 0 3.263381529450271e-07
( O 0 4.015326737771829e-09
hex O 0 1.7343234048894374e-07
A O 0 3.0471305478840804e-08
) O 0 6.062051971511551e-10
activity O 0 9.095063591146868e-10
has O 0 8.162226450281196e-09
been O 0 1.0900705227356866e-08
detected O 0 3.005352766649594e-08
in O 0 2.0489163699011215e-09
cultured O 0 6.182756806083489e-06
skin O 1 0.7838001251220703
fibroblasts O 0 6.067157301004045e-06
and O 0 2.016060534515418e-05
melanoma B-Disease 1 0.9595264196395874
tissue O 0 1.3439928807201795e-05
from O 0 1.8053375683280137e-08
healthy O 0 2.0371265918583958e-07
individuals O 0 4.2467935834622494e-09
previously O 0 7.694956849491064e-08
reported O 0 6.314203915280814e-08
as O 0 3.987776153735467e-08
having O 0 2.513316758268047e-06
deficiency B-Disease 0 1.9289641386421863e-06
of I-Disease 0 1.7001242080816326e-10
hex I-Disease 0 1.764826578209977e-07
A I-Disease 0 2.3769036516796405e-08
activity O 0 2.030495327431936e-09
indistinguishable O 0 9.077945506419383e-09
from O 0 2.1087680213138782e-10
that O 0 5.806546909958854e-10
of O 0 1.7677660446580035e-09
patients O 0 3.948489029426128e-05
with O 0 0.0032473786268383265
Tay B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
Sachs I-Disease 1 0.9999998807907104
disease I-Disease 1 0.5457329154014587
( O 0 7.993845940745814e-08
TSD B-Disease 0 6.509561353595927e-05
) O 0 1.0713466735978727e-07
. O 0 1.1509404629350684e-07

Identification O 0 4.114623607165413e-06
and O 0 4.8002231523014416e-08
quantitation O 0 1.2887785487691872e-06
of O 0 1.938610161289489e-09
hex O 0 3.818071263594902e-07
A O 0 3.830518124914306e-08
, O 0 3.1596172345160767e-09
amounting O 0 1.0195673638691005e-08
to O 0 9.565059855276559e-09
3 O 0 7.256246448150705e-08
. O 0 1.0855561072276032e-07

5 O 0 1.0178254342463333e-05
% O 0 7.823933856343501e-07
- O 0 6.9296593210310675e-06
6 O 0 1.429134840691404e-06
. O 0 2.619316603613697e-07

9 O 0 5.134340881340904e-06
% O 0 6.46057642939013e-08
of O 0 4.006626419528203e-10
total O 0 1.3105038165761584e-09
beta O 0 3.457686581498365e-09
hexosaminidase O 0 1.5569133893222897e-07
activity O 0 5.065625696687448e-09
, O 0 8.702506493207807e-10
has O 0 1.093961277121025e-08
been O 0 4.092226557617096e-09
obtained O 0 1.534819271675758e-09
by O 0 9.268754097568888e-10
cellulose O 0 6.975348583182495e-07
acetate O 0 2.6727449949248694e-05
gel O 0 0.00028739197296090424
electrophoresis O 0 9.335684012512502e-07
, O 0 4.249256946309288e-09
DEAE O 0 5.167224799151882e-07
- O 0 2.0248542398348945e-07
cellulose O 0 3.083917192725494e-07
ion O 0 8.689864898769883e-07
- O 0 5.882409936930344e-07
exchange O 0 1.2811628202769043e-08
chromatography O 0 8.23673573790984e-08
, O 0 3.8286538384113555e-09
radial O 0 1.3832166132488055e-06
immunodiffusion O 0 7.613516572746448e-06
, O 0 1.9694702757533378e-08
and O 0 2.386634534445875e-08
radioimmunoassay O 0 3.1667874281993136e-05
. O 0 3.861062793930614e-07

Previous O 0 2.3091072307579452e-06
family O 0 3.419511926949781e-07
studies O 0 1.1567897750808243e-08
suggested O 0 7.3376478226805375e-09
that O 0 1.184483622296284e-09
these O 0 9.800591449504736e-10
individuals O 0 6.373037653162328e-10
may O 0 1.3516917363176617e-08
be O 0 5.189731311361356e-09
compound O 0 7.383728473087103e-08
heterozygotes O 0 2.1833676555615966e-07
for O 0 4.4094161655294783e-10
the O 0 6.788580808603228e-10
common O 0 6.220803872025726e-09
mutant O 0 1.025568622026185e-06
TSD B-Disease 0 3.339628392495797e-06
gene O 0 1.0592388122176999e-07
and O 0 7.272606961095107e-09
a O 0 3.6649002055355595e-08
rare O 0 5.055503606854472e-07
( O 0 1.4862089336986628e-08
allelic O 0 1.8731856243903167e-06
) O 0 1.0474391132220262e-08
mutant O 0 2.517087750675273e-06
gene O 0 1.1966133115492994e-06
. O 0 2.0665876832026697e-07

Thus O 0 2.679090584933874e-06
, O 0 1.5309840506461114e-08
the O 0 1.9082380120494236e-09
postulated O 0 2.787958521821565e-07
rate O 0 1.3932165643382177e-08
mutant O 0 2.9220636577065306e-08
gene O 0 1.0446897569238445e-08
appears O 0 2.0691151902951788e-08
to O 0 4.419916654896383e-10
code O 0 6.65708710378965e-10
for O 0 2.729489967379095e-10
the O 0 2.2625978868262564e-10
expression O 0 4.402989528529133e-09
of O 0 1.5056865476648085e-10
low O 0 1.5507216843957394e-08
amounts O 0 9.852094695617097e-10
of O 0 1.3659293141010664e-10
hex O 0 3.0612574164479156e-07
A O 0 1.538097080810985e-07
. O 0 1.404058593834634e-07

Heterozygotes O 0 0.0009218964260071516
for O 0 7.598580253898035e-08
the O 0 5.128554914080041e-09
rare O 0 3.2273369754420855e-08
mutant O 0 1.8304077684661024e-06
may O 0 1.1003568545220332e-07
be O 0 3.2125035964725157e-09
indistinguishable O 0 1.8106343091517374e-08
from O 0 1.5186807367228994e-09
heterozygotes O 0 1.5729419544641132e-07
for O 0 7.293495252191917e-10
the O 0 2.0828976321496384e-09
common O 0 4.358174265917114e-08
TSD B-Disease 0 2.7897884137928486e-05
mutant O 0 1.5779913155711256e-05
. O 0 3.1060687888384564e-07

However O 0 1.173342297988711e-06
, O 0 1.2678269989407909e-08
direct O 0 7.459513895469172e-09
visualization O 0 7.68143664231502e-08
and O 0 1.0638710357113723e-08
quantitation O 0 5.549874231292051e-07
of O 0 1.2799945547925518e-09
hex O 0 2.993870680256805e-07
A O 0 1.2409997474094325e-08
by O 0 1.8479365260226643e-10
the O 0 7.62173518742415e-11
methods O 0 3.1501214969864577e-09
described O 0 2.59131070379226e-07
may O 0 2.2247746755965636e-08
prevent O 0 5.671998426493019e-09
false O 0 3.914160018325674e-08
- O 0 3.7321165109460708e-06
positive O 0 4.109688234166242e-07
prenatal O 0 9.061573655344546e-05
diagnosis O 0 2.6713511033449322e-05
of O 0 2.73933808969673e-09
TSD B-Disease 0 1.1152865226904396e-05
in O 0 3.3520482389803874e-08
fetuses O 0 1.310111656493973e-06
having O 0 5.243940393029334e-09
the O 0 6.057278012505662e-10
incomplete O 0 4.3248196135436956e-08
hex B-Disease 0 5.634720309899421e-06
A I-Disease 0 7.672315405216068e-06
deficiency I-Disease 0 5.2749583119293675e-06
of O 0 5.912333123081481e-11
the O 0 5.149126125481018e-10
type O 0 3.30980668650227e-07
described O 0 9.476645601580458e-08
in O 0 1.1932046461993195e-09
the O 0 2.00789984639016e-09
four O 0 3.461132891402485e-08
healthy O 0 4.4315115133031213e-07
individuals O 0 1.334551598120015e-07

The O 0 8.038581427172176e-07
tumor B-Disease 0 1.6317868357873522e-05
suppressor O 0 2.3789280021446757e-05
gene O 0 1.942010385391768e-06
Smad4 O 0 8.327776413352694e-06
/ O 0 7.951265956762654e-07
Dpc4 O 0 1.4814648920946638e-06
is O 0 5.15444442683588e-09
required O 0 1.97050642469776e-09
for O 0 6.329258228632284e-10
gastrulation O 0 6.73181403954004e-08
and O 0 9.112624432816574e-09
later O 0 1.0305945430388874e-08
for O 0 8.09709743698761e-10
anterior O 0 2.639708718277234e-08
development O 0 3.534931791726592e-10
of O 0 1.8084718444999481e-10
the O 0 1.9754398117299843e-09
mouse O 0 6.02636589519534e-07
embryo O 0 1.1398536798878922e-06
. O 0 9.6306187913342e-08

Mutations O 0 0.0010648841271176934
in O 0 1.7695994358746248e-07
the O 0 3.269155968155246e-08
SMAD4 O 0 0.0029938805382698774
/ O 0 2.1873243895242922e-05
DPC4 O 0 0.0012278668582439423
tumor B-Disease 0 5.85800371482037e-05
suppressor O 0 1.326952587987762e-05
gene O 0 1.2495412704538467e-07
, O 0 1.0417761098224787e-09
a O 0 1.547975636562171e-09
key O 0 6.038962663268421e-09
signal O 0 3.5863934044755297e-07
transducer O 0 2.157285734938341e-06
in O 0 7.0588623835021735e-09
most O 0 5.989316598231653e-09
TGFbeta O 0 4.553455255518202e-06
- O 0 1.7619116761125042e-06
related O 0 2.2275004951666233e-08
pathways O 0 8.494580150397724e-09
, O 0 5.042257167353625e-10
are O 0 7.140577712450025e-11
involved O 0 5.490632948301766e-10
in O 0 7.70364272373314e-10
50 O 0 6.9843459904461724e-09
% O 0 2.1126458360498646e-09
of O 0 5.757232912628751e-09
pancreatic B-Disease 1 0.9648808836936951
cancers I-Disease 0 0.23920494318008423
. O 0 9.576342563377693e-07

Homozygous O 0 0.004004970192909241
Smad4 O 0 0.0014330768026411533
mutant O 0 0.0003406585310585797
mice O 0 0.0015524234622716904
die O 0 2.4001663405215368e-05
before O 0 1.445574948633066e-08
day O 0 2.3044815833372922e-08
7 O 0 1.1300232927169418e-07
. O 0 9.318590343809774e-08

5 O 0 2.2005224309396e-06
of O 0 7.795469514348952e-08
embryogenesis O 0 1.0724014828156214e-05
. O 0 9.54576876210922e-07

Mutant O 0 1.2450273970898706e-05
embryos O 0 1.813084850255109e-06
have O 0 9.764569597336958e-08
reduced O 0 2.8701791165985924e-08
size O 0 1.6380946377125838e-08
, O 0 2.7536548596884813e-09
fail O 0 1.5255105267897306e-07
to O 0 2.0668274203217152e-08
gastrulate O 0 1.3588150068244431e-05
or O 0 5.792281321248538e-09
express O 0 1.698343332634522e-08
a O 0 4.209238291252859e-09
mesodermal O 0 7.981884664332028e-07
marker O 0 4.384113253763644e-06
, O 0 9.312599580368897e-09
and O 0 6.028122001566771e-09
show O 0 1.148729751321298e-07
abnormal O 0 6.197558946041681e-07
visceral O 0 2.8612685127882287e-05
endoderm O 0 8.465051905659493e-06
development O 0 9.457865246531583e-08
. O 0 1.858064706539153e-07

Growth B-Disease 1 0.9992173910140991
retardation I-Disease 1 0.9999876022338867
of O 0 2.400247645084619e-08
the O 0 2.537924537193703e-08
Smad4 O 0 2.518523069738876e-05
- O 0 0.00024357375514227897
deficient O 0 1.9874147255904973e-05
embryos O 0 7.167592741552653e-08
results O 0 9.567650671726824e-09
from O 0 4.910407636060654e-10
reduced O 0 1.1800441512832549e-08
cell O 0 2.904421592120343e-08
proliferation O 0 4.299829825527013e-09
rather O 0 3.5010347954056442e-09
than O 0 4.248600582457129e-09
increased O 0 6.971770716290848e-08
apoptosis O 0 2.7770042834163178e-06
. O 0 2.9733868700532184e-07

Aggregation O 0 1.744407018122729e-05
of O 0 1.0897237956442041e-07
mutant O 0 7.280496902239975e-06
Smad4 O 0 1.3805683920509182e-05
ES O 0 3.932539698325854e-07
cells O 0 4.21935268946072e-08
with O 0 1.6263292934581841e-09
wild O 0 2.7715348238643855e-08
- O 0 3.763820359381498e-06
type O 0 2.9025472940702457e-06
tetraploid O 0 1.2435261851351243e-05
morulae O 0 1.784779306035489e-05
rescues O 0 2.2536260075867176e-06
the O 0 1.757050327455545e-08
gastrulation B-Disease 0 1.2146484550612513e-05
defect I-Disease 0 6.280907109612599e-05
. O 0 1.0421641718494357e-06

These O 0 5.343863449525088e-07
results O 0 1.6910131250824634e-07
indicate O 0 3.319295416304158e-08
that O 0 4.8075508018996516e-09
Smad4 O 0 7.157004233704356e-07
is O 0 5.3843143277276795e-09
initially O 0 1.9317383248562692e-08
required O 0 4.714912349434996e-10
for O 0 4.4914193891854026e-11
the O 0 5.796298163662783e-11
differentiation O 0 6.765326632240942e-10
of O 0 1.4555114058456553e-10
the O 0 8.406362828061731e-10
visceral O 0 4.0377076402364764e-06
endoderm O 0 6.037030857442005e-07
and O 0 7.004891333650676e-09
that O 0 8.034207743534694e-10
the O 0 7.305412941249756e-10
gastrulation B-Disease 0 2.89562223088069e-07
defect I-Disease 0 1.009522520689643e-06
in O 0 1.9534271977761364e-09
the O 0 1.4984933294215352e-09
epiblast O 0 2.0147294890193734e-06
is O 0 2.05585397594632e-08
secondary O 0 3.514751156785678e-09
and O 0 1.8799906076338857e-09
non O 0 1.6309241956946607e-08
- O 0 5.093539584777318e-06
cell O 0 3.753952114493586e-05
autonomous O 0 1.0674502846086398e-06
. O 0 2.1261007532302756e-07

Rescued O 0 0.00013036416203249246
embryos O 0 8.879370398062747e-06
show O 0 1.20664517453406e-05
severe O 0 0.014453394338488579
anterior O 0 3.687291973619722e-05
truncations O 0 5.389542639022693e-05
, O 0 7.752809239036651e-08
indicating O 0 3.787581448477795e-08
a O 0 2.285230005227845e-09
second O 0 1.9951262864026376e-09
important O 0 3.1717037329848097e-10
role O 0 2.4525872444058905e-09
for O 0 2.471479021437517e-09
Smad4 O 0 7.827829335838032e-07
in O 0 7.3545596279700476e-09
anterior O 0 4.6512136009368987e-07
patterning O 0 5.06328979099635e-06
during O 0 9.555472502142948e-08
embryogenesis O 0 3.3643193546595285e-06
. O 0 9.218863397109089e-07

Prevalence O 0 0.0008006521966308355
of O 0 5.594256791141561e-08
p16 O 0 3.43066767527489e-06
and O 0 6.003821084732408e-08
CDK4 O 0 1.7740580005920492e-05
germline O 0 2.7689911803463474e-06
mutations O 0 1.1161718020957778e-06
in O 0 1.4306805518060628e-08
48 O 0 1.0749552529887296e-05
melanoma B-Disease 1 0.5194698572158813
- O 0 0.002057550475001335
prone O 0 0.0284805279225111
families O 0 1.7671322893875185e-07
in O 0 2.9241544297065047e-08
France O 0 4.192393589619314e-06
. O 0 4.866209337706096e-07

The O 0 3.200596211172524e-06
French O 0 6.624668458243832e-05
Familial B-Disease 0 0.05899345502257347
Melanoma I-Disease 1 0.9988718628883362
Study O 0 9.651449772718479e-07
Group O 0 5.293182994137169e-07
. O 0 1.5415214704717073e-07

Germline O 0 0.002522597089409828
mutations O 0 0.0008163463207893074
in O 0 1.7499156967915042e-07
the O 0 1.0784399151475554e-08
p16 O 0 5.340689313015901e-07
and O 0 4.998768687869415e-08
CDK4 O 0 5.5647310546191875e-06
genes O 0 5.139476400017884e-08
have O 0 1.2497434198621704e-08
been O 0 1.5938185882191647e-08
reported O 0 5.9685385522811885e-09
in O 0 6.682017439363364e-11
a O 0 1.0736040945147352e-09
subset O 0 8.337575962968913e-09
of O 0 3.662117276093113e-09
melanoma B-Disease 0 0.1477769911289215
pedigrees O 0 9.253638495465566e-07
, O 0 3.3862330717226996e-09
but O 0 3.449452723458535e-09
their O 0 1.7842390898081817e-09
prevalence O 0 2.3827803374842915e-07
is O 0 4.851683499396131e-09
not O 0 5.619877896378966e-09
well O 0 4.816756771219843e-09
known O 0 4.046782819955297e-08
. O 0 9.448724114236029e-08

We O 0 6.252805633266689e-07
searched O 0 2.249270636411893e-07
for O 0 2.905594875812767e-09
such O 0 1.351464162802074e-09
germline O 0 5.56794134354277e-07
mutations O 0 2.5675868187136075e-07
in O 0 5.133301339554919e-09
48 O 0 3.819932317128405e-07
French O 0 0.00010211116023128852
melanoma B-Disease 1 0.9943745136260986
- O 0 0.011153791099786758
prone O 0 0.055958379060029984
families O 0 2.7390209211830552e-08
selected O 0 1.9668640049985697e-09
according O 0 2.0909531051049868e-10
to O 0 3.4201144694101515e-10
two O 0 3.935731740511983e-10
major O 0 1.2961998141491904e-09
criteria O 0 9.813746260078915e-09
families O 0 7.472553686937999e-10
with O 0 2.4751339866568856e-10
at O 0 4.606078296554017e-10
least O 0 2.1365098579195774e-09
three O 0 7.38983596537679e-10
affected O 0 2.4841544377096625e-09
members O 0 5.106639000551638e-10
( O 0 3.4108052493486696e-10
n O 0 3.686571048433507e-08
= O 0 1.185745546194994e-08
20 O 0 6.638676275372291e-10
) O 0 8.721577626769061e-11
or O 0 3.304359286193659e-10
families O 0 8.43043135301258e-10
with O 0 4.716540491500609e-10
two O 0 2.7346815922868473e-09
affected O 0 5.966375837829219e-09
members O 0 4.0463776773691507e-10
, O 0 2.8454999467797393e-10
one O 0 1.579291836195651e-10
of O 0 1.77462888134583e-11
them O 0 3.8710129546259964e-10
affected O 0 6.654268802641639e-10
before O 0 2.3113419511666677e-10
the O 0 2.4893942462966834e-10
age O 0 6.767972293708624e-10
of O 0 6.818748343739855e-11
50 O 0 1.9228634240420206e-09
( O 0 5.667431524081223e-10
n O 0 1.0817529982887208e-07
= O 0 7.632424114945024e-08
28 O 0 3.4744275012599246e-08
) O 0 3.317570662630942e-10
, O 0 5.717429862883705e-10
and O 0 7.574595395354322e-10
one O 0 2.7599120766552687e-09
additional O 0 1.0959285923206608e-08
minor O 0 2.6607426661939826e-07
criterion O 0 6.0674988162645604e-06
. O 0 5.723512686017784e-07

Sixteen O 0 6.834175110270735e-06
different O 0 9.906749198762554e-08
p16 O 0 2.5056560843950137e-06
germline O 0 5.375725777412299e-06
mutations O 0 3.658828291008831e-06
were O 0 7.945158841948796e-08
found O 0 2.2520646680845857e-08
in O 0 3.953617877527904e-09
21 O 0 5.812093206714053e-08
families O 0 3.1486078189146838e-09
, O 0 3.927917435753159e-10
while O 0 4.804935893609752e-10
one O 0 2.7314235317987823e-09
germline O 0 3.50524373970984e-07
mutation O 0 2.408294221822871e-07
, O 0 3.038411744427094e-09
Arg24His O 0 3.6073112141821184e-07
, O 0 1.6160847104984555e-09
was O 0 3.878710685967235e-08
detected O 0 2.7972816951660207e-08
in O 0 1.4999288477923756e-09
the O 0 6.291516196910152e-09
CDK4 O 0 4.181847543804906e-05
gene O 0 1.4442211977439001e-06
. O 0 2.024833065661369e-07

The O 0 2.656787216892553e-07
frequency O 0 3.7462123714249174e-07
of O 0 2.0046395654560456e-09
p16 O 0 2.1127080174210278e-07
gene O 0 5.621446064196789e-08
mutation O 0 4.8816406916785127e-08
in O 0 7.916259869844566e-10
our O 0 7.092760823113053e-10
sample O 0 4.692835009478813e-09
( O 0 4.668629927095935e-10
44 O 0 9.751816243408484e-09
% O 0 2.8991717360149494e-10
) O 0 1.1635887392502653e-10
is O 0 1.4121305236258763e-09
among O 0 2.181899522168962e-10
the O 0 2.833687451353484e-10
highest O 0 4.109193696422153e-08
rates O 0 3.202551113190566e-08
yet O 0 2.169369750504302e-08
reported O 0 2.174398794352328e-08
and O 0 1.139673910799388e-09
the O 0 1.888075917833021e-09
CDK4 O 0 0.00013630276953335851
mutation O 0 1.690435880163932e-07
is O 0 5.201322705872258e-10
the O 0 1.7273155128449957e-10
second O 0 2.457336734096316e-08
mutation O 0 1.9651893978789303e-07
detected O 0 2.903480122995461e-08
in O 0 3.56879137353161e-10
this O 0 7.056892847856489e-10
gene O 0 8.668685325119441e-08
worldwide O 0 1.4851922003344953e-07
. O 0 1.876989585980482e-07

In O 0 4.912145072921703e-07
summary O 0 4.123940016143024e-07
, O 0 2.2059534199314612e-09
our O 0 8.206024193491146e-10
results O 0 2.2733226412441354e-09
show O 0 6.453873435674495e-09
frequent O 0 1.2612184185911701e-08
involvement O 0 2.2875805694155815e-09
of O 0 9.012893903426189e-11
the O 0 2.1822700591034305e-10
p16 O 0 3.3253915177056115e-08
gene O 0 7.318554651192244e-09
in O 0 2.0827783941967937e-09
familial B-Disease 0 0.00037353855441324413
melanoma I-Disease 1 0.9975582361221313
and O 0 7.370501009518193e-08
confirm O 0 1.1320133808112587e-07
the O 0 1.8264909029674925e-10
role O 0 1.3421855848960718e-09
of O 0 8.543235563429619e-11
the O 0 3.8314423855823065e-10
CDK4 O 0 1.0485224493095302e-06
gene O 0 1.599708809862932e-08
as O 0 6.480789682683508e-09
a O 0 2.6958394983012113e-07
melanoma B-Disease 1 0.6231545805931091
- O 0 2.8163940442027524e-05
predisposing O 0 2.7698612029780634e-05
gene O 0 3.6504178524410236e-07
. O 0 1.5508222261928495e-08
. O 0 4.71524117529043e-08

Progression O 0 3.333433051011525e-05
of O 0 4.5244945567901595e-08
somatic O 0 3.674774006867665e-06
CTG O 0 1.5987341612344608e-05
repeat O 0 1.835097350522119e-06
length O 0 7.718695655967167e-07
heterogeneity O 0 6.667918910352455e-07
in O 0 7.641276944525544e-09
the O 0 4.499157491011374e-09
blood O 0 3.045213645691547e-07
cells O 0 2.777049417090893e-07
of O 0 3.278079248048016e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999686479568481
. O 0 4.293941401556367e-06

The O 0 2.812770958371402e-07
genetic O 0 9.93507455859799e-07
basis O 0 7.274537949797377e-08
of O 0 2.4597969172646117e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0007039083866402507
DM B-Disease 1 1.0
) O 0 5.559282456601977e-08
is O 0 3.012588178918918e-09
the O 0 3.233692480453243e-10
expansion O 0 7.654051281669183e-10
of O 0 1.3732749659656207e-10
an O 0 4.386593754901469e-09
unstable O 0 2.3531774786533788e-06
CTG O 0 1.120305341828498e-06
repeat O 0 7.285841263637849e-08
in O 0 1.0199208144712202e-09
the O 0 9.768379438668262e-10
34 O 0 1.4872354014983102e-08
UTR O 0 1.9193252853710874e-07
of O 0 6.335466040674476e-10
the O 0 2.2199678539891465e-08
DM B-Disease 1 0.9999996423721313
protein O 0 1.7684468502920936e-06
kinase O 0 6.928879088263784e-07
gene O 0 3.0169999831741734e-08
on O 0 2.602866366885337e-08
chromosome O 0 1.7423419194528833e-05
19 O 0 3.786040281283931e-07
. O 0 1.0265809180509677e-07

One O 0 2.5728763830557e-07
of O 0 1.6708867622838852e-09
the O 0 8.968296105749118e-10
principal O 0 5.748827636153919e-09
features O 0 1.0961041851942355e-08
of O 0 7.565600368408809e-10
the O 0 1.0576741971135561e-07
DM B-Disease 1 1.0
mutation O 0 8.738251199247316e-05
is O 0 4.897361627342889e-09
an O 0 1.9031238807087902e-09
extraordinarily O 0 6.615044867430697e-07
high O 0 2.0536084832656343e-08
level O 0 9.07960318041745e-10
of O 0 2.96601104787797e-10
somatic O 0 3.4307944929423684e-07
mosaicism O 0 5.389048965298571e-05
, O 0 3.106908064154368e-09
due O 0 3.8961927018021925e-09
to O 0 4.272801668037118e-09
an O 0 1.5109238304944483e-08
extremely O 0 2.7280150334263453e-06
high O 0 5.664368174507217e-08
degree O 0 8.661525718878238e-09
of O 0 4.736491199253123e-10
somatic O 0 3.770686305415438e-07
instability O 0 2.7521136303221283e-07
both O 0 5.674833492008702e-09
within O 0 2.1128181149077108e-10
and O 0 1.1241577668741343e-09
between O 0 9.499693254255703e-10
different O 0 5.5792503950158334e-09
tissues O 0 1.3309638688951964e-06
. O 0 1.0198245092851721e-07

This O 0 4.7471232278439857e-07
instability O 0 4.464666858439159e-07
appears O 0 1.055447356179684e-07
to O 0 3.3514966357728326e-09
be O 0 3.2058866672457498e-09
biased O 0 4.943509779309352e-08
towards O 0 2.4527651021344354e-09
further O 0 1.775037006268576e-09
expansion O 0 1.98607108536919e-09
and O 0 4.793054841911726e-10
continuous O 0 4.287414423487235e-09
throughout O 0 4.5001852244652696e-10
the O 0 1.0886772733309513e-10
life O 0 4.937323327958154e-10
of O 0 3.2735501809266765e-11
an O 0 8.443740151520274e-10
individual O 0 5.002750436133852e-10
, O 0 4.71253924771986e-10
features O 0 1.0558879104394236e-08
that O 0 3.450992824838295e-09
could O 0 1.1883530959266864e-07
be O 0 9.719617111159096e-09
associated O 0 2.4174389157138876e-09
with O 0 3.763690470393044e-10
the O 0 1.6523844514892971e-09
progressive O 0 1.950600790223689e-06
nature O 0 3.0248925586562336e-09
of O 0 4.2154069124222815e-10
the O 0 4.0904886589032685e-08
disease O 0 2.673677954589948e-05
. O 0 2.0179798809749627e-07

Although O 0 3.7527815948124044e-06
increasing O 0 1.5153950982949027e-07
measured O 0 7.239559636218473e-07
allele O 0 2.4858721303644415e-07
size O 0 2.3098856161141157e-08
between O 0 1.543332928122254e-08
patients O 0 3.7679616070818156e-05
clearly O 0 5.824366553497384e-07
correlates O 0 2.0156065261289768e-07
with O 0 1.2041903030279855e-09
an O 0 2.85875900729593e-09
increased O 0 2.468560182933288e-07
severity O 0 6.793525244574994e-05
of O 0 2.4072623006077265e-08
symptoms O 0 0.03642670437693596
and O 0 1.4245973289916947e-08
an O 0 5.955892667941498e-09
earlier O 0 1.0060474409101516e-07
age O 0 8.099264370287074e-09
of O 0 2.328386095040713e-10
onset O 0 1.0440088971108707e-07
, O 0 9.575533699290872e-10
this O 0 1.7959561615654707e-10
correlation O 0 2.497661411027252e-09
is O 0 1.1854871528882427e-09
not O 0 1.7847870958931367e-09
precise O 0 4.787267116057592e-08
and O 0 3.339183507478083e-08
measured O 0 4.359390004538e-06
allele O 0 2.8651342631746957e-07
length O 0 3.240722534769702e-08
cannot O 0 1.499065760413032e-08
be O 0 6.917391659477801e-10
used O 0 3.6157954408366777e-09
as O 0 1.8253216715891085e-09
an O 0 1.0349828771794023e-09
accurate O 0 2.3200216503482807e-07
predictor O 0 5.47913089121721e-07
of O 0 4.956420829316244e-10
age O 0 1.5395109187466005e-08
of O 0 2.0533175160153405e-09
onset O 0 2.8522465527203167e-06
. O 0 4.144259833083197e-07

In O 0 9.31365065071077e-08
order O 0 7.019818060172156e-09
to O 0 2.5919855151101956e-09
further O 0 3.090984357356774e-09
characterize O 0 3.5583955337870066e-08
the O 0 2.571000301543336e-09
dynamics O 0 3.8308914440676745e-07
of O 0 1.0764054536593903e-08
DM B-Disease 1 0.9999977350234985
CTG O 0 4.6537195885321125e-05
repeat O 0 5.369220730244706e-07
somatic O 0 4.746054855786497e-07
instability O 0 1.6772423805377912e-07
, O 0 1.6393909563205966e-09
we O 0 6.301817401244136e-10
have O 0 7.601529961043241e-10
studied O 0 2.6903745897755016e-09
repeat O 0 1.3095749373803756e-08
length O 0 2.1407450034871545e-08
changes O 0 2.40225261904925e-09
over O 0 2.1062245281200376e-09
time O 0 2.610208049702578e-09
in O 0 8.871800183385403e-09
111 O 0 0.0003424040914978832
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9995760321617126
with O 0 3.77113877902957e-08
varying O 0 1.998194647967466e-06
clinical O 0 1.7022442989400588e-05
severity O 0 0.004937305580824614
and O 0 1.207832696081823e-07
CTG O 0 8.761036269788747e-07
repeat O 0 8.741009338564254e-08
size O 0 1.130240612212674e-08
over O 0 3.987355778889423e-09
time O 0 3.654609281866783e-09
intervals O 0 4.550959609161964e-09
of O 0 4.198748293493537e-10
1 O 0 9.622223906546878e-09
- O 0 2.6471739147382323e-06
7 O 0 1.2118617576106772e-07
years O 0 5.775052969170247e-08
. O 0 7.383784605963228e-08

We O 0 1.883980189631984e-07
have O 0 1.1726064563788441e-08
found O 0 1.9886372548683084e-09
a O 0 1.1658931597935407e-09
direct O 0 1.0536306938035978e-08
progression O 0 4.787522556171098e-08
of O 0 1.401025684355517e-10
the O 0 2.528258991052468e-10
size O 0 4.3065599975022906e-09
heterogeneity O 0 3.504269940890481e-08
over O 0 3.44255135509286e-09
time O 0 1.6738245234293458e-09
related O 0 1.3348686600522797e-09
to O 0 3.2738529665010674e-09
initial O 0 1.832452767303039e-08
CTG O 0 2.773608400730154e-07
repeat O 0 3.077960641917343e-08
size O 0 3.1326261584752046e-09
and O 0 6.257476758975145e-10
the O 0 1.1546458927869097e-10
time O 0 4.1469827571916085e-10
interval O 0 1.949764572017898e-09
and O 0 1.4460347363964843e-09
always O 0 4.033742229125892e-09
biased O 0 2.344467198156508e-08
towards O 0 1.2241875291252313e-09
further O 0 4.2855017312604105e-09
expansion O 0 8.286909292110067e-08
. O 0 1.6023555815536383e-07

Attempts O 0 6.042229870217852e-06
to O 0 9.505936304776696e-08
mathematically O 0 9.59361841523787e-07
model O 0 6.615297820644628e-08
the O 0 1.6869041719047573e-09
dynamics O 0 1.7266198426568735e-07
have O 0 2.361503348424776e-08
proved O 0 1.0479391221451806e-07
only O 0 2.3848767405354465e-09
partially O 0 1.050222238063725e-07
successful O 0 1.1550501888279996e-08
suggesting O 0 1.0448073517466128e-08
that O 0 3.756977229318892e-10
individual O 0 8.07157396476299e-11
specific O 0 8.731764616909388e-11
genetic O 0 6.546011288577347e-09
and O 0 5.307617012562105e-09
/ O 0 8.644926197121094e-08
or O 0 2.9858562289319934e-09
environmental O 0 5.973939209980017e-08
factors O 0 6.166333221813147e-09
also O 0 8.319434918746538e-09
play O 0 1.0565279762175805e-09
a O 0 2.5477835396969795e-09
role O 0 4.275394260844223e-09
in O 0 4.854460833314533e-09
somatic O 0 1.9990868622699054e-06
mosaicism O 0 7.24238998373039e-05
. O 0 3.02781479888381e-08
. O 0 7.533553514349478e-08

Aspartylglucosaminuria B-Disease 1 0.9962969422340393
among O 0 1.5985984646249563e-05
Palestinian O 0 2.065302396658808e-05
Arabs O 0 1.3716209650738165e-05
. O 0 1.1388225402697572e-06

Aspartylglucosaminuria B-Disease 1 0.9999853372573853
( O 0 0.0040060291066765785
AGU B-Disease 1 0.9999834299087524
) O 0 7.594769613206154e-08
is O 0 1.4887737265212309e-08
a O 0 3.7212370074257706e-08
rare O 0 1.559898919367697e-05
disorder B-Disease 0 0.02839331328868866
of I-Disease 0 2.6064568281469747e-09
glycoprotein I-Disease 0 1.9034761862712912e-05
metabolism I-Disease 0 4.3790328163595404e-06
caused O 0 1.0853631238205708e-06
by O 0 8.110919935688798e-09
the O 0 5.1914962995169844e-08
deficiency B-Disease 0 2.9955128411529586e-05
of I-Disease 0 1.0327625421524544e-09
the I-Disease 0 9.420270785653884e-09
lysosomal I-Disease 0 6.757058872608468e-05
enzyme I-Disease 0 7.51929803755047e-07
aspartylglucosaminidase I-Disease 0 1.6446696463390253e-05
( O 0 1.63412519071926e-08
AGA O 0 2.867487182811601e-06
) O 0 3.143065185895466e-08
. O 0 8.476003898749696e-08

AGU B-Disease 1 0.99997878074646
is O 0 2.7997322831652127e-05
inherited O 0 0.0001129891024902463
as O 0 7.481688157895405e-08
an O 0 6.198563795578593e-08
autosomal O 0 0.33320140838623047
recessive O 1 0.9449529051780701
trait O 0 0.05505036562681198
and O 0 2.0906128384012845e-07
occurs O 0 2.2259365461962943e-09
with O 0 7.684653469119951e-10
a O 0 3.569108031342694e-08
high O 0 1.6218761800246284e-07
frequency O 0 1.8773883994072094e-06
in O 0 3.3539524491033035e-09
Finland O 0 1.4561742318619508e-05
because O 0 3.352372601739262e-09
of O 0 2.4359519956718145e-10
a O 0 2.8901091297939274e-08
founder O 0 9.479751952312654e-07
effect O 0 3.565114923276269e-07
. O 0 1.3094367545818386e-07

While O 0 1.2938584177391022e-06
very O 0 1.9738689616133342e-07
few O 0 1.7444521915876976e-07
patients O 0 2.509080331947189e-06
with O 0 1.4174884199746884e-07
AGU B-Disease 1 0.9999984502792358
have O 0 2.32660522669903e-06
been O 0 1.4771364931220887e-07
reported O 0 1.710087538242533e-08
from O 0 1.3132807341609265e-10
non O 0 4.148235088763386e-09
- O 0 6.741412335031782e-07
Finnish O 0 0.0007604705751873553
origin O 0 1.7765078297315995e-08
, O 0 2.0914128207039084e-09
we O 0 1.4908623668929977e-08
diagnosed O 0 1.8305321646039374e-05
the O 0 6.896843540715736e-09
disorder O 0 7.979998918017372e-05
in O 0 7.731099316288237e-09
8 O 0 1.847251667186356e-07
patients O 0 1.2606649306690088e-06
originating O 0 2.566625134647893e-09
from O 0 5.084441201397283e-10
3 O 0 3.669193171518259e-09
unrelated O 0 1.8248771382900486e-08
families O 0 2.496794548889625e-09
, O 0 1.7793172490954134e-10
all O 0 1.2960310602494474e-10
Palestinian O 0 2.1973416863829698e-08
Arabs O 0 2.7295655513626116e-08
from O 0 2.513531327519303e-10
the O 0 2.3598259457635606e-10
region O 0 1.235314739389537e-09
of O 0 1.3114265229319244e-09
Jerusalem O 0 1.5118715737116872e-06
. O 0 1.234140682981888e-07

The O 0 2.3391351078316802e-06
clinical O 0 9.87177190836519e-05
diagnosis O 0 0.007074770517647266
of O 0 9.792079680437382e-08
AGU B-Disease 1 0.9999979734420776
is O 0 4.831323963117029e-07
often O 0 6.628281568055172e-08
difficult O 0 3.3216384309753266e-08
, O 0 9.827377800419868e-10
in O 0 1.5418427645741417e-10
particular O 0 7.128089229979651e-10
early O 0 1.2032651541815653e-09
in O 0 2.1101480285334873e-10
the O 0 1.484247030836272e-10
course O 0 1.1718009895744785e-09
of O 0 7.722719685965274e-11
the O 0 2.5521704749564833e-09
disease O 0 2.3364992784991045e-07
, O 0 9.181393423318696e-10
and O 0 1.1967008495261666e-09
most O 0 5.031650651687869e-10
of O 0 7.087617992507234e-11
the O 0 9.027182557019842e-09
patients O 0 2.8157979613752104e-05
are O 0 1.8849284799671295e-08
diagnosed O 0 3.3471111237304285e-05
after O 0 2.5087287802705305e-09
the O 0 5.186987506178298e-10
age O 0 2.106196328455212e-09
of O 0 1.4180083496295737e-10
5 O 0 3.3199649696058486e-09
years O 0 1.8755002884063288e-08
. O 0 1.4756398059034836e-07

However O 0 5.5933769544935785e-06
, O 0 4.5590503816583805e-08
since O 0 9.941271805757879e-09
these O 0 2.4841875223557963e-09
patients O 0 1.0134063188615983e-07
excrete O 0 1.518930758948045e-08
early O 0 8.44900815977212e-10
large O 0 2.1405469063928706e-10
amounts O 0 6.06439953809712e-10
of O 0 1.7248266703795423e-10
aspartylglucosamine O 0 2.9305485327313363e-07
in O 0 2.3842763319237292e-09
urine O 0 1.066189199150358e-07
, O 0 1.3232684947794837e-09
biochemical O 0 2.1815521833445928e-08
screening O 0 1.5721315804739788e-08
is O 0 2.7484445830339155e-09
easy O 0 1.71098459844643e-08
by O 0 1.5386186547061698e-08
urine O 0 1.2301965170991025e-06
chromatography O 0 4.375933428946155e-07
. O 0 1.0327708466206786e-08
. O 0 6.002745323030467e-08

Detection O 0 1.2462626727938186e-05
of O 0 6.124969331722241e-08
heterozygous O 0 2.085185997202643e-06
carriers O 0 6.530039087238038e-08
of O 0 2.117111375099512e-09
the O 0 1.4442597375818877e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 0.9999998807907104
( O 0 2.857408354373092e-08
ATM O 0 1.2357577361399308e-07
) O 0 1.3420115019258105e-09
gene O 0 9.631533792742175e-09
by O 0 6.814867781201883e-09
G2 O 0 2.356024651817279e-06
phase O 0 2.573700896846276e-07
chromosomal O 0 1.0261036550218705e-05
radiosensitivity O 0 4.843863735004561e-06
of O 0 1.902014368226901e-08
peripheral O 0 0.00031060786568559706
blood O 0 0.00015617195458617061
lymphocytes O 0 1.983571200980805e-05
. O 0 5.116974648444739e-07

In O 0 0.0015883544692769647
ataxia B-Disease 1 1.0
- I-Disease 1 0.999995231628418
telangiectasia I-Disease 1 0.9999996423721313
( O 0 8.588623313698918e-05
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999959468841553
T I-Disease 1 0.9999998807907104
) O 0 1.228960513799393e-06
patients O 0 0.0036985587794333696
, O 0 5.009781034459593e-09
mutations O 0 2.8192317813591217e-08
in O 0 3.8335914998022247e-10
a O 0 4.0074006335544254e-09
single O 0 3.660687752926606e-08
gene O 0 1.5552062748724893e-08
, O 0 7.037497251616287e-10
ATM O 0 2.5451084795236056e-08
, O 0 1.289856665920297e-09
result O 0 2.0063226635613773e-09
in O 0 5.063925279102932e-09
an O 0 0.0002935219672508538
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 9.92149580270052e-07
embraces O 0 1.6077483167009632e-07
a O 0 2.218808070608702e-08
variety O 0 1.8292880543668844e-09
of O 0 6.148350162327176e-10
clinical O 0 2.8406421392901393e-07
features O 0 5.154653877070814e-07
and O 0 7.412612745838487e-08
manifests O 0 3.2756090604380006e-06
extreme O 0 3.235632539144717e-05
radiosensitivity O 0 2.3544973828393267e-06
and O 0 2.0887855889384355e-09
a O 0 4.3224916979056616e-09
strong O 0 2.608596894049242e-08
pre O 0 2.100773599522654e-07
- O 0 1.802039514586795e-05
disposition O 0 6.6202283051097766e-06
to O 0 3.680062548028218e-07
malignancy B-Disease 0 5.549702109419741e-05
. O 0 2.2157593093652395e-07

Heterozygotes O 0 0.0002657340082805604
for O 0 5.5424912659418624e-08
the O 0 2.6415909459842624e-09
ATM O 0 4.3988450215692865e-08
gene O 0 2.5485380916734357e-08
have O 0 5.562122318281126e-09
no O 0 4.0709968729402135e-09
clinical O 0 6.994934409476627e-08
expression O 0 6.128369278712853e-08
of O 0 2.9396658440816736e-09
A B-Disease 1 0.9999654293060303
- I-Disease 1 0.9999535083770752
T I-Disease 1 0.9999995231628418
but O 0 7.333421308430843e-06
may O 0 1.7178145981233683e-06
be O 0 5.258827400211885e-07
cancer B-Disease 0 6.052969638403738e-06
prone O 0 9.668806342233438e-07
with O 0 2.0071073691951824e-09
a O 0 4.4481176075805706e-08
moderate O 0 0.0001470312272431329
increase O 0 5.5666145470922856e-08
in O 0 3.739435427974058e-09
in O 0 1.322111131685233e-08
vitro O 0 7.046998689475004e-06
radiosensitivity O 0 4.14799214922823e-05
. O 0 1.5267505659721792e-07

We O 0 1.3368742202146677e-06
performed O 0 4.760755700772279e-07
a O 0 4.7347256781904434e-08
blind O 0 1.0085159374284558e-06
chromosomal O 0 1.1072449979110388e-06
analysis O 0 1.6421301651803333e-08
on O 0 1.828626139399603e-08
G2 O 0 9.87173098110361e-06
- O 0 3.366238615853945e-06
phase O 0 1.421549740143746e-07
lymphocytes O 0 1.1166450519795035e-07
from O 0 4.927633301399226e-10
7 O 0 4.194507852162133e-09
unrelated O 0 9.949906143447151e-08
A B-Disease 1 0.9999849796295166
- I-Disease 1 0.9999984502792358
T I-Disease 1 1.0
patients O 1 0.9926809668540955
, O 0 7.238232235806663e-09
13 O 0 7.717206429447288e-09
obligate O 0 1.3517541219698614e-07
A B-Disease 1 0.9998503923416138
- I-Disease 1 0.9999368190765381
T I-Disease 1 0.9999995231628418
heterozygotes O 0 0.0003167417598888278
( O 0 4.950149623539346e-09
parents O 0 6.136039676363225e-09
of O 0 8.82441897331887e-11
the O 0 6.231087645858224e-09
patients O 0 2.6418954348628176e-06
) O 0 6.003335051296688e-10
, O 0 2.4270627729805483e-09
and O 0 5.619470666573534e-09
14 O 0 6.43170450231878e-09
normal O 0 4.819440402314967e-09
controls O 0 9.888113936540321e-07
following O 0 8.522476946382085e-09
X O 0 1.1545213283170597e-06
- O 0 2.1926658178017533e-07
irradiation O 0 3.7516466022680106e-07
with O 0 5.889042586915139e-09
1 O 0 3.785709079551225e-09
Gy O 0 1.852828859227884e-07
in O 0 2.54933268939439e-10
order O 0 3.4331729126257926e-10
to O 0 7.34013572145642e-10
evaluate O 0 7.141307101221628e-09
this O 0 4.189069091609099e-10
cytogenetic O 0 2.439260526898579e-07
method O 0 6.257671270049059e-09
as O 0 4.90160190214084e-10
a O 0 1.028365392841124e-09
tool O 0 9.87041914868314e-09
for O 0 2.8752719649638436e-10
detection O 0 5.666137781190628e-09
of O 0 1.1128763466317082e-09
ATM O 0 1.8249452296004165e-06
carriers O 0 1.3999247130414005e-06
. O 0 1.6370303512758255e-07

Both O 0 4.971026646671817e-05
A B-Disease 1 0.9949386119842529
- I-Disease 1 0.9987525939941406
T I-Disease 1 0.9999840259552002
homozygotes O 0 0.0002619856677483767
and O 0 8.262871631359303e-08
heterozygotes O 0 2.246377562187263e-06
showed O 0 6.855898391222581e-07
significantly O 0 1.2814187755338935e-07
increased O 0 2.653682074083008e-08
levels O 0 2.668633758418082e-09
of O 0 1.7801430329811296e-09
radiation O 0 0.10116530954837799
- O 0 0.0003708897274918854
induced O 1 0.6655954122543335
chromatid O 0 0.05143987014889717
damage O 0 9.934024092217442e-06
relative O 0 5.623119037068136e-08
to O 0 2.3211594868399743e-09
that O 0 1.5892948068696455e-09
of O 0 1.1105736330563332e-09
normal O 0 1.6288328197333612e-07
controls O 0 3.9541784644825384e-05
. O 0 3.0697648867317184e-07

These O 0 2.4509012064299895e-07
results O 0 6.376739491997796e-08
show O 0 1.3959616573799849e-08
that O 0 6.383232276085948e-10
the O 0 4.2990402904230507e-10
G2 O 0 1.0734468105511041e-06
- O 0 9.94346237348509e-07
phase O 0 1.111727527813855e-07
chromosomal O 0 3.5187213143217377e-06
radiosensitivity O 0 1.3990037359690177e-06
assay O 0 1.8004824653417018e-07
can O 0 5.074841880059466e-09
be O 0 1.1977443481470118e-09
used O 0 3.984694796344002e-09
for O 0 1.537684146679652e-10
the O 0 2.608315508023651e-10
detection O 0 9.640116260811737e-09
of O 0 4.100281891794566e-09
A B-Disease 1 0.9999759197235107
- I-Disease 1 0.9999678134918213
T I-Disease 1 0.9999985694885254
heterozygotes O 0 0.002815152518451214
. O 0 1.0255823781335494e-06

In O 0 6.624628667850629e-07
combination O 0 5.566703862314171e-07
with O 0 1.625130074955905e-08
molecular O 0 1.4456664132467267e-07
genetic O 0 2.3048713160278567e-07
analyses O 0 7.875589602690525e-08
, O 0 8.912653393089442e-10
this O 0 3.9374961624538685e-10
test O 0 1.4386214886030757e-08
may O 0 1.5060413360856728e-08
be O 0 2.735071336079642e-10
of O 0 2.176229335626445e-11
value O 0 1.3755425964934176e-10
in O 0 9.99758470454637e-11
studies O 0 1.438082292137821e-10
of O 0 4.760689412131036e-11
familial B-Disease 0 1.0421924656611736e-07
and I-Disease 0 5.318036500057133e-08
sporadic I-Disease 0 2.5696452212287113e-05
cancers I-Disease 0 1.4066833500692155e-05
aimed O 0 1.6181337159082432e-08
at O 0 1.0461448374243787e-09
determination O 0 1.3554301681040215e-08
of O 0 4.033314654483533e-11
the O 0 1.0945863659905797e-10
potential O 0 9.188260707837514e-10
involvement O 0 1.5138627018629336e-09
of O 0 2.383929442739685e-10
ATM O 0 2.8482730840551085e-07
mutations O 0 3.335632356993301e-07
in O 0 4.861011593249032e-09
tumor B-Disease 0 9.124758071266115e-05
risk O 0 1.939451124144398e-07
or O 0 1.8725183625889485e-09
development O 0 1.9796682071415717e-09
. O 0 1.4242931278829474e-08
. O 0 6.589594647721242e-08

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999810457229614
telangiectasia I-Disease 1 0.9999935626983643
: O 0 6.926123887751601e-07
identification O 0 1.0198206013001254e-07
and O 0 6.49452491785496e-09
detection O 0 1.203922206371999e-08
of O 0 1.2132808091536162e-09
founder O 0 5.776153670922213e-07
- O 0 4.031224307254888e-06
effect O 0 4.526613963662385e-07
mutations O 0 1.0767117686327765e-07
in O 0 2.7962812620963007e-10
the O 0 1.6599872865175058e-10
ATM O 0 3.385589053550575e-08
gene O 0 1.2262773019244833e-08
in O 0 1.3723803204968021e-09
ethnic O 0 5.4112703651298943e-08
populations O 0 1.7723930056945392e-07
. O 0 1.4408408333110856e-07

To O 0 1.6498523791597108e-07
facilitate O 0 2.1090716728622283e-08
the O 0 1.4909183887468203e-09
evaluation O 0 2.5823925220436195e-09
of O 0 4.637991379841111e-10
ATM O 0 1.1082173756449265e-07
heterozygotes O 0 5.136252525517193e-07
for O 0 7.335870133573508e-09
susceptibility O 0 1.9394214177737013e-05
to O 0 1.2202744414935296e-07
other O 0 5.15795832711774e-08
diseases O 0 6.422188789656502e-07
, O 0 1.7082676384561069e-09
such O 0 1.5013398302343717e-09
as O 0 0.00012662481458391994
breast B-Disease 1 0.9975236058235168
cancer I-Disease 0 0.004299784079194069
, O 0 3.291252159698388e-09
we O 0 8.894788239288687e-10
have O 0 5.063903740776254e-10
attempted O 0 1.1840505464988382e-08
to O 0 7.913421584682112e-10
define O 0 2.8054767398089098e-09
the O 0 2.7413857295321975e-10
most O 0 2.0195609629070077e-09
common O 0 3.418524796572342e-09
mutations O 0 4.5249951341475025e-08
and O 0 1.9562163000585997e-09
their O 0 4.542339393509565e-09
frequencies O 0 2.709693490032805e-06
in O 0 5.180890639167046e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 0.9999998807907104
( O 0 3.762973392440472e-06
A B-Disease 1 0.9999946355819702
- I-Disease 1 0.9999665021896362
T I-Disease 1 0.9999980926513672
) O 0 5.392785951130463e-08
homozygotes O 0 1.0845756150956731e-06
from O 0 9.242273613097041e-10
10 O 0 1.6213766995676338e-09
ethnic O 0 2.752385697135651e-08
populations O 0 1.204287940481663e-07
. O 0 9.813450674300839e-08

Both O 0 3.9349180269709905e-07
genomic O 0 3.3072382166210446e-07
mutations O 0 1.1757304037018912e-06
and O 0 4.274757881006508e-09
their O 0 1.2238839941502988e-09
effects O 0 8.096178305549984e-08
on O 0 2.241505292488455e-08
cDNA O 0 1.7898918258651975e-07
were O 0 1.0219742563322143e-07
characterized O 0 9.693060292192968e-07
. O 0 2.1706988206915412e-07

Protein O 0 5.451409833767684e-06
- O 0 2.0214963569742395e-06
truncation O 0 7.07588981185836e-07
testing O 0 2.9619547703418903e-08
of O 0 2.2814790334724222e-10
the O 0 1.6752706166744957e-10
entire O 0 2.0750463569640942e-09
ATM O 0 1.85539743569052e-08
cDNA O 0 4.375140250090226e-08
detected O 0 9.144542190142602e-08
92 O 0 3.477510546190388e-08
( O 0 1.3669777532143712e-09
66 O 0 5.698927552089117e-08
% O 0 1.2531801152348976e-09
) O 0 4.749880488930103e-10
truncating O 0 9.513536269878387e-08
mutations O 0 2.072878260150901e-07
in O 0 1.3003822463275583e-09
140 O 0 2.9438753657018424e-08
mutant O 0 4.560748038784368e-06
alleles O 0 1.07651624148275e-06
screened O 0 8.36459639685927e-06
. O 0 2.972040249460406e-07

The O 0 2.4848102953001217e-07
haplotyping O 0 5.6885833146225195e-06
of O 0 1.1198952876156909e-08
patients O 0 2.277843350384501e-06
with O 0 2.827696077289943e-09
identical O 0 2.0156921891612e-06
mutations O 0 4.0601355522085214e-07
indicates O 0 5.585659934581599e-09
that O 0 8.198530743186438e-10
almost O 0 4.984843648969672e-10
all O 0 1.6597013693941953e-11
of O 0 1.808588175056247e-11
these O 0 1.9188067801323427e-10
represent O 0 1.3816146005041219e-09
common O 0 2.891182848685503e-09
ancestry O 0 3.6804937764145507e-08
and O 0 1.4554287774970476e-09
that O 0 3.1368589947788905e-09
very O 0 4.367608941180379e-09
few O 0 5.525557345009702e-09
spontaneously O 0 5.5357080697149286e-08
recurring O 0 2.970209891373088e-07
ATM O 0 1.5828873074497096e-06
mutations O 0 2.0685015442722943e-06
exist O 0 7.75637403194196e-08
. O 0 1.0583200094060885e-07

Assays O 0 0.00014831374573986977
requiring O 0 5.964824140392011e-06
minimal O 0 8.071583579294384e-07
amounts O 0 1.4022141670011479e-08
of O 0 5.196048036282264e-10
genomic O 0 1.75210068675824e-08
DNA O 0 5.0984201749315616e-08
were O 0 2.878379090631711e-09
designed O 0 4.9046274597230877e-08
to O 0 3.3838702950816923e-09
allow O 0 1.5018246202203045e-08
rapid O 0 7.28734264043851e-08
screening O 0 1.1273431255176547e-07
for O 0 4.044805823610886e-09
common O 0 1.6731455332319456e-08
ethnic O 0 3.8861531947986805e-07
mutations O 0 1.4108321920502931e-05
. O 0 2.2704860214162181e-07

These O 0 2.439265358589182e-07
rapid O 0 4.374919342353678e-07
assays O 0 1.2180345265733195e-06
detected O 0 6.438838795475021e-07
mutations O 0 2.9453028105308476e-07
in O 0 4.153349220104019e-09
76 O 0 2.4744289817135723e-07
% O 0 1.1412771838692493e-09
of O 0 2.569283397146904e-10
Costa O 0 1.0536350458778543e-07
Rican O 0 1.5878595149843022e-05
patients O 0 8.922229608288035e-05
( O 0 2.661003084547531e-10
3 O 0 8.147819086090635e-10
) O 0 1.533004417852979e-10
, O 0 1.1633651819664692e-09
50 O 0 1.8027627168848426e-09
% O 0 2.2411698885616005e-10
of O 0 3.365626388696086e-10
Norwegian O 0 0.16654519736766815
patients O 0 0.0003728476585820317
( O 0 1.7657701689710592e-10
1 O 0 5.295459626353249e-10
) O 0 3.1781713372147635e-10
, O 0 5.776126243972612e-10
25 O 0 7.573252025494526e-10
% O 0 1.4705577033868877e-10
of O 0 1.6731056817764767e-10
Polish O 0 0.14740057289600372
patients O 0 0.0023041449021548033
( O 0 5.200241903757785e-10
4 O 0 1.4222779620709503e-09
) O 0 3.333974485375535e-10
, O 0 5.617924458967138e-10
and O 0 1.2517801240008453e-09
14 O 0 2.1528314686491967e-09
% O 0 1.4913870138855145e-10
of O 0 1.5599192770832104e-10
Italian O 0 0.0010905192466452718
patients O 0 0.04981733113527298
( O 0 9.194045524907324e-10
1 O 0 1.6555897763836924e-09
) O 0 2.941211996176918e-10
, O 0 3.435413342689486e-10
as O 0 4.403659381591041e-10
well O 0 2.651766861649918e-10
as O 0 7.808974578082939e-10
in O 0 2.182241942705332e-09
patients O 0 1.0558984087083445e-07
of O 0 5.424554694322126e-10
Amish O 0 2.7561450224311557e-06
/ O 0 1.224279628786462e-07
Mennonite O 0 2.841322270796809e-07
and O 0 4.5854132935119196e-08
Irish O 0 1.8804799140070827e-07
English O 0 6.037628708099874e-08
backgrounds O 0 7.089480646982338e-08
. O 0 8.048372279745308e-08

Additional O 0 5.455216978589306e-06
mutations O 0 1.4365163224283606e-05
were O 0 1.3956534417047806e-07
observed O 0 4.7079620202339356e-08
in O 0 1.1198306726356577e-09
Japanese O 0 1.157376772198404e-08
, O 0 1.0589873422617302e-09
Utah O 0 8.967155018524409e-09
Mormon O 0 1.675745231466408e-08
, O 0 5.85664461372204e-10
and O 0 1.2795869919202119e-09
African O 0 2.1352306589506043e-09
American O 0 5.574753103587682e-08
patients O 0 4.29279907621094e-06
. O 0 1.0005037154314778e-07

These O 0 1.3216956062933605e-07
assays O 0 4.5161488060330157e-07
should O 0 4.4502534990442655e-09
facilitate O 0 3.1995459615075106e-09
screening O 0 4.408268594602305e-08
for O 0 1.593438803126901e-08
A B-Disease 1 0.9999746084213257
- I-Disease 1 0.9999001026153564
T I-Disease 1 0.9999984502792358
heterozygotes O 0 2.1662559447577223e-05
in O 0 4.591397040343281e-09
the O 0 1.9238026727208535e-09
populations O 0 7.510710275937527e-09
studied O 0 2.5876252252032828e-08
. O 0 1.0920890858301391e-08
. O 0 6.191875456806883e-08

The O 0 5.578375748882536e-06
von B-Disease 1 0.9073078036308289
Hippel I-Disease 1 0.9933116436004639
- I-Disease 1 0.9137193560600281
Lindau I-Disease 1 0.9930423498153687
tumor I-Disease 0 0.000735469744540751
suppressor O 0 2.6832563889911398e-05
gene O 0 1.8373179955233354e-07
is O 0 3.463944464598967e-09
required O 0 1.7848892364114022e-09
for O 0 4.6138862175304496e-10
cell O 0 9.815790491529697e-08
cycle O 0 3.670475479111701e-08
exit O 0 7.193737872057682e-08
upon O 0 3.660387193349379e-08
serum O 0 1.245825842488557e-06
withdrawal O 0 6.979481099733675e-07
. O 0 1.9826151742563525e-07

The O 0 3.1843032388678694e-07
inactivation O 0 2.6702216473495355e-06
of O 0 9.979379989033532e-09
the O 0 4.9382421707377944e-08
von B-Disease 1 0.9856494069099426
Hippel I-Disease 1 0.9993065595626831
- I-Disease 1 0.9976217150688171
Lindau I-Disease 1 0.9981839060783386
( I-Disease 0 1.904083859471939e-07
VHL I-Disease 0 1.7294429198955186e-05
) I-Disease 0 3.2760596013758914e-08
tumor I-Disease 0 4.896896825812291e-06
suppressor O 0 2.790813050523866e-05
gene O 0 4.688739636549144e-07
predisposes O 0 4.914516830467619e-05
affected O 0 5.2426230467972346e-08
individuals O 0 8.679647001130775e-10
to O 0 4.501251815725027e-09
the O 0 2.9719146255047235e-08
human O 0 7.021683268249035e-05
VHL B-Disease 1 0.9999964237213135
cancer I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999991655349731
and O 0 1.3184275360345055e-07
is O 0 2.8099767845901624e-08
associated O 0 2.5414800930434467e-08
with O 0 4.559772293077913e-08
sporadic B-Disease 1 0.955623984336853
renal I-Disease 1 0.9999994039535522
cell I-Disease 1 0.9999980926513672
carcinomas I-Disease 1 1.0
( O 0 1.9911335584765766e-06
RCC B-Disease 0 0.003868096973747015
) O 0 1.3065511339505065e-08
and O 0 8.321342903627738e-08
brain B-Disease 0 0.0014201812446117401
hemangioblastomas I-Disease 0 0.00023072483600117266
. O 0 5.436190804175567e-07

VHL O 0 0.002673046663403511
- O 0 0.0003642961091827601
negative O 0 2.3429138309438713e-05
786 O 0 9.498388862994034e-06
- O 0 0.00012690911535173655
0 O 0 2.266649062221404e-06
RCC B-Disease 0 4.5426622818922624e-05
cells O 0 1.3271382215407357e-07
are O 0 4.6280610455085025e-09
tumorigenic O 0 2.6838163194042863e-06
in O 0 2.5539003800645332e-08
nude O 0 0.0024752800818532705
mice O 0 1.5519073713221587e-05
which O 0 1.5552922505435163e-08
is O 0 6.4731544568985555e-09
suppressed O 0 2.034555457441911e-08
by O 0 8.550999353040822e-10
the O 0 8.54014414741755e-10
reintroduction O 0 1.503203748143278e-07
of O 0 1.0470197153722438e-08
VHL B-Disease 0 3.060382732655853e-05
. O 0 5.425127937996876e-07

Remarkably O 0 0.0013204236747696996
, O 0 8.239013737920686e-08
this O 0 3.538778603484616e-09
occurs O 0 1.8024429726537505e-09
without O 0 2.605545779132967e-10
affecting O 0 1.1350165252110855e-09
the O 0 1.9887044788724495e-10
growth O 0 2.477619442942114e-09
rate O 0 3.88713683463493e-09
and O 0 1.0066358857585556e-09
cell O 0 4.262840036517446e-08
cycle O 0 1.2612088262642374e-08
profile O 0 3.1478769813020335e-08
of O 0 2.1263535376903064e-10
these O 0 3.246738711215613e-10
cells O 0 2.4306343604507674e-09
in O 0 7.050784955886513e-10
culture O 0 1.6058290697174016e-08
. O 0 4.464453695618431e-08

The O 0 3.3000674193317536e-07
786 O 0 3.461906771917711e-06
- O 0 3.6430624277272727e-06
0 O 0 3.3593710213608574e-07
cell O 0 5.236622087068099e-07
line O 0 2.1069493527647865e-07
, O 0 7.886510333676711e-10
like O 0 2.945008459320775e-09
many O 0 6.5444130115110966e-09
cancer B-Disease 0 5.082648044663074e-07
cells O 0 6.789321993494468e-09
, O 0 9.06925257115887e-10
fails O 0 6.082116499328549e-08
to O 0 2.2581110314945363e-09
exit O 0 1.6203573593998044e-08
the O 0 6.244409433975306e-10
cell O 0 1.2785305614215758e-07
cycle O 0 3.9877839697055606e-08
upon O 0 1.1109640318807124e-08
serum O 0 3.837158715214173e-07
withdrawal O 0 4.6754516347391473e-07
. O 0 1.3879629534585547e-07

Here O 0 1.7506262111055548e-06
, O 0 1.5997636992892694e-08
it O 0 1.8596765238854118e-09
is O 0 1.063085508512529e-09
shown O 0 4.061395220134045e-09
that O 0 4.2597636529251304e-10
reintroduction O 0 5.244460421494068e-09
of O 0 8.54261661409339e-11
the O 0 1.8969258108736398e-10
wild O 0 6.147649500576335e-09
- O 0 1.0837498848559335e-05
type O 0 7.995994565135334e-06
VHL B-Disease 0 3.1121701340453e-06
gene O 0 7.127565737619079e-08
restores O 0 8.044735011480952e-08
the O 0 7.925142764264592e-10
ability O 0 6.242269368073039e-09
of O 0 5.841717110044442e-10
VHL O 0 1.503604380559409e-05
- O 0 0.001583098666742444
negative O 0 0.0008972017094492912
RCC B-Disease 0 0.21054136753082275
cancer I-Disease 0 2.442090590193402e-05
cells O 0 6.734817148412731e-09
to O 0 7.752905539781807e-10
exit O 0 1.0945874429069136e-08
the O 0 4.91541141123264e-10
cell O 0 4.368819261912904e-08
cycle O 0 1.432717677829487e-08
and O 0 1.9538259898865817e-09
enter O 0 5.490311316691532e-09
G0 O 0 2.0015093014080776e-06
/ O 0 1.585659674674389e-07
quiescence O 0 6.554246851919743e-07
in O 0 1.932829185591345e-08
low O 0 1.3675856962436228e-06
serum O 0 1.0546224984864239e-05
. O 0 1.894798487001026e-07

Both O 0 4.250907295499928e-06
VHL O 0 0.00011852230818476528
- O 0 2.8188986107124947e-05
positive O 0 3.1341878070634266e-07
and O 0 4.435967682070441e-08
VHL O 0 1.1636435374384746e-05
- O 0 4.819613241124898e-05
negative O 0 3.1671540909883333e-06
RCC B-Disease 0 1.3934224625700153e-05
cells O 0 5.2235787251220245e-08
exit O 0 3.073138898912475e-08
the O 0 6.483703574033939e-10
cell O 0 1.072882369612671e-07
cycle O 0 1.1963956936256182e-08
by O 0 4.462510805325337e-09
contact O 0 7.817073566229737e-08
inhibition O 0 5.073006263955904e-07
. O 0 2.6216659421152144e-07

The O 0 5.211696247897635e-07
cyclin O 0 1.3480890629580244e-05
- O 0 9.703669547889149e-07
dependent O 0 2.6506802441872424e-07
kinase O 0 1.1254969649598934e-06
inhibitor O 0 2.449725684527948e-07
, O 0 1.9245218751962057e-09
p27 O 0 1.2511128488768009e-07
, O 0 8.102674642351815e-10
accumulates O 0 5.873497599395705e-08
upon O 0 4.561326871765914e-09
serum O 0 7.644094068837148e-08
withdrawal O 0 7.047535000026528e-09
, O 0 4.320857560635716e-10
only O 0 3.3907426866264245e-10
in O 0 9.435779935174082e-11
the O 0 1.7486369296992876e-10
presence O 0 2.1873676203654213e-09
of O 0 4.103377915232187e-10
VHL B-Disease 0 2.187603968195617e-06
, O 0 1.9502777170998797e-09
as O 0 1.07525577330847e-09
a O 0 3.6872440656310346e-09
result O 0 1.8122918721275028e-09
of O 0 8.756214503469195e-11
the O 0 2.6250548956774367e-10
stabilization O 0 4.128596131636186e-09
of O 0 1.4074887089154942e-10
the O 0 1.357685741609771e-09
protein O 0 1.5750345028209267e-07
. O 0 8.485305613703531e-08

We O 0 2.69172147682184e-07
propose O 0 1.825842019798074e-07
that O 0 4.095467076581372e-09
the O 0 1.4181875673813238e-09
loss O 0 2.7427065063534428e-08
of O 0 8.455118272188145e-10
wild O 0 3.393269309981406e-08
- O 0 7.179417298175395e-05
type O 0 3.491820098133758e-05
VHL B-Disease 0 5.689668341801735e-06
gene O 0 1.8192596940025396e-07
results O 0 6.568949384444522e-09
in O 0 2.158656725592678e-10
a O 0 4.25437418627439e-09
specific O 0 2.4574386969788975e-09
cellular O 0 3.6352500387693e-07
defect O 0 2.5938470571418293e-06
in O 0 6.680137776271522e-09
serum O 0 4.232967683037714e-07
- O 0 2.0102122277876333e-07
dependent O 0 6.32870893468862e-08
growth O 0 3.045014018709935e-09
control O 0 3.99882793544748e-08
, O 0 1.3867866854866406e-09
which O 0 1.5401278474769242e-08
may O 0 1.0464750488381469e-07
initiate O 0 2.678809778444702e-07
tumor B-Disease 0 6.031151860952377e-05
formation O 0 1.9573411691453657e-07
. O 0 1.4240599455206393e-07

This O 0 2.8075774594071845e-07
is O 0 3.7169666455838524e-08
corrected O 0 1.1907843600056367e-07
by O 0 6.570374799785839e-10
the O 0 2.8871310897571334e-10
reintroduction O 0 1.8097711773634728e-08
of O 0 5.109805356617869e-10
wild O 0 1.241383262851059e-08
- O 0 4.84205738757737e-05
type O 0 0.0002547136100474745
VHL B-Disease 0 0.00020983204012736678
, O 0 7.863581430456179e-08
implicating O 0 3.312482476758305e-06
VHL B-Disease 0 3.740768306670361e-06
as O 0 6.361357662854061e-09
the O 0 5.222576815455682e-10
first O 0 5.193513619161649e-09
tumor B-Disease 0 1.7501076854387065e-07
suppressor O 0 3.4308141039218754e-07
involved O 0 3.011467963887071e-09
in O 0 1.8087548125933495e-10
the O 0 8.791507799532639e-11
regulation O 0 1.90697546642582e-09
of O 0 2.0453701232714394e-10
cell O 0 5.561297555800593e-08
cycle O 0 8.468486356605354e-09
exit O 0 3.1784107790144844e-08
, O 0 8.618148417127713e-10
which O 0 1.955779760365317e-09
is O 0 2.8574778099255127e-09
consistent O 0 1.315141862079372e-08
with O 0 2.408573618328802e-10
its O 0 1.2448420072530553e-09
gatekeeper O 0 2.3625176481800736e-07
function O 0 3.597517617137669e-09
in O 0 5.045758810773293e-10
the O 0 5.676652481412248e-09
kidney O 0 9.663307537266519e-06
. O 0 2.6864480417998493e-08
. O 0 7.825070014177982e-08

Piebaldism B-Disease 1 0.9999823570251465
with O 0 0.27776768803596497
deafness B-Disease 1 1.0
: O 0 1.2613608646461216e-07
molecular O 0 1.6335820873791818e-07
evidence O 0 1.1199636773540078e-08
for O 0 2.2057473625380908e-09
an O 0 1.5520716090122733e-07
expanded O 0 0.028049206361174583
syndrome O 1 0.9999692440032959
. O 0 4.91377591060882e-07

In O 0 2.975233712732006e-07
a O 0 6.03848064884005e-08
South O 0 6.493211746061434e-09
African O 0 1.8150385638904254e-09
girl O 0 1.1720903358991563e-07
of O 0 8.97430241231234e-10
Xhosa O 0 8.439174052909948e-07
stock O 0 2.0243748011239404e-08
with O 0 8.09077249641632e-09
severe O 0 0.008512799628078938
piebaldism B-Disease 0 0.028486505150794983
and O 0 3.09181723423535e-06
profound O 0 0.17816580832004547
congenital O 1 0.9999998807907104
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
we O 0 1.120291472034296e-05
identified O 0 1.0543789130679215e-07
a O 0 8.60995452711677e-09
novel O 0 4.5784744884258544e-08
missense O 0 9.190038952056057e-08
substitution O 0 2.602045690025534e-09
at O 0 2.7512334077606226e-10
a O 0 3.3625739970233326e-09
highly O 0 6.633008808876184e-09
conserved O 0 6.1749840796210265e-09
residue O 0 1.5039402612160302e-08
in O 0 2.667553400392819e-10
the O 0 2.2814268529902648e-10
intracellular O 0 1.153911721729628e-08
kinase O 0 4.337972114853983e-08
domain O 0 1.0644651826652307e-09
of O 0 5.096896169010101e-11
the O 0 1.1868174221163486e-09
KIT O 0 1.0085918802360538e-05
proto O 0 0.0005171028897166252
- O 0 4.2800093069672585e-05
oncogene O 0 1.7954969735001214e-05
, O 0 3.731329201173139e-08
R796G O 0 2.504511712686508e-06
. O 0 1.3320847358500032e-07

Though O 0 1.3931461580796167e-05
auditory B-Disease 0 1.852314562711399e-05
anomalies I-Disease 0 0.0003595322777982801
have O 0 1.0756546942047862e-07
been O 0 4.9097192089675445e-08
observed O 0 4.095336336717992e-08
in O 0 4.315884982730722e-09
mice O 0 1.3176147149351891e-05
with O 0 8.131769924091259e-09
dominant O 0 5.691111709893448e-06
white O 0 9.548546131554758e-07
spotting O 0 9.881968253466766e-06
( O 0 2.266526522021195e-08
W O 0 0.0013128826394677162
) O 0 1.630587553869134e-09
due O 0 3.31844702827766e-08
to O 0 1.9773037251979986e-07
KIT O 0 0.22932109236717224
mutations O 0 0.00261559896171093
, O 0 3.531994479999412e-06
deafness B-Disease 1 1.0
is O 0 2.0843551737925736e-06
not O 0 3.0151131369393624e-08
typical O 0 8.50536565621951e-08
in O 0 1.320994513775986e-08
human O 0 4.9790525480375436e-08
piebaldism B-Disease 0 3.550396650098264e-05
. O 0 1.709271373329102e-07

Thus O 0 2.268474190714187e-06
, O 0 8.240534477010897e-09
the O 0 4.839223466390763e-10
occurrence O 0 1.129038373903768e-08
of O 0 1.0802721384095548e-08
sensorineural B-Disease 1 0.9999909400939941
deafness I-Disease 1 1.0
in O 0 7.902144716354087e-07
this O 0 3.8816267533547943e-08
patient O 0 2.7429990950622596e-05
extends O 0 2.678186490356893e-07
considerably O 0 2.1955304418952437e-07
the O 0 1.2491755407850746e-09
phenotypic O 0 5.882763502995658e-07
range O 0 8.99315466540429e-09
of O 0 4.1793168925607915e-10
piebaldism B-Disease 0 1.5732675819890574e-06
due O 0 2.5448075646750112e-08
to O 0 1.343738453840615e-08
KIT O 0 2.9013544917688705e-06
gene O 0 8.264085238351981e-08
mutation O 0 3.5287918365156656e-08
in O 0 4.01700256391635e-10
humans O 0 3.2682692108210176e-09
and O 0 3.793934943985278e-09
tightens O 0 0.011926255188882351
the O 0 1.6380916179059568e-08
clinical O 0 5.287340627546655e-07
similarity O 0 6.233111093933985e-08
between O 0 2.5098296774217488e-09
piebaldism B-Disease 0 1.1515237474668538e-06
and O 0 8.113577587565146e-10
the O 0 9.16670767070471e-11
various O 0 1.9754350932821296e-10
forms O 0 1.0354315627125743e-08
of O 0 3.258231799918576e-07
Waardenburg B-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999958276748657
. O 0 3.3995529946651004e-08
. O 0 5.391304824797771e-08

Cycloheximide O 0 0.00011885775893460959
facilitates O 0 1.5236348644975806e-06
the O 0 9.486027074956382e-09
identification O 0 8.074399815427569e-09
of O 0 5.111014389491686e-10
aberrant O 0 1.482497822280493e-07
transcripts O 0 1.3892844208385213e-07
resulting O 0 3.390746172726722e-08
from O 0 8.786936178672988e-10
a O 0 1.1519809106630419e-08
novel O 0 4.4989196368305784e-08
splice O 0 8.437113478976244e-07
- O 0 1.7323906149613322e-06
site O 0 1.2632581558591482e-07
mutation O 0 5.2042260278994945e-08
in O 0 8.493393210962097e-10
COL17A1 O 0 7.755810429443954e-07
in O 0 1.2152030492984522e-09
a O 0 5.465583186037293e-08
patient O 0 1.6066391253843904e-05
with O 0 7.750044517251808e-08
generalized O 0 0.002935911761596799
atrophic B-Disease 1 0.9997532963752747
benign I-Disease 1 0.9971711039543152
epidermolysis I-Disease 1 0.9927056431770325
bullosa I-Disease 1 0.877044677734375
. O 0 1.6452673662570305e-05

Patients O 1 0.9392620921134949
with O 0 2.2569511202163994e-06
generalized O 0 0.0015330826863646507
atrophic B-Disease 1 0.9992719292640686
benign I-Disease 1 0.9931208491325378
epidermolysis I-Disease 1 0.9831406474113464
bullosa I-Disease 0 0.42217105627059937
often O 0 6.952111561986385e-06
show O 0 3.47984666859702e-07
decreased O 0 1.5341095149778994e-07
expression O 0 8.82003625690686e-09
of O 0 1.3198000470282523e-09
type O 0 6.010208380757831e-06
XVII O 0 0.011573228053748608
collagen O 0 0.00021594774443656206
, O 0 1.1821843060033643e-08
a O 0 3.100563716884608e-08
transmembrane O 0 1.3407683354671462e-06
hemidesmosomal O 0 1.0327441941626603e-06
protein O 0 2.1911937153618055e-08
encoded O 0 2.7413570080625504e-08
by O 0 1.1148400425042837e-08
COL17A1 O 0 2.9396973332040943e-05
. O 0 5.215554210735718e-07

This O 0 1.3975899548768211e-07
report O 0 1.8911078925043512e-08
documents O 0 2.5028787931091756e-09
a O 0 5.168896866081241e-09
novel O 0 4.813342968645884e-08
splice O 0 5.895113304177357e-07
- O 0 1.9542837890185183e-06
site O 0 3.968995443415224e-08
mutation O 0 4.797458430516599e-08
in O 0 6.566678867336861e-10
COL17A1 O 0 1.6602316463831812e-06
in O 0 2.324451520152593e-09
a O 0 3.8074059460768694e-08
patient O 0 1.72777126863366e-05
with O 0 8.543459983911816e-08
generalized O 0 0.0008051654440350831
atrophic B-Disease 1 0.9997226595878601
benign I-Disease 1 0.9832667112350464
epidermolysis I-Disease 1 0.9585578441619873
bullosa I-Disease 0 0.05135563760995865
, O 0 3.6367129752079563e-08
and O 0 2.9581537219769416e-09
applies O 0 1.9500703274388798e-08
a O 0 4.353585936200943e-09
new O 0 1.9194554834456312e-09
methodology O 0 3.357510935941832e-09
to O 0 9.54537227038088e-10
define O 0 3.0908385184602594e-08
and O 0 5.223675714205456e-09
characterize O 0 7.053710504578703e-08
the O 0 1.7567076682212246e-09
resulting O 0 1.6532426982962534e-08
mRNA O 0 4.114338381100424e-08
splice O 0 2.8236204343556892e-06
variants O 0 1.496829327152227e-06
. O 0 2.9764026976408786e-07

Mutational O 0 0.008441570214927197
analysis O 0 3.167449904140085e-06
of O 0 2.6635195382596066e-08
COL17A1 O 0 1.578921546752099e-05
identified O 0 1.8192510253811633e-07
a O 0 4.4207475013990916e-08
maternally O 0 5.607253115158528e-06
inherited O 0 9.990037142415531e-06
G O 0 3.1959247280610725e-05
- O 0 1.6057363154686755e-06
to O 0 2.157321574713933e-07
- O 0 1.4099873624218162e-05
T O 0 4.7955977606761735e-06
transversion O 0 1.463151164671217e-07
at O 0 3.6025077365664515e-10
the O 0 1.6625632814903923e-10
- O 0 3.68035308895287e-08
1 O 0 2.626779460612738e-09
position O 0 1.3912303309382423e-08
of O 0 6.170789434989388e-10
exon O 0 6.770488880647463e-07
32 O 0 2.195691592987714e-07
. O 0 1.1592086934797408e-07

This O 0 7.832819903796917e-08
acceptor O 0 1.616823084304997e-07
splice O 0 8.221492748816672e-07
- O 0 1.792308808035159e-06
site O 0 1.0218923307547811e-07
mutation O 0 5.667718738777694e-08
led O 0 2.9450870631109183e-09
to O 0 1.5116468077280842e-09
the O 0 3.3488881112653246e-10
formation O 0 7.109149380291058e-10
of O 0 1.9360740788343378e-10
aberrant O 0 8.89098004108746e-08
transcripts O 0 4.05641173983895e-08
present O 0 4.2877910111371875e-09
at O 0 1.282912998057384e-09
extremely O 0 2.57588624208438e-07
low O 0 4.110529062018031e-06
levels O 0 2.0141747825164202e-07
. O 0 1.3222478401075932e-07

Based O 0 1.8105604340235004e-06
on O 0 2.7205945940522724e-08
our O 0 1.7742719515823069e-09
recent O 0 2.8808835317306603e-09
finding O 0 2.3718800257199746e-09
that O 0 3.304007956117516e-09
cycloheximide O 0 2.547149506426649e-06
stabilized O 0 6.090944225434214e-06
mutant O 0 6.211286063262378e-07
COL17A1 O 0 1.8625580651132623e-06
transcripts O 0 7.638555388211898e-08
in O 0 3.6717693330245993e-09
keratinocytes O 0 2.9939675982859626e-07
homozygous O 0 2.715669893404993e-07
for O 0 1.5038704725967023e-09
a O 0 1.0254125726305574e-07
frameshift O 0 0.1662885993719101
mutation O 0 8.345302262569021e-07
, O 0 5.062599783833832e-10
the O 0 1.5611932580039678e-10
effects O 0 1.1786068121466542e-08
of O 0 1.1152429674199382e-10
the O 0 3.5524647112872287e-10
splice O 0 3.6976700812374474e-07
- O 0 1.738428181852214e-06
site O 0 6.399304908200065e-08
mutation O 0 1.61872328874324e-08
on O 0 7.730107665082642e-10
splicing O 0 1.2783167413488172e-08
of O 0 4.890312044203426e-10
COL17A1 O 0 1.262799401047232e-06
transcripts O 0 3.4783461444476416e-08
were O 0 2.0419563817597464e-09
determined O 0 2.1380670567339166e-09
using O 0 7.366784404716498e-10
reverse O 0 4.425539401609058e-08
transcriptase O 0 1.1142750366843757e-07
polymerase O 0 8.16830407757152e-08
chain O 0 3.812958482285467e-08
reaction O 0 2.60316768141422e-09
of O 0 3.262965245220961e-11
total O 0 3.1426064528439213e-10
RNA O 0 3.3101266172508303e-09
from O 0 8.929362804721563e-10
keratinocytes O 0 2.0409125056630728e-07
incubated O 0 2.1203702260663704e-07
for O 0 2.618845140744952e-09
2 O 0 4.714710399866817e-08
. O 0 1.15493172359038e-07

5 O 0 1.547340843899292e-06
h O 0 6.099880351939646e-07
in O 0 1.4071458442899143e-09
the O 0 3.3485431094604223e-10
presence O 0 3.818742211336712e-09
or O 0 9.63049973101704e-10
absence O 0 5.5000271004246315e-09
of O 0 8.546336416337397e-10
10 O 0 1.5753432336396145e-08
microg O 0 3.022909822902875e-06
cycloheximide O 0 5.114840860187542e-06
per O 0 1.9627806580047036e-07
ml O 0 2.824414877977688e-06
. O 0 1.80377881520144e-07

Using O 0 3.618481514422456e-07
this O 0 5.770215860678718e-09
approach O 0 2.670763521450681e-08
, O 0 3.801134962344577e-09
an O 0 8.380112603845191e-09
abnormally O 0 2.5205633846780984e-06
spliced O 0 0.0005430344608612359
transcript O 0 3.863840174744837e-05
was O 0 5.933309239480877e-07
identified O 0 1.1119816178961628e-08
that O 0 3.6020267324410327e-10
contains O 0 2.54372772845457e-10
an O 0 2.17150353254425e-10
extra O 0 4.084841798146499e-09
264 O 0 1.6144989345434624e-08
bases O 0 2.1211290501810254e-09
upstream O 0 5.923875612268148e-09
from O 0 5.431304295200334e-10
exon O 0 3.819509331037807e-08
32 O 0 7.871650886670523e-09
, O 0 3.6094266464559155e-10
resulting O 0 2.4119122254973036e-09
in O 0 1.0396363769871186e-09
a O 0 8.627382896975178e-08
premature O 0 7.1929607656784356e-06
termination O 0 3.781955228987499e-07
codon O 0 2.1031270591720386e-07
27 O 0 1.2180305475339992e-07
bp O 0 5.015567694499623e-07
downstream O 0 2.8917963135199898e-08
from O 0 8.583844746112845e-10
the O 0 1.2306912156034855e-09
cryptic O 0 7.289788186426449e-07
splice O 0 2.9255322715471266e-06
site O 0 7.950068265927257e-07
. O 0 2.0641708431412553e-07

Three O 0 1.221182515109831e-07
other O 0 4.111590623523398e-09
splice O 0 5.850620823366626e-07
variants O 0 6.874722089378338e-07
, O 0 9.76275948971761e-09
including O 0 8.0298573346127e-10
one O 0 2.360052153704828e-09
derived O 0 9.92166127034011e-10
from O 0 6.914670919178079e-11
the O 0 9.275753082294003e-11
skipping O 0 7.300513971131295e-09
of O 0 2.0848681114848944e-10
exon O 0 9.083803576004357e-08
32 O 0 3.356859679115587e-08
, O 0 3.21888826704253e-09
were O 0 1.757278411673724e-08
also O 0 2.032348902503145e-07
identified O 0 3.7281924392118526e-07
. O 0 6.783189121506439e-08

These O 0 1.9802588724360248e-07
results O 0 5.35132933521254e-08
indicate O 0 7.876532315265194e-09
the O 0 2.3206804533604242e-10
usefulness O 0 8.102694515343956e-09
of O 0 5.1169346537705e-10
cycloheximide O 0 5.3453077271115035e-06
treatment O 0 3.7334764328988967e-06
in O 0 1.7421394327143958e-09
evaluating O 0 4.328250202689787e-09
the O 0 4.751085636023333e-10
abnormal O 0 4.566454325782843e-09
processing O 0 4.2648037879011724e-10
of O 0 5.553159321269874e-11
mRNA O 0 1.4064320819073828e-09
due O 0 8.487012759239576e-10
to O 0 7.579553096270786e-10
splice O 0 2.5390679070369515e-07
- O 0 5.180298103368841e-06
site O 0 2.484097194610513e-07
mutations O 0 1.53290145021856e-07
, O 0 1.354220069416101e-09
because O 0 4.425452448941769e-09
( O 0 1.8470062979059065e-10
i O 0 6.442214317559092e-09
) O 0 3.396607162198251e-10
aberrant O 0 1.4812394866225986e-08
splicing O 0 5.741116382296241e-08
often O 0 2.2655063602883274e-08
generates O 0 1.9659198713384285e-08
a O 0 1.7264643048520156e-08
premature O 0 1.1363046041878988e-06
termination O 0 1.8631394027579518e-07
codon O 0 6.640949123948303e-08
, O 0 3.033362450111099e-09
( O 0 4.714102996850045e-10
ii O 0 1.7551873554566555e-07
) O 0 6.663693485897682e-10
transcripts O 0 8.132111872782843e-09
with O 0 2.503126816932877e-09
premature O 0 5.194626737647923e-07
termination O 0 4.94517919946702e-08
codons O 0 9.62947677152215e-09
can O 0 3.148764138316551e-09
occur O 0 7.184393080450491e-10
at O 0 2.7062971308389194e-10
low O 0 3.921491043001879e-08
or O 0 1.3416999067317192e-08
undetectable O 0 3.084220168148022e-07
levels O 0 5.909543521198657e-09
due O 0 3.1215676710161233e-09
to O 0 6.817857833851804e-09
nonsense O 0 4.2274970724065497e-07
- O 0 8.247755545198743e-08
mediated O 0 1.048073130505145e-07
mRNA O 0 5.56987211908222e-09
decay O 0 1.4233044964839792e-08
, O 0 3.994585495714631e-10
and O 0 6.551153508560503e-10
( O 0 2.600139548114555e-10
iii O 0 4.198648468900501e-07
) O 0 1.951943884304086e-10
the O 0 2.206137494908944e-10
levels O 0 2.045916214221677e-10
of O 0 1.2896757446700935e-11
these O 0 7.321646761093703e-11
transcripts O 0 1.888659229010159e-09
can O 0 1.0649404691420727e-09
be O 0 8.099044213061291e-10
increased O 0 8.489251079879523e-09
by O 0 1.3638479678945714e-08
cycloheximide O 0 1.0725774700404145e-05
. O 0 1.1940889521611098e-07

A O 0 3.787679133893107e-06
deletion O 0 1.5822768546058796e-05
mutation O 0 2.2640997485723346e-06
in O 0 9.543975387771297e-09
COL17A1 O 0 4.199584054731531e-06
in O 0 2.8765623216742142e-09
five O 0 4.552505039612242e-09
Austrian O 0 8.564717427361757e-05
families O 0 2.3387235259519912e-08
with O 0 2.6349798787350664e-08
generalized O 0 0.0055864485912024975
atrophic B-Disease 1 0.9999330043792725
benign I-Disease 1 0.9993770718574524
epidermolysis I-Disease 1 0.9960883855819702
bullosa I-Disease 1 0.6058607697486877
represents O 0 2.2461804292106535e-06
propagation O 0 2.185976200053119e-07
of O 0 2.926116904333753e-09
an O 0 4.088834870685787e-08
ancestral O 0 1.8525773839428439e-06
allele O 0 2.5410847229068168e-05
. O 0 3.039033913410094e-07

Patients O 1 0.8838517665863037
with O 0 1.0926517006737413e-06
generalized O 0 0.0004669315239880234
atrophic B-Disease 1 0.999319314956665
benign I-Disease 1 0.9977462887763977
epidermolysis I-Disease 1 0.9963884353637695
bullosa I-Disease 1 0.7101097702980042
, O 0 1.8994265360561258e-07
a O 0 4.274629716860545e-08
usually O 0 2.4308210555545884e-08
nonlethal O 0 2.5943418791030126e-07
form O 0 1.9457754518725778e-08
of O 0 1.645993563670345e-08
junctional B-Disease 0 0.3685366213321686
epidermolysis I-Disease 1 0.9170002937316895
bullosa I-Disease 0 0.04828713461756706
, O 0 5.505928868387855e-08
have O 0 7.893225628663458e-09
generalized O 0 4.298954650039377e-07
blistering B-Disease 0 0.00931473821401596
, O 0 9.851555660134181e-07
nail B-Disease 1 0.9999524354934692
dystrophy I-Disease 1 0.9999886751174927
, O 0 1.3645053513755556e-05
patchy B-Disease 1 0.9867765307426453
alopecia I-Disease 1 0.9999936819076538
, O 0 1.1784459275077097e-06
and O 0 8.504490324412473e-06
dental B-Disease 1 0.9434540867805481
abnormalities I-Disease 1 0.9995306730270386
. O 0 1.0089007673741435e-06

Skin B-Disease 1 0.9994833469390869
fragility I-Disease 0 0.00125130417291075
in O 0 6.901873206288656e-08
most O 0 1.286643325215664e-08
cases O 0 9.632324271535708e-09
is O 0 3.991814878645528e-09
due O 0 9.54020773491493e-09
to O 0 8.352442293357853e-09
mutations O 0 5.101153632836031e-08
in O 0 2.433885315511475e-10
the O 0 3.734123565912739e-10
gene O 0 3.6402937553248194e-08
encoding O 0 9.326040384394219e-08
type O 0 2.7915525606658775e-06
XVII O 0 0.00021393914357759058
collagen O 0 0.00014515621296595782
( O 0 5.6207813514674854e-08
COL17A1 O 0 1.975472696358338e-05
) O 0 5.0905981652249466e-08
. O 0 1.3213629301844776e-07

Recently O 0 4.112324859306682e-06
, O 0 2.211300298426977e-08
we O 0 3.0136342310527198e-09
reported O 0 1.2814854066789394e-08
five O 0 2.1565136343326685e-09
Austrian O 0 2.1450778149301186e-05
families O 0 2.7601348762118505e-08
with O 0 3.5245808049921834e-08
generalized O 0 0.0012783074053004384
atrophic B-Disease 1 0.9997267127037048
benign I-Disease 1 0.9864805936813354
epidermolysis I-Disease 1 0.9721664786338806
bullosa I-Disease 0 0.34647104144096375
who O 0 7.479100531782024e-06
share O 0 2.2896161411267713e-08
the O 0 2.7154916093508064e-09
same O 0 4.7656026680442665e-08
COL17A1 O 0 0.00021244589879643172
mutation O 0 8.424735824519303e-06
. O 0 1.6119979306949972e-07

Affected O 0 2.4744180336710997e-05
individuals O 0 1.1362477891907474e-07
in O 0 3.75349840098238e-09
three O 0 4.212210136245176e-09
families O 0 7.450384309493074e-09
are O 0 1.4439317519432393e-09
homozygous O 0 1.4886195742747077e-07
for O 0 2.0807375822329277e-09
4003delTC O 0 2.1056256116480654e-07
, O 0 3.4155787087541967e-09
whereas O 0 2.9475035745463174e-09
those O 0 4.046855905937008e-10
in O 0 1.7822757159002833e-10
two O 0 1.2090233258987837e-09
others O 0 6.500052052160754e-09
are O 0 2.1849240194882213e-09
compound O 0 4.428165709668974e-07
heterozygotes O 0 1.5158017959038261e-05
. O 0 2.3400380655402842e-07

To O 0 3.97430653720221e-07
determine O 0 7.299166782104294e-08
if O 0 2.063513804273498e-09
the O 0 4.226194671996808e-10
occurrence O 0 4.057570279769607e-09
of O 0 3.3851854652766633e-10
4003delTC O 0 1.3863461845176062e-07
in O 0 1.1988369186255454e-09
these O 0 3.2130839655586385e-10
unrelated O 0 9.760264596536672e-09
families O 0 3.171330309470477e-09
signifies O 0 6.3532090699425225e-09
propagation O 0 5.529711355478639e-09
of O 0 1.375440317197274e-10
an O 0 2.5709563367115607e-09
ancestral O 0 6.247250894375611e-08
allele O 0 1.8612604435475077e-07
or O 0 8.408030383044718e-10
a O 0 1.708626840013494e-08
mutational O 0 4.520665970630944e-05
hot O 0 6.267770459089661e-06
spot O 0 5.118370154377772e-07
, O 0 7.557642511812901e-09
haplotypes O 0 2.9952585123282915e-07
were O 0 3.621581257107209e-08
determined O 0 5.6868746156624184e-08
for O 0 1.926141246499924e-09
polymorphisms O 0 2.4652428010085714e-07
both O 0 2.5447091100971875e-09
within O 0 1.132780202972583e-09
and O 0 2.2702385749084897e-08
flanking O 0 4.359433296485804e-05
COL17A1 O 0 0.004226141609251499
. O 0 9.814120858209208e-07

Five O 0 1.3193460972615867e-06
intragenic O 0 9.648104423831683e-06
polymorphisms O 0 7.677277608308941e-06
were O 0 6.896425475133583e-08
chosen O 0 9.069015760587718e-09
based O 0 3.5135714337997115e-09
on O 0 8.672023099620674e-09
their O 0 1.468028631990137e-08
informativeness O 0 6.790947372792289e-05
. O 0 2.112570882673026e-07

One O 0 1.1649160569504602e-07
of O 0 7.276876878847816e-10
these O 0 2.6202529035401767e-10
, O 0 5.81490411377672e-10
not O 0 5.602999397780195e-09
previously O 0 3.996860797883528e-08
reported O 0 1.1233266761223604e-08
, O 0 4.2790629373179456e-10
was O 0 2.965527556852976e-08
2988 O 0 3.0857197685918436e-08
A O 0 3.599296860556933e-08
or O 0 3.6747960230343324e-09
C O 0 2.3545860372564675e-08
that O 0 1.4896194278080088e-09
introduces O 0 1.420183348699311e-08
a O 0 3.812658189161766e-09
new O 0 1.0533769412290894e-09
restriction O 0 9.221605701270619e-09
site O 0 4.405702913601317e-09
for O 0 7.909890520352292e-10
Eco0109 O 0 1.7957410136659746e-07
I O 0 2.852355862614786e-07
. O 0 3.28880638278406e-08

All O 0 3.8938470225957644e-08
the O 0 4.31165592118532e-09
4003delTC O 0 3.1115655474422965e-07
alleles O 0 1.736597425860964e-07
showed O 0 6.738892466273683e-08
the O 0 9.463072547788443e-10
same O 0 5.641970446390587e-09
haplotype O 0 2.4773501081654103e-06
for O 0 7.760968534498147e-10
these O 0 7.014675507122092e-10
five O 0 3.1027271862882344e-09
polymorphic O 0 7.787125468894374e-06
markers O 0 1.3710665371036157e-05
. O 0 4.2836651914512913e-07

Fourteen O 0 5.758275437983684e-05
microsatellite O 0 0.00012907663767691702
polymorphisms O 0 8.438042277703062e-05
were O 0 9.933586397892213e-07
selected O 0 2.1298788510648592e-08
based O 0 3.1711606673923143e-09
on O 0 3.291095174162706e-09
their O 0 3.955624272578007e-09
high O 0 1.272893968007338e-07
heterozygosity O 0 7.710286240580899e-07
and O 0 2.9221123298839302e-09
their O 0 4.321517033112343e-10
location O 0 2.8626876424908687e-09
within O 0 1.0801397554160985e-09
10q23 O 0 8.401735840379843e-07
- O 0 2.5266331249440555e-06
q25 O 0 3.381928081580554e-06
near O 0 2.2702825219766964e-07
COL17A1 O 0 1.709611024125479e-05
. O 0 1.03684108410107e-07

Three O 0 9.66661218626541e-07
families O 0 1.8119476408173796e-07
shared O 0 9.88560913128822e-08
microsatellite O 0 7.969098987814505e-06
polymorphisms O 0 5.160780801816145e-06
covering O 0 1.1035432123662758e-07
at O 0 2.49707565735946e-09
most O 0 6.613756209361554e-09
19 O 0 2.658788744724916e-08
cM O 0 2.5892256871884456e-06
, O 0 7.227829890155135e-09
whereas O 0 4.170193523833632e-09
the O 0 7.781557620489821e-10
others O 0 1.0607568157183778e-08
shared O 0 2.474106031158385e-09
smaller O 0 3.6454683716158343e-09
regions O 0 3.1607987338588828e-09
consistent O 0 3.346618271393709e-08
with O 0 1.6700902882860191e-09
cross O 0 1.4180205454294992e-08
- O 0 5.064117090114451e-07
over O 0 1.2280984229562364e-08
events O 0 1.496083035235074e-09
during O 0 1.3293246503565115e-09
passage O 0 2.2608390715106452e-09
of O 0 5.697429680817656e-11
this O 0 3.292016659273145e-10
mutation O 0 9.421726510083772e-09
through O 0 6.345164949017601e-10
several O 0 3.442669704867285e-09
generations O 0 5.7615089588125556e-08
. O 0 7.568075233166383e-08

These O 0 6.647956638516916e-07
results O 0 1.3297847090143478e-07
indicate O 0 5.253894386214597e-08
that O 0 6.676597053001387e-09
4003delTC O 0 5.027578708904912e-07
occurs O 0 2.4227704287227425e-09
on O 0 1.8013225355772988e-09
a O 0 7.429496129418567e-09
single O 0 6.503328364715344e-08
ancestral O 0 2.0023331614993367e-07
allele O 0 9.811407153392793e-07
. O 0 1.2357019407716052e-08
. O 0 6.481582914830142e-08

The O 0 1.5071957477630349e-06
haptoglobin O 0 0.00010573109466349706
- O 0 9.948225851985626e-06
gene O 0 9.452884910388093e-07
deletion O 0 1.4224870028556325e-06
responsible O 0 1.4858721897326177e-07
for O 0 2.16996163260319e-08
anhaptoglobinemia B-Disease 0 4.745555997942574e-05
. O 0 5.270364908938063e-07

We O 0 7.009845717220742e-07
have O 0 3.006075033340494e-08
found O 0 2.5559556693366403e-09
an O 0 1.096266744049501e-09
allelic O 0 2.0636316833133606e-07
deletion O 0 1.6462044527543185e-07
of O 0 1.4567673733978381e-09
the O 0 5.47506440184975e-09
haptoglobin O 0 7.947241101646796e-06
( O 0 3.537651949159226e-09
Hp O 0 2.6732045910193847e-08
) O 0 5.749888343231646e-10
gene O 0 2.9806439538759832e-09
from O 0 2.595006709515957e-10
an O 0 1.6451953133156394e-09
individual O 0 2.596195924908784e-09
with O 0 1.1947810740764453e-08
anhaptoglobinemia B-Disease 0 0.0003616914036683738
. O 0 4.85601447053341e-07

The O 0 3.7340066683100304e-07
Hp O 0 1.2311048749324982e-06
gene O 0 2.5708379780553514e-07
cluster O 0 1.0719066523279253e-07
consists O 0 5.915137268885928e-09
of O 0 6.983037481589349e-10
coding O 0 1.4467147479990672e-07
regions O 0 3.0832711939154933e-09
of O 0 1.1959085111090673e-10
the O 0 3.769208001269675e-10
alpha O 0 4.373243989164166e-09
chain O 0 1.0277030781935537e-08
and O 0 2.593977255216373e-10
beta O 0 4.0966213754600744e-10
chain O 0 3.3934746124231197e-09
of O 0 8.058990280668255e-11
the O 0 9.82104397806438e-10
haptoglobin O 0 8.46364343942696e-07
gene O 0 3.542549009694085e-08
( O 0 6.939990249144046e-10
Hp O 0 2.0026799774086612e-08
) O 0 2.4871921189273394e-10
and O 0 2.5056670627243705e-10
of O 0 5.373433642485992e-11
the O 0 2.476777394289087e-10
alpha O 0 3.5230465211810724e-09
chain O 0 1.4024147176883162e-08
and O 0 2.4046994950843725e-10
beta O 0 2.983668589973121e-10
chain O 0 9.629158581603292e-10
of O 0 2.3582861358173446e-11
the O 0 6.138624053519948e-10
haptoglobin O 0 6.669420145044569e-07
- O 0 4.5770340761919215e-07
related O 0 2.0046099891146696e-08
gene O 0 4.2210107409346165e-08
( O 0 1.7549462993926568e-09
Hpr O 0 3.501478147427406e-07
) O 0 6.578211864116668e-10
, O 0 7.7492984251748e-10
in O 0 4.240858497706057e-10
tandem O 0 1.2423335249422962e-07
from O 0 4.284673726928645e-10
the O 0 9.884770779677865e-10
5 O 0 1.5659873398021773e-08
side O 0 1.988962367249769e-06
. O 0 2.164724435260723e-07

Southern O 0 4.070785053045256e-06
blot O 0 8.826973498798907e-05
and O 0 4.7416296666824564e-08
PCR O 0 3.314087734906934e-06
analyses O 0 1.3263752407510765e-07
have O 0 1.0155730478800251e-08
indicated O 0 2.9187384953388573e-08
that O 0 4.8663617580047e-10
the O 0 2.2863930193572912e-10
individual O 0 2.3624288636447943e-10
with O 0 8.851090416150953e-10
anhaptoglobinemia B-Disease 0 1.8081791495205835e-06
was O 0 2.739917874805542e-07
homozygous O 0 3.1335716244029754e-08
for O 0 1.5624772309319468e-10
the O 0 1.7549854625098504e-10
gene O 0 8.192125200423561e-09
deletion O 0 1.0491530844092267e-07
and O 0 1.3416149302614144e-09
that O 0 6.806173957762951e-10
the O 0 2.629514939123112e-10
gene O 0 8.118891337005607e-09
deletion O 0 8.888267188922327e-08
was O 0 6.68404069870121e-08
included O 0 1.2993979225939256e-09
at O 0 1.913270097908537e-10
least O 0 8.074226842680332e-10
from O 0 1.5895790239639496e-10
the O 0 5.149145554383949e-10
promoter O 0 2.218613843751882e-07
region O 0 3.3831086820867995e-09
of O 0 1.6816605052927258e-10
Hp O 0 5.236326927615664e-08
to O 0 1.8905344845165928e-08
Hpr O 0 3.093144869126263e-07
alpha O 0 6.393080287381281e-09
but O 0 7.815202929251086e-10
not O 0 1.215189060488342e-09
to O 0 1.1050255821487553e-08
Hpr O 0 3.860535798594356e-06
beta O 0 4.150120247459199e-08
( O 0 4.7158144056425044e-09
Hpdel O 0 1.489431951995357e-06
) O 0 3.24590629929844e-08
. O 0 7.761212827972486e-08

In O 0 1.5876571524131577e-07
addition O 0 1.1958389833921501e-08
, O 0 1.7967897170123592e-09
we O 0 5.619467668971367e-10
found O 0 4.2566611346828154e-10
seven O 0 2.321353248513347e-10
individuals O 0 6.096707860780981e-11
with O 0 1.7950965713886546e-10
hypohaptoglobinemia B-Disease 0 8.046589528021286e-07
in O 0 1.41036471390521e-09
three O 0 1.1791233545110913e-09
families O 0 1.1733665150615025e-09
, O 0 2.191567621823154e-10
and O 0 6.144703634802795e-10
the O 0 4.886694382477685e-10
genotypes O 0 2.7748038533559338e-08
of O 0 7.196540585674427e-11
six O 0 4.773912931632651e-10
of O 0 1.6907936856158656e-11
the O 0 2.2233893892664724e-10
seven O 0 1.0085537960335955e-09
individuals O 0 1.6661631796477394e-10
were O 0 9.703349235223868e-10
found O 0 1.0796248339772774e-09
to O 0 4.3232177837637664e-09
be O 0 8.95116301080634e-08
Hp2 O 0 2.6402449293527752e-05
/ O 0 1.5363422107839142e-06
Hpdel O 0 6.138177923276089e-06
. O 0 1.4608089315970574e-07

The O 0 7.638117267561029e-07
phenotypes O 0 3.2685558835510164e-05
and O 0 9.774650777671923e-08
genotypes O 0 1.2389821222313913e-06
in O 0 1.5572296785393291e-09
one O 0 1.1392023990808298e-09
of O 0 5.6496318040499816e-11
these O 0 1.0823334589682432e-10
three O 0 4.751076754239136e-10
families O 0 7.771708832038371e-10
showed O 0 6.155017384656958e-09
the O 0 2.1336010735950595e-10
father O 0 6.339703162439037e-08
to O 0 2.640522911434573e-09
be O 0 1.7880999791941576e-08
hypohaptoglobinemic B-Disease 0 2.1576850031124195e-06
( O 0 1.3995493652885216e-09
Hp2 O 0 1.9612652124578744e-07
) O 0 1.046755571110225e-09
and O 0 4.392219921101059e-09
Hp2 O 0 8.861536002768844e-07
/ O 0 8.948841667688612e-08
Hpdel O 0 7.487511197723506e-07
, O 0 1.506908375858984e-09
the O 0 4.828316080285333e-10
mother O 0 5.220251964033196e-08
to O 0 1.2939321836213935e-09
be O 0 2.3745778676698137e-09
Hp2 O 0 1.4549279114817182e-07
- O 0 5.597266294898873e-08
1 O 0 2.5334445652447357e-09
and O 0 5.528825397504988e-09
Hp1 O 0 6.720088663314527e-07
/ O 0 2.4616523930376388e-08
Hp2 O 0 1.603947197281741e-07
, O 0 3.5730277070378236e-10
one O 0 8.77000416732443e-11
of O 0 1.0393933977392855e-11
the O 0 1.297666002431086e-10
two O 0 1.1736395189032578e-09
children O 0 2.2349897488282977e-09
to O 0 1.1988712245170063e-09
be O 0 1.3596040737695603e-08
hypohaptoglobinemic B-Disease 0 3.664561972982483e-06
( O 0 4.5770554013557785e-10
Hp2 O 0 1.0115504522900665e-07
) O 0 3.165635809043721e-10
and O 0 3.5695826294812605e-09
Hp2 O 0 3.4103452435374493e-06
/ O 0 1.566766485439075e-07
Hpdel O 0 1.5806260762474267e-06
, O 0 1.1033611801991583e-09
and O 0 2.5279600635030874e-10
the O 0 1.1992914994429782e-10
other O 0 2.9000898904563144e-10
child O 0 9.487764351945316e-09
to O 0 3.720057151213041e-09
be O 0 1.2476689903451188e-08
Hp1 O 0 1.1761151199607411e-06
and O 0 2.262406084696522e-08
Hp1 O 0 4.540156169241527e-06
/ O 0 3.05995285998506e-07
Hpdel O 0 7.974176696734503e-07
, O 0 2.433849344285477e-09
showing O 0 1.6354098519855143e-08
an O 0 2.5837572081854887e-09
anomalous O 0 5.060413741375669e-07
inheritance O 0 2.706646284877934e-07
of O 0 2.34468955362388e-09
Hp O 0 1.1203096619283315e-06
phenotypes O 0 3.353319470988936e-06
in O 0 2.1577069020395356e-09
the O 0 2.0263479783011462e-09
child O 0 3.353449358201033e-07
with O 0 3.470996290388939e-08
Hp1 O 0 8.634858386358246e-05
. O 0 4.779922164743766e-07

The O 0 9.666666755947517e-07
Hp2 O 0 3.342212221468799e-05
/ O 0 1.8750480421658722e-06
Hpdel O 0 3.3648134376562666e-06
individuals O 0 1.2000729299188606e-08
had O 0 2.4816930732640685e-08
an O 0 1.8511653321340305e-09
extremely O 0 2.3937951709740446e-07
low O 0 7.885614650149364e-08
level O 0 1.409023120402253e-09
of O 0 2.0290812086098953e-10
Hp O 0 3.5249978935780746e-08
( O 0 4.0299871773008533e-10
mean O 0 3.7609226843926535e-09
+ O 0 6.360690196771657e-09
/ O 0 8.455057987077907e-09
- O 0 2.601827304715698e-07
SD O 0 6.532121915370226e-06
= O 0 8.242204785346985e-08
0 O 0 9.75769509636848e-09
. O 0 8.799195816422412e-10
049 O 0 2.9772431275887357e-07
+ O 0 2.2158221923973542e-08
/ O 0 1.4355103772345501e-08
- O 0 1.001893963348266e-07
0 O 0 2.408759769423341e-08
. O 0 1.16157805596373e-09
043 O 0 1.8067675000565941e-07
mg O 0 1.811175252441899e-06
/ O 0 7.339862406752218e-08
ml O 0 1.9077228330388607e-07
; O 0 3.591696717819559e-09
n O 0 2.3213777566866156e-08
= O 0 1.4362417921631732e-08
6 O 0 2.377600782921263e-09
) O 0 2.8305383037441345e-10
, O 0 7.020216075126484e-10
compared O 0 6.61181376315767e-09
with O 0 1.9106262405532703e-10
the O 0 4.957375621117421e-10
level O 0 4.5098264012111144e-10
( O 0 9.962559249787617e-11
1 O 0 7.992390638200675e-10
. O 0 3.167930917591377e-10
64 O 0 4.530675390412853e-09
+ O 0 4.3600509869179405e-09
/ O 0 4.147111543062465e-09
- O 0 5.593488339172836e-08
1 O 0 1.1222581086656191e-08
. O 0 2.4050859082080933e-09
07 O 0 4.010843568380551e-08
mg O 0 2.023064325840096e-06
/ O 0 8.295653941559067e-08
ml O 0 1.3659025910328637e-07
) O 0 8.032675635760711e-10
obtained O 0 2.1115058590481794e-09
from O 0 4.907972916967651e-10
52 O 0 6.407829999943715e-08
healthy O 0 8.454380306943676e-09
volunteers O 0 4.887610316473001e-09
having O 0 1.3727735392876639e-08
phenotype O 0 5.287317890179111e-06
Hp2 O 0 4.913270004180958e-07
, O 0 1.0123621940749672e-09
whereas O 0 8.203238643922361e-10
the O 0 3.8885289432855075e-10
serum O 0 7.466805129752174e-08
Hp O 0 1.504844071575917e-08
level O 0 3.8289293957660675e-10
of O 0 5.1887365931646556e-11
an O 0 6.102551242115339e-10
individual O 0 5.702999184009627e-10
with O 0 2.02107908187088e-09
Hp1 O 0 2.732824214035645e-05
/ O 0 5.719016940020083e-07
Hpdel O 0 3.583293619158212e-06
was O 0 2.46403533310513e-06
0 O 0 2.569423998011189e-07
. O 0 1.1045329273429161e-07

50 O 0 1.1301938684482593e-05
mg O 0 6.721096724504605e-05
/ O 0 1.3199338582126074e-06
ml O 0 1.1152791330459877e-06
, O 0 3.0417168783714033e-09
which O 0 1.0736819211487614e-09
was O 0 1.8740413665341293e-08
approximately O 0 3.437051754318077e-10
half O 0 3.959834682376595e-10
the O 0 6.440979000155167e-11
level O 0 1.2407121163793278e-10
of O 0 9.393778116484341e-11
Hp O 0 1.58819855045067e-08
in O 0 1.2845191577071091e-09
control O 0 1.0274721518044316e-07
sera O 0 6.047125111763307e-08
from O 0 2.544290611528055e-10
the O 0 1.260515580803201e-09
Hp1 O 0 5.519721071323147e-06
phenotype O 0 8.588226592110004e-06
( O 0 5.713942097251845e-10
1 O 0 8.673076701271043e-10
. O 0 6.03526340015037e-10
26 O 0 3.804964787690324e-09
+ O 0 2.2132444765787795e-09
/ O 0 2.2449955228154295e-09
- O 0 7.750030306397093e-08
0 O 0 2.6684009668542785e-08
. O 0 2.2558122036997474e-09
33 O 0 3.340100818149949e-08
mg O 0 1.0076430498884292e-06
/ O 0 9.318146254599924e-08
ml O 0 3.0599849765167164e-07
; O 0 1.0218607293666082e-08
n O 0 5.6393371750118604e-08
= O 0 2.9081578034606537e-08
9 O 0 3.854680574733038e-09
) O 0 2.4336022086401954e-10
, O 0 4.276884679743631e-10
showing O 0 1.1754996975810172e-08
a O 0 9.477635565247056e-09
gene O 0 1.018858242218812e-07
- O 0 7.910975909908302e-06
dosage O 0 8.182431338354945e-05
effect O 0 1.857463644228119e-06
. O 0 2.2934629839710396e-07

The O 0 4.1755922097763687e-07
other O 0 3.111155422175216e-08
allele O 0 6.582177434211189e-07
( O 0 3.447571783610215e-09
Hp2 O 0 2.2078324946050998e-07
) O 0 5.858633023159143e-10
of O 0 3.2022914875362574e-10
individuals O 0 9.190696537153542e-10
with O 0 2.3037070029374718e-09
Hp2 O 0 7.438349712174386e-06
/ O 0 1.2427625506461482e-07
Hpdel O 0 4.837548885916476e-07
was O 0 1.6013015624594118e-07
found O 0 1.6041323824822484e-09
to O 0 1.3305371249217046e-09
have O 0 7.083381436956415e-09
, O 0 6.311296485428386e-10
in O 0 1.822409168017458e-10
all O 0 2.057994191728696e-10
exons O 0 2.7226501941868264e-08
, O 0 2.0707209280601546e-09
no O 0 6.781427419610964e-09
mutation O 0 1.508706404251825e-08
, O 0 3.3264158094681306e-10
by O 0 1.0827573282412573e-09
DNA O 0 5.982148820748989e-08
sequencing O 0 2.3786867586750304e-07
. O 0 1.2183929243292368e-07

On O 0 1.8810843016581202e-07
the O 0 1.078085620775937e-09
basis O 0 2.3445720365167233e-10
of O 0 8.612491275705736e-11
the O 0 4.714948431683297e-10
present O 0 3.0503852777030716e-09
study O 0 1.0882251766375362e-09
, O 0 1.787539005704275e-10
the O 0 6.612298902863856e-11
mechanism O 0 2.973749024803851e-10
of O 0 1.8753838759710817e-10
anhaptoglobinemia B-Disease 0 7.279312512764591e-07
and O 0 2.6641124861725984e-09
the O 0 1.7295474774581265e-10
mechanism O 0 1.0993552734817058e-09
of O 0 2.936078047355295e-10
anomalous O 0 2.52176533876991e-07
inheritance O 0 1.760026293595729e-07
of O 0 2.5630928490727456e-09
Hp O 0 1.0597414075164124e-06
phenotypes O 0 1.288582461711485e-05
were O 0 6.28483860509732e-08
well O 0 4.204650849715108e-08
explained O 0 8.77891807249398e-07
. O 0 1.2411375394094648e-07

However O 0 1.6827264062158065e-06
, O 0 7.022121994992858e-09
the O 0 3.0016833463264447e-10
mechanism O 0 3.133946657740694e-09
of O 0 1.144080052917218e-09
hypohaptoglobinemia B-Disease 0 5.190442971070297e-05
remains O 0 6.907759143359726e-06
unknown O 0 2.344083895877702e-06

ATM O 0 0.00018790989997796714
mutations O 0 0.002583883935585618
and O 0 2.0227287222951418e-06
phenotypes O 0 0.009262690320611
in O 0 2.7206024242332205e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999977350234985
telangiectasia I-Disease 1 0.9999997615814209
families O 0 8.345345122506842e-05
in O 0 1.1335242078303054e-08
the O 0 6.636526883596616e-09
British O 0 5.895720732951304e-06
Isles O 0 1.2558251683003618e-07
: O 0 3.4471886456444167e-10
expression O 0 4.848259016476675e-10
of O 0 2.445988550592304e-11
mutant O 0 9.162381964245014e-09
ATM O 0 8.644476245933674e-09
and O 0 5.073058639837313e-10
the O 0 6.326433821257638e-10
risk O 0 1.6204870334490806e-08
of O 0 8.34282598560776e-09
leukemia B-Disease 1 0.9302791357040405
, O 0 0.000100307421234902
lymphoma B-Disease 1 1.0
, O 0 5.882802724954672e-07
and O 0 6.234427564777434e-05
breast B-Disease 1 0.9997325539588928
cancer I-Disease 0 0.0859663337469101
. O 0 4.338952805937879e-07

We O 0 3.465605402652727e-07
report O 0 1.4604237819071386e-08
the O 0 3.4653038771814693e-10
spectrum O 0 1.4318461971640772e-08
of O 0 2.19968362968892e-10
59 O 0 5.6382404522992147e-08
ATM O 0 6.75150033657701e-07
mutations O 0 2.1286457467795117e-06
observed O 0 7.67159576753329e-07
in O 0 4.724216523754876e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 6.15071076026652e-06
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999933242797852
T I-Disease 1 0.9999998807907104
) O 0 1.7962599940801738e-07
patients O 0 6.106700311647728e-06
in O 0 1.3529962705760568e-09
the O 0 1.0934773087001304e-08
British O 0 1.4455149539571721e-05
Isles O 0 2.7021635560231516e-06
. O 0 1.1426907775557993e-07

Of O 0 3.825167311788391e-07
51 O 0 1.4459189969784347e-06
ATM O 0 8.098817829704785e-07
mutations O 0 7.420052838824631e-07
identified O 0 4.330795988494174e-08
in O 0 9.225330499518236e-10
families O 0 1.4193728414824136e-09
native O 0 4.326613789462641e-10
to O 0 3.3652689523933077e-09
the O 0 5.156067128808672e-09
British O 0 1.1057592018914875e-05
Isles O 0 1.6103278710488667e-07
, O 0 1.0548808493382467e-09
11 O 0 9.807734624445175e-10
were O 0 2.2086394935172393e-09
founder O 0 1.0887369228385069e-07
mutations O 0 6.382701656093559e-08
, O 0 7.380820954416834e-10
and O 0 1.1911853725621313e-09
2 O 0 3.352351729546399e-10
of O 0 5.3778016761985015e-11
these O 0 3.473085430361067e-10
11 O 0 1.4790366709149794e-09
conferred O 0 3.269692072649377e-08
a O 0 8.632419934428981e-08
milder O 1 0.9419629573822021
clinical O 0 0.01582505740225315
phenotype O 0 0.025303445756435394
with O 0 5.1519379873354865e-09
respect O 0 5.868377339623976e-09
to O 0 1.60597597442802e-08
both O 0 1.528904078895721e-07
cerebellar B-Disease 0 0.2215576469898224
degeneration I-Disease 1 0.9936503767967224
and O 0 2.044444471493989e-07
cellular O 0 1.6105701661217608e-06
features O 0 1.835470243349846e-06
. O 0 4.104768436263839e-07

We O 0 5.901734994040453e-07
report O 0 3.130823600372423e-08
, O 0 7.117859635030754e-10
in O 0 2.1637804048513232e-10
two O 0 4.436659484241545e-09
A B-Disease 1 0.9999415874481201
- I-Disease 1 0.9999693632125854
T I-Disease 1 0.9999997615814209
families O 0 1.2912424551814183e-07
, O 0 1.2196008647435974e-09
an O 0 1.0157081842265825e-09
ATM O 0 2.038315756180964e-07
mutation O 0 1.5963522059792012e-07
( O 0 6.865210067097394e-10
7271T O 0 2.2838419511117536e-07
- O 0 1.1640759112196974e-06
- O 0 2.0789888367289677e-05
> O 0 3.5878784387932683e-07
G O 0 5.112558028486092e-06
) O 0 5.430910721138105e-10
that O 0 1.8300523318970363e-09
may O 0 4.9166914095621905e-08
be O 0 1.970491325664625e-09
associated O 0 7.851329586472389e-10
with O 0 1.551308803637852e-10
an O 0 2.0509887121988868e-09
increased O 0 1.5633990813057608e-07
risk O 0 1.6824900583856106e-08
of O 0 2.9476048268861632e-09
breast B-Disease 1 0.783061146736145
cancer I-Disease 0 7.018911855993792e-05
in O 0 2.368475859881869e-09
both O 0 1.795858572961606e-08
homozygotes O 0 2.5519732389511773e-06
and O 0 1.963993412346099e-08
heterozygotes O 0 8.390926495849271e-07
( O 0 1.1032854629888789e-09
relative O 0 9.141978551951979e-08
risk O 0 2.0778236020646546e-08
12 O 0 2.7987212547486706e-09
. O 0 6.796081475357596e-10
7 O 0 8.668368245423608e-09
; O 0 2.0309029125087363e-08
P O 0 3.959185050916858e-06
= O 0 3.28556524209489e-08
. O 0 1.8364686438232525e-09
0025 O 0 7.207471242054453e-08
) O 0 5.366717070742766e-10
, O 0 6.309394673387203e-10
although O 0 1.6085627274620151e-09
there O 0 3.3611999294969053e-10
is O 0 7.682952607446225e-10
a O 0 1.0343952361324682e-08
less O 0 2.5934414793482574e-07
severe O 1 0.7282597422599792
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999982118606567
T I-Disease 1 1.0
phenotype O 1 0.7860286831855774
in O 0 2.7812825376116734e-09
terms O 0 8.351832558872729e-10
of O 0 7.636228455121241e-11
the O 0 5.638890465675672e-10
degree O 0 1.5876354453325803e-08
of O 0 2.0651764742751766e-08
cerebellar B-Disease 0 0.4419039785861969
degeneration I-Disease 1 0.9985582232475281
. O 0 2.1089247184136184e-06

This O 0 8.285034596156038e-07
mutation O 0 4.098895260540303e-06
( O 0 3.632996836699931e-08
7271T O 0 1.1669859532048577e-06
- O 0 5.088335001346422e-06
- O 0 4.87706383864861e-05
> O 0 8.619929303677054e-07
G O 0 9.252524250769056e-06
) O 0 9.189434768686056e-10
also O 0 2.6395763352837776e-09
allows O 0 3.901918788073999e-09
expression O 0 3.8049505768356084e-09
of O 0 1.0056335625341362e-10
full O 0 2.896813011687982e-09
- O 0 7.534545432008599e-08
length O 0 2.4169331425127893e-08
ATM O 0 1.6621779508341206e-08
protein O 0 2.328476078616859e-09
at O 0 1.0982460080244394e-10
a O 0 1.0701326491613372e-09
level O 0 1.0665565097767171e-09
comparable O 0 3.897292710774991e-09
with O 0 3.782863189361052e-10
that O 0 3.7235212690944763e-09
in O 0 6.248201955827426e-09
unaffected O 0 1.5874067685217597e-05
individuals O 0 1.013023176454908e-08
. O 0 4.773407624725223e-08

In O 0 4.803612227988197e-07
addition O 0 1.76851564503977e-08
, O 0 1.0312685150282164e-09
we O 0 6.162379495577852e-10
have O 0 3.0706059916951745e-09
studied O 0 4.586664203998225e-08
18 O 0 2.45110925334302e-07
A B-Disease 1 0.9999732971191406
- I-Disease 1 0.9999973773956299
T I-Disease 1 1.0
patients O 1 0.8154554963111877
, O 0 1.4416972060615763e-09
in O 0 6.528103058123236e-10
15 O 0 6.006498853849962e-09
families O 0 2.609053195712363e-09
, O 0 2.565063939030665e-09
who O 0 1.513832330601872e-06
developed O 0 4.774507397087291e-05
leukemia B-Disease 1 0.9823598861694336
, O 0 0.00036607301444746554
lymphoma B-Disease 1 1.0
, O 0 9.736635320223286e-08
preleukemic O 0 6.99687225278467e-05
T O 0 2.5332741643069312e-05
- O 0 6.971437755964871e-07
cell O 0 4.88013313315605e-07
proliferation O 0 3.4930522474496684e-08
, O 0 1.9907330894852748e-08
or O 0 7.633261702721938e-06
Hodgkin B-Disease 1 0.9999998807907104
lymphoma I-Disease 1 1.0
, O 0 1.130120281800373e-07
mostly O 0 1.5634386230090058e-08
in O 0 1.1984534253883794e-08
childhood O 0 9.82669007498771e-07
. O 0 1.2462923848488572e-07

A O 0 3.815774107351899e-06
wide O 0 6.563241186086088e-07
variety O 0 1.066054622356205e-08
of O 0 1.0615476275788183e-09
ATM O 0 3.854396481983713e-07
mutation O 0 8.908699555831845e-07
types O 0 1.721108233709856e-08
, O 0 1.6775671962676597e-09
including O 0 6.978913447142077e-09
missense O 0 5.5356584198307246e-05
mutations O 0 1.735079081299773e-06
and O 0 8.958367381239896e-09
in O 0 5.627128540908188e-09
- O 0 4.3081663534394465e-06
frame O 0 0.01313199382275343
deletions O 0 4.018861829990783e-07
, O 0 4.20633305964202e-09
were O 0 3.804210280122788e-09
seen O 0 1.8306431925907418e-08
in O 0 1.7240381344763023e-09
these O 0 1.3121877806554494e-08
patients O 0 4.840510882786475e-06
. O 0 1.7174117772356112e-07

We O 0 3.392920575606695e-07
also O 0 3.0173165299629545e-08
show O 0 1.6700209215514406e-08
that O 0 2.0091566188540355e-09
25 O 0 3.2423157492189603e-09
% O 0 9.211436474698687e-11
of O 0 2.1801761784789875e-11
all O 0 1.3638316032071884e-09
A B-Disease 1 0.9999852180480957
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
patients O 1 0.5560605525970459
carried O 0 8.166808385112745e-08
in O 0 8.125363160083054e-10
- O 0 3.3638656304901815e-07
frame O 0 8.13166843727231e-05
deletions O 0 3.294112218554801e-07
or O 0 2.4067619008860675e-08
missense O 0 3.0331611924339086e-05
mutations O 0 2.1573864614765625e-06
, O 0 3.1561235847021862e-09
many O 0 3.4532954273913674e-10
of O 0 9.374214599011665e-11
which O 0 2.2569754065671077e-08
were O 0 8.392864714323878e-08
also O 0 1.7139660712928162e-07
associated O 0 1.521504700008336e-09
with O 0 3.436343987139878e-10
expression O 0 1.0143805795337357e-08
of O 0 3.1513339160404996e-10
mutant O 0 3.3777109820221085e-07
ATM O 0 3.146653000385413e-07
protein O 0 3.303896676243312e-07
. O 0 8.769214332460251e-08

The O 0 3.177047744884476e-07
DMPK O 0 1.449180763302138e-05
gene O 0 3.912627164481819e-07
of O 0 2.8104803817541324e-08
severely O 0 0.20078282058238983
affected O 0 0.027129320427775383
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999957084655762
is O 0 6.363490001604077e-07
hypermethylated O 0 4.9686632337397896e-06
proximal O 0 6.086531357141212e-06
to O 0 2.506692275972e-08
the O 0 5.9944249564125585e-09
largely O 0 1.6108361933220294e-07
expanded O 0 3.420333882786508e-07
CTG O 0 9.642631084716413e-06
repeat O 0 3.1655715702072484e-06
. O 0 3.8904991583876836e-07

Using O 0 7.364654948105454e-07
methylation O 0 2.8941033178853104e-06
- O 0 3.0602348033426097e-06
sensitive O 0 3.105144799064874e-07
restriction O 0 2.176133619968823e-07
enzymes O 0 1.4275539861330344e-08
, O 0 1.4625973765447497e-09
we O 0 6.920637951601805e-10
characterized O 0 4.280460874639402e-09
the O 0 2.574566670965339e-10
methylation O 0 3.399475190235535e-08
pattern O 0 4.705879419475423e-08
on O 0 1.3528266507023545e-08
the O 0 7.238642463214262e-10
5 O 0 2.395919462827578e-09
side O 0 9.598706718350059e-09
of O 0 1.2962288187257087e-10
the O 0 1.0263332406168502e-09
CTG O 0 2.3983903929547523e-07
repeat O 0 1.6269599001361712e-08
in O 0 3.089014322110728e-10
the O 0 2.57176918649904e-10
DMPK O 0 3.608694498780096e-07
gene O 0 4.234071315778465e-09
of O 0 1.1553772522043815e-10
normal O 0 3.1954596746430752e-09
individuals O 0 2.7519786449659023e-10
and O 0 1.0046332654667367e-09
of O 0 2.4998159098288397e-09
patients O 0 3.6706340324599296e-05
affected O 0 1.846857173859462e-07
with O 0 1.1125162018288393e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.7251285555630602e-07
showing O 0 1.0881723255806719e-07
expansions O 0 1.1364640783995128e-08
of O 0 5.067362640609474e-10
the O 0 2.742605698102807e-09
repetitive O 0 3.531880111040664e-06
sequence O 0 4.4066300119993684e-07
. O 0 1.272002094765412e-07

The O 0 1.3474296167714783e-07
gene O 0 1.395381872271173e-07
segment O 0 9.678921486511172e-08
analyzed O 0 5.4971248886204194e-08
corresponds O 0 1.0193884847353729e-08
to O 0 9.33469856967406e-10
the O 0 3.65353386433398e-10
genomic O 0 5.3229481267180745e-08
SacI O 0 2.7561659408092964e-06
- O 0 3.950100619931618e-07
HindIII O 0 6.186870109559095e-07
fragment O 0 2.6892737992056936e-07
carrying O 0 2.1814939188402604e-08
exons O 0 1.5003607245489547e-07
11 O 0 2.683887423415854e-08
- O 0 1.0359184443586855e-06
15 O 0 2.1537775296565087e-07
. O 0 6.522508044781716e-08

There O 0 8.064827738962776e-07
is O 0 2.6749644277401785e-08
constitutive O 0 7.817207858806796e-08
methylation O 0 9.385874477629841e-08
in O 0 2.161801626598958e-09
intron O 0 1.9681274352478795e-06
12 O 0 4.065720204948775e-09
at O 0 7.841612775782991e-11
restriction O 0 2.4662285547094598e-09
sites O 0 4.824054489205309e-10
of O 0 1.4248920099380058e-10
SacII O 0 3.316720267321216e-07
and O 0 5.614456899394327e-09
HhaI O 0 8.833963960341862e-08
, O 0 5.440916051036027e-10
localized O 0 1.6231442856451395e-08
1 O 0 2.3627277911941746e-09
, O 0 1.2166038176886218e-09
159 O 0 2.4694871925134976e-08
- O 0 1.2880632027645333e-07
1 O 0 2.2788100295656477e-09
, O 0 3.717983698692251e-10
232 O 0 7.777555488530652e-09
bp O 0 1.8197091833371815e-07
upstream O 0 1.8661361345095884e-09
of O 0 1.5342448145272414e-10
the O 0 6.000095420510831e-10
CTG O 0 4.35184091429619e-07
repeat O 0 9.633392750174607e-08
, O 0 1.5550689624888037e-09
whereas O 0 2.7881714714794725e-09
most O 0 6.17434492422575e-10
, O 0 3.060150743916523e-10
if O 0 6.87079004801916e-10
not O 0 8.226569425673347e-10
all O 0 5.2239493980588136e-11
, O 0 5.263073657446604e-11
of O 0 6.771154383716782e-12
the O 0 3.6725920915525734e-11
other O 0 4.166906056313202e-11
sites O 0 5.70805659683149e-11
of O 0 7.067746388145224e-11
SacII O 0 1.8348175956361956e-07
, O 0 2.5942754611207874e-09
HhaI O 0 1.0970583730340877e-07
, O 0 6.0535015888874e-10
and O 0 5.734598906848021e-10
HpaII O 0 2.6704679356726047e-08
in O 0 1.8244644683917954e-10
this O 0 1.761955026324813e-10
region O 0 1.4629936151422385e-09
are O 0 7.218292075172883e-10
unmethylated O 0 2.427712786357006e-07
, O 0 1.157451245958896e-09
in O 0 3.282004390481319e-10
normal O 0 3.5851943636089345e-09
individuals O 0 2.697608247892447e-10
and O 0 4.1058986766095984e-10
most O 0 2.7094421151119263e-10
of O 0 3.4892333466984837e-10
the O 0 2.231727691537344e-08
patients O 0 6.927520007593557e-05
. O 0 2.0920069232488459e-07

In O 0 1.7418653897038894e-07
a O 0 2.690740430466576e-08
number O 0 2.4121975528146322e-09
of O 0 5.417874482382956e-10
young O 0 5.916459855370704e-08
and O 0 2.0800329991743638e-07
severely O 0 0.29180002212524414
affected O 0 1.788012741599232e-05
patients O 0 0.0016284037847071886
, O 0 4.441214507266977e-09
however O 0 3.867539177804247e-09
, O 0 1.3952521082938318e-10
complete O 0 3.9582867539245115e-10
methylation O 0 3.999405695509495e-09
of O 0 7.525127743157611e-11
these O 0 8.893086961281327e-11
restriction O 0 3.981306395672846e-09
sites O 0 1.0966432206771515e-09
was O 0 1.7696596188443436e-08
found O 0 1.1746854600147572e-09
in O 0 3.215033239634124e-10
the O 0 1.860087972538338e-09
mutated O 0 1.6936524843913503e-05
allele O 0 6.619982286792947e-06
. O 0 1.2575149810345465e-07

In O 0 1.6278312386930338e-07
most O 0 5.653895573942691e-09
of O 0 2.7464100438301386e-10
these O 0 3.813567239774329e-09
patients O 0 4.523317329585552e-07
, O 0 4.5923759239840933e-10
the O 0 4.1815334528294557e-10
onset O 0 3.702644946201872e-08
of O 0 5.947670689288032e-10
the O 0 8.246387039889669e-08
disease O 0 0.0005976841785013676
was O 0 0.04157508909702301
congenital O 1 0.9999438524246216
. O 0 8.75814748724224e-06

Preliminary O 0 5.0501193982199766e-06
in O 0 1.1784352693666733e-07
vivo O 0 4.785030796483625e-06
footprinting O 0 2.7181698897038586e-05
data O 0 1.830524354318186e-08
gave O 0 1.286015294255094e-08
evidence O 0 2.426317369241815e-09
for O 0 4.416646770533106e-10
protein O 0 6.8284120580131e-09
- O 0 8.614146196350703e-08
DNA O 0 3.0428093822365554e-08
contact O 0 4.449549173557443e-09
in O 0 4.6273351816950026e-10
normal O 0 3.178148411109305e-09
genes O 0 1.9817385510378926e-09
at O 0 3.8282721437354894e-10
an O 0 1.6745813624652328e-09
Sp1 O 0 8.260917638835963e-08
consensus O 0 3.4440423846149315e-09
binding O 0 1.6698903593237446e-08
site O 0 2.9061713036071524e-09
upstream O 0 1.0989003040862144e-09
of O 0 5.4308977454065044e-11
the O 0 3.3826938472536483e-10
CTG O 0 3.676431674648484e-07
repeat O 0 6.700762611444588e-08
and O 0 7.574653682063115e-10
for O 0 1.4137011006276623e-10
a O 0 1.13489950770429e-09
significant O 0 3.0415892027235714e-09
reduction O 0 2.783410613105275e-09
of O 0 3.722779029491363e-11
this O 0 1.1835908642066073e-10
interaction O 0 5.373221312332532e-10
in O 0 4.584656820849631e-10
cells O 0 2.4555735222975272e-09
with O 0 1.282619455089673e-09
a O 0 7.268130985949028e-08
hypermethylated O 0 6.462386954808608e-05
DMPK O 0 1.4350718629430048e-05
gene O 0 1.7345814740110654e-07
. O 0 1.324279175207721e-08
. O 0 5.785019041582018e-08

The O 0 7.406220902339555e-06
hemochromatosis B-Disease 1 0.9999473094940186
gene O 0 1.45191597766825e-06
product O 0 7.402073265438958e-08
complexes O 0 2.0952668933205132e-08
with O 0 1.1807933519847325e-09
the O 0 2.9012310331921753e-09
transferrin O 0 2.0614022560039302e-06
receptor O 0 1.0175841680393205e-07
and O 0 9.950946733283672e-09
lowers O 0 6.446691145356453e-07
its O 0 2.109022512186698e-09
affinity O 0 1.1897281382289293e-08
for O 0 2.018120781599464e-09
ligand O 0 5.286231612444681e-07
binding O 0 1.14620331714832e-06
. O 0 1.7981145106205076e-07

We O 0 2.238554543509963e-06
recently O 0 3.6689294802272343e-07
reported O 0 7.564305626317491e-09
the O 0 2.40389236294547e-10
positional O 0 1.9666930484163458e-07
cloning O 0 3.375549439965653e-08
of O 0 5.201858943593152e-10
a O 0 1.880608380133708e-08
candidate O 0 2.879512521758443e-07
gene O 0 9.382184771311586e-07
for O 0 7.20549041943741e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.4950031042098999
HFE O 0 0.4259839951992035
. O 0 2.4589483018644387e-06

The O 0 7.598217166560062e-08
gene O 0 8.951368357656975e-08
product O 0 1.1018097545445471e-08
, O 0 6.827172160939199e-10
a O 0 1.756885414927467e-09
member O 0 8.065775825016885e-10
of O 0 3.432765183219999e-11
the O 0 2.4580421031927813e-10
major O 0 4.902100059211989e-09
histocompatibility O 0 4.3505670532795193e-07
complex O 0 3.778907853302371e-08
class O 0 2.5666851755090647e-08
I O 0 7.076295105434838e-08
- O 0 5.3796259891214504e-08
like O 0 6.1589751076951416e-09
family O 0 1.0115615900474495e-08
, O 0 6.108816785754811e-10
was O 0 2.3611791633015855e-08
found O 0 6.977884381420552e-10
to O 0 5.269605307667291e-10
have O 0 6.133126895235819e-09
a O 0 4.898326366742367e-08
mutation O 0 2.89610824211195e-07
, O 0 3.5460219205418753e-09
Cys O 0 2.4656806090206373e-06
- O 0 8.147645758072031e-07
282 O 0 3.607723897403048e-07
- O 0 8.006762072909623e-06
- O 0 0.00012588514073286206
> O 0 9.51018591877073e-07
Tyr O 0 3.2738539630372543e-06
( O 0 2.2394914811485478e-09
C282Y O 0 9.288335434121109e-08
) O 0 2.6060381630443885e-10
, O 0 2.994912373655012e-10
in O 0 4.184661228645581e-10
85 O 0 1.3001275611657093e-08
% O 0 7.123699963251795e-10
of O 0 4.31445074111636e-10
patient O 0 3.932947947760113e-06
chromosomes O 0 1.246538886334747e-06
. O 0 1.4077188836836285e-07

This O 0 4.114809826205601e-07
mutation O 0 1.6338468640242354e-06
eliminates O 0 1.170256354043886e-07
the O 0 2.0434953729164818e-09
ability O 0 1.659232218287343e-08
of O 0 6.687375653235961e-10
HFE O 0 1.1553778676898219e-05
to O 0 3.483192756448261e-08
associate O 0 2.0268087652652866e-08
with O 0 1.0956068052792034e-08
beta2 O 0 5.388329373090528e-05
- O 0 0.00013531754666473716
microglobulin O 0 4.771821841131896e-05
( O 0 3.4179250540944395e-09
beta2m O 0 3.030785080682108e-07
) O 0 6.341571157086889e-10
and O 0 1.1934412347258672e-09
prevents O 0 5.470067421242675e-08
cell O 0 2.9203479243733454e-06
- O 0 4.0142702346201986e-05
surface O 0 0.00011826219997601584
expression O 0 5.599653832177864e-06
. O 0 4.2318856685596984e-07

A O 0 1.1626734703895636e-06
second O 0 3.386245168712776e-07
mutation O 0 4.1671356143524463e-07
that O 0 5.748904463587223e-09
has O 0 9.487764351945316e-09
no O 0 2.9206190799158094e-09
effect O 0 9.423001934294462e-09
on O 0 6.121442197581928e-08
beta2m O 0 4.893052755505778e-05
association O 0 6.154688758641669e-09
, O 0 1.1888678930205288e-09
H63D O 0 1.7523918813822092e-06
, O 0 1.5779045847708062e-09
was O 0 3.0381468008044976e-08
found O 0 8.776819271361092e-10
in O 0 1.2503334478886075e-10
eight O 0 4.4887499273116305e-10
out O 0 6.994967938211971e-10
of O 0 1.9447309040909744e-10
nine O 0 7.782499977793123e-08
patients O 0 1.0156581993214786e-06
heterozygous O 0 9.929828337362778e-08
for O 0 4.805678077701714e-10
the O 0 1.6816614767378724e-09
C282Y O 0 2.1379719328251667e-06
mutant O 0 7.469947831850732e-06
. O 0 1.8560139380952023e-07

In O 0 1.0987923104721631e-07
this O 0 3.119972502574342e-09
report O 0 2.536287624366196e-09
, O 0 2.3771370982750284e-10
we O 0 4.3312212150148355e-10
demonstrate O 0 4.892646732201911e-09
in O 0 8.959286090792773e-10
cultured O 0 1.140510050845478e-07
293 O 0 7.420634062782483e-08
cells O 0 3.256621994296438e-08
overexpressing O 0 2.8040344091095903e-07
wild O 0 4.449082435797891e-09
- O 0 1.9902172709862498e-07
type O 0 2.927163222921081e-07
or O 0 2.5549806714764145e-09
mutant O 0 3.9470313595302287e-07
HFE O 0 6.097938012317172e-07
proteins O 0 1.3657422970325683e-09
that O 0 9.538383416440865e-10
both O 0 3.155989636294265e-10
the O 0 4.141118281619782e-10
wild O 0 7.2105348358775245e-09
- O 0 4.929273472953355e-06
type O 0 8.37570769363083e-06
and O 0 1.1359986018533164e-07
H63D O 0 0.00018814779468812048
HFE O 0 6.054840014257934e-06
proteins O 0 8.063965495352932e-09
form O 0 1.25562111819022e-08
stable O 0 8.175380372676955e-08
complexes O 0 8.499116965765552e-09
with O 0 7.680344693561381e-10
the O 0 6.296774213154777e-09
transferrin O 0 5.882567711523734e-05
receptor O 0 4.218900812702486e-06
( O 0 3.857197938827994e-08
TfR O 0 1.449023238819791e-05
) O 0 2.679693089646662e-08
. O 0 7.797164869316475e-08

The O 0 3.6010828807775397e-07
C282Y O 0 5.806452918477589e-06
mutation O 0 9.487656598139438e-07
nearly O 0 1.3986374725050155e-08
completely O 0 2.7358098009244713e-08
prevents O 0 1.296153495644603e-08
the O 0 9.503553499712325e-10
association O 0 7.272381030709596e-10
of O 0 7.027004672588433e-11
the O 0 6.671094232579833e-10
mutant O 0 6.229735163287842e-07
HFE O 0 1.489008809585357e-06
protein O 0 9.8482670907174e-09
with O 0 1.1564846857936573e-09
the O 0 1.7250391337597648e-08
TfR O 0 0.00015534204430878162
. O 0 3.2975947306113085e-07

Studies O 0 9.380181040796742e-07
on O 0 3.7853787659969385e-08
cell O 0 2.7548864522941585e-07
- O 0 1.705230033621774e-06
associated O 0 9.715468252124992e-08
transferrin O 0 3.1824393431634235e-07
at O 0 1.0726113330861153e-09
37 O 0 2.11202255684384e-08
degrees O 0 4.131528541506668e-08
C O 0 7.425418857565091e-08
suggest O 0 1.0467601008201655e-08
that O 0 1.8083899933074576e-09
the O 0 1.5169148159799306e-09
overexpressed O 0 1.0663696912160958e-06
wild O 0 1.8370300836068054e-08
- O 0 9.479498999098723e-07
type O 0 1.3530094520319835e-06
HFE O 0 5.515321845450671e-06
protein O 0 6.166300181575934e-08
decreases O 0 4.3623991530239437e-08
the O 0 2.6736968194995825e-10
affinity O 0 2.672504884060345e-09
of O 0 1.704923702217087e-10
the O 0 5.153451887451865e-09
TfR O 0 2.3613409211975522e-05
for O 0 4.274882314803108e-08
transferrin O 0 2.1587349692708813e-05
. O 0 2.920627082403371e-07

The O 0 5.085523184789054e-07
overexpressed O 0 2.0396028048708104e-05
H63D O 0 5.26935764355585e-06
protein O 0 5.460508489818494e-08
does O 0 9.7849994773469e-09
not O 0 8.954331720545383e-10
have O 0 4.939282871596617e-10
this O 0 1.9305540499559015e-10
effect O 0 2.390935627261115e-08
, O 0 8.289240960301925e-10
providing O 0 2.643867902385466e-10
the O 0 5.3913588871079554e-11
first O 0 1.8479505425883502e-10
direct O 0 8.631094172706355e-10
evidence O 0 2.8510809269022275e-09
for O 0 2.3934973447659047e-10
a O 0 6.273446206961353e-09
functional O 0 6.93245496563577e-08
consequence O 0 1.0329658906016448e-08
of O 0 2.332626869439025e-10
the O 0 9.29446386521704e-09
H63D O 0 0.0004460357304196805
mutation O 0 7.497167644032743e-06
. O 0 1.666407030143091e-07

Addition O 0 9.58436430664733e-07
of O 0 1.9455267619150618e-08
soluble O 0 7.785927778058976e-07
wild O 0 9.406807777168069e-08
- O 0 2.4633756765979342e-05
type O 0 3.0341559977387078e-05
HFE O 0 0.0011143687879666686
/ O 0 3.28525038639782e-06
beta2m O 0 7.85110387369059e-06
heterodimers O 0 1.4902190059729037e-06
to O 0 2.473786508971898e-08
cultured O 0 2.4438199375254044e-07
cells O 0 6.129491936235354e-08
also O 0 2.1308458997282287e-08
decreased O 0 1.771462798672019e-08
the O 0 2.2693184831279467e-10
apparent O 0 7.073839469740051e-08
affinity O 0 1.01078434511237e-08
of O 0 3.936797832171379e-10
the O 0 4.841940182132021e-09
TfR O 0 1.8894405684477533e-06
for O 0 2.8393468132215105e-10
its O 0 3.7214320514067367e-10
ligand O 0 3.295732753372249e-08
under O 0 1.6173560268839537e-08
steady O 0 4.052190263337252e-07
- O 0 1.7945615127246128e-07
state O 0 1.2517091363406507e-08
conditions O 0 5.05793423144496e-07
, O 0 7.87305831639884e-10
both O 0 2.3150481531786227e-10
in O 0 5.021267290850062e-10
293 O 0 1.330010057642994e-08
cells O 0 1.4782815860314713e-08
and O 0 4.068792414102518e-09
in O 0 9.95998483688254e-09
HeLa O 0 9.547631634632125e-06
cells O 0 6.045892178008216e-07
. O 0 9.366185338421928e-08

Furthermore O 0 1.0140951417270117e-05
, O 0 1.53421702009382e-08
at O 0 8.878312529603249e-10
4 O 0 4.277792342577413e-09
degrees O 0 1.8390271350199328e-07
C O 0 2.619866279474081e-07
, O 0 2.6312270140493865e-09
the O 0 7.428387349683874e-10
added O 0 2.248364872059483e-08
soluble O 0 3.621664035335925e-08
complex O 0 2.9893778563661044e-09
of O 0 1.336075916569257e-09
HFE O 0 3.307335646240972e-05
/ O 0 1.968036400512574e-07
beta2m O 0 9.090646813092462e-07
inhibited O 0 8.550111374461267e-08
binding O 0 1.9239063675513535e-08
of O 0 8.296375253458166e-10
transferrin O 0 3.95475950654145e-07
to O 0 4.2106055531121456e-08
HeLa O 0 3.815493528236402e-06
cell O 0 3.470875299171894e-06
TfR O 0 2.735129555730964e-06
in O 0 1.7174870414748966e-09
a O 0 1.7813530206467476e-08
concentration O 0 1.2691233450823347e-06
- O 0 1.507402771494526e-06
dependent O 0 6.262664555833908e-07
manner O 0 1.0686400173653965e-06
. O 0 2.2658873888303788e-07

Scatchard O 0 0.00015610942500643432
plots O 0 2.452496119076386e-06
of O 0 3.493044298252812e-09
these O 0 3.900295086900485e-10
data O 0 6.110797423630743e-10
indicate O 0 1.333346877352426e-09
that O 0 2.301953350158925e-10
the O 0 3.434024176129924e-10
added O 0 4.913576656662144e-09
heterodimer O 0 6.817443818363245e-07
substantially O 0 5.478153752846993e-07
reduced O 0 6.5364043067006605e-09
the O 0 3.7869060665052245e-10
affinity O 0 5.013585546720378e-09
of O 0 1.2955571060402349e-09
TfR O 0 4.143266323808348e-06
for O 0 2.3082515454575514e-08
transferrin O 0 2.4050559659372084e-05
. O 0 4.2477887518543866e-07

These O 0 2.812942909713456e-07
results O 0 2.4998170644607853e-08
establish O 0 5.77023850922842e-09
a O 0 9.825039448685402e-09
molecular O 0 9.787672894390198e-08
link O 0 5.020181674808555e-07
between O 0 1.4566571060470324e-08
HFE O 0 0.00014586714678443968
and O 0 1.3964863043725018e-08
a O 0 9.863117433894786e-09
key O 0 7.501889776051485e-09
protein O 0 6.002627728207699e-09
involved O 0 1.7936327978418376e-09
in O 0 7.753615527406055e-10
iron O 0 4.188505045021884e-05
transport O 0 2.330090076441138e-08
, O 0 1.4673867676506802e-09
the O 0 2.268237819791352e-09
TfR O 0 4.899802661384456e-06
, O 0 1.1873539929041499e-09
and O 0 1.2235524815551457e-09
raise O 0 2.723874681365146e-09
the O 0 1.1472545136115286e-10
possibility O 0 6.18776085925532e-10
that O 0 5.56187540468045e-10
alterations O 0 4.4827391576518494e-08
in O 0 2.353811312527654e-10
this O 0 1.8709822580120772e-10
regulatory O 0 1.0987038834286977e-08
mechanism O 0 3.87771770249401e-09
may O 0 2.4368420170617355e-08
play O 0 9.109821230701698e-10
a O 0 1.2234825375045943e-09
role O 0 1.92701210544044e-09
in O 0 3.78920339549893e-10
the O 0 2.0303521086617593e-09
pathogenesis O 0 7.30921044578281e-07
of O 0 4.727930047465634e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.0769880645966623e-05
. O 0 8.024044291232713e-07

Genomic O 0 1.448581042495789e-05
organization O 0 1.7299822729910375e-07
of O 0 2.9378719457184843e-09
the O 0 1.465801346967055e-08
UBE3A O 0 0.00018733010801952332
/ O 0 5.911090283916565e-06
E6 O 0 2.5492861823295243e-05
- O 0 0.00013857532758265734
AP O 0 4.137366886425298e-06
gene O 0 6.868202007126456e-08
and O 0 1.5606559600200853e-08
related O 0 5.445832584882737e-08
pseudogenes O 0 1.0058754014607985e-05
. O 0 6.016178986101295e-07

The O 0 1.13639885057637e-06
UBE3A O 0 4.446043385541998e-05
gene O 0 4.4385748765307653e-07
encodes O 0 2.68024592742222e-07
the O 0 1.985628905742942e-08
E6 O 0 5.461744876811281e-06
- O 0 1.312851054535713e-05
AP O 0 1.8179136986873345e-06
ubiquitin O 0 2.409491060006985e-07
- O 0 1.8429757631110988e-07
protein O 0 2.0833278213672202e-08
ligase O 0 1.408252714441005e-08
and O 0 3.1662048538549925e-09
has O 0 1.3557404088260228e-08
recently O 0 9.532205247353431e-09
been O 0 3.804340842350484e-09
shown O 0 2.9243536481260435e-09
to O 0 1.339686805934548e-09
be O 0 2.0633809327819108e-08
mutated O 0 0.0009917175630107522
in O 0 0.10341061651706696
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9997822642326355
who O 0 8.047180017456412e-06
lack O 0 3.8939063529142004e-08
15q11 O 0 1.9004642126674298e-06
- O 0 2.2052031454222742e-06
q13 O 0 1.1971429785262444e-06
deletions O 0 3.355413582539768e-07
or O 0 2.1896060076187496e-08
chromosome O 0 1.6878446331247687e-05
15 O 0 3.670297985536308e-07
paternal O 0 0.00013965604011900723
uniparental B-Disease 0 0.005991735961288214
disomy I-Disease 0 0.0006284095579758286
. O 0 9.598797987564467e-07

Previous O 0 9.211839824274648e-06
UBE3A O 0 3.53007999365218e-05
cDNA O 0 9.344180966763815e-07
analysis O 0 5.550213444394103e-08
has O 0 1.3861289005490107e-08
shown O 0 5.834682514915812e-09
a O 0 4.541889087050777e-09
coding O 0 7.11384871010523e-08
region O 0 1.0572683173393216e-08
of O 0 1.1434124758125108e-09
approximately O 0 1.955836559375257e-08
2 O 0 7.471648189039115e-08
. O 0 9.145310286839958e-08

6 O 0 4.68947882836801e-06
kb O 0 7.111791092029307e-06
and O 0 4.201444170348623e-08
a O 0 4.0014679569821965e-08
3 O 0 1.1169582592174265e-07
- O 0 9.474172838963568e-05
untranslated O 0 0.0014880698872730136
region O 0 3.94510124124281e-07
( O 0 3.247849322818297e-09
UTR O 0 3.4904525136880693e-07
) O 0 2.1901302993398986e-10
of O 0 1.1021070861483295e-10
< O 0 9.705834358442189e-09
50 O 0 3.1407685341378055e-09
bp O 0 3.942986950278282e-07
, O 0 1.0858097754251617e-09
whereas O 0 3.718780172690117e-09
Northern O 0 2.4812845111910065e-09
analysis O 0 2.6321456125799614e-09
has O 0 1.1989450321436834e-08
indicated O 0 6.413036324204313e-09
mRNA O 0 8.033135823204418e-10
sizes O 0 2.516098884797202e-09
of O 0 1.4296369643673756e-10
5 O 0 4.083330562565379e-09
- O 0 1.1298405979687232e-06
8 O 0 7.283298941729299e-08
kb O 0 1.8310227460460737e-05
. O 0 2.1651662507338187e-07

We O 0 5.666069569087995e-07
have O 0 2.385710651253703e-08
analyzed O 0 2.5772026290837857e-08
additional O 0 2.5297843819771515e-09
cDNA O 0 3.6257002733464105e-08
clones O 0 2.572797264122073e-08
and O 0 1.4140603132872798e-09
provide O 0 1.2116989633881303e-09
evidence O 0 2.59491894638586e-09
for O 0 2.34935765286437e-10
an O 0 1.7352151937544136e-09
additional O 0 6.448585310181443e-08
0 O 0 3.4375278801235254e-07
. O 0 9.535790468362393e-08

5 O 0 2.1300511434674263e-06
kb O 0 1.6234512258961331e-06
of O 0 6.804360186407621e-09
5 O 0 2.5772715517291545e-08
- O 0 1.6517162748641567e-06
UTR O 0 1.819218414311763e-05
and O 0 3.1764169960979416e-08
> O 0 1.0522549942493242e-08
2 O 0 1.4950445326178396e-09
kb O 0 7.918985289734337e-08
of O 0 1.053714560050878e-09
3 O 0 3.627830835739587e-08
- O 0 7.772844401188195e-05
UTR O 0 0.001991014927625656
. O 0 4.5723135144726257e-07

We O 0 4.54911770475519e-07
have O 0 1.3077428917540601e-08
established O 0 1.1220669948741602e-09
the O 0 1.5260843977404903e-10
genomic O 0 4.194300018411923e-09
organization O 0 4.3870934662848526e-10
of O 0 2.0942100831256028e-10
UBE3A O 0 8.917327249946538e-07
and O 0 1.5011822895871774e-09
the O 0 1.883208866626518e-10
sequence O 0 1.3144040300616666e-09
of O 0 6.277369180018866e-10
intron O 0 2.912415766331833e-06
- O 0 4.837991582462564e-06
exon O 0 4.034485755255446e-06
borders O 0 3.7857367374272144e-07
. O 0 1.4573663520422997e-07

We O 0 1.2628187278096448e-06
have O 0 5.852496087754844e-08
also O 0 1.0366271396833326e-08
mapped O 0 1.1204748062709768e-07
two O 0 1.111503999950969e-09
highly O 0 4.073979820162776e-09
homologous O 0 1.1517963471874282e-08
processed O 0 4.9995698248039844e-08
pseudogenes O 0 2.742927165400033e-07
, O 0 4.691662613964809e-09
UBE3AP1 O 0 1.3185825764594483e-06
and O 0 5.257460689023219e-09
UBE3AP2 O 0 1.5958620451783645e-06
, O 0 8.561411579677269e-10
to O 0 7.483579311795552e-10
chromosomes O 0 4.564607802848286e-09
2 O 0 3.4034570717267343e-09
and O 0 5.7513500628658676e-09
21 O 0 1.9419713837010022e-08
, O 0 1.0629152003005515e-09
respectively O 0 8.56233040025245e-09
, O 0 5.847067829911623e-10
and O 0 1.0542694495185856e-09
determined O 0 1.8476775665021705e-08
their O 0 4.935421515916971e-10
genomic O 0 4.35162910150666e-08
organization O 0 2.0465856565010654e-08
. O 0 4.601112735258539e-08

These O 0 2.809929071645456e-07
results O 0 6.295936572087157e-08
will O 0 2.2664474741418417e-09
form O 0 5.319776286150102e-10
the O 0 2.1735092892161134e-10
basis O 0 3.2865959953554125e-10
for O 0 1.51865686692787e-10
studies O 0 3.997817354939315e-10
of O 0 1.2333271903752774e-10
mutation O 0 5.691594751056073e-08
and O 0 4.049437229980413e-09
imprinting O 0 6.634706437580462e-07
of O 0 3.114682556315529e-08
UBE3A O 0 0.00016520304779987782
. O 0 2.889870245326165e-07

Mutation O 0 0.012098705396056175
spectrum O 0 0.000310284027364105
and O 0 1.4645739838670124e-06
genotype O 0 0.023272307589650154
- O 0 0.02253546379506588
phenotype O 1 0.5244566202163696
analyses O 0 7.818861718078551e-07
in O 0 1.309330599497116e-07
Cowden B-Disease 1 0.9921982884407043
disease I-Disease 0 0.010295872576534748
and O 0 3.3918345252459403e-06
Bannayan B-Disease 1 0.9667937159538269
- I-Disease 1 0.9999613761901855
Zonana I-Disease 1 0.9999881982803345
syndrome I-Disease 1 0.9999972581863403
, O 0 3.198534770376682e-08
two O 0 1.2983461772364535e-07
hamartoma B-Disease 1 0.9979265928268433
syndromes I-Disease 1 0.9470087289810181
with O 0 4.911620976599806e-07
germline O 0 0.000451376021374017
PTEN O 0 0.14479249715805054
mutation O 0 0.000104528822703287
. O 0 5.96552524712024e-07

The O 0 5.7057304729823954e-06
tumour B-Disease 1 0.9998619556427002
suppressor O 0 0.0006251943996176124
gene O 0 8.935740879678633e-06
PTEN O 0 0.00025128069682978094
, O 0 1.8369355814229493e-08
which O 0 5.5241660135152415e-09
maps O 0 1.0639607239681936e-07
to O 0 5.963260463204278e-08
10q23 O 0 1.3384903468249831e-05
. O 0 3.243929143081914e-07

3 O 0 1.9876995338563574e-06
and O 0 1.8455573069786624e-08
encodes O 0 3.4826147299327204e-08
a O 0 1.4509365264814278e-08
403 O 0 3.5354410954369087e-08
amino O 0 2.3668695448009203e-08
acid O 0 9.597721373211243e-08
dual O 0 6.526310016852221e-07
specificity O 0 1.8643939938556287e-06
phosphatase O 0 0.010067721828818321
( O 0 7.3203416661726806e-09
protein O 0 8.982495813825153e-08
tyrosine O 0 1.450559693694231e-06
phosphatase O 0 0.00018335574714001268
; O 0 1.3817999189313923e-08
PTPase O 0 2.3667345772082626e-07
) O 0 7.657234291080783e-10
, O 0 8.966568598722802e-10
was O 0 8.075666357854061e-08
shown O 0 1.2793753612072578e-08
recently O 0 3.834676132186132e-09
to O 0 8.855498001558715e-10
play O 0 2.5091020372514095e-09
a O 0 7.907933863293692e-09
broad O 0 3.047967567226806e-08
role O 0 2.7256740864345375e-08
in O 0 1.0362238178629468e-08
human O 0 1.2754226474953612e-07
malignancy B-Disease 0 4.0887673094403e-05
. O 0 3.5561095046432456e-07

Somatic O 0 0.0011556342942640185
PTEN O 0 0.014136668294668198
deletions O 0 0.00010860220208996907
and O 0 1.1489262305985903e-06
mutations O 0 2.487347501300974e-06
were O 0 3.030969963901953e-08
observed O 0 2.7979966787938793e-08
in O 0 1.0543745432300966e-08
sporadic B-Disease 0 0.003245104104280472
breast I-Disease 1 0.9786370992660522
, I-Disease 0 2.5117830659837637e-07
brain I-Disease 0 0.0020362739451229572
, I-Disease 0 3.170135016716813e-07
prostate I-Disease 0 0.015303120017051697
and I-Disease 0 2.06401073228335e-05
kidney I-Disease 1 0.7928978800773621
cancer I-Disease 0 0.02131662704050541
cell O 0 6.4708019635872915e-06
lines O 0 5.666853439834085e-07
and O 0 4.292520561222091e-09
in O 0 1.2610397170931265e-09
several O 0 7.198662999030603e-09
primary O 0 3.097258968409733e-06
tumours B-Disease 1 0.9999887943267822
such O 0 1.4288860761269007e-08
as O 0 2.900710387621075e-05
endometrial B-Disease 1 0.9998519420623779
carcinomas I-Disease 1 0.9999998807907104
, O 1 0.6728412508964539
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9808556437492371
thyroid B-Disease 1 0.9999772310256958
tumours I-Disease 1 0.9999994039535522
. O 0 6.834226951468736e-06

In O 0 3.148279574816115e-07
addition O 0 7.69571997238927e-08
, O 0 6.926372808635506e-09
PTEN O 0 1.087387772713555e-05
was O 0 2.0867186378836777e-07
identified O 0 7.21617654519946e-09
as O 0 7.258219025807477e-10
the O 0 9.956598878702039e-10
susceptibility O 0 3.0513809178955853e-05
gene O 0 1.1174356018273102e-07
for O 0 1.352176592916976e-08
two O 0 2.5561578240740346e-06
hamartoma B-Disease 1 0.9998501539230347
syndromes I-Disease 1 0.9999427795410156
Cowden B-Disease 1 0.9999548196792603
disease I-Disease 1 0.8957704305648804
( O 0 4.0240308862848906e-08
CD B-Disease 0 1.947556302184239e-05
; O 0 1.1758925211324822e-07
MIM O 0 6.316050075838575e-06
158350 O 0 7.082600177454879e-07
) O 0 2.5913675649746892e-09
and O 0 1.5402394026864386e-08
Bannayan B-Disease 0 4.110786903765984e-05
- I-Disease 0 0.0004127205756958574
Zonana I-Disease 0 0.0004040579660795629
( I-Disease 0 6.501639226996758e-09
BZS I-Disease 0 1.2448341522031114e-06
) I-Disease 0 7.357239262262283e-09
or I-Disease 0 1.3517433394838463e-08
Ruvalcaba I-Disease 0 3.7318146496545523e-05
- I-Disease 0 2.081515958707314e-05
Riley I-Disease 0 2.7931853765039705e-05
- I-Disease 1 0.5584463477134705
Smith I-Disease 1 0.9726990461349487
syndrome I-Disease 1 0.9997732043266296
( O 0 2.259352882560961e-08
MIM O 0 8.861436072038487e-06
153480 O 0 2.9600287234643474e-06
) O 0 2.873991711282997e-08
. O 0 7.899434706359898e-08

Constitutive O 0 4.448503386811353e-05
DNA O 0 4.754616838908987e-06
from O 0 2.3836502549556826e-08
37 O 0 6.642836325454482e-08
CD B-Disease 0 2.469440687491442e-07
families O 0 9.666297984267658e-09
and O 0 6.2954654822533485e-09
seven O 0 6.6798575559801066e-09
BZS B-Disease 0 1.156329517471022e-06
families O 0 1.6886369635926712e-08
was O 0 1.0725611332418339e-07
screened O 0 3.8588026995967084e-07
for O 0 3.6211599052649035e-08
germline O 0 3.771045885514468e-05
PTEN O 0 0.006610950455069542
mutations O 0 1.4877404282742646e-05
. O 0 3.823606107289379e-07

PTEN O 0 0.3077343702316284
mutations O 0 0.0031369717326015234
were O 0 4.218556171053933e-07
identified O 0 7.466989870863472e-08
in O 0 1.3423775424570294e-09
30 O 0 1.449826592114789e-09
of O 0 1.9352545954642864e-10
37 O 0 4.2744179751252886e-08
( O 0 1.4512042678660464e-09
81 O 0 2.925971500644664e-07
% O 0 1.3217903438444978e-09
) O 0 2.9184069050280925e-10
CD B-Disease 0 9.636715958549757e-07
families O 0 4.1029104558276686e-09
, O 0 3.7634251270901586e-10
including O 0 6.58245402629376e-10
missense O 0 6.607012892345665e-07
and O 0 4.3801557936262725e-09
nonsense O 0 1.4820879812305066e-07
point O 0 1.7107399941096446e-08
mutations O 0 7.960419168284716e-08
, O 0 1.3396306286495019e-09
deletions O 0 7.18450934300563e-08
, O 0 3.1677391820750245e-09
insertions O 0 8.000084505965788e-08
, O 0 1.7336470037321305e-09
a O 0 2.002447097027016e-08
deletion O 0 5.869594588148175e-06
/ O 0 1.102979254596903e-07
insertion O 0 9.411096613121117e-08
and O 0 1.71279701532967e-08
splice O 0 5.9755966503871605e-06
site O 0 2.107336285916972e-06
mutations O 0 4.12245526604238e-06
. O 0 1.2696933993083803e-07

These O 0 7.433722544192278e-07
mutations O 0 2.923778083641082e-06
were O 0 1.977706531874901e-08
scattered O 0 8.702726539411287e-09
over O 0 5.0278639029954775e-09
the O 0 1.6288095316951967e-09
entire O 0 5.3116879783488e-09
length O 0 2.5066254849548386e-08
of O 0 9.535636724677943e-10
PTEN O 0 1.8880926290876232e-05
, O 0 1.2490660727948466e-09
with O 0 3.3973457380653826e-10
the O 0 3.6082567489437167e-10
exception O 0 1.5621800519838303e-09
of O 0 3.0470560102857647e-11
the O 0 2.3278355631983771e-10
first O 0 2.8599478341106988e-09
, O 0 9.626459629430428e-10
fourth O 0 5.5387708641774225e-08
and O 0 3.6558311933276855e-08
last O 0 2.81017037195852e-07
exons O 0 5.828906523674959e-06
. O 0 4.991708806301176e-07

A O 0 1.0593979595796554e-06
hot O 0 1.2896526868644287e-06
spot O 0 3.425269312629098e-07
for O 0 7.944428226380751e-09
PTEN O 0 0.00011735137377399951
mutation O 0 3.428478692057979e-07
in O 0 2.759496409154849e-09
CD B-Disease 0 5.850676529917109e-07
was O 0 7.145689551180112e-07
identified O 0 7.821976844013534e-09
in O 0 2.874569748900768e-10
exon O 0 2.8653547090584652e-08
5 O 0 2.215837957564304e-09
that O 0 9.373540832413596e-10
contains O 0 1.242906000342714e-09
the O 0 5.332921881873176e-10
PTPase O 0 3.222183124762523e-07
core O 0 2.742664584332033e-08
motif O 0 1.1154781986988382e-08
, O 0 4.1460021527051083e-10
with O 0 2.659394648940605e-10
13 O 0 5.947489167823505e-10
of O 0 1.5090531602091062e-10
30 O 0 3.515287394506572e-09
( O 0 4.264771313877702e-10
43 O 0 1.0803219652189e-07
% O 0 1.2102299162819463e-09
) O 0 3.9257005979287385e-10
CD B-Disease 0 2.173583425246761e-06
mutations O 0 5.042887210038316e-07
identified O 0 1.1736805305417874e-08
in O 0 3.960854144668957e-10
this O 0 2.224294082253664e-09
exon O 0 1.081848495232407e-06
. O 0 1.263515940763682e-07

Seven O 0 7.18677767963527e-07
of O 0 3.810229909362306e-09
30 O 0 4.609086001750029e-09
( O 0 6.975702238065651e-10
23 O 0 2.0820328572312974e-08
% O 0 6.140450925506968e-10
) O 0 2.04258637781507e-10
were O 0 2.293846002032751e-09
within O 0 8.782910509985697e-11
the O 0 2.3161257634018995e-10
core O 0 2.0055509253325e-08
motif O 0 1.796907156403904e-08
, O 0 4.296703826067727e-10
the O 0 3.8388817125145636e-10
majority O 0 6.744691916082957e-08
( O 0 1.2941117621956266e-10
five O 0 1.1541483047050605e-10
of O 0 3.3025807782971484e-11
seven O 0 5.542950543002689e-10
) O 0 4.151191196344328e-11
of O 0 4.065824413257424e-11
which O 0 6.791886608681352e-09
were O 0 3.7432048571872656e-08
missense O 0 1.2315426829445641e-05
mutations O 0 2.957445417450799e-07
, O 0 1.4837016060198494e-09
possibly O 0 5.570881089766999e-09
pointing O 0 2.507027119236227e-08
to O 0 2.6383080165004458e-09
the O 0 4.846696377569515e-10
functional O 0 1.0278599305024727e-08
significance O 0 7.715892924586853e-10
of O 0 9.336724449138245e-11
this O 0 1.959218343117186e-09
region O 0 1.1972510094437894e-07
. O 0 1.6103354028018657e-07

Germline O 0 0.01708497479557991
PTEN O 1 0.5160446763038635
mutations O 0 0.004055550787597895
were O 0 5.159833449397411e-07
identified O 0 9.034489067971663e-08
in O 0 2.465194048895114e-09
four O 0 1.372207458771868e-09
of O 0 2.364809459365347e-10
seven O 0 5.523723700662231e-09
( O 0 3.062429421163415e-09
57 O 0 6.188062116052606e-07
% O 0 5.914922773797571e-09
) O 0 5.02057151408053e-09
BZS B-Disease 0 8.891317520465236e-06
families O 0 8.249423899542307e-08
studied O 0 1.62232169031995e-07
. O 0 1.205441435558896e-07

Interestingly O 0 0.00010877600288949907
, O 0 7.709074623107881e-08
none O 0 1.1549555090084596e-08
of O 0 1.477828970308792e-10
these O 0 9.557723501529836e-10
mutations O 0 9.751857277251474e-08
was O 0 1.3300346779487882e-07
observed O 0 5.343238740351808e-09
in O 0 3.181798435836214e-10
the O 0 1.7534471652425054e-09
PTPase O 0 3.0909031920600682e-06
core O 0 6.914027039783832e-07
motif O 0 1.256495238521893e-06
. O 0 1.371630418134373e-07

It O 0 7.420704264404776e-07
is O 0 2.893859907260321e-08
also O 0 4.618872395667495e-09
worthy O 0 4.157407307303629e-09
of O 0 1.1373173236517431e-10
note O 0 4.2040633196904764e-09
that O 0 2.2970847446401876e-10
a O 0 1.4723939845140421e-09
single O 0 2.0707457082380643e-08
nonsense O 0 1.1496942420308187e-07
point O 0 7.973878446421168e-09
mutation O 0 2.8957925835015885e-08
, O 0 5.813173831192842e-10
R233X O 0 4.0301298298572874e-08
, O 0 1.3692166289658303e-09
was O 0 2.2559509815778256e-08
observed O 0 4.3147081463246195e-09
in O 0 2.232180967842723e-10
the O 0 8.23657031467917e-10
germline O 0 1.1415808387482684e-07
DNA O 0 2.2123591847389434e-08
from O 0 3.4237301882455995e-10
two O 0 1.0977606601514367e-09
unrelated O 0 2.98182278868353e-08
CD B-Disease 0 9.632049113861285e-07
families O 0 1.3522488018224976e-08
and O 0 4.92523000161782e-09
one O 0 3.878695764569784e-08
BZS B-Disease 0 2.853377372957766e-05
family O 0 9.22126446312177e-07
. O 0 1.4883201515658584e-07

Genotype O 1 0.9891809821128845
- O 1 0.932380735874176
phenotype O 1 0.9936745166778564
studies O 0 2.533533631776663e-07
were O 0 2.712294211448807e-08
not O 0 2.7912046007827485e-09
performed O 0 1.4052904617756212e-08
on O 0 1.6893223486746933e-09
this O 0 2.658933073718117e-10
small O 0 1.3103188534202559e-09
group O 0 3.0039297715944713e-09
of O 0 6.957431297749395e-10
BZS B-Disease 0 5.804100055684103e-06
families O 0 1.4969491246574762e-07
. O 0 1.0947277928607946e-07

However O 0 8.703219464223366e-06
, O 0 1.623157430685751e-07
genotype O 0 5.631569365505129e-05
- O 0 8.85532790562138e-05
phenotype O 0 0.0004767035134136677
analysis O 0 1.6872975905357634e-08
inthe O 0 8.312205324045863e-08
group O 0 3.88749299418123e-09
of O 0 1.0593969451688778e-10
CD B-Disease 0 5.014463226871158e-07
families O 0 6.437546939963568e-09
revealed O 0 8.833421105691741e-09
two O 0 2.0331412942109495e-10
possible O 0 7.208551533466334e-10
associations O 0 2.758021866444693e-10
worthy O 0 2.728278714059229e-09
of O 0 1.1525292525904618e-10
follow O 0 3.256788394523369e-09
- O 0 9.229474784433478e-08
up O 0 5.07533570726082e-09
in O 0 1.2746542710218023e-09
independent O 0 2.8766024229298637e-08
analyses O 0 1.4426750283291767e-07
. O 0 9.466727135531983e-08

The O 0 1.0288822238635476e-07
first O 0 4.486348714749511e-08
was O 0 5.509753009391716e-08
an O 0 2.8257065576298146e-09
association O 0 2.6061584001979554e-09
noted O 0 3.9586813826986145e-09
in O 0 2.0566913450092983e-10
the O 0 3.3164951340758364e-10
group O 0 2.93677393514713e-09
of O 0 9.325956673578162e-11
CD B-Disease 0 1.4385166196007049e-06
families O 0 3.1310506187764986e-08
with O 0 2.3891584532975685e-07
breast B-Disease 1 0.9971244931221008
disease I-Disease 0 0.006257136818021536
. O 0 8.119434369291412e-07

A O 0 1.8964086621053866e-06
correlation O 0 9.386784540765802e-07
was O 0 7.394016421358174e-08
observed O 0 4.367183947806552e-09
between O 0 2.067886140100228e-10
the O 0 4.959541666238465e-10
presence O 0 2.88104988754867e-08
/ O 0 1.4893821287387254e-07
absence O 0 1.1355150597580632e-08
of O 0 3.055135033847023e-10
a O 0 5.191655105818427e-08
PTEN O 0 0.00285786809399724
mutation O 0 2.566517025570647e-07
and O 0 1.0169720621178158e-09
the O 0 2.561312828497364e-10
type O 0 7.740899832242576e-08
of O 0 3.9365595227991435e-09
breast O 0 0.008237134665250778
involvement O 0 2.016999815168674e-06
( O 0 3.5166102918537945e-08
unaffected O 0 1.756570054567419e-05
versus O 0 7.021626970526995e-06
benign O 0 0.0003367523895576596
versus O 0 5.443550617201254e-05
malignant O 0 0.006684607360512018
) O 0 1.277793160170404e-07
. O 0 1.5614307358191581e-07

Specifically O 0 3.0700477964273887e-06
and O 0 2.3480293265265573e-08
more O 0 2.7219217990648303e-09
directly O 0 6.9442305239419966e-09
, O 0 9.523150046319984e-10
an O 0 3.204810417045678e-09
association O 0 3.4727694053771074e-09
was O 0 2.4219636429734237e-07
also O 0 1.7941399477194864e-08
observed O 0 1.7926545803348404e-09
between O 0 7.020681258573802e-11
the O 0 1.4421146221632597e-10
presence O 0 1.0811415096512178e-09
of O 0 1.9677409701657211e-10
a O 0 4.10186409283142e-08
PTEN O 0 0.026392340660095215
mutation O 0 7.386780453089159e-06
and O 0 1.0341584584239172e-06
malignant B-Disease 1 0.9996868371963501
breast I-Disease 1 0.9999715089797974
disease I-Disease 0 0.4047852158546448
. O 0 1.7643903902353486e-06

Secondly O 0 6.881909212097526e-05
, O 0 5.273150094353696e-08
there O 0 1.0844588338443373e-08
appeared O 0 1.843991981331783e-07
to O 0 2.2134725163880375e-09
be O 0 3.768411804827565e-09
an O 0 4.266937914110258e-09
interdependent O 0 5.409257823885127e-07
association O 0 3.49579032388192e-09
between O 0 1.1036790370511085e-09
mutations O 0 2.5381956092473956e-08
upstream O 0 8.65123972459969e-09
and O 0 1.9032111442385258e-09
within O 0 2.0389391564012982e-10
the O 0 2.929823605946069e-10
PTPase O 0 4.3767596480392967e-07
core O 0 3.773556400687994e-08
motif O 0 1.1670372224159564e-08
, O 0 1.800844195987139e-10
the O 0 7.21023935001952e-11
core O 0 6.185994383400839e-09
motif O 0 4.994039404238038e-09
containing O 0 8.169324661189137e-10
the O 0 2.5568808181830605e-10
majority O 0 7.093683862535727e-09
of O 0 4.968081501743882e-10
missense O 0 1.0530547115195077e-05
mutations O 0 4.6430056954704924e-07
, O 0 1.815003924932057e-09
and O 0 7.579379346367432e-10
the O 0 2.1305186781450658e-10
involvement O 0 3.370844936512185e-09
of O 0 7.447422539774706e-11
all O 0 1.652484399317089e-10
major O 0 1.3435712542531064e-09
organ O 0 1.4173683666740544e-06
systems O 0 3.2903977853493416e-07
( O 0 4.982001478026632e-10
central O 0 1.19000453935314e-09
nervous O 0 6.270398102969921e-07
system O 0 2.3463891807296022e-07
, O 0 1.601497103820293e-07
thyroid O 0 0.004357080906629562
, O 0 1.179843707177497e-06
breast O 0 0.048356711864471436
, O 0 2.746382051554974e-06
skin O 1 0.9998345375061035
and O 1 0.5671288967132568
gastrointestinal O 1 0.9999948740005493
tract O 1 0.9973093271255493
) O 0 1.9000169970695424e-07
. O 0 3.7868417734898685e-07

However O 0 8.98124255854782e-07
, O 0 3.568541018239557e-09
these O 0 1.9685518493073317e-10
observations O 0 6.831304411036854e-09
would O 0 3.699283102065465e-09
need O 0 1.2251311076738602e-09
to O 0 3.5358236338822735e-09
be O 0 3.2056863830121074e-08
confirmed O 0 4.2431768321193886e-08
by O 0 2.2381793640668945e-10
studying O 0 4.0187958516568756e-10
a O 0 1.1486015472073063e-09
larger O 0 9.933874833834011e-10
number O 0 2.8505139915147026e-10
of O 0 1.5215474713503596e-10
CD B-Disease 0 2.729282414293266e-06
families O 0 8.796368433650059e-08
. O 0 5.538496239410051e-08

Molecular O 0 0.007487130351364613
defects O 1 0.9938836097717285
leading O 0 6.946020789655449e-07
to O 0 2.8903848203754023e-08
human O 0 1.7312785871581582e-08
complement B-Disease 0 1.4177509228829877e-06
component I-Disease 0 0.0689338892698288
C6 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999988079071045
in O 0 2.0724684191009146e-08
an O 0 4.272695530715964e-09
African O 0 6.313611411457032e-09
- O 0 2.286026074216352e-06
American O 0 2.226897919399562e-07
family O 0 2.636064095895563e-07
. O 0 7.404558033385911e-08

Complement B-Disease 0 0.0009218318737111986
component I-Disease 1 0.7663824558258057
C6 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999996423721313
( O 0 6.121582600826514e-07
C6D B-Disease 0 0.0002228121884400025
) O 0 7.269863999681547e-08
was O 0 5.7177720009349287e-05
diagnosed O 0 0.0004514541069511324
in O 0 1.0157585883519005e-09
a O 0 1.3753288286011411e-08
16 O 0 1.7445012545636018e-08
- O 0 2.909434897446772e-07
year O 0 2.2409880173768215e-08
- O 0 2.602107542770682e-07
old O 0 2.869889783596591e-07
African O 0 2.134758148031324e-09
- O 0 9.410199197645852e-08
American O 0 2.4869288850482008e-08
male O 0 1.6558120705667534e-06
with O 0 3.062950327148428e-06
meningococcal B-Disease 1 0.9999986886978149
meningitis I-Disease 1 0.9999990463256836
. O 0 8.71651809575269e-06

The O 0 1.8044927401206223e-06
patients O 0 0.0002148985950043425
father O 0 7.420668453050894e-07
and O 0 1.1870421978699142e-08
two O 0 1.0062638722274642e-08
brothers O 0 5.087230761091632e-07
also O 0 7.824591818916815e-08
had O 0 3.422833287913818e-07
C6D B-Disease 0 4.217448349663755e-06
, O 0 2.078722527443233e-09
but O 0 2.2499082596993958e-09
gave O 0 6.032308430548028e-09
no O 0 1.1112368802912442e-09
history O 0 1.2747320976558285e-09
of O 0 2.6933013597130184e-09
meningitis B-Disease 1 0.9997419714927673
or O 0 1.8040088534121423e-08
other O 0 2.6609500380914142e-08
neisserial B-Disease 0 0.09989411383867264
infection I-Disease 0 0.0016076044412329793
. O 0 2.8164646437289775e-07

By O 0 1.28785430320022e-07
using O 0 3.175605201022336e-08
exon O 0 1.8740705343134323e-07
- O 0 3.90716401454938e-08
specific O 0 4.0429393166618866e-09
polymerase O 0 1.417135706560657e-07
chain O 0 3.622797635216557e-07
reaction O 0 3.4947252203210155e-08
( O 0 2.2026223900351027e-10
PCR O 0 1.1715851400140309e-07
) O 0 6.686087794527396e-10
/ O 0 1.0094819202777217e-08
single O 0 1.7415555220168244e-08
- O 0 2.09641470405586e-07
strand O 0 5.795217248305562e-07
conformation O 0 1.1693862234096741e-07
polymorphism O 0 4.637849997379817e-07
as O 0 1.2348694289343598e-09
a O 0 2.8531863538461266e-09
screening O 0 1.241878244684358e-08
step O 0 8.479897672941661e-09
and O 0 6.061739998841631e-10
nucleotide O 0 4.879132098345451e-10
sequencing O 0 3.9775396865060486e-10
of O 0 6.455356388324063e-11
target O 0 3.3316116532233764e-09
exons O 0 1.6681426018294587e-08
, O 0 7.144737024233905e-10
we O 0 2.8368726812111333e-10
determined O 0 3.0989300014994114e-09
that O 0 2.9862876060882115e-10
the O 0 4.2241637965290124e-10
proband O 0 3.6695243466056127e-07
was O 0 2.1391777238477516e-08
a O 0 3.217280442058268e-09
compound O 0 4.210678028471193e-08
heterozygote O 0 5.229011890151014e-07
for O 0 5.349714449209841e-09
two O 0 1.1941249766778128e-08
C6 O 0 0.00017717572336550802
gene O 0 3.664366431621602e-06
mutations O 0 7.179562089731917e-06
. O 0 3.69722584991905e-07

The O 0 8.012087704400983e-08
first O 0 1.8459127559822264e-08
, O 0 2.69431854604818e-09
1195delC O 0 7.122007161797228e-08
located O 0 3.6252836288497292e-09
in O 0 1.0088346824588257e-09
exon O 0 5.16158991104021e-08
7 O 0 7.1409940183286835e-09
, O 0 6.996769275069425e-10
is O 0 7.381707467501997e-10
a O 0 7.532228174511602e-09
novel O 0 5.679849834905326e-08
mutation O 0 3.272262816267357e-08
, O 0 3.2208397060529137e-10
while O 0 3.0667240968895726e-10
the O 0 1.931272225474956e-10
second O 0 4.5007024773724424e-09
, O 0 1.4923438040881365e-09
1936delG O 0 4.4088910300388306e-08
in O 0 8.140114693411249e-10
exon O 0 4.034405520769724e-08
12 O 0 3.675223458898813e-09
, O 0 6.881518133106113e-10
has O 0 6.383138018151158e-09
been O 0 6.07797412399691e-09
described O 0 1.9634466497109315e-08
before O 0 4.320215019060214e-10
to O 0 2.5136430714667313e-09
cause O 0 8.22364398800346e-08
C6D B-Disease 0 3.016784148712759e-06
in O 0 1.6349412934602015e-09
an O 0 2.525118114604652e-09
unrelated O 0 4.0790592237271994e-08
African O 0 3.051461971992353e-09
- O 0 2.3133340221193066e-07
American O 0 3.4487573685737516e-08
individual O 0 1.2533743820597465e-08
. O 0 7.611896535308915e-08

Both O 0 1.2094503745174734e-06
mutations O 0 4.798136160388822e-06
result O 0 7.464241491561552e-08
in O 0 2.945054866643204e-08
premature O 0 2.0566189050441608e-05
termination O 0 2.670677531568799e-06
codons O 0 6.409737238755042e-07
and O 0 2.5331905817438383e-07
C6 O 0 0.00032525157439522445
null O 0 0.00020835337636526674
alleles O 0 4.260216883267276e-06
. O 0 9.48150557178451e-07

Allele O 0 0.0007720620487816632
- O 0 9.1350721049821e-06
specific O 0 1.073727844413952e-07
PCR O 0 2.840173010554281e-06
indicated O 0 3.6885126064589713e-07
that O 0 1.7777135319363424e-09
the O 0 5.297156602246389e-10
probands O 0 1.0348807109039626e-06
two O 0 9.321911242921033e-09
brothers O 0 2.375291074940833e-07
also O 0 1.3638687512695924e-08
inherited O 0 4.839643708010044e-08
the O 0 7.645004629353025e-10
1195delC O 0 7.25205325124989e-07
mutation O 0 5.2636938363548325e-08
from O 0 4.679577281230252e-10
their O 0 1.9830694863998133e-09
heterozygous O 0 1.0638516414473997e-06
mother O 0 1.9028786368835426e-07
and O 0 7.242398902818081e-10
the O 0 5.149027870743339e-10
1936delG O 0 6.516334565276338e-07
mutation O 0 7.103760424342909e-08
from O 0 2.582593305877623e-10
their O 0 1.3750159899572623e-09
homozygous O 0 4.1579176013328834e-07
father O 0 4.734527010441525e-07
. O 0 3.8151242165440635e-09
. O 0 2.580640945382129e-08

PAX6 O 1 0.8111107349395752
mutations O 0 0.27811747789382935
reviewed O 0 0.0002354189200559631
. O 0 1.0556547749729361e-05

Mutations O 0 0.0038314731791615486
in O 0 7.38915105102933e-07
PAX6 O 0 8.604863978689536e-05
are O 0 1.7786607742209526e-08
responsible O 0 1.2928794923539044e-08
for O 0 4.424625554833028e-09
human O 0 2.8913442307043624e-08
aniridia B-Disease 1 0.9999939203262329
and O 0 4.2606700390024344e-07
have O 0 5.313818363106293e-08
also O 0 2.0170057624113724e-08
been O 0 1.7285829656543683e-08
found O 0 3.7707055255964406e-09
in O 0 3.013570948340316e-09
patients O 0 7.557654953416204e-06
with O 0 2.099095581797883e-07
Peters B-Disease 1 0.9999995231628418
anomaly I-Disease 1 0.9999998807907104
, O 0 2.3273353235708782e-06
with O 0 0.0002856121282093227
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999897480010986
, O 0 8.071123858144347e-08
with O 0 1.264938589429221e-07
autosomal B-Disease 1 0.8812445998191833
dominant I-Disease 1 0.6110208034515381
keratitis I-Disease 1 0.9991668462753296
, O 0 2.502150380223611e-07
and O 0 2.7702347082936285e-08
with O 0 1.0189300780893973e-07
isolated B-Disease 0 0.012817694805562496
foveal I-Disease 1 0.9999990463256836
hypoplasia I-Disease 1 0.9999991655349731
. O 0 9.383202268509194e-06

No O 0 9.747726608111407e-07
locus O 0 9.664943263487658e-07
other O 0 3.2369338320847874e-09
than O 0 1.0030887231948782e-08
chromosome O 0 1.9693140984600177e-06
11p13 O 0 1.8239953760712524e-06
has O 0 1.969414427094307e-07
been O 0 2.1510551562187175e-08
implicated O 0 9.656609734065569e-08
in O 0 3.111108171083288e-08
aniridia B-Disease 1 0.9999960660934448
, O 0 1.7910149807676135e-08
and O 0 4.642312756431011e-09
PAX6 O 0 1.4553522305504885e-05
is O 0 1.924082404514138e-08
clearly O 0 9.673306600177511e-09
the O 0 8.810090157407302e-11
major O 0 7.504347698805702e-10
, O 0 6.701472154979626e-10
if O 0 5.958866733379864e-10
not O 0 1.0807703620940856e-09
only O 0 1.2079468536541071e-09
, O 0 1.53770840505274e-09
gene O 0 2.3972187790377575e-08
responsible O 0 1.5009389642273163e-07
. O 0 1.1228966201315416e-07

Twenty O 0 1.907808837131597e-05
- O 0 3.1418539947480895e-06
eight O 0 9.467160566600796e-08
percent O 0 1.0137306993840411e-08
of O 0 1.9621157476557016e-10
identified O 0 9.68937570178241e-08
PAX6 O 0 8.037321822484955e-05
mutations O 0 2.519304416637169e-06
are O 0 6.9066246055626834e-09
C O 0 1.722527827041631e-07
- O 0 3.446795744821429e-05
T O 0 4.6941549953771755e-05
changes O 0 1.3056244085873914e-08
at O 0 1.0832840180441394e-09
CpG O 0 1.3085217176467268e-07
dinucleotides O 0 6.611110165977152e-07
, O 0 1.9938672934927126e-09
20 O 0 6.857253098679905e-10
% O 0 1.2149521666504626e-10
are O 0 5.3849247977355574e-11
splicing O 0 2.0404545608698754e-08
errors O 0 3.191477659925113e-08
, O 0 1.285043627063942e-09
and O 0 9.929195243785216e-10
more O 0 8.138686391490069e-10
than O 0 1.7998905699201373e-09
30 O 0 2.404938914679633e-09
% O 0 3.9611866564648324e-10
are O 0 1.9336091061639138e-10
deletion O 0 6.563066534681639e-08
or O 0 1.2961107742626155e-09
insertion O 0 7.402228874298089e-08
events O 0 3.848665741656987e-08
. O 0 9.872871231664249e-08

There O 0 9.377766332363535e-07
is O 0 2.3963366402313113e-08
a O 0 6.634517291104203e-08
noticeably O 0 7.727569754933938e-05
elevated O 0 1.4273125998442993e-05
level O 0 2.1459276577928676e-09
of O 0 2.87302431845049e-10
mutation O 0 4.2992741811076485e-08
in O 0 4.784286300463236e-10
the O 0 6.77689848682661e-10
paired O 0 2.6064581604146042e-08
domain O 0 1.0165187802613218e-08
compared O 0 7.736291607329804e-09
with O 0 2.1016167972565114e-10
the O 0 3.1273111877894166e-10
rest O 0 7.945454294500109e-10
of O 0 5.628067456520114e-11
the O 0 7.509473598510397e-10
gene O 0 8.349388025408189e-08
. O 0 6.687049847187154e-08

Increased O 0 1.2120864994358271e-05
mutation O 0 3.2323166578862583e-06
in O 0 6.812099773156888e-09
the O 0 3.4135860804695994e-09
homeodomain O 0 7.91936088262446e-07
is O 0 8.075509150273774e-09
accounted O 0 5.43567058031158e-09
for O 0 2.0390014676685553e-10
by O 0 6.528177443065886e-10
the O 0 3.277295546055825e-09
hypermutable O 0 9.823122127272654e-06
CpG O 0 3.765665724131395e-06
dinucleotide O 0 1.2817686183552723e-06
in O 0 1.522452031110788e-08
codon O 0 1.3041389479440113e-07
240 O 0 1.9327100631016947e-07
. O 0 8.342001223127227e-08

Very O 0 3.192502845195122e-06
nearly O 0 9.831360614498408e-08
all O 0 2.309289870439102e-09
mutations O 0 9.21619331961665e-08
appear O 0 4.908867268227368e-08
to O 0 3.038755380657676e-08
cause O 0 1.5578281818307005e-05
loss O 0 1.0491645525689819e-06
of O 0 2.60059557222192e-10
function O 0 4.078394011397535e-10
of O 0 2.8469697085919954e-11
the O 0 4.934103681186741e-10
mutant O 0 3.9418364394805394e-07
allele O 0 8.943773366354435e-08
, O 0 2.1252100079749425e-10
and O 0 2.4137977727711757e-10
more O 0 6.675804353761805e-10
than O 0 1.6092807086920402e-09
80 O 0 1.668848281788371e-09
% O 0 1.3033837897857836e-10
of O 0 8.867510892240915e-11
exonic O 0 5.418225441644609e-07
substitutions O 0 7.136585367106818e-08
result O 0 1.8949062763340407e-08
in O 0 6.739044433601293e-09
nonsense O 0 1.5662316172893043e-06
codons O 0 1.292824890697375e-06
. O 0 1.133998210889331e-07

In O 0 1.904176514244682e-07
a O 0 2.92422139835935e-08
gene O 0 2.1902074820445705e-08
with O 0 9.45874156776938e-10
such O 0 2.674835464233638e-09
extraordinarily O 0 2.4734172257012688e-06
high O 0 4.720009982861484e-08
sequence O 0 3.0419315955043658e-09
conservation O 0 9.094057729086558e-10
throughout O 0 3.0096977687854576e-10
evolution O 0 7.025507398061848e-10
, O 0 2.4087112859838555e-10
there O 0 3.711196350231205e-10
are O 0 9.926601762799692e-10
presumed O 0 4.013425041193841e-06
undiscovered O 0 1.107738285099913e-06
missense O 0 6.22353991275304e-06
mutations O 0 5.424786309049523e-07
, O 0 1.27929655757697e-09
these O 0 3.681613347517043e-10
are O 0 9.344265361477255e-10
hypothesized O 0 7.075687591395763e-08
to O 0 7.888108832787566e-09
exist O 0 1.0201659517150574e-09
in O 0 7.254647993448771e-10
as O 0 8.576648724556435e-09
- O 0 2.3608874926139833e-06
yet O 0 7.916174808997312e-07
unidentified O 0 4.345292552443425e-07
phenotypes O 0 5.32541605480219e-07
. O 0 3.0093549874266046e-09
. O 0 2.3451201869306715e-08

Genetic O 0 0.0006631490541622043
heterogeneity O 0 0.0005171886296011508
and O 0 1.0734406714618672e-06
penetrance O 0 9.79541346168844e-06
analysis O 0 3.847454621563884e-08
of O 0 8.715097532530081e-10
the O 0 3.896757583277122e-09
BRCA1 O 0 1.2213507943670265e-05
and O 0 2.1531943161789968e-07
BRCA2 O 0 1.7105079678003676e-05
genes O 0 3.2936472393885197e-07
in O 0 1.0230063480776153e-06
breast B-Disease 1 0.9996336698532104
cancer I-Disease 0 0.4078827500343323
families O 0 8.418065817750175e-07
. O 0 2.8680346986220684e-07

The O 0 0.0003501024912111461
Breast B-Disease 1 0.9999988079071045
Cancer I-Disease 1 0.9999879598617554
Linkage O 0 0.0004917731857858598
Consortium O 0 9.675720320956316e-06
. O 0 6.478165914813871e-07

The O 0 7.96801344904452e-08
contribution O 0 6.427475796044746e-08
of O 0 3.4234577395153565e-09
BRCA1 O 0 4.884397640125826e-06
and O 0 7.582812031614594e-07
BRCA2 O 0 0.01002373918890953
to O 0 0.0223573949187994
inherited B-Disease 1 1.0
breast I-Disease 1 0.9999998807907104
cancer I-Disease 1 1.0
was O 0 0.0012063852045685053
assessed O 0 3.1180471182779e-07
by O 0 7.400446477845435e-09
linkage O 0 4.0342794704884e-07
and O 0 1.5889471072227934e-08
mutation O 0 4.408243725606553e-08
analysis O 0 1.410426664349984e-09
in O 0 5.245067713488538e-10
237 O 0 2.680981481262279e-08
families O 0 2.938376431060874e-09
, O 0 1.2606592159070118e-10
each O 0 7.152668735077583e-11
with O 0 1.3274235877158702e-10
at O 0 1.9347377866463233e-10
least O 0 1.2161676110622466e-09
four O 0 8.307094456760922e-10
cases O 0 7.391460332684119e-09
of O 0 1.3379944263647303e-08
breast B-Disease 1 0.9990224838256836
cancer I-Disease 0 0.0011125613236799836
, O 0 6.87934043064331e-10
collected O 0 6.693041121330623e-10
by O 0 1.560065965300339e-09
the O 0 2.402671555046254e-07
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.999995231628418
Linkage O 0 5.820028673042543e-05
Consortium O 0 1.8271848603035323e-06
. O 0 1.4898992617418116e-07

Families O 0 1.760682243912015e-05
were O 0 1.104610873881029e-07
included O 0 7.864837670013003e-09
without O 0 2.079670213817053e-09
regard O 0 1.5956246324222434e-09
to O 0 1.2925360781679274e-09
the O 0 2.880959082407486e-10
occurrence O 0 7.79876785372835e-09
of O 0 3.278308513543493e-09
ovarian B-Disease 0 3.59712794306688e-05
or I-Disease 0 6.705029864662038e-09
other I-Disease 0 2.103539920028652e-08
cancers I-Disease 0 0.00025569976423867047
. O 0 5.327265171217732e-07

Overall O 0 0.00028263783315196633
, O 0 2.2652702682535164e-06
disease O 0 6.6187826632813085e-06
was O 0 2.355471480086635e-07
linked O 0 7.183056993653736e-08
to O 0 1.1683066958312338e-08
BRCA1 O 0 6.367186529132596e-07
in O 0 1.360438539599329e-09
an O 0 1.596979548601496e-09
estimated O 0 5.713781003890972e-09
52 O 0 2.6508590877938332e-08
% O 0 1.533999038905165e-10
of O 0 6.253632334196624e-11
families O 0 9.73081726307612e-10
, O 0 7.571981375242842e-10
to O 0 1.3188093284099978e-08
BRCA2 O 0 2.192401325373794e-06
in O 0 3.0075244517036026e-09
32 O 0 1.6606506392236042e-08
% O 0 2.6091065419286963e-10
of O 0 7.274874452845026e-11
families O 0 1.987181308393815e-09
, O 0 4.732896297099387e-10
and O 0 7.577471428099614e-10
to O 0 4.1179002430169476e-09
neither O 0 1.1216589435036894e-08
gene O 0 1.9404486906182683e-09
in O 0 4.024595101626005e-10
16 O 0 2.3354549405496527e-09
% O 0 2.4503418738497373e-10
( O 0 5.915536810396915e-11
95 O 0 6.586112100137598e-09
% O 0 1.8645209820533637e-09
confidence O 0 2.5204133891065794e-08
interval O 0 1.4211344101511258e-08
[ O 0 1.1412690348322485e-08
CI O 0 7.149473191248035e-08
] O 0 9.502723941068325e-09
6 O 0 3.3535558774389074e-09
% O 0 8.075443647115321e-10
- O 0 4.711995700290572e-07
28 O 0 1.0260910130455159e-06
% O 0 8.903036641250139e-10
) O 0 1.3862702652467362e-10
, O 0 9.145650348152401e-10
suggesting O 0 3.1130316102689903e-08
other O 0 3.3447851155443686e-09
predisposition O 0 4.7977671783883125e-05
genes O 0 6.966666319385695e-07
. O 0 1.7724640599681152e-07

The O 0 5.356793053579167e-07
majority O 0 1.6022715954022715e-06
( O 0 1.0166467667716006e-08
81 O 0 1.8466846540832194e-07
% O 0 5.760558696721318e-10
) O 0 3.6401357622617425e-11
of O 0 1.6268215941028785e-10
the O 0 3.5078622317996633e-07
breast B-Disease 1 0.9999845027923584
- I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.0825826990412679e-07
were O 0 1.9687417918134997e-08
due O 0 1.384105186019724e-08
to O 0 9.429568592622672e-08
BRCA1 O 0 9.808678441913798e-06
, O 0 2.3618895728105826e-09
with O 0 1.5731235203375604e-09
most O 0 9.576798021271316e-09
others O 0 2.621410111203204e-08
( O 0 5.105820766182489e-10
14 O 0 5.1796544831006486e-09
% O 0 5.436756600474268e-10
) O 0 4.36878977438937e-10
due O 0 3.490375277692692e-08
to O 0 1.5545736005151412e-06
BRCA2 O 0 0.003290437161922455
. O 0 5.158558451512363e-07

Conversely O 0 3.292742621852085e-05
, O 0 1.5756949522938157e-08
the O 0 6.809004471364233e-10
majority O 0 6.418150899634156e-09
of O 0 1.0912384884598225e-10
families O 0 1.4622124622221122e-09
with O 0 3.0755646918123603e-09
male B-Disease 0 2.8697808375000022e-05
and I-Disease 0 2.2514047941513127e-06
female I-Disease 0 0.3297784924507141
breast I-Disease 1 0.9583840370178223
cancer I-Disease 0 0.0002689150278456509
were O 0 6.123380558165081e-08
due O 0 4.189904245777143e-08
to O 0 1.5890674376350944e-06
BRCA2 O 0 0.0035460367798805237
( O 0 1.3320258673843455e-08
76 O 0 2.428375864838017e-06
% O 0 1.4122659486304201e-08
) O 0 6.935785279438278e-09
. O 0 1.1195839277888808e-07

The O 0 9.931912359206763e-08
largest O 0 8.538849982642205e-08
proportion O 0 5.0991399547228866e-08
( O 0 2.2642436814379607e-09
67 O 0 2.5251441115869966e-07
% O 0 1.10296360933404e-09
) O 0 1.1856447768021638e-10
of O 0 2.0617738072381542e-10
families O 0 2.677545962725958e-09
due O 0 5.9973865873530485e-09
to O 0 4.427310074106572e-09
other O 0 3.1899530239520857e-10
genes O 0 2.6974242839372664e-09
was O 0 5.8744614506167636e-08
found O 0 1.5961542088049896e-09
in O 0 4.738696102180029e-10
families O 0 8.105039972505779e-10
with O 0 3.5659131203402694e-10
four O 0 1.2075229705033053e-09
or O 0 2.5390209379416717e-10
five O 0 9.830770641983122e-10
cases O 0 3.9531129480963045e-09
of O 0 4.3306283004085344e-09
female O 0 0.21240104734897614
breast B-Disease 1 0.9962297081947327
cancer I-Disease 0 0.0030528276693075895
only O 0 2.0429475000582897e-07
. O 0 2.3292864170798566e-07

These O 0 7.725485602350091e-07
estimates O 0 4.579452763664449e-07
were O 0 5.137878744676527e-08
not O 0 2.1535223382329605e-08
substantially O 0 3.257548257806775e-07
affected O 0 6.610603175971619e-09
either O 0 2.5395550107276676e-09
by O 0 6.596379553691634e-10
changing O 0 5.029618943552805e-09
the O 0 1.6084398257731891e-09
assumed O 0 1.8090503317580442e-07
penetrance O 0 1.3777133744952152e-07
model O 0 3.271938098237115e-08
for O 0 1.461487486587032e-09
BRCA1 O 0 1.6299455296575616e-07
or O 0 5.392944979476511e-10
by O 0 7.22585491441663e-10
including O 0 1.1369708508013332e-09
or O 0 8.534384754455004e-09
excluding O 0 1.5315498558265972e-06
BRCA1 O 0 0.00018519500736147165
mutation O 0 2.5033536985574756e-06
data O 0 3.029739161775069e-07
. O 0 1.1934012889014411e-07

Among O 0 2.2218671347218333e-06
those O 0 4.987949253631996e-08
families O 0 7.162232584789763e-09
with O 0 1.1687123269155109e-08
disease O 0 1.6217707070609322e-06
due O 0 1.1754619322346116e-07
to O 0 6.008134505464113e-07
BRCA1 O 0 2.201642928412184e-05
that O 0 4.346386361930854e-08
were O 0 5.284769244440213e-08
tested O 0 1.8080218211480314e-08
by O 0 1.3868890758050867e-10
one O 0 1.1007542100038847e-10
of O 0 1.196010564891159e-11
the O 0 7.634363974329261e-11
standard O 0 6.436184030178538e-09
screening O 0 4.05249656054707e-09
methods O 0 5.08161246415284e-09
, O 0 9.406100343056778e-10
mutations O 0 1.699000939936468e-08
were O 0 1.9492958358569012e-09
detected O 0 9.585807703160754e-09
in O 0 1.4639754686296413e-10
the O 0 1.748877154206241e-10
coding O 0 4.847872769886408e-09
sequence O 0 4.4183992575774766e-10
or O 0 7.118208800171999e-11
splice O 0 3.646108304167228e-09
sites O 0 2.765707385332661e-10
in O 0 5.270889627539965e-11
an O 0 3.2638444724675253e-10
estimated O 0 3.216249488957601e-09
63 O 0 4.655402818798393e-08
% O 0 6.178774158982492e-10
( O 0 1.2774671598325682e-10
95 O 0 9.548799972947108e-09
% O 0 3.5408111997980996e-09
CI O 0 3.6422596849661204e-07
51 O 0 1.3751448477705708e-06
% O 0 5.4208544320033525e-09
- O 0 1.4077163541514892e-06
77 O 0 2.4911291802709457e-06
% O 0 6.8781758066904786e-09
) O 0 1.0404977324185438e-08
. O 0 7.967148007992364e-08

The O 0 3.8099565813354275e-07
estimated O 0 1.9996633682239917e-07
sensitivity O 0 9.660880095907487e-07
was O 0 2.581392664069426e-07
identical O 0 5.150555537625223e-08
for O 0 1.821453404771134e-10
direct O 0 7.768596321788834e-10
sequencing O 0 2.690405453975586e-09
and O 0 1.0641810765932291e-09
other O 0 2.1336701849783424e-10
techniques O 0 6.236619043420433e-08
. O 0 1.270376372985993e-07

The O 0 2.6986666057382536e-07
penetrance O 0 4.816363798454404e-06
of O 0 1.2089016898642058e-08
BRCA2 O 0 1.012095162877813e-05
was O 0 9.454997496050055e-08
estimated O 0 1.2513551306270188e-09
by O 0 1.692401357944462e-10
maximizing O 0 4.326154101619295e-09
the O 0 1.8260111200874007e-09
LOD O 0 0.00027199069154448807
score O 0 7.606845287000397e-08
in O 0 1.2818839323358588e-08
BRCA2 O 0 0.00014193427341524512
- O 0 2.2280237317318097e-05
mutation O 0 6.029267296980834e-06
families O 0 9.964392866379512e-09
, O 0 3.812547222370455e-10
over O 0 1.0201504085927127e-09
all O 0 4.439145717682891e-10
possible O 0 7.480914554491847e-09
penetrance O 0 9.695204425952397e-07
functions O 0 1.8193858863924106e-08
. O 0 4.315426238576947e-08

The O 0 1.6554110970901093e-07
estimated O 0 6.192394863546724e-08
cumulative O 0 6.411534059225232e-08
risk O 0 2.7642599320643058e-08
of O 0 5.848108219907999e-09
breast B-Disease 0 0.13386408984661102
cancer I-Disease 0 0.00031159489299170673
reached O 0 5.3591328708080255e-08
28 O 0 7.407878399590118e-08
% O 0 1.3784295926910772e-09
( O 0 1.8708110061105288e-10
95 O 0 1.1567367508291682e-08
% O 0 2.9089550768190975e-09
CI O 0 1.0035675046538017e-07
9 O 0 1.2729056031446362e-08
% O 0 1.0840529585109948e-09
- O 0 1.1784184295038358e-07
44 O 0 1.4077349419494567e-07
% O 0 2.9186464356456554e-10
) O 0 4.437129136336537e-11
by O 0 5.276605818949065e-10
age O 0 4.0908765264191516e-09
50 O 0 5.097277600007999e-10
years O 0 8.521725547439019e-10
and O 0 1.828834528261325e-09
84 O 0 3.407082971307318e-08
% O 0 5.975711592220989e-10
( O 0 7.99153312969203e-11
95 O 0 6.799365515064437e-09
% O 0 4.140298770494155e-09
CI O 0 2.4943975063251855e-07
43 O 0 1.230582000744107e-07
% O 0 1.5281766962971233e-09
- O 0 5.3355833529167285e-08
95 O 0 9.845904713756681e-08
% O 0 1.3506756824099853e-09
) O 0 3.188115882402087e-10
by O 0 1.7395694884569934e-09
age O 0 1.6258864476981216e-08
70 O 0 1.0442235520713439e-08
years O 0 1.767713087019729e-08
. O 0 2.3342847654816978e-08

The O 0 3.035001554962946e-06
corresponding O 0 0.003396720392629504
ovarian B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999991655349731
risks O 0 0.00010144305997528136
were O 0 3.7023349364062597e-07
0 O 0 2.69883094006218e-06
. O 0 6.392460818460677e-07

4 O 0 2.1731646029365947e-06
% O 0 5.358008792200053e-08
( O 0 1.6842487404744588e-09
95 O 0 2.132858689662953e-08
% O 0 6.947701525206185e-09
CI O 0 1.8851088157134654e-07
0 O 0 5.642285216822529e-08
% O 0 2.478262262073372e-09
- O 0 1.2274665550648933e-07
1 O 0 1.3349584548905113e-08
% O 0 9.618109642062223e-10
) O 0 1.077538266947009e-10
by O 0 6.701676436016157e-10
age O 0 3.945971549512706e-09
50 O 0 4.718133106429434e-10
years O 0 9.79775038878472e-10
and O 0 4.167140410515913e-09
27 O 0 2.0617994422877928e-08
% O 0 3.144351445882876e-10
( O 0 5.3486680362535566e-11
95 O 0 6.595414880905537e-09
% O 0 1.864179477450989e-09
CI O 0 1.001330360850261e-07
0 O 0 6.078417413846182e-08
% O 0 3.114181801322502e-09
- O 0 3.5651930829772027e-07
47 O 0 2.335101271455642e-06
% O 0 9.771472520014868e-10
) O 0 2.063181986367013e-10
by O 0 2.310814206651912e-09
age O 0 3.986529151234208e-08
70 O 0 2.031185708517569e-08
years O 0 3.96515176248613e-08
. O 0 1.0165967267994347e-07

The O 0 3.4410373928039917e-07
lifetime O 0 1.3040959174759337e-06
risk O 0 1.7822544862156064e-07
of O 0 1.4666403203023037e-08
breast B-Disease 1 0.9717400074005127
cancer I-Disease 0 0.0065557160414755344
appears O 0 3.9382479144478566e-07
similar O 0 2.002556787061849e-09
to O 0 1.264672144785095e-09
the O 0 1.874430166637353e-09
risk O 0 2.031650758738124e-08
in O 0 2.886020311620996e-09
BRCA1 O 0 1.3804926766169956e-06
carriers O 0 2.4188700820104714e-08
, O 0 1.3157559486387527e-09
but O 0 2.4818054278341606e-09
there O 0 1.4199035280881844e-09
was O 0 2.6552919862865565e-08
some O 0 1.5369013006694132e-10
suggestion O 0 1.0343040868221465e-09
of O 0 6.285152953644513e-11
a O 0 1.1963454227270631e-08
lower O 0 5.423358970801928e-07
risk O 0 9.460121219717621e-08
in O 0 1.0490226465265096e-08
BRCA2 O 0 8.582757800468244e-06
carriers O 0 6.864613766310868e-08
< O 0 2.6438049971488908e-08
50 O 0 2.3494797218859276e-09
years O 0 1.3288379285825158e-09
of O 0 1.1297550672750845e-09
age O 0 9.490754848684446e-08
. O 0 6.413490893919516e-08

Eye B-Disease 1 0.9978227615356445
movement I-Disease 0 0.001503390958532691
abnormalities I-Disease 1 0.9721218943595886
correlate O 0 8.525051271135453e-06
with O 0 1.0304651709702739e-07
genotype O 0 0.005218902602791786
in O 0 4.424417170412198e-07
autosomal O 1 0.9977515339851379
dominant O 1 0.9918397665023804
cerebellar B-Disease 1 0.9998362064361572
ataxia I-Disease 1 0.9999932050704956
type I-Disease 1 0.6750280261039734
I I-Disease 0 0.0008070443873293698
. O 0 6.820714588684496e-07

We O 0 3.306347025500145e-06
compared O 0 1.1971600315519026e-06
horizontal O 0 5.685984797310084e-05
eye O 0 0.10798792541027069
movements O 0 3.070648062930559e-06
( O 0 2.116951058894756e-08
visually O 0 1.924644038808765e-06
guided O 0 6.078991532376676e-07
saccades O 0 1.1774038284784183e-05
, O 0 1.4490116662102537e-08
antisaccades O 0 5.261244950816035e-07
, O 0 1.8263908163618225e-09
and O 0 9.818104107495174e-10
smooth O 0 7.065438722975159e-08
pursuit O 0 1.5729083813198486e-08
) O 0 3.9731723466829294e-10
in O 0 4.796511521298896e-10
control O 0 2.495577575700736e-07
subjects O 0 1.2736396115542448e-07
( O 0 1.1162736290870612e-09
n O 0 1.2631134893581475e-07
= O 0 4.0194667150217356e-08
14 O 0 4.5334069831426405e-09
) O 0 8.658762595814551e-10
and O 0 2.2385749787190434e-07
patients O 0 3.7613012864312623e-06
with O 0 3.925970104567966e-10
three O 0 4.732634839577088e-10
forms O 0 1.5258232455295229e-09
of O 0 2.917167174487645e-09
autosomal O 0 0.014757192693650723
dominant O 0 0.000530649907886982
cerebellar B-Disease 0 0.0006192650180310011
ataxias I-Disease 0 0.0004292734956834465
type I-Disease 0 4.0075192373478785e-05
I I-Disease 0 1.3351769666769542e-05
spinocerebellar B-Disease 0 0.00026608791085891426
ataxias I-Disease 0 6.6593802330316976e-06
1 I-Disease 0 1.4099458489624794e-08
and I-Disease 0 5.362995825208827e-09
2 I-Disease 0 6.058749058013291e-09
( O 0 1.7776187188900394e-09
SCA1 B-Disease 0 7.13786266715033e-06
, O 0 5.139414671617715e-09
n O 0 2.5232031575228575e-08
= O 0 2.660483033878336e-08
11 O 0 5.781088940892687e-09
; O 0 2.9509121812765216e-09
SCA2 B-Disease 0 5.705491275875829e-06
, O 0 5.3843143277276795e-09
n O 0 4.629670513622841e-08
= O 0 2.1197632094072105e-08
10 O 0 1.2635822388418205e-09
) O 0 7.103673205222094e-10
and O 0 7.597377305046393e-08
SCA3 B-Disease 1 0.9999988079071045
/ O 0 5.240956397756236e-06
Machado B-Disease 0 1.203111651193467e-06
- I-Disease 0 0.00035626787575893104
Joseph I-Disease 0 0.012215519323945045
disease I-Disease 0 0.0005035994690842927
( O 0 3.9495649417631284e-08
MJD B-Disease 1 0.9999927282333374
) O 0 2.0689769897330734e-08
( O 0 2.3560853268378423e-09
n O 0 2.465351087721501e-07
= O 0 1.5280804177564278e-07
16 O 0 2.1143200967799203e-08
) O 0 5.2343271939037095e-09
. O 0 4.6602888659208475e-08

In O 0 2.4761102395132184e-06
SCA1 B-Disease 0 2.0955458239768632e-05
, O 0 2.0619724594439504e-08
saccade O 0 8.174802132998593e-07
amplitude O 0 6.121658202573599e-07
was O 0 3.7503983207898273e-07
significantly O 0 1.5044055601265427e-07
increased O 0 1.5383193385787308e-08
, O 0 2.4118294028596665e-09
resulting O 0 4.1863899014060735e-08
in O 0 1.2608287747184477e-08
hypermetria B-Disease 0 0.00013254796795081347
. O 0 2.753652097453596e-07

The O 0 4.2743445760606846e-07
smooth O 0 1.7768758198144496e-06
pursuit O 0 1.1953177363466239e-06
gain O 0 1.627936512704764e-06
was O 0 1.8674564898901735e-06
decreased O 0 2.2892331799084786e-06
. O 0 7.161825266166488e-08

In O 0 1.3196544159654877e-06
SCA2 B-Disease 0 1.2097332728444599e-05
, O 0 1.059693044425103e-08
saccade O 0 5.291209390634322e-07
velocity O 0 6.854499474684417e-07
was O 0 7.041678600216983e-07
markedly O 0 2.6009911380242556e-05
decreased O 0 2.164548050131998e-06
. O 0 1.8939728363420727e-07

The O 0 1.0563838515054158e-07
percentage O 0 4.8316838530126915e-08
of O 0 4.606271475360302e-10
errors O 0 2.9630738751507124e-08
in O 0 3.4904399370816463e-09
antisaccades O 0 1.2363638234091923e-05
was O 0 2.529895482439315e-06
greatly O 0 9.932726641181944e-08
increased O 0 1.6496613852723385e-08
and O 0 3.6976322004278472e-09
was O 0 4.769840415974613e-07
significantly O 0 2.6486182491680665e-07
correlated O 0 7.175484029176005e-08
with O 0 7.157452408534937e-09
age O 0 8.819955610306351e-08
at O 0 1.2926354209241708e-08
disease O 0 1.296913978876546e-05
onset O 0 1.3068425687379204e-05
. O 0 1.06304128166812e-06

In O 0 1.5921422402698227e-07
addition O 0 1.1728480409090025e-08
, O 0 7.461231632532872e-10
a O 0 2.7061384244575493e-09
correlation O 0 1.4043259000118269e-08
between O 0 7.810523894313803e-10
smooth O 0 3.330000026835478e-07
pursuit O 0 8.869384515719503e-08
gain O 0 1.6213780895668606e-07
and O 0 1.2462911813670985e-09
the O 0 1.4535471437593372e-10
number O 0 6.877162173068996e-10
of O 0 3.250754110339926e-10
trinucleotide O 0 9.353631753583613e-07
repeats O 0 1.653331764828181e-07
was O 0 1.494390318157457e-07
found O 0 4.15190157809775e-08
. O 0 5.31359596323e-08

In O 0 5.368245638237568e-06
SCA3 B-Disease 1 0.9996384382247925
, O 0 9.303722663389635e-07
gaze B-Disease 0 5.013229019823484e-05
- I-Disease 0 0.00015409424668177962
evoked I-Disease 0 0.000676964467857033
nystagmus I-Disease 0 0.0006685933913104236
was O 0 2.038731054199161e-06
often O 0 1.2671501181671374e-08
present O 0 2.099161955371187e-09
as O 0 2.6092821237000408e-09
was O 0 9.675949996790223e-08
saccade O 0 4.7052867557795253e-07
hypometria O 0 9.709908681543311e-07
and O 0 7.793087952734368e-09
smooth O 0 1.535259883667095e-07
pursuit O 0 2.151677307438149e-07
gain O 0 1.1243480457778787e-06
was O 0 8.68182451085886e-06
markedly O 0 7.586256833747029e-05
decreased O 0 3.5250022847321816e-06
. O 0 9.991364890993282e-08

Three O 0 3.7659282270396943e-07
major O 0 3.972464313051205e-08
criteria O 0 2.6180174472756335e-08
, O 0 2.1634183333674173e-09
saccade O 0 3.2598137522654724e-07
amplitude O 0 2.7967541882389924e-07
, O 0 2.8670150697962526e-09
saccade O 0 2.171332482703292e-07
velocity O 0 2.066629178898438e-07
, O 0 2.219560313321267e-09
and O 0 9.620274576960242e-10
presence O 0 1.5673133901827896e-09
of O 0 4.5234546663941444e-10
gaze B-Disease 0 3.4564534871606156e-05
- I-Disease 0 0.00011013293988071382
evoked I-Disease 0 0.0002703775535337627
nystagmus I-Disease 0 3.5480345104588196e-05
, O 0 1.551253347997772e-09
permitted O 0 1.2532446191926283e-09
the O 0 2.857961367563888e-10
correct O 0 1.768637147847585e-08
assignment O 0 5.531008540060611e-09
of O 0 1.934383625501468e-10
90 O 0 1.918306402615144e-09
% O 0 1.6993234597251217e-10
of O 0 3.911422921665242e-11
the O 0 7.988458783358965e-10
SCA1 B-Disease 0 4.100420028407825e-06
, O 0 9.23043474987395e-10
90 O 0 8.74351813173746e-10
% O 0 6.973570332302614e-11
of O 0 2.3852838107463192e-11
the O 0 8.456214617424962e-10
SCA2 B-Disease 0 9.142559974861797e-06
, O 0 1.654800407813184e-09
and O 0 6.397297691584924e-10
93 O 0 4.584344015512443e-09
% O 0 9.273152384858818e-11
of O 0 2.503616237936601e-11
the O 0 9.995687832997646e-09
patients O 0 2.6748153686639853e-05
with O 0 3.0740533674133985e-08
SCA3 B-Disease 1 0.9999963045120239
to O 0 3.9436560683725475e-08
their O 0 3.4370666313066067e-09
genetically O 0 3.5144921639584936e-07
confirmed O 0 3.713618752954062e-06
patient O 0 4.884267127636122e-06
group O 0 1.1399571953063514e-08
and O 0 3.5763294548019076e-09
, O 0 1.9985768595631725e-09
therefore O 0 4.776009809859261e-09
, O 0 1.8445603933159305e-09
may O 0 2.3546983030087176e-08
help O 0 7.598895734872713e-09
orient O 0 4.45871546617127e-06
diagnoses O 0 7.446428207913414e-05
of O 0 6.073567204722963e-10
SCA1 B-Disease 0 1.1705432370945346e-05
, O 0 9.108053866668797e-09
SCA2 B-Disease 0 5.505253739102045e-06
, O 0 6.4529994681095104e-09
and O 0 1.2310580999042031e-08
SCA3 B-Disease 1 0.999962329864502
at O 0 3.3431393209326643e-09
early O 0 1.686345285634161e-08
clinical O 0 5.13271665170123e-08
stages O 0 6.318393808157907e-09
of O 0 5.917954459810915e-10
the O 0 1.502308855094725e-08
diseases O 0 2.4236651370301843e-06
. O 0 2.0058799066191568e-08
. O 0 8.898682324343099e-08

Genetic O 0 0.0001642082934267819
basis O 0 5.364496473703184e-07
and O 0 3.8774825128484736e-08
molecular O 0 3.8114316680548654e-07
mechanism O 0 8.683213081894792e-07
for O 0 4.6934019337641075e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999998807907104
fibrillation I-Disease 1 1.0
. O 0 0.00043866841588169336

Ventricular B-Disease 1 0.9991232752799988
fibrillation I-Disease 1 0.999777615070343
causes O 0 7.340007141465321e-05
more O 0 2.9254710653958682e-08
than O 0 1.0995465871133092e-08
300 O 0 2.262827702992354e-09
, O 0 1.1166484403801746e-09
000 O 0 3.1852609438942636e-09
sudden O 0 2.6352094550929905e-07
deaths O 0 5.809976073578582e-07
each O 0 8.642658810842363e-10
year O 0 1.133722560275885e-09
in O 0 1.0364743507906837e-09
the O 0 5.12829112508939e-09
USA O 0 3.9941406271282176e-07
alone O 0 3.8851118233651505e-07
. O 0 6.501529981051135e-08

In O 0 2.0381098408961407e-07
approximately O 0 2.771915497135069e-08
5 O 0 7.131751633693284e-09
- O 0 1.26295219615713e-07
12 O 0 1.364737922671111e-08
% O 0 2.5180083018661037e-10
of O 0 5.914904677162269e-11
these O 0 5.427711058381135e-10
cases O 0 4.764464378581579e-09
, O 0 1.0095083657901682e-09
there O 0 1.0509446646267406e-09
are O 0 3.724698327545184e-10
no O 0 9.042484983012855e-09
demonstrable O 0 0.000455589615739882
cardiac O 0 0.28986725211143494
or O 0 1.8537665624762667e-08
non O 0 1.297358522833747e-07
- O 0 0.2038663923740387
cardiac O 1 0.9998032450675964
causes O 0 2.4004093575058505e-06
to O 0 1.4624921718109363e-08
account O 0 2.4794917230508418e-09
for O 0 2.2864453386173267e-10
the O 0 3.14118037136879e-10
episode O 0 1.2848094854689407e-07
, O 0 1.0622706048124542e-09
which O 0 1.0926781701670052e-09
is O 0 1.8629071618647686e-09
therefore O 0 1.2097089552298712e-08
classified O 0 5.634993627268159e-08
as O 0 4.9606846005190164e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999998807907104
fibrillation I-Disease 1 1.0
( O 0 0.00022794697724748403
IVF B-Disease 1 0.9999940395355225
) O 0 7.118802045624761e-07
. O 0 3.733860580723558e-07

A O 0 2.373267307120841e-06
distinct O 0 8.895897281036014e-07
group O 0 1.7454139822348225e-07
of O 0 1.3652689645482496e-08
IVF B-Disease 1 0.9999994039535522
patients O 1 0.8511683344841003
has O 0 4.7159699079202255e-07
been O 0 2.511650443182134e-08
found O 0 2.830577550128055e-09
to O 0 8.730969836001634e-10
present O 0 7.17981785136601e-10
with O 0 1.1197751614844265e-09
a O 0 1.0778810377587433e-07
characteristic O 0 9.35136654334201e-07
electrocardiographic O 0 0.00011615247058216482
pattern O 0 1.2749542293022387e-05
. O 0 4.027072009193944e-07

Because O 0 6.200230018293951e-07
of O 0 1.939327587408002e-09
the O 0 2.049583697205648e-10
small O 0 3.8275421720967984e-10
size O 0 1.0749277024046933e-09
of O 0 1.337498028997075e-10
most O 0 3.695432404526855e-09
pedigrees O 0 9.25777285942786e-08
and O 0 2.2633286356210647e-09
the O 0 5.441964101571273e-10
high O 0 8.539778661997843e-08
incidence O 0 2.6893583253695397e-06
of O 0 1.3786505270729776e-09
sudden B-Disease 0 2.4951854356913827e-05
death I-Disease 0 0.005578454118221998
, O 0 5.751327858405375e-09
however O 0 8.24647727881711e-09
, O 0 8.842670484732196e-10
molecular O 0 7.175673388815085e-09
genetic O 0 1.8748350427699734e-08
studies O 0 9.53663703562313e-10
of O 0 5.559446791814082e-10
IVF B-Disease 1 0.9999411106109619
have O 0 2.0962387736744859e-07
not O 0 3.9666021578455e-09
yet O 0 6.767730376111558e-09
been O 0 1.2013164685242828e-08
done O 0 6.506355276769682e-08
. O 0 3.8285971726281787e-08

Because O 0 0.00021269216085784137
IVF B-Disease 1 0.9999040365219116
causes O 0 0.020276503637433052
cardiac O 1 0.8621231317520142
rhythm O 0 0.013102130964398384
disturbance O 0 4.268318662070669e-05
, O 0 3.468949572038582e-09
we O 0 1.0502713143623055e-09
investigated O 0 7.961447501259045e-09
whether O 0 3.970621609283853e-09
malfunction O 0 9.202367436955683e-07
of O 0 6.358152337959666e-10
ion O 0 7.165773467932013e-07
channels O 0 1.0605872802216254e-07
could O 0 8.060076197580202e-07
cause O 0 6.724371246491501e-07
the O 0 4.863499114549086e-08
disorder O 0 0.0004941112129017711
by O 0 1.1843841463132776e-09
studying O 0 5.169764616397288e-09
mutations O 0 5.573913597345381e-08
in O 0 4.782835794081564e-10
the O 0 5.987923046291144e-09
cardiac O 0 0.12484588474035263
sodium O 0 0.002784568816423416
channel O 0 8.721175618120469e-06
gene O 0 1.0307398952136282e-06
SCN5A O 0 1.6242262063315138e-05
. O 0 2.7119276069242915e-07

We O 0 3.9289074038606486e-07
have O 0 2.4786180219393827e-08
now O 0 4.10800016226176e-09
identified O 0 7.117482603291592e-09
a O 0 1.2903740298497723e-08
missense O 0 2.453456363582518e-05
mutation O 0 2.301846535601726e-07
, O 0 1.2461200959990038e-09
a O 0 6.699226062778507e-09
splice O 0 2.0894894987577572e-06
- O 0 5.967783181404229e-06
donor O 0 2.2720240622220444e-07
mutation O 0 7.194210525085509e-07
, O 0 1.974863383935599e-09
and O 0 3.1562381597183276e-09
a O 0 3.5000223874703806e-07
frameshift O 0 0.11283523589372635
mutation O 0 3.449126495524979e-07
in O 0 7.283041947303559e-10
the O 0 3.727982367252025e-10
coding O 0 6.73481892476957e-08
region O 0 4.511996554157349e-09
of O 0 7.760065923179127e-10
SCN5A O 0 5.58520059712464e-06
in O 0 1.1783146014465729e-08
three O 0 3.656033342736009e-08
IVF B-Disease 1 0.9997804760932922
families O 0 8.235751920437906e-07
. O 0 1.1294059731881134e-07

We O 0 3.2167304198083e-07
show O 0 5.206013042879931e-08
that O 0 2.720883740536806e-09
sodium O 0 4.1635512815219045e-08
channels O 0 4.610809511973457e-09
with O 0 2.842056034957352e-10
the O 0 6.888215553502164e-10
missense O 0 3.7041677387605887e-06
mutation O 0 1.8983472216405062e-07
recover O 0 1.463547505409224e-07
from O 0 7.311393712683412e-10
inactivation O 0 1.0741698588390136e-06
more O 0 1.4777733481352584e-09
rapidly O 0 3.2725107068642956e-09
than O 0 1.0335743372280604e-09
normal O 0 1.4043787244233386e-09
and O 0 4.976749568008643e-10
that O 0 5.258099511351588e-10
the O 0 1.871361510197289e-09
frameshift O 0 0.006415473762899637
mutation O 0 3.0306406983982015e-07
causes O 0 1.0020369423102693e-08
the O 0 3.1832006475163155e-10
sodium O 0 7.049083023957792e-07
channel O 0 1.227918602353384e-07
to O 0 2.3994819464689954e-09
be O 0 4.691277588619869e-09
non O 0 1.3864885239911473e-08
- O 0 2.25950088861282e-06
functional O 0 2.6780817279359326e-06
. O 0 1.5761615657083894e-07

Our O 0 4.3700859464479436e-07
results O 0 1.1797790477885428e-07
indicate O 0 4.187954871781585e-08
that O 0 3.735586062703078e-09
mutations O 0 8.000344564607076e-08
in O 0 3.823224403731729e-09
cardiac O 0 2.3164180674939416e-05
ion O 0 4.771523890667595e-06
- O 0 2.553584863562719e-06
channel O 0 3.290256813670567e-07
genes O 0 4.117853613649913e-09
contribute O 0 5.411492365325898e-10
to O 0 4.4539028021262084e-10
the O 0 6.496428950342192e-10
risk O 0 7.252037192984062e-09
of O 0 4.4082054673211246e-10
developing O 0 4.3523591841676534e-08
IVF B-Disease 1 0.9998927116394043
. O 0 1.0021385321579146e-07
. O 0 1.1246864062286477e-07

Molecular O 0 1.8188940885011107e-05
heterogeneity O 0 5.191907621338032e-05
in O 0 3.1570201031172473e-07
mucopolysaccharidosis B-Disease 0 2.004626367124729e-05
IVA I-Disease 0 1.5152641935856082e-05
in O 0 4.824298827088569e-08
Australia O 0 3.258734437849853e-08
and O 0 1.2199621757247314e-08
Northern O 0 7.453841277538231e-08
Ireland O 0 4.441911372055074e-08
: O 0 4.374459960931887e-10
nine O 0 5.8057532115185495e-09
novel O 0 2.84498735680927e-08
mutations O 0 2.702214452199314e-08
including O 0 7.145404268271704e-10
T312S O 0 1.8524806932873616e-07
, O 0 1.5663810248867094e-09
a O 0 8.577204724247167e-09
common O 0 1.4422645300271597e-08
allele O 0 2.705995996166166e-07
that O 0 4.66201122151233e-09
confers O 0 1.634948830542271e-06
a O 0 5.2170894377923105e-06
mild O 1 0.9950531125068665
phenotype O 1 0.9977072477340698
. O 0 8.683345527060737e-07

Mucopolysaccharidosis B-Disease 0 0.35661840438842773
IVA I-Disease 1 0.9702954888343811
( O 0 0.00041469288407824934
MPS B-Disease 1 0.9999966621398926
IVA I-Disease 1 0.9999628067016602
) O 0 6.0147790748033e-08
is O 0 2.1249851656079954e-08
an O 0 1.0846682130249974e-07
autosomal B-Disease 1 0.9963356256484985
recessive I-Disease 1 0.9996943473815918
lysosomal I-Disease 1 0.9985907673835754
storage I-Disease 1 0.9884127974510193
disorder I-Disease 1 0.9990469813346863
caused O 0 5.2239947763155214e-06
by O 0 3.874274412396517e-08
a O 0 7.128212018869817e-05
genetic B-Disease 1 0.9999977350234985
defect I-Disease 1 0.9999979734420776
in O 0 1.0176403719697191e-07
N O 0 3.575469463612535e-06
- O 0 2.018353552557528e-05
acetylgalactosamine O 0 0.0001479005004512146
- O 0 8.244430500781164e-05
6 O 0 9.03731290691212e-07
- O 0 0.0032922360114753246
sulfate O 0 0.007496497593820095
sulfatase O 0 2.9486767743946984e-05
( O 0 2.4336046067219286e-08
GALNS O 0 7.2949324021465145e-06
) O 0 3.0384310178988017e-08
. O 0 1.010069752283016e-07

Previous O 0 4.0461145545123145e-06
studies O 0 1.0002805339581755e-07
of O 0 3.6665346314634917e-09
patients O 0 4.6575166834372794e-07
from O 0 8.7739071563675e-10
a O 0 2.4121344921468335e-08
British O 0 5.03661931361421e-06
- O 0 1.6392157249356387e-06
Irish O 0 4.05833930017252e-07
population O 0 1.3515261132468481e-09
showed O 0 7.566556270433011e-09
that O 0 2.9043023541674984e-10
the O 0 3.4974823037714486e-10
I113F O 0 4.387993328691664e-07
mutation O 0 3.178174523554844e-08
is O 0 2.857874215056455e-10
the O 0 1.028047091899964e-10
most O 0 5.290502480548298e-10
common O 0 1.3994319036925162e-09
single O 0 1.3585547264938214e-07
mutation O 0 5.386414613894885e-06
among O 0 9.35190143991349e-07
MPS B-Disease 1 0.9999996423721313
IVA I-Disease 1 0.9999998807907104
patients O 1 0.9992915391921997
and O 0 6.685787212745709e-08
produces O 0 1.943891589917257e-07
a O 0 8.74666000072466e-07
severe O 1 0.9854589700698853
clinical O 0 0.298038512468338
phenotype O 1 0.9843160510063171
. O 0 1.7614094076634501e-06

We O 0 9.310486461799883e-07
studied O 0 1.4038096196600236e-07
mutations O 0 2.7213710040996375e-07
in O 0 1.8169540316748112e-09
the O 0 2.322948944311065e-09
GALNS O 0 4.328667728259461e-06
gene O 0 4.263913311319811e-08
from O 0 1.6472583297399979e-09
23 O 0 4.528068942022401e-08
additional O 0 2.1949777817553695e-07
MPS B-Disease 1 0.9999984502792358
IVA I-Disease 1 0.9999994039535522
patients O 1 0.991151750087738
( O 0 2.651247221763242e-09
15 O 0 2.211480554237255e-09
from O 0 4.45869674514654e-10
Australia O 0 2.8305020549623805e-09
, O 0 3.842126894415543e-10
8 O 0 4.985128976287001e-10
from O 0 3.3045860492464385e-10
Northern O 0 1.7658695838917993e-08
Ireland O 0 3.4864825693148305e-08
) O 0 1.9401849571387686e-10
, O 0 1.8569179527361257e-10
with O 0 1.8531533252375e-10
various O 0 1.1386637188692816e-09
clinical O 0 4.37968401456601e-06
phenotypes O 0 0.00017371434660162777
( O 0 7.210700037063589e-09
severe O 0 0.03855974227190018
, O 0 1.138386735988206e-07
16 O 0 8.04600901460617e-08
cases O 0 9.706059955760793e-08
; O 0 1.4917581836471072e-08
intermediate O 0 4.552385490796951e-08
, O 0 1.5134642428193956e-09
4 O 0 7.681140168358525e-09
cases O 0 9.205740525430883e-08
; O 0 2.982602609336027e-07
mild O 1 0.6157985329627991
, O 0 7.31699500988725e-08
3 O 0 7.689762782092657e-08
cases O 0 9.31686656713282e-08
) O 0 2.8432948440126893e-08
. O 0 2.0748858275965176e-07

We O 0 4.1531660599503084e-07
found O 0 3.750823651671453e-08
two O 0 2.30830332625942e-09
common O 0 4.300863221118334e-09
mutations O 0 2.5012001358959424e-08
that O 0 1.4281605897892291e-09
together O 0 2.0630019914591458e-09
accounted O 0 6.0687073144549686e-09
for O 0 3.6479216869444997e-10
32 O 0 5.214935150377187e-09
% O 0 8.16551964932799e-11
of O 0 1.2169877952605823e-11
the O 0 7.404198920646365e-10
44 O 0 2.5580689566595538e-08
unrelated O 0 2.7698753513050178e-08
alleles O 0 4.795592545292493e-08
in O 0 4.270650499904605e-09
these O 0 2.1789821502693485e-08
patients O 0 1.1134587111882865e-05
. O 0 2.2815822831034893e-07

One O 0 2.958534253139078e-07
is O 0 1.1684939238421066e-08
the O 0 1.7651347050673394e-09
T312S O 0 1.0760594477687846e-06
mutation O 0 1.6899652166557644e-07
, O 0 6.481477576869565e-10
a O 0 6.388131357226712e-09
novel O 0 2.1837570329807932e-07
mutation O 0 8.726283340365626e-08
found O 0 3.734702325175476e-09
exclusively O 0 1.2451702779969764e-08
in O 0 2.4163846035207825e-08
milder O 1 0.9415807723999023
patients O 1 0.7562662959098816
. O 0 1.0330239774702932e-06

The O 0 1.2264742110801308e-07
other O 0 2.2629917939553934e-09
is O 0 9.899450148509459e-10
the O 0 5.176244988192025e-10
previously O 0 5.390225510382152e-08
described O 0 1.1178661907251808e-07
I113F O 0 1.0331475408520419e-07
that O 0 2.934567699952595e-09
produces O 0 3.6356517796320986e-08
a O 0 5.697774554391799e-07
severe O 1 0.9292631149291992
phenotype O 1 0.9911009669303894
. O 0 1.616337272025703e-06

The O 0 6.940286425560771e-07
I113F O 0 2.0971315279894043e-06
and O 0 2.153920775072038e-08
T312S O 0 4.454434190392931e-07
mutations O 0 2.003414181217522e-07
accounted O 0 2.5508528622708582e-08
for O 0 9.405095591219492e-10
8 O 0 2.9671554102606024e-09
( O 0 7.002750601614594e-10
18 O 0 1.2204113275515738e-08
% O 0 5.553977833194779e-10
) O 0 2.5141594361954844e-10
and O 0 6.011014797024927e-09
6 O 0 1.088819612249381e-08
( O 0 7.872112961493372e-10
14 O 0 7.740586838167474e-09
% O 0 2.7815091896421507e-10
) O 0 4.326603311732846e-11
of O 0 2.1710480635483975e-10
44 O 0 4.3833424001604726e-08
unrelated O 0 6.707731614596923e-08
alleles O 0 1.484495442127809e-07
, O 0 2.0405012790547516e-08
respectively O 0 1.1793785859026684e-07
. O 0 7.893349618370848e-08

The O 0 4.883573296865507e-07
relatively O 0 4.6104250372991373e-07
high O 0 9.155205304978153e-08
residual O 0 1.0483444157216582e-06
GALNS O 0 3.1065803796082037e-06
activity O 0 1.319146392120274e-08
seen O 0 2.172127189226103e-08
when O 0 9.566933911742126e-10
the O 0 2.7387359047281734e-10
T312S O 0 5.1297416092666026e-08
mutant O 0 8.083356561883193e-08
cDNA O 0 2.8967427567749837e-08
is O 0 2.522994924092359e-09
overexpressed O 0 1.269422114091867e-07
in O 0 1.0465759370248406e-09
mutant O 0 3.271464663612278e-07
cells O 0 3.665067893621199e-08
provides O 0 5.252849266668136e-09
an O 0 1.0647515091832815e-09
explanation O 0 1.3405590415516144e-08
for O 0 7.135394497481684e-10
the O 0 7.235967824925638e-09
mild O 1 0.9372789263725281
phenotype O 1 0.9972437620162964
in O 0 3.4233752899126557e-07
patients O 0 7.3345127020729706e-06
with O 0 1.0303856656790344e-09
this O 0 1.071329958080014e-08
mutation O 0 2.219122507085558e-06
. O 0 7.57557003794318e-08

The O 0 7.944128554981944e-08
distribution O 0 7.388824663223659e-09
and O 0 2.60137600349708e-09
relative O 0 6.543140251835666e-09
frequencies O 0 8.765915104902433e-09
of O 0 9.904826958617718e-11
the O 0 3.7219502480034805e-10
I113F O 0 8.696988373912973e-08
and O 0 2.9201512319332323e-09
T312S O 0 7.340996432958491e-08
mutations O 0 1.8410849733641044e-08
in O 0 6.855003786832015e-10
Australia O 0 1.3177676727593735e-09
corresponded O 0 6.715729750084165e-09
to O 0 1.4050270946697196e-09
those O 0 3.066636389270627e-10
observed O 0 2.806450627446111e-09
in O 0 7.972795201816041e-10
Northern O 0 2.1915282033546646e-08
Ireland O 0 4.5107256596566e-08
and O 0 1.279909178641958e-09
are O 0 1.6711663997082127e-10
unique O 0 2.634379381305507e-10
to O 0 1.029234586447103e-09
these O 0 2.0933553501745195e-10
two O 0 6.329233803725742e-10
populations O 0 1.507287850088801e-09
, O 0 2.0772390751933045e-10
suggesting O 0 2.2999049331673405e-09
that O 0 6.229444737826384e-10
both O 0 1.095530999251082e-09
mutations O 0 1.706112762178691e-08
were O 0 3.9864662682020935e-09
probably O 0 6.477551828254491e-09
introduced O 0 9.004757828279253e-09
to O 0 5.409905412534499e-09
Australia O 0 3.687518512762722e-09
by O 0 7.567837467803429e-10
Irish O 0 6.391446927267452e-09
migrants O 0 1.4649146340417474e-09
during O 0 3.59885399259241e-10
the O 0 1.592209836198677e-10
19th O 0 1.4049876817523455e-08
century O 0 8.223580749699977e-08
. O 0 1.4873182863084367e-07

Haplotype O 0 0.36406251788139343
analysis O 0 8.664997608320846e-07
using O 0 1.1557095547232166e-07
6 O 0 5.158863558563098e-08
RFLPs O 0 6.714803362228849e-07
provides O 0 9.008571666413445e-09
additional O 0 1.286210915552033e-09
data O 0 1.5699043176553573e-09
that O 0 3.5282227139887823e-10
the O 0 3.2164809704582353e-10
I113F O 0 7.678358997509349e-07
mutation O 0 7.236647547870234e-08
originated O 0 1.1954962575444483e-09
from O 0 2.0839856229581954e-10
a O 0 1.1028568280835316e-08
common O 0 3.8483207731587754e-08
ancestor O 0 7.04317017152789e-07
. O 0 4.0637382880959194e-07

The O 0 1.0738179412328464e-07
other O 0 5.925141266516221e-09
9 O 0 1.5315915646851863e-08
novel O 0 3.4165449136480674e-08
mutations O 0 9.01541667985839e-08
identified O 0 1.3034821222390747e-08
in O 0 3.5192973535380645e-10
these O 0 1.0821441520647568e-09
23 O 0 2.9422429292935703e-07
patients O 0 1.731891643430572e-06
were O 0 4.730408065256597e-09
each O 0 1.9277832108421933e-10
limited O 0 8.106801896445859e-10
to O 0 1.3555276900945046e-09
a O 0 2.157646150635628e-08
single O 0 2.264185212652592e-07
family O 0 2.407657859748724e-07
. O 0 6.864038226694902e-08

These O 0 1.754519445285041e-07
data O 0 1.8159674652906688e-08
provide O 0 6.786422090954147e-09
further O 0 1.947415562142396e-09
evidence O 0 3.641639212403902e-09
for O 0 7.387412348514033e-10
extensive O 0 5.616730192059549e-08
allelic O 0 2.5756653485586867e-06
heterogeneity O 0 1.9818504370050505e-05
in O 0 1.061578473127156e-06
MPS B-Disease 1 0.9999947547912598
IVA I-Disease 1 0.999886155128479
in O 0 3.027711557024304e-07
British O 0 2.9204116799519397e-05
- O 0 9.979186143027619e-05
Irish O 0 3.264403130742721e-05
patients O 0 1.0974610631819814e-05
and O 0 2.5489110822007888e-09
provide O 0 2.8130424656325204e-09
evidence O 0 2.3672837023980264e-09
for O 0 2.117998970652124e-10
their O 0 9.877929585400125e-10
transmission O 0 5.0923365080279837e-08
to O 0 5.236484135195951e-09
Australia O 0 6.620900272480412e-09
by O 0 2.643662622148213e-09
British O 0 6.505896408270928e-07
- O 0 4.7615415610380296e-07
Irish O 0 8.466906820103759e-08
migrants O 0 1.715883612973812e-08
. O 0 3.6875467124275474e-09
. O 0 1.8573517834852282e-08

Identification O 0 3.089712436121772e-06
of O 0 2.8225674242321475e-08
constitutional O 0 3.416412710066652e-06
WT1 O 0 0.00995517149567604
mutations O 0 3.690070298034698e-05
, O 0 1.4326684727450356e-08
in O 0 1.804800398019779e-08
patients O 0 6.476457201642916e-06
with O 0 7.324632633753936e-08
isolated O 0 0.006046948954463005
diffuse B-Disease 1 0.9999333620071411
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.1054025246012316e-07
and O 0 8.652328631342243e-09
analysis O 0 3.0991667010482615e-09
of O 0 2.779193319923934e-09
genotype O 0 0.019478555768728256
/ O 0 3.226034459657967e-05
phenotype O 0 0.0027781056705862284
correlations O 0 1.8348211483498744e-07
by O 0 1.1114615894314284e-09
use O 0 1.0703653519072986e-09
of O 0 1.4519123403555767e-10
a O 0 2.0578784898361846e-08
computerized O 0 3.1001469324110076e-05
mutation O 0 3.9211727198562585e-06
database O 0 1.1019993451100163e-07
. O 0 1.0582816400983575e-07

Constitutional O 0 3.255627234466374e-05
mutations O 0 3.0310502552310936e-05
of O 0 1.1657690812683086e-08
the O 0 1.989017661685466e-08
WT1 O 0 2.382401544309687e-05
gene O 0 1.3598794623703725e-07
, O 0 1.4632893785559986e-09
encoding O 0 1.4284772476003127e-08
a O 0 4.687568377903517e-08
zinc O 0 5.897143182664877e-06
- O 0 1.9043217491798714e-07
finger O 0 6.114126449574542e-07
transcription O 0 2.2275346012179398e-08
factor O 0 8.310997223759387e-09
involved O 0 4.3510293146198364e-09
in O 0 1.1547395040167885e-08
renal O 1 0.8803036212921143
and O 0 7.594920248266135e-07
gonadal O 0 1.2488044376368634e-06
development O 0 1.9179478005781903e-09
, O 0 8.876382406874939e-10
are O 0 1.1493680313057197e-10
found O 0 9.580831683564384e-10
in O 0 5.739796415937803e-10
most O 0 4.869941250262855e-08
patients O 0 7.51672632759437e-06
with O 0 4.35616357208346e-07
Denys B-Disease 1 0.9997984766960144
- I-Disease 1 0.9999966621398926
Drash I-Disease 1 0.9999990463256836
syndrome I-Disease 1 0.9999998807907104
( O 0 2.8009367269987706e-07
DDS B-Disease 1 0.9999990463256836
) O 0 5.8520498669167864e-08
, O 0 2.4269851905955875e-08
or O 0 4.4236827534405165e-07
diffuse B-Disease 1 0.9999346733093262
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 2.3626896563655464e-06
DMS B-Disease 0 0.4219949245452881
) O 0 2.093561235483321e-08
associated O 0 4.590120994407698e-08
with O 0 3.219528821318818e-08
pseudohermaphroditism B-Disease 1 0.9999983310699463
and O 0 9.578237950336188e-06
/ O 0 1.392853937431937e-05
or O 0 8.216429137064551e-07
Wilms B-Disease 1 0.76683109998703
tumor I-Disease 0 0.2673976421356201
( O 0 2.3722348885257816e-07
WT B-Disease 1 0.99954754114151
) O 0 9.910340281749086e-08
. O 0 2.584054925591772e-07

Most O 0 8.110882845357992e-06
mutations O 0 0.00015316507779061794
in O 0 2.3467141545552295e-06
DDS B-Disease 1 1.0
patients O 1 0.9997237324714661
lie O 0 5.2037075874977745e-06
in O 0 5.090449839428857e-09
exon O 0 2.628064237342187e-07
8 O 0 1.0792424731675965e-08
or O 0 1.4962713290600504e-09
exon O 0 1.0299130792645883e-07
9 O 0 1.5129108632550015e-08
, O 0 1.4887047150580202e-09
encoding O 0 5.065918173841055e-08
zinc O 0 6.189329269545851e-06
finger O 0 4.194649136479711e-06
2 O 0 3.080586097325977e-08
or O 0 9.519940391555792e-09
zinc O 0 3.0129056540317833e-05
finger O 0 4.109242217964493e-05
3 O 0 3.2002983374468386e-08
, O 0 1.2552182626635044e-09
respectively O 0 7.356454112539268e-09
, O 0 3.3639191432399684e-10
with O 0 5.794134061432032e-10
a O 0 4.4883517347216184e-08
hot O 0 6.6422735471860506e-06
spot O 0 6.247631745281979e-07
( O 0 2.1227155588832147e-09
R394W O 0 1.2249687131316023e-07
) O 0 1.3396765918827214e-09
in O 0 3.0556492891520293e-09
exon O 0 6.701733354930184e-07
9 O 0 2.1824038753948116e-07
. O 0 1.3837626511303824e-07

We O 0 2.2354220163833816e-07
analyzed O 0 9.824500324384644e-08
a O 0 5.176503670156762e-09
series O 0 4.287193711149939e-09
of O 0 6.410268982293132e-10
24 O 0 5.779073717349092e-07
patients O 0 2.092089744110126e-06
, O 0 1.7029095911169634e-09
10 O 0 1.3217348326932665e-09
with O 0 1.1597545146457833e-08
isolated B-Disease 0 7.423661736538634e-05
DMS I-Disease 1 0.9666878581047058
( O 0 1.5086749627357676e-08
IDMS B-Disease 0 2.2346544938045554e-05
) O 0 2.328067738588402e-09
, O 0 2.614932048672358e-09
10 O 0 2.2335067129120034e-09
with O 0 9.192668670721105e-08
DDS B-Disease 1 1.0
, O 0 2.8146172326160013e-07
and O 0 1.5439514555737333e-08
4 O 0 7.141552682554675e-09
with O 0 2.5297376637922753e-08
urogenital B-Disease 1 0.6831950545310974
abnormalities I-Disease 1 0.9999692440032959
and O 0 9.821941603149753e-06
/ O 0 0.00033735844772309065
or O 0 1.3363361176743638e-05
WT B-Disease 1 0.9999935626983643
. O 0 4.461612206796417e-06

We O 0 1.325820448982995e-06
report O 0 2.919268240475503e-07
WT1 O 0 3.0966333724791184e-05
heterozygous O 0 1.359994803351583e-05
mutations O 0 1.0463907074154122e-06
in O 0 1.2599297605220272e-08
16 O 0 7.330536959671008e-07
patients O 0 2.7074904210167006e-05
, O 0 3.548809690556709e-09
4 O 0 3.5163467693166695e-09
of O 0 1.0652247972586792e-09
whom O 0 8.425582791460329e-07
presented O 0 4.484928695092094e-08
with O 0 4.2363918595356154e-08
IDMS B-Disease 0 0.007639323826879263
. O 0 5.368319193621574e-07

One O 0 2.0129530184931355e-06
male O 0 2.519371491871425e-06
and O 0 1.1629730067852506e-08
two O 0 4.864065061838119e-08
female O 0 0.00024907098850235343
IDMS B-Disease 1 0.9755669832229614
patients O 0 0.07253877818584442
with O 0 6.097711207075918e-07
WT1 O 1 0.5952646732330322
mutations O 0 0.00041956306085921824
underwent O 0 0.0006232851883396506
normal O 0 2.5511678813927574e-06
puberty O 0 5.20180219609756e-06
. O 0 4.2911719333460496e-07

Two O 0 4.990270099369809e-06
mutations O 0 5.1320643251528963e-05
associated O 0 1.007218628501505e-07
with O 0 1.121254644687042e-08
IDMS B-Disease 0 0.000431265274528414
are O 0 2.7660200796475465e-09
different O 0 3.0672564488298804e-10
from O 0 5.281358128605973e-10
those O 0 1.7643638772213421e-09
described O 0 1.157357814918214e-06
in O 0 4.6196234393391933e-07
DDS B-Disease 1 1.0
patients O 1 0.9990208148956299
. O 0 6.029193855283665e-07

No O 0 6.762636530766031e-06
WT1 O 0 0.00032686052145436406
mutations O 0 2.348958696529735e-05
were O 0 4.774537032403714e-08
detected O 0 2.5913097445595668e-08
in O 0 5.589941287631461e-10
the O 0 6.045966505219269e-10
six O 0 1.8554398906189817e-08
other O 0 2.093469397834724e-08
IDMS B-Disease 1 0.9946222305297852
patients O 1 0.548305332660675
, O 0 8.792287786718589e-09
suggesting O 0 5.879000752884167e-08
genetic O 0 5.989569729081268e-08
heterogeneity O 0 1.9953790797444526e-07
of O 0 1.5369518990837605e-09
this O 0 6.530798657422565e-08
disease O 0 3.210303111700341e-05
. O 0 3.5703817502508173e-07

We O 0 2.982806336149224e-06
analyzed O 0 1.3661668162967544e-05
genotype O 0 0.0012030842481181026
/ O 0 1.832205271057319e-05
phenotype O 0 0.0011470518074929714
correlations O 0 3.5198625027987873e-06
, O 0 3.427508499243004e-09
on O 0 5.9875118196828225e-09
the O 0 5.685925064113917e-10
basis O 0 5.989313489607184e-10
of O 0 4.975826348174728e-11
the O 0 2.804351750818057e-10
constitution O 0 4.386694119062895e-09
of O 0 2.4784690966228595e-10
a O 0 3.1861738136740314e-08
WT1 O 0 2.1431822460726835e-05
mutation O 0 6.1446037591395e-08
database O 0 1.1939672583949346e-09
of O 0 2.1052715126756993e-10
84 O 0 1.9696317465900393e-08
germ O 0 2.17954180925517e-07
- O 0 9.476675586483907e-06
line O 0 7.03462364981533e-06
mutations O 0 9.700951864033414e-08
, O 0 3.9891490111187977e-10
to O 0 8.442982979417479e-10
compare O 0 2.3318182940101906e-09
the O 0 1.7973406096771782e-10
distribution O 0 6.51325271494585e-10
and O 0 1.3005831966950154e-09
type O 0 9.852062277104778e-09
of O 0 2.816143984674113e-10
mutations O 0 8.797257322612495e-08
, O 0 5.845328665543548e-10
according O 0 1.5762313676503936e-10
to O 0 6.532150931271019e-10
the O 0 6.006244390732718e-10
different O 0 1.662511017741508e-08
symptoms O 0 9.495807898929343e-05
. O 0 1.5421684906868904e-07

This O 0 4.7566578587066033e-07
demonstrated O 0 8.817329444354982e-07
( O 0 2.3385751113380593e-09
1 O 0 2.460064818521346e-09
) O 0 2.953828015517246e-10
the O 0 5.141098657901466e-10
association O 0 1.0501632896620094e-09
between O 0 3.8692637982506994e-10
mutations O 0 5.113652079558051e-08
in O 0 1.4886450960815978e-09
exons O 0 1.1095202268052162e-07
8 O 0 8.668515683041278e-09
and O 0 9.463509975660145e-09
9 O 0 4.585806934187531e-08
and O 0 1.0643711902957875e-06
DMS B-Disease 1 0.8275085687637329
; O 0 2.6225054128303782e-08
( O 0 7.758704789750936e-10
2 O 0 5.402810643317935e-09
) O 0 2.342767313479044e-09
among O 0 5.0393971662288095e-08
patients O 0 3.711218369062408e-06
with O 0 1.873855559608728e-08
DMS B-Disease 0 0.16589318215847015
, O 0 4.810054576864786e-09
a O 0 5.412692072326308e-09
higher O 0 3.4634224377327882e-09
frequency O 0 1.5733464309164447e-08
of O 0 1.644084174357019e-10
exon O 0 8.261847739277073e-08
8 O 0 7.396975032492037e-09
mutations O 0 1.2438961505267798e-07
among O 0 6.211011260859323e-09
46 O 0 1.2578843211485946e-07
, O 0 2.3027856954627168e-08
XY O 0 0.07576506584882736
patients O 0 0.0005729817203246057
with O 0 7.110657840314616e-09
female O 0 2.3705260900896974e-05
phenotype O 0 7.607831503264606e-05
than O 0 6.791303519548819e-09
among O 0 2.682841948598025e-09
46 O 0 6.944458874613701e-08
, O 0 1.1239182029498807e-08
XY O 0 0.08439767360687256
patients O 0 0.00021727182320319116
with O 0 4.568318612285793e-09
sexual O 0 1.3894853267970575e-08
ambiguity O 0 7.984368721736246e-08
or O 0 7.683532032842777e-08
male O 0 0.024089083075523376
phenotype O 0 0.3740788400173187
; O 0 4.344869708461374e-08
and O 0 3.3846461633402214e-08
( O 0 7.219807529601496e-10
3 O 0 1.4262931946618096e-09
) O 0 3.0942270967670993e-10
statistically O 0 6.627507875833771e-09
significant O 0 2.7633624277711988e-09
evidence O 0 4.486089721922326e-09
that O 0 4.292012967255232e-09
mutations O 0 4.931756691917144e-08
in O 0 1.621395240292145e-09
exons O 0 1.091344188353105e-07
8 O 0 6.139447172870405e-09
and O 0 2.0845032366878513e-09
9 O 0 1.2127006954187891e-08
preferentially O 0 3.234356142911565e-07
affect O 0 1.6664571944602358e-08
amino O 0 3.209674082071956e-09
acids O 0 9.938346812177201e-10
with O 0 1.2363229884293503e-10
different O 0 1.0959608914840047e-10
functions O 0 1.0395451166544944e-09
. O 0 3.1888596208062836e-09
. O 0 2.759792572248898e-08

The O 0 6.496050559690048e-07
185delAG O 0 2.4970326194306836e-05
BRCA1 O 0 2.5612293029553257e-05
mutation O 0 4.1700337760630646e-07
originated O 0 7.337675800300758e-09
before O 0 8.98716601138716e-10
the O 0 6.211386960330856e-10
dispersion O 0 9.451247962033449e-08
of O 0 7.241363064736106e-10
Jews O 0 1.8058058159908796e-08
in O 0 4.908740636189179e-10
the O 0 6.005373420769899e-10
diaspora O 0 1.1941933664161297e-08
and O 0 4.772076067638409e-09
is O 0 3.230975265111624e-09
not O 0 3.6079970122671057e-09
limited O 0 9.404382161903868e-09
to O 0 6.076562186763113e-08
Ashkenazim O 0 3.485304205241846e-06
. O 0 1.6406814040692552e-07

The O 0 8.867995120453998e-07
185delAG O 0 1.576281283632852e-05
mutation O 0 3.0933035759517225e-06
in O 0 8.43085423696266e-09
BRCA1 O 0 1.1913560911125387e-06
is O 0 1.5709774814354205e-08
detected O 0 5.65624986847979e-08
in O 0 3.2858327170259827e-09
Ashkenazi O 0 4.871372425441223e-07
Jews O 0 1.0446758125226552e-08
both O 0 1.6542512915052043e-09
in O 0 3.2518039372320118e-09
familial B-Disease 0 0.04190189391374588
breast I-Disease 1 0.9999822378158569
and I-Disease 1 0.9998512268066406
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
and O 0 2.4816314336817413e-08
in O 0 7.062763707210706e-10
the O 0 7.412450653276892e-10
general O 0 3.3653730469040966e-08
population O 0 4.475964132666377e-08
. O 0 1.330271857113985e-07

All O 0 4.899961822957266e-07
tested O 0 1.135475940827746e-06
Ashkenazi O 0 1.419413706571504e-06
mutation O 0 2.8743295388267143e-07
carriers O 0 1.4375407531019846e-08
share O 0 1.2329749443651394e-09
the O 0 2.0132639999559387e-10
same O 0 4.333693848224129e-09
allelic O 0 2.448887244099751e-07
pattern O 0 3.0464801170637656e-07
at O 0 1.5661090202456762e-09
the O 0 8.462333944692091e-09
BRCA1 O 0 1.1653726687654853e-05
locus O 0 3.7150359730730997e-06
. O 0 2.0569216019339365e-07

Our O 0 3.851368717278092e-07
previous O 0 4.918867801961824e-08
study O 0 8.579037036327009e-09
showed O 0 2.359580975053177e-08
that O 0 2.79891193555315e-10
this O 0 1.0903007385820729e-09
Ashkenazi O 0 2.875804284485639e-06
mutation O 0 2.390238762473018e-07
also O 0 4.148885679455816e-08
occurs O 0 1.6804941882497815e-09
in O 0 5.964745919406766e-10
Iraqi O 0 4.0301298298572874e-08
Jews O 0 3.0890514590709017e-09
with O 0 1.3190595837819785e-10
a O 0 8.287348585156451e-09
similar O 0 6.548786046778332e-08
allelic O 0 5.571942438109545e-06
pattern O 0 1.0179885066463612e-05
. O 0 5.657220754073933e-07

We O 0 5.122721518091566e-07
extended O 0 1.4240477241855842e-07
our O 0 2.1837573971339452e-09
analysis O 0 1.0350973411732411e-09
to O 0 5.633139510408114e-10
other O 0 9.353889884877731e-11
non O 0 8.175310428626403e-10
- O 0 9.328815764320098e-08
Ashkenazi O 0 1.1302819302727585e-07
subsets O 0 8.22793833066271e-09
354 O 0 1.3642408092096048e-08
of O 0 2.0747367712736775e-10
Moroccan O 0 2.106700236481629e-07
origin O 0 3.3394875753600672e-09
, O 0 3.826797490003031e-10
200 O 0 6.767494897808035e-10
Yemenites O 0 9.561306058003538e-08
and O 0 1.4977104001445696e-09
150 O 0 3.3766875962015774e-09
Iranian O 0 5.992243501395933e-08
Jews O 0 1.1198721949767787e-07
. O 0 6.719986345160578e-08

Heteroduplex O 0 0.00023817697365302593
analysis O 0 8.291587505482312e-07
complemented O 0 3.129865717710345e-07
by O 0 3.529833314530606e-09
direct O 0 4.040402679095223e-09
DNA O 0 1.5330002156588307e-08
sequencing O 0 9.012661728036164e-09
of O 0 2.3004180782493222e-09
abnormally O 0 4.910773441224592e-07
migrating O 0 3.262154990579802e-08
bands O 0 3.8309934780045296e-08
were O 0 2.5298149353147892e-08
employed O 0 6.714112146255502e-07
. O 0 1.5358953930899588e-07

Four O 0 1.673720788630817e-07
of O 0 3.7171206113129074e-09
Moroccan O 0 8.261104653684015e-07
origin O 0 2.041770486016503e-08
( O 0 6.167000798917854e-10
1 O 0 1.5596017810537433e-09
. O 0 7.023939763151077e-10
1 O 0 1.4936195613657333e-09
% O 0 4.821625876338942e-10
) O 0 2.4065574533160827e-10
and O 0 5.751547682564251e-09
none O 0 3.4555902583832676e-09
of O 0 5.0713343247021925e-11
the O 0 4.269247733112991e-10
Yemenites O 0 9.029268710492033e-08
or O 0 4.5056994246728266e-10
Iranians O 0 9.196768679942124e-09
was O 0 8.2177757931845e-09
a O 0 9.257870581258487e-10
carrier O 0 8.044915844607203e-09
of O 0 1.5306554634886282e-10
the O 0 2.1050758913787604e-09
185delAG O 0 7.84302937972825e-06
mutation O 0 2.0232553197274683e-06
. O 0 9.562582903299699e-08

BRCA1 O 0 0.005874894559383392
allelic O 0 0.00036144323530606925
patterns O 0 2.0026163838338107e-05
were O 0 1.8968704296185024e-07
determined O 0 1.596734335862493e-07
for O 0 1.6293160154390307e-09
four O 0 5.565664040751983e-10
of O 0 5.858228485644545e-11
these O 0 3.297930539769567e-10
individuals O 0 1.8416521085917736e-10
and O 0 6.001869556904182e-10
for O 0 6.369501037717384e-10
12 O 0 2.8356623715808382e-09
additional O 0 3.823355854137844e-09
non O 0 1.0916268777805271e-08
- O 0 4.627640919352416e-06
Ashkenazi O 0 6.464411853812635e-06
185delAG O 0 1.1765559975174256e-06
mutation O 0 4.543182399174839e-07
carriers O 0 1.3097178452881053e-07
who O 0 6.779676482437935e-07
had O 0 0.0015977360308170319
breast B-Disease 1 0.9999449253082275
/ I-Disease 1 0.9999954700469971
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 1.6332081713699154e-06

Six O 0 3.217498715457623e-06
non O 0 5.092487072033691e-07
- O 0 7.811073373886757e-06
Ashkenazi O 0 1.5113847439351957e-05
individuals O 0 2.6091229177183095e-09
shared O 0 1.5806126407724719e-09
the O 0 1.4238685785983307e-09
common O 0 3.9782268146382194e-08
Ashkenazi O 0 0.0003525819047354162
haplotype O 0 0.004254115745425224
, O 0 3.1675519984730727e-09
four O 0 8.992979139144097e-10
had O 0 1.1635743923932296e-08
a O 0 2.96809488098404e-09
closely O 0 6.631314164451396e-09
related O 0 2.9850477645254614e-09
pattern O 0 2.06132042990248e-07
, O 0 4.652488616585515e-09
and O 0 6.391080997758536e-09
the O 0 3.2130855753820242e-09
rest O 0 1.7044312627945146e-08
( O 0 6.837166943718387e-10
n O 0 6.474737546113829e-08
= O 0 3.190229946881118e-08
6 O 0 2.3857595898846284e-09
) O 0 2.7204566377392325e-10
displayed O 0 1.589507725441308e-08
a O 0 1.6062916330383814e-08
distinct O 0 7.797521561769827e-08
BRCA1 O 0 1.0656322046997957e-05
allelic O 0 7.242056653922191e-06
pattern O 0 9.70497785601765e-06
. O 0 5.804138822895766e-07

We O 0 7.30688270778046e-07
conclude O 0 2.0756932883614354e-07
that O 0 5.779898337721079e-09
the O 0 2.6156301569102425e-09
185delAG O 0 2.8546576231747167e-06
BRCA1 O 0 1.263214653590694e-05
mutation O 0 5.09009851157316e-07
occurs O 0 3.5052043489969265e-09
in O 0 5.542612480091691e-10
some O 0 1.4142167437114495e-09
non O 0 1.7265927354515043e-08
- O 0 6.850579666206613e-06
Ashkenazi O 0 1.324973527516704e-05
populations O 0 9.296821978921344e-09
at O 0 7.440553728699228e-10
rates O 0 9.126695843519883e-09
comparable O 0 1.9664063710678192e-09
with O 0 2.9088703668023186e-10
that O 0 2.5283277693688433e-09
of O 0 3.1735205574534575e-09
Ashkenazim O 0 3.573328740458237e-06
. O 0 1.5435546174558112e-07

The O 0 7.531010481898193e-08
majority O 0 9.384908139509207e-08
of O 0 9.859087990449211e-10
Jewish O 0 1.8186435468692252e-08
185delAG O 0 1.0389865110482788e-06
mutation O 0 3.464518272267014e-07
carriers O 0 1.4619232047152764e-08
have O 0 1.5062416869326967e-09
a O 0 4.8284940490361805e-09
common O 0 1.3998491255051704e-08
allelic O 0 1.79111270881549e-06
pattern O 0 9.691797458799556e-06
, O 0 5.968492811092574e-09
supporting O 0 2.5479729437449805e-09
the O 0 3.981585894319295e-10
founder O 0 2.0795681621166295e-08
effect O 0 7.868798945764865e-09
notion O 0 3.1831961511130658e-09
, O 0 3.306628859611749e-10
but O 0 7.534495249927886e-10
dating O 0 1.408544725300942e-09
the O 0 3.3449937264506957e-10
mutations O 0 1.3192722470023455e-08
origin O 0 3.919535251917239e-10
to O 0 5.204677244741163e-10
an O 0 1.219531142737651e-09
earlier O 0 1.1576571701255034e-08
date O 0 4.71638994525847e-09
than O 0 3.2345577327674846e-09
currently O 0 1.7733356116877985e-08
estimated O 0 2.350215844160175e-08
. O 0 2.63022492674736e-08

However O 0 9.42450355978508e-07
, O 0 4.937137365601529e-09
the O 0 2.4439472667836526e-10
different O 0 3.895388178687398e-10
allelic O 0 1.0031062913640199e-07
pattern O 0 7.065236218295468e-08
at O 0 7.200691154451988e-10
the O 0 1.244628289320815e-09
BRCA1 O 0 9.979162314266432e-07
locus O 0 1.5540000219971262e-07
even O 0 7.284768344106851e-09
in O 0 3.184724983729126e-10
some O 0 4.786476770490822e-10
Jewish O 0 7.440443816619791e-09
mutation O 0 5.7648179563329904e-08
carriers O 0 8.816520846721687e-09
, O 0 8.512757720957609e-10
might O 0 8.317879718333643e-09
suggest O 0 3.803586334782949e-09
that O 0 9.494457442471571e-10
the O 0 8.349156921383383e-10
mutation O 0 1.1429141721919223e-07
arose O 0 1.1321112047824045e-08
independently O 0 3.5988986013535396e-08
. O 0 5.7605498149371215e-09
. O 0 3.984559882042049e-08

Crystal O 0 0.0001518694480182603
structure O 0 4.6201301984183374e-07
of O 0 8.914153859507223e-09
the O 0 1.0122510474275259e-07
hemochromatosis B-Disease 1 0.9999994039535522
protein O 0 1.188234909932362e-05
HFE O 0 4.875831655226648e-05
and O 0 3.1640695397072705e-08
characterization O 0 5.267580860390808e-08
of O 0 1.735929316959428e-10
its O 0 1.4353974675529457e-09
interaction O 0 6.113225481385598e-09
with O 0 2.4457964542534683e-08
transferrin O 0 4.691876893048175e-05
receptor O 0 6.2947992773843e-06
. O 0 3.5741840065384167e-07

HFE O 0 0.012896441854536533
is O 0 3.15536635753233e-06
an O 0 1.3279142763167329e-07
MHC O 0 1.2643282389035448e-05
- O 0 6.578056854777969e-06
related O 0 4.7275783288114326e-08
protein O 0 9.105726839209183e-09
that O 0 1.0886591628178621e-09
is O 0 1.7013253028608233e-09
mutated O 0 5.6190664565747284e-08
in O 0 1.9508021864567127e-09
the O 0 8.149315888772435e-09
iron B-Disease 1 0.9837325215339661
- I-Disease 1 0.9997841715812683
overload I-Disease 1 0.9999645948410034
disease I-Disease 1 0.9999200105667114
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0008223765762522817

HFE O 0 0.0018160258186981082
binds O 0 2.14833089557942e-05
to O 0 6.647518944191688e-07
transferrin O 0 1.1051099136238918e-05
receptor O 0 1.2568224292408559e-06
( O 0 1.7615066738585483e-08
TfR O 0 3.7030447401775746e-06
) O 0 1.0005218875619448e-09
and O 0 1.3592091896441616e-09
reduces O 0 2.3704791018985816e-08
its O 0 9.812580747947663e-10
affinity O 0 1.0962882157627973e-08
for O 0 3.662760095224371e-09
iron O 0 0.0004271716170478612
- O 0 2.7440307803772157e-06
loaded O 0 5.475495186146873e-07
transferrin O 0 3.861964614770841e-06
, O 0 1.358206969115372e-08
implicating O 0 1.2319152347117779e-06
HFE O 0 2.6798503313330002e-05
in O 0 1.061252987710759e-07
iron O 0 0.006350447423756123
metabolism O 0 9.437299013370648e-06
. O 0 2.843154618403787e-07

The O 0 1.2196362604299793e-06
2 O 0 1.2437008081178647e-06
. O 0 5.190412366573582e-07

6 O 0 1.0656921404006425e-05
A O 0 1.7110471617343137e-06
crystal O 0 7.794615157763474e-06
structure O 0 6.289226917033375e-08
of O 0 2.190908343635556e-09
HFE O 0 6.252243565540994e-06
reveals O 0 1.941172058650409e-07
the O 0 1.1506057218113597e-09
locations O 0 5.025821536719377e-09
of O 0 1.333182364504637e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0004238281399011612
and O 0 7.431820936432132e-09
a O 0 4.6874340853264584e-08
patch O 0 0.0001552044996060431
of O 0 2.8350837233404036e-09
histidines O 0 2.59538637692458e-06
that O 0 5.21762100191836e-09
could O 0 6.007667696650287e-09
be O 0 9.109907828097619e-10
involved O 0 9.140889156711296e-10
in O 0 1.9985768595631725e-09
pH O 0 7.407287739624735e-06
- O 0 4.78068841403001e-06
dependent O 0 7.939354986774561e-07
interactions O 0 2.1512281023206015e-07
. O 0 8.959516151207936e-08

We O 0 6.677649366793048e-07
also O 0 6.91196433422192e-08
demonstrate O 0 7.583724226378763e-08
that O 0 4.02518232078819e-08
soluble O 0 3.124338718407671e-06
TfR O 0 1.7399443095200695e-05
and O 0 1.0509412007309038e-08
HFE O 0 1.6465889984829118e-06
bind O 0 1.1466588745179251e-07
tightly O 0 2.2444537250976282e-07
at O 0 1.4717481677806177e-09
the O 0 1.0042405795829268e-09
basic O 0 5.899902788542022e-09
pH O 0 3.880575505377237e-08
of O 0 7.192067774663968e-11
the O 0 2.3876201016292953e-10
cell O 0 2.209165614885933e-07
surface O 0 3.0696730846102582e-06
, O 0 1.3669725351661555e-09
but O 0 1.946773187100348e-09
not O 0 2.3924213721215892e-09
at O 0 1.9965794295639938e-10
the O 0 1.382262970750503e-09
acidic O 0 3.366745659150183e-06
pH O 0 3.704729465425771e-07
of O 0 9.782177290418304e-10
intracellular O 0 2.054757146652264e-07
vesicles O 0 2.184160166507354e-06
. O 0 2.7612307462732133e-07

TfR O 1 0.8787052631378174
HFE O 0 0.011079023592174053
stoichiometry O 0 0.00010397084406577051
( O 0 1.8189942352364596e-07
2 O 0 4.305017853312165e-08
1 O 0 1.119811976479923e-08
) O 0 3.6389451452123467e-09
differs O 0 1.3506588913969608e-07
from O 0 9.758068131304753e-09
TfR O 0 9.162477908830624e-06
transferrin O 0 9.763151638253476e-07
stoichiometry O 0 1.552897828105415e-07
( O 0 6.628806947794885e-10
2 O 0 1.0817767792659083e-09
2 O 0 1.2156203821334088e-09
) O 0 3.666336956253957e-10
, O 0 4.263152886263555e-10
implying O 0 3.27657034837614e-09
a O 0 1.1602538929622597e-09
different O 0 1.8864228235049296e-10
mode O 0 1.7979415734004078e-09
of O 0 8.934025741424989e-11
binding O 0 1.2286700545871554e-08
for O 0 1.8718970817843683e-09
HFE O 0 3.8612211028521415e-06
and O 0 3.6362827415814536e-08
transferrin O 0 1.5125925756365177e-06
to O 0 2.2521942355524516e-07
TfR O 0 5.431488898466341e-05
, O 0 1.978509356348468e-09
consistent O 0 1.0404184180856646e-08
with O 0 2.43597975124743e-10
our O 0 4.134417530554657e-10
demonstration O 0 6.815608966093123e-09
that O 0 3.6281060378229313e-09
HFE O 0 3.1604135983798187e-06
, O 0 5.447450490692063e-09
transferrin O 0 3.4205621091132343e-07
, O 0 6.091529503038373e-09
and O 0 2.9801567436038567e-08
TfR O 0 1.3813189980282914e-05
form O 0 1.3435002443884514e-08
a O 0 3.3546577071774664e-08
ternary O 0 9.382363828080997e-07
complex O 0 7.388812832687108e-07
. O 0 5.97829966864083e-07

Identification O 0 5.257325483398745e-06
of O 0 2.952388733490352e-08
three O 0 1.0182943377401443e-08
novel O 0 1.1138415345612884e-07
mutations O 0 1.3024263978422823e-07
and O 0 1.631938029156288e-09
a O 0 7.031798698875491e-09
high O 0 1.4488817257074516e-08
frequency O 0 5.310535655667081e-08
of O 0 8.256258871019995e-11
the O 0 1.6621581888642822e-09
Arg778Leu O 0 3.2303164516633842e-06
mutation O 0 1.1953355283367273e-07
in O 0 1.953069705962207e-09
Korean O 0 1.468065562448828e-07
patients O 0 1.2952007637068164e-05
with O 0 8.854222954823854e-08
Wilson B-Disease 0 6.721693353028968e-05
disease I-Disease 0 1.7467426005168818e-05
. O 0 2.299748871337215e-07

Four O 0 2.776077508315211e-06
mutations O 0 1.4260498574003577e-05
- O 0 5.410617632151116e-06
- O 0 1.0749962711997796e-05
R778L O 0 2.1416697109089e-06
, O 0 7.933193657549964e-09
A874V O 0 7.283841085836684e-08
, O 0 1.6679636560823496e-09
L1083F O 0 3.8673860558446904e-08
, O 0 8.050483613075698e-10
and O 0 1.2678795791032371e-09
2304delC O 0 2.8739651725118165e-07
- O 0 6.140351160865976e-07
- O 0 3.621118764840503e-07
in O 0 2.3933890425098525e-09
the O 0 1.2470044996604202e-09
copper O 0 5.6549339433331625e-08
- O 0 1.4712493445756536e-08
transporting O 0 6.736281310537606e-09
enzyme O 0 5.341516562396009e-09
, O 0 9.095202924136458e-10
P O 0 8.01330983790649e-08
- O 0 2.9000190693295735e-07
type O 0 1.157561996478762e-06
ATPase O 0 9.932781495081144e-07
( O 0 1.7122798734447997e-09
ATP7B O 0 7.945777724671643e-07
) O 0 5.437648109563042e-10
, O 0 4.237535322637598e-10
were O 0 1.4744905296737443e-09
identified O 0 9.439389714316349e-09
in O 0 7.634164411740585e-10
Korean O 0 2.2743870431440882e-07
Patients O 0 4.388731667859247e-06
with O 0 2.5722624030777297e-08
Wilson B-Disease 0 2.5791465304791927e-05
disease I-Disease 0 1.2017415428999811e-05
. O 0 2.889222514568246e-07

Arg778Leu O 0 0.00035222445148974657
, O 0 1.1307822944672807e-07
the O 0 2.2924289133641196e-09
most O 0 4.519662422097781e-09
frequently O 0 9.79475132112384e-08
reported O 0 6.852343403807026e-08
mutation O 0 1.524131398866757e-08
of O 0 8.865616574205148e-11
this O 0 4.441330914151109e-10
enzyme O 0 8.588467714787384e-09
, O 0 1.0016485418873344e-09
was O 0 3.05186489413245e-08
found O 0 1.5236305550558882e-09
in O 0 1.5341101999855056e-10
six O 0 4.0007006041342663e-10
of O 0 5.3712412989570524e-11
eight O 0 9.94476057059046e-09
unrelated O 0 2.8328861390036764e-07
patients O 0 7.382815056189429e-06
studied O 0 7.810825763954199e-09
, O 0 6.201987257092867e-10
an O 0 1.4393782832300417e-09
allele O 0 6.416366460371137e-08
frequency O 0 2.5570686901232875e-08
of O 0 1.6150678572302013e-09
37 O 0 2.50993451800241e-07
. O 0 1.18187365671929e-07

5 O 0 3.3925559819181217e-06
% O 0 6.227953974757838e-08
, O 0 1.0402552153010447e-09
which O 0 2.4947095500493788e-09
is O 0 4.431162103912811e-09
considerably O 0 2.7441149086371297e-07
higher O 0 2.760391248912697e-09
than O 0 9.593484895376037e-10
those O 0 1.6278892123189337e-10
in O 0 1.3927581310468895e-10
other O 0 2.492235307016699e-10
Asian O 0 1.5517919171870176e-09
populations O 0 3.5814302634662454e-08
. O 0 5.309452433266415e-08

The O 0 1.367863120549373e-07
novel O 0 1.5876267411840672e-07
single O 0 1.8803142154411034e-08
nucleotide O 0 2.2702948854202987e-08
deletion O 0 1.8363054721248773e-07
, O 0 4.671571574021982e-09
2304delC O 0 2.3106221647140046e-07
, O 0 1.6402886826583085e-09
was O 0 2.1425465845936742e-08
found O 0 1.7673548180496823e-09
in O 0 8.119398486883256e-10
one O 0 2.7159801518905624e-08
patient O 0 1.4464471860264894e-05
. O 0 1.420102648808097e-07

Since O 0 1.0734459010564024e-06
a O 0 2.105874727931223e-07
mutation O 0 3.8770988908254367e-07
at O 0 4.9243564781420446e-09
cDNA O 0 2.622956571940449e-07
nucleotide O 0 4.321026949583029e-07
2302 O 0 2.7918399609916378e-06
( O 0 7.0282046849001745e-09
2302insC O 0 1.983320601084415e-07
) O 0 2.760838890836226e-09
had O 0 8.96855993914869e-08
been O 0 1.6942893310556428e-08
previously O 0 3.2705408159472427e-08
described O 0 6.071048375133614e-08
, O 0 2.7881383313221875e-10
this O 0 1.1063382848730541e-10
region O 0 4.1453934729318576e-10
of O 0 6.360477422528987e-11
the O 0 1.0068624822778816e-09
ATP7B O 0 2.3777896785759367e-05
gene O 0 6.631658067135504e-08
may O 0 3.1465262395613536e-08
be O 0 8.481611857291682e-09
susceptible O 0 7.523977728851605e-06
to O 0 1.9774130066707585e-07
gene O 0 7.107918918336509e-06
rearrangements O 0 0.011601932346820831
causing O 0 0.000523395137861371
Wilson B-Disease 0 0.000827609037514776
disease I-Disease 0 0.00014591585204470903
. O 0 3.6351252674649004e-07

Disruption O 0 4.516744229476899e-05
of O 0 8.285454811129966e-08
splicing O 0 1.6008769989639404e-06
regulated O 0 1.996389897840345e-07
by O 0 3.901457379384965e-09
a O 0 2.4191331604583866e-08
CUG O 0 3.204262247891165e-05
- O 0 1.7141945818366366e-06
binding O 0 9.463492460781708e-07
protein O 0 7.812570288479037e-07
in O 0 4.4127784804004477e-07
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
. O 0 2.1654690499417484e-05

Myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
( O 1 0.9915298223495483
DM B-Disease 1 1.0
) O 0 1.7876280935524846e-06
is O 0 8.932062911526373e-08
caused O 0 1.4375261514487647e-07
by O 0 3.0121802829796707e-09
a O 0 3.393372693949459e-08
CTG O 0 5.254656230135879e-07
expansion O 0 1.3240543772496949e-08
in O 0 1.0860272681156857e-09
the O 0 1.0247880322111769e-09
3 O 0 1.5006364151304297e-08
untranslated O 0 1.5550733678537654e-06
region O 0 8.623825209497227e-09
of O 0 6.388322648653855e-10
the O 0 6.623378112635692e-08
DM B-Disease 1 0.9999992847442627
gene O 0 1.7529086107970215e-05
. O 0 2.174324720272125e-07

One O 0 8.05024285455147e-07
model O 0 7.561811798950657e-07
of O 0 5.1342734508352805e-08
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 0.00019592486205510795
suggests O 0 1.700668406101613e-07
that O 0 1.5064888225779782e-09
RNAs O 0 1.006214045418119e-08
from O 0 1.0499223018767267e-10
the O 0 1.0186566867798064e-10
expanded O 0 3.833381612139419e-09
allele O 0 2.1893596269251248e-08
create O 0 1.6041598049909567e-09
a O 0 4.302397549338366e-09
gain O 0 6.055527990156406e-08
- O 0 8.003366502862264e-08
of O 0 1.4098537892692775e-09
- O 0 1.6689054973539896e-06
function O 0 1.6531291890942157e-08
mutation O 0 9.529369293659329e-09
by O 0 1.2428390261387534e-10
the O 0 1.5364703953579806e-10
inappropriate O 0 7.271816038212364e-09
binding O 0 3.413937355034591e-09
of O 0 2.7844062125415014e-11
proteins O 0 3.4743577459472874e-10
to O 0 1.50714984936684e-09
the O 0 4.288559729559438e-09
CUG O 0 0.00016775171388871968
repeats O 0 2.539378101573675e-06
. O 0 1.2255155468210432e-07

Data O 0 1.5557217238892918e-06
presented O 0 1.273247249855558e-07
here O 0 4.717568558021412e-09
indicate O 0 1.03270778595288e-08
that O 0 6.027245369466527e-10
the O 0 5.294570892822037e-10
conserved O 0 2.2961758716633085e-08
heterogeneous O 0 7.3872215011761e-08
nuclear O 0 7.776965560424287e-08
ribonucleoprotein O 0 1.9901938230759697e-06
, O 0 9.041518644892221e-09
CUG O 0 2.149691226804862e-06
- O 0 2.6103444383807073e-07
binding O 0 1.302240093536966e-07
protein O 0 4.860948976670443e-08
( O 0 1.90984739134592e-09
CUG O 0 3.0911096473573707e-06
- O 0 6.0036777540517505e-06
BP O 0 3.958524757763371e-05
) O 0 7.010461655632128e-10
, O 0 6.51627252157283e-10
may O 0 6.738928970406732e-09
mediate O 0 5.080103733234864e-07
the O 0 5.488102416961738e-09
trans O 0 9.139520074086249e-08
- O 0 1.4126519545243355e-06
dominant O 0 2.5049533292076376e-07
effect O 0 6.246605011028805e-09
of O 0 9.26447182858503e-11
the O 0 1.0590257559783822e-09
RNA O 0 1.4603045883632149e-07
. O 0 1.0570167319201573e-07

CUG O 0 0.004076014272868633
- O 0 0.0011542064603418112
BP O 0 0.00011105081648565829
was O 0 1.1062786597904051e-07
found O 0 1.2397380899642485e-09
to O 0 2.7159047233382694e-10
bind O 0 4.490687377511904e-09
to O 0 3.1922007259765905e-09
the O 0 5.046329132341043e-09
human O 0 1.8140156043955358e-07
cardiac O 1 0.6881862282752991
troponin O 0 0.009405238553881645
T O 0 2.3522181436419487e-05
( O 0 1.9521684269108164e-09
cTNT O 0 7.468015184031174e-08
) O 0 3.3051281156382117e-10
pre O 0 1.1468924476787379e-08
- O 0 9.430808489696574e-08
messenger O 0 2.106161289816555e-08
RNA O 0 2.233276452656696e-09
and O 0 2.1766455304828014e-10
regulate O 0 5.125455171395288e-09
its O 0 5.468416386378294e-09
alternative O 0 5.5606612647807196e-08
splicing O 0 1.4424620076169958e-06
. O 0 2.412217838809738e-07

Splicing O 0 3.0759845685679466e-05
of O 0 1.9898796210782166e-07
cTNT O 0 8.073137905739713e-06
was O 0 1.0825584695339785e-06
disrupted O 0 1.3622252481582109e-06
in O 0 1.5242322604080982e-07
DM B-Disease 1 0.9999997615814209
striated O 0 0.15484781563282013
muscle O 0 0.016438718885183334
and O 0 6.798525475915085e-08
in O 0 3.848759533298107e-09
normal O 0 3.538740145359043e-08
cells O 0 4.210525261783005e-08
expressing O 0 2.3060865217416904e-08
transcripts O 0 1.726335874252527e-08
that O 0 5.664538615945958e-09
contain O 0 6.494638427056998e-08
CUG O 0 4.691022331826389e-05
repeats O 0 1.5720407873232034e-06
. O 0 9.104496712097898e-08

Altered O 0 0.00011315882875351235
expression O 0 1.490980935159314e-06
of O 0 2.838535850813173e-09
genes O 0 2.1771461078401444e-08
regulated O 0 4.416693499820212e-08
posttranscriptionally O 0 6.667295906481741e-07
by O 0 7.017114000973379e-09
CUG O 0 1.1325882042001467e-05
- O 0 1.4827038285147864e-05
BP O 0 7.254590309457853e-05
therefore O 0 5.0563421893912164e-08
may O 0 2.690607026067937e-08
contribute O 0 1.2620077427527576e-08
to O 0 9.302924013354641e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.004454263020306826
. O 0 7.465281015583969e-08
. O 0 9.503670383992358e-08

Identification O 0 1.327234713244252e-06
of O 0 7.227140663701448e-09
a O 0 3.263804160269501e-08
novel O 0 4.047408879159775e-07
nonsense O 0 2.082054606944439e-06
mutation O 0 2.590692815829243e-07
and O 0 1.2716965258618984e-09
a O 0 7.377249477968917e-09
missense O 0 1.3622782546462986e-07
substitution O 0 4.667830566518205e-09
in O 0 1.0908977055024138e-09
the O 0 8.274960716647684e-10
vasopressin O 0 9.549638662065263e-07
- O 0 1.9894519027729984e-06
neurophysin O 0 7.909633495728485e-06
II O 0 2.3174641228251858e-06
gene O 0 1.4335432396705983e-08
in O 0 6.63918253707152e-10
two O 0 1.049900832938988e-09
Spanish O 0 2.535137788584052e-08
kindreds O 0 6.992479484324576e-07
with O 0 8.683529983954941e-08
familial B-Disease 0 0.027610914781689644
neurohypophyseal I-Disease 1 0.9993818998336792
diabetes I-Disease 1 0.9999693632125854
insipidus I-Disease 1 0.9336917400360107
. O 0 3.1986830890673446e-06

Familial B-Disease 1 0.999626874923706
neurohypophyseal I-Disease 1 0.9999428987503052
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999557733535767
( O 0 5.162365414435044e-05
FNDI B-Disease 1 0.9999959468841553
) O 0 2.4467901482694288e-08
is O 0 1.2927192649669905e-08
an O 0 4.214872362240385e-08
autosomal B-Disease 1 0.973515510559082
dominant I-Disease 1 0.9975578784942627
disease I-Disease 1 0.7017963528633118
caused O 0 0.0012860966380685568
by O 0 4.588909632730065e-06
deficiency O 0 0.003868181724101305
in O 0 3.417064631250355e-09
the O 0 1.78827050945074e-08
antidiuretic O 0 1.384096140100155e-05
hormone O 0 2.171354481106391e-06
arginine O 0 5.67088648040226e-07
vasopressin O 0 8.256442356469051e-07
( O 0 3.3797999954288116e-09
AVP O 0 1.90086538509604e-07
) O 0 3.266360515397082e-10
encoded O 0 1.970867247180763e-09
by O 0 5.268138147940249e-10
the O 0 1.1002132538351361e-09
AVP O 0 1.9044994132855209e-06
- O 0 9.281282473239116e-06
neurophysin O 0 5.877829244127497e-05
II O 0 3.867677878588438e-05
( O 0 4.277572074329328e-09
AVP O 0 1.5591080000376678e-06
- O 0 4.3508512135304045e-06
NPII O 0 2.2889033061801456e-05
) O 0 2.6931470387125955e-09
gene O 0 2.457786685283736e-08
on O 0 3.5507813578306013e-08
chromosome O 0 1.5331836038967595e-05
20p13 O 0 1.1894298950210214e-05
. O 0 1.9271553242106165e-07

In O 0 2.3474252941468876e-07
this O 0 5.4381694702954064e-09
study O 0 2.851896718780722e-09
, O 0 2.4071589166396734e-10
we O 0 2.0399078259902836e-10
analyzed O 0 5.470357056225339e-09
two O 0 5.577885375807057e-10
families O 0 1.0669898298232283e-09
with O 0 1.419860229390224e-09
FNDI B-Disease 1 0.9995673298835754
using O 0 7.981030947235013e-09
direct O 0 2.9190931893907646e-09
automated O 0 2.426438960867472e-08
fluorescent O 0 1.8154243264234537e-07
, O 0 6.66084631895103e-10
solid O 0 7.888108832787566e-09
phase O 0 2.8690938513875608e-09
, O 0 1.4460899144808081e-09
single O 0 6.099319271868353e-09
- O 0 6.75791724802366e-08
stranded O 0 3.734298203994513e-08
DNA O 0 3.8046601424923665e-09
sequencing O 0 1.1145674383428172e-09
of O 0 1.6015327952700886e-10
PCR O 0 1.4305365994005115e-06
- O 0 2.1542100512306206e-06
amplified O 0 1.503492512711091e-05
AVP O 0 1.030613111652201e-05
- O 0 6.819825102866162e-06
NPII O 0 6.74395269015804e-05
DNA O 0 3.930109414795879e-06
. O 0 2.418233862044872e-07

In O 0 2.0274512735340977e-07
one O 0 1.0183798693219615e-08
of O 0 2.1447398024232456e-10
the O 0 5.992695228940192e-10
families O 0 4.753707205651381e-09
, O 0 1.655488635066149e-09
affected O 0 1.0867656108359824e-08
individuals O 0 6.741445179869743e-10
presented O 0 6.157905740877823e-09
a O 0 2.116716757427639e-08
novel O 0 1.3311473878729885e-07
nonsense O 0 2.2228664420254063e-07
mutation O 0 4.405898579307177e-08
in O 0 5.404158232025225e-10
exon O 0 2.245266550460201e-08
3 O 0 1.0329003208298104e-09
of O 0 5.943245201533998e-11
the O 0 3.979330753800525e-10
gene O 0 9.358966934769342e-09
, O 0 5.413887116390015e-10
consisting O 0 7.233370014070317e-10
in O 0 5.393027691091845e-10
a O 0 1.3247364094581826e-08
G O 0 4.4500266085378826e-05
to O 0 9.649999554994793e-08
T O 0 1.399007715008338e-06
transition O 0 1.157125062434261e-08
at O 0 4.586685753427133e-10
nucleotide O 0 3.843081408660964e-09
2101 O 0 7.088926423648445e-08
, O 0 5.791482293737715e-10
which O 0 8.520684713353432e-10
produces O 0 2.807676757754507e-09
a O 0 2.6898305804934353e-09
stop O 0 1.3460728531811128e-08
signal O 0 1.1440951652730291e-07
in O 0 2.9900735221133345e-09
codon O 0 1.6427198090696038e-07
82 O 0 1.7047700850980618e-07
( O 0 7.219838504823883e-09
Glu O 0 8.165847248164937e-06
) O 0 3.792878455755044e-09
of O 0 3.6986480544953793e-09
NPII O 0 7.789153460180387e-05
. O 0 3.637528322997241e-07

The O 0 8.499428076902404e-07
premature O 0 9.991876140702516e-06
termination O 0 5.266034008855058e-07
eliminates O 0 1.70221639450574e-07
part O 0 5.990744345041321e-09
of O 0 5.443147599315523e-10
the O 0 2.8253452910576016e-09
C O 0 4.6373679651878774e-07
- O 0 2.9101502150297165e-06
terminal O 0 7.1319033168038e-07
domain O 0 5.228819155433939e-09
of O 0 4.751828375226808e-10
NPII O 0 1.4648059050159645e-06
, O 0 5.0432569231873e-10
including O 0 5.835278094057372e-11
a O 0 5.54517098905194e-10
cysteine O 0 1.044864528232381e-09
residue O 0 9.261601263688135e-09
in O 0 5.769585920134546e-10
position O 0 9.398343081556959e-08
85 O 0 1.2943747407234696e-08
, O 0 5.147770543167951e-10
which O 0 9.568923431402254e-10
could O 0 1.0500796676637947e-08
be O 0 1.0361403957048765e-09
involved O 0 6.405527219754958e-10
in O 0 1.7155023235293498e-10
the O 0 3.215082367002964e-10
correct O 0 3.866641051786246e-08
folding O 0 2.1956581974791334e-07
of O 0 1.8731256545834185e-09
the O 0 1.6732794705376364e-08
prohormone O 0 5.795432662125677e-05
. O 0 3.641092689576908e-07

In O 0 1.1404447519680616e-07
the O 0 2.950478972252313e-09
second O 0 1.228913859563363e-08
family O 0 5.013451875868213e-09
, O 0 1.9621718139184452e-10
a O 0 1.7398350538044838e-09
G279A O 0 2.3170692031726503e-08
substitution O 0 1.6354900767012737e-09
at O 0 3.704506146284814e-10
position O 0 1.2716995456685254e-08
- O 0 2.17510400801757e-08
1 O 0 7.208441621386896e-10
of O 0 6.734655888518404e-11
the O 0 3.110808277639876e-10
signal O 0 8.500597203919824e-08
peptide O 0 8.707027099319475e-09
was O 0 9.031556835736865e-09
observed O 0 1.1214635886602764e-09
in O 0 1.4935390424408723e-10
all O 0 5.972395356046434e-10
affected O 0 2.267815091272496e-08
individuals O 0 9.579885329458193e-09
. O 0 7.539979662851692e-08

This O 0 1.362503326163278e-06
missense O 0 0.00033599656308069825
mutation O 0 3.544301216606982e-05
, O 0 2.029609724729653e-08
which O 0 1.4618841248648096e-08
replaces O 0 1.960376494025695e-06
Ala O 0 1.8659540046428447e-06
with O 0 2.778733509956055e-08
Thr O 0 3.7583608900604304e-06
, O 0 5.929776669688636e-09
is O 0 4.63742733103345e-09
frequent O 0 5.117838099977234e-07
among O 0 1.6626939896013937e-06
FNDI B-Disease 1 0.9999998807907104
patients O 1 0.9676403999328613
and O 0 6.350059589266266e-09
is O 0 2.6018571741559526e-09
thought O 0 1.793482140577396e-09
to O 0 6.000530072824972e-10
reduce O 0 4.659771235537846e-09
the O 0 4.126562702655434e-10
efficiency O 0 6.3468501565466795e-09
of O 0 3.725885155958508e-10
cleavage O 0 8.70796057483858e-08
by O 0 8.510781412951474e-09
signal O 0 5.818648105559987e-07
peptidases O 0 1.444376835024741e-06
. O 0 1.8282007019365665e-08
. O 0 2.789582609352692e-08

Genetic O 0 0.00011948378960369155
heterogeneity O 0 7.182840636232868e-05
of O 0 5.342100166672026e-07
Saethre B-Disease 0 0.21050094068050385
- I-Disease 1 0.9992042183876038
Chotzen I-Disease 1 0.9999536275863647
syndrome I-Disease 1 0.9999977350234985
, O 0 1.6716112938297556e-08
due O 0 6.725779932992282e-09
to O 0 1.4761740274593649e-08
TWIST O 0 4.3035011913161725e-05
and O 0 2.2856468149257125e-06
FGFR O 0 0.06366511434316635
mutations O 0 2.5348886993015185e-05
. O 0 2.340526918942487e-07

Thirty O 0 2.361079714319203e-05
- O 0 7.153563274187036e-06
two O 0 5.082351961505083e-08
unrelated O 0 6.481001832980837e-07
patients O 0 3.46068532053323e-06
with O 0 1.7933864393526733e-09
features O 0 6.550809672489777e-08
of O 0 7.739848761900703e-09
Saethre B-Disease 0 0.12967583537101746
- I-Disease 1 0.9954419136047363
Chotzen I-Disease 1 0.9998631477355957
syndrome I-Disease 1 0.9999860525131226
, O 0 2.8216617931065002e-09
a O 0 2.408584975910344e-08
common O 0 5.15805709255801e-07
autosomal B-Disease 1 0.8705044388771057
dominant I-Disease 0 0.41720423102378845
condition I-Disease 0 0.000523223599884659
of O 0 1.383331937887533e-08
craniosynostosis B-Disease 1 0.7443535327911377
and O 0 3.415687388041988e-05
limb B-Disease 1 0.9510689377784729
anomalies I-Disease 0 0.09295137971639633
, O 0 3.068886300638951e-08
were O 0 5.493184218607894e-08
screened O 0 3.4585468711156864e-07
for O 0 1.8169886706331795e-09
mutations O 0 6.493473847513087e-08
in O 0 1.3463237191757571e-09
TWIST O 0 6.904242582095321e-06
, O 0 2.713706770407498e-08
FGFR2 O 0 2.1843599824933335e-05
, O 0 5.865479213440494e-09
and O 0 1.9627538705435654e-08
FGFR3 O 0 0.00011068017192883417
. O 0 4.158726767400367e-07

Nine O 0 8.787513252173085e-06
novel O 0 8.783875387052831e-07
and O 0 1.0272896311391833e-08
three O 0 3.259441827552223e-09
recurrent O 0 7.937371151456318e-07
TWIST O 0 0.00022068944235797971
mutations O 0 1.3390035746851936e-05
were O 0 2.0351917484617843e-08
found O 0 6.976597077823499e-09
in O 0 3.0662752337207166e-09
12 O 0 4.6788859009438966e-08
families O 0 2.6829251709159507e-08
. O 0 8.470525614256985e-08

Seven O 0 6.655441779912508e-07
families O 0 7.073771257637418e-08
were O 0 4.0654257738026445e-09
found O 0 1.137504423986968e-09
to O 0 2.457082315387993e-09
have O 0 9.696804248449098e-09
the O 0 2.913408403415474e-09
FGFR3 O 0 4.420305776875466e-05
P250R O 0 9.175866466648586e-07
mutation O 0 1.0440268738420855e-07
, O 0 3.5929142994106655e-10
and O 0 6.837609922705212e-10
one O 0 1.7797424645138449e-09
individual O 0 3.548293603383712e-10
was O 0 2.480003757909799e-08
found O 0 1.0887817314397807e-09
to O 0 1.7936293561504613e-09
have O 0 4.591169222578628e-09
an O 0 6.632578930521049e-09
FGFR2 O 0 6.338682578643784e-05
VV269 O 0 2.1940600163361523e-06
- O 0 2.1430448668979807e-06
270 O 0 1.1023878414562205e-06
deletion O 0 1.8381066183792427e-05
. O 0 5.601484076578345e-07

To O 0 6.483431320702948e-07
date O 0 9.515024146367068e-08
, O 0 2.71942046659035e-09
our O 0 5.441694317376289e-10
detection O 0 4.685939192228261e-09
rate O 0 2.8506512705916975e-09
for O 0 2.7352747844489045e-10
TWIST O 0 1.022602532430028e-06
or O 0 1.7730549473071733e-08
FGFR O 0 0.00019179470837116241
mutations O 0 8.876202173269121e-07
is O 0 9.783768462057196e-09
68 O 0 8.22944912215462e-08
% O 0 7.292049186702343e-10
in O 0 3.114334901077598e-10
our O 0 6.764504512091207e-09
Saethre B-Disease 0 0.0005404843250289559
- I-Disease 1 0.9886046648025513
Chotzen I-Disease 1 0.999975323677063
syndrome I-Disease 1 0.9999996423721313
patients O 0 0.01984264887869358
, O 0 1.286942108436051e-09
including O 0 6.829229404203829e-10
our O 0 1.3022513067895147e-09
five O 0 1.4399996750569244e-08
patients O 0 1.0734898978626006e-06
elsewhere O 0 1.3511582075409478e-08
reported O 0 1.7283785069821533e-08
with O 0 3.4049765229582363e-09
TWIST O 0 0.00028990147984586656
mutations O 0 5.572304507950321e-05
. O 0 2.7911772804145585e-07

More O 0 8.023677082746872e-07
than O 0 2.3717138475376487e-08
35 O 0 1.6135722091803473e-08
different O 0 1.0473507616737265e-09
TWIST O 0 3.133780410280451e-06
mutations O 0 1.2953300938534085e-06
are O 0 3.126632730499068e-09
now O 0 3.073776122519689e-09
known O 0 2.0752441987070824e-09
in O 0 2.5702784345327245e-10
the O 0 1.1336015459662008e-09
literature O 0 2.3658223824440938e-08
. O 0 9.614284124381811e-08

The O 0 6.721127476794209e-08
most O 0 1.8359020970137863e-08
common O 0 1.4443788387552559e-08
phenotypic O 0 1.3490410992744728e-06
features O 0 1.7373561433942086e-07
, O 0 2.0308168480198674e-09
present O 0 7.021662695727571e-10
in O 0 3.258756320345668e-10
more O 0 1.0160008390158737e-09
than O 0 9.515397358939026e-10
a O 0 2.4077755345075502e-09
third O 0 4.81940309882134e-09
of O 0 3.098047929306347e-10
our O 0 6.158798804278831e-09
patients O 0 1.1529244403618577e-07
with O 0 1.7998766921323295e-09
TWIST O 0 5.198745202505961e-05
mutations O 0 3.1696797577751568e-06
, O 0 2.894002149034236e-09
are O 0 1.4451992935704538e-09
coronal B-Disease 0 1.1600714060477912e-05
synostosis I-Disease 0 3.986756564700045e-05
, O 0 9.725180660780097e-09
brachycephaly B-Disease 0 2.07191328627232e-06
, O 0 1.8580745830831802e-08
low B-Disease 0 6.0542970459209755e-06
frontal I-Disease 1 0.9998699426651001
hairline I-Disease 1 0.9999743700027466
, O 0 4.312285000196425e-06
facial B-Disease 1 0.9965534210205078
asymmetry I-Disease 0 0.05124639719724655
, O 0 9.759464774106164e-07
ptosis B-Disease 0 0.1248997375369072
, O 0 4.828045234717138e-07
hypertelorism B-Disease 0 0.0010404265485703945
, O 0 3.579020102506547e-08
broad B-Disease 0 8.537383422435596e-08
great I-Disease 0 2.534882241889136e-07
toes I-Disease 0 4.235976666677743e-05
, O 0 2.526959796966821e-08
and O 0 3.0783365190245604e-08
clinodactyly B-Disease 0 2.6604469894664362e-05
. O 0 2.1047443965471757e-07

Significant O 0 4.280543180357199e-06
intra O 0 2.508659235900268e-06
- O 0 1.5892697774688713e-05
and O 0 7.92097907265088e-08
interfamilial O 0 2.7304429750074632e-05
phenotypic O 0 6.773781933588907e-05
variability O 0 3.4473350751795806e-06
is O 0 6.49588738355078e-09
present O 0 9.567427960988084e-10
for O 0 8.562195397132655e-10
either O 0 2.4956436917022984e-08
TWIST O 0 0.00022613469627685845
mutations O 0 2.9905777410021983e-05
or O 0 1.2058599452302587e-07
FGFR O 0 0.018063385039567947
mutations O 0 7.090200233506039e-05
. O 0 3.36916286869382e-07

The O 0 1.2045910580127384e-07
overlap O 0 1.5804994291102048e-07
in O 0 1.5425561272763844e-08
clinical O 0 1.8424380243686755e-07
features O 0 6.999004398267061e-08
and O 0 2.0410024781369884e-09
the O 0 6.032949695367051e-10
presence O 0 2.4324384728657833e-09
, O 0 2.8082164371667773e-10
in O 0 1.2687158268409604e-10
the O 0 8.469996232163268e-11
same O 0 6.224029069912262e-10
genes O 0 9.608940310101843e-10
, O 0 1.0557176660652701e-10
of O 0 4.722065100049022e-11
mutations O 0 6.405016961252841e-09
for O 0 1.176337360853097e-10
more O 0 5.434630523382111e-10
than O 0 1.3322334346810294e-09
one O 0 1.3609687599114295e-08
craniosynostotic B-Disease 0 1.425508799002273e-05
condition I-Disease 0 6.152279752313916e-07
- O 0 2.7327224927375937e-08
such O 0 6.745162206556188e-10
as O 0 1.0200050581943287e-08
Saethre B-Disease 0 1.0591443242446985e-06
- I-Disease 0 5.944103804722545e-07
Chotzen I-Disease 0 2.0217605651851045e-06
, I-Disease 0 5.185436968702106e-09
Crouzon I-Disease 0 2.1627309365612746e-07
, I-Disease 0 2.593562919983583e-09
and I-Disease 0 2.352987849008059e-08
Pfeiffer I-Disease 0 7.520093640778214e-05
syndromes I-Disease 0 0.0014517729869112372
- O 0 2.6879915822064504e-06
support O 0 3.13936254769942e-08
the O 0 1.024793805370905e-09
hypothesis O 0 3.3140953092924974e-08
that O 0 1.3949441601823764e-09
TWIST O 0 4.2436911940058053e-07
and O 0 2.239881347065875e-08
FGFRs O 0 1.4256906410992087e-07
are O 0 2.752692518370736e-10
components O 0 3.197884457240008e-10
of O 0 1.8818828440014812e-11
the O 0 1.0768355651613604e-10
same O 0 1.0488900858973693e-09
molecular O 0 6.802517660275953e-09
pathway O 0 5.354471532825755e-09
involved O 0 1.3720923286442144e-09
in O 0 2.2026182266987604e-10
the O 0 7.803406254502931e-10
modulation O 0 1.7607864037927357e-06
of O 0 7.790382561267961e-09
craniofacial O 1 0.9867384433746338
and O 0 1.2700132856480195e-06
limb O 0 0.0008728888351470232
development O 0 3.3564993007217936e-09
in O 0 5.085035059693155e-09
humans O 0 2.519836606040826e-08
. O 0 8.13203371308191e-09
. O 0 4.094157191047998e-08

Mutation O 0 0.0003954872954636812
analysis O 0 1.5809034721314674e-06
of O 0 7.425207115829835e-08
UBE3A O 0 0.45427486300468445
in O 0 0.21197549998760223
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9996219873428345
. O 0 2.7876044441654813e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.005872827488929033
AS B-Disease 1 0.9998970031738281
) O 0 1.5336670600163416e-08
is O 0 2.4399394504825977e-08
caused O 0 4.055128215441073e-07
by O 0 1.5802124053720945e-08
chromosome O 0 7.747347808617633e-06
15q11 O 0 1.273489260711358e-06
- O 0 1.0475948784005595e-06
q13 O 0 5.23064727531164e-07
deletions O 0 7.606903551504729e-08
of O 0 2.0870971617625855e-09
maternal O 0 1.9120170691167004e-06
origin O 0 1.770425939184861e-08
, O 0 2.721490810486671e-09
by O 0 1.4416484006574137e-08
paternal O 0 0.0017201907467097044
uniparental B-Disease 0 0.120590940117836
disomy I-Disease 0 0.02579881064593792
( O 0 2.3308373897634738e-07
UPD B-Disease 1 0.9999772310256958
) O 0 1.6861458007610963e-08
15 O 0 5.273428804741798e-09
, O 0 1.020033613130522e-09
by O 0 1.6071213249091443e-09
imprinting O 0 0.001456302241422236
defects O 1 0.9906882047653198
, O 0 6.849752764992445e-09
and O 0 2.3023014605882963e-09
by O 0 2.598375958839938e-09
mutations O 0 8.24970669555114e-08
in O 0 1.2018475104014215e-09
the O 0 7.595649442748709e-09
UBE3A O 0 8.022007386898622e-05
gene O 0 1.7793125834941748e-06
. O 0 1.6156994320226659e-07

UBE3A O 0 0.0011939916294068098
encodes O 0 1.3151291568647139e-05
a O 0 7.90852254795027e-07
ubiquitin O 0 2.6087541300512385e-06
- O 0 1.7203967672685394e-06
protein O 0 2.0580341697495896e-07
ligase O 0 1.2302675145292596e-07
and O 0 1.7236839511269864e-08
shows O 0 7.550038816361848e-08
brain O 0 4.836164407606702e-06
- O 0 1.0441438007546822e-06
specific O 0 3.8596855489458903e-08
imprinting O 0 1.42288072311203e-05
. O 0 6.137564696473419e-07

Here O 0 9.444234478905855e-07
we O 0 7.544223734612387e-08
describe O 0 3.398147043753852e-07
UBE3A O 0 1.857617826317437e-05
coding O 0 2.5157628442684654e-06
- O 0 3.314479499749723e-06
region O 0 1.0156393415172715e-07
mutations O 0 6.61399838008947e-07
detected O 0 1.0150777285389267e-07
by O 0 3.2892628620828646e-09
SSCP O 0 4.163824542047223e-06
analysis O 0 4.54972726160463e-09
in O 0 7.508098587294398e-10
13 O 0 7.275187119404336e-09
AS B-Disease 1 0.9158660769462585
individuals O 0 3.6064007336022996e-09
or O 0 2.253249142825098e-09
families O 0 2.113086239319273e-08
. O 0 5.3446171932591824e-08

Two O 0 5.057027010479942e-07
identical O 0 3.8692829207320756e-07
de O 0 4.9753975162047936e-08
novo O 0 2.194607162664397e-07
5 O 0 1.1444297953744353e-08
- O 0 1.8783164534852403e-07
bp O 0 9.276859032070206e-07
duplications O 0 5.838693084569968e-08
in O 0 3.9842387167254856e-09
exon O 0 3.4447083407940227e-07
16 O 0 3.125418146510128e-08
were O 0 1.6346302089687015e-08
found O 0 5.693397042705328e-08
. O 0 6.00469221012645e-08

Among O 0 5.348931608750718e-07
the O 0 2.9851443539286038e-09
other O 0 5.108178324775281e-10
11 O 0 1.880033684287241e-09
unique O 0 3.928676051145885e-09
mutations O 0 3.152305509956932e-07
, O 0 3.189029929018261e-09
8 O 0 2.356642658796204e-09
were O 0 2.024497458563701e-09
small O 0 7.11414038789826e-10
deletions O 0 3.1333446059989e-08
or O 0 1.693564732896391e-09
insertions O 0 4.6949236320870114e-07
predicted O 0 5.3262865549186245e-06
to O 0 1.6101297717341367e-07
cause O 0 6.045423106115777e-06
frameshifts O 0 6.117098382674158e-05
, O 0 2.5153743532513317e-09
1 O 0 9.108257481571513e-10
was O 0 2.5207739895449777e-08
a O 0 4.3521248827005365e-09
mutation O 0 2.243036512084018e-08
to O 0 2.126476106312225e-09
a O 0 9.225617603192404e-09
stop O 0 5.2174947029470786e-08
codon O 0 1.7117288919621387e-08
, O 0 7.780771027476874e-10
1 O 0 3.1036490044655807e-10
was O 0 4.528740493725536e-09
a O 0 1.866279397688686e-08
missense O 0 1.2666672773775645e-05
mutation O 0 1.617399902897887e-07
, O 0 9.791809585379951e-10
and O 0 2.916399566288419e-09
1 O 0 5.5117470587617845e-09
was O 0 2.2798080863140058e-06
predicted O 0 5.132012574904365e-07
to O 0 1.9636864578842506e-08
cause O 0 7.667340184980276e-08
insertion O 0 2.3841593588258547e-08
of O 0 4.776390394312102e-10
an O 0 6.972074473310386e-09
isoleucine O 0 2.302273060195148e-06
in O 0 9.598279948619393e-10
the O 0 4.349732796171679e-10
hect O 0 1.3832111278588854e-07
domain O 0 2.1306902908690972e-09
of O 0 7.836305215835893e-11
the O 0 7.631514309380805e-10
UBE3A O 0 1.7636232314544031e-06
protein O 0 8.318799871176452e-09
, O 0 1.693467033270224e-10
which O 0 1.5185641633053137e-10
functions O 0 8.785875499350837e-11
in O 0 3.8745365249504005e-10
E2 O 0 2.541587491577957e-07
binding O 0 5.8371455224914826e-08
and O 0 3.9250735994755814e-09
ubiquitin O 0 2.0174776693693275e-07
transfer O 0 1.6588754192525812e-07
. O 0 1.2714114916434482e-07

Eight O 0 6.070828248994076e-07
of O 0 3.223828315412902e-09
the O 0 2.8190045853193624e-09
cases O 0 1.4412306015287868e-08
were O 0 4.3531645843586375e-08
familial O 0 5.234547643340193e-06
, O 0 3.138650228606821e-08
and O 0 9.15273989932075e-09
five O 0 9.06998387506519e-09
were O 0 2.8184198086478318e-08
sporadic O 0 2.4258617941086413e-06
. O 0 3.250274573929346e-07

In O 0 2.5461798713877215e-07
two O 0 1.9737271372832765e-08
familial O 0 6.1634177654923405e-06
cases O 0 4.32295195196275e-07
and O 0 1.3169893620101902e-08
one O 0 1.922666470477452e-08
sporadic O 0 1.41208488457778e-06
case O 0 3.03488309327804e-06
, O 0 1.7908577731873265e-08
mosaicism O 0 3.6118760817771545e-06
for O 0 1.2152592709924193e-08
UBE3A O 0 7.331626693485305e-05
mutations O 0 1.8579048628453165e-06
was O 0 1.2328867171618185e-07
detected O 0 1.6840694172515214e-08
in O 0 5.474957154305571e-10
the O 0 8.146421315302632e-10
mother O 0 9.279482071633538e-08
of O 0 2.458290515594541e-10
three O 0 2.1940374850260014e-08
AS B-Disease 1 0.9995631575584412
sons O 0 2.5410836315131746e-06
, O 0 2.898508377757736e-10
in O 0 2.1766081992335984e-10
the O 0 2.3190620535018525e-09
maternal O 0 5.94575965351396e-07
grandfather O 0 1.0667750416359922e-07
of O 0 1.1672630917392013e-10
two O 0 1.7186209122499463e-09
AS B-Disease 1 0.8149393796920776
first O 0 4.4259696352355604e-08
cousins O 0 8.988511268626098e-08
, O 0 6.162085841587839e-10
and O 0 5.949281622896763e-10
in O 0 6.145629560805332e-10
the O 0 1.0175891240749024e-09
mother O 0 1.0935131911082863e-07
of O 0 2.6887728155067236e-10
an O 0 2.392942910489637e-08
AS B-Disease 1 0.9998904466629028
daughter O 0 0.002314798068255186
. O 0 2.4098494577629026e-07

The O 0 1.16824701024143e-07
frequencies O 0 2.4901430606405484e-07
with O 0 1.4284112781481895e-09
which O 0 2.4050950120368952e-09
we O 0 2.2400170607284053e-09
detected O 0 7.506602628382097e-08
mutations O 0 7.426127268672644e-08
were O 0 6.0881610863816604e-09
5 O 0 1.3234754403512738e-09
( O 0 2.834606438462117e-10
14 O 0 3.8292524706662334e-09
% O 0 1.816298084156287e-10
) O 0 3.1725129467918833e-11
of O 0 5.4619690714741154e-11
35 O 0 2.185265746135201e-09
in O 0 7.130632750929067e-10
sporadic O 0 6.139320589682029e-07
cases O 0 2.765510771496338e-07
and O 0 3.320397112815954e-08
8 O 0 6.988490230952493e-09
( O 0 4.776754547464179e-10
80 O 0 7.2636789916202815e-09
% O 0 2.886239303112603e-10
) O 0 2.287683063817436e-11
of O 0 3.839839210484364e-11
10 O 0 5.385872858809648e-10
in O 0 1.1918944720079594e-09
familial O 0 7.83601626608288e-06
cases O 0 1.2683054819717654e-06
. O 0 4.2440831293788506e-08
. O 0 8.478397006683736e-08

The O 0 1.0035194463853259e-05
hemochromatosis B-Disease 1 0.999966025352478
845 O 0 0.00044192239874973893
G O 0 0.005333808716386557
- O 0 2.410160050203558e-05
- O 0 1.2139189493609592e-05
> O 0 1.2917462299810722e-07
A O 0 3.6150112237010035e-08
and O 0 5.300757166537551e-09
187 O 0 5.829768667808821e-08
C O 0 1.3861611591892142e-07
- O 0 5.314454028848559e-06
- O 0 0.0012319942470639944
> O 0 1.8007743847192614e-06
G O 0 0.0011153463274240494
mutations O 0 8.847721346683102e-07
: O 0 2.5019575300433416e-09
prevalence O 0 1.092610446562503e-07
in O 0 3.533322523452398e-09
non O 0 4.9805720436779666e-08
- O 0 3.9812664908822626e-05
Caucasian O 0 4.2094110540347174e-05
populations O 0 4.310523422645929e-07
. O 0 1.671336065101059e-07

Hemochromatosis B-Disease 1 0.9965389966964722
, O 0 1.4306772300187731e-06
the O 0 5.957156190561363e-07
inherited B-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999996423721313
of I-Disease 0 1.469213462002017e-08
iron I-Disease 1 0.9191285967826843
metabolism I-Disease 0 9.368788596475497e-06
, O 0 8.614619240177035e-09
leads O 0 5.895957500001714e-08
, O 0 5.37000710565394e-09
if O 0 8.170034249133096e-08
untreated O 0 0.0001779939339030534
, O 0 3.111860324978011e-09
to O 0 3.823022254323405e-08
progressive O 0 0.0028287526220083237
iron B-Disease 1 0.9943342208862305
overload I-Disease 0 0.016324156895279884
and O 0 6.107855483605817e-07
premature B-Disease 0 0.00011386031110305339
death I-Disease 0 0.0007258564000949264
. O 0 4.728182432245376e-07

The O 0 1.63259628607193e-05
hemochromatosis B-Disease 1 0.999987006187439
gene O 0 1.711173536023125e-05
, O 0 1.6376517919525213e-07
HFE O 0 4.126434578211047e-05
, O 0 4.897289684890893e-08
recently O 0 1.1568916136184271e-07
has O 0 4.4931141474080505e-08
been O 0 1.0174459497136468e-08
identified O 0 9.655040322797959e-09
, O 0 1.930476750677812e-10
and O 0 3.2564076435370737e-10
characterization O 0 8.351279667806466e-09
of O 0 4.172823198089759e-11
this O 0 5.181025608536061e-10
gene O 0 1.4812733262203892e-08
has O 0 7.59114868742472e-08
shown O 0 8.546862773073371e-09
that O 0 4.229032957159262e-10
it O 0 3.7721639700727394e-10
contains O 0 4.0697373249187763e-10
two O 0 6.126973373099531e-10
mutations O 0 1.2216526457109467e-08
that O 0 6.262539931078948e-10
result O 0 2.1666972660483452e-09
in O 0 1.2609965294174685e-09
amino O 0 5.072248399073942e-09
acid O 0 1.2141981642344035e-08
substitutions O 0 8.168129284058523e-09
- O 0 8.987187882780745e-09
cDNA O 0 4.932095265530734e-08
nucleotides O 0 3.0715803234215855e-08
845 O 0 1.588649212180826e-07
G O 0 3.0487954063573852e-06
- O 0 6.162068189041747e-07
- O 0 1.599894176251837e-06
> O 0 7.947159730292697e-08
A O 0 5.075832021361748e-08
( O 0 1.1160650181807341e-09
C282Y O 0 6.309942079951725e-08
) O 0 4.0226763586836967e-10
and O 0 1.0269638472948373e-09
187 O 0 2.6110159367931374e-08
C O 0 2.013347142337807e-07
- O 0 3.839674172922969e-05
- O 0 0.05894259363412857
> O 0 1.2639183296414558e-05
G O 0 0.001031039748340845
( O 0 1.715883612973812e-08
H63D O 0 1.2309978956182022e-05
) O 0 2.991678016428523e-08
. O 0 5.63462805303061e-08

Although O 0 0.0007486391114071012
hemochromatosis B-Disease 1 0.9999947547912598
is O 0 3.1947246270647156e-07
common O 0 1.2612472843898104e-08
in O 0 6.7648269208575584e-09
Caucasians O 0 9.275213415094186e-07
, O 0 1.7678850383617828e-08
affecting O 0 2.119868369732103e-08
> O 0 2.0804568734433815e-08
= O 0 1.6536716884729685e-08
1 O 0 3.067292864145088e-09
/ O 0 1.1790744380846263e-08
300 O 0 1.234400914817968e-09
individuals O 0 1.7297883958544702e-10
of O 0 8.196290868234257e-11
northern O 0 1.2486998102190228e-08
European O 0 3.0744036205732073e-09
origin O 0 3.926661218400795e-09
, O 0 7.858850792352712e-10
it O 0 1.2806685711908017e-09
has O 0 8.060490053196645e-09
not O 0 1.203276589478719e-09
been O 0 2.3059403275738077e-09
recognized O 0 3.2951449902007823e-10
in O 0 2.0567383907099668e-10
other O 0 7.015745207006319e-10
populations O 0 1.5958811161453923e-08
. O 0 5.5643852192588383e-08

The O 0 9.407938961203399e-08
present O 0 1.833263851835909e-08
study O 0 1.3462518877460639e-09
used O 0 2.7578861416799327e-09
PCR O 0 3.135204451609752e-07
and O 0 4.561718558449002e-09
restriction O 0 2.6033182720652803e-08
- O 0 4.013437759908811e-08
enzyme O 0 4.765909000781221e-09
digestion O 0 3.1570328573593542e-09
to O 0 3.0876831647042025e-10
analyze O 0 5.66926949829849e-10
the O 0 1.0023245428092409e-10
frequency O 0 6.092018001169208e-09
of O 0 6.028713639416594e-11
the O 0 4.991808633114658e-10
845 O 0 2.4290605438181956e-07
G O 0 5.7871096942108124e-05
- O 0 1.7569334431755124e-06
- O 0 3.2031491628004005e-06
> O 0 3.421383709678594e-08
A O 0 2.3469278076504452e-08
and O 0 3.666625447706906e-09
187 O 0 3.5440223200566834e-08
C O 0 1.1863658500033125e-07
- O 0 1.304329771301127e-06
- O 0 8.788189734332263e-05
> O 0 6.538077741424786e-07
G O 0 6.762152042938396e-05
mutations O 0 2.706811699226819e-07
in O 0 3.759474065390123e-09
HLA O 0 2.0367276647448307e-06
- O 0 1.6232735333687742e-07
typed O 0 1.2805233495782886e-07
samples O 0 7.351937281185883e-09
from O 0 3.49300227631133e-10
non O 0 2.5155710847712953e-09
- O 0 4.075490380728297e-07
Caucasian O 0 1.5629816516593564e-06
populations O 0 1.5445964507421195e-08
, O 0 8.437075482703449e-10
comprising O 0 1.5461608660061188e-09
Australian O 0 2.5653537960579342e-08
Aboriginal O 0 1.2651746317260404e-08
, O 0 2.4806068310567753e-10
Chinese O 0 3.060395548093453e-10
, O 0 1.381999403804457e-09
and O 0 5.9804126095741594e-09
Pacific O 0 1.1739312633096688e-08
Islanders O 0 7.265101658049389e-07
. O 0 8.00010084844871e-08

Results O 0 4.045200512337033e-06
showed O 0 4.934278194923536e-07
that O 0 3.765142864153859e-09
the O 0 1.2988577990924455e-09
845 O 0 5.723545655200724e-07
G O 0 0.0002019304665736854
- O 0 8.428641194768716e-06
- O 0 2.8876909709651954e-05
> O 0 6.962349630157405e-08
A O 0 6.429058174717284e-08
mutation O 0 1.770291504499255e-07
was O 0 2.8893925474449134e-08
present O 0 6.183513145963104e-10
in O 0 2.642718543999223e-10
these O 0 3.3716532343852634e-10
populations O 0 1.1942655753216513e-09
( O 0 2.680508037755658e-10
allele O 0 4.4908777141472456e-08
frequency O 0 1.074039204240762e-07
0 O 0 1.195699894651625e-08
. O 0 1.0095315694513829e-09
32 O 0 1.7165906029958933e-08
% O 0 3.220618494115257e-10
) O 0 1.3483687777426923e-10
, O 0 5.472315933729988e-10
and O 0 2.660390574504845e-09
, O 0 1.7785479755616507e-09
furthermore O 0 2.9219453523410266e-09
, O 0 1.5368514794111832e-10
it O 0 3.7587116752391125e-10
was O 0 3.018657679376702e-08
always O 0 4.516146567823398e-09
seen O 0 4.592991320606643e-09
in O 0 3.0557059660374364e-10
conjunction O 0 2.3448594177466475e-09
with O 0 9.232024034133701e-09
HLA O 0 4.529218131210655e-05
haplotypes O 0 5.819231319037499e-06
common O 0 3.225380140747802e-08
in O 0 9.568526415648648e-09
Caucasians O 0 2.988000176173955e-07
, O 0 2.8207254310075314e-09
suggesting O 0 1.4262558245548007e-08
that O 0 6.510573413720522e-09
845 O 0 2.6044861556329124e-07
G O 0 0.00016054059960879385
- O 0 1.3523770576284733e-05
- O 0 8.671156683703884e-05
> O 0 1.4698137817958923e-07
A O 0 4.114311593639286e-07
may O 0 3.5240168472228106e-07
have O 0 4.677973119981971e-09
been O 0 2.64723998277816e-09
introduced O 0 1.5291330424105354e-09
into O 0 1.7383347539201566e-10
these O 0 2.667370213593756e-10
populations O 0 6.816229247696981e-10
by O 0 1.0216106849370021e-09
Caucasian O 0 1.0241337804473005e-06
admixture O 0 3.723271674971329e-06
. O 0 4.054424493915576e-07

187 O 0 3.6533441743813455e-05
C O 0 1.0680067134671845e-05
- O 0 1.132262059400091e-05
- O 0 4.483511656871997e-05
> O 0 4.908089863420173e-07
G O 0 7.946679943415802e-06
was O 0 6.941783681213565e-08
present O 0 8.955766683804711e-10
at O 0 1.3866563453035496e-10
an O 0 1.0842060582660906e-09
allele O 0 1.514955982884203e-07
frequency O 0 2.5300222361579472e-08
of O 0 1.285136774775708e-09
2 O 0 6.588401646467901e-08
. O 0 2.5173824269586476e-07

68 O 0 0.0001467404654249549
% O 0 1.0437162956122847e-07
in O 0 1.0489760171594753e-09
the O 0 7.288683545603192e-10
two O 0 6.250013395714404e-09
populations O 0 1.1222002882504967e-08
analyzed O 0 4.6328505476367354e-08
( O 0 1.132296256756149e-09
Australian O 0 1.3585210467681463e-07
Aboriginal O 0 8.681095664542227e-08
and O 0 5.2827711094494134e-09
Chinese O 0 4.604595815749235e-09
) O 0 6.1289751052129304e-09
. O 0 6.886054393362429e-08

In O 0 3.891568098879361e-07
the O 0 1.4665928027568498e-08
Australian O 0 2.7681959835490488e-08
Aboriginal O 0 2.1440795805460766e-08
samples O 0 4.575084755487069e-09
, O 0 6.012364495155964e-10
187 O 0 1.74977294875589e-08
C O 0 8.861420752737104e-08
- O 0 1.6233893802564126e-06
- O 0 0.00010652278433553874
> O 0 4.844177965424024e-07
G O 0 7.699624802626204e-06
was O 0 5.092151766916686e-08
found O 0 1.2380887426388654e-09
to O 0 1.1076289885281199e-09
be O 0 5.15412024171269e-09
associated O 0 9.66836388727188e-09
with O 0 4.968614408795702e-09
HLA O 0 4.501333023654297e-05
haplotypes O 0 5.6338826652790885e-06
common O 0 2.1786123127753854e-08
in O 0 4.746006698752581e-09
Caucasians O 0 3.5024200428779295e-07
, O 0 1.7671794028117915e-09
suggesting O 0 9.103851006386776e-09
that O 0 8.071131540887677e-10
it O 0 1.895154699838031e-09
was O 0 2.240240348783118e-08
introduced O 0 7.84938780640232e-09
by O 0 9.087677277364037e-10
recent O 0 3.6631529809483254e-08
admixture O 0 2.41383395405137e-06
. O 0 4.0616848195895727e-07

In O 0 7.305921911893165e-08
the O 0 9.664855582514065e-10
Chinese O 0 7.39829753015897e-10
samples O 0 1.4793273273028262e-09
analyzed O 0 5.75628877896861e-09
, O 0 4.906438033636107e-10
187 O 0 1.775362790112922e-08
C O 0 9.837250303235123e-08
- O 0 1.257433723367285e-06
- O 0 0.00011816999176517129
> O 0 5.523189088307845e-07
G O 0 1.96967685042182e-05
was O 0 9.098420861164414e-08
present O 0 1.393008597361245e-09
in O 0 8.455860456280107e-10
association O 0 6.747877256962909e-10
with O 0 4.0813508128678677e-10
a O 0 1.4228485056833051e-08
wide O 0 3.8964024895449256e-08
variety O 0 6.752373771234943e-09
of O 0 2.224722628341169e-09
HLA O 0 5.276279989629984e-05
haplotypes O 0 2.6706470634962898e-06
, O 0 3.287199623613901e-09
showing O 0 1.235815094702275e-08
this O 0 4.113933915750323e-10
mutation O 0 7.28003168859459e-09
to O 0 9.838762027314374e-10
be O 0 6.2969669478718515e-09
widespread O 0 2.6168791578129458e-08
and O 0 6.885857573024623e-08
likely O 0 2.419511986317957e-07
to O 0 5.58616086721031e-09
predate O 0 6.174079203447036e-08
the O 0 7.451517736178914e-10
more O 0 1.5736487668505106e-09
genetically O 0 5.3463303117951e-08
restricted O 0 4.309487522391464e-08
845 O 0 9.746090654516593e-07
G O 0 0.0005231949035078287
- O 0 1.820216311898548e-05
- O 0 6.479417788796127e-05
> O 0 4.3873740196431754e-07
A O 0 6.507906959996035e-07
mutation O 0 4.953863026457839e-06
. O 0 9.236624975983432e-08

Genotype O 1 0.9892289638519287
- O 1 0.6226430535316467
phenotype O 1 0.8972691893577576
correlations O 0 0.0001165709036285989
in O 0 4.6287882469187025e-06
attenuated B-Disease 1 0.9978062510490417
adenomatous I-Disease 1 0.9999957084655762
polyposis I-Disease 1 0.9999198913574219
coli I-Disease 1 0.9999104738235474
. O 0 3.2959316740743816e-05

Germ O 0 0.00022639354574494064
- O 0 0.0005282263737171888
line O 0 7.247625944728497e-06
mutations O 0 2.763496240731911e-07
of O 0 6.385521000851213e-10
the O 0 7.799377144124264e-09
tumor B-Disease 0 8.214006811613217e-06
suppressor O 0 9.130755643127486e-05
APC O 0 8.348550295522728e-07
are O 0 1.2952861005999239e-08
implicated O 0 1.055348207046336e-06
in O 0 8.692790629538649e-07
attenuated B-Disease 1 0.9997957348823547
adenomatous I-Disease 1 0.9999991655349731
polyposis I-Disease 1 0.9999853372573853
coli I-Disease 1 0.9999946355819702
( O 0 1.8436472601024434e-05
AAPC B-Disease 1 0.9999852180480957
) O 0 5.871884312114162e-08
, O 0 7.1814376667589386e-09
a O 0 5.771132904897058e-08
variant O 0 8.737592725083232e-05
of O 0 6.528308063025179e-07
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999892711639404
polyposis I-Disease 1 0.9999996423721313
( O 0 1.0790387932502199e-05
FAP B-Disease 0 0.00030505063477903605
) O 0 4.830624220630853e-07
. O 0 2.8381023753354384e-07

AAPC B-Disease 1 0.9999258518218994
is O 0 6.188125098560704e-06
recognized O 0 1.063159444925077e-07
by O 0 2.2877029159928952e-09
the O 0 4.935750697043773e-10
occurrence O 0 5.380249135100712e-09
of O 0 1.4990564345396251e-09
< O 0 1.6541739000786038e-07
100 O 0 1.4608138698690709e-08
colonic B-Disease 0 7.766033377265558e-06
adenomas I-Disease 0 5.431099452835042e-06
and O 0 1.373048608144245e-08
a O 0 1.518281855794612e-08
later O 0 1.103924276435464e-07
onset O 0 1.9591541331465123e-06
of O 0 0.00010967264825012535
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.062111536498378e-07
age O 0 2.886328331896948e-07
> O 0 7.491355091815421e-08
40 O 0 2.786508801477794e-08
years O 0 1.418139650155581e-08
) O 0 1.4584363050573756e-08
. O 0 4.2122284327206216e-08

The O 0 3.016338467887181e-08
aim O 0 2.2961671675147954e-08
of O 0 2.0382276422203915e-10
this O 0 3.0064048472944194e-10
study O 0 9.334966133422995e-10
was O 0 1.1502113039796313e-08
to O 0 3.9080187974605e-09
assess O 0 1.0742855920398142e-06
genotype O 0 0.011136491782963276
- O 0 0.0034232225734740496
phenotype O 0 0.08884692192077637
correlations O 0 1.1677067050186452e-05
in O 0 8.908665449780528e-07
AAPC B-Disease 1 0.9999828338623047
families O 0 3.513638148433529e-06
. O 0 2.332500628199341e-07

By O 0 3.0183761623447936e-07
protein O 0 1.614641291780572e-07
- O 0 3.636699261733156e-07
truncation O 0 1.120953015742998e-06
test O 0 3.699744013374584e-07
( O 0 1.9319326138855786e-09
PTT O 0 1.023152265133831e-07
) O 0 1.0119413085263318e-09
assay O 0 2.1343359080105984e-08
, O 0 4.602407344123094e-10
the O 0 7.607821317368035e-11
entire O 0 1.3348940841595436e-09
coding O 0 2.0827874536166746e-08
region O 0 1.246609815375166e-09
of O 0 1.4449036411789962e-10
the O 0 8.947877994103237e-10
APC B-Disease 0 7.16694970037679e-08
gene O 0 1.484851708255519e-08
was O 0 4.417645627086131e-08
screened O 0 5.664131208504841e-08
in O 0 2.149922018190864e-09
affected O 0 9.49630951652125e-09
individuals O 0 1.2854751707536138e-09
from O 0 3.0513629400985565e-09
11 O 0 3.2260788884741487e-07
AAPC B-Disease 1 0.9999951124191284
kindreds O 0 0.00012239403440617025
, O 0 6.111593009450189e-09
and O 0 1.3394747533368445e-09
their O 0 1.8114970634641736e-09
phenotypic O 0 2.401611482127919e-06
differences O 0 4.22398272803548e-07
were O 0 2.4493215278198477e-07
examined O 0 7.91480215411866e-06
. O 0 2.0383312460126035e-07

Five O 0 1.0280421065544942e-06
novel O 0 6.373067549247935e-07
germ O 0 7.944489652800257e-07
- O 0 7.2328421083511785e-06
line O 0 2.051077672149404e-06
APC B-Disease 0 8.891079232853372e-07
mutations O 0 3.3450106684540515e-07
were O 0 1.1581893666345877e-08
identified O 0 3.5419546406956215e-08
in O 0 3.1938751643423302e-09
seven O 0 6.861446166794849e-08
kindreds O 0 1.4805884347879328e-05
. O 0 2.0857558524767228e-07

Mutations O 0 0.0029809416737407446
were O 0 6.988039444877359e-07
located O 0 1.563796558912145e-08
in O 0 9.22768861322254e-10
three O 0 1.047230857587067e-09
different O 0 2.5902002764865983e-10
regions O 0 3.0299376896358865e-10
of O 0 9.89472531687241e-11
the O 0 1.0642378089897875e-09
APC B-Disease 0 1.612345528201331e-07
gene O 0 1.4273552118027055e-08
( O 0 2.0770134223635495e-10
1 O 0 3.9256256578745763e-10
) O 0 1.7233665883242821e-10
at O 0 1.0497341190740528e-10
the O 0 1.5386229790248507e-10
5 O 0 7.160070869538515e-10
end O 0 1.5987655643812104e-09
spanning O 0 4.313646329023868e-09
exons O 0 3.8966106785665033e-08
4 O 0 2.756466388476042e-09
and O 0 1.911323321834857e-09
5 O 0 1.5601551162092164e-09
, O 0 9.84232806366947e-10
( O 0 1.5022987021051648e-10
2 O 0 5.187333895761981e-10
) O 0 1.9788592986458298e-10
within O 0 2.3184330844028267e-10
exon O 0 2.000023435755338e-08
9 O 0 4.696228739220487e-09
, O 0 7.610495011967089e-10
and O 0 1.2774532542891848e-09
( O 0 1.1443631459107095e-10
3 O 0 3.9046718636193134e-10
) O 0 1.3846161717179228e-10
at O 0 1.6092861765404365e-10
the O 0 1.8515845801037045e-10
3 O 0 2.5135182823987634e-09
distal O 0 4.046111996558466e-07
end O 0 5.14484810310023e-09
of O 0 2.6063562419409436e-10
the O 0 1.615548583799864e-09
gene O 0 1.0544192008410391e-07
. O 0 8.457464417688243e-08

Variability O 0 0.0004479036433622241
in O 0 3.6881747433881173e-08
the O 0 3.883935395521121e-09
number O 0 7.140612545697422e-09
of O 0 1.3154108557955624e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999992847442627
was O 0 0.002001919085159898
most O 0 1.3566405776543888e-08
apparent O 0 4.478043535982579e-07
in O 0 2.3379909119825015e-09
individuals O 0 6.863298818160501e-10
with O 0 1.212348443857536e-09
mutations O 0 5.9514668748761324e-08
in O 0 1.8384593847287078e-09
region O 0 2.306579105493256e-08
1 O 0 2.5966334860072493e-08
, O 0 1.3252746455805209e-08
and O 0 7.944007762716865e-08
upper O 0 0.00040461376192979515
- O 1 0.8894641995429993
gastrointestinal O 1 0.9979919195175171
manifestations O 0 7.354291938099777e-06
were O 0 1.0206651523958499e-07
more O 0 1.1195450788648031e-08
severe O 0 0.003999858163297176
in O 0 3.525011038618686e-08
them O 0 4.0575649506990885e-08
. O 0 1.0181957321719892e-07

In O 0 4.1633180103417544e-07
individuals O 0 3.848967011776949e-08
with O 0 6.384623496558106e-09
mutations O 0 1.1325889204272244e-07
in O 0 2.2971735624821576e-09
either O 0 1.4683533500203794e-08
region O 0 1.4181855689798795e-08
2 O 0 1.1637252050888947e-08
or O 0 1.63826263666067e-09
region O 0 6.172581556995738e-09
3 O 0 4.7792538815372154e-09
, O 0 3.3523389619816157e-10
the O 0 2.1369245262192749e-10
average O 0 2.6363662364303764e-09
number O 0 2.2136739663558558e-10
of O 0 1.3243282859232153e-10
adenomas B-Disease 0 2.624137209750188e-07
tended O 0 1.1158333563798806e-06
to O 0 6.180498335339735e-09
be O 0 5.951940718063042e-09
lower O 0 1.8514098698574344e-08
than O 0 1.6216056275553115e-09
those O 0 3.3196972948346115e-10
in O 0 1.8333878859522201e-10
individuals O 0 1.041684238867191e-10
with O 0 2.1742556366444177e-10
mutations O 0 2.24133014370409e-08
in O 0 8.022677522312449e-10
region O 0 4.8153050435928435e-09
1 O 0 4.257539654162201e-09
, O 0 2.6513431450325697e-09
although O 0 9.426112335120251e-09
age O 0 1.1791981613384905e-08
at O 0 2.4872028880906782e-09
diagnosis O 0 9.758629857969936e-06
was O 0 6.551065894200292e-07
similar O 0 8.999816003552041e-08
. O 0 2.433609722629626e-07

In O 0 2.5284844014095142e-06
all O 0 2.8171683652544743e-07
AAPC B-Disease 1 0.9996680021286011
kindreds O 0 9.311431495007128e-05
, O 0 1.1682398159962304e-08
a O 0 1.1478006101128813e-08
predominance O 0 7.214719630610489e-07
of O 0 1.2286349715395772e-08
right O 0 0.009990661405026913
- O 1 0.9999597072601318
sided O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999988079071045
and O 0 0.00021197061869315803
rectal B-Disease 1 0.9988358616828918
polyp I-Disease 0 0.0462036058306694
sparing O 0 1.1079718206019606e-05
was O 0 2.942370883829426e-06
observed O 0 3.9900061210573767e-07
. O 0 9.418494784085851e-08

No O 0 4.3472075049066916e-05
desmoid B-Disease 0 0.10140246152877808
tumors I-Disease 1 0.9999903440475464
were O 0 6.224782964636688e-07
found O 0 2.8407201924096626e-08
in O 0 3.654414104659054e-09
these O 0 1.4942813209017913e-08
kindreds O 0 1.3460759873851202e-05
. O 0 2.9637894272127596e-07

Our O 0 3.037984868115018e-07
data O 0 5.494305455044923e-08
suggest O 0 3.708355578169176e-08
that O 0 2.5825797056455713e-09
, O 0 3.5303922008012023e-09
in O 0 1.4876326837054421e-08
AAPC B-Disease 1 0.9999938011169434
families O 0 1.212232803027291e-07
, O 0 6.76949551969841e-10
the O 0 1.4077999876960234e-10
location O 0 1.3960834710502468e-09
of O 0 1.9518546501284817e-10
the O 0 5.279023884696699e-09
APC B-Disease 0 1.749932016537059e-05
mutation O 0 7.154123068175977e-06
may O 0 1.6255522439223569e-07
partially O 0 6.773595373488206e-07
predict O 0 4.7466838282161916e-07
specific O 0 3.673508430779293e-08
phenotypic O 0 1.861018972704187e-05
expression O 0 2.3736608909530332e-06
. O 0 1.7611746727652644e-07

This O 0 1.118587107384883e-07
should O 0 1.7001550389750264e-08
help O 0 2.5409940818121868e-09
in O 0 3.2389391169118653e-10
the O 0 2.81501627563685e-10
design O 0 6.176234279564596e-08
of O 0 3.4334692866622163e-09
tailored O 0 1.3427386875264347e-05
clinical O 0 3.977517735620495e-06
- O 0 8.459225682599936e-06
management O 0 9.4175574005817e-09
protocols O 0 4.279571363952073e-09
in O 0 2.864313508599281e-10
this O 0 1.8335556684068166e-10
subset O 0 4.555215316059957e-09
of O 0 2.0727322080915656e-09
FAP B-Disease 0 0.002608504146337509
patients O 0 0.48237305879592896
. O 0 1.730733956151198e-08
. O 0 4.364196470874049e-08

Wilms B-Disease 0 0.0769193097949028
' I-Disease 0 7.048458064673468e-05
tumor I-Disease 0 1.007439277600497e-05
1 O 0 2.8776996785495612e-08
and O 0 1.9349243984834175e-08
Dax O 0 4.6628800191683695e-05
- O 0 2.69053839474509e-06
1 O 0 2.980821633968844e-08
modulate O 0 2.9336970897020365e-07
the O 0 3.614257781947572e-09
orphan O 0 3.725562294221163e-07
nuclear O 0 5.3197815930161596e-08
receptor O 0 1.5187228541435616e-07
SF O 0 0.00014560201088897884
- O 0 3.034660949197132e-07
1 O 0 4.227930006095448e-09
in O 0 7.237566101991888e-10
sex O 0 1.0726425969664888e-08
- O 0 5.749817688638359e-08
specific O 0 3.4956502137362122e-09
gene O 0 8.16923915181178e-08
expression O 0 1.94628455574275e-07
. O 0 1.000580098775572e-07

Products O 0 2.029911684076069e-06
of O 0 1.7794276274685217e-08
steroidogenic O 0 4.8215761125902645e-06
factor O 0 8.227204517652353e-08
1 O 0 1.6601280350414527e-08
( O 0 8.997684375344761e-09
SF O 0 0.28688573837280273
- O 0 2.358484925935045e-05
1 O 0 4.1754486090894716e-08
) O 0 2.8490640957556934e-09
and O 0 8.012698771153737e-08
Wilms B-Disease 0 0.0005977135733701289
tumor I-Disease 0 1.4334250408865046e-05
1 O 0 2.525678155507194e-08
( O 0 2.4723183500441337e-09
WT1 O 0 1.2317954087848193e-06
) O 0 5.055507679152527e-10
genes O 0 1.640157232252193e-09
are O 0 8.885355645693593e-11
essential O 0 1.7148871211958294e-10
for O 0 1.6967001414958105e-10
mammalian O 0 2.3576465224550702e-08
gonadogenesis O 0 4.893937557426398e-07
prior O 0 5.794866808628285e-09
to O 0 5.404089176153093e-09
sexual O 0 3.63679610870804e-08
differentiation O 0 1.849395232511597e-07
. O 0 1.4916464863290457e-07

In O 0 1.5762592511237017e-06
males O 0 1.662248337197525e-06
, O 0 5.148326209791776e-08
SF O 0 0.003664373653009534
- O 0 5.690753823728301e-06
1 O 0 2.104511054312752e-08
participates O 0 4.272296294516309e-09
in O 0 8.853015542875653e-10
sexual O 0 1.0487980484086279e-09
development O 0 8.296323350531765e-11
by O 0 1.6871286312447609e-10
regulating O 0 1.1065146132693826e-08
expression O 0 7.319392203442021e-09
of O 0 3.0728192212947647e-10
the O 0 2.9160991399379554e-09
polypeptide O 0 2.143120354958228e-06
hormone O 0 9.97411120806646e-07
Mullerian O 0 2.1613507215079153e-06
inhibiting O 0 9.14088673198421e-07
substance O 0 8.558070021535968e-07
( O 0 2.816544331096793e-08
MIS O 0 8.191313099814579e-06
) O 0 9.7606779547732e-08
. O 0 2.4515836116734135e-07

Here O 0 1.0399442089692457e-06
, O 0 1.757553214076779e-08
we O 0 1.6196705088233898e-09
show O 0 9.297407288499926e-09
that O 0 5.577919903743123e-09
WT1 O 0 1.5623048966517672e-05
- O 0 5.939751190453535e-06
KTS O 0 1.833163150877226e-05
isoforms O 0 1.3513661656361364e-07
associate O 0 1.5295304578444302e-08
and O 0 3.592313335687436e-09
synergize O 0 4.465629501737567e-07
with O 0 3.9256743633586666e-08
SF O 1 0.6872044801712036
- O 0 7.636247573827859e-06
1 O 0 8.525501193901164e-09
to O 0 7.79933273520328e-09
promote O 0 6.001577190772878e-08
MIS O 0 1.9904553482774645e-05
expression O 0 1.921557441164623e-06
. O 0 1.1764219465248971e-07

In O 0 2.076367536574253e-06
contrast O 0 4.308149982534815e-06
, O 0 2.059194486037086e-07
WT1 O 0 0.00028316432144492865
missense O 0 0.00025915823061950505
mutations O 0 9.815847079153173e-06
, O 0 1.227166457340445e-08
associated O 0 2.7059126495032615e-08
with O 0 5.448700335364265e-08
male B-Disease 0 0.003437971230596304
pseudohermaphroditism I-Disease 1 0.9999929666519165
in O 0 3.0259038794611115e-06
Denys B-Disease 1 0.9882981181144714
- I-Disease 1 0.9995563626289368
Drash I-Disease 1 0.9999164342880249
syndrome I-Disease 1 0.999991774559021
, O 0 1.3690605982219495e-08
fail O 0 1.5394735441986995e-07
to O 0 2.011880262386967e-08
synergize O 0 5.297634743328672e-06
with O 0 3.721939947354258e-07
SF O 1 0.9664556384086609
- O 0 8.7660679128021e-05
1 O 0 2.446755900109565e-07
. O 0 6.091485715842282e-08

Additionally O 0 4.13618317907094e-06
, O 0 1.9720113542120998e-08
the O 0 1.8588146577513953e-09
X O 0 5.030277679907158e-05
- O 0 5.3909818234387785e-05
linked O 0 1.409549167874502e-05
, O 0 6.966650811790487e-09
candidate O 0 7.804128188126924e-08
dosage O 0 8.849619916873053e-07
- O 0 3.049410111088946e-07
sensitive O 0 9.998017702628204e-08
sex O 0 6.892558701565576e-08
- O 0 1.4093335209963698e-07
reversal O 0 4.5100716761226067e-07
gene O 0 4.261035613239983e-08
, O 0 3.188348696170351e-09
Dax O 0 6.215425855771173e-06
- O 0 7.917412290225911e-07
1 O 0 1.617115330532215e-08
, O 0 2.1357804413923986e-09
antagonizes O 0 4.945952696289169e-07
synergy O 0 6.589608148033221e-08
between O 0 5.9431375376561846e-09
SF O 0 0.36855268478393555
- O 0 1.6079633496701717e-05
1 O 0 2.957906808376265e-08
and O 0 1.7611034408560045e-08
WT1 O 0 4.416872343426803e-06
, O 0 2.3953117267438984e-09
most O 0 1.1226278795462008e-09
likely O 0 3.0440732157188677e-09
through O 0 1.3883924565583072e-10
a O 0 2.4289845690361744e-09
direct O 0 4.573732503843075e-09
interaction O 0 5.2554152141226496e-09
with O 0 1.7210952663049284e-08
SF O 1 0.9167534112930298
- O 0 0.00013826687063556165
1 O 0 3.168811133491545e-07
. O 0 1.38299483865012e-07

We O 0 3.067561351599579e-07
propose O 0 3.066970464260521e-07
that O 0 2.993630232595024e-08
WT1 O 0 4.801936029252829e-06
and O 0 7.582769967484637e-08
Dax O 0 6.160640623420477e-05
- O 0 3.3250223623326747e-06
1 O 0 3.850934859883637e-08
functionally O 0 2.0121417776408634e-07
oppose O 0 2.884607397390937e-08
each O 0 3.5794259223287384e-10
other O 0 2.4072321913592987e-10
in O 0 1.3428974598994614e-09
testis O 0 4.2068612060575106e-07
development O 0 1.5102115114018488e-09
by O 0 6.568648736049454e-09
modulating O 0 9.093299922824372e-06
SF O 0 0.491252064704895
- O 0 1.5694216926931404e-05
1 O 0 4.885357185457906e-08
- O 0 1.293207105845795e-06
mediated O 0 1.0020781701314263e-05
transactivation O 0 2.1297777493600734e-05
. O 0 2.7665596036285933e-08
. O 0 4.0478326468473824e-08

A O 0 7.650753104826435e-06
mouse O 0 2.6833178708329797e-05
model O 0 1.3657186173077207e-05
for O 0 6.036056220182218e-06
Prader B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
imprinting O 0 0.004155706614255905
- O 0 0.013911212794482708
centre O 0 2.174736619053874e-05
mutations O 0 2.3993745344341733e-05
. O 0 2.1560566665357328e-07

Imprinting O 0 0.00017472999752499163
in O 0 2.0068638661996374e-07
the O 0 1.7332048685148038e-08
15q11 O 0 1.5436266949109267e-06
- O 0 9.045142519426008e-07
q13 O 0 1.120141973842692e-06
region O 0 1.1586401171825855e-08
involves O 0 1.5534918906823236e-09
an O 0 1.460668253017161e-09
imprinting O 0 5.726395215788216e-07
centre O 0 8.356111180773951e-08
( O 0 7.495907783372502e-10
IC O 0 1.5355117000126484e-07
) O 0 1.349774292336292e-09
, O 0 4.4073900085095374e-10
mapping O 0 1.589370524079925e-09
in O 0 1.799662918688938e-10
part O 0 3.038619078576943e-10
to O 0 5.836727767771777e-10
the O 0 5.03991071099108e-10
promoter O 0 1.841935528545946e-07
and O 0 4.010405341148271e-09
first O 0 8.16138534531774e-09
exon O 0 1.1660698362447874e-07
of O 0 9.452271854115679e-09
SNRPN O 0 8.463281119475141e-05
. O 0 3.0361661629285663e-07

Deletion O 0 3.54993280780036e-05
of O 0 1.6055533791359267e-08
this O 0 1.0593859123275706e-08
IC O 0 2.085333107970655e-06
abolishes O 0 1.4714742974319961e-05
local O 0 9.778413634364824e-09
paternally O 0 2.384755930506799e-07
derived O 0 7.894430886778991e-09
gene O 0 1.5275071874043533e-08
expression O 0 1.6377260436684082e-08
and O 0 3.835348483249845e-09
results O 0 2.6896586291513813e-07
in O 0 5.80339074076619e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.1482130503281951e-05
PWS B-Disease 1 0.9999732971191406
) O 0 9.571083410264691e-07
. O 0 5.756685936830763e-07

We O 0 5.046062483415881e-07
have O 0 3.6753938559286325e-08
created O 0 7.235775090208563e-09
two O 0 2.604628068780812e-09
deletion O 0 1.110718244490272e-06
mutations O 0 4.970730742570595e-07
in O 0 4.891340221746532e-09
mice O 0 2.1293044483172707e-05
to O 0 1.1107250941222446e-07
understand O 0 3.395217936486006e-05
PWS B-Disease 1 0.9999947547912598
and O 0 1.038950969700636e-08
the O 0 1.374753089145031e-10
mechanism O 0 6.421037590520484e-10
of O 0 2.7381927281133756e-10
this O 0 4.195892522318445e-09
IC O 0 9.039760698215105e-06
. O 0 2.6891018478636397e-07

Mice O 0 0.014118079096078873
harbouring O 0 5.3952499001752585e-05
an O 0 1.1480484829462512e-07
intragenic O 0 5.156742190592922e-06
deletion O 0 1.4858595704936306e-06
in O 0 1.3532215348277532e-08
Snrpn O 0 3.872135948768118e-06
are O 0 2.0952787949113372e-08
phenotypically O 0 1.6419022358604707e-05
normal O 0 1.767463508883793e-08
, O 0 1.2160562556928767e-09
suggesting O 0 1.3753314931364002e-08
that O 0 3.980395568703443e-09
mutations O 0 1.673451954786742e-08
of O 0 2.4750254623562284e-10
SNRPN O 0 4.861264187638881e-06
are O 0 1.3969837509009153e-09
not O 0 2.3976931551317193e-09
sufficient O 0 1.6393636670386513e-08
to O 0 1.1801932231492174e-07
induce O 0 0.0003008113126270473
PWS B-Disease 1 0.9999889135360718
. O 0 7.756840204820037e-06

Mice O 0 0.0012851390056312084
with O 0 5.1028955283527466e-08
a O 0 2.7195257601420053e-08
larger O 0 1.3562472922501456e-08
deletion O 0 1.4756679433958197e-07
involving O 0 8.536468421027621e-09
both O 0 1.696184170896231e-08
Snrpn O 0 1.7515413901492138e-06
and O 0 1.1960328727411706e-08
the O 0 6.514648376310106e-09
putative O 0 5.715504812542349e-05
PWS O 1 0.999990701675415
- O 0 0.0011054271599277854
IC O 0 3.051375097129494e-05
lack O 0 1.4954966331970354e-07
expression O 0 2.020170342120764e-08
of O 0 1.8657508871200434e-10
the O 0 5.969628125157556e-10
imprinted O 0 1.0474470855115214e-06
genes O 0 5.163490257587e-08
Zfp127 O 0 4.528151009708381e-07
( O 0 8.34852020847876e-10
mouse O 0 5.300456962231692e-08
homologue O 0 4.1798313077379134e-07
of O 0 4.892133365075324e-09
ZNF127 O 0 1.4525195183523465e-05
) O 0 3.204352116981113e-09
, O 0 4.183210666752757e-09
Ndn O 0 7.601499305565085e-07
and O 0 6.756560644305409e-09
Ipw O 0 6.481818104475678e-07
, O 0 4.917655171965407e-09
and O 0 3.4089535638770485e-09
manifest O 0 3.767947021060536e-07
several O 0 1.813233296843464e-08
phenotypes O 0 3.3082269510487095e-06
common O 0 7.97385197870426e-08
to O 0 3.5024491808144376e-05
PWS B-Disease 1 0.9999998807907104
infants O 1 0.9994169473648071
. O 0 8.802592788015318e-07

These O 0 2.376077219423678e-07
data O 0 2.567889900717546e-08
demonstrate O 0 2.7954575543276405e-08
that O 0 1.4850634055818546e-09
both O 0 2.858866476884714e-10
the O 0 1.6569093319596107e-10
position O 0 7.3865416005958195e-09
of O 0 1.2269966986888647e-10
the O 0 4.3784834091731284e-10
IC O 0 1.1546982392474092e-07
and O 0 3.5242968543514053e-09
its O 0 4.286611066106616e-10
role O 0 1.3031009604702604e-09
in O 0 1.3725837133549135e-10
the O 0 1.2707793151101043e-10
coordinate O 0 7.48508188763708e-09
expression O 0 8.974015308638172e-09
of O 0 6.131155305677538e-11
genes O 0 2.370364793335966e-09
is O 0 5.273587122545109e-10
conserved O 0 1.3852428093485969e-09
between O 0 2.7002644564788625e-10
mouse O 0 8.186396627252179e-08
and O 0 4.7927093405064625e-09
human O 0 5.855460560866277e-10
, O 0 5.592341034699189e-10
and O 0 2.225095885322048e-09
indicate O 0 9.991799387876199e-09
that O 0 4.5537876247614406e-10
the O 0 1.04050872085093e-10
mouse O 0 2.318470748718937e-08
is O 0 1.4846441853677561e-09
a O 0 2.4542814447414685e-09
suitable O 0 2.146305355665845e-08
model O 0 1.266935498733801e-07
system O 0 2.9277305024777434e-09
in O 0 3.7857214585379495e-10
which O 0 1.2972707352787438e-09
to O 0 1.3898980855131526e-09
investigate O 0 4.264594899439089e-09
the O 0 2.906896112708779e-10
molecular O 0 1.8594032979990516e-09
mechanisms O 0 2.627168760316323e-10
of O 0 4.415355928100162e-11
imprinting O 0 6.799549367997315e-08
in O 0 8.866196665735515e-10
this O 0 3.310610952045323e-10
region O 0 8.794783235011039e-10
of O 0 9.07817918061049e-11
the O 0 4.1158723651513185e-10
genome O 0 6.683999576040378e-09
. O 0 3.2790337112231782e-09
. O 0 2.642912555472776e-08

Mutations O 0 0.00016274851805064827
of O 0 2.051240244327346e-08
the O 0 4.818998977640376e-09
ATM O 0 2.549134308083012e-07
gene O 0 2.1783385761864338e-07
detected O 0 2.4516725716239307e-07
in O 0 1.0112279014151682e-08
Japanese O 0 0.0005939402035437524
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9999821186065674
: O 0 6.551307052404809e-09
possible O 0 5.06014075085659e-09
preponderance O 0 1.84126818680852e-07
of O 0 2.3263709014731404e-10
the O 0 6.513873884728127e-10
two O 0 4.7804027403230975e-09
founder O 0 7.62071977078449e-07
mutations O 0 4.482777740122401e-07
4612del165 O 0 8.979487233773398e-07
and O 0 5.3761691987119775e-08
7883del5 O 0 6.810193553974386e-06
. O 0 1.3694764788851899e-07

The O 0 2.387623112554138e-07
ATM O 0 1.778052251211193e-06
( O 0 1.0504465564054044e-07
A O 1 0.9996724128723145
- O 1 0.9998677968978882
T O 1 0.999998927116394
, O 0 5.734353436537276e-08
mutated O 0 3.2282670758831955e-07
) O 0 1.0645241355078383e-09
gene O 0 9.296147851500791e-09
on O 0 2.7770115096359405e-08
human O 0 5.830925076111271e-08
chromosome O 0 3.648591518867761e-05
11q22 O 0 1.3594451047538314e-05
. O 0 2.858526499949221e-07

3 O 0 5.322468041413231e-06
has O 0 2.4651791363794473e-07
recently O 0 3.557105898721602e-08
been O 0 4.930136299208243e-09
identified O 0 3.619038180247003e-09
as O 0 2.2497526064313433e-10
the O 0 1.1723146065012457e-10
gene O 0 3.930242797878236e-09
responsible O 0 2.0817221280111653e-09
for O 0 2.851884284282846e-10
the O 0 4.068652526001415e-09
human O 0 2.4636451598780695e-06
recessive B-Disease 1 0.9999803304672241
disease I-Disease 1 0.9999923706054688
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 1.966474883374758e-05
A B-Disease 1 0.9999966621398926
- I-Disease 1 0.9999804496765137
T I-Disease 1 0.9999974966049194
) O 0 2.944528034731775e-07
. O 0 1.3943602539256972e-07

In O 0 1.631032233717633e-07
order O 0 1.634767521352387e-08
to O 0 2.7826780879536273e-09
define O 0 2.8454975264935456e-08
the O 0 7.843726224088243e-10
types O 0 7.690111658575915e-09
of O 0 2.353686801015442e-09
disease O 0 1.2103296285204124e-05
- O 0 5.980477362754755e-05
causing O 0 2.0087952634639805e-06
ATM O 0 5.94524919961259e-07
mutations O 0 1.8388676892300282e-07
in O 0 2.406435051227618e-09
Japanese O 0 1.8580752225716424e-07
A B-Disease 1 0.9999866485595703
- I-Disease 1 0.9999953508377075
T I-Disease 1 1.0
patients O 1 0.770902693271637
as O 0 8.52033110732009e-09
well O 0 9.59590074067762e-10
as O 0 8.08740463487112e-10
to O 0 1.0872086564361894e-09
look O 0 5.035224681648742e-09
for O 0 4.0951525503984954e-10
possible O 0 3.2748836975571294e-09
mutational O 0 2.3600478016305715e-06
hotspots O 0 1.630155281873158e-07
, O 0 2.149196376421969e-09
reverse O 0 3.8293686088763934e-07
- O 0 7.924422789074015e-07
transcribed O 0 8.587636557422229e-08
RNA O 0 9.437067127748833e-09
derived O 0 1.9449803989601833e-09
from O 0 3.0759975122585104e-10
ten O 0 4.176776702280449e-09
patients O 0 3.0585898258550515e-08
belonging O 0 9.583353000053307e-10
to O 0 1.6173490324788986e-09
eight O 0 5.94788929220158e-09
unrelated O 0 2.813392896428013e-08
Japanese O 0 1.0879066536517712e-07
A B-Disease 1 0.9975636005401611
- I-Disease 1 0.9983428716659546
T I-Disease 1 0.9999985694885254
families O 0 2.3704753004949453e-07
was O 0 1.3961673062112823e-07
analyzed O 0 1.6494126953148225e-08
for O 0 5.897233812390823e-10
mutations O 0 9.27218835045096e-09
by O 0 1.8535456502988268e-10
the O 0 1.0364368252524514e-09
restriction O 0 2.958215361559269e-07
endonuclease O 0 8.705270374775864e-06
fingerprinting O 0 1.931878387040342e-06
method O 0 8.365820463041018e-07
. O 0 1.2082796274626162e-07

As O 0 1.1925894796149805e-06
has O 0 1.0275643091972597e-07
been O 0 2.211696781273531e-08
reported O 0 7.245607669403853e-09
by O 0 5.158169447128103e-10
others O 0 7.593911277581356e-09
, O 0 6.877398095461729e-10
mutations O 0 1.0653309345798334e-08
that O 0 1.0660480276314388e-09
lead O 0 1.4684514049179143e-08
to O 0 1.0319320509211138e-08
exon O 0 2.1444152764615865e-07
skipping O 0 9.244132570529473e-08
or O 0 7.225072984340386e-09
premature O 0 1.940516796139491e-07
protein O 0 1.314813324881925e-08
truncation O 0 1.3013462307753798e-07
were O 0 9.344432783109369e-08
also O 0 2.4659476238753086e-08
predominant O 0 1.1701470015168525e-07
in O 0 1.916127034817805e-09
our O 0 1.039724040197143e-08
mutants O 0 2.0054608285136055e-06
. O 0 1.331403893800598e-07

Six O 0 1.415787664882373e-06
different O 0 3.5077274418426896e-08
mutations O 0 2.0349790474938345e-07
were O 0 1.0331767441584816e-08
identified O 0 1.43870373392474e-08
on O 0 4.3470307353743465e-09
12 O 0 1.8040354765602729e-09
of O 0 1.585793579783612e-10
the O 0 2.2232888863271683e-09
16 O 0 6.944326003122114e-08
alleles O 0 3.362005713825056e-07
examined O 0 4.9411391955800354e-06
. O 0 2.0058556060575938e-07

Four O 0 2.228425444172899e-07
were O 0 1.2133831717164867e-08
deletions O 0 9.302181780412866e-08
involving O 0 1.6031879823685813e-08
a O 0 1.340889497214448e-07
loss O 0 2.939163437076786e-07
of O 0 6.690412113208311e-10
a O 0 2.2383396469649597e-08
single O 0 1.0966420660452059e-07
exon O 0 2.795405009692331e-07
exon O 0 2.9883821639486996e-07
7 O 0 1.7891302661610098e-08
, O 0 2.785779384950615e-09
exon O 0 9.428614333728547e-08
16 O 0 1.1770207031247537e-08
, O 0 1.24933763334667e-09
exon O 0 1.0337408440364015e-07
33 O 0 4.0574022364125994e-08
or O 0 3.981921903317698e-09
exon O 0 6.176941838020866e-07
35 O 0 2.739967328579951e-07
. O 0 8.373565663077898e-08

The O 0 5.918931833548413e-07
others O 0 1.3001168497339677e-07
were O 0 6.721368350781631e-09
minute O 0 3.171821916225781e-08
deletions O 0 2.5696004968267516e-07
, O 0 6.7896586131155345e-09
4649delA O 0 1.463360632669719e-07
in O 0 4.354889782121063e-09
exon O 0 1.8890482067490666e-07
33 O 0 8.142963991986107e-08
and O 0 5.594466667702136e-09
7883del5 O 0 1.7347434777548187e-07
in O 0 7.151939485083858e-09
exon O 0 1.056258497555973e-06
55 O 0 4.2405636691000836e-07
. O 0 5.569598826582478e-08

The O 0 5.856745133314689e-07
mutations O 0 5.49365222468623e-06
4612del165 O 0 1.6032879557315027e-06
and O 0 1.9047663002424997e-08
7883del5 O 0 1.580849158244746e-07
were O 0 8.508021842601465e-09
found O 0 8.382809446594308e-10
in O 0 8.69042615647686e-11
more O 0 2.7595475904362843e-10
than O 0 6.239790351081353e-10
two O 0 6.561420295980724e-10
unrelated O 0 2.1001643091267397e-08
families O 0 5.125924573690099e-09
; O 0 1.6729596596931628e-09
44 O 0 3.4656906677810184e-08
% O 0 6.745058955814898e-10
( O 0 9.570579745377117e-11
7 O 0 1.0142909845356485e-09
of O 0 2.024195255856398e-10
16 O 0 1.2064087506757915e-09
) O 0 5.185441659394385e-11
of O 0 4.694737307242569e-11
the O 0 4.841439471547915e-10
mutant O 0 2.8515617600533005e-07
alleles O 0 1.7070437507982206e-08
had O 0 8.995727718286162e-09
one O 0 1.9229945413812288e-10
of O 0 2.102982891993843e-11
the O 0 5.019878956957768e-10
two O 0 9.587489913087666e-09
mutations O 0 6.248430395316973e-07
. O 0 7.817237701601698e-08

The O 0 1.8992271577644715e-07
4612del165 O 0 2.233134409834747e-06
mutations O 0 2.9196414175203245e-07
in O 0 1.131201909920776e-09
three O 0 4.263705777329818e-10
different O 0 3.4386121727791874e-10
families O 0 6.54695686552742e-10
were O 0 1.3752206040607007e-09
all O 0 1.166697710663911e-10
ascribed O 0 1.0616473034019691e-08
to O 0 3.956643013225403e-09
the O 0 1.5623825566635219e-09
same O 0 1.7114187400579794e-08
T O 0 9.595796655048616e-07
- O 0 3.584711123494344e-07
- O 0 8.900665875444247e-07
> O 0 7.773403254418554e-09
A O 0 2.3688688788325862e-09
substitution O 0 1.5512652273841354e-09
at O 0 1.0304145731110381e-10
the O 0 1.2428959250687655e-10
splice O 0 1.008666217217069e-07
donor O 0 6.9423502502274914e-09
site O 0 1.2594779441599258e-08
in O 0 4.093140049121757e-09
intron O 0 3.262047175667249e-05
33 O 0 7.609702947775077e-07
. O 0 8.731976919307272e-08

Microsatellite O 0 0.0007970439619384706
genotyping O 0 0.0001734625839162618
around O 0 3.544361106833094e-07
the O 0 4.937655617709424e-09
ATM O 0 7.283841085836684e-08
locus O 0 2.852938223441015e-07
also O 0 5.3635403673979454e-08
indicated O 0 4.7855323259682336e-08
that O 0 7.211617969460349e-10
a O 0 1.4445991070033415e-08
common O 0 1.577195973823109e-07
haplotype O 0 0.023496538400650024
was O 0 2.616640585983987e-06
shared O 0 1.2103084090497873e-09
by O 0 2.127148457375938e-10
the O 0 2.5476801224222356e-10
mutant O 0 2.108573653458734e-07
alleles O 0 5.7185157942285514e-08
in O 0 2.510394558896678e-09
both O 0 4.107171847067548e-08
mutations O 0 1.9912818061129656e-06
. O 0 2.882941601001221e-07

This O 0 1.6835515737056994e-07
suggests O 0 6.235037375290631e-08
that O 0 4.266984265921536e-10
these O 0 1.310923175568135e-10
two O 0 6.860327306235092e-10
founder O 0 3.1154254998000397e-07
mutations O 0 2.0183667004403105e-07
may O 0 4.927215613292901e-08
be O 0 3.8783238842654555e-09
predominant O 0 1.0897112900920547e-07
among O 0 1.3263209419633881e-09
Japanese O 0 1.3008270016712231e-08
ATM O 0 2.406955559308699e-07
mutant O 0 2.8057406780135352e-06
alleles O 0 1.4580645029127481e-06
. O 0 2.5579743123671506e-07

W474C O 0 0.00010502558870939538
amino O 0 1.8178511709265877e-06
acid O 0 5.553082473852555e-07
substitution O 0 4.9794227408028746e-08
affects O 0 5.302762673409234e-08
early O 0 1.3574551482875563e-09
processing O 0 4.3473022404150186e-10
of O 0 4.1675975170907265e-11
the O 0 7.958205622271564e-11
alpha O 0 1.2794113546377162e-09
- O 0 2.5695445771134473e-09
subunit O 0 8.36359703715317e-10
of O 0 3.92141770444443e-11
beta O 0 9.553258184524793e-10
- O 0 2.6047684897889667e-08
hexosaminidase O 0 3.1557948432237026e-07
A O 0 2.3691638872946896e-08
and O 0 3.916750035415362e-09
is O 0 1.0936191507937565e-08
associated O 0 3.095977874068012e-08
with O 0 7.554288572464429e-08
subacute O 1 0.9849001169204712
G B-Disease 1 0.8285465836524963
( I-Disease 0 3.410580973195465e-08
M2 I-Disease 0 1.96777114069846e-06
) I-Disease 0 1.029606622182655e-07
gangliosidosis I-Disease 0 3.88137050322257e-05
. O 0 2.646050916155218e-07

Mutations O 0 0.0011167182819917798
in O 0 1.5866339708736632e-07
the O 0 1.5320004820296163e-08
HEXA O 0 3.788195317611098e-05
gene O 0 1.8292406878117617e-07
, O 0 1.0747022161083919e-09
encoding O 0 2.2344781580585504e-09
the O 0 2.1348263434806114e-10
alpha O 0 1.3507993612549285e-09
- O 0 2.824257050448864e-09
subunit O 0 1.2825607242916703e-09
of O 0 1.3061859926999375e-10
beta O 0 3.391003255970304e-09
- O 0 1.559927511607384e-07
hexosaminidase O 0 9.155141924566124e-07
A O 0 1.1057935012104281e-07
( O 0 1.290038631474033e-09
Hex O 0 1.8913159749445185e-07
A O 0 7.611316021893799e-08
) O 0 1.0179423970413382e-09
, O 0 4.3174472330598235e-10
that O 0 9.937664025017057e-10
abolish O 0 6.513432992960588e-08
Hex O 0 1.491131627062714e-07
A O 0 6.267299124118608e-09
enzyme O 0 2.6421465904036268e-08
activity O 0 2.4486157101932804e-08
cause O 0 0.0006343983695842326
Tay B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
Sachs I-Disease 1 1.0
disease I-Disease 1 0.6656258702278137
( O 0 1.983410768957583e-08
TSD B-Disease 0 1.2764726307068486e-05
) O 0 2.2463320092924732e-09
, O 0 7.284750580538457e-10
the O 0 1.1239948971564218e-09
fatal O 0 0.0005105587770231068
infantile B-Disease 0 0.0002994164533447474
form I-Disease 0 9.581479076814503e-08
of I-Disease 0 5.165181615751635e-09
G I-Disease 0 0.007340696174651384
( I-Disease 0 8.378801652497714e-09
M2 I-Disease 0 3.1704917091701645e-07
) I-Disease 0 4.333338576856249e-09
gangliosidosis I-Disease 0 1.0180301615037024e-06
, I-Disease 0 5.320631046856761e-09
Type I-Disease 0 7.581728311834013e-08
1 I-Disease 0 2.5654516733197852e-08
. O 0 1.2376094105093216e-07

Less O 0 0.0002467832819093019
severe O 1 0.5558801889419556
, O 0 6.710021693834278e-07
subacute O 0 0.07899007201194763
( O 0 8.756695279998894e-08
juvenile O 0 0.0014721626648679376
- O 0 0.015042515471577644
onset O 0 5.627521386486478e-05
) O 0 3.580316842999309e-08
and O 0 6.408724857465131e-06
chronic O 1 0.9930949807167053
( O 0 6.188533774320604e-08
adult O 0 6.404168379958719e-05
- O 0 0.00014764432853553444
onset O 0 5.645790224662051e-06
) O 0 6.172805822046712e-09
variants O 0 5.777652845040393e-08
are O 0 2.737833737498363e-09
characterized O 0 3.366734091514445e-08
by O 0 1.7122472328878757e-09
a O 0 2.6371418826443005e-08
broad O 0 3.0650198823423125e-07
spectrum O 0 7.120974601093621e-07
of O 0 1.5869260350243053e-09
clinical O 0 2.2107738573140523e-07
manifestations O 0 1.250850374390211e-07
and O 0 6.192935941840005e-09
are O 0 1.3857555103413688e-09
associated O 0 3.3712113101103114e-09
with O 0 1.5745824644142203e-09
residual O 0 1.344626161881024e-05
levels O 0 4.38049019280129e-09
of O 0 2.1890109169753202e-10
Hex O 0 2.194096708763027e-07
A O 0 3.71459236703231e-08
enzyme O 0 7.801701684684303e-08
activity O 0 3.2685949946653636e-08
. O 0 5.662964497332723e-08

We O 0 1.4155392591419513e-06
identified O 0 4.83056396660686e-07
a O 0 1.0907552194794334e-07
1422 O 0 1.1468351658550091e-05
G O 0 0.0004073200689163059
- O 0 3.553316855686717e-05
- O 0 0.00042541592847555876
> O 0 1.532011424387747e-06
C O 0 1.60023134299081e-07
( O 0 1.5154862920141454e-09
amino O 0 2.9646549659645416e-09
acid O 0 1.0143456741218415e-08
W474C O 0 7.2236678860804204e-09
) O 0 6.5319111230977e-11
substitution O 0 2.596709791635732e-10
in O 0 1.3216785998970693e-10
the O 0 1.0843212439048955e-10
first O 0 8.211347712894224e-10
position O 0 6.1984901655876e-09
of O 0 2.779080576775783e-10
exon O 0 5.4109712266381393e-08
13 O 0 2.137887644693137e-09
of O 0 4.745044912546348e-10
HEXA O 0 1.1523630973897525e-06
of O 0 3.5837841028119044e-10
a O 0 1.0263260463716506e-08
non O 0 6.152411469173558e-09
- O 0 2.663814768766315e-07
Jewish O 0 6.353187842478292e-08
proband O 0 5.130131285113748e-06
who O 0 4.2167943092863425e-07
manifested O 0 1.5987090762337175e-07
a O 0 1.27064296862045e-07
subacute O 0 0.00428742403164506
variant O 0 4.685201929532923e-05
of O 0 2.6065528402341442e-08
G B-Disease 0 0.02108812890946865
( I-Disease 0 2.2016166667526704e-08
M2 I-Disease 0 1.0569738151389174e-06
) I-Disease 0 3.3775073404740397e-08
gangliosidosis I-Disease 0 1.2102869732188992e-05
. O 0 1.5768816297168087e-07

On O 0 3.7104291550349444e-07
the O 0 9.932211497698518e-09
second O 0 1.0910174097489289e-07
maternally O 0 9.469565156905446e-06
inherited O 0 1.3759655303147156e-05
allele O 0 9.530269267088443e-07
, O 0 9.035653336653127e-10
we O 0 4.953547572128514e-10
identified O 0 3.879922161331706e-09
the O 0 9.95549753746161e-10
common O 0 1.4540871973167668e-07
infantile O 1 0.9823097586631775
disease O 0 0.041403695940971375
- O 0 0.0006193987210281193
causing O 0 5.513481937668985e-06
4 O 0 2.899650475285398e-08
- O 0 1.4075941408009385e-06
bp O 0 3.6274966532801045e-06
insertion O 0 8.261122275143862e-08
, O 0 7.510881694372529e-09
+ O 0 2.628574691243557e-08
TATC O 0 8.162890026142122e-07
1278 O 0 1.7576608115632553e-06
, O 0 2.4495485639874914e-09
in O 0 1.3119143549289447e-09
exon O 0 5.170053896108584e-07
11 O 0 9.29572578911575e-08
. O 0 7.213206743017508e-08

Pulse O 0 0.00024416015367023647
- O 0 1.5319646990974434e-05
chase O 0 7.482800583602511e-07
analysis O 0 1.3096848938687344e-08
using O 0 7.746050911805469e-09
proband O 0 4.429322757459886e-07
fibroblasts O 0 1.0695662666648786e-07
revealed O 0 7.424541337286428e-08
that O 0 9.066382089528702e-10
the O 0 3.222099254074351e-10
W474C O 0 9.848233162301767e-08
- O 0 2.7301696903236916e-08
containing O 0 2.4161481704254584e-09
alpha O 0 1.1888611206600785e-09
- O 0 3.1974045633376136e-09
subunit O 0 2.254207931429164e-09
precursor O 0 2.7484026166035846e-09
was O 0 1.80431172225326e-08
normally O 0 5.375305089927451e-09
synthesized O 0 3.547985727436753e-08
, O 0 1.0542774431243629e-09
but O 0 1.0406917549943273e-09
not O 0 1.3070140525428542e-09
phosphorylated O 0 1.0924099846931767e-08
or O 0 4.382995355545205e-10
secreted O 0 4.020821897654514e-09
, O 0 4.0842165760501814e-10
and O 0 4.2024497770576374e-10
the O 0 1.0311680398444878e-09
mature O 0 3.1406681699763794e-08
lysosomal O 0 1.4648685464635491e-07
alpha O 0 1.0077620515858143e-08
- O 0 8.374583693182558e-09
subunit O 0 1.2901033130674477e-08
was O 0 6.34270236332668e-08
not O 0 1.2939008087187176e-08
detected O 0 2.5522260216348513e-07
. O 0 1.2419735639923601e-07

When O 0 1.7410765451586485e-07
the O 0 3.1237477049472773e-09
W474C O 0 9.655909138928109e-08
- O 0 3.597306630354069e-08
containing O 0 3.2398059790494926e-09
alpha O 0 3.994648611893581e-09
- O 0 1.337361599240694e-08
subunit O 0 2.0387506793895227e-08
was O 0 1.3100975593260955e-07
transiently O 0 4.142580678490049e-07
co O 0 1.2821411132790672e-07
- O 0 1.6827506499339506e-07
expressed O 0 6.3049108156576494e-09
with O 0 1.031128238349055e-10
the O 0 9.790516314334141e-11
beta O 0 1.9308449283883533e-10
- O 0 1.727738285772773e-09
subunit O 0 1.3266042708792725e-09
to O 0 1.227156487537684e-09
produce O 0 6.599416124686286e-09
Hex O 0 2.5255533842027944e-07
A O 0 4.031036837659485e-08
( O 0 1.063953702917786e-09
alphabeta O 0 1.748924773892213e-07
) O 0 9.52623868677449e-10
in O 0 1.15595100158572e-09
COS O 0 1.2950459904459422e-06
- O 0 8.498179226990032e-07
7 O 0 2.255043440868576e-08
cells O 0 5.260289093200754e-09
, O 0 2.2311212599657182e-10
the O 0 1.4883291821199407e-10
mature O 0 1.1941562183537258e-09
alpha O 0 1.1085419249212691e-09
- O 0 2.9162436909757616e-09
subunit O 0 2.7263693525014787e-09
was O 0 1.591285325730496e-08
present O 0 6.169612043471773e-10
, O 0 1.941776739400325e-10
but O 0 4.468061198803497e-10
its O 0 1.7197906987398426e-10
level O 0 4.924457508437285e-10
was O 0 2.0382142196240238e-08
much O 0 1.651580983086376e-09
lower O 0 7.435223547958003e-09
than O 0 9.294423564121246e-10
that O 0 3.32773586464441e-10
from O 0 1.2981289654323547e-10
normal O 0 5.032341765520698e-10
alpha O 0 1.2206690103155893e-09
- O 0 6.274619046564567e-09
subunit O 0 4.7402166636345555e-09
transfections O 0 7.980470684287866e-08
, O 0 3.7802377894635697e-10
although O 0 4.48074327641379e-10
higher O 0 3.1283253765224117e-10
than O 0 4.0589617777975207e-10
in O 0 4.6228096350908743e-10
those O 0 1.2177808761393294e-09
cells O 0 4.6183790125553514e-09
transfected O 0 9.647808951740444e-08
with O 0 4.816441689925455e-10
an O 0 4.152460320039353e-10
alpha O 0 3.664744729903191e-09
- O 0 2.2765782148326252e-08
subunit O 0 2.485340466762409e-08
associated O 0 1.3572048374044243e-08
with O 0 1.1772587349412333e-08
infantile O 0 0.007573054637759924
TSD B-Disease 0 0.002115977229550481
. O 0 1.236415982930339e-06

Furthermore O 0 6.863133876322536e-06
, O 0 1.2543333482994967e-08
the O 0 4.787892304847219e-10
precursor O 0 2.2121049436663043e-09
level O 0 4.2005426914570876e-10
of O 0 7.389690942494198e-11
the O 0 1.2209105948457477e-10
W474C O 0 3.692179362246861e-08
alpha O 0 1.3964882583650251e-09
- O 0 2.8771276472383533e-09
subunit O 0 1.6650838485787745e-09
was O 0 1.2702498608518908e-08
found O 0 6.421796983069328e-10
to O 0 1.31425359484183e-09
accumulate O 0 1.378477776370346e-08
in O 0 2.501999163406765e-10
comparison O 0 1.778832969812072e-09
to O 0 7.440383309464949e-10
the O 0 2.2200628835289393e-10
normal O 0 1.5223552418675013e-09
alpha O 0 2.8454092415586274e-09
- O 0 7.417290781575048e-09
subunit O 0 1.6169488858963632e-08
precursor O 0 3.126968195488189e-08
levels O 0 1.683896044823996e-08
. O 0 3.104575796442077e-08

We O 0 4.1051325183616427e-07
conclude O 0 1.2157929063505435e-07
that O 0 2.077026106661606e-09
the O 0 1.8778905097605048e-09
1422 O 0 3.6181129416945623e-06
G O 0 0.0006234628963284194
- O 0 2.106923784594983e-05
- O 0 0.0012630984419956803
> O 0 8.484210525239178e-07
C O 0 1.4331391184896347e-07
mutation O 0 3.567324924347304e-08
is O 0 1.0029982400183712e-09
the O 0 7.011812797053096e-10
cause O 0 5.555572712978574e-08
of O 0 1.1083644002596316e-09
Hex B-Disease 0 2.334331838937942e-05
A I-Disease 0 8.974734373623505e-05
enzyme I-Disease 1 0.9999419450759888
deficiency I-Disease 1 0.999970555305481
in O 0 6.189050605343027e-09
the O 0 2.0390540811376923e-08
proband O 0 8.86681882548146e-05
. O 0 4.5711624352406943e-07

The O 0 2.714173490403482e-07
resulting O 0 2.3074686339441541e-07
W474C O 0 6.50155470793834e-07
substitution O 0 3.108225499204309e-08
clearly O 0 9.189722760538643e-08
interferes O 0 8.702647136260566e-08
with O 0 1.3046279612183298e-09
alpha O 0 3.8419969428105105e-09
- O 0 7.450982053569533e-09
subunit O 0 4.602637826423006e-09
processing O 0 2.344582306079701e-09
, O 0 6.011149356055512e-10
but O 0 5.710585893048403e-10
because O 0 3.052717800766658e-10
the O 0 5.319509763235253e-11
base O 0 1.0768278491113392e-09
substitution O 0 1.8026458104003495e-09
falls O 0 5.751594400749127e-08
at O 0 9.684817531274703e-11
the O 0 6.989709505633712e-11
first O 0 1.2929995962807084e-09
position O 0 7.077655794773818e-09
of O 0 3.102305357050028e-10
exon O 0 6.599935176154759e-08
13 O 0 3.7720000456431535e-09
, O 0 3.7220140858273965e-10
aberrant O 0 2.51230218850651e-08
splicing O 0 1.248778858098376e-07
may O 0 3.6215126897332084e-07
also O 0 1.4825848992927604e-08
contribute O 0 1.9989352395555215e-09
to O 0 1.1277878186888302e-08
Hex B-Disease 0 1.2950476047990378e-05
A I-Disease 0 4.2875009967247024e-05
deficiency I-Disease 0 1.4420314073504414e-05
in O 0 1.113029224342199e-09
this O 0 3.467765408160517e-09
proband O 0 4.391427864902653e-06
. O 0 1.505599200868346e-08
. O 0 5.603130759368469e-08

Two O 0 6.557199867529562e-06
frequent O 0 3.969737372244708e-05
missense O 0 0.009751719422638416
mutations O 0 0.00931391492486
in O 0 5.667833465849981e-05
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 2.213258994743228e-05

Pendred B-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
is O 0 5.7878987718140706e-05
an O 0 0.00022122709196992218
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.737238883972168
by O 0 1.8284817997482605e-06
early O 0 6.651546573266387e-05
childhood O 1 0.9738653302192688
deafness B-Disease 1 1.0
and O 1 0.9991025924682617
goiter B-Disease 1 1.0
. O 0 4.8392783355666324e-05

A O 0 1.2425888371581095e-06
century O 0 9.211624529825713e-08
after O 0 9.091478681000353e-09
its O 0 1.0361363989019878e-09
recognition O 0 4.988146340423327e-09
as O 0 2.3251487846209784e-08
a O 0 4.3694599298760295e-05
syndrome O 1 0.9998801946640015
by O 0 2.8228690496234776e-08
Vaughan O 0 5.113689439895097e-06
Pendred O 0 1.5356889662143658e-06
, O 0 2.424809242285164e-09
the O 0 8.118845151727783e-09
disease O 0 3.0749206416658126e-06
gene O 0 1.2095456725091935e-07
( O 0 8.791063876856242e-09
PDS O 0 8.173687820089981e-05
) O 0 4.359984817625673e-09
was O 0 2.953110538328474e-07
mapped O 0 3.891211690643104e-07
to O 0 2.3612331645495033e-08
chromosome O 0 6.561390819115331e-06
7q22 O 0 5.716951363865519e-06
- O 0 6.22847983322572e-06
q31 O 0 1.4242166798794642e-05
. O 0 2.774365270852286e-07

1 O 0 2.2253873339650454e-06
and O 0 1.5275691112037748e-07
, O 0 5.180929019132918e-09
recently O 0 2.3232560764085974e-08
, O 0 6.202732771853903e-10
found O 0 6.809264263551995e-10
to O 0 5.812009762351522e-10
encode O 0 2.385014497008342e-08
a O 0 1.7046986044988444e-07
putative O 0 2.3231987142935395e-05
sulfate O 0 0.00015112677647266537
transporter O 0 0.00018597254529595375
. O 0 3.0640205750387395e-07

We O 0 2.181275021939655e-06
performed O 0 5.766015647168388e-07
mutation O 0 1.168960253039586e-07
analysis O 0 2.9081785868356747e-09
of O 0 2.788595465652577e-10
the O 0 1.7131194240960212e-09
PDS B-Disease 0 3.7866277125431225e-05
gene O 0 1.2340018429313204e-07
in O 0 1.068652366598144e-08
patients O 0 2.038756292677135e-06
from O 0 1.0527543281568796e-09
14 O 0 6.852445277871766e-09
Pendred B-Disease 0 3.1596974281455914e-07
families O 0 1.3721106473241207e-09
originating O 0 4.4528750131611616e-10
from O 0 1.7928108997367076e-10
seven O 0 6.348930270405617e-10
countries O 0 7.875428087444902e-11
and O 0 2.8926996353817458e-09
identified O 0 2.737626303428442e-08
all O 0 1.2395489079608524e-09
mutations O 0 2.2110310737843974e-07
. O 0 7.244008060069973e-08

The O 0 4.4253158648643875e-07
mutations O 0 2.0536299416562542e-06
include O 0 6.921037964957577e-09
three O 0 3.7779472883414655e-09
single O 0 2.9730260919791363e-08
base O 0 2.0024549129971092e-08
deletions O 0 7.458975659346834e-08
, O 0 1.2161884832551095e-09
one O 0 7.622116826588865e-10
splice O 0 3.837832025510579e-07
site O 0 1.533585702873097e-07
mutation O 0 2.5252813884435454e-07
and O 0 1.6016382886618885e-08
10 O 0 5.471956043834325e-08
missense O 0 0.00012198321928735822
mutations O 0 2.322966065548826e-05
. O 0 7.647556117262866e-07

One O 0 1.6727675756555982e-05
missense O 0 0.001102873240597546
mutation O 0 4.3515959987416863e-05
( O 0 2.0484758778138712e-08
L236P O 0 5.079076572656049e-07
) O 0 3.796686076640299e-09
was O 0 1.8989121031154355e-07
found O 0 2.633752549385804e-09
in O 0 2.0874864337105947e-10
a O 0 7.393815337763954e-09
homozygous O 0 1.0406867545498244e-07
state O 0 5.363177124628749e-10
in O 0 1.3601628157111634e-10
two O 0 3.680918347903628e-10
consanguineous O 0 3.9518789662906784e-07
families O 0 9.199751183075477e-09
and O 0 8.674119200691166e-10
in O 0 5.046452145052172e-10
a O 0 1.3439461099551409e-08
heterozygous O 0 3.1410044698532147e-07
state O 0 4.24958707112566e-10
in O 0 1.984377384633973e-10
five O 0 6.824321108211961e-10
additional O 0 1.930580806330795e-09
non O 0 1.500750812510887e-08
- O 0 3.847627795039443e-06
consanguineous O 0 6.965469947317615e-05
families O 0 2.238707423884989e-07
. O 0 1.7020637699260988e-07

Another O 0 3.3214637369383126e-05
missense O 0 0.003894733963534236
mutation O 0 3.4967990359291434e-05
( O 0 1.6966369642545942e-08
T416P O 0 2.984121749705082e-07
) O 0 1.5259978836112964e-09
was O 0 5.3045226877657115e-08
found O 0 1.7097669946508631e-09
in O 0 2.9378369181820574e-10
a O 0 1.3705994561519219e-08
homozygous O 0 4.464198255504925e-08
state O 0 3.8610803443361874e-10
in O 0 1.444167979647304e-10
one O 0 1.6201648911362554e-09
family O 0 4.213158266708206e-09
and O 0 1.2332288523708712e-09
in O 0 3.421628258504228e-10
a O 0 1.2564308704554605e-08
heterozygous O 0 2.0096027242288983e-07
state O 0 5.509936396030923e-10
in O 0 3.0264837858062776e-10
four O 0 5.930986812785477e-09
families O 0 1.839235252987237e-08
. O 0 4.446963686177696e-08

Pendred B-Disease 0 0.058499470353126526
patients O 0 0.18692228198051453
in O 0 2.1721644927197303e-08
three O 0 4.703041067699587e-09
non O 0 1.0577827502800119e-08
- O 0 1.1554797083590529e-06
consanguineous O 0 9.179120752378367e-06
families O 0 2.2801589949494883e-08
were O 0 5.53089263277684e-09
shown O 0 5.851444218052393e-09
to O 0 1.5167268552218616e-09
be O 0 5.9335327762255474e-09
compound O 0 7.899223675167377e-08
heterozygotes O 0 6.331630402200972e-07
for O 0 3.76149644765178e-09
L236P O 0 6.051199079593061e-07
and O 0 1.6504261068917003e-08
T416P O 0 3.0895828331267694e-06
. O 0 1.7282128794704477e-07

In O 0 1.335118042788963e-07
total O 0 1.1465709270908064e-08
, O 0 2.204464388810834e-09
one O 0 8.349952951292039e-10
or O 0 1.698928081550477e-10
both O 0 1.3184960068191032e-10
of O 0 6.928757567692401e-11
these O 0 7.059478002169328e-10
mutations O 0 2.0171365022747523e-08
were O 0 1.0553423024362019e-08
found O 0 3.6410696679922694e-09
in O 0 2.647783936549075e-10
nine O 0 3.623698840993228e-10
of O 0 1.3186362592121359e-11
the O 0 3.231497291977803e-10
14 O 0 7.545312818990624e-09
families O 0 2.7009456893267725e-09
analyzed O 0 1.657885349004573e-07
. O 0 1.0290824548064847e-07

The O 0 6.519075412825259e-08
identification O 0 3.252562308375673e-08
of O 0 4.235264638996483e-10
two O 0 4.536520936682109e-09
frequent O 0 3.527655735524604e-06
PDS B-Disease 0 0.2001059651374817
mutations O 0 2.019704197664396e-06
will O 0 3.987812302597149e-09
facilitate O 0 2.224871176181864e-09
the O 0 3.3617146844022727e-09
molecular O 0 5.3434932851814665e-06
diagnosis O 0 0.06079171970486641
of O 0 1.828680524340598e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.072694875707384e-06

Insertional O 0 0.001293900771997869
mutation O 0 8.385981345782056e-05
by O 0 1.0510076720038342e-07
transposable O 0 5.1945594350399915e-06
element O 0 2.7276408331999846e-07
, O 0 2.3675738702877425e-08
L1 O 0 1.2855637123720953e-06
, O 0 5.415356163496199e-09
in O 0 1.4345709065111123e-09
the O 0 2.8112953742720492e-08
DMD B-Disease 1 0.9999997615814209
gene O 0 3.910276063834317e-06
results O 0 2.5467892328379094e-07
in O 0 2.262492238003233e-08
X B-Disease 1 0.9944538474082947
- I-Disease 1 0.9992610812187195
linked I-Disease 1 0.9998064637184143
dilated I-Disease 1 0.9998623132705688
cardiomyopathy I-Disease 1 0.9999997615814209
. O 0 1.0838511116162408e-05

X B-Disease 1 0.9971781969070435
- I-Disease 1 0.9995521903038025
linked I-Disease 1 0.9995198249816895
dilated I-Disease 1 0.9999526739120483
cardiomyopathy I-Disease 1 1.0
( O 0 6.686437359348929e-07
XLDCM B-Disease 0 0.0004158483643550426
) O 0 4.035928036216774e-09
is O 0 2.2473434224679067e-09
a O 0 3.3031650303883e-08
clinical O 0 7.430302503053099e-06
phenotype O 0 0.000659680925309658
of O 0 9.156611580074525e-10
dystrophinopathy B-Disease 0 2.5318349798908457e-05
which O 0 3.5151682453715694e-08
is O 0 3.041148444182795e-09
characterized O 0 6.158495580166345e-08
by O 0 1.0419435980679737e-08
preferential O 0 4.159505806455854e-06
myocardial B-Disease 1 0.963175892829895
involvement I-Disease 0 1.4465325648416183e-07
without O 0 2.7639317501382266e-09
any O 0 9.983563975524135e-10
overt O 0 2.645949734869646e-07
clinical O 0 2.9259676921356004e-06
signs O 0 3.004682184837293e-06
of O 0 2.003658892135718e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.00014808282139711082

To O 0 4.429103057645989e-07
date O 0 5.31590700347806e-08
, O 0 1.238294133898421e-09
several O 0 1.0619951584800447e-09
mutations O 0 3.180866769980639e-08
in O 0 2.362561035695876e-09
the O 0 9.00192773656272e-08
Duchenne B-Disease 1 0.9997872710227966
muscular I-Disease 1 0.99998939037323
dystrophy I-Disease 1 0.9999878406524658
gene O 0 0.0005585861508734524
, O 0 2.566172042861581e-06
DMD O 1 0.9999997615814209
, O 0 1.1520319276314694e-07
have O 0 1.4779375945295214e-08
been O 0 3.018565664092421e-08
identified O 0 4.905432149371336e-08
in O 0 5.695805604943871e-09
patients O 0 2.105343810399063e-06
with O 0 5.5493534212303075e-09
XLDCM B-Disease 0 0.0001379479217575863
, O 0 1.5250553042633896e-09
but O 0 1.1097457397468702e-09
a O 0 3.488350275304697e-09
pathogenic O 0 1.5395139385532275e-08
correlation O 0 4.091438299269612e-09
of O 0 1.7757471881818532e-10
these O 0 1.3158738543239679e-09
cardiospecific O 0 1.2150841030234005e-05
mutations O 0 1.5808567468411638e-06
in O 0 1.7090050263846024e-08
DMD O 1 0.9999992847442627
with O 0 1.6241050104781607e-07
the O 0 7.06379452708461e-08
XLDCM B-Disease 1 0.9192496538162231
phenotype O 1 0.5557005405426025
has O 0 6.077490297684562e-07
remained O 0 8.381666560808299e-08
to O 0 7.050210637515875e-09
be O 0 6.20952107510675e-08
elucidated O 0 1.5806659575900994e-05
. O 0 2.1225027069249336e-07

We O 0 1.1812273896794068e-06
report O 0 5.105495404222893e-08
here O 0 5.413474113424854e-10
the O 0 5.803909089441284e-11
identification O 0 2.37214581311207e-10
of O 0 2.414984878740256e-11
a O 0 1.1904585095479092e-09
unique O 0 3.171596318907177e-09
de O 0 4.903998540584098e-09
novo O 0 5.643275358124811e-08
L1 O 0 1.8292963943622453e-07
insertion O 0 4.787595742072881e-08
in O 0 1.064603294409494e-09
the O 0 1.2557402895296832e-09
muscle O 0 6.027147492204676e-07
exon O 0 4.7592351393177523e-07
1 O 0 1.796536963638573e-08
in O 0 3.7511810546675406e-08
DMD O 1 0.9999996423721313
in O 0 2.820152076310478e-07
three O 0 9.065750106174164e-08
XLDCM B-Disease 0 0.036460865288972855
patients O 0 1.4349309822137002e-05
from O 0 4.101390616018108e-10
two O 0 7.566206550180254e-10
unrelated O 0 1.9042140309011302e-08
Japanese O 0 5.161166427569697e-08
families O 0 3.299714634863449e-08
. O 0 4.2760323282209356e-08

The O 0 1.9171264398210042e-07
insertion O 0 7.115109497135563e-07
was O 0 1.7374772198763822e-07
a O 0 2.5552258975380937e-08
5 O 0 1.5952725362922138e-08
- O 0 4.6075328441474994e-07
truncated O 0 4.583577322136989e-07
form O 0 1.5056535573876317e-08
of O 0 6.830701559934482e-10
human O 0 2.934523068987005e-09
L1 O 0 1.9026572317670798e-07
inversely O 0 2.175670914539296e-07
integrated O 0 3.442389129304502e-08
in O 0 1.8522565703449345e-09
the O 0 1.2134566684807169e-09
5 O 0 4.530165575999945e-09
- O 0 1.0399908205727115e-06
untranslated O 0 2.619124416014529e-06
region O 0 6.528106943903822e-09
in O 0 6.942584840352595e-10
the O 0 1.0581756582084267e-09
muscle O 0 5.835786964780709e-07
exon O 0 1.5005538500645343e-07
1 O 0 2.39960118442184e-09
, O 0 4.952263044089023e-10
which O 0 1.951014461099021e-09
affected O 0 6.618396386492975e-10
the O 0 1.0129719979490304e-10
transcription O 0 3.346552812644177e-09
or O 0 4.168139999816134e-10
the O 0 2.023523709704378e-10
stability O 0 3.777126167392453e-09
of O 0 1.2628444123752303e-10
the O 0 6.295066135031391e-10
muscle O 0 4.737299832413555e-07
form O 0 4.007851384102423e-09
of O 0 4.366465522487317e-10
dystrophin O 0 1.3625891597257578e-06
transcripts O 0 2.812282140496336e-08
but O 0 3.0859301780594706e-09
not O 0 4.569675471355339e-10
that O 0 1.0160099150891e-10
of O 0 3.8441846927916856e-11
the O 0 1.031837060239127e-09
brain O 0 1.8907420553659904e-06
or O 0 1.8370992505012396e-09
Purkinje O 0 8.009197927094647e-07
cell O 0 1.2475069297579466e-06
form O 0 1.7139308639002593e-08
, O 0 2.428340417637287e-09
probably O 0 2.860909376067866e-08
due O 0 3.087649469435405e-09
to O 0 1.1213674433463439e-09
its O 0 1.0003922135126686e-09
unique O 0 2.174007862620897e-09
site O 0 4.011009746562877e-09
of O 0 3.3946123689787555e-10
integration O 0 3.417509475411862e-08
. O 0 1.250344610070897e-07

We O 0 3.9760351455697673e-07
speculate O 0 6.18670469521021e-07
that O 0 8.837898191060845e-10
this O 0 1.7458343104514995e-10
insertion O 0 3.819973670715626e-09
of O 0 2.2836819935090347e-10
an O 0 1.965956286653636e-09
L1 O 0 4.651160452340264e-07
sequence O 0 1.6236304745120833e-08
in O 0 9.439282244727565e-09
DMD O 1 0.9999990463256836
is O 0 2.391752786934376e-07
responsible O 0 1.5605250425210215e-08
for O 0 2.2054347237343563e-10
some O 0 8.841569837381158e-11
of O 0 1.9326934150298847e-11
the O 0 2.0817765566949475e-10
population O 0 2.984476832335048e-10
of O 0 5.440446010362976e-11
Japanese O 0 5.641144440460266e-08
patients O 0 1.3040362318861298e-06
with O 0 8.845593590933731e-09
XLDCM B-Disease 0 7.11885149939917e-05
. O 0 3.1748299988976214e-08
. O 0 4.652784113545749e-08

Severe O 1 0.8725629448890686
early O 0 1.6580859664827585e-05
- O 1 0.8516088128089905
onset O 1 0.9439854621887207
obesity B-Disease 1 0.9999997615814209
, O 0 0.0006880701403133571
adrenal B-Disease 1 0.9999979734420776
insufficiency I-Disease 1 0.9999996423721313
and O 0 6.66413689032197e-05
red O 0 0.0001862229109974578
hair O 1 0.95384281873703
pigmentation O 1 0.9684028029441833
caused O 0 0.0029764047358185053
by O 0 4.2510305320320185e-07
POMC O 0 0.0495520681142807
mutations O 0 8.23776008473942e-06
in O 0 1.925815418246657e-08
humans O 0 1.6360471022380807e-07
. O 0 1.0843042019814675e-07

Sequential O 0 1.60940398927778e-05
cleavage O 0 5.275743660604348e-06
of O 0 4.86261564347501e-09
the O 0 9.273050660674187e-10
precursor O 0 7.432883641911303e-09
protein O 0 6.580398448363667e-09
pre O 0 6.889720083336215e-08
- O 0 1.5503956092288718e-06
pro O 0 3.5164941891707713e-06
- O 0 2.807973032759037e-05
opiomelanocortin O 0 4.890598575002514e-05
( O 0 5.277956738325429e-09
POMC O 0 1.1023563502021716e-06
) O 0 2.1807939898366158e-09
generates O 0 1.8850686345217582e-08
the O 0 2.8046902578182653e-09
melanocortin O 0 1.7104517837651656e-06
peptides O 0 6.788359314668924e-07
adrenocorticotrophin O 0 3.7787676774314605e-06
( O 0 1.3371116658333904e-08
ACTH O 0 1.734022134769475e-06
) O 0 4.478130755103393e-09
, O 0 4.159215638566138e-09
melanocyte O 0 3.5736798054131214e-06
- O 0 6.402298367902404e-06
stimulating O 0 1.0851250635823817e-06
hormones O 0 1.0668904906196985e-06
( O 0 5.448073991942692e-09
MSH O 0 1.8153565406464622e-06
) O 0 3.844765894545077e-10
alpha O 0 1.1251058973371642e-09
, O 0 9.13515027511913e-11
beta O 0 2.1981948206128976e-10
and O 0 1.3382892016799985e-10
gamma O 0 1.101846947015872e-09
as O 0 5.204439101902381e-10
well O 0 2.627258965937074e-10
as O 0 2.4240126572649956e-10
the O 0 2.133902221590489e-10
opioid O 0 1.886867693201566e-07
- O 0 6.499458891084942e-07
receptor O 0 3.3467813409515657e-07
ligand O 0 6.284730034167296e-07
beta O 0 3.3628168694121996e-07
- O 0 4.627826001524227e-06
endorphin O 0 8.32790246931836e-05
. O 0 6.128545919636963e-07

While O 0 7.183220986917149e-07
a O 0 2.485909256222385e-08
few O 0 8.45896153123249e-09
cases O 0 7.4094010926728515e-09
of O 0 8.21670997908086e-09
isolated O 0 0.1185254156589508
ACTH B-Disease 1 0.9996819496154785
deficiency I-Disease 1 0.5279459357261658
have O 0 3.902200660377275e-07
been O 0 1.2024555644529755e-06
reported O 0 8.980009624792729e-07
( O 0 1.3775735219212493e-08
OMIM O 0 7.44290737202391e-05
201400 O 0 8.902533750188013e-07
) O 0 1.861223619670227e-09
, O 0 1.22343590813756e-09
an O 0 1.5511062656514696e-08
inherited O 0 0.0003844564489554614
POMC O 0 0.0314781628549099
defect O 0 0.0004354310513008386
has O 0 3.0991625976639625e-07
not O 0 7.2591501698582306e-09
been O 0 1.9507549353647846e-08
described O 0 2.613166429910052e-07
so O 0 2.67173145829247e-08
far O 0 5.8124260959857565e-08
. O 0 1.0297441122020246e-07

Recent O 0 1.7752769281287328e-06
studies O 0 5.2289813368133764e-08
in O 0 2.663639975253318e-09
animal O 0 9.157909097723405e-09
models O 0 2.981032309889997e-08
elucidated O 0 1.602369366082712e-07
a O 0 2.9496798337191876e-09
central O 0 2.551589772803453e-10
role O 0 4.891766991477198e-10
of O 0 1.0774231506971432e-10
alpha O 0 1.122495696392889e-08
- O 0 7.900607670308091e-07
MSH O 0 3.5616353670775425e-06
in O 0 1.0140240869205286e-09
the O 0 9.516390453434553e-11
regulation O 0 1.937478844027396e-09
of O 0 2.954842204250241e-10
food O 0 5.309611417203541e-09
intake O 0 1.6038065098200605e-07
by O 0 7.179900007869833e-10
activation O 0 1.7598601464996477e-09
of O 0 1.9129052508670696e-10
the O 0 1.7168386712285155e-09
brain O 0 1.7886341083794832e-06
melanocortin O 0 9.627907502363087e-07
- O 0 8.192986342692166e-07
4 O 0 3.3483868122630156e-08
- O 0 3.259636685015721e-07
receptor O 0 3.9375532878693775e-07
( O 0 6.932531881886916e-09
MC4 O 0 9.573982424626593e-06
- O 0 2.9545180950663052e-06
R O 0 1.6315940229105763e-05
; O 0 6.035830502071349e-09
refs O 0 1.3450878100229602e-07
3 O 0 9.404095280274305e-09
- O 0 1.1530057975051022e-07
5 O 0 3.351605215584641e-09
) O 0 1.558052020733669e-10
and O 0 1.7845888655720898e-10
the O 0 2.2716398206945598e-10
linkage O 0 4.8820410825101135e-08
of O 0 7.648680577787559e-10
human O 0 8.743077017925316e-08
obesity B-Disease 1 0.9999372959136963
to O 0 1.6834762561757088e-07
chromosome O 0 9.616776424081763e-07
2 O 0 2.384117347986603e-09
in O 0 3.3963348800014614e-10
close O 0 2.4810056231672206e-09
proximity O 0 1.2965194251535195e-08
to O 0 1.3709628099434212e-08
the O 0 5.1631721120770635e-09
POMC O 0 1.2515974958660081e-05
locus O 0 2.483583045886917e-07
, O 0 2.2945285671482907e-09
led O 0 1.8763723907966323e-09
to O 0 9.109230592052597e-10
the O 0 3.6070044173719396e-10
proposal O 0 1.871483767956761e-08
of O 0 1.8715175242878246e-10
an O 0 4.566602207489723e-09
association O 0 2.423805822715508e-09
of O 0 6.044652556269625e-10
POMC O 0 1.275705926673254e-05
with O 0 4.193894298509804e-08
human O 0 1.4215404462447623e-06
obesity B-Disease 1 0.999953031539917
. O 0 2.773550477286335e-06

The O 0 1.2102056246021675e-07
dual O 0 1.7256485307370895e-07
role O 0 8.806134488281714e-09
of O 0 4.5936901504894934e-10
alpha O 0 4.6969116596073945e-08
- O 0 2.098776121783885e-06
MSH O 0 2.682110425666906e-05
in O 0 3.5535918652129794e-09
regulating O 0 2.5521279312101797e-08
food O 0 1.9695754360782303e-08
intake O 0 3.628309173109301e-07
and O 0 9.719284044251708e-09
influencing O 0 1.311800303938071e-07
hair O 0 0.005252245347946882
pigmentation O 0 0.008769022300839424
predicts O 0 8.593011443736032e-06
that O 0 1.141297367723837e-08
the O 0 5.802609059912811e-09
phenotype O 0 0.0027141047175973654
associated O 0 5.839481342917452e-09
with O 0 5.441154748986321e-10
a O 0 2.3129898352181044e-07
defect O 0 6.764937279513106e-05
in O 0 3.2298249408313495e-08
POMC O 0 4.632784111890942e-05
function O 0 3.535265946652544e-08
would O 0 1.0088817958830987e-07
include O 0 9.330933181672663e-08
obesity B-Disease 1 0.9999867677688599
, O 0 5.96058882251782e-08
alteration O 0 2.6988361696567154e-06
in O 0 2.2869235749567451e-07
pigmentation O 1 0.9076293110847473
and O 0 0.1922096312046051
ACTH B-Disease 1 0.9997109770774841
deficiency I-Disease 1 0.8376170992851257
. O 0 9.144086448031885e-07

The O 0 9.03249031125597e-08
observation O 0 3.147790437196818e-07
of O 0 6.54977960756753e-10
these O 0 6.3853540233083095e-09
symptoms O 0 8.899002750695217e-06
in O 0 2.76095990514591e-09
two O 0 6.232074412082511e-09
probands O 0 1.793752062440035e-06
prompted O 0 4.33158930945865e-08
us O 0 1.964022500189344e-09
to O 0 6.41090458497473e-10
search O 0 2.3521518066615954e-09
for O 0 1.7645792604881194e-09
mutations O 0 4.8563709498239405e-08
within O 0 4.789307839203616e-10
their O 0 4.77858863590086e-09
POMC O 0 6.5706241002772e-05
genes O 0 6.298350854194723e-07
. O 0 1.117533656724845e-07

Patient O 0 0.09142325073480606
1 O 0 5.941043355051079e-07
was O 0 1.0171417130777627e-07
found O 0 2.686682432084808e-09
to O 0 7.40100758456208e-10
be O 0 1.0652532189681096e-09
a O 0 9.937688005834389e-09
compound O 0 8.749098867610883e-08
heterozygote O 0 4.919271532344283e-07
for O 0 9.509283360742415e-10
two O 0 1.0902113656285906e-09
mutations O 0 1.7952798359033295e-08
in O 0 1.3317761338171863e-09
exon O 0 1.0594832389188014e-07
3 O 0 1.818244577123096e-08
( O 0 1.3316746594327356e-09
G7013T O 0 3.0487470326079347e-07
, O 0 7.928623979580607e-09
C7133delta O 0 1.95574770600615e-07
) O 0 3.489047106786103e-10
which O 0 8.18307976935273e-10
interfere O 0 9.453208882348463e-09
with O 0 5.132163582999283e-10
appropriate O 0 1.5322978441645319e-09
synthesis O 0 5.77835557180606e-09
of O 0 1.301059593394882e-09
ACTH O 0 2.999236812684103e-06
and O 0 2.2781289743534217e-08
alpha O 0 3.2511175618310517e-07
- O 0 1.4893161278450862e-05
MSH O 0 0.0003482164756860584
. O 0 4.77228809359076e-07

Patient O 0 0.03669163957238197
2 O 0 4.838558993469633e-07
was O 0 1.900774719842957e-07
homozygous O 0 1.2364591839286732e-07
for O 0 1.384268255577581e-09
a O 0 1.2542806793192085e-08
mutation O 0 1.7647946037868678e-07
in O 0 2.567839496592228e-09
exon O 0 3.4178492569481023e-07
2 O 0 2.8059920609280198e-08
( O 0 3.0605025180818757e-09
C3804A O 0 7.934442010082421e-07
) O 0 4.8664201557357956e-09
which O 0 1.5107085005183762e-07
abolishes O 0 0.0011216811835765839
POMC O 0 0.0003622364019975066
translation O 0 2.0354070784378564e-06
. O 0 3.637302938841458e-07

These O 0 3.7129990460016415e-07
findings O 0 1.3457909631142684e-07
represent O 0 2.418901079437319e-09
the O 0 1.6845819184041488e-10
first O 0 5.93214921629226e-10
examples O 0 1.0695265784121943e-09
of O 0 1.17494708407051e-10
a O 0 1.874136160040507e-06
genetic B-Disease 1 0.9999935626983643
defect I-Disease 1 0.9999940395355225
within O 0 5.7434572653392024e-09
the O 0 5.622225796031444e-09
POMC O 0 8.668205737194512e-06
gene O 0 4.219336346977798e-08
and O 0 1.9395531847266057e-09
define O 0 1.3562886813645036e-08
a O 0 2.94635267295007e-08
new O 0 2.268507870439862e-07
monogenic B-Disease 0 0.03727244585752487
endocrine I-Disease 0 0.07144124060869217
disorder I-Disease 0 0.13419301807880402
resulting O 0 1.39074799676564e-07
in O 0 1.5605131409301976e-08
early O 0 9.147593118541408e-07
- O 1 0.912889301776886
onset O 1 0.9431845545768738
obesity B-Disease 1 1.0
, O 0 0.0019067225512117147
adrenal B-Disease 1 0.9999977350234985
insufficiency I-Disease 1 0.9999991655349731
and O 0 2.184776712965686e-05
red O 0 3.674581239465624e-05
hair O 0 0.10237535834312439
pigmentation O 0 0.006632847711443901
. O 0 1.2579563701820007e-07
. O 0 1.4206172238573345e-07

A O 0 1.26320746858255e-05
European O 0 1.693700255600561e-06
multicenter O 0 0.0002785427786875516
study O 0 5.772937470283068e-07
of O 0 1.866470284994648e-07
phenylalanine B-Disease 1 0.9999997615814209
hydroxylase I-Disease 1 0.999998927116394
deficiency I-Disease 1 0.9999997615814209
: O 0 1.193487442208152e-08
classification O 0 2.4970768564003265e-08
of O 0 2.680963229195754e-10
105 O 0 6.430529708723043e-08
mutations O 0 2.540831189890014e-07
and O 0 3.509485591024486e-09
a O 0 1.537427607445352e-08
general O 0 7.54488116427865e-09
system O 0 9.614885776443316e-09
for O 0 6.650871409163983e-09
genotype O 0 1.2517311915871687e-05
- O 0 5.229839530329627e-07
based O 0 3.7463475877075325e-08
prediction O 0 1.7054952650141786e-07
of O 0 2.9992526240363304e-09
metabolic O 0 0.012018714100122452
phenotype O 0 0.047243207693099976
. O 0 2.5963888106161903e-07

Phenylketonuria B-Disease 1 0.9972746968269348
( O 0 8.54365571285598e-05
PKU B-Disease 0 0.04938410967588425
) O 0 7.40282757760724e-07
and O 0 3.956268119509332e-05
mild B-Disease 1 0.9999725818634033
hyperphenylalaninemia I-Disease 1 1.0
( O 0 5.1295399316586554e-05
MHP B-Disease 1 0.9999998807907104
) O 0 9.184396532191386e-08
are O 0 1.9702955000866496e-07
allelic B-Disease 0 0.282358855009079
disorders I-Disease 1 0.9985398054122925
caused O 0 2.819011569954455e-05
by O 0 3.839258866378259e-08
mutations O 0 1.408034563610272e-06
in O 0 2.780921937173275e-09
the O 0 3.535958637002068e-09
gene O 0 8.768208203946415e-07
encoding O 0 3.58583702109172e-06
phenylalanine O 0 0.0028552331496030092
hydroxylase O 0 0.011161035858094692
( O 0 2.0262761779576977e-07
PAH O 0 2.914007563958876e-05
) O 0 5.834997196529912e-08
. O 0 2.036978941077905e-07

Previous O 0 3.112419335593586e-06
studies O 0 3.841361362333373e-08
have O 0 3.537780068896268e-09
suggested O 0 6.208689118381017e-09
that O 0 3.680756810453545e-10
the O 0 3.4580940888595535e-10
highly O 0 7.40701651125164e-08
variable O 0 1.781517858034931e-05
metabolic O 0 0.0789152979850769
phenotypes O 0 0.0016624522395431995
of O 0 8.948497907113051e-07
PAH B-Disease 1 0.999964714050293
deficiency I-Disease 1 0.9955605268478394
correlate O 0 5.7912613556254655e-05
with O 0 5.830519057781203e-06
PAH O 1 0.8579864501953125
genotypes O 0 0.0015339070232585073
. O 0 1.4285217275755713e-06

We O 0 4.772434181177232e-07
identified O 0 1.4009901860845275e-07
both O 0 3.697914197076102e-09
causative O 0 3.8682571812387323e-07
mutations O 0 9.409568519913591e-07
in O 0 1.6729348573107927e-08
686 O 0 0.00018053731764666736
patients O 0 0.018418023362755775
from O 0 2.2656694298461844e-09
seven O 0 1.0670474281937459e-08
European O 0 2.2235953522908858e-08
centers O 0 4.6254601926420946e-08
. O 0 1.3033631773851084e-07

On O 0 1.680442949236749e-07
the O 0 1.5661957286638994e-09
basis O 0 7.212375141563143e-10
of O 0 6.425836945878061e-11
the O 0 9.162866576595263e-10
phenotypic O 0 6.547113002852711e-07
characteristics O 0 2.0114198306941944e-08
of O 0 3.353797239924461e-10
297 O 0 3.5451421354082413e-07
functionally O 0 2.407644387858454e-05
hemizygous O 0 0.000522277900017798
patients O 0 0.00014550820924341679
, O 0 9.328416927800731e-10
105 O 0 1.5967693833829344e-09
of O 0 9.360457547957779e-11
the O 0 7.030628301762931e-10
mutations O 0 3.1138984724066177e-08
were O 0 3.43938144631295e-09
assigned O 0 3.443851870343906e-09
to O 0 1.4189965868993681e-09
one O 0 4.871998915412235e-10
of O 0 1.0253466131704414e-10
four O 0 3.6892915389330483e-09
arbitrary O 0 1.4241049939300865e-06
phenotype O 0 0.022975657135248184
categories O 0 2.1330137656150328e-07
. O 0 2.545089614613971e-07

We O 0 5.590304112956801e-07
proposed O 0 5.479851949985459e-08
and O 0 1.0791723958902821e-08
tested O 0 2.7352463405350136e-08
a O 0 3.444692753262757e-09
simple O 0 7.069964613748425e-09
model O 0 2.645969310322016e-08
for O 0 3.915037460888726e-10
correlation O 0 7.99507837712099e-09
between O 0 2.602720927669111e-09
genotype O 0 3.3769811125239357e-06
and O 0 2.3410709815152586e-08
phenotypic O 0 1.3819752894050907e-05
outcome O 0 2.334791588509688e-06
. O 0 4.0291234881806304e-07

The O 0 1.038515961226949e-06
observed O 0 4.861273282585898e-06
phenotype O 0 0.0001352535473415628
matched O 0 1.7270561158966302e-07
the O 0 3.658486846802589e-09
predicted O 0 1.716219571790134e-06
phenotype O 0 8.698411693330854e-05
in O 0 3.274621462878713e-09
79 O 0 1.5441420941897377e-07
% O 0 3.275781590428295e-10
of O 0 2.2290272058689276e-11
the O 0 8.340196311351633e-10
cases O 0 9.421477642490572e-08
, O 0 3.1235869446533115e-09
and O 0 2.309523239318878e-09
in O 0 5.09393416336934e-10
only O 0 1.2999110676759074e-09
5 O 0 3.73169578571364e-10
of O 0 1.6827643445349594e-10
184 O 0 9.18232956337306e-08
patients O 0 8.7046728367568e-06
was O 0 3.4934988235590936e-08
the O 0 3.1312624715340576e-10
observed O 0 1.832973595128351e-08
phenotype O 0 9.31584168029076e-07
more O 0 4.0534223200161534e-10
than O 0 6.753955172911219e-10
one O 0 1.1347827122420995e-09
category O 0 1.7891294001870506e-09
away O 0 2.1997350607705357e-09
from O 0 2.47119963381337e-10
that O 0 3.6631231381534235e-09
expected O 0 8.317027067050731e-08
. O 0 1.0988615173346261e-07

Among O 0 5.849861963724834e-07
the O 0 6.176350542119735e-09
seven O 0 5.2158100061205914e-09
contributing O 0 3.0625462166256057e-09
centers O 0 1.4590475494458133e-09
, O 0 2.669273690969476e-10
the O 0 1.977018132537367e-10
proportion O 0 5.9573013189151425e-09
of O 0 7.573049964904044e-10
patients O 0 7.485954824915098e-07
for O 0 1.0898454361196741e-09
whom O 0 2.2190322468418344e-08
the O 0 7.673667812291285e-10
observed O 0 1.9126960637549928e-07
phenotype O 0 4.849965080211405e-06
did O 0 7.278768698881777e-09
not O 0 4.1316428056603627e-10
match O 0 1.107295144464615e-09
the O 0 5.837796357432978e-10
predicted O 0 1.229821009474108e-06
phenotype O 0 1.0194573405897245e-05
was O 0 4.9227157461473325e-08
4 O 0 1.7473775759668797e-09
% O 0 9.201150952264925e-10
- O 0 7.564913744317892e-07
23 O 0 2.103824272126076e-06
% O 0 6.52713527671267e-09
( O 0 1.9183465926886356e-09
P O 0 2.91223227577575e-06
< O 0 3.421403249603827e-08
. O 0 2.519575881265723e-09
0001 O 0 1.8115946076591172e-08
) O 0 3.7473443792457317e-10
, O 0 1.8324929074164942e-10
suggesting O 0 2.617491778877934e-09
that O 0 7.554497027939533e-10
differences O 0 5.149098925016915e-09
in O 0 1.8931883838391173e-10
methods O 0 8.419536734471933e-10
used O 0 2.1874257960519117e-09
for O 0 8.963422226671014e-10
mutation O 0 8.982306809457441e-08
detection O 0 3.5346857885087957e-08
or O 0 5.2624791635480506e-08
phenotype O 1 0.9308241605758667
classification O 0 1.8019089111476205e-05
may O 0 2.3473185137845576e-06
account O 0 5.600285568618801e-09
for O 0 5.699127836322759e-10
a O 0 9.481812668354905e-09
considerable O 0 2.3864160425546288e-08
proportion O 0 3.403354753572785e-08
of O 0 3.902417500256661e-09
genotype O 0 0.018554115667939186
- O 0 0.09318801760673523
phenotype O 0 0.35085153579711914
inconsistencies O 0 6.626652066188399e-06
. O 0 6.667639809165848e-07

Our O 0 4.3642967284540646e-07
data O 0 5.05901454062041e-08
indicate O 0 1.89545943385383e-08
that O 0 2.226947293237913e-09
the O 0 8.83857786959652e-09
PAH O 0 0.0003151552227791399
- O 0 0.0003023861791007221
mutation O 0 1.2076364328095224e-05
genotype O 0 3.0399751267395914e-06
is O 0 6.331311031004816e-10
the O 0 1.3067989745874087e-10
main O 0 1.0360771129924728e-09
determinant O 0 2.7379293499052437e-08
of O 0 2.365297735451577e-09
metabolic O 0 0.007046728860586882
phenotype O 0 0.008240855298936367
in O 0 1.6705753225210174e-08
most O 0 1.3337465816221084e-06
patients O 0 0.27655690908432007
with O 0 0.0007376151042990386
PAH B-Disease 1 0.9999697208404541
deficiency I-Disease 1 0.995303750038147
. O 0 6.767274385310884e-07

In O 0 8.907682769176972e-08
the O 0 3.0939868445045704e-09
present O 0 4.309337331420693e-09
study O 0 1.9285675278979397e-09
, O 0 4.711541157220722e-10
the O 0 4.643674056392655e-10
classification O 0 2.0924872501382197e-08
of O 0 1.2391967452174413e-09
105 O 0 1.857725806075905e-06
PAH O 0 0.011388166807591915
mutations O 0 2.4234584998339415e-05
may O 0 9.733832229130712e-08
allow O 0 4.0211136642653855e-09
the O 0 6.058191170943417e-10
prediction O 0 3.09750163296485e-08
of O 0 1.7576989863599124e-10
the O 0 1.4447251173166364e-09
biochemical O 0 2.4498056063748663e-06
phenotype O 0 1.5670275388401933e-05
in O 0 2.3301955920373985e-09
> O 0 1.628592904978632e-08
10 O 0 2.135809085146434e-09
, O 0 3.495176814638512e-09
000 O 0 1.5366625305546222e-08
genotypes O 0 5.821856348120491e-07
, O 0 3.85905751798532e-09
which O 0 6.664942375778082e-09
may O 0 2.2707540736632836e-08
be O 0 1.2803412774431422e-09
useful O 0 5.235003541770311e-10
for O 0 1.961954765317131e-10
the O 0 7.681282832017189e-10
management O 0 2.125519094064998e-09
of O 0 9.129302869226308e-10
hyperphenylalaninemia B-Disease 1 0.9999462366104126
in O 0 5.767489597019448e-07
newborns O 0 0.00014592698425985873
. O 0 1.9178322929747083e-07

Somatic O 0 0.00029129284666851163
instability O 0 1.4687403563584667e-05
of O 0 1.2436583318731209e-08
the O 0 1.1389531096028804e-08
CTG O 0 2.284208676428534e-06
repeat O 0 2.2725484427610354e-07
in O 0 5.485255805126599e-09
mice O 0 4.870559564551513e-07
transgenic O 0 1.418555513055253e-07
for O 0 1.166917051875771e-08
the O 0 4.0311604720955074e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.4769373592571355e-05
is O 0 2.682818376342766e-07
age O 0 1.6517990530928728e-08
dependent O 0 5.970383298858906e-09
but O 0 2.31224284164e-09
not O 0 1.2971198559696973e-09
correlated O 0 4.1412779872018746e-09
to O 0 7.516351985259462e-10
the O 0 4.6056389257920216e-10
relative O 0 3.770721690443679e-08
intertissue O 0 4.2760487417581317e-07
transcription O 0 1.2584123965098115e-07
levels O 0 2.4861890324245906e-08
and O 0 3.882759358475596e-08
proliferative O 0 0.013437891378998756
capacities O 0 6.612966444663471e-06
. O 0 5.363341415431933e-07

A O 0 1.1288829227851238e-05
( O 0 2.119609945339107e-07
CTG O 0 3.833372829831205e-06
) O 0 1.1326791948818027e-08
nexpansion O 0 3.56544120450053e-07
in O 0 1.4942720394373055e-09
the O 0 1.061727816775715e-09
3 O 0 4.4504254503863194e-08
- O 0 7.165197166614234e-05
untranslated O 0 0.0003749607130885124
region O 0 1.4547876503456791e-07
( O 0 3.010325100305522e-09
UTR O 0 6.287572205110337e-07
) O 0 4.3091133439254747e-10
of O 0 1.7659958218008143e-10
the O 0 1.1823488854645348e-08
DM O 1 0.9999998807907104
protein O 0 3.751038821064867e-05
kinase O 0 9.162836249743123e-06
gene O 0 1.3343834837087343e-07
( O 0 1.9081907165485745e-09
DMPK O 0 1.564517788210651e-06
) O 0 8.944772145191848e-10
is O 0 1.7506200933326e-09
responsible O 0 1.8527874345863893e-08
for O 0 4.1287083973884364e-08
causing O 1 0.6394458413124084
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0009554432472214103
DM B-Disease 1 0.9999998807907104
) O 0 9.16943690754124e-07
. O 0 4.1285835550297634e-07

Major O 0 3.4034635518764844e-06
instability O 0 3.3373103178746533e-06
, O 0 8.98204710608752e-09
with O 0 1.1066301208728646e-09
very O 0 2.427344991673408e-09
large O 0 1.702854302010337e-09
expansions O 0 1.2213660305349094e-08
between O 0 1.8091075304482729e-09
generations O 0 3.728567232741398e-09
and O 0 2.7188706841485555e-09
high O 0 1.0002820793886258e-08
levels O 0 7.909060628641384e-10
of O 0 3.403637094390177e-10
somatic O 0 4.669934412504517e-07
mosaicism O 0 4.27147897426039e-05
, O 0 5.355420995556415e-09
is O 0 3.563745964996201e-09
observed O 0 2.871723303599083e-08
in O 0 1.883153366577517e-08
patients O 0 3.2635034585837275e-05
. O 0 2.7525439350029046e-07

There O 0 5.634423132505617e-07
is O 0 8.887228730714014e-09
a O 0 5.792943902349634e-09
good O 0 1.1903092733689391e-08
correlation O 0 1.6075881958954596e-08
between O 0 1.2431479179397797e-09
repeat O 0 3.443052420948334e-08
size O 0 2.306117252715012e-08
( O 0 3.0719754517960496e-10
at O 0 2.1819537843192904e-10
least O 0 2.0363284392033165e-09
in O 0 9.056461136580651e-10
leucocytes O 0 8.299656997223792e-07
) O 0 1.4924746993827398e-09
, O 0 3.5810121534751715e-09
clinical O 0 3.078331189954042e-07
severity O 0 0.00044913365854881704
and O 0 9.64745936471445e-08
age O 0 3.517985547318858e-08
of O 0 2.0256871735568893e-09
onset O 0 3.048612143174978e-06
. O 0 8.435214340352104e-07

The O 0 1.6592692873018677e-06
trinucleotide O 0 7.87288008723408e-05
repeat O 0 4.211990017211065e-06
instability O 0 8.756976512813708e-07
mechanisms O 0 1.1668663546515745e-07
involved O 0 5.988518836375079e-08
in O 0 8.038400522991651e-08
DM B-Disease 1 0.9999998807907104
and O 0 7.22776292150229e-07
other O 0 9.492470809391307e-09
human O 0 3.21214429277461e-07
genetic B-Disease 1 0.9999973773956299
diseases I-Disease 1 0.9999879598617554
are O 0 3.188505957041343e-07
unknown O 0 8.37631091599178e-07
. O 0 1.2505020663411415e-07

We O 0 5.405080401033047e-07
studied O 0 2.26528655389302e-07
somatic O 0 1.0698096275518765e-06
instability O 0 3.74749163256638e-07
by O 0 6.607955516102493e-09
measuring O 0 1.783422476364649e-07
the O 0 4.121428531789206e-09
CTG O 0 8.243334264079749e-07
repeat O 0 7.807388158198592e-08
length O 0 4.7846381079352795e-08
at O 0 3.3035399416014855e-10
several O 0 1.2698883056216914e-09
ages O 0 2.9087943165251318e-09
in O 0 2.89319485036188e-10
various O 0 3.970687389998062e-10
tissues O 0 1.34375897076211e-08
of O 0 3.6202654762895747e-10
transgenic O 0 6.994093268986035e-07
mice O 0 4.411744612298207e-06
carrying O 0 1.9824652142119703e-08
a O 0 2.555186817687627e-08
( O 0 4.148219101551831e-09
CTG O 0 1.3438354926620377e-06
) O 0 2.8560391829302034e-09
55expansion O 0 4.5458259023689607e-07
surrounded O 0 2.6338595304764567e-08
by O 0 8.324478328880502e-10
45 O 0 1.740545152451034e-09
kb O 0 2.7165189209199525e-08
of O 0 1.7293198817380784e-10
the O 0 3.607432796925991e-09
human O 0 1.6820270332118525e-07
DM B-Disease 1 0.9999998807907104
region O 0 5.310029678184947e-07
, O 0 1.7585113365470306e-09
using O 0 2.519825681446264e-09
small O 0 6.096388283083343e-09
- O 0 2.103545284626307e-06
pool O 0 1.0294745607097866e-06
PCR O 0 1.5933428585412912e-05
. O 0 2.776609733246005e-07

These O 0 1.2538629334812867e-06
mice O 0 9.474867511016782e-06
have O 0 2.207191762693128e-08
been O 0 6.865069401840174e-09
shown O 0 9.3084429053647e-09
to O 0 2.6412381171070365e-09
reproduce O 0 2.2838659674562223e-07
the O 0 8.036721288462445e-10
intergenerational O 0 3.913742219197047e-08
and O 0 3.188360908623622e-09
somatic O 0 6.05760703820124e-08
instability O 0 1.9947771434658534e-08
of O 0 2.366180862356515e-10
the O 0 2.3418735839442206e-09
55 O 0 8.099390669258355e-08
CTG O 0 7.991862389644666e-07
repeat O 0 9.875206075093956e-08
suggesting O 0 2.805414034412479e-08
that O 0 1.601408561313633e-09
surrounding O 0 1.9197632372680573e-09
sequences O 0 1.9679371465741724e-09
and O 0 7.624559872354553e-10
the O 0 1.9085028002407967e-10
chromatin O 0 2.0692612068273775e-08
environment O 0 1.4214325716466192e-08
are O 0 4.34885322198042e-10
involved O 0 8.169449561279407e-10
in O 0 2.430726953051021e-09
instability O 0 2.6488584126127535e-07
mechanisms O 0 6.76099091379001e-07
. O 0 3.024164811904484e-07

As O 0 8.818305445856822e-07
observed O 0 1.1647227182720599e-07
in O 0 7.87718945627347e-10
some O 0 2.813582977712059e-10
of O 0 1.2954873285231372e-10
the O 0 3.620267197135263e-09
tissues O 0 6.293925025602221e-07
of O 0 6.756383186257153e-08
DM B-Disease 1 1.0
patients O 1 0.9999618530273438
, O 0 4.90571050448807e-09
there O 0 6.883225101006474e-10
is O 0 5.596833552168334e-10
a O 0 2.583776970155327e-09
tendency O 0 6.246416717203829e-08
for O 0 1.707596508637721e-09
repeat O 0 1.0087740065500839e-07
length O 0 4.4269413024267124e-07
and O 0 7.009329117124707e-09
somatic O 0 1.400135261064861e-07
mosaicism O 0 2.417379391772556e-06
to O 0 1.0809399597633274e-08
increase O 0 9.180837423627963e-09
with O 0 1.7027050880358274e-09
the O 0 1.0009113537989833e-09
age O 0 5.315661244509329e-09
of O 0 1.3224957240431934e-10
the O 0 4.218771110231501e-09
mouse O 0 4.0663535401108675e-06
. O 0 1.354855498902907e-07

Furthermore O 0 3.089993697358295e-05
, O 0 7.612477048724031e-08
we O 0 5.690126592128308e-09
observed O 0 5.007010805968548e-09
no O 0 9.859256744348954e-10
correlation O 0 2.0182671089941095e-09
between O 0 2.1917766213075396e-10
the O 0 6.990473200296776e-10
somatic O 0 7.673754680581624e-07
mutation O 0 2.510387048459961e-06
rate O 0 3.6501386802001434e-08
and O 0 4.811963272288722e-09
tissue O 0 1.8912721770902863e-06
proliferation O 0 1.300182645991299e-07
capacity O 0 2.876978726362722e-07
. O 0 1.6435973293482675e-07

The O 0 6.71323505230248e-07
somatic O 0 8.72345390234841e-06
mutation O 0 1.72736599779455e-05
rates O 0 1.1462259408290265e-07
in O 0 6.84635403924716e-10
different O 0 5.832543337191964e-10
tissues O 0 4.065350012183444e-08
were O 0 3.804349901770365e-08
also O 0 2.1599973365482583e-08
not O 0 1.7220170844822746e-09
correlated O 0 3.832635986356081e-09
to O 0 4.453528934522666e-10
the O 0 1.5514005358152616e-10
relative O 0 1.085576428749846e-08
inter O 0 5.6091260525192865e-09
- O 0 2.710861963350908e-06
tissue O 0 1.8573148281575413e-06
difference O 0 1.4649628177210161e-08
in O 0 1.1087909757012682e-10
transcriptional O 0 1.0607243972060587e-08
levels O 0 2.4237503115642767e-09
of O 0 6.739898916752196e-11
the O 0 1.610889061032239e-10
three O 0 8.687381369831826e-10
genes O 0 9.011149160187415e-09
( O 0 2.0122246091602847e-09
DMAHP O 0 6.822167051723227e-06
, O 0 1.0422079199656764e-08
DMPK O 0 4.047419224662008e-06
and O 0 2.1003165429078763e-08
59 O 0 2.8057510093049132e-08
) O 0 2.093379497525305e-10
surrounding O 0 1.0388157001273157e-09
the O 0 1.0605296640875395e-09
repeat O 0 2.425266529826331e-07
. O 0 1.8634516152360447e-08
. O 0 7.823129521966621e-08

A O 0 7.551775979663944e-06
novel O 0 6.478569957835134e-06
missense O 0 0.00010640238178893924
mutation O 0 4.208239715808304e-06
in O 0 2.916234187466671e-08
patients O 0 3.1502459023613483e-06
from O 0 1.3187130276648418e-09
a O 0 1.151555224510048e-07
retinoblastoma B-Disease 0 0.00048092924407683313
pedigree O 0 1.591912041476462e-05
showing O 0 8.190018547793443e-07
only O 0 3.3552144174109344e-08
mild O 0 6.213920278241858e-05
expression O 0 8.47547028115514e-08
of O 0 1.6803756164307515e-09
the O 0 4.026134803325476e-08
tumor B-Disease 0 0.008117594756186008
phenotype O 0 0.008070744574069977
. O 0 2.9800696665915893e-07

We O 0 4.245848401751573e-07
have O 0 1.4171634532544886e-08
used O 0 7.777184229951217e-09
single O 0 1.946929906182504e-08
strand O 0 1.8523111577906093e-07
conformation O 0 1.36424915808675e-07
polymorphism O 0 1.425349523742625e-06
analysis O 0 6.191802182087258e-09
to O 0 2.5235964429271007e-09
study O 0 1.447660213926838e-09
the O 0 7.638853993796602e-10
27 O 0 1.2798732740293417e-08
exons O 0 1.8375837740336465e-08
of O 0 2.0817052248656154e-10
the O 0 2.333144122346198e-09
RB1 O 0 1.3652113466378069e-06
gene O 0 7.499243892539198e-09
in O 0 4.885799542719838e-10
individuals O 0 2.8784982730734043e-10
from O 0 8.394181877369178e-11
a O 0 1.2599633336662919e-08
family O 0 1.0982433451545148e-07
showing O 0 2.4432681584585225e-06
mild O 0 0.0013172663748264313
expression O 0 5.7122804264508886e-08
of O 0 7.745175611972854e-10
the O 0 3.006797655302762e-08
retinoblastoma B-Disease 0 0.017360040917992592
phenotype O 0 0.03666882589459419
. O 0 3.982091527632292e-07

In O 0 1.1964668544806045e-07
this O 0 4.504661532678256e-09
family O 0 4.4820808398071676e-08
affected O 0 1.5361203864472373e-08
individuals O 0 1.9264829731469035e-09
developed O 0 2.1898823376886867e-07
unilateral B-Disease 0 0.0641096979379654
tumors I-Disease 1 1.0
and O 0 3.9600809031981044e-07
, O 0 2.3529507231501157e-09
as O 0 7.735977969325347e-10
a O 0 1.918778469445215e-09
result O 0 3.204517096122572e-09
of O 0 1.829880275083795e-10
linkage O 0 6.394448632818239e-07
analysis O 0 2.313249503060888e-08
, O 0 7.935796020319685e-09
unaffected O 0 9.051251481650979e-07
mutation O 0 2.0175680504053162e-07
carriers O 0 1.8616256980408252e-08
were O 0 9.194681460655829e-09
also O 0 2.6820144327643902e-08
identified O 0 1.1779325959082598e-08
within O 0 1.6139091452149756e-10
the O 0 1.6162234883765336e-09
pedigree O 0 3.0912331112631364e-06
. O 0 1.953592771997137e-07

A O 0 1.228512928719283e-06
single O 0 1.45963070963262e-07
band O 0 5.1968662262424914e-08
shift O 0 3.2733613153368424e-08
using O 0 1.1769759389324008e-08
SSCP O 0 3.0368516945600277e-06
was O 0 1.3491501249518478e-07
identified O 0 1.3270858190139734e-08
in O 0 6.879655178870792e-10
exon O 0 1.296792078164799e-07
21 O 0 1.3695515832523597e-08
which O 0 1.7507804095373558e-09
resulted O 0 4.128926978097525e-09
in O 0 7.658870204707569e-10
a O 0 5.6035901252471376e-08
missense O 0 5.857873929926427e-06
mutation O 0 9.947761725470627e-08
converting O 0 9.18271148009353e-09
a O 0 3.846632878889977e-08
cys O 0 6.630856660194695e-05
- O 0 8.920601430872921e-06
- O 0 7.115630978660192e-06
> O 0 1.2912116176266863e-07
arg O 0 1.0530604299674451e-07
at O 0 6.321874135295502e-10
nucleotide O 0 2.872828419597795e-09
position O 0 1.2749758582231152e-08
28 O 0 5.160504468193494e-09
in O 0 4.529532859898211e-10
the O 0 4.441392142950917e-09
exon O 0 3.0004298423591536e-06
. O 0 1.764681769600429e-07

The O 0 3.3261753173974284e-07
mutation O 0 2.66669712800649e-06
destroyed O 0 1.9390702732380305e-07
an O 0 1.2526787607214374e-08
NdeI O 0 1.1340063110765186e-06
restriction O 0 2.3664864556849352e-07
enzyme O 0 1.0385848270288989e-07
site O 0 1.133777658424151e-07
. O 0 7.323836825889884e-08

Analysis O 0 1.1735169209714513e-06
of O 0 9.99549687463741e-09
all O 0 8.260027106743451e-10
family O 0 5.304317873822129e-09
members O 0 6.773667737824951e-10
demonstrated O 0 8.791835703902962e-09
that O 0 1.4611585275048355e-09
the O 0 3.985652696769648e-09
missense O 0 2.3397164113703184e-05
mutation O 0 1.0245655630569672e-06
co O 0 5.532593831958366e-07
- O 0 1.2287987374293152e-06
segregated O 0 2.1634468794218265e-07
with O 0 1.5477260717489116e-07
patients O 0 0.0007651759078726172
with O 0 3.1644729006075067e-06
tumors B-Disease 1 0.9999995231628418
or O 0 1.0956907914305702e-07
who O 0 3.171433718307526e-06
, O 0 1.4835063177898178e-09
as O 0 8.735900336453994e-10
a O 0 3.6397782565700254e-09
result O 0 2.4675976817434275e-09
of O 0 2.2606265470681564e-10
linkage O 0 3.00739429803798e-07
analysis O 0 2.338206073204674e-08
had O 0 1.0988929233235467e-07
been O 0 6.444475619815648e-09
predicted O 0 1.3318810054840924e-08
to O 0 1.4024674754864463e-09
carry O 0 1.5242243023294577e-08
the O 0 5.176424622277409e-09
predisposing O 0 8.58092425914947e-06
mutation O 0 3.7363079172791913e-06
. O 0 1.576227646182815e-07

These O 0 2.61694481196173e-07
observations O 0 1.4457575048254512e-07
point O 0 7.968618653819703e-09
to O 0 9.764188346750302e-10
another O 0 4.422195498676729e-09
region O 0 1.309664265924937e-09
of O 0 2.89269802555836e-10
the O 0 8.999451850399964e-09
RB1 O 0 4.240775979269529e-06
gene O 0 9.250250343484367e-09
where O 0 6.010716369075908e-09
mutations O 0 1.9335187673164e-08
only O 0 1.00637098654488e-09
modify O 0 1.1778427122521862e-08
the O 0 1.7011848874037838e-10
function O 0 1.8311792360226065e-10
of O 0 1.1591444817882213e-11
the O 0 6.628170928779653e-11
gene O 0 2.4962185651844493e-09
and O 0 7.685415082114844e-10
raise O 0 2.5445927587242068e-09
important O 0 2.430582124457459e-10
questions O 0 8.279886776207945e-10
for O 0 3.5418021293587287e-10
genetic O 0 1.5515443152480657e-08
counseling O 0 4.99314412039098e-09
in O 0 6.092886195574465e-10
families O 0 1.0216341106428217e-09
with O 0 9.093537589599521e-10
these O 0 5.795065760594298e-09
distinctive O 0 7.856092452129815e-06
phenotypes O 0 1.7437518181395717e-05
. O 0 2.2067077054543915e-08
. O 0 5.231056121601796e-08

Maternal B-Disease 0 0.14480721950531006
disomy I-Disease 0 0.048379167914390564
and O 0 0.10346447676420212
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
consistent O 0 5.476703790918691e-06
with O 0 3.90763155166951e-09
gamete O 0 2.596765398266143e-07
complementation O 0 1.8578357412479818e-06
in O 0 2.0998027761010007e-09
a O 0 5.521469503833032e-09
case O 0 3.965106287751041e-08
of O 0 9.734232309099866e-10
familial O 0 6.158993073768215e-06
translocation O 0 5.746501301473472e-06
( O 0 4.588928348425725e-09
3 O 0 1.1600642224607327e-08
; O 0 1.3312943636378805e-08
15 O 0 7.2622663438437485e-09
) O 0 1.242005609469743e-09
( O 0 1.6689692960980551e-09
p25 O 0 4.885953330813209e-07
; O 0 9.606361928149454e-09
q11 O 0 1.3098902229558007e-07
. O 0 7.86796960916547e-10
2 O 0 3.0736180267609825e-09
) O 0 3.2252429615908795e-09
. O 0 6.903348293008094e-08

Maternal B-Disease 1 0.9833577275276184
uniparental I-Disease 1 0.9912749528884888
disomy I-Disease 1 0.8753763437271118
( I-Disease 0 2.59552489296766e-05
UPD I-Disease 1 0.9999799728393555
) I-Disease 0 1.1875862071519805e-07
for I-Disease 0 1.4229299516443916e-08
chromosome I-Disease 0 2.1652622308465652e-06
15 I-Disease 0 7.263484924635577e-09
is O 0 8.706325105301005e-10
responsible O 0 1.2409896443799084e-09
for O 0 2.0235853270822446e-10
an O 0 1.4637360212788053e-09
estimated O 0 2.3385884340143548e-09
30 O 0 1.4078705978803896e-09
% O 0 1.2596113041496437e-10
of O 0 1.0030570124497373e-10
cases O 0 6.069172542311208e-08
of O 0 9.904451871989295e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.169461580109783e-06
PWS B-Disease 1 0.9999768733978271
) O 0 5.508049980562646e-07
. O 0 3.977013705025456e-07

We O 0 5.351865297598124e-07
report O 0 2.282756916827111e-08
on O 0 9.91464244037843e-10
an O 0 6.877476921296477e-10
unusual O 0 6.5075442812201345e-09
case O 0 3.1533033961750334e-08
of O 0 7.023001624695269e-10
maternal B-Disease 0 2.855942739188322e-06
disomy I-Disease 0 5.584262908087112e-06
15 I-Disease 0 1.8522928968423003e-08
in O 0 7.486424813407666e-09
PWS B-Disease 1 0.9999810457229614
that O 0 6.975934496722402e-08
is O 0 4.806349540587007e-09
most O 0 2.3233210910689195e-09
consistent O 0 3.191258457491131e-08
with O 0 1.889336687099785e-09
adjacent O 0 1.3423500533349397e-08
- O 0 9.87046107070455e-08
1 O 0 2.9732738493493116e-09
segregation O 0 5.894571497577772e-09
of O 0 2.1749937961779153e-10
a O 0 3.415619787006108e-08
paternal O 0 2.536329884605948e-05
t O 0 5.729804115617299e-07
( O 0 5.999100105569255e-10
3 O 0 3.043515883760506e-09
; O 0 2.2530901588879715e-09
15 O 0 1.472601818264252e-09
) O 0 4.112843399184385e-10
( O 0 5.585231166449489e-10
p25 O 0 1.642544305013871e-07
; O 0 5.5562692224953025e-09
q11 O 0 8.407540974531003e-08
. O 0 6.848809297466119e-10
2 O 0 5.55071599794843e-10
) O 0 8.125172062944941e-11
with O 0 2.3173232777118358e-10
simultaneous O 0 5.272486092167128e-08
maternal O 0 1.0726568007157766e-06
meiotic O 0 8.284473551611882e-07
nondisjunction O 0 2.6530599370744312e-06
for O 0 1.562496620977072e-08
chromosome O 0 4.5720530579274055e-06
15 O 0 1.4671921633180318e-07
. O 0 1.6658604806707444e-07

The O 0 6.612711445086461e-07
patient O 0 2.3052189135341905e-05
( O 0 2.0626176322480205e-08
J O 0 1.6511759895365685e-05
. O 0 8.485948832515078e-09
B O 0 1.926043147193468e-08
. O 0 2.6944663167327576e-10
) O 0 1.6956777648680088e-10
, O 0 3.029128892162447e-10
a O 0 5.577909245602086e-09
17 O 0 9.394450550814781e-09
- O 0 7.133019863658774e-08
year O 0 1.4929309344324793e-08
- O 0 1.7953436781681376e-06
old O 0 9.793816388992127e-06
white O 0 4.97488997552864e-07
male O 0 1.7260944105146336e-06
with O 0 1.1461580839977614e-07
PWS B-Disease 1 0.9999977350234985
, O 0 4.2561943303098815e-08
was O 0 8.03974984364686e-08
found O 0 1.5073166048651387e-09
to O 0 1.5708867540098481e-09
have O 0 1.0555838869663603e-08
47 O 0 2.5749230303517834e-08
chromosomes O 0 3.602942610925197e-09
with O 0 7.67554131364534e-10
a O 0 3.472029419526734e-08
supernumerary O 0 3.663380994112231e-05
, O 0 2.2046590331115112e-08
paternal O 0 6.236962235561805e-06
der O 0 1.8962651665788144e-05
( O 0 1.5314418622125459e-09
15 O 0 1.65818114794547e-09
) O 0 1.3780451779688008e-10
consisting O 0 4.927802610410481e-10
of O 0 5.280328257972755e-11
the O 0 9.187436922353243e-10
short O 0 4.479123916212302e-08
arm O 0 3.770592797991412e-07
and O 0 9.463794192754449e-10
the O 0 9.27621757185193e-10
proximal O 0 1.3086633771308698e-05
long O 0 7.192447810666636e-07
arm O 0 1.615141513866547e-06
of O 0 8.463298395433583e-10
chromosome O 0 8.576977847951639e-07
15 O 0 1.0026850461031245e-08
, O 0 1.8707941862317057e-09
and O 0 1.647497960277633e-08
distal O 0 0.008762219920754433
chromosome O 1 0.6704752445220947
arm O 0 0.005033672321587801
3p O 0 0.00014050155004952103
. O 0 1.1539357274159556e-06

The O 0 7.450273074027791e-07
t O 0 3.2766995445854263e-06
( O 0 7.471388840940563e-09
3 O 0 4.6289971855628664e-09
; O 0 3.881047483389466e-09
15 O 0 2.4097235318265575e-09
) O 0 3.293762762535124e-10
was O 0 9.34815957975843e-08
present O 0 4.974073375407784e-10
in O 0 1.1522611337300148e-10
the O 0 1.8941348489676102e-10
balanced O 0 9.074327067537524e-09
state O 0 1.1936734933826187e-09
in O 0 5.050226903335897e-10
the O 0 6.7080869747826455e-09
patients O 0 4.9615982788964175e-06
father O 0 2.7992305717816635e-07
and O 0 6.672955965569827e-09
a O 0 1.008976084904134e-07
sister O 0 4.852648999076337e-06
. O 0 8.15487055660924e-08

Fluorescent O 0 4.116687341593206e-05
in O 0 5.256640989159678e-08
situ O 0 2.27645273298549e-07
hybridization O 0 1.0030488795109704e-07
analysis O 0 3.4923264280450894e-08
demonstrated O 0 4.5393452552389135e-08
that O 0 2.5886899290838983e-09
the O 0 7.490209341654008e-09
PWS B-Disease 1 0.9999527931213379
critical O 0 3.613616399888997e-06
region O 0 2.6867965630117396e-08
resided O 0 3.888495925252755e-08
on O 0 1.0490041058019983e-09
the O 0 4.3360481871701495e-10
derivative O 0 3.19810773419249e-08
chromosome O 0 1.4903170608704386e-07
3 O 0 1.9321499955538e-09
and O 0 1.3236370888236593e-09
that O 0 1.7153852782669787e-09
there O 0 1.4352440347309425e-09
was O 0 7.979040361760781e-08
no O 0 1.3487089223218618e-09
deletion O 0 1.2021370565662437e-08
of O 0 3.517364455252192e-10
the O 0 1.0672184025395381e-08
PWS B-Disease 1 0.9999765157699585
region O 0 4.686603105596987e-08
on O 0 1.4077477850094056e-08
the O 0 7.789130451740789e-10
normal O 0 1.6460585117172855e-09
pair O 0 3.573561224712307e-09
of O 0 1.6055762275257734e-10
15s O 0 6.584908618378904e-08
present O 0 9.688946533970011e-09
in O 0 1.5732023683767693e-08
J O 0 0.00032328939414583147
. O 0 4.4507444840746757e-07

B O 0 0.0007296353578567505
. O 0 6.714202754665166e-06

Methylation O 0 1.5450255887117237e-05
analysis O 0 6.501821303572797e-07
at O 0 8.158833608717941e-09
exon O 0 7.230397613966488e-08
alpha O 0 3.725482145000569e-09
of O 0 1.566027724164698e-10
the O 0 1.6505566358127055e-10
small O 0 8.178445698447945e-10
nuclear O 0 2.411398192236902e-08
ribonucleoprotein O 0 1.2328860066190828e-06
- O 0 2.038390903180698e-06
associated O 0 1.0232205482907375e-07
polypeptide O 0 4.766539234424272e-07
N O 0 2.5069059006455063e-07
( O 0 4.115056351228219e-10
SNRPN O 0 4.203067192065646e-07
) O 0 5.145022186070491e-10
gene O 0 8.998593870046534e-09
showed O 0 2.6029111310776898e-08
a O 0 2.3752029232326777e-09
pattern O 0 1.1648583608803165e-07
characteristic O 0 2.0532990419042108e-08
of O 0 1.5171514045064782e-10
only O 0 2.496175488531094e-09
the O 0 1.3565415457605923e-09
maternal O 0 3.2543609904678306e-06
chromosome O 0 3.823288807325298e-06
15 O 0 2.3586585129464765e-08
in O 0 1.2935874593722474e-08
J O 0 0.0011383398668840528
. O 0 3.195870021954761e-07

B O 0 0.0013324128231033683
. O 0 7.728028322162572e-06

Maternal B-Disease 0 0.012976125814020634
disomy I-Disease 0 0.00033617790904827416
was O 0 3.2438847483717836e-06
confirmed O 0 3.20311350776592e-08
by O 0 4.375277640189523e-10
polymerase O 0 8.47296490746885e-08
chain O 0 2.421626561499579e-07
reaction O 0 3.2042255071473846e-08
analysis O 0 2.3965227580191595e-09
of O 0 4.775351780672565e-10
microsatellite O 0 7.967069564074336e-07
repeats O 0 4.829472644019006e-08
at O 0 5.27710874997922e-10
the O 0 4.113714091591447e-10
gamma O 0 2.0505829922967678e-08
- O 0 8.241856903623557e-07
aminobutyric O 0 1.196704943140503e-05
acid O 0 9.401226179761579e-07
receptor O 0 2.401455105882633e-07
beta3 O 0 1.0456305972184055e-06
subunit O 0 1.6772295907685475e-07
( O 0 1.0002304762224412e-08
GABRB3 O 0 5.625185167446034e-06
) O 0 3.0807683515376993e-08
locus O 0 2.3028528630675282e-06
. O 0 3.533375547704054e-07

A O 0 9.66234892985085e-06
niece O 0 4.4871132558910176e-05
( O 0 3.29538067944668e-08
B O 0 9.614889506792679e-08
. O 0 1.2307476149331364e-09
B O 0 9.092276265221244e-09
. O 0 1.2402484594886687e-10
) O 0 5.656456900093865e-11
with O 0 2.029743179088328e-10
45 O 0 6.436229882389455e-10
chromosomes O 0 7.858131367832755e-10
and O 0 2.8687860420539835e-10
the O 0 8.01611138578906e-11
derivative O 0 7.60838059221669e-09
3 O 0 8.54014414741755e-10
but O 0 1.5785608376006621e-09
without O 0 2.8713917354927787e-10
the O 0 4.851958834706238e-10
der O 0 1.9451799744274467e-06
( O 0 2.2058554982606893e-10
15 O 0 5.616274667552545e-10
) O 0 1.764578344554124e-10
demonstrated O 0 2.00405185779573e-08
a O 0 8.461869782649956e-08
phenotype O 0 0.011596662923693657
consistent O 0 1.1947633993258933e-07
with O 0 1.127989479599023e-09
that O 0 9.80508385595158e-09
reported O 0 1.6314158912678067e-08
for O 0 2.5073401688224806e-10
haploinsufficiency O 0 1.4864703246075806e-07
of O 0 1.0093601510163808e-09
distal O 0 4.967491258867085e-05
3 O 0 2.356033974137972e-06
p O 0 9.604194929124787e-06
. O 0 1.7479041503065673e-07

Uniparental B-Disease 1 0.9998683929443359
disomy I-Disease 1 0.9993990659713745
associated O 0 2.291900455020368e-05
with O 0 1.0410303019625644e-07
unbalanced O 0 1.3122376003593672e-05
segregation O 0 3.3189286341439583e-07
of O 0 1.370784485921206e-09
non O 0 1.1054387627495998e-08
- O 0 2.3066641006153077e-06
Robertsonian O 0 2.3356678866548464e-05
translocations O 0 8.100029845081735e-06
has O 0 7.83126495207398e-07
been O 0 6.999231771942505e-08
reported O 0 2.3901421286609548e-08
previously O 0 1.0207367395764777e-08
but O 0 3.1287088475551172e-09
has O 0 2.6086963700322485e-08
not O 0 3.2401767935397174e-09
, O 0 1.858930648301893e-10
to O 0 5.055922902563736e-10
our O 0 1.376944391839885e-10
knowledge O 0 5.5004837490324476e-11
, O 0 1.0978774833692029e-10
been O 0 1.0582644760503968e-09
observed O 0 6.731217805366896e-10
in O 0 8.7298501760813e-11
a O 0 3.7455598622671005e-09
case O 0 1.3659415287747834e-07
of O 0 4.078491144809959e-08
PWS B-Disease 1 0.9999802112579346
. O 0 3.1461806884180987e-06

Furthermore O 0 1.400101427861955e-05
, O 0 3.7058384805277456e-08
our O 0 3.201230613925077e-09
findings O 0 6.94910662346615e-09
are O 0 3.7556446841335855e-10
best O 0 4.621128368853533e-09
interpreted O 0 2.362021511714829e-08
as O 0 2.0756163454649368e-09
true O 0 8.387051941838308e-09
gamete O 0 2.3245020486228896e-07
complementation O 0 8.318167488141626e-07
resulting O 0 1.6249013867764006e-07
in O 0 4.335697312285447e-08
maternal B-Disease 0 0.095893494784832
UPD I-Disease 1 0.9999964237213135
15 I-Disease 0 1.352253275399562e-05
and O 0 7.517365247622365e-06
PWS B-Disease 1 0.999984622001648

Schwartz B-Disease 0 0.48559194803237915
- I-Disease 1 0.9976353645324707
Jampel I-Disease 1 0.9985626339912415
syndrome I-Disease 1 0.9999860525131226
type I-Disease 0 4.287770934752189e-06
2 I-Disease 0 1.1499376739720901e-07
and O 0 6.756040988875611e-07
Stuve B-Disease 1 0.8791733384132385
- I-Disease 1 0.9999843835830688
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999984502792358
: O 0 3.354976074732008e-09
a O 0 1.2352777467583564e-08
case O 0 8.340251866911785e-08
for O 0 1.6047504436400573e-09
" O 0 1.0680145656749573e-08
lumping O 0 1.8121117761893402e-07
" O 0 5.5994235026446404e-08
. O 0 4.149875110215362e-08

Recent O 0 2.293925263074925e-06
studies O 0 9.829091851543126e-08
demonstrated O 0 3.648510116249781e-08
the O 0 2.5643287493437583e-10
existence O 0 5.569869565569263e-10
of O 0 1.271036331740305e-10
a O 0 6.41594777306409e-09
genetically O 0 7.276967295410941e-08
distinct O 0 1.184533982012681e-08
, O 0 2.4126853848116525e-09
usually O 0 6.285135523143026e-09
lethal O 0 3.279060223349006e-08
form O 0 9.689368196674764e-10
of O 0 2.402022192260489e-10
the O 0 1.1885578743431324e-08
Schwartz B-Disease 0 0.002086969092488289
- I-Disease 1 0.9899514317512512
Jampel I-Disease 1 0.9999479055404663
syndrome I-Disease 1 0.9999955892562866
( O 0 2.3006606397757423e-08
SJS B-Disease 0 2.489799226168543e-05
) O 0 2.822156952575483e-09
of O 0 4.561909960898447e-09
myotonia B-Disease 1 0.5103568434715271
and O 0 1.1827473826997448e-05
skeletal B-Disease 1 0.9987486600875854
dysplasia I-Disease 1 0.9999803304672241
, O 0 1.0317651799596206e-07
which O 0 4.3666197768743586e-08
we O 0 9.143108492537522e-09
called O 0 1.252203816193287e-07
SJS B-Disease 0 7.861318590585142e-05
type I-Disease 0 1.2466208545447444e-06
2 I-Disease 0 8.41309173438276e-08
. O 0 9.535536094062991e-08

This O 0 1.5436589819728397e-05
disorder O 0 0.24675054848194122
is O 0 1.7055725720638293e-08
reminiscent O 0 1.284045225702357e-07
of O 0 5.313387507754896e-10
another O 0 5.576890771408216e-08
rare O 0 8.132639663926966e-07
condition O 0 5.4013580665923655e-06
, O 0 4.516594653836137e-09
the O 0 1.1164104307681555e-08
Stuve B-Disease 0 0.44578132033348083
- I-Disease 1 0.9999353885650635
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999994039535522
( O 0 5.9133125063226544e-08
SWS B-Disease 0 0.00018069628276862204
) O 0 1.6052096318830422e-09
, O 0 1.2990361009102003e-09
which O 0 3.0421696273208454e-09
comprises O 0 2.191079540025953e-09
campomelia B-Disease 0 3.128516823380778e-07
at O 0 1.5104189010628488e-09
birth O 0 3.874851017826586e-08
with O 0 2.354357064859869e-08
skeletal B-Disease 1 0.9976363182067871
dysplasia I-Disease 1 0.9999938011169434
, O 0 1.3036831205681665e-06
contractures B-Disease 0 0.002693085465580225
, O 0 9.739362205607449e-09
and O 0 5.338125053100384e-09
early B-Disease 0 1.4012013593855954e-07
death I-Disease 0 0.0009493564139120281
. O 0 2.6907898131867114e-07

To O 0 4.0452209759678226e-07
test O 0 8.191378952915329e-08
for O 0 6.59385102075305e-10
possible O 0 5.685776294228617e-09
nosologic O 0 1.7531423281980096e-06
identity O 0 1.821455342110312e-08
between O 0 3.1353817320223243e-09
these O 0 1.1092319951444551e-08
disorders O 0 0.00010860674956347793
, O 0 2.6762592142404174e-09
we O 0 1.3541838761454983e-09
reviewed O 0 5.2079967005624894e-09
the O 0 4.4744233318461113e-10
literature O 0 1.4565673112088007e-09
and O 0 5.149911608270941e-10
obtained O 0 7.304521432160982e-10
a O 0 7.84537212972225e-10
follow O 0 1.8081554031823543e-09
- O 0 1.880457745073727e-08
up O 0 1.3505572216132578e-09
of O 0 5.315178852605129e-11
the O 0 2.590457015561043e-10
only O 0 2.2982078462518984e-09
two O 0 3.0458389144172315e-09
surviving O 0 3.620656798375421e-06
patients O 0 1.0257388112222543e-06
, O 0 2.8211330493910225e-10
one O 0 5.456868845676865e-10
with O 0 2.4896329442469778e-09
SJS B-Disease 0 1.206256274599582e-05
type I-Disease 0 2.3968675577634713e-07
2 I-Disease 0 3.0938629436150222e-09
at O 0 7.538433766107744e-10
age O 0 6.0330913598249936e-09
10 O 0 6.328473300953874e-10
years O 0 9.525275013189116e-10
and O 0 7.791611800200826e-10
another O 0 4.406568443471315e-09
with O 0 5.121077339964586e-09
SWS B-Disease 0 0.00012825021985918283
at O 0 4.1622154611786755e-09
age O 0 1.8526037592891953e-08
7 O 0 1.820225925541763e-08
years O 0 2.4063535164486893e-08
. O 0 5.218042176124982e-08

Patients O 1 0.9822344183921814
reported O 0 1.765316028468078e-06
as O 0 1.8604721319093187e-08
having O 0 3.7729808610720283e-08
either O 0 5.198759822633292e-07
neonatal O 1 0.9999014139175415
SJS B-Disease 1 0.9372437596321106
or O 0 9.849695743469056e-07
SWS B-Disease 0 0.003576405579224229
presented O 0 2.7274007052824345e-08
a O 0 3.0693998454012217e-09
combination O 0 6.487047343739505e-09
of O 0 1.5345784365461412e-10
a O 0 1.0405717176809048e-07
severe O 0 0.3066680431365967
, O 0 1.2864564951087232e-06
prenatal O 0 0.2677622437477112
- O 1 0.9835147857666016
onset O 1 0.9620463252067566
neuromuscular B-Disease 1 0.9999954700469971
disorder I-Disease 1 0.9999761581420898
( O 0 6.691183784823806e-08
with O 0 1.7125704516729456e-06
congenital B-Disease 1 0.9999922513961792
joint I-Disease 0 0.40040406584739685
contractures I-Disease 1 0.9999852180480957
, O 0 0.0026202418375760317
respiratory O 1 0.999639630317688
and O 0 4.908576556772459e-06
feeding O 0 2.249588987979223e-06
difficulties O 0 9.28419083834342e-08
, O 0 1.7302247412587235e-09
tendency O 0 1.903208897147124e-07
to O 0 3.8380372302526666e-07
hyperthermia B-Disease 1 0.9974353909492493
, O 0 4.9570498816819963e-08
and O 0 2.2741131644465895e-08
frequent O 0 8.799824172456283e-06
death O 0 0.025970233604311943
in O 0 2.5413926962869482e-08
infancy O 0 1.0963091199300834e-06
) O 0 4.1578812615128413e-10
with O 0 3.8606384755723866e-10
a O 0 2.2915733310924224e-08
distinct O 0 1.6507588895819936e-07
campomelic B-Disease 0 0.00041075533954426646
- I-Disease 0 0.020986830815672874
metaphyseal I-Disease 1 0.5370901226997375
skeletal I-Disease 1 0.9962937235832214
dysplasia I-Disease 1 0.9998557567596436
. O 0 3.933138941647485e-06

The O 0 1.341511079999691e-07
similarity O 0 2.810781438711274e-07
of O 0 1.5934197294953378e-09
the O 0 3.289030825470718e-09
clinical O 0 3.176169229845982e-07
and O 0 7.750990960175841e-08
radiographic O 0 0.03853633999824524
findings O 0 1.3478502296493389e-06
is O 0 3.431118944519085e-09
so O 0 2.559682910074912e-09
extensive O 0 1.060222754034612e-08
that O 0 1.4049796881465682e-08
these O 0 1.189986864602588e-08
disorders O 0 1.6661937479511835e-05
appear O 0 8.034538012680059e-08
to O 0 3.6554250737452776e-09
be O 0 6.8384222728923305e-09
a O 0 2.2635626706346557e-08
single O 0 2.6635657945917046e-07
entity O 0 5.420174034043157e-07
. O 0 1.5537065678472572e-07

The O 0 1.3965880896193994e-07
follow O 0 8.499122117200386e-08
- O 0 2.3769814561092062e-07
up O 0 1.6102518429761403e-08
observation O 0 5.0735380341393466e-08
of O 0 1.5009640752516873e-10
an O 0 1.3192916759052764e-09
identical O 0 8.267096518466133e-08
and O 0 1.4411802862213108e-09
unique O 0 2.923282949041095e-09
pattern O 0 4.6077698101498754e-08
of O 0 1.1111668252183904e-09
progressive O 0 0.009423951618373394
bone B-Disease 0 0.2519266605377197
dysplasia I-Disease 1 0.9999558925628662
in O 0 6.7945578052786e-08
the O 0 6.0381797339914556e-09
two O 0 6.552659783665149e-07
patients O 0 1.5783283743076026e-05
( O 0 3.623809308184178e-10
one O 0 1.8361253628640384e-09
with O 0 4.3136298977231036e-09
SJS B-Disease 0 8.689681271789595e-05
type I-Disease 0 3.6856717997579835e-06
2 I-Disease 0 1.0400037275815066e-08
, O 0 8.084751756953779e-10
one O 0 1.8147131575219078e-09
with O 0 5.7224189831117656e-09
SWS B-Disease 0 9.597273310646415e-05
) O 0 3.482340638072401e-09
surviving O 0 1.6225753540766163e-07
beyond O 0 1.7300211041515468e-08
infancy O 0 1.3232154572051513e-07
adds O 0 4.38810010550128e-09
to O 0 5.318781526320038e-10
the O 0 1.4259768366109427e-10
evidence O 0 2.2548787281806426e-09
in O 0 3.9287265107823544e-10
favor O 0 4.1507677295271606e-09
of O 0 9.270840761743671e-10
identity O 0 1.8228494980121468e-07
. O 0 1.094141168778151e-07

The O 0 3.8570658489334164e-07
hypothesis O 0 2.5490155621810118e-06
that O 0 6.59823555793082e-08
SWS B-Disease 0 0.00010692028445191681
and O 0 7.459260586983874e-08
SJS B-Disease 0 3.1696457881480455e-05
type I-Disease 0 3.3908955288097786e-07
2 I-Disease 0 2.76446932012675e-09
are O 0 6.20014206642594e-10
the O 0 1.0831332497573953e-09
same O 0 6.647354098276992e-07
disorder O 0 0.0009379104594700038
should O 0 1.8456628225749228e-08
be O 0 3.1086391238943634e-09
testable O 0 1.0306004050164574e-08
by O 0 4.012025434096955e-10
molecular O 0 7.448395678011366e-09
methods O 0 1.0665264227327498e-08
. O 0 8.732373046882458e-09
. O 0 3.9541554031075066e-08

A O 0 4.155438091402175e-06
mouse O 0 5.760020940215327e-06
model O 0 1.1935873089896631e-06
of O 0 9.807649803406093e-08
severe O 1 0.9997575879096985
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 4.4227341277292e-05
defects O 1 0.9964333772659302
in O 0 3.025604371487134e-07
hemostasis O 0 0.0351376011967659
and O 0 0.0001194814030895941
thrombosis B-Disease 1 0.9287854433059692
. O 0 3.906153779098531e-06

von B-Disease 1 0.9943501353263855
Willebrand I-Disease 1 0.9931625127792358
factor I-Disease 0 0.00045167835196480155
( I-Disease 0 2.922983412645408e-06
vWf I-Disease 0 0.0008629225194454193
) I-Disease 0 1.7764146832632832e-05
deficiency I-Disease 1 0.9492552876472473
causes O 0 0.017244748771190643
severe O 1 0.9999896287918091
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 7.530732546001673e-06
humans O 0 2.10237203646102e-06
. O 0 3.778915811381012e-07

We O 0 9.87803261409681e-08
generated O 0 1.8308597304894647e-08
a O 0 5.3732343019419204e-09
mouse O 0 9.81771890451455e-08
model O 0 5.963738658465445e-08
for O 0 8.520538719025694e-10
this O 0 7.188344586239737e-09
disease O 0 3.582735814688931e-07
by O 0 1.8797683409843557e-09
using O 0 2.1755187873395698e-08
gene O 0 1.583080546652127e-07
targeting O 0 3.8922846101741015e-07
. O 0 1.4251835978029703e-07

vWf B-Disease 0 0.051478300243616104
- I-Disease 1 0.9864382743835449
deficient I-Disease 1 0.976673424243927
mice O 0 0.0015783860580995679
appeared O 0 2.3661170871491777e-06
normal O 0 1.2208211330744234e-08
at O 0 1.003118699216543e-09
birth O 0 6.508266636728877e-08
; O 0 2.049189928854389e-09
they O 0 2.6425586163725256e-09
were O 0 5.756925602895535e-09
viable O 0 4.23483257350199e-08
and O 0 2.4472242898809782e-08
fertile O 0 9.48966487612779e-07
. O 0 4.425737927249429e-07

Neither O 0 0.00015647080726921558
vWf O 0 0.0005293621798045933
nor O 0 4.545808769762516e-05
vWf O 0 0.00010788256622618064
propolypeptide O 0 0.00012555738794617355
( O 0 2.6055491275656095e-07
von B-Disease 0 0.18495281040668488
Willebrand I-Disease 1 0.8420816659927368
antigen O 0 0.00014713052951265126
II O 0 2.4854058210621588e-05
) O 0 5.4645798996943995e-09
were O 0 9.967111580522214e-09
detectable O 0 4.196014558033312e-08
in O 0 1.3376544316656691e-09
plasma O 0 2.349113970012695e-07
, O 0 3.0332121259135647e-09
platelets O 0 1.219871847979448e-07
, O 0 1.7467310930996405e-09
or O 0 6.151728015879598e-10
endothelial O 0 1.9270635220891563e-07
cells O 0 1.3790563357929386e-08
of O 0 2.2002207000770824e-10
the O 0 3.088603817147373e-09
homozygous O 0 4.83681969853933e-06
mutant O 0 7.280990303115686e-06
mice O 0 2.150130421796348e-05
. O 0 1.8683741132008436e-07

The O 0 1.6066018133642501e-06
mutant O 0 9.653087181504816e-05
mice O 0 0.04837675020098686
exhibited O 0 0.0017452434403821826
defects O 0 0.3416684567928314
in O 0 3.3099514240575445e-08
hemostasis O 0 1.432204862794606e-05
with O 0 1.0874497746726774e-08
a O 0 7.933665102655141e-08
highly O 0 2.7173746275366284e-07
prolonged O 0 0.0007765896152704954
bleeding O 0 0.22716204822063446
time O 0 8.553745267647628e-09
and O 0 7.082692654591938e-09
spontaneous O 0 5.444908168783513e-08
bleeding O 0 4.3773467041319236e-05
events O 0 1.870926080727031e-09
in O 0 7.275239299886493e-10
approximately O 0 1.3968771694905513e-09
10 O 0 1.497421964202772e-09
% O 0 7.204098428914563e-10
of O 0 1.5358558869138506e-09
neonates O 0 0.009023502469062805
. O 0 3.2433817409582844e-07

As O 0 2.5986454943449644e-07
in O 0 5.970679062272666e-09
the O 0 2.112327646131007e-09
human O 0 1.6787042866894808e-08
disease O 0 2.274534551816032e-07
, O 0 4.128467845365691e-10
the O 0 2.9541716295433673e-10
factor O 0 9.039415438394371e-09
VIII O 0 0.0005031338660046458
level O 0 4.375195761241457e-09
in O 0 1.7498389404124737e-09
these O 0 9.411502688294604e-10
mice O 0 1.6262048347925884e-06
was O 0 3.400241155304684e-07
reduced O 0 2.65246757891191e-08
strongly O 0 4.888368110300689e-08
as O 0 1.1298347812882525e-09
a O 0 2.641026508598543e-09
result O 0 1.6409833492048165e-09
of O 0 4.078344953417634e-11
the O 0 4.800941866278663e-10
lack O 0 7.455615680385108e-09
of O 0 1.4753851473869872e-09
protection O 0 1.2210719546601467e-07
provided O 0 5.3597460691889864e-08
by O 0 3.77429785203276e-08
vWf O 0 1.2786486877303105e-05
. O 0 3.3458718462497927e-07

Defective O 1 0.8561087250709534
thrombosis B-Disease 1 0.9929855465888977
in O 0 6.193600370352215e-07
mutant O 0 2.146950464521069e-05
mice O 0 6.191408465383574e-05
was O 0 2.5117662971751997e-07
also O 0 7.849252803282525e-09
evident O 0 7.65023155935296e-09
in O 0 2.602228155179631e-10
an O 0 7.943696811452128e-10
in O 0 1.760981693799124e-09
vivo O 0 1.0027941925727646e-06
model O 0 9.772245590511375e-08
of O 0 5.7478080073281035e-09
vascular B-Disease 1 0.96169513463974
injury I-Disease 1 0.917022705078125
. O 0 1.9207147943234304e-06

In O 0 3.2877159128474887e-07
this O 0 1.2830899009941277e-08
model O 0 1.041707591298291e-07
, O 0 2.5120996394178974e-09
the O 0 4.304113065956017e-09
exteriorized O 0 1.1880389138241298e-05
mesentery O 0 1.0019595720223151e-05
was O 0 5.242628162704932e-07
superfused O 0 6.670030643363134e-07
with O 0 4.114320439896346e-09
ferric O 0 2.5107128749368712e-06
chloride O 0 2.1603534605674213e-06
and O 0 3.043957086390492e-09
the O 0 5.90429038993534e-10
accumulation O 0 1.1396723564871536e-08
of O 0 1.415112693692322e-09
fluorescently O 0 1.3902979844715446e-05
labeled O 0 2.3091822640708415e-06
platelets O 0 1.0383159860793967e-06
was O 0 1.1856239012786318e-07
observed O 0 1.3051862701729533e-08
by O 0 4.124637076330373e-09
intravital O 0 4.295300641388167e-06
microscopy O 0 2.0667191620304948e-06
. O 0 1.2388693448883714e-07

We O 0 5.251976062936592e-07
conclude O 0 2.1782473424991622e-07
that O 0 5.18510079317025e-09
these O 0 1.9620716162904728e-09
mice O 0 3.631120080171968e-07
very O 0 6.7630079314540126e-09
closely O 0 7.927538803187417e-08
mimic O 0 7.100043876562268e-05
severe O 1 0.8920864462852478
human O 0 0.0004617517697624862
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999997615814209
disease I-Disease 1 1.0
and O 0 3.3835283375083236e-06
will O 0 1.7629594140089466e-07
be O 0 8.033445908495196e-09
very O 0 1.5602921177304552e-09
useful O 0 9.152333890760644e-10
for O 0 1.8397527945523962e-10
investigating O 0 7.993762318747599e-10
the O 0 1.1928875942590622e-10
role O 0 6.150484566092018e-10
of O 0 1.828498741307527e-10
vWf O 0 9.082140195459942e-08
in O 0 1.3598652204294126e-09
normal O 0 6.462101964643807e-09
physiology O 0 2.3728812692525025e-08
and O 0 8.538617812803295e-09
in O 0 3.673017801020251e-08
disease O 0 4.868120868195547e-06
models O 0 7.060008897497028e-07
. O 0 2.1731796806534476e-08
. O 0 1.3766312179086526e-07

Oral O 0 0.0018217647448182106
contraceptives O 0 0.008506327867507935
and O 0 3.3022452328168583e-08
the O 0 3.273360027478134e-09
risk O 0 7.00228923733448e-08
of O 0 1.040670909446817e-07
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 7.138972250686493e-06

Hereditary B-Disease 1 0.9999933242797852
Ovarian I-Disease 1 0.9999891519546509
Cancer I-Disease 1 0.9993517994880676
Clinical O 0 0.0001759269944159314
Study O 0 1.8225589428766398e-06
Group O 0 6.274333941291843e-07
. O 0 1.3806781851144478e-07

BACKGROUND O 0 0.0006241975352168083
Women O 0 1.1343935284457984e-06
with O 0 8.17862044755202e-09
mutations O 0 1.830032800853587e-07
in O 0 1.6640361311104357e-09
either O 0 5.23844212452218e-09
the O 0 4.447954005115662e-09
BRCA1 O 0 2.656609694895451e-06
or O 0 2.595562431650933e-09
the O 0 2.261731690822444e-09
BRCA2 O 0 1.898522327792307e-06
gene O 0 2.2991734738297964e-08
have O 0 7.062767704013595e-09
a O 0 1.9083882918380368e-08
high O 0 1.445980757353027e-07
lifetime O 0 8.019316624086059e-07
risk O 0 4.6871750214450003e-07
of O 0 6.846254905212845e-07
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999972581863403
. O 0 1.7442005173506914e-06

Oral O 0 0.0009235597099177539
contraceptives O 0 0.19090847671031952
protect O 0 4.753155735670589e-05
against O 0 0.15979549288749695
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.999997615814209
in O 0 2.3099207879795358e-08
general O 0 1.575676833454054e-08
, O 0 1.9643295878779554e-09
but O 0 2.944862353970734e-09
it O 0 1.3450249802815506e-09
is O 0 1.050758258180906e-09
not O 0 1.0116942839033527e-09
known O 0 9.474522277841402e-10
whether O 0 1.4289180949589309e-09
they O 0 5.764196342461503e-10
also O 0 2.8245479288813158e-09
protect O 0 3.233114442835472e-09
against O 0 1.9500889791856935e-08
hereditary B-Disease 0 0.020435186102986336
forms I-Disease 0 5.50857521375292e-07
of I-Disease 0 1.4174916032061446e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 2.6089260245498735e-06

METHODS O 0 6.76468789606588e-06
We O 0 5.179331097338036e-08
enrolled O 0 3.1275884992965075e-08
207 O 0 3.2566468632921897e-08
women O 0 1.203557644657849e-07
with O 0 1.3733440482610604e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 1.1038526537276994e-07
161 O 0 2.8367782789473495e-08
of O 0 4.5519987779130133e-10
their O 0 3.3232976370811684e-09
sisters O 0 2.4069684911864897e-08
as O 0 4.284387566944048e-10
controls O 0 1.1797903454180414e-07
in O 0 1.3049614722149272e-09
a O 0 5.246694101401772e-08
case O 0 1.5215700841508806e-06
- O 0 6.530004156957148e-06
control O 0 4.522175458987476e-06
study O 0 5.55522312595258e-08
. O 0 5.58327677424586e-08

All O 0 1.1050091330844225e-07
the O 0 1.153458395464213e-08
patients O 0 3.8451443629128335e-07
carried O 0 5.861833241027625e-09
a O 0 1.0352676937941396e-08
pathogenic O 0 1.675170722137409e-07
mutation O 0 1.649177505669286e-07
in O 0 4.238644990550711e-09
either O 0 5.595494201315887e-08
BRCA1 O 0 8.43430188979255e-06
( O 0 5.7297584454829575e-09
179 O 0 2.460465680087509e-07
women O 0 1.1545682809810387e-07
) O 0 5.5775264407031955e-09
or O 0 6.664740936912494e-08
BRCA2 O 0 9.59467506618239e-05
( O 0 1.4336362319511409e-08
28 O 0 6.081630203880195e-07
women O 0 1.133963678512373e-07
) O 0 1.0688399498803847e-08
. O 0 1.4878914100791008e-07

The O 0 1.5889234816768294e-07
control O 0 5.807926299894461e-07
women O 0 7.00882338833253e-08
were O 0 1.2332577625784324e-08
enrolled O 0 6.492220983034258e-09
regardless O 0 1.048334086206637e-09
of O 0 4.544388823579659e-11
whether O 0 1.8602227536135274e-09
or O 0 4.163611122542932e-10
not O 0 4.17472989511225e-09
they O 0 3.0945945805882502e-09
had O 0 6.744293301608195e-08
either O 0 2.7791999812620816e-08
mutation O 0 4.1454100596638455e-07
. O 0 7.645901689556922e-08

Lifetime O 0 4.109242217964493e-05
histories O 0 1.598532207935932e-06
of O 0 1.8289121328507463e-08
oral O 0 6.084043207010836e-07
- O 0 5.956638688076055e-06
contraceptive O 0 0.00022519228514283895
use O 0 1.742060540266266e-08
were O 0 7.073256202971834e-09
obtained O 0 3.0941935680317556e-09
by O 0 1.255436088420936e-09
interview O 0 1.3771143869689695e-07
or O 0 4.702752076646277e-10
by O 0 6.41773134635315e-10
written O 0 1.0395000415996947e-08
questionnaire O 0 3.717732255381634e-08
and O 0 1.6704725380733976e-09
were O 0 9.363163577802425e-09
compared O 0 1.2455599218696989e-08
between O 0 4.89193752173378e-09
patients O 0 1.4997032849350944e-05
and O 0 2.253740483126876e-08
control O 0 5.0933408601849806e-06
women O 0 7.353594355663517e-08
, O 0 5.733504782057253e-10
after O 0 1.3064855863831326e-09
adjustment O 0 9.991665272934824e-09
for O 0 3.669219095225884e-10
year O 0 3.765370792940814e-10
of O 0 1.2862542975167202e-10
birth O 0 5.989855367261043e-08
and O 0 1.3840999457670478e-08
parity O 0 2.820426630023576e-07
. O 0 1.4145552995614707e-07

RESULTS O 0 5.346883426682325e-06
The O 0 8.863123568403353e-09
adjusted O 0 4.967887434759177e-07
odds O 0 2.7370945190341445e-06
ratio O 0 6.152517926238943e-06
for O 0 8.756676834309474e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
associated O 0 6.307414679440626e-08
with O 0 5.032053662645808e-10
any O 0 3.754054567206566e-10
past O 0 1.0326010047023715e-09
use O 0 1.5433823108423894e-09
of O 0 8.740367318793574e-10
oral O 0 2.0684462924691616e-06
contraceptives O 0 0.11550748348236084
was O 0 9.878763194137719e-07
0 O 0 1.4643741508280073e-07
. O 0 1.0382897386307377e-07

5 O 0 1.772488872120448e-06
( O 0 1.3220581962514188e-08
95 O 0 1.8427432024736845e-08
percent O 0 2.9909532628380475e-08
confidence O 0 3.1667500621779254e-08
interval O 0 1.0147404694293982e-08
, O 0 1.2931427040285826e-09
0 O 0 2.038839097551204e-09
. O 0 1.4443497786675863e-10
3 O 0 2.90386464874004e-10
to O 0 3.2146303396984877e-09
0 O 0 2.6965409460899536e-08
. O 0 2.1536856742443433e-09
8 O 0 9.421726510083772e-09
) O 0 7.433564430670003e-09
. O 0 7.084479136665323e-08

The O 0 6.975854489610356e-07
risk O 0 1.057475060406432e-06
decreased O 0 2.0175103543351725e-07
with O 0 1.602951771317862e-09
increasing O 0 4.013267496105755e-09
duration O 0 1.469376087470664e-08
of O 0 1.434102281372418e-10
use O 0 4.986044466193107e-09
( O 0 7.733101381468543e-10
P O 0 5.77198058238082e-08
for O 0 4.5073150767294123e-10
trend O 0 1.559703655118483e-08
, O 0 1.6084829024265446e-09
< O 0 5.4948054994952145e-09
0 O 0 4.38830927151912e-09
. O 0 5.704021699415307e-10
001 O 0 1.3740519833049802e-08
) O 0 2.200665621954201e-10
; O 0 1.1246397563224875e-10
use O 0 5.325684893087157e-10
for O 0 4.1210257428758723e-10
six O 0 1.0858781651634786e-09
or O 0 2.652090491661596e-10
more O 0 1.4930554570469212e-09
years O 0 1.6328321805758605e-08
was O 0 2.1950341988485889e-07
associated O 0 4.616870497020642e-10
with O 0 4.400315528618748e-11
a O 0 5.089838328586893e-09
60 O 0 1.6548201031696408e-08
percent O 0 1.9689295527314243e-08
reduction O 0 2.0963142333130236e-08
in O 0 1.4211994248114479e-08
risk O 0 8.112391469694558e-07
. O 0 1.132982134777194e-07

Oral O 0 0.00017006378038786352
- O 0 0.0001088014105334878
contraceptive O 0 0.00026661003357730806
use O 0 3.0771161618758924e-07
protected O 0 2.662756924109999e-05
against O 0 0.07992658019065857
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
both O 0 2.3269722149166228e-08
for O 0 2.2428299217835956e-09
carriers O 0 3.158014516557728e-09
of O 0 1.726630505238802e-10
the O 0 5.302871031176437e-09
BRCA1 O 0 9.084113116841763e-06
mutation O 0 4.125623433992587e-07
( O 0 2.0215187301886317e-09
odds O 0 1.2806176528101787e-06
ratio O 0 1.2021627071590046e-07
, O 0 1.2393315262926308e-09
0 O 0 5.021050242248748e-09
. O 0 2.0629853381137764e-10
5 O 0 2.1422623397437945e-10
; O 0 2.312258995385008e-10
95 O 0 2.6420645671265675e-09
percent O 0 6.162488741523475e-09
confidence O 0 8.676589224876352e-09
interval O 0 2.2527679721662253e-09
, O 0 1.772458013693523e-10
0 O 0 1.090140644421922e-09
. O 0 1.547227901355086e-10
3 O 0 3.3273550581469635e-10
to O 0 3.037461393518015e-09
0 O 0 2.7834122562353514e-08
. O 0 7.842035354421739e-10
9 O 0 8.013639196668976e-10
) O 0 6.460160184573738e-11
and O 0 2.574566670965339e-10
for O 0 2.0437554426600002e-10
carriers O 0 1.2372671776006428e-09
of O 0 5.509408207426958e-11
the O 0 6.156191556527801e-09
BRCA2 O 0 4.150251334067434e-05
mutation O 0 3.0898723935024464e-07
( O 0 1.347621125802334e-09
odds O 0 5.539499170481577e-07
ratio O 0 1.2090912093754014e-07
, O 0 1.1001711763825028e-09
0 O 0 3.2093372404062848e-09
. O 0 2.6490770688170073e-10
4 O 0 5.6799415171227e-10
; O 0 3.51125128972285e-10
95 O 0 3.5624001526457505e-09
percent O 0 1.0044921339158464e-08
confidence O 0 6.513256600726436e-09
interval O 0 2.5284965232685863e-09
, O 0 5.008593539912454e-10
0 O 0 1.5634050720692017e-09
. O 0 1.7656252848663456e-10
2 O 0 4.366448869141948e-10
to O 0 1.543208671961338e-09
1 O 0 2.283918387746553e-09
. O 0 9.425819014197145e-10
1 O 0 4.1005323581089215e-09
) O 0 5.095501354190901e-09
. O 0 6.732019386390675e-08

CONCLUSIONS O 0 0.00010775292321341112
Oral O 0 2.764271994237788e-05
- O 0 2.8264465072425082e-05
contraceptive O 0 0.00011278296733507887
use O 0 4.429829303376209e-08
may O 0 3.1001203382174936e-08
reduce O 0 8.829108111285677e-09
the O 0 2.2694928158983885e-09
risk O 0 1.2689670825238863e-07
of O 0 5.110941287966853e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
in O 0 3.197485298755964e-08
women O 0 2.4942684362372347e-08
with O 0 3.7100233996056886e-09
pathogenic O 0 4.2115297560485487e-07
mutations O 0 4.587224111674004e-07
in O 0 6.000590691002117e-09
the O 0 2.7522229828491618e-08
BRCA1 O 0 0.00017766497330740094
or O 0 6.419599003493204e-07
BRCA2 O 0 0.0004029576084576547
gene O 0 2.7532643798622303e-05

A O 0 1.6316947721861652e-06
Japanese O 0 4.1115069393526937e-07
family O 0 1.4138215931325249e-07
with O 0 2.96590645376682e-08
adrenoleukodystrophy B-Disease 1 0.9999531507492065
with O 0 1.3976855228747809e-08
a O 0 2.5781959678283783e-08
codon O 0 1.9460357236766868e-07
291 O 0 9.526282696015187e-08
deletion O 0 2.483185141954891e-07
: O 0 1.2837354512740262e-09
a O 0 2.467048609844369e-08
clinical O 0 3.219442987756338e-07
, O 0 6.17686835013842e-09
biochemical O 0 2.5930509650606837e-07
, O 0 5.243080192229854e-09
pathological O 0 1.6947568610703456e-06
, O 0 1.3206721050096348e-08
and O 0 7.893560649563369e-08
genetic O 0 1.2106988833693322e-06
report O 0 1.803230134100886e-07
. O 0 1.0015156703957473e-07

We O 0 5.304446517584438e-07
report O 0 4.650548035556312e-08
a O 0 7.64238450301491e-09
Japanese O 0 4.213803350694434e-08
family O 0 2.2367099461462203e-07
with O 0 2.462064458086388e-06
adrenoleukodystrophy B-Disease 1 0.9999998807907104
( O 0 1.2152997442171909e-05
ALD B-Disease 1 0.9999996423721313
) O 0 6.845730649018833e-09
with O 0 8.536008011539309e-10
a O 0 9.08657238340993e-09
three O 0 3.098575396265346e-09
base O 0 1.680302830209257e-08
pair O 0 5.484986331794062e-08
deletion O 0 2.407309125374013e-07
( O 0 1.2516631064940498e-09
delGAG O 0 3.0423106522903254e-07
291 O 0 3.016056737692452e-08
) O 0 7.249198463732398e-10
in O 0 2.667463361305522e-09
the O 0 5.646354850341595e-08
ALD B-Disease 1 0.9999986886978149
gene O 0 7.796138379490003e-05
. O 0 3.639141823441605e-07

A O 0 1.8257547935718321e-06
variety O 0 3.827976513548492e-08
of O 0 3.225513633964283e-09
phenotypes O 0 2.8516806196421385e-06
were O 0 2.486990524630528e-08
observed O 0 1.6510306011241482e-08
within O 0 3.8298494930977256e-10
this O 0 1.6387876611290153e-09
family O 0 1.1580771541730428e-07
. O 0 6.310531830422406e-08

While O 0 8.934343327382521e-07
the O 0 1.647340752697346e-08
proband O 0 3.3046130738512147e-06
( O 0 1.942667893217731e-08
patient O 0 3.437689429119928e-06
1 O 0 6.237461214197992e-09
) O 0 1.7524909301513958e-09
was O 0 2.3291219974908017e-07
classified O 0 5.554256166107052e-09
as O 0 1.964689300137934e-09
having O 0 1.819919437373585e-09
a O 0 2.3359405521006238e-09
rare O 0 4.456303770439263e-08
intermediate O 0 4.106341577880812e-08
type O 0 3.872870379950655e-08
of O 0 8.1895751291583e-10
adult O 0 1.2043057722621597e-05
cerebral O 0 0.0020366169046610594
and O 0 2.0579517467922415e-07
cerebello O 0 0.007302587851881981
- O 0 0.003286954713985324
brain O 0 0.0008354659657925367
stem O 0 1.3897681583330268e-07
forms O 0 3.102657686326893e-08
, O 0 9.428053893145716e-09
his O 0 6.573802693310427e-07
younger O 0 1.0818591363204177e-05
brother O 0 5.247162334853783e-06
( O 0 2.8517879169243088e-09
patient O 0 2.155399897674215e-06
2 O 0 6.0952487501708674e-09
) O 0 2.2691377665751133e-09
and O 0 1.4436302819831326e-07
nephew O 0 0.0173278097063303
( O 0 1.3721087377405183e-08
patient O 0 2.2579526557819918e-05
3 O 0 1.5720235779781433e-08
) O 0 2.3185402486802786e-09
had O 0 1.9783419702434912e-06
a O 0 8.07901506050257e-06
childhood O 0 0.0050374967977404594
ALD B-Disease 1 0.9999984502792358
type O 0 0.0074272858910262585
. O 0 1.2689853292613407e-06

Another O 0 2.4084067263174802e-05
nephew O 0 0.0003677572531159967
( O 0 1.4632657041602215e-07
patient O 0 1.219665318785701e-05
4 O 0 9.495258801450746e-09
) O 0 4.109330375978715e-10
of O 0 9.391222244303776e-10
patient O 0 3.625927638495341e-05
1 O 0 1.782746572587257e-08
was O 0 4.723450501842308e-07
classified O 0 7.553635938961634e-09
as O 0 2.6939794839364595e-09
having O 0 3.641680956789628e-09
an O 0 3.2523621573687933e-09
adolescent O 0 1.2470644605855341e-06
form O 0 1.0455951837684552e-07
. O 0 1.63825163213005e-07

The O 0 4.474171788615422e-08
tau O 0 4.646053497481262e-08
level O 0 7.1593366790523305e-09
in O 0 1.1536382960031233e-09
the O 0 1.0380397874598657e-08
cerebrospinal O 0 0.0004766832571476698
fluid O 0 0.0008985953754745424
( O 0 4.988577373410408e-08
CSF O 0 0.004673661198467016
) O 0 4.007989051757477e-09
in O 0 7.888936615074726e-09
patient O 0 1.3727176337852143e-05
1 O 0 1.0180206011511927e-08
was O 0 4.832596118831134e-07
as O 0 4.337390446806921e-09
high O 0 4.539948861292942e-09
as O 0 1.0673888439782786e-09
that O 0 7.979504834665363e-10
of O 0 1.1893850349053992e-09
patients O 0 1.4303948773886077e-05
with O 0 4.379045094538014e-06
Alzheimers B-Disease 1 0.9999468326568604
disease I-Disease 0 0.029196936637163162
( O 0 1.0261968164115842e-08
AD B-Disease 0 1.9707156297954498e-06
) O 0 7.59743485900799e-08
. O 0 1.1720266002157587e-07

His O 0 9.39609708439093e-06
brain O 0 3.964077768614516e-05
magnetic O 0 4.886873284704052e-05
resonance O 0 0.00029158874531276524
image O 0 0.0005659587332047522
( O 0 4.661053409904525e-08
MRI O 0 0.0010550860315561295
) O 0 4.003085862791522e-08
showed O 0 0.0006318447412922978
abnormalities B-Disease 0 0.02480006031692028
in I-Disease 0 1.3551063604566593e-09
the I-Disease 0 1.7330420432060123e-09
bilateral I-Disease 0 9.904407249905489e-08
cerebellar I-Disease 0 0.11957831680774689
hemispheres I-Disease 0 0.11026781797409058
and O 0 2.5405140036127705e-07
brain O 0 4.680796791944886e-06
stem O 0 4.360419225690748e-08
, O 0 2.6225941418545062e-09
but O 0 1.7557429954351278e-09
not O 0 7.914629507332904e-10
in O 0 2.3078441935275862e-10
the O 0 2.962891265667622e-09
cerebral O 0 0.027951432392001152
white O 0 2.345939407177866e-07
matter O 0 7.1927610534316955e-09
, O 0 3.5616035121144307e-10
where O 0 7.367936816216059e-10
marked O 0 5.243220524420167e-09
reductions O 0 9.395292543956657e-09
of O 0 1.5717131762738035e-10
the O 0 4.237803885587255e-09
cerebral O 0 0.0018566877115517855
blood O 0 3.182815646596282e-07
flow O 0 3.116286961812875e-08
and O 0 2.1719863241287385e-08
oxygen O 0 1.5378095952200965e-07
metabolism O 0 1.648720804325876e-08
were O 0 5.231173272335354e-09
clearly O 0 4.949293241907071e-08
demonstrated O 0 1.7672343588515105e-08
by O 0 1.7740283686507041e-09
positron O 0 1.3020308870181907e-05
emission O 0 2.609649982332485e-06
tomography O 0 6.2022460042499e-05
( O 0 2.3845597496574555e-08
PET O 0 3.449998757787398e-06
) O 0 3.25170645965045e-08
. O 0 1.5206995840344462e-07

In O 0 5.002554189559305e-06
patients O 0 0.00012311931641306728
2 O 0 1.7308593669440597e-08
and O 0 4.344163251346345e-09
3 O 0 4.381710105860748e-09
, O 0 1.541090810519563e-09
the O 0 2.7964588422690895e-09
autopsy O 0 0.4669908583164215
findings O 0 5.342288886822644e-07
showed O 0 5.244433509687951e-07
massive O 0 3.2103218927659327e-07
demyelination B-Disease 1 0.9999358654022217
of I-Disease 0 6.718317457909961e-09
the I-Disease 0 1.6560198545789717e-08
cerebral I-Disease 0 0.0049768309108912945
white I-Disease 0 7.992398565193071e-08
matter I-Disease 0 5.782390566366757e-09
with O 0 6.701638133321808e-10
sparing O 0 1.5542276798896637e-08
of O 0 4.088698268844837e-10
the O 0 1.2477802124877257e-09
U O 0 2.59884400293231e-05
- O 0 0.0017067743465304375
fibers O 0 6.964586646063253e-05
, O 0 3.0425988395421655e-09
compatible O 0 5.683856940663645e-09
with O 0 3.679998528127726e-10
the O 0 1.0741816325321452e-09
findings O 0 5.076548603710762e-08
of O 0 7.882453800789335e-09
childhood O 0 6.605485395994037e-05
ALD B-Disease 1 0.9999936819076538
. O 0 6.5676949816406704e-06

Oleic O 1 0.5243275165557861
and O 0 1.4998006008681841e-05
erucic O 0 0.01568148098886013
acids O 0 1.0770604603749234e-06
( O 0 8.612318858070012e-09
Lorenzos O 0 6.572686856998189e-07
Oil O 0 2.581650271338276e-08
) O 0 4.4010142752348713e-10
were O 0 4.51006965107581e-09
administered O 0 7.639935795111796e-09
to O 0 4.111263507411422e-08
patients O 0 1.3785981991532026e-06
1 O 0 1.9824490937736527e-09
and O 0 1.0213833334660194e-08
4 O 0 3.5755860494646186e-09
, O 0 5.094983324127611e-10
but O 0 2.8706703680825285e-09
sufficient O 0 1.0186343324392055e-08
effectiveness O 0 1.7743067459718986e-08
was O 0 9.485053453772707e-08
not O 0 3.0425757469032533e-09
obtained O 0 2.7889070608466682e-08
. O 0 5.109138356829135e-08

The O 0 1.762638248692383e-07
findings O 0 9.182399196561164e-08
in O 0 1.0612378753549478e-09
this O 0 4.986555612873644e-10
family O 0 7.622469766488393e-09
suggest O 0 7.545255975571763e-09
that O 0 2.1273687256240237e-09
delGAG291 O 0 1.1508635822110591e-07
is O 0 1.0144574069670398e-09
part O 0 3.135559589750869e-10
of O 0 3.894985028951581e-11
the O 0 3.0581726040423973e-10
cause O 0 2.113977259909916e-08
of O 0 7.75394082275227e-10
Japanese O 0 2.727598939600284e-06
ALD B-Disease 1 0.9999936819076538
with O 0 1.5380207685211644e-07
phenotypic O 0 9.555776341585442e-05
variations O 0 9.398139809491113e-06
. O 0 4.973746854375349e-07

Moreover O 0 1.3408167433226481e-05
, O 0 2.8244741656635597e-08
although O 0 2.561587608695959e-09
the O 0 1.0511867765128358e-10
scale O 0 1.6184383833106608e-09
of O 0 1.0197257621635814e-10
the O 0 4.669146180802386e-10
study O 0 2.6791193707964567e-09
is O 0 3.5270066867099104e-09
limited O 0 6.008768149712296e-09
, O 0 5.930950175425664e-10
there O 0 3.745257992626705e-10
is O 0 3.99402955153505e-10
a O 0 9.647358467645972e-10
possibility O 0 2.1230719404741194e-09
that O 0 3.048076235856456e-09
PET O 0 1.6253105172836513e-07
can O 0 3.4404641358065646e-09
detect O 0 9.204809714447038e-08
an O 0 1.1718596759635602e-08
insidious B-Disease 0 0.0006860808352939785
lesion I-Disease 0 0.31368255615234375
which O 0 3.1049464155330497e-07
is O 0 3.647577884180464e-08
undetectable O 0 7.931894430157627e-08
by O 0 1.2499621337980216e-09
computed O 0 1.0279956086378661e-07
tomogram O 0 1.7579205859874492e-06
( O 0 4.5920627300688466e-09
CT O 0 5.696976586477831e-06
) O 0 1.2880766453449155e-09
or O 0 1.4511046808607375e-09
MRI O 0 6.638359627686441e-05
analysis O 0 1.5903568240105415e-08
, O 0 1.097827717622124e-09
and O 0 6.632348004131927e-10
that O 0 4.84897066943546e-10
the O 0 1.4856575691890583e-10
higher O 0 1.060495247173776e-09
level O 0 1.556302586802616e-10
of O 0 2.0986636040110085e-11
tau O 0 1.2478895694556513e-09
reflects O 0 1.2110403790899227e-09
the O 0 1.8972904844427596e-11
process O 0 1.5275172793316472e-10
of O 0 6.201100188896191e-10
neuronal B-Disease 0 2.0068300727871247e-05
degeneration I-Disease 1 0.8682785034179688
in O 0 3.5510909128788626e-06
ALD B-Disease 1 0.9999983310699463
. O 0 4.324112524045631e-06

Lorenzos O 0 0.00011139040725538507
Oil O 0 9.63460365710489e-07
should O 0 1.9244128068862665e-08
be O 0 6.546207464985798e-10
given O 0 2.928315367967116e-10
in O 0 5.086746995841551e-11
the O 0 1.3293036116301948e-10
early O 0 9.024737401830407e-09
stage O 0 2.001536927309644e-07
. O 0 1.4866000874746987e-08
. O 0 7.194080353656318e-08

Nonsense O 0 0.0003996635496150702
mutation O 0 7.410407124552876e-05
in O 0 4.837991696149402e-08
exon O 0 4.7018059490255837e-07
4 O 0 7.12696479610031e-09
of O 0 4.255816532516832e-10
human O 0 2.8598277079794343e-09
complement O 0 3.460683828393485e-08
C9 O 0 2.875818154279841e-06
gene O 0 4.6247102147845e-08
is O 0 1.4675575199518676e-09
the O 0 3.499177059218539e-10
major O 0 3.4144713723094355e-09
cause O 0 3.0538448214656455e-08
of O 0 9.269001677303379e-10
Japanese O 0 2.4048031832535344e-07
complement B-Disease 0 6.104540261731017e-06
C9 I-Disease 1 0.8247405886650085
deficiency I-Disease 0 0.1533229649066925
. O 0 4.3711366970455856e-07

Deficiency B-Disease 1 0.9653311371803284
of I-Disease 0 8.943718654563781e-09
the I-Disease 0 1.8194404871607617e-09
ninth I-Disease 0 1.2991707265541663e-08
component I-Disease 0 5.574325001589386e-09
of I-Disease 0 3.0968075326320843e-10
human I-Disease 0 3.267483617008793e-09
complement I-Disease 0 3.152413441398494e-08
( O 0 3.915114010766274e-09
C9 O 0 6.209533012224711e-07
) O 0 6.440343813807203e-10
is O 0 7.834157211838999e-10
the O 0 2.1815416140213983e-10
most O 0 4.5877031062957485e-09
common O 0 2.870042976610421e-07
complement B-Disease 1 0.9999837875366211
deficiency I-Disease 1 0.9999982118606567
in O 0 1.3154780376112285e-08
Japan O 0 1.7799877127799846e-08
but O 0 1.138477401241289e-08
is O 0 3.903064982324622e-09
rare O 0 6.929650187004199e-09
in O 0 8.521383598747434e-10
other O 0 5.120752155640673e-10
countries O 0 1.9721757560375863e-09
. O 0 6.474812153101084e-08

We O 0 2.9835183568138746e-07
studied O 0 5.489026122518226e-08
the O 0 1.5497657601670767e-09
molecular O 0 1.8568702131460668e-08
basis O 0 4.573819545328206e-09
of O 0 1.700401597304335e-08
C9 B-Disease 1 0.9631611704826355
deficiency I-Disease 0 0.19675803184509277
in O 0 7.755779130036444e-09
four O 0 1.0695516472480904e-08
Japanese O 0 2.3520281899891415e-07
C9 B-Disease 0 0.0006100719911046326
- I-Disease 1 0.8210262060165405
deficient I-Disease 1 0.975681483745575
patients O 0 0.02160278894007206
who O 0 2.4438015771011123e-06
had O 0 1.05061917565763e-05
suffered O 0 0.4566783308982849
from O 0 5.160840373719111e-06
meningococcal B-Disease 1 0.9999995231628418
meningitis I-Disease 1 0.9999996423721313
. O 0 1.9694007278303616e-05

Direct O 0 3.4289566883671796e-06
sequencing O 0 5.543388965634222e-07
of O 0 1.4853926977309584e-08
amplified O 0 1.8693488073040498e-06
C9 O 0 4.210351562505821e-06
cDNA O 0 4.897279950455413e-07
and O 0 1.8061916406963974e-08
DNA O 0 6.301318222767804e-08
revealed O 0 3.0609825785177236e-08
a O 0 7.809752844423201e-09
nonsense O 0 1.1891592066604062e-07
substitution O 0 1.4903674738775408e-08
( O 0 2.495766260324217e-09
CGA O 0 1.2841055649914779e-06
- O 0 7.0702503762731794e-06
- O 0 8.935263394960202e-06
> O 0 1.2898701129415713e-07
TGA O 0 1.263304170606716e-06
) O 0 9.686965674049475e-10
at O 0 1.7216909842243666e-10
codon O 0 4.037760348296615e-09
95 O 0 2.3469983734258903e-09
in O 0 4.0997166772527294e-10
exon O 0 3.278885429836009e-08
4 O 0 2.5764443911668877e-09
in O 0 2.9739358198277444e-10
the O 0 7.796860379549742e-10
four O 0 3.6199100605927015e-08
C9 B-Disease 0 0.00021601490152534097
- I-Disease 0 0.022733235731720924
deficient I-Disease 0 0.01068230252712965
individuals O 0 4.246480145297937e-08
. O 0 1.0994589416668532e-07

An O 0 9.761680530573358e-07
allele O 0 1.1492372323118616e-05
- O 0 2.711788056330988e-07
specific O 0 3.171076068397838e-09
polymerase O 0 1.4490316857518337e-07
chain O 0 1.9804136286438734e-07
reaction O 0 3.5795935104943055e-08
system O 0 2.131226972679201e-09
designed O 0 6.120075823901061e-08
to O 0 6.142832020827882e-09
detect O 0 4.542965825748979e-07
exclusively O 0 2.209575988842971e-08
only O 0 1.329086396495427e-09
one O 0 1.7642215466295852e-10
of O 0 1.9609211823756745e-11
the O 0 1.0395050098477299e-10
normal O 0 1.1062714078136082e-09
and O 0 8.169137588609487e-10
mutant O 0 1.1505716912552089e-07
alleles O 0 2.8324691925263323e-08
indicated O 0 3.707690865439872e-08
that O 0 6.917840189579749e-10
all O 0 4.920530302654491e-11
the O 0 1.0667267763553312e-10
four O 0 6.780910055681488e-09
patients O 0 2.2164714152950182e-07
were O 0 4.162119981998558e-09
homozygous O 0 1.3798929110464542e-08
for O 0 1.3199605297664618e-10
the O 0 1.6204514119433355e-10
mutation O 0 1.342562594430774e-08
in O 0 7.845342153700585e-10
exon O 0 6.702283172899115e-08
4 O 0 3.2651599202182524e-09
and O 0 9.63292445810282e-10
that O 0 6.420645126681279e-10
the O 0 5.488665077990618e-10
parents O 0 7.820605496533517e-09
of O 0 6.146848585686371e-10
patient O 0 1.844950361373776e-06
2 O 0 2.5708596140816553e-08
were O 0 1.214600473531391e-07
heterozygous O 0 5.7355618992005475e-06
. O 0 8.799422346328356e-08

The O 0 1.7352731163100543e-07
common O 0 5.218917920046806e-08
mutation O 0 4.980790535569213e-08
at O 0 4.685847265761822e-10
codon O 0 6.020194120992528e-09
95 O 0 3.0636329029221088e-09
in O 0 6.969478327789602e-10
exon O 0 4.44119976350521e-08
4 O 0 3.4029508100275052e-09
might O 0 1.0230327696092445e-08
be O 0 7.936972745703486e-10
responsible O 0 2.9616933350240515e-09
for O 0 6.313126132972968e-10
most O 0 8.774748039286351e-09
Japanese O 0 1.8160975514547317e-06
C9 B-Disease 0 0.39420294761657715
deficiency I-Disease 0 0.004605107009410858
. O 0 2.3281842231881456e-08
. O 0 8.410877683218132e-08

BRCA1 O 0 0.007172310259193182
required O 0 1.5519724456680706e-06
for O 0 1.5456778967859464e-08
transcription O 0 3.7888682413722563e-07
- O 0 9.627047802496236e-06
coupled O 0 4.51940741186263e-06
repair O 0 4.194609118712833e-06
of O 0 1.1916450048943261e-08
oxidative O 0 0.00017504615243524313
DNA O 0 0.00012373580830171704
damage O 0 0.0001447586837457493
. O 0 7.051570491967141e-07

The O 0 9.0020539573743e-06
breast B-Disease 1 0.9946094751358032
and I-Disease 1 0.7103769183158875
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9996730089187622
gene O 0 6.591730198124424e-05
BRCA1 O 0 1.6367743228329346e-05
encodes O 0 6.901306619511161e-07
a O 0 8.999882652460656e-07
zinc O 0 0.00013250841584522277
finger O 0 3.5698069495992968e-06
protein O 0 4.066482262032878e-08
of O 0 6.146801956319337e-10
unknown O 0 3.7731822999376163e-08
function O 0 2.15818545257207e-08
. O 0 9.462412720040447e-08

Association O 0 1.7944843193617999e-06
of O 0 5.0717936517230555e-09
the O 0 8.229633863265917e-09
BRCA1 O 0 5.759343935096695e-07
protein O 0 8.787409910837596e-09
with O 0 6.737588820193707e-10
the O 0 8.64890881135949e-10
DNA O 0 1.926594848100649e-07
repair O 0 8.142418437273591e-07
protein O 0 3.494338329801394e-08
Rad51 O 0 4.057069986629358e-07
and O 0 1.5649893603253417e-09
changes O 0 1.2552804351528835e-09
in O 0 1.1140227629269361e-10
the O 0 1.0161901875527235e-10
phosphorylation O 0 2.3192567866203717e-09
and O 0 1.7052399492456516e-09
cellular O 0 8.55622506179543e-09
localization O 0 3.3280929123691294e-09
of O 0 2.2174253752615947e-11
the O 0 1.3979851998247028e-10
protein O 0 6.497374638314568e-09
after O 0 4.710528411777659e-09
exposure O 0 4.665136188464203e-08
to O 0 5.115668777477822e-09
DNA O 0 7.378687882919621e-08
- O 0 4.943321414430102e-07
damaging O 0 4.0198352735387743e-07
agents O 0 8.339579693483756e-09
are O 0 5.062744667938546e-10
consistent O 0 9.044847537609257e-09
with O 0 3.0032581976868755e-10
a O 0 4.576114598364711e-09
role O 0 5.309935602326732e-09
for O 0 4.200368497464524e-09
BRCA1 O 0 1.124767322835396e-06
in O 0 5.735509400750516e-09
DNA O 0 1.1314493804093217e-06
repair O 0 2.6836887627723627e-05
. O 0 1.1985376886514132e-06

Here O 0 7.276737505890196e-07
, O 0 1.0679880979580503e-08
it O 0 2.6154556298507714e-09
is O 0 3.1241709219642644e-09
shown O 0 6.339881952754922e-09
that O 0 1.6217663878492772e-09
mouse O 0 1.5981268575160357e-07
embryonic O 0 2.0362426766951103e-07
stem O 0 2.7893224796571303e-07
cells O 0 8.71349129738519e-07
deficient B-Disease 0 1.0449314686411526e-05
in I-Disease 0 4.756119942328496e-09
BRCA1 I-Disease 0 1.1287238521617837e-06
are O 0 3.527982128659346e-09
defective O 0 9.723975153974607e-07
in O 0 1.6241407108097405e-09
the O 0 8.609358781441756e-10
ability O 0 7.563280668421157e-09
to O 0 2.302577906121428e-09
carry O 0 1.1273146860446559e-08
out O 0 3.932462355749067e-09
transcription O 0 4.092439453984298e-08
- O 0 5.057249268247688e-07
coupled O 0 1.1084346169809578e-06
repair O 0 7.732532480986265e-07
of O 0 1.074456190686135e-09
oxidative O 0 1.742248969094362e-05
DNA O 0 1.2952440556546208e-05
damage O 0 2.46587169385748e-05
, O 0 1.1504395658334943e-08
and O 0 1.0181525844643602e-08
are O 0 6.253566553482415e-09
hypersensitive O 0 0.0004357200232334435
to O 0 1.4704182831337675e-06
ionizing O 0 0.025563672184944153
radiation O 0 0.06843258440494537
and O 0 9.670026912544927e-08
hydrogen O 0 1.549208718643058e-06
peroxide O 0 8.974786760518327e-05
. O 0 1.8153879466353828e-07

These O 0 6.553946718668158e-07
results O 0 1.795287118966371e-07
suggest O 0 5.5511662822027574e-08
that O 0 6.452322676153699e-09
BRCA1 O 0 7.044634457997745e-07
participates O 0 1.329092125246234e-08
, O 0 1.3916356955689935e-09
directly O 0 1.927957127279001e-09
or O 0 7.63862084696143e-10
indirectly O 0 1.0432604824472946e-07
, O 0 6.663744001045302e-10
in O 0 8.065991208283663e-10
transcription O 0 7.465765605729757e-08
- O 0 3.3715848530846415e-06
coupled O 0 1.0107498837896856e-06
repair O 0 2.748473093561188e-07
of O 0 1.0192304777945083e-09
oxidative O 0 8.556441571272444e-06
DNA O 0 5.006424999010051e-06
damage O 0 8.751602763368282e-06
. O 0 3.072529253245193e-08
. O 0 9.838320380595178e-08

Truncation O 0 0.00016293468070216477
mutations O 0 0.00021959838340990245
in O 0 3.804081316616248e-08
the O 0 9.033917613976428e-09
transactivation O 0 2.5499223283986794e-06
region O 0 2.159474199459055e-08
of O 0 1.5842647194119763e-09
PAX6 O 0 2.3483855329686776e-05
result O 0 2.8697630938268048e-08
in O 0 2.6569624278494075e-09
dominant O 0 3.8339689467647986e-07
- O 0 7.2055659074976575e-06
negative O 0 2.679300223462633e-06
mutants O 0 7.441961770382477e-06
. O 0 1.493909991268083e-07

PAX6 O 0 0.004578586667776108
is O 0 6.716423968100571e-07
a O 0 2.732185500065043e-08
transcription O 0 4.219851845732592e-08
factor O 0 9.670687362017816e-09
with O 0 4.5613507415609433e-10
two O 0 2.234111784460424e-09
DNA O 0 5.0894328751383e-08
- O 0 5.666324227604491e-07
binding O 0 3.185159869190102e-07
domains O 0 1.968385099360148e-08
( O 0 6.180683742584847e-10
paired O 0 3.990416175270184e-08
box O 0 4.318728201724298e-07
and O 0 4.106600215436629e-08
homeobox O 0 1.2351856639725156e-06
) O 0 6.665142326944817e-10
and O 0 8.1004963847775e-10
a O 0 1.3368261164714568e-08
proline O 0 7.949234372972569e-07
- O 0 2.3461005582703365e-07
serine O 0 1.2351533484888932e-07
- O 0 1.3921813888373435e-06
threonine O 0 7.666753845114727e-07
( O 0 6.651328376960919e-09
PST O 0 1.4226525308913551e-06
) O 0 1.8924140476883622e-08
- O 0 7.179187377914786e-07
rich O 0 1.7473058733230573e-07
transactivation O 0 7.393623945972649e-06
domain O 0 4.5835159312446194e-07
. O 0 1.5782491402660526e-07

PAX6 O 0 0.012093296274542809
regulates O 0 3.9292564906645566e-05
eye O 0 0.00035918885259889066
development O 0 2.039217328331233e-08
in O 0 5.349908072105336e-09
animals O 0 6.788415163327954e-09
ranging O 0 2.1658637550103776e-08
from O 0 1.0391010274446444e-09
jellyfish O 0 9.437574988169217e-08
to O 0 8.208392188180369e-09
Drosophila O 0 3.8646430056132886e-08
to O 0 4.013269361280436e-08
humans O 0 1.4145931004350132e-07
. O 0 1.4043826013221405e-07

Heterozygous O 0 0.016555896028876305
mutations O 0 0.00021558362641371787
in O 0 3.8910329180907866e-08
the O 0 5.4118149961368545e-09
human O 0 1.379277225765918e-08
PAX6 O 0 1.3970578038424719e-05
gene O 0 1.5188807367394475e-07
result O 0 1.987098841027546e-08
in O 0 1.5771193240254888e-09
various O 0 2.862873049735981e-09
phenotypes O 0 6.1593805185111705e-06
, O 0 8.087054581551456e-09
including O 0 2.934188714220909e-08
aniridia B-Disease 1 0.9999997615814209
, O 0 2.253903767268639e-05
Peters B-Disease 1 0.999996542930603
anomaly I-Disease 1 0.9999978542327881
, O 0 9.444252100365702e-07
autosomal B-Disease 0 0.03620901331305504
dominant I-Disease 0 0.0078080277889966965
keratitis I-Disease 1 0.9956145286560059
, O 0 3.7439195921251667e-07
and O 0 9.023998472912353e-07
familial B-Disease 0 0.19848774373531342
foveal I-Disease 1 0.9985804557800293
dysplasia I-Disease 1 0.9999818801879883
. O 0 2.2194264602148905e-05

It O 0 5.599043220172462e-07
is O 0 1.7418877007457922e-08
believed O 0 1.504841229404974e-08
that O 0 5.790841695052507e-10
the O 0 6.794448337288372e-10
mutated O 0 4.5228728140500607e-07
allele O 0 1.6361282462185045e-07
of O 0 1.1324906568077608e-09
PAX6 O 0 1.0923184163402766e-05
produces O 0 1.2557173079130735e-07
an O 0 5.258704138810799e-09
inactive O 0 3.7609819258932475e-08
protein O 0 1.4855739749464192e-08
and O 0 1.584591835523952e-08
aniridia B-Disease 1 0.9999854564666748
is O 0 1.9600666689711943e-07
caused O 0 5.905613988943514e-07
due O 0 6.17720061768523e-08
to O 0 1.4476228216153686e-07
genetic O 0 1.1900267054443248e-05
haploinsufficiency O 0 0.0010055557359009981
. O 0 1.061766738530423e-06

However O 0 1.8491231230655103e-06
, O 0 6.674610641965728e-09
several O 0 2.249590513869748e-09
truncation O 0 2.008748083426326e-07
mutations O 0 4.61930625306195e-07
have O 0 1.9299742248790608e-08
been O 0 1.4131227743519048e-08
found O 0 4.272989073683675e-09
to O 0 2.0170740633318474e-09
occur O 0 1.0138964112726967e-09
in O 0 4.657920715800401e-10
the O 0 2.88785950708359e-09
C O 0 1.8710167637436825e-07
- O 0 1.8955281575472327e-06
terminal O 0 6.53421295737644e-07
half O 0 3.0816835749902793e-09
of O 0 3.376428303614176e-10
PAX6 O 0 4.856639407080365e-06
in O 0 3.4225191569703384e-08
patients O 0 6.696802756778197e-06
with O 0 2.4916960938980992e-08
Aniridia B-Disease 1 0.9999666213989258
resulting O 0 2.091262985004505e-07
in O 0 6.265072349798118e-10
mutant O 0 3.476097631960329e-08
proteins O 0 5.749493658946392e-10
that O 0 7.014942515759515e-10
retain O 0 3.642613677357076e-08
the O 0 6.697485344098197e-10
DNA O 0 2.1539660721714426e-08
- O 0 5.086259946551763e-08
binding O 0 1.8740054841259735e-08
domains O 0 2.2704194080347406e-09
but O 0 3.191305442129533e-09
have O 0 3.095367961947204e-09
lost O 0 8.086020741870925e-09
most O 0 1.1337392830101933e-10
of O 0 4.384623566999757e-11
the O 0 8.798575201751646e-10
transactivation O 0 2.955414174721227e-06
domain O 0 3.70905667068655e-07
. O 0 1.3990889158321806e-07

It O 0 4.0070744944387116e-07
is O 0 1.622342615803518e-08
not O 0 3.403093806753077e-09
clear O 0 6.93956980768462e-09
whether O 0 1.1147629486174537e-09
such O 0 2.5890642407766506e-10
mutants O 0 1.8807882895544026e-07
really O 0 8.752386548849245e-08
behave O 0 1.4076350751679456e-08
as O 0 1.0675558215211822e-09
loss O 0 1.0675583084207574e-08
- O 0 3.843860696406409e-08
of O 0 7.632562359916051e-10
- O 0 5.086988039693097e-07
function O 0 5.6126685521462605e-09
mutants O 0 4.514081908268963e-08
as O 0 2.0071417861089458e-09
predicted O 0 3.269280668405372e-08
by O 0 9.604291584253133e-09
haploinsufficiency O 0 1.5021882973087486e-05
. O 0 1.6059048846273072e-07

Contrary O 0 2.7761329874920193e-06
to O 0 1.5790345031518882e-08
this O 0 6.999705814969559e-10
theory O 0 2.9349149777146977e-09
, O 0 4.5405354476280024e-10
our O 0 9.733447381421456e-11
data O 0 3.740517895423068e-10
showed O 0 6.924735007629579e-09
that O 0 8.973749521246077e-11
these O 0 6.30924756883644e-11
mutants O 0 7.130092516405284e-09
are O 0 2.1284876638993921e-10
dominant O 0 1.9723271904581452e-08
- O 0 1.8731735451638087e-07
negative O 0 5.9440704802682376e-08
in O 0 9.514943277721954e-10
transient O 0 2.7273546265860205e-07
transfection O 0 1.0240488563795225e-06
assays O 0 2.739366493642592e-07
when O 0 4.712343404378316e-09
they O 0 1.808320937435326e-09
are O 0 3.221755084936717e-10
coexpressed O 0 1.8017330205566395e-07
with O 0 1.865203991258113e-09
wild O 0 2.534518905861205e-08
- O 0 5.926509038545191e-05
type O 0 0.00014760268095415086
PAX6 O 0 0.0005075889639556408
. O 0 5.732947556680301e-07

We O 0 1.4084507427014614e-07
found O 0 7.524044498552485e-09
that O 0 3.155881111993608e-10
the O 0 1.549023270763783e-10
dominant O 0 1.0981700171441844e-07
- O 0 1.065236347130849e-06
negative O 0 7.82453071224154e-07
effects O 0 3.398419039513101e-07
result O 0 3.749219601445475e-09
from O 0 1.612789068961007e-10
the O 0 1.7508261507259704e-10
enhanced O 0 3.078788779475872e-08
DNA O 0 3.680928983840204e-08
binding O 0 1.3196371995150002e-08
ability O 0 6.520142203925161e-09
of O 0 1.682237960043409e-10
these O 0 1.0163128116857933e-09
mutants O 0 3.331372226966778e-07
. O 0 6.781765904406711e-08

Kinetic O 0 4.185921170574147e-06
studies O 0 5.827612170605789e-08
of O 0 1.1710747926940712e-09
binding O 0 8.387135608245444e-08
and O 0 3.243554758114442e-08
dissociation O 0 1.1469829814814148e-06
revealed O 0 2.1651533899103015e-08
that O 0 5.220047727405586e-10
various O 0 9.447774507176376e-11
truncation O 0 7.894433906585618e-08
mutants O 0 4.114558578294236e-07
have O 0 1.4434204054225575e-08
3 O 0 2.328085280112191e-09
- O 0 1.6543931735668593e-07
5 O 0 1.399705062965495e-08
- O 0 5.553230835175782e-07
fold O 0 3.9562493725497916e-07
higher O 0 3.005500071040501e-09
affinity O 0 1.1535987720634466e-09
to O 0 2.554239042495965e-10
various O 0 1.2848469510551297e-10
DNA O 0 1.4599002895465674e-08
- O 0 3.228777600838839e-08
binding O 0 1.9818752861056055e-08
sites O 0 1.8496476572593679e-09
when O 0 3.3727098891489504e-09
compared O 0 1.8580597060946502e-09
with O 0 7.242394878259617e-11
the O 0 2.850802371945349e-10
wild O 0 8.221522129758796e-09
- O 0 9.81064385996433e-06
type O 0 1.6012516425689682e-05
PAX6 O 0 0.00014727130474057049
. O 0 2.2029990986993653e-07

These O 0 2.7275575575913535e-07
results O 0 6.002665031701326e-08
provide O 0 3.849405239009229e-09
a O 0 2.9190485584251746e-09
new O 0 2.222839246002195e-09
insight O 0 6.681947439801661e-09
into O 0 1.8431492443404807e-10
the O 0 1.0909679409865092e-10
role O 0 1.2584472353083243e-09
of O 0 2.577878466247796e-10
mutant O 0 4.6390888996938884e-07
PAX6 O 0 7.5131220000912435e-06
in O 0 4.712364187753337e-08
causing O 0 3.1366298571811058e-06
aniridia B-Disease 1 0.9999042749404907
. O 0 2.058707480045996e-07
. O 0 2.5356558808198315e-07

Reversal O 0 0.0002521569258533418
of O 0 1.7908923837239854e-06
severe O 1 0.9987678527832031
hypertrophic B-Disease 1 0.9999736547470093
cardiomyopathy I-Disease 1 1.0
and O 0 4.920997525914572e-05
excellent O 0 2.3280567802430596e-06
neuropsychologic O 0 2.322658292541746e-05
outcome O 0 1.4766392553156038e-07
in O 0 4.047321588984687e-09
very B-Disease 0 6.260192719764746e-08
- I-Disease 0 7.5276452662365045e-06
long I-Disease 0 9.17110696718737e-07
- I-Disease 0 9.438891538593452e-06
chain I-Disease 0 3.315412186566391e-06
acyl I-Disease 0 1.1088977771578357e-06
- I-Disease 0 1.2623733027794515e-06
coenzyme I-Disease 0 8.334159247169737e-07
A I-Disease 0 5.251462425803766e-06
dehydrogenase I-Disease 0 0.0030744795221835375
deficiency I-Disease 0 0.009579611010849476
. O 0 5.422329536486359e-07

Very B-Disease 0 1.358482040814124e-05
- I-Disease 0 3.330278195790015e-05
long I-Disease 0 1.2478830058171297e-06
- I-Disease 0 5.992123078613076e-06
chain I-Disease 0 3.660210268208175e-06
acyl I-Disease 0 2.3569416498503415e-06
- I-Disease 0 9.186084639623004e-07
coenzyme I-Disease 0 2.5509848455840256e-07
A I-Disease 0 3.250838460644445e-07
dehydrogenase I-Disease 0 2.9417030873446492e-06
( I-Disease 0 5.106683431677084e-08
VLCAD I-Disease 0 0.002666858024895191
) I-Disease 0 1.1015513337042648e-06
deficiency I-Disease 0 0.0008520419942215085
is O 0 2.1236724379036787e-08
a O 0 3.674598701763898e-06
disorder O 0 0.013452243991196156
of O 0 2.2050026249331722e-09
fatty O 0 9.962703870769474e-07
acid O 0 2.231081310810623e-07
beta O 0 1.5802990027680153e-09
oxidation O 0 4.697303435108324e-09
that O 0 2.074104665794607e-09
reportedly O 0 2.373635652475059e-07
has O 0 2.3611701038817046e-08
high O 0 1.5139095310701123e-08
rates O 0 1.8629933151714795e-08
of O 0 1.871433008560075e-09
morbidity O 0 0.018021393567323685
and O 0 7.156035053412779e-07
mortality O 0 2.0541296180454083e-05
. O 0 1.6401088487327797e-07

We O 0 4.903720309812343e-07
describe O 0 2.1765072233392857e-07
the O 0 2.472285265398e-09
outcome O 0 6.015866471642539e-09
of O 0 2.3113594371793056e-10
a O 0 7.359190590250364e-09
5 O 0 7.285255065880847e-09
- O 0 5.401349767453212e-07
year O 0 3.04069196488399e-08
- O 0 2.060626002275967e-06
old O 0 7.870970875956118e-06
girl O 0 2.3230724764289334e-05
with O 0 4.814692715626734e-07
VLCAD B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999994039535522
who O 0 3.727168405021075e-07
was O 0 1.3998544545756886e-08
first O 0 1.1307855762865415e-09
seen O 0 1.029046714506876e-08
at O 0 1.8484300201571102e-10
5 O 0 5.78077752333428e-10
months O 0 2.569397361540382e-09
of O 0 3.7481306947029225e-10
age O 0 4.624692806487474e-08
with O 0 8.10362479342075e-08
severe O 1 0.9998113512992859
hypertrophic B-Disease 1 0.9999974966049194
cardiomyopathy I-Disease 1 1.0
, O 1 0.5426166653633118
hepatomegaly B-Disease 1 0.9999998807907104
, O 0 0.00023755079018883407
encephalopathy B-Disease 0 0.00037994724698364735
, O 0 6.710636313300711e-08
and O 0 4.7340796527350903e-07
hypotonia B-Disease 1 0.7101657390594482
. O 0 3.1323461371357553e-06

Biochemical O 0 0.002478275913745165
studies O 0 9.735815547173843e-05
indicated O 1 0.9939275979995728
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 6.632001895923167e-05
by O 0 1.0892911461723997e-08
a O 0 1.0771061198511234e-07
stable O 0 2.528021468606312e-06
yet O 0 1.2062119481015543e-07
inactive O 0 6.373766723299923e-07
enzyme O 0 2.282470035197548e-07
. O 0 4.7774886269280614e-08

Molecular O 0 2.8477825253503397e-05
genetic O 0 1.657961001910735e-05
analysis O 0 1.1085112561204369e-07
of O 0 1.3435687007401498e-09
her O 0 2.0484804963416536e-07
VLCAD O 0 3.768062015296891e-05
gene O 0 1.5416480891872197e-07
revealed O 0 1.139920655646165e-07
a O 0 2.6283743181920727e-08
T1372C O 0 1.1683600860123988e-06
( O 0 2.565656131992e-09
F458L O 0 2.0013442281197058e-07
) O 0 6.1276894669504145e-09
missense O 0 5.422436515800655e-06
mutation O 0 4.95733388561348e-07
and O 0 1.2818839323358588e-08
a O 0 1.307213779000449e-06
1668 O 0 0.07398790121078491
ACAG O 0 0.005200590472668409
1669 O 0 2.1375813958002254e-05
splice O 0 1.9664203136926517e-05
site O 0 2.229850679213996e-06
mutation O 0 4.0059571801975835e-06
. O 0 1.270970102495994e-07

After O 0 2.6596160296321614e-06
initial O 0 1.0543392363615567e-06
treatment O 0 9.846070270214113e-07
with O 0 1.3956954703076008e-08
intravenous O 0 1.0509238563827239e-05
glucose O 0 2.0194182070554234e-05
and O 0 4.304845901970111e-08
carnitine O 0 1.4107038168731378e-06
, O 0 2.848982605385686e-09
the O 0 2.1937434091512387e-09
patient O 0 2.753872195171425e-06
has O 0 3.323400221688644e-08
thrived O 0 1.8487316566506706e-08
on O 0 2.103225815730525e-09
a O 0 2.9010886137825764e-08
low O 0 9.746620435180375e-07
- O 0 1.4026859389559831e-05
fat O 0 0.00011464571434771642
diet O 0 3.7066871527713374e-07
supplemented O 0 2.5558788863122572e-08
with O 0 9.93599647003407e-10
medium O 0 4.769203343357731e-08
- O 0 8.027649869291054e-07
chain O 0 1.1811091553681763e-06
triglyceride O 0 6.387866164914158e-07
oil O 0 3.8185479667163236e-08
and O 0 5.468937747110658e-09
carnitine O 0 2.811140689118474e-07
and O 0 7.130391388443513e-09
avoidance O 0 2.7550913728191517e-07
of O 0 6.519694562001632e-09
fasting O 0 2.517099574106396e-06
. O 0 1.7284288844621187e-07

Her O 0 5.538577897823416e-05
ventricular O 0 0.012545694597065449
hypertrophy O 0 0.0027667637914419174
resolved O 0 1.0733007911767345e-05
significantly O 0 1.478459921600006e-06
over O 0 2.2575479263764464e-08
1 O 0 1.2871343102460742e-08
year O 0 7.433266446810194e-09
, O 0 2.227270146093474e-09
and O 0 1.8552983149788815e-08
cognitively O 0 2.887651817218284e-06
, O 0 9.152107405263621e-10
she O 0 3.952223437408975e-09
is O 0 2.8980659538824227e-10
in O 0 1.1043291281431777e-10
the O 0 2.47615400406076e-10
superior O 0 2.1799507976538735e-08
range O 0 3.033628681592404e-09
for O 0 2.821005207209737e-09
age O 0 7.87185001627222e-08
. O 0 3.8727669959826017e-08

Clinical O 0 0.00047901016660034657
recognition O 0 4.601587534125429e-06
of O 0 6.652776392002124e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
is O 0 2.4315720992262868e-08
important O 0 5.443459016873931e-10
because O 0 2.1334150002161323e-09
it O 0 1.7330453738750862e-09
is O 0 6.879208869214892e-10
one O 0 1.3537235221683375e-10
of O 0 8.802896779569469e-12
the O 0 2.3818663708041754e-10
few O 0 8.25053714237356e-09
directly O 0 5.577794581768103e-07
treatable O 0 0.0011695392895489931
causes O 0 1.9529706207777053e-07
of O 0 1.065367616348567e-08
cardiomyopathy B-Disease 1 0.9999997615814209
in O 0 3.077584779020981e-06
children O 0 1.698097662483633e-06
. O 0 1.7314041755867038e-08
. O 0 6.523515594381024e-08

Cloning O 0 9.60201577981934e-06
of O 0 4.5245123203585536e-08
a O 0 5.0250765326609326e-08
novel O 0 4.2268275990409165e-08
member O 0 1.4541856607763748e-09
of O 0 2.5532936875904966e-10
the O 0 3.150097516169126e-09
low O 0 8.952876555667899e-07
- O 0 0.0002192322863265872
density O 0 8.631449600216001e-05
lipoprotein O 0 0.00017365718667861074
receptor O 0 6.420776571758324e-06
family O 0 6.538595016536419e-07
. O 0 1.0472717804077547e-07

A O 0 2.0844504433625843e-06
gene O 0 1.4873141935822787e-06
encoding O 0 2.694672787129093e-07
a O 0 9.620153917921925e-08
novel O 0 1.597080085957714e-07
transmembrane O 0 3.7960944609949365e-07
protein O 0 2.7318780126961428e-08
was O 0 4.533582398380531e-08
identified O 0 7.528379697419041e-09
by O 0 2.281688032956808e-10
DNA O 0 3.935778813968227e-09
sequence O 0 2.3263986292931804e-09
analysis O 0 1.7017115494510904e-09
within O 0 2.0921499255255327e-10
the O 0 2.1670609751112124e-09
insulin B-Disease 0 0.038044147193431854
- I-Disease 1 0.9753166437149048
dependent I-Disease 1 0.9989696741104126
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.409332975934376e-07
IDDM B-Disease 0 0.0005828425055369735
) O 0 3.5085772509546587e-08
locus O 0 8.297218982988852e-07
IDDM4 O 0 9.77341096586315e-06
on O 0 2.538789658501628e-07
chromosome O 0 3.8559337554033846e-05
11q13 O 0 2.060832230199594e-05
. O 0 5.440246013677097e-07

Based O 0 1.2508365898611373e-06
on O 0 1.385082359917078e-08
its O 0 3.848076524093358e-09
chromosomal O 0 2.7967912501480896e-06
position O 0 1.650506987971312e-06
, O 0 1.0611022061013387e-09
this O 0 2.646531882533054e-10
gene O 0 2.830545353660341e-09
is O 0 7.28737736821472e-10
a O 0 5.002352310157221e-09
candidate O 0 3.473128984410323e-08
for O 0 1.660786064228148e-09
conferring O 0 4.865791538577469e-07
susceptibility O 0 0.2173006236553192
to O 0 7.847335655242205e-05
diabetes B-Disease 1 0.9990605711936951
. O 0 1.6747311519793584e-06

The O 0 2.391323903339071e-07
gene O 0 3.54984109662837e-07
, O 0 1.5648110363031265e-08
termed O 0 2.2408475786050985e-07
low O 0 3.703500226492906e-07
- O 0 4.314555553719401e-06
density O 0 3.973976163251791e-06
lipoprotein O 0 6.137592663435498e-06
receptor O 0 3.1033951586323383e-07
related O 0 2.425319323151598e-08
protein O 0 3.812493076793544e-08
5 O 0 8.624253311495522e-09
( O 0 1.1652172560161489e-09
LRP5 O 0 1.2715991942968685e-05
) O 0 9.44089695309458e-10
, O 0 4.195321867683788e-10
encodes O 0 3.788200864107694e-09
a O 0 4.2687937629182215e-09
protein O 0 8.77540085042483e-09
of O 0 8.159047326650182e-10
1615 O 0 8.575750030104246e-07
amino O 0 2.8347878711088015e-08
acids O 0 5.2826703011987775e-09
that O 0 3.4943084536998015e-10
contains O 0 3.2659869253492957e-10
conserved O 0 9.789568045093233e-10
modules O 0 3.1742228845388354e-09
which O 0 8.943237261860304e-10
are O 0 1.6929115054242772e-10
characteristic O 0 1.6258980828354197e-09
of O 0 8.172141435780489e-11
the O 0 1.7386441175659684e-09
low O 0 1.5480951560675749e-06
- O 0 0.0057907709851861
density O 0 0.0018259533680975437
lipoprotein O 0 0.0044305878691375256
( O 0 1.4529837244481314e-07
LDL O 0 5.4843803809490055e-05
) O 0 3.6175908491031805e-08
receptor O 0 1.1398765309422743e-06
family O 0 7.703612254772452e-07
. O 0 1.9543305995739502e-07

These O 0 1.9789825955740525e-07
modules O 0 9.58080264013006e-08
include O 0 2.4685158361847925e-09
a O 0 5.2036872588701044e-09
putative O 0 2.338287004022277e-07
signal O 0 2.0149836643668095e-07
peptide O 0 8.073691937227068e-09
for O 0 1.4328473130209574e-10
protein O 0 8.783953564517333e-10
export O 0 7.186408135240185e-10
, O 0 4.332212644175826e-10
four O 0 7.278417313294483e-10
epidermal O 0 9.012665458385527e-08
growth O 0 2.4961291700265065e-08
factor O 0 3.355080124833876e-08
( O 0 3.2723237453069487e-09
EGF O 0 3.629814386840735e-07
) O 0 4.1504986114659914e-09
repeats O 0 3.9220669378892126e-08
with O 0 3.0635278758239792e-09
associated O 0 5.871994002148995e-09
spacer O 0 1.6160738880444114e-07
domains O 0 2.8709786548120064e-08
, O 0 1.2185312758816735e-09
three O 0 1.9709951448732e-09
LDL O 0 9.117335935115989e-07
- O 0 5.408790912042605e-06
receptor O 0 1.886451741484052e-06
( O 0 4.4161270196241276e-09
LDLR O 0 3.915627075912198e-06
) O 0 2.689594769123005e-09
repeats O 0 2.570996748829657e-08
, O 0 1.3051382197204475e-09
a O 0 4.4000176835368165e-09
single O 0 5.546043979620663e-08
transmembrane O 0 9.242158682809531e-08
spanning O 0 6.144647901606959e-09
domain O 0 4.4545509503279845e-09
, O 0 3.057548658702558e-10
and O 0 4.0441092141740853e-10
a O 0 1.5482717330428386e-08
cytoplasmic O 0 1.3596048802355654e-06
domain O 0 3.594796567085723e-07
. O 0 1.8598446160922322e-07

The O 0 8.50108392569382e-08
encoded O 0 6.523279694192752e-08
protein O 0 1.732517418417956e-08
has O 0 2.8402797891402543e-09
a O 0 1.196908572254074e-09
unique O 0 2.1388788518095225e-09
organization O 0 3.996658282101606e-10
of O 0 2.7795415968867587e-10
EGF O 0 3.8697183413205494e-07
and O 0 6.17298425709123e-08
LDLR O 0 0.0001604595163371414
repeats O 0 2.460451469232794e-07
; O 0 3.42375816586582e-09
therefore O 0 3.973402051826724e-09
, O 0 6.371239091862435e-10
LRP5 O 0 1.4422515732803731e-06
likely O 0 7.499217957729343e-08
represents O 0 2.0051520444042126e-09
a O 0 1.6243668632398567e-09
new O 0 1.946331318336547e-09
category O 0 3.326461994745955e-09
of O 0 3.091153999434937e-10
the O 0 7.784916711273127e-09
LDLR O 0 0.0004305279580876231
family O 0 6.047644660611695e-07
. O 0 8.132921180958874e-08

Both O 0 9.122502433456248e-07
human O 0 5.912015410558524e-08
and O 0 2.3819140437808528e-08
mouse O 0 1.39548581046256e-06
LRP5 O 0 1.4670015843876172e-05
cDNAs O 0 9.014090096570726e-07
have O 0 2.7068729480106413e-08
been O 0 3.3616650796375325e-08
isolated O 0 4.662867070237553e-08
and O 0 1.6998624730035772e-09
the O 0 3.869632669850631e-10
encoded O 0 8.327658562734541e-09
mature O 0 1.5889249915801429e-09
proteins O 0 2.168333429475311e-10
are O 0 1.8562910930608467e-10
95 O 0 2.6843365308337752e-09
% O 0 8.886444913258629e-10
identical O 0 1.3343118610009697e-08
, O 0 5.675999670273768e-10
indicating O 0 1.2946217431419882e-08
a O 0 1.953644357399753e-08
high O 0 2.1694855689702308e-08
degree O 0 6.773257510417352e-09
of O 0 2.8264113272058466e-10
evolutionary O 0 2.9096005604856146e-08
conservation O 0 8.917793614671155e-09
. O 0 2.667280174506459e-09
. O 0 4.858993207790263e-08

The O 0 5.469472057484381e-07
APC B-Disease 0 4.869532858720049e-06
variants O 0 1.044525333782076e-06
I1307K O 0 1.307571551478759e-06
and O 0 2.306913593486115e-08
E1317Q O 0 6.580049216609041e-07
are O 0 8.288043140680657e-09
associated O 0 5.530494036065647e-07
with O 1 0.9566454887390137
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.0973730013574823e-06
but O 0 2.6295477795201805e-08
not O 0 5.410380143899829e-09
always O 0 3.972848716671251e-09
with O 0 2.1691108631483047e-10
a O 0 2.773914786757814e-08
family O 0 6.663520935035194e-08
history O 0 3.473460097325187e-08
. O 0 1.1436598867931025e-07

Classical O 0 0.029794270172715187
familial B-Disease 1 0.9999974966049194
adenomatous I-Disease 1 0.9999833106994629
polyposis I-Disease 1 0.9999991655349731
( O 0 0.00020468560978770256
FAP B-Disease 0 0.000791391299571842
) O 0 6.711455569075042e-08
is O 0 1.881017297478138e-08
a O 0 9.518581833845019e-08
high O 0 6.389434929587878e-06
- O 1 0.902616024017334
penetrance O 1 0.8648852109909058
autosomal B-Disease 1 0.9789188504219055
dominant I-Disease 0 0.3061177432537079
disease I-Disease 0 0.00010192039917455986
that O 0 2.0832562341865923e-08
predisposes O 0 1.158847317128675e-05
to O 0 2.5527951308390584e-08
hundreds O 0 7.071893293186804e-09
or O 0 1.3140180055160045e-09
thousands O 0 8.444549948194435e-09
of O 0 9.084251360036433e-07
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9983377456665039
carcinoma I-Disease 1 1.0
and O 0 2.050921239060699e-06
that O 0 9.946869994337248e-08
results O 0 4.233161021716114e-08
from O 0 1.9260824046796188e-09
truncating O 0 2.771244851373922e-07
mutations O 0 2.2751744666038576e-07
in O 0 1.063272025980666e-09
the O 0 2.7689284198828545e-09
APC B-Disease 0 2.405065515631577e-06
gene O 0 1.6283526065308251e-06
. O 0 3.3735744864316075e-07

A O 0 4.997619271307485e-06
variant O 0 1.7911685063154437e-05
of O 0 2.4769358120124707e-08
FAP B-Disease 0 9.670694271335378e-05
is O 0 4.819742025574669e-05
attenuated B-Disease 1 0.9966076612472534
adenomatous I-Disease 1 0.9999967813491821
polyposis I-Disease 1 0.9998002648353577
coli I-Disease 1 0.9997816681861877
, O 0 1.911729583525812e-07
which O 0 3.018795879938807e-08
results O 0 6.660799023450181e-09
from O 0 9.689958835323864e-10
germ O 0 1.9353863933702087e-07
- O 0 2.579475449238089e-06
line O 0 1.5999429479052196e-06
mutations O 0 4.4444366409379654e-08
in O 0 3.1437397129963074e-10
the O 0 6.877253766468527e-10
5 O 0 2.7525470791545104e-09
and O 0 1.9233989956290998e-09
3 O 0 2.8331594847941233e-09
regions O 0 2.637226215185251e-09
of O 0 4.794645236394501e-10
the O 0 5.0615307500834206e-09
APC B-Disease 0 1.675561975389428e-06
gene O 0 1.0099548717334983e-06
. O 0 1.502553033105869e-07

Attenuated B-Disease 1 0.9992353916168213
adenomatous I-Disease 1 0.9999897480010986
polyposis I-Disease 1 0.9999780654907227
coli I-Disease 1 0.999997615814209
patients O 1 0.999944806098938
have O 0 1.0381743322795955e-06
" O 0 2.710407329686859e-07
multiple O 0 3.980355813837377e-06
" O 0 0.15981972217559814
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999949932098389
( O 0 4.665020369998274e-08
typically O 0 7.514710631539856e-08
fewer O 0 1.018958872833764e-08
than O 0 2.055021930402745e-09
100 O 0 7.618454200830627e-10
) O 0 3.4701191919950247e-10
without O 0 1.493528301033109e-09
the O 0 2.643354868325787e-09
florid O 0 0.001529841567389667
phenotype O 0 0.0005845435662195086
of O 0 2.5016473337302614e-09
classical O 0 2.5219722488145635e-07
FAP B-Disease 0 4.556624480756e-05
. O 0 1.225503183377441e-06

Another O 0 3.699613671415136e-06
group O 0 3.363833513958525e-07
of O 0 8.838796361487766e-09
patients O 0 1.1317483767925296e-06
with O 0 1.2956048678347543e-08
multiple O 0 9.345482112621539e-07
adenomas B-Disease 0 1.5467121556866914e-05
has O 0 5.551917752200097e-07
no O 0 1.0038485598329316e-08
mutations O 0 1.5991414414884275e-08
in O 0 3.078051702409823e-10
the O 0 5.176837292175662e-10
APC B-Disease 0 2.7778864364336187e-07
gene O 0 2.7215858011686578e-08
, O 0 9.14401054874503e-10
and O 0 1.2076334376942555e-09
their O 0 4.236559547621255e-09
phenotype O 0 0.00011498862295411527
probably O 0 1.8506690935282677e-07
results O 0 4.548824428241005e-09
from O 0 1.9437111642428562e-10
variation O 0 8.126390227403135e-09
at O 0 5.384147572229381e-10
a O 0 1.770685820190465e-08
locus O 0 2.533780047997425e-07
, O 0 2.0710528847445175e-09
or O 0 3.462357345274114e-10
loci O 0 5.9871236857134136e-09
, O 0 1.9796304595587344e-09
elsewhere O 0 3.0180000720747557e-09
in O 0 4.682506049569213e-10
the O 0 3.2249969361686226e-09
genome O 0 7.633094156744846e-08
. O 0 8.742226498270611e-08

Recently O 0 1.0263385775033385e-05
, O 0 2.5191541297431286e-08
however O 0 4.659735708401058e-09
, O 0 4.272954212680702e-10
a O 0 1.3277364985242457e-08
missense O 0 1.581480319146067e-05
variant O 0 2.6514740056882147e-06
of O 0 2.243565999648922e-09
APC B-Disease 0 1.3429938690023846e-06
( O 0 4.13587075698274e-09
I1307K O 0 3.3423700074308726e-07
) O 0 3.049675623145731e-09
was O 0 2.0165640535196871e-07
described O 0 4.96912875291855e-08
that O 0 1.8291030912109818e-09
confers O 0 8.849445265468603e-08
an O 0 4.769000749860197e-09
increased O 0 1.6467195962377446e-07
risk O 0 7.576335292469594e-07
of O 0 2.9265926059451886e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.796575912128901e-07
including O 0 2.150985523030613e-08
multiple O 0 1.400753944835742e-06
adenomas B-Disease 0 7.654271030332893e-06
, O 0 2.8827924936081217e-08
in O 0 2.7878964914407334e-08
Ashkenazim O 0 7.503662800445454e-06
. O 0 1.9634920533917466e-07

We O 0 5.126460109750042e-07
have O 0 1.2852845010513647e-08
studied O 0 1.858180165292822e-09
a O 0 7.619529451829976e-10
set O 0 9.588326799203628e-10
of O 0 4.6140621878798527e-10
164 O 0 2.818979680796474e-07
patients O 0 1.110216362576466e-05
with O 0 2.7629641863313736e-07
multiple O 1 0.9305970072746277
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999994039535522
and I-Disease 0 0.006956363562494516
/ I-Disease 0 0.010356282815337181
or I-Disease 0 0.0006321562104858458
carcinoma I-Disease 1 1.0
and O 0 3.3415778943890473e-06
analyzed O 0 1.4568219057764509e-06
codons O 0 5.683886001861538e-07
1263 O 0 5.048795173934195e-06
- O 0 7.81225026003085e-06
1377 O 0 1.2419784980011173e-05
( O 0 2.5074193388263666e-08
exon O 0 5.156128963790252e-07
15G O 0 1.0841930588867399e-06
) O 0 5.853271756173228e-10
of O 0 4.178637297291843e-11
the O 0 1.873289023901492e-10
APC B-Disease 0 5.6030131645457004e-08
gene O 0 1.5932563712794945e-08
for O 0 2.728705483789895e-09
germ O 0 4.638075949969789e-07
- O 0 5.756709470006172e-06
line O 0 8.146183972712606e-06
variants O 0 9.666879350334057e-07
. O 0 1.4112998769633123e-07

Three O 0 9.770260476216208e-06
patients O 0 1.961382440640591e-05
with O 0 3.1086151430770315e-09
the O 0 3.6772009881502754e-09
I1307K O 0 7.4334320743219e-07
allele O 0 7.250130806824018e-07
were O 0 2.083156758203586e-08
detected O 0 3.733763875857221e-08
, O 0 4.4181128200371234e-10
each O 0 2.8693222797748774e-10
of O 0 1.585715669882859e-09
Ashkenazi O 0 1.1769559023377951e-05
descent O 0 7.649798135389574e-06
. O 0 2.3005736693448853e-07

Four O 0 1.836673436628189e-05
patients O 0 0.00024852779461070895
had O 0 1.906904287807265e-07
a O 0 4.984801194041211e-08
germ O 0 2.0263912574591814e-06
- O 0 3.5793545976048335e-05
line O 0 7.305988219741266e-06
E1317Q O 0 2.1251287307677558e-06
missense O 0 3.152082172164228e-06
variant O 0 4.865976848122955e-07
of O 0 6.36336927595238e-10
APC O 0 1.1099435681671821e-07
that O 0 5.204779274237126e-09
was O 0 7.484656805445411e-08
not O 0 1.9642021342747285e-09
present O 0 5.809283609714555e-10
in O 0 6.070973168625926e-10
controls O 0 9.135054824582767e-06
; O 0 9.975950066021255e-10
one O 0 2.3896840062320734e-10
of O 0 3.380860175150602e-11
these O 0 1.9499046821636057e-10
individuals O 0 8.316031196997642e-11
had O 0 8.035529575067812e-09
an O 0 1.411618932856129e-09
unusually O 0 6.056752681615762e-07
large O 0 2.2119108766816e-09
number O 0 1.3793448605525782e-09
of O 0 5.447561846061433e-10
metaplastic B-Disease 0 5.5453574532293715e-06
polyps I-Disease 0 2.609672264952678e-07
of I-Disease 0 6.94221402586237e-10
the I-Disease 0 4.49235759703015e-09
colorectum I-Disease 0 2.0421992303454317e-05
. O 0 3.4146887628594413e-07

There O 0 7.996451927283488e-07
is O 0 2.7529161172878958e-08
increasing O 0 4.819329824101715e-09
evidence O 0 5.4266475757458466e-09
that O 0 1.495449541977223e-09
there O 0 1.4489032196252083e-09
exist O 0 1.3964854828074635e-09
germ O 0 6.80476546222053e-08
- O 0 3.470166234365024e-07
line O 0 1.974104293367418e-07
variants O 0 6.655021422830032e-09
of O 0 1.7524098838705982e-10
the O 0 5.941015457366916e-10
APC B-Disease 0 4.608560999486144e-08
gene O 0 6.9907168942506814e-09
that O 0 1.5047714185811856e-09
predispose O 0 8.030416154269915e-08
to O 0 1.8625837538976953e-09
the O 0 2.99565483530273e-10
development O 0 4.669573616666867e-10
of O 0 6.858341894400155e-09
multiple O 1 0.9637390375137329
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999175071716309
carcinoma I-Disease 1 1.0
, O 0 5.373667022467998e-07
but O 0 2.9401999057654393e-08
without O 0 1.914720382245605e-09
the O 0 1.7441809108120765e-09
florid O 0 0.000212458660826087
phenotype O 0 0.00013926959945820272
of O 0 8.970537646035837e-10
classical O 0 8.660654060577144e-08
FAP B-Disease 0 4.124492534174351e-06
, O 0 9.762275432478873e-09
and O 0 2.5278261706063176e-09
possibly O 0 3.4554781258577805e-09
with O 0 1.137127059180898e-09
importance O 0 2.2952301392820118e-08
for O 0 0.03706984966993332
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 3.8143077745189657e-06
in O 0 8.722679800676758e-10
the O 0 4.552111743105769e-10
general O 0 1.1755085793652142e-08
population O 0 6.230065796586359e-09
. O 0 4.4669046239675936e-09
. O 0 2.910627294738788e-08

Genomic O 0 1.016327860270394e-05
structure O 0 6.05304535383766e-07
of O 0 4.625290372928248e-09
the O 0 3.2616821243891536e-08
human O 0 2.284633410454262e-05
congenital B-Disease 1 0.9999997615814209
chloride I-Disease 1 0.9999997615814209
diarrhea I-Disease 1 1.0
( O 0 7.58080423111096e-05
CLD B-Disease 0 0.1155911460518837
) O 0 6.175621791726371e-08
gene O 0 1.684592120909656e-06
. O 0 2.475425162629108e-07

Congenital B-Disease 1 0.9999996423721313
chloride I-Disease 1 0.999998927116394
diarrhea I-Disease 1 1.0
( O 0 0.00037772144423797727
CLD B-Disease 1 0.5945297479629517
) O 0 7.652948852410191e-08
is O 0 5.376609735208149e-08
caused O 0 2.716105029776372e-07
by O 0 7.873558693916038e-09
mutations O 0 5.150064907866181e-07
in O 0 1.4066305897841858e-09
a O 0 3.4454963326879806e-08
gene O 0 3.7755576443032624e-08
which O 0 5.555442328386562e-09
encodes O 0 1.6780903422386473e-07
an O 0 1.1165855084982468e-07
intestinal O 0 0.05309409275650978
anion O 0 8.472680201521143e-05
transporter O 0 5.559692726819776e-05
. O 0 3.803965853421687e-07

We O 0 6.067332378734136e-07
report O 0 1.721193854109515e-08
here O 0 1.1040748315593873e-09
the O 0 1.0983675080566968e-10
complete O 0 1.0918324022668457e-09
genomic O 0 5.3093383023394836e-09
organization O 0 2.7194604901303876e-10
of O 0 6.579450873012149e-11
the O 0 4.2368158981176407e-10
human O 0 1.0927204918687039e-08
CLD B-Disease 0 7.436881787725724e-06
gene O 0 5.4653117587122324e-08
which O 0 1.1736133842532581e-08
spans O 0 5.570618810679662e-08
approximately O 0 2.2669663923835515e-09
39kb O 0 3.6863113450635865e-07
, O 0 3.7252829709899515e-09
and O 0 4.83498174830288e-09
comprises O 0 9.368325670777722e-09
21 O 0 8.496188286244433e-08
exons O 0 1.1796614671766292e-06
. O 0 9.151330004897318e-08

All O 0 2.1210618683653593e-07
exon O 0 2.960311121569248e-06
/ O 0 5.640826543640287e-07
intron O 0 2.3054215034790104e-06
boundaries O 0 2.5616623489099766e-08
conform O 0 2.403179522048049e-08
to O 0 5.455373486284998e-09
the O 0 8.912896198864928e-09
GT O 0 7.241255389089929e-06
/ O 0 0.00011178560816915706
AG O 1 0.5925758481025696
rule O 0 3.2634609397064196e-06
. O 0 3.8720182260476577e-07

An O 0 9.770903375283524e-08
analysis O 0 1.3798140408027848e-08
of O 0 4.520376017946859e-10
the O 0 7.014193670329405e-10
putative O 0 1.3982459279304749e-07
promoter O 0 5.193576271267375e-07
region O 0 5.600755415002823e-09
sequence O 0 1.8939658730232622e-09
shows O 0 4.982117829399613e-09
a O 0 6.57298526718364e-09
putative O 0 4.6932942154853663e-07
TATA O 0 1.3067027566648903e-06
box O 0 1.2418739459008066e-07
and O 0 7.459115103358727e-09
predicts O 0 9.349746221687383e-08
multiple O 0 4.02346866934522e-09
transcription O 0 2.2862515436372632e-08
factor O 0 1.7913841077188408e-08
binding O 0 9.795927979894259e-08
sites O 0 6.74518076948516e-08
. O 0 1.0340742306880202e-07

The O 0 1.4111975588093628e-07
genomic O 0 2.9810382784489775e-07
structure O 0 8.327677392117039e-08
was O 0 2.437915824771153e-08
determined O 0 7.403100799052709e-09
using O 0 1.7109740291232356e-09
DNA O 0 1.1073887584700515e-08
from O 0 1.9198280465371198e-10
several O 0 2.2948558331403746e-10
sources O 0 3.1352725970990036e-10
including O 0 1.2087528200588338e-10
multiple O 0 2.326580483824614e-09
large O 0 2.623814943092384e-09
- O 0 2.076975533782388e-06
insert O 0 5.52667370357085e-06
libaries O 0 1.5414553899972816e-06
and O 0 9.54974321842883e-10
genomic O 0 1.0639095826547873e-08
DNA O 0 4.256843766370366e-08
from O 0 2.6420141630012495e-09
Finnish O 0 0.06357927620410919
CLD B-Disease 1 0.9210888743400574
patients O 0 0.03994991257786751
and O 0 4.621086446832123e-08
controls O 0 0.00018495993572287261
. O 0 7.020490215836617e-07

Exon O 0 5.6521537771914154e-05
- O 0 8.00830457592383e-06
specific O 0 2.6874579006630483e-08
primers O 0 7.739851071164594e-07
developed O 0 4.535433362207186e-08
in O 0 3.815580906785243e-10
this O 0 2.115576464012392e-10
study O 0 6.042485400925557e-10
will O 0 8.594329692357405e-10
facilitate O 0 2.597751347366284e-09
mutation O 0 7.815523161980309e-08
screening O 0 1.4774359513580748e-08
studies O 0 9.466538664071322e-10
of O 0 7.834366488879141e-10
patients O 0 9.567843335389625e-07
with O 0 3.4832241535553976e-09
the O 0 8.067122081456546e-08
disease O 0 7.529334834543988e-05
. O 0 1.4895653066560044e-07

Genomic O 0 8.890223398339003e-06
sequencing O 0 7.658540539523528e-07
of O 0 6.733647861523195e-09
a O 0 9.60184109999318e-08
BAC O 0 2.95748559437925e-05
clone O 0 1.0218946954410058e-05
H O 1 0.9998894929885864
_ O 0 3.234645973293482e-08
RG364P16 O 0 1.2343477351350884e-07
revealed O 0 1.0286149709770598e-08
the O 0 8.941032636489155e-11
presence O 0 7.414939218186589e-10
of O 0 6.817604120135101e-11
another O 0 3.881950760842301e-09
, O 0 1.0946286099766667e-09
highly O 0 1.6979959660545774e-09
homologous O 0 2.2540489474920378e-09
gene O 0 8.271398677095476e-09
3 O 0 5.268479541520321e-10
of O 0 4.286919777496401e-11
the O 0 4.9367607779515765e-09
CLD B-Disease 0 7.614422065671533e-05
gene O 0 1.718003233008858e-07
, O 0 1.5537584552305361e-09
with O 0 4.0400233158877086e-10
a O 0 1.021159334868571e-08
similar O 0 1.2237585167440557e-08
genomic O 0 1.6950069792187605e-08
structure O 0 2.495991324735769e-08
, O 0 9.906779840918034e-10
recently O 0 2.2159953871891958e-08
identified O 0 1.1186997994627745e-08
as O 0 9.760227293043044e-09
the O 0 1.0345629561925307e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 1.410503864462953e-05
( O 0 3.182408292445871e-08
PDS B-Disease 0 6.305031274678186e-05
) O 0 1.935514859496834e-08
. O 0 2.215053029885894e-08
. O 0 1.0369519287678486e-07

The O 0 1.0271346582158003e-06
APCI1307K O 0 7.774934056214988e-05
allele O 0 4.0129958506440744e-05
and O 0 4.962124648955069e-07
cancer B-Disease 0 5.879707168787718e-05
risk O 0 6.77889531175424e-08
in O 0 1.350304756897458e-09
a O 0 5.785669898727974e-08
community O 0 7.151025549489987e-09
- O 0 4.071372359248926e-07
based O 0 2.843804658425597e-08
study O 0 1.8113449629098e-09
of O 0 1.617089906424951e-09
Ashkenazi O 0 2.39314522332279e-06
Jews O 0 2.0288825908210129e-07
. O 0 1.2498870205490675e-07

Mutations O 0 0.013266676105558872
in O 0 6.405948056453781e-07
APC O 0 1.008999788609799e-05
are O 0 1.1354158857557195e-07
classically O 0 0.15047667920589447
associated O 0 1.7314623619313352e-06
with O 0 2.8821419618907385e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999986886978149
polyposis I-Disease 1 0.9999998807907104
( O 0 1.2535030009530601e-06
FAP B-Disease 0 3.236681368434802e-05
) O 0 1.7657182382890824e-08
, O 0 4.356152327744667e-09
a O 0 8.704905241074812e-08
highly O 0 5.6010245316429064e-05
penetrant O 1 0.9995657801628113
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999971389770508
disorder I-Disease 1 1.0
characterized O 0 0.008180726319551468
by O 0 9.491439527664625e-07
multiple O 0 9.315675561083481e-05
intestinal O 1 0.9938327074050903
polyps B-Disease 0 0.0006782456766813993
and O 0 1.0185744514501494e-07
, O 0 3.7792444729234376e-09
without O 0 3.192608399871233e-09
surgical O 0 1.047475052473601e-06
intervention O 0 2.4005590404385657e-08
, O 0 9.553312585453e-10
the O 0 3.439176443631453e-10
development O 0 2.1925889992502334e-09
of O 0 3.466845373623073e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.061975111355423e-07
CRC B-Disease 0 6.753837806172669e-05
) O 0 8.63314397747672e-08
. O 0 1.8731591922005464e-07

APC B-Disease 0 0.0001349227677565068
is O 0 7.814836067154829e-07
a O 0 1.8544830027167336e-06
tumour O 1 0.9999829530715942
- O 0 5.737128958571702e-05
suppressor O 0 9.977587615139782e-05
gene O 0 1.975286920696817e-07
, O 0 4.049530044625271e-09
and O 0 4.56403359549995e-09
somatic O 0 9.68216795627086e-07
loss O 0 7.6293176789477e-06
occurs O 0 2.3531679005373007e-07
in O 0 4.732093827897188e-07
tumours B-Disease 1 0.9999980926513672
. O 0 2.4702703740331344e-06

The O 0 1.299393261433579e-06
germline O 0 3.5011733416467905e-05
T O 0 2.07543489523232e-05
- O 0 1.43887064041337e-06
to O 0 3.3783514652441227e-08
- O 0 9.122693995777809e-07
A O 0 2.408944226317544e-07
transversion O 0 2.5465956241532695e-06
responsible O 0 1.2778778923916434e-08
for O 0 2.7115465428551033e-10
the O 0 1.0652390081133944e-09
APC O 0 1.5481660398108943e-07
I1307K O 0 3.6624899735215877e-07
allele O 0 7.572955240675583e-08
converts O 0 2.6290610577461848e-08
the O 0 3.731738251744332e-10
wild O 0 1.5217079818441448e-09
- O 0 7.928763778863868e-08
type O 0 4.877387382862253e-08
sequence O 0 1.6930867818842898e-09
to O 0 3.891795774535467e-09
a O 0 2.8704289434244856e-07
homopolymer O 1 0.5602573752403259
tract O 0 0.4914454519748688
( O 0 1.8457754435985407e-08
A8 O 0 0.00016236890223808587
) O 0 2.443836466525795e-09
that O 0 5.9750990821783034e-09
is O 0 2.076845007081829e-08
genetically O 0 7.981001317602932e-07
unstable O 0 6.180399941513315e-05
and O 0 6.36174846135873e-08
prone O 0 1.0631067198119126e-05
to O 0 9.916277576849097e-08
somatic O 0 4.6517408918589354e-05
mutation O 0 3.560317782103084e-05
. O 0 4.566151687868114e-07

The O 0 3.716481558058149e-07
I1307K O 0 6.688849680358544e-06
allele O 0 4.252609869581647e-06
was O 0 1.4524891867040424e-07
found O 0 1.0240108316850183e-08
in O 0 2.3016646366613713e-09
6 O 0 5.1162182046482485e-08
. O 0 7.669855506264867e-08

1 O 0 1.7567977010912728e-06
% O 0 4.777561457558477e-08
of O 0 1.9491583902464527e-09
unselected O 0 1.1322706995997578e-05
Ashkenazi O 0 6.026450137142092e-06
Jews O 0 1.608966186950056e-07
and O 0 4.2923731236044205e-09
higher O 0 6.70525990287274e-09
proportions O 0 5.2661345506521684e-08
of O 0 1.2930785331377592e-09
Ashkenazim O 0 7.129727350729809e-07
with O 0 7.241518051870344e-09
family O 0 2.803317045163567e-08
or O 0 6.26557472571676e-10
personal O 0 6.318263956472947e-08
histories O 0 2.6019678855959683e-08
of O 0 3.6525047431013036e-09
CRC B-Disease 0 9.777634659258183e-06
( O 0 1.195471810433446e-08
ref O 0 1.719031024549622e-05
. O 0 8.144700025525253e-09
2 O 0 1.2230492174580831e-08
) O 0 6.799041329941247e-09
. O 0 5.247514778261575e-08

To O 0 3.434126938373083e-07
evaluate O 0 1.4581921448098e-07
the O 0 5.409840908576768e-10
role O 0 1.3015162281249104e-09
of O 0 5.188748875006866e-10
I1307K O 0 3.2253188919639797e-07
in O 0 1.4971513806472103e-08
cancer B-Disease 0 1.1930820846828283e-06
, O 0 1.3960248512745466e-09
we O 0 2.4517734509288402e-09
genotyped O 0 3.7524196727645176e-07
5 O 0 3.8235743460290905e-09
, O 0 1.87364013193303e-09
081 O 0 4.251043037584168e-07
Ashkenazi O 0 2.9833023518222035e-07
volunteers O 0 8.341647372844818e-09
in O 0 4.766906869235754e-10
a O 0 1.320505749191625e-08
community O 0 1.367077473446443e-08
survey O 0 1.5059816860230058e-07
. O 0 3.737854115115624e-08

Risk O 0 4.296128827263601e-05
of O 0 5.013970394429634e-08
developing O 0 1.3233533309175982e-06
colorectal B-Disease 1 0.9999997615814209
, I-Disease 0 6.212954303919105e-06
breast I-Disease 0 0.010495373979210854
and I-Disease 0 1.2233132906658284e-07
other I-Disease 0 1.488032719265675e-08
cancers I-Disease 0 7.588572043459862e-05
were O 0 1.2996743237181363e-07
compared O 0 2.842839386119067e-08
between O 0 1.950798633743034e-09
genotyped O 0 3.433122401474975e-06
I1307K O 0 8.821551773507963e-07
carriers O 0 3.65974521798762e-08
and O 0 1.3742400550853517e-09
non O 0 2.4445869772904416e-09
- O 0 2.687704636628041e-07
carriers O 0 3.2834226004752054e-08
and O 0 1.496231361031164e-09
their O 0 2.1945960326785752e-10
first O 0 4.8207549063761235e-09
- O 0 4.6026053723835503e-07
degree O 0 3.5854978364113776e-07
relatives O 0 6.275207624639734e-07
. O 0 1.0483029910801633e-07

Sperm O 0 1.7328553440165706e-05
DNA O 0 2.8939402909600176e-06
analysis O 0 4.735529302024588e-08
in O 0 4.76863704079733e-09
a O 0 1.0180388017033692e-06
Friedreich B-Disease 1 0.9985672235488892
ataxia I-Disease 1 0.9999070167541504
premutation O 0 0.2191539704799652
carrier O 0 2.4134054910973646e-05
suggests O 0 2.630159734451354e-08
both O 0 1.4683947391347374e-09
meiotic O 0 3.506315948698102e-08
and O 0 2.2759083506684874e-09
mitotic O 0 2.467255555416159e-08
expansion O 0 9.023136904318108e-09
in O 0 1.848092456846473e-09
the O 0 5.027576133187495e-09
FRDA B-Disease 0 6.043103712727316e-05
gene O 0 1.6759166783231194e-06
. O 0 1.297373444231198e-07

Friedreich B-Disease 1 0.9998281002044678
ataxia I-Disease 1 0.9999816417694092
is O 0 0.0023211101070046425
usually O 0 5.762119599239668e-06
caused O 0 2.3537828042208275e-07
by O 0 5.11250597412527e-10
an O 0 3.707269768948862e-10
expansion O 0 2.8215596525882347e-09
of O 0 3.5398572961753416e-10
a O 0 3.694180250590762e-08
GAA O 0 1.4656315272532083e-07
trinucleotide O 0 1.0000933343690122e-06
repeat O 0 6.30937648793406e-08
in O 0 2.387689601590637e-09
intron O 0 6.959534175621229e-07
1 O 0 3.375773216518496e-09
of O 0 4.793018204551913e-10
the O 0 5.875421926759827e-09
FRDA B-Disease 0 8.414884359808639e-05
gene O 0 2.5609917884139577e-06
. O 0 1.6202420738409273e-07

Occasionally O 0 1.1917847587028518e-05
, O 0 1.9054384736705288e-08
a O 0 9.65524193929923e-09
fully O 0 1.3854680958047538e-08
expanded O 0 6.9898371535259685e-09
allele O 0 1.8589933858947916e-07
has O 0 1.1167277769175143e-08
been O 0 6.514759842701778e-09
found O 0 3.2064979560431084e-09
to O 0 3.191944708547112e-09
arise O 0 3.0348092927567905e-09
from O 0 3.717799401670163e-10
a O 0 6.787198802982175e-09
premutation O 0 1.7776135052827158e-07
of O 0 2.407108401492053e-10
100 O 0 9.768714726021699e-10
or O 0 1.8341442808988973e-09
less O 0 8.426950870443761e-08
triplet O 0 0.0004360572202131152
repeats O 0 1.1948332030442543e-06
. O 0 1.3034501478159655e-07

We O 0 5.81799326937471e-07
have O 0 5.502590738615254e-08
examined O 0 2.805553123153004e-08
the O 0 5.865946062222349e-10
sperm O 0 8.107424953607278e-09
DNA O 0 1.3513334451431547e-08
of O 0 3.50621892630798e-10
a O 0 3.587706842722582e-08
premutation O 0 0.00010871430276893079
carrier O 0 2.353802483412437e-05
. O 0 2.6116393314623565e-07

This O 0 3.3539737387400237e-07
mans O 0 7.285123047040543e-06
leucocyte O 0 7.387463938357541e-06
DNA O 0 6.176636020427395e-07
showed O 0 2.2652498898878548e-07
one O 0 2.3024990802866796e-09
normal O 0 2.3309425500883663e-09
allele O 0 4.838951639385414e-08
and O 0 1.4473896525757368e-09
one O 0 1.4038377127434387e-09
allele O 0 2.3581277375228638e-08
of O 0 2.10788331234113e-10
approximately O 0 6.754448111934153e-09
100 O 0 9.518251964379942e-09
repeats O 0 2.2331121840579726e-07
. O 0 4.053147861782236e-08

His O 0 1.228046585310949e-06
sperm O 0 4.834246283280663e-07
showed O 0 8.672357409977849e-08
an O 0 1.569323559991176e-09
expanded O 0 1.1187552217961638e-08
allele O 0 7.434985604959365e-08
in O 0 3.4314839858495816e-10
a O 0 5.412351455902353e-09
tight O 0 7.318459438465652e-07
range O 0 1.4180747243131009e-08
centering O 0 2.1609531941635396e-08
on O 0 4.913426554509215e-09
a O 0 3.5515859142520867e-09
size O 0 7.2814620999395174e-09
of O 0 7.84761644556653e-10
approximately O 0 6.964498311390344e-09
320 O 0 9.779126486364476e-08
trinucleotide O 0 9.431810212845448e-06
repeats O 0 1.3060910077911103e-06
. O 0 1.7995074585996917e-07

His O 0 1.3005651453568134e-05
affected O 0 1.5986922790034441e-06
son O 0 3.806313543464057e-06
has O 0 3.756336397486848e-08
repeat O 0 2.999517434432164e-08
sizes O 0 2.37406734271417e-08
of O 0 1.0276967055133923e-09
1040 O 0 2.5274763970628555e-07
and O 0 3.147792781987846e-08
540 O 0 6.154703555694141e-07
. O 0 1.6849121209361329e-07

These O 0 5.0875211599077375e-08
data O 0 9.94381288421664e-09
suggest O 0 9.036467574219387e-09
that O 0 4.2165326785692514e-10
expansion O 0 1.982116470955475e-09
occurs O 0 5.503739686218978e-10
in O 0 1.137512584126199e-10
two O 0 7.073711616456535e-10
stages O 0 4.939812559001666e-09
, O 0 5.373211320325311e-10
the O 0 9.334142486716601e-11
first O 0 9.734640871172928e-10
during O 0 5.975939187941037e-10
meiosis O 0 2.339177296306616e-09
followed O 0 1.2966152596050051e-09
by O 0 1.9850550370126285e-10
a O 0 1.094584756167194e-09
second O 0 5.8475948527814126e-09
mitotic O 0 3.276010431818577e-07
expansion O 0 2.1550432904859917e-07
. O 0 1.760083279123137e-07

We O 0 4.2199201288894983e-07
also O 0 1.5177201717619937e-08
show O 0 6.684458320194153e-09
that O 0 4.772565120880756e-10
in O 0 1.7594230239392772e-10
all O 0 1.1032975227864839e-10
informative O 0 1.048076736509529e-08
carrier O 0 1.3867192194538802e-07
father O 0 3.4895830225423197e-08
to O 0 4.199487424472181e-09
affected O 0 2.844086743891694e-08
child O 0 3.0163101882862975e-07
transmissions O 0 5.212392011344491e-07
, O 0 1.4266685610664354e-09
with O 0 3.711224660918333e-10
the O 0 3.630921674435683e-10
notable O 0 6.535855856526496e-09
exception O 0 2.4832400580265812e-09
of O 0 6.667605356724948e-11
the O 0 1.2700385187969232e-09
premutation O 0 1.8655126723388094e-06
carrier O 0 9.26690617575332e-08
, O 0 1.9172592680138933e-10
the O 0 6.837215515975714e-11
expansion O 0 2.7245605771497594e-09
size O 0 3.245014923436429e-08
decreases O 0 8.742190402699634e-07
. O 0 1.1342077499421066e-08
. O 0 4.235899098148366e-08

The O 0 1.37501365315984e-06
R496H O 0 9.686650628282223e-06
mutation O 0 6.919574389030458e-07
of O 0 1.1821431611380717e-09
arylsulfatase O 0 1.193735215565539e-06
A O 0 1.3792278252822143e-07
does O 0 1.463159691184046e-07
not O 0 2.371940723833177e-07
cause O 0 0.0002068202302325517
metachromatic B-Disease 1 0.9999985694885254
leukodystrophy I-Disease 1 0.9999942779541016
. O 0 4.491615982260555e-06

Deficiency B-Disease 1 0.9972032308578491
of I-Disease 0 3.3885032735270215e-07
arylsulfatase I-Disease 0 6.975140422582626e-05
A I-Disease 0 2.675337555047008e-06
( O 0 5.848612971703915e-08
ARSA O 0 0.00010994007607223466
) O 0 7.121407019639037e-09
enzyme O 0 7.185304440326945e-08
activity O 0 9.757160057688452e-08
causes O 0 2.8939683033968322e-05
metachromatic B-Disease 1 0.9999994039535522
leukodystrophy I-Disease 1 0.9999997615814209
( O 0 3.475842822808772e-05
MLD B-Disease 1 0.9999532699584961
) O 0 1.5252181810865295e-06
. O 0 5.542363510357973e-07

A O 0 9.106621519094915e-07
number O 0 1.664303539428147e-08
of O 0 1.7367780547061784e-09
ARSA O 0 0.0005180516163818538
gene O 0 8.021282837944455e-07
mutations O 0 5.409871164374636e-07
responsible O 0 9.494918629116e-08
for O 0 1.3395678877259343e-07
MLD B-Disease 1 0.9999918937683105
have O 0 1.1095758964074776e-05
been O 0 2.118253178196028e-06
identified O 0 1.4516723467750126e-06
. O 0 8.670074436167852e-08

Recently O 0 8.066788723226637e-06
, O 0 1.605256372272379e-08
the O 0 8.827706343694786e-10
R496H O 0 3.780231452310545e-07
mutation O 0 9.627110841847752e-08
of O 0 1.2669898463713025e-09
ARSA O 0 2.521675924072042e-05
was O 0 2.502374627511017e-07
proposed O 0 7.480386088332125e-09
to O 0 2.4469710702135217e-09
be O 0 3.2297369223499572e-09
a O 0 5.9367280869082606e-08
cause O 0 1.7347448419968714e-06
of O 0 8.28436483857331e-08
MLD B-Disease 1 0.9999899864196777
( O 0 1.1529958499068016e-07
Draghia O 0 3.8720692828064784e-05
et O 0 6.056059760339849e-07
al O 0 4.974709781890851e-07
. O 0 5.200978314690019e-09
, O 0 1.564717688751216e-09
1997 O 0 5.393750335258574e-09
) O 0 3.5223881589274697e-09
. O 0 3.0804272910245345e-08

We O 0 2.8151700348644226e-07
have O 0 1.5145449339115657e-08
investigated O 0 2.5103094714040708e-08
the O 0 1.4983561058556916e-09
R496H O 0 8.811402949504554e-07
mutation O 0 2.144169855000655e-07
and O 0 2.0155894731033186e-09
found O 0 1.8329132656091929e-09
this O 0 2.3097200541055685e-10
mutation O 0 5.730304675211073e-09
at O 0 8.16413395221538e-11
a O 0 4.255340080305814e-09
relatively O 0 4.4584371750033824e-08
high O 0 1.6952654391388933e-08
frequency O 0 1.2038469776598504e-07
in O 0 4.43785896919735e-10
an O 0 1.1763513496632072e-09
African O 0 7.141889302175741e-10
American O 0 2.167755752680023e-09
population O 0 8.386663585824294e-10
( O 0 4.1038633602497043e-10
f O 0 8.503483428512482e-08
= O 0 3.845217122488975e-08
0 O 0 6.57037801943261e-09
. O 0 7.354836184525482e-10
09 O 0 1.1568073610135343e-08
, O 0 3.750263655177832e-09
n O 0 1.7505283267382765e-07
= O 0 2.6859521540245623e-07
61 O 0 3.362717393429193e-07
subjects O 0 6.312481559689331e-08
) O 0 2.0580277038106942e-08
. O 0 8.672787288332984e-08

The O 0 1.4059038448976935e-06
ARSA O 0 9.092178515857086e-05
enzyme O 0 3.963231733905559e-07
activity O 0 1.576876407227701e-08
in O 0 2.2324162518572166e-09
subjects O 0 2.074422056352887e-08
with O 0 2.544850108421315e-09
and O 0 1.1190987692089038e-08
without O 0 1.3901154671813742e-09
the O 0 8.624512215504865e-10
R496H O 0 3.5349023619346553e-07
mutation O 0 5.693418714258769e-08
was O 0 2.9448415261867922e-08
determined O 0 3.437468265587995e-08
and O 0 2.303641055689809e-09
found O 0 3.3842639801662244e-09
to O 0 2.9042872551343635e-09
be O 0 2.4925421726607055e-08
normal O 0 7.23957427339883e-08
. O 0 1.4110226231878187e-07

It O 0 5.157614282325085e-07
is O 0 2.890925010490264e-08
therefore O 0 1.0118568205541578e-08
concluded O 0 4.279718357480533e-09
that O 0 6.234128213655765e-10
the O 0 7.334216012289119e-10
R496H O 0 4.5223293909657514e-07
mutation O 0 6.719819367617674e-08
of O 0 1.3829539735610297e-09
ARSA O 0 2.494150430720765e-05
does O 0 2.7699387672441844e-08
not O 0 2.155247091906176e-09
negatively O 0 9.681169643727117e-09
influence O 0 1.4724613750516369e-09
the O 0 3.221257427465929e-10
activity O 0 7.774584864783662e-10
of O 0 4.96009011641263e-10
ARSA O 0 6.830356869613752e-05
and O 0 3.6318168472604384e-09
is O 0 2.007164656703253e-09
not O 0 2.6759836568857054e-09
a O 0 3.3152652179069264e-08
cause O 0 1.333916998191853e-06
of O 0 3.5887612170881766e-07
MLD B-Disease 1 0.9999572038650513

Down O 0 4.744506895804079e-06
- O 0 1.3417558193395962e-06
regulation O 0 1.1463024662816679e-07
of O 0 5.87867265977593e-09
transmembrane O 0 1.2369254136501695e-06
carbonic O 0 5.359876467991853e-06
anhydrases O 0 3.285294496890856e-06
in O 0 1.1471860261735856e-07
renal B-Disease 1 0.9997472167015076
cell I-Disease 1 0.9999486207962036
carcinoma I-Disease 1 1.0
cell O 0 0.05719134956598282
lines O 0 1.7239771068489063e-06
by O 0 3.5167224687882026e-09
wild O 0 2.4933980213859286e-08
- O 0 2.7995989512419328e-05
type O 0 0.00023669142683502287
von B-Disease 1 0.9895697832107544
Hippel I-Disease 1 0.9459649324417114
- I-Disease 0 0.05387170985341072
Lindau I-Disease 0 0.06251681596040726
transgenes O 0 0.00019811544916592538
. O 0 1.9405126749916235e-06

To O 0 3.6160011518404644e-07
discover O 0 1.469085191274644e-07
genes O 0 5.385313528449842e-08
involved O 0 1.237971325451781e-08
in O 0 1.98479970237031e-08
von B-Disease 1 0.9995684027671814
Hippel I-Disease 1 0.9998452663421631
- I-Disease 1 0.9991794228553772
Lindau I-Disease 1 0.9964021444320679
( O 0 8.383569394254664e-08
VHL B-Disease 0 6.99573365636752e-06
) O 0 9.366467601523709e-09
- O 0 1.1362883469701046e-06
mediated O 0 8.110944690997712e-06
carcinogenesis O 0 2.87835173367057e-05
, O 0 5.31174881857055e-09
we O 0 3.6968141881033034e-09
used O 0 3.047844757020357e-06
renal B-Disease 1 0.9998072981834412
cell I-Disease 1 0.999977707862854
carcinoma I-Disease 1 1.0
cell O 1 0.5991352796554565
lines O 0 3.984924478572793e-05
stably O 0 1.0870663572859485e-05
transfected O 0 6.750452030246379e-06
with O 0 1.0912646786209734e-08
wild O 0 5.6852154983744185e-08
- O 0 6.937051512068138e-05
type O 0 0.0001588978193467483
VHL O 0 0.00015340697427745908
- O 0 3.352535713929683e-05
expressing O 0 2.4064006538537797e-06
transgenes O 0 1.6076353858807124e-05
. O 0 2.4206568127738137e-07

Large O 0 1.2621107998711523e-06
- O 0 1.43959266551974e-06
scale O 0 1.0283996232374193e-07
RNA O 0 9.297250613826691e-08
differential O 0 1.100503368434147e-06
display O 0 4.897588823382648e-08
technology O 0 9.20122467107376e-09
applied O 0 2.4009070287434042e-08
to O 0 2.7828690463138628e-09
these O 0 7.022935011313791e-10
cell O 0 6.445486064876604e-07
lines O 0 3.9696092812846473e-07
identified O 0 1.9289439379122086e-08
several O 0 1.5269878694823547e-09
differentially O 0 7.590625727971201e-07
expressed O 0 3.0236137149586284e-08
genes O 0 8.045007326984432e-09
, O 0 3.4495825640412647e-10
including O 0 2.507321017475306e-10
an O 0 2.701924683989887e-09
alpha O 0 1.2133986615481263e-07
carbonic O 0 2.81647749034164e-06
anhydrase O 0 2.6217660433758283e-06
gene O 0 1.1555452772427088e-07
, O 0 8.786940952631994e-09
termed O 0 7.608288115079631e-07
CA12 O 0 0.00013713818043470383
. O 0 4.714252099802252e-07

The O 0 2.620715804368956e-07
deduced O 0 9.834189995672205e-07
protein O 0 3.622713862228011e-08
sequence O 0 8.753618274681685e-09
was O 0 1.2928992987326637e-08
classified O 0 3.481709809349809e-09
as O 0 1.3797027964557174e-09
a O 0 6.52245635279769e-09
one O 0 1.6148653969594307e-08
- O 0 2.9943323625047924e-06
pass O 0 2.1950395421299618e-06
transmembrane O 0 9.89031150311348e-07
CA O 0 1.5598962477270106e-07
possessing O 0 7.004798074916607e-09
an O 0 2.644408914065366e-09
apparently O 0 1.9180865251655632e-07
intact O 0 1.547613237562473e-08
catalytic O 0 1.2740837718183684e-08
domain O 0 3.92276833238725e-09
in O 0 3.127621217569043e-10
the O 0 3.413987981204514e-10
extracellular O 0 9.505119891173308e-08
CA O 0 1.5144778444664553e-06
module O 0 3.465847612460493e-06
. O 0 1.2934498272443307e-07

Reintroduced O 0 5.600356962531805e-05
wild O 0 1.5167324818321504e-06
- O 0 2.552290607127361e-05
type O 0 6.0718284657923505e-06
VHL B-Disease 0 1.529885958007071e-05
strongly O 0 8.42992335492454e-07
inhibited O 0 1.1371866293075072e-07
the O 0 8.386360494938572e-10
overexpression O 0 5.4696087659067416e-08
of O 0 2.4805027476482167e-10
the O 0 8.572588194866171e-10
CA12 O 0 1.317489022767404e-06
gene O 0 1.706802876810798e-08
in O 0 9.328986472212364e-10
the O 0 8.53913917353566e-09
parental O 1 0.6084166765213013
renal B-Disease 1 0.9999871253967285
cell I-Disease 1 0.9999878406524658
carcinoma I-Disease 1 1.0
cell O 1 0.9362089037895203
lines O 0 0.00011809777788585052
. O 0 9.28214205941913e-07

Similar O 0 1.0729047971835826e-05
results O 0 4.743900490211672e-07
were O 0 2.0232784336826626e-08
obtained O 0 1.044729547317047e-08
with O 0 6.062575330645359e-09
CA9 O 0 0.00032377708703279495
, O 0 7.953676828265088e-09
encoding O 0 1.3490080164046958e-08
another O 0 2.023309342291668e-08
transmembrane O 0 2.984895957069966e-07
CA O 0 1.0736398081689913e-07
with O 0 8.235910842202543e-10
an O 0 1.9562909070458545e-09
intact O 0 1.243182197185888e-07
catalytic O 0 1.0736336975014638e-07
domain O 0 9.688876900781906e-08
. O 0 6.862702406351673e-08

Although O 0 1.5584480479446938e-06
both O 0 7.104950405789623e-09
domains O 0 2.9045035265795605e-09
of O 0 1.500420204747499e-10
the O 0 8.952726338051775e-10
VHL B-Disease 0 6.682574280603149e-07
protein O 0 7.81544517991506e-09
contribute O 0 1.2862452214434938e-09
to O 0 5.322028928667066e-10
regulation O 0 8.02543631550634e-09
of O 0 8.581634847182329e-10
CA12 O 0 0.0002585313923191279
expression O 0 1.1211289319135176e-07
, O 0 2.9995944617056125e-10
the O 0 1.3593873249284627e-10
elongin O 0 1.367912716432329e-07
binding O 0 3.35808927331982e-08
domain O 0 2.322268066734523e-08
alone O 0 2.7195465435170263e-08
could O 0 1.1963682489124494e-08
effectively O 0 9.90814754686653e-08
regulate O 0 3.093291525146924e-06
CA9 O 0 0.0007523347740061581
expression O 0 4.018304480268853e-06
. O 0 2.6381187012702867e-07

We O 0 1.9927711036871187e-06
mapped O 0 1.610538674867712e-05
CA12 O 0 4.897328108199872e-05
and O 0 1.2664233395298652e-07
CA9 O 0 1.6237243471550755e-05
loci O 0 2.5290964345003886e-07
to O 0 3.566794148923691e-08
chromosome O 0 3.540996431183885e-06
bands O 0 3.884960051436792e-07
15q22 O 0 2.7317666990711587e-06
and O 0 8.836963161229505e-08
17q21 O 0 9.025960935105104e-06
. O 0 3.5441684076431557e-07

2 O 0 2.660666496012709e-06
respectively O 0 4.070735712957685e-07
, O 0 1.328319054749727e-08
regions O 0 1.9305264942204303e-08
prone O 0 3.26100644088001e-06
to O 0 2.6322272361767318e-08
amplification O 0 1.158776967713493e-06
in O 0 2.667819298807217e-09
some O 0 3.438836992941674e-09
human O 0 1.2615232947155164e-07
cancers B-Disease 0 0.00023374593001790345
. O 0 4.786171530213323e-07

Additional O 0 1.0678677426767536e-06
experiments O 0 6.077304988139076e-07
are O 0 4.266905051508729e-09
needed O 0 1.2203019039702667e-08
to O 0 2.8609081770269995e-09
define O 0 1.101108093592984e-08
the O 0 6.282735443008391e-10
role O 0 4.610668735693935e-09
of O 0 1.5623171645273715e-09
CA O 0 2.6721806989371544e-06
IX O 0 0.00041076549678109586
and O 0 1.9018045804841677e-07
CA O 0 2.4276855583593715e-06
XII O 0 7.523353360738838e-06
enzymes O 0 1.2744385990970386e-08
in O 0 2.897435902315948e-10
the O 0 1.5780812767651753e-10
regulation O 0 4.1659324878651205e-09
of O 0 6.552490772193664e-10
pH O 0 3.923874771771807e-07
in O 0 5.806989888945679e-10
the O 0 4.843009326904735e-10
extracellular O 0 2.0827080504659534e-08
microenvironment O 0 6.745450491507654e-07
and O 0 2.023771594750201e-09
its O 0 5.000231895202489e-10
potential O 0 2.075988492222791e-09
impact O 0 1.3037977808494361e-08
on O 0 6.455390462178912e-07
cancer B-Disease 0 6.24239255557768e-05
cell O 0 1.456192535442824e-06
growth O 0 1.0124094274033268e-07
. O 0 8.721823974155996e-08

A O 0 3.811438773482223e-06
gene O 0 9.620023320167093e-07
encoding O 0 1.6818971459997556e-07
a O 0 4.273667641996326e-08
transmembrane O 0 7.439665523634176e-07
protein O 0 3.9795470030412616e-08
is O 0 2.184457281728669e-09
mutated O 0 1.8434151627388928e-07
in O 0 2.438152968409213e-08
patients O 0 0.00391435157507658
with O 0 0.02938162535429001
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9994457364082336
optic B-Disease 1 0.9999998807907104
atrophy I-Disease 1 0.9999938011169434
( O 0 0.017660794779658318
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.5810426740899857e-07
. O 0 6.068640345802123e-07

Wolfram B-Disease 1 0.9999990463256836
syndrome I-Disease 1 1.0
( O 0 0.0014060254907235503
WFS B-Disease 1 0.822411835193634
; O 0 2.9875505788368173e-05
OMIM O 0 0.0022984312381595373
222300 O 0 5.563330432778457e-06
) O 0 9.80686021279098e-09
is O 0 7.357127351781401e-09
an O 0 8.226498948715744e-08
autosomal B-Disease 1 0.9997932314872742
recessive I-Disease 1 0.999996542930603
neurodegenerative I-Disease 1 0.9999995231628418
disorder I-Disease 1 0.9999781847000122
defined O 0 5.096106860946747e-07
by O 0 1.552444039987222e-08
young O 0 1.3556076794429828e-07
- O 0 5.1808415264531504e-06
onset O 0 2.385739207966253e-06
non O 0 1.437415164673439e-07
- O 0 0.0019498566398397088
immune O 0 0.0020345605444163084
insulin B-Disease 1 0.9923229217529297
- I-Disease 1 0.7361912727355957
dependent I-Disease 1 0.9292972087860107
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0009457253618165851
progressive O 1 0.9980039000511169
optic B-Disease 1 0.9999940395355225
atrophy I-Disease 1 0.9988505840301514
. O 0 8.716452612134162e-06

Linkage O 0 8.058196544880047e-05
to O 0 6.104920657890034e-07
markers O 0 4.130069555685623e-06
on O 0 2.730311052800971e-07
chromosome O 0 0.0002605585614219308
4p O 0 0.0007635505171492696
was O 0 2.284282572873053e-06
confirmed O 0 1.2689065442827996e-07
in O 0 2.1973782793338614e-09
five O 0 1.0135450700943238e-08
families O 0 5.1959148095193086e-08
. O 0 4.594781088940181e-08

On O 0 1.2422340489592898e-07
the O 0 2.8250759509518275e-09
basis O 0 9.97028126725752e-10
of O 0 4.0195774486662117e-10
meiotic O 0 8.265092219517101e-07
recombinants O 0 9.343647252535447e-05
and O 0 2.8663932880590437e-06
disease O 0 1.9749526472878642e-05
- O 0 0.00023752790002617985
associated O 0 5.286047780828085e-06
haplotypes O 0 1.473493375669932e-05
, O 0 5.997455421180575e-09
the O 0 3.3604004023857215e-09
WFS B-Disease 0 2.0918303107464453e-06
gene O 0 4.400892450462379e-08
was O 0 5.3864024351923945e-08
localized O 0 5.820202630957283e-08
to O 0 1.1089993812163357e-08
a O 0 6.044209044375748e-07
BAC O 0 8.932957280194387e-05
/ O 0 3.0138488682496245e-07
P1 O 0 3.7562438137683785e-07
contig O 0 2.177038567197087e-07
of O 0 2.0859142191298474e-10
less O 0 4.325510616354222e-09
than O 0 5.829710048033121e-09
250 O 0 3.627623357260745e-08
kb O 0 1.7608199414098635e-05
. O 0 2.621096086841135e-07

Mutations O 0 0.0022622246760874987
in O 0 1.320969857943055e-07
a O 0 1.225500341206498e-07
novel O 0 7.327699336201476e-07
gene O 0 1.5174951784047153e-07
( O 0 4.690230870352252e-09
WFS1 O 0 1.9628682821348775e-06
) O 0 7.177257677071225e-10
encoding O 0 6.304682109714577e-09
a O 0 6.887365344709906e-09
putative O 0 1.859365852396877e-07
transmembrane O 0 4.49874839603126e-08
protein O 0 3.629178957353929e-09
were O 0 1.6148276049676724e-09
found O 0 7.682499081340666e-10
in O 0 1.083585235428508e-10
all O 0 1.8592853645582608e-10
affected O 0 3.4439306961786542e-09
individuals O 0 3.4523078840109633e-10
in O 0 6.597222768078836e-10
six O 0 6.10772659115355e-08
WFS B-Disease 0 3.101232505287044e-05
families O 0 2.856383751748126e-08
, O 0 7.304995497392497e-10
and O 0 6.875719438248495e-10
these O 0 5.678100212236359e-10
mutations O 0 2.710137714245775e-08
were O 0 6.030468124862409e-09
associated O 0 4.097600481145491e-09
with O 0 3.3526730280897254e-09
the O 0 8.325135354425584e-07
disease O 0 0.10892385244369507
phenotype O 1 0.8185646533966064
. O 0 1.305131036133389e-06

WFS1 O 0 0.0010303667513653636
appears O 0 5.175014393898891e-06
to O 0 1.9085010904973387e-08
function O 0 9.723659211147151e-09
in O 0 3.738279907850028e-09
survival O 0 1.4647568491454876e-07
of O 0 1.0451157717028536e-09
islet O 0 1.8130034504793002e-06
beta O 0 2.5693106309176983e-08
- O 0 3.354907960329001e-07
cells O 0 2.834063472789694e-08
and O 0 9.768868380888307e-09
neurons O 0 1.2682387762197322e-07
. O 0 3.4225959844036424e-09
. O 0 2.200856741296775e-08

Stable O 0 3.672853927128017e-05
interaction O 0 1.264386213506441e-07
between O 0 3.6897416233472313e-09
the O 0 4.762998884189074e-10
products O 0 1.0642459136178672e-09
of O 0 1.2768337775970195e-10
the O 0 5.2655391158396014e-09
BRCA1 O 0 1.84807267942233e-05
and O 0 9.68312747318123e-07
BRCA2 O 0 0.00010107710841111839
tumor B-Disease 0 2.8875692805740982e-06
suppressor O 0 2.2209137569007e-06
genes O 0 4.914384987841913e-08
in O 0 1.6406641600852367e-09
mitotic O 0 1.8604406193389877e-07
and O 0 6.83245389154763e-08
meiotic O 0 7.0126334321685135e-06
cells O 0 4.082417035533581e-06
. O 0 1.8697575399073685e-07

BRCA1 O 0 0.3171483278274536
and O 0 5.522806532098912e-06
BRCA2 O 0 2.974138806166593e-05
account O 0 5.308854866825641e-08
for O 0 1.0727198018756212e-09
most O 0 2.275986510369421e-09
cases O 0 4.757181315540038e-09
of O 0 6.863639101517549e-10
familial O 0 3.406184760024189e-06
, O 0 9.14705111654257e-09
early O 0 1.0156858110121902e-07
onset O 0 3.572149216779508e-05
breast B-Disease 1 0.739560604095459
and I-Disease 0 6.484190816991031e-05
/ I-Disease 1 0.7682623267173767
or I-Disease 1 0.9370227456092834
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
and O 0 1.3580697455495283e-08
encode O 0 1.4499268452539127e-08
products O 0 2.0204209860708033e-08
that O 0 1.532335813791974e-09
each O 0 4.0943795576176e-10
interact O 0 2.0296317959633825e-09
with O 0 4.22431067903517e-09
hRAD51 O 0 5.552592028834624e-06
. O 0 2.3609545962699485e-07

Results O 0 5.159531156095909e-06
presented O 0 1.50571452195436e-07
here O 0 7.001419000118858e-09
show O 0 2.0085138885406195e-08
that O 0 1.0268742300922895e-08
BRCA1 O 0 1.5317309589590877e-06
and O 0 8.85994992927408e-08
BRCA2 O 0 1.6181933460757136e-05
coexist O 0 1.7874255320293742e-07
in O 0 5.05124775340704e-10
a O 0 1.592505860514848e-08
biochemical O 0 2.0565096292557428e-07
complex O 0 8.494336789510726e-09
and O 0 1.0005644313082485e-08
colocalize O 0 9.513641998637468e-07
in O 0 3.5931975173042474e-09
subnuclear O 0 1.0091548574564513e-06
foci O 0 5.470797646012215e-07
in O 0 2.2380950426281743e-09
somatic O 0 2.2938368715585966e-07
cells O 0 5.645019029998366e-08
and O 0 1.7650774175592687e-09
on O 0 3.4584848318530703e-09
the O 0 7.467424456564231e-10
axial O 0 4.4232356799511763e-07
elements O 0 9.101211340123427e-09
of O 0 7.135217416909256e-10
developing O 0 4.901167827142672e-08
synaptonemal O 0 1.7819018466980197e-05
complexes O 0 2.132947884092573e-06
. O 0 1.877220512369604e-07

Like O 0 1.2559857168525923e-05
BRCA1 O 0 0.0003152853751089424
and O 0 4.915969498142658e-07
RAD51 O 0 0.00022352290397975594
, O 0 9.944859158395047e-08
BRCA2 O 0 2.6783193334267708e-06
relocates O 0 5.942692382632231e-07
to O 0 5.697872751397881e-08
PCNA O 0 4.631437604984967e-06
+ O 0 1.3543085763956242e-08
replication O 0 2.1565425001313088e-09
sites O 0 1.8011749869373261e-09
following O 0 1.8186980810241948e-09
exposure O 0 2.5213559240455652e-08
of O 0 3.1008798306864094e-10
S O 0 1.2631993513423367e-06
phase O 0 3.509581247840288e-08
cells O 0 2.8106732941068913e-08
to O 0 1.8230471354740985e-08
hydroxyurea O 0 5.099986810819246e-05
or O 0 5.01756751702942e-08
UV O 0 0.0009503359906375408
irradiation O 0 1.806013642635662e-05
. O 0 4.869468170909386e-07

Thus O 0 1.2320219866523985e-05
, O 0 1.6269791558443103e-07
BRCA1 O 0 2.960204028568114e-06
and O 0 7.175566452133353e-08
BRCA2 O 0 2.3042632619763026e-06
participate O 0 3.902187017956749e-09
, O 0 7.740937335576348e-10
together O 0 6.41807440526776e-10
, O 0 5.316996842807953e-10
in O 0 2.395360854112738e-10
a O 0 2.3300589901964486e-08
pathway O 0 5.199325059379589e-08
( O 0 2.1183796938828436e-09
s O 0 1.7511606529296841e-06
) O 0 8.659308270431154e-10
associated O 0 2.2145620892644047e-09
with O 0 1.4015361093910883e-10
the O 0 1.439380281631486e-10
activation O 0 1.296664664529601e-09
of O 0 2.0838343550710903e-10
double O 0 9.397160738444654e-08
- O 0 2.461587882862659e-06
strand O 0 1.7300758372584824e-06
break O 0 5.973870997877384e-08
repair O 0 1.4934114460629644e-06
and O 0 2.92307262839131e-08
/ O 0 7.763433984564472e-08
or O 0 4.519455476525991e-09
homologous O 0 1.515057022061228e-07
recombination O 0 4.7112854417719063e-07
. O 0 6.300682002802205e-07

Dysfunction O 0 0.000733714085072279
of O 0 2.115304198468948e-08
this O 0 5.233428801432183e-09
pathway O 0 2.9011330227035614e-08
may O 0 8.184148470036234e-08
be O 0 2.9290094794021115e-09
a O 0 4.111528006944809e-09
general O 0 4.945751808094201e-09
phenomenon O 0 1.2398711390915196e-08
in O 0 2.509464580580101e-10
the O 0 3.847950014179702e-10
majority O 0 1.4266802850215754e-08
of O 0 3.108329149625888e-10
cases O 0 1.8600958995307337e-08
of O 0 6.01684169154737e-09
hereditary B-Disease 1 0.9998822212219238
breast I-Disease 1 0.9989405274391174
and I-Disease 0 0.0011940774274989963
/ I-Disease 0 0.2873709797859192
or I-Disease 1 0.586205005645752
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 2.9871912943235657e-07
. O 0 1.6880805731034343e-07

A O 0 4.64670074507012e-06
novel O 0 1.4113848010310903e-06
Arg362Ser O 0 4.0634618017065804e-06
mutation O 0 3.697391264267935e-07
in O 0 2.4837991663417824e-09
the O 0 2.855859548844819e-09
sterol O 0 4.403023558552377e-05
27 O 0 1.2330813206062885e-06
- O 0 4.344150966062443e-06
hydroxylase O 0 2.739132833085023e-05
gene O 0 1.1324549831215336e-07
( O 0 1.8739010343438167e-09
CYP27 O 0 1.3183059763832716e-06
) O 0 8.398894357775077e-10
: O 0 2.5298604877654896e-10
its O 0 5.904920996613328e-10
effects O 0 4.297445954648538e-08
on O 0 2.1910933512003794e-08
pre O 0 1.3488902084191068e-07
- O 0 9.541012246927494e-08
mRNA O 0 1.2641470981122893e-08
splicing O 0 3.8488273901293724e-08
and O 0 1.499453894382441e-09
enzyme O 0 1.0696719954239597e-08
activity O 0 9.584418592112343e-09
. O 0 2.267832321933838e-08

A O 0 4.174408331891755e-06
novel O 0 1.7881532130559208e-06
C O 0 1.4747985233043437e-07
to O 0 2.0468851058552673e-09
A O 0 3.716456120628209e-08
mutation O 0 1.42823537885306e-07
in O 0 1.1738500171887267e-09
the O 0 2.4755033578571783e-09
sterol O 0 0.00010898812615778297
27 O 0 8.504982247359294e-07
- O 0 6.201157248142408e-06
hydroxylase O 0 3.2940992241492495e-05
gene O 0 1.4120928426564205e-07
( O 0 2.1529626970107074e-09
CYP27 O 0 3.923305030184565e-06
) O 0 4.0552960989259645e-09
was O 0 1.7373859861891106e-07
identified O 0 6.883964065451664e-09
by O 0 2.874164239941024e-10
sequencing O 0 9.550293889049044e-09
amplified O 0 9.902306601361488e-07
CYP27 O 0 7.875001415413863e-07
gene O 0 1.3682251776003795e-08
products O 0 4.0012371194109164e-09
from O 0 5.796145785552653e-10
a O 0 7.384939948451574e-08
patient O 0 0.0003919588343705982
with O 0 3.905073754140176e-06
cerebrotendinous B-Disease 1 0.9999985694885254
xanthomatosis I-Disease 1 0.9999932050704956
( O 0 6.17925195456337e-07
CTX B-Disease 0 0.0006534065469168127
) O 0 2.3629952750070515e-07
. O 0 3.235142855828599e-07

The O 0 4.572142984216043e-07
mutation O 0 1.622661898181832e-06
changed O 0 2.25645884199821e-08
the O 0 1.4675967108246368e-09
adrenodoxin O 0 6.340138156701869e-07
cofactor O 0 3.8716822814421903e-07
binding O 0 1.601367216608196e-07
residue O 0 2.1762581070561282e-07
362Arg O 0 6.006175112815981e-07
to O 0 4.740834214089773e-08
362Ser O 0 2.1213018044363707e-06
( O 0 8.524005501442389e-09
CGT O 0 1.0060740578410332e-06
362Arg O 0 1.1642335948636173e-06
to O 0 6.123567430904586e-08
AGT O 0 6.187216513353633e-06
362Ser O 0 1.4179199752106797e-06
) O 0 5.062264385458093e-09
, O 0 1.3725713898793401e-09
and O 0 1.931092619145147e-09
was O 0 2.1260640892251104e-07
responsible O 0 2.071729454655724e-08
for O 0 2.262285114795759e-08
deficiency O 0 4.703941613115603e-06
in O 0 1.350758171980715e-09
the O 0 5.511116452083797e-09
sterol O 0 3.211702642147429e-05
27 O 0 1.930737028033036e-07
- O 0 1.4317771501737298e-07
hydroxylase O 0 8.113436251733219e-07
activity O 0 1.687290307472722e-09
, O 0 2.0593213245767572e-10
as O 0 9.824098201605125e-10
confirmed O 0 6.041451339200421e-09
by O 0 2.3461332876451024e-10
expression O 0 1.008413463843283e-09
of O 0 9.666509953598634e-11
mutant O 0 2.989824210430925e-08
cDNA O 0 1.6616453990536684e-08
into O 0 4.771548489657107e-09
COS O 0 8.347157063326449e-07
- O 0 4.835786739931791e-07
1 O 0 4.253751484384338e-08
cells O 0 1.4322645824904612e-07
. O 0 6.475453773191475e-08

Quantitative O 0 3.455234264038154e-06
analysis O 0 2.8421081310625596e-07
showed O 0 1.5948411657973338e-07
that O 0 1.0294622931894537e-09
the O 0 6.321970169587132e-10
expression O 0 1.0993180588059204e-08
of O 0 3.481747945510705e-10
CYP27 O 0 6.623984063480748e-07
gene O 0 1.366467383689951e-08
mRNA O 0 4.915995166498988e-09
in O 0 1.2315906072757343e-09
the O 0 6.016566356237263e-09
patient O 0 5.96991230850108e-06
represented O 0 3.431828758948541e-07
52 O 0 2.523300508983084e-06
. O 0 1.6422013970895932e-07

5 O 0 2.1365879092627438e-06
% O 0 1.924882653270288e-08
of O 0 5.924007950852683e-10
the O 0 1.7139070163096903e-09
normal O 0 5.203789754659738e-08
level O 0 4.511852225164148e-08
. O 0 1.295426272918121e-07

As O 0 3.4542944149507093e-07
the O 0 7.806506552299197e-09
mutation O 0 5.271742153922787e-08
occurred O 0 4.750897897309869e-09
at O 0 9.641137194149607e-11
the O 0 1.3727644021521712e-10
penultimate O 0 4.121234198350976e-08
nucleotide O 0 6.878031477697277e-09
of O 0 3.402325920998095e-10
exon O 0 5.8542266145877875e-08
6 O 0 4.992362967470854e-09
( O 0 2.820896294331021e-10
- O 0 3.3453865455612686e-08
2 O 0 3.1568461178466123e-09
position O 0 7.608162100325444e-09
of O 0 1.2403052196408026e-10
exon O 0 3.6808025072332384e-08
6 O 0 9.174552673130165e-09
- O 0 1.29702954154709e-07
intron O 0 2.0776590190507704e-06
6 O 0 7.511511412872096e-09
splice O 0 6.065446456204882e-08
site O 0 7.68536079220894e-09
) O 0 9.301814180018297e-11
of O 0 2.818544703186987e-11
the O 0 3.881770738178858e-10
gene O 0 8.129847905991028e-09
, O 0 5.013812143239704e-10
we O 0 3.5863964575888474e-10
hypothesized O 0 9.050077132144452e-09
that O 0 5.304476857759255e-10
the O 0 1.02275710123223e-09
mutation O 0 4.6914951212784217e-07
may O 0 1.0390564142426228e-07
partially O 0 2.7184321993445337e-07
affect O 0 4.475389836500199e-09
the O 0 5.332372876587499e-10
normal O 0 2.4039117363372497e-09
splicing O 0 1.5515263740439877e-08
efficiency O 0 1.514585434847504e-08
in O 0 1.1703178426358818e-09
exon O 0 9.190284089299894e-08
6 O 0 6.849909528483522e-09
and O 0 2.6924487084301063e-09
cause O 0 6.097577198715953e-08
alternative O 0 1.1947173028659108e-08
splicing O 0 1.2755211287185375e-07
elsewhere O 0 5.9055579981759365e-08
, O 0 1.0288813134806674e-09
which O 0 1.0670121453060233e-09
resulted O 0 9.257168365195412e-09
in O 0 4.010741960769337e-09
decreased O 0 3.4190523479082913e-07
transcript O 0 9.367114017777567e-08
in O 0 1.4886480936837643e-09
the O 0 1.0901744396107915e-08
patient O 0 1.6599513401160948e-05
. O 0 2.601286155368143e-07

Transfection O 0 0.0001941601949511096
of O 0 1.648790686203938e-07
constructed O 0 3.1455717817152617e-06
minigenes O 0 4.390876347315498e-05
, O 0 1.0889442236816649e-08
with O 0 1.057096521428491e-09
or O 0 1.0346276058115222e-09
without O 0 1.301541097120662e-09
the O 0 1.3998751047239466e-09
mutation O 0 2.5027748762340707e-08
, O 0 5.428508198512816e-10
into O 0 1.5400947184218694e-09
COS O 0 3.596940132410964e-07
- O 0 2.5463378960921546e-07
1 O 0 4.178569934509824e-09
cells O 0 5.814086545541386e-09
confirmed O 0 1.2562343165711809e-08
that O 0 3.3689664946656706e-10
the O 0 4.207695303293235e-10
mutant O 0 1.2333711651990598e-07
minigene O 0 3.556235128598928e-07
was O 0 2.6297582778056494e-08
responsible O 0 2.0947623635692025e-09
for O 0 2.557236922218209e-10
a O 0 4.127131969511311e-09
mRNA O 0 9.600573669388268e-09
species O 0 1.0254018745214921e-09
alternatively O 0 2.3803835347280256e-08
spliced O 0 1.9227288703405065e-06
at O 0 2.0022856705992353e-09
an O 0 2.3642512392285653e-09
activated O 0 4.099416628378094e-07
cryptic O 0 1.4153596339383512e-07
5 O 0 1.5451996349113983e-09
splice O 0 7.478906383084905e-08
site O 0 2.3350152034140592e-08
88 O 0 2.3823002237577384e-08
bp O 0 1.0584107457134451e-07
upstream O 0 1.897802581751762e-09
from O 0 7.550676056622407e-11
the O 0 2.0708780523737147e-10
3 O 0 4.427510302829063e-10
end O 0 8.032216558540028e-10
of O 0 1.1288417978150278e-09
exon O 0 7.457865649485029e-07
6 O 0 1.2152308670465573e-07
. O 0 4.0065234685471296e-08

Our O 0 3.965780024373089e-07
data O 0 2.592526016087504e-08
suggest O 0 1.3966807266285741e-08
that O 0 4.870614467300527e-10
the O 0 2.896154149834018e-10
C O 0 7.523756728744502e-09
to O 0 7.726422279752398e-10
A O 0 1.4976689044488012e-07
mutation O 0 4.370961192989853e-08
at O 0 1.2453163500403264e-10
the O 0 2.3048574160355884e-10
penultimate O 0 1.614307976183227e-08
nucleotide O 0 2.7047657447099027e-09
of O 0 1.471057026192213e-10
exon O 0 2.763574613595665e-08
6 O 0 1.4686131200036812e-09
of O 0 7.626184406195335e-11
the O 0 7.365604237641321e-10
CYP27 O 0 5.807843081129249e-06
gene O 0 3.811416604548867e-08
not O 0 4.325106495173259e-09
only O 0 5.088867549574161e-09
causes O 0 6.096460936078074e-08
the O 0 2.1206853162425432e-08
deficiency B-Disease 0 1.6173709809663706e-05
in I-Disease 0 1.7043069178157566e-09
the I-Disease 0 5.208314224347532e-09
sterol I-Disease 0 5.432649777503684e-05
27 I-Disease 0 3.1685689805271977e-07
- I-Disease 0 3.0379734994312457e-07
hydroxylase I-Disease 0 1.0207990044364124e-06
activity I-Disease 0 3.6478193798927805e-09
, O 0 9.245588739048571e-10
but O 0 2.3439561402938125e-09
also O 0 2.3144323790802446e-08
partially O 0 1.3757754402377032e-07
leads O 0 5.827986981898903e-09
to O 0 8.29167623450644e-10
alternative O 0 3.796070568995447e-09
pre O 0 1.6040353045809752e-08
- O 0 1.953037020996362e-08
mRNA O 0 1.7424386378195322e-09
splicing O 0 5.374115819023473e-09
of O 0 9.961722419182806e-11
the O 0 1.0119663995666883e-09
gene O 0 1.241521090378228e-07
. O 0 7.151847114528209e-08

To O 0 5.817005899189098e-07
our O 0 1.0905509384429024e-08
knowledge O 0 9.32046662072139e-10
, O 0 1.418057060664779e-10
this O 0 5.86017276371642e-11
is O 0 3.0060548494859063e-10
the O 0 1.144996250590502e-10
first O 0 2.992424086301071e-09
report O 0 1.4343847221098827e-09
regarding O 0 5.375087042125415e-10
effects O 0 8.866758882675185e-09
on O 0 3.987895791368601e-09
pre O 0 2.78702980693879e-08
- O 0 2.558332212743153e-08
mRNA O 0 1.9240959936439594e-09
splicing O 0 4.815194909468801e-09
of O 0 6.224382120834093e-11
a O 0 1.1151372047990549e-09
mutation O 0 7.960385239869083e-09
at O 0 6.628853715939798e-11
the O 0 1.5118188645413255e-10
- O 0 2.568561399129976e-07
2 O 0 5.708117090108544e-09
position O 0 1.3297462686523431e-08
of O 0 6.869882440696529e-11
a O 0 7.459200368487018e-09
5 O 0 6.240388650269324e-09
splice O 0 8.997462259685562e-07
site O 0 3.872863771903212e-07
. O 0 1.695046449867732e-07

ATM O 0 0.00016829321975819767
germline O 0 0.0010664754081517458
mutations O 0 0.0009913817048072815
in O 0 7.20680475296831e-07
classical O 0 0.12885557115077972
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.9999548196792603
in O 0 9.35343535957145e-09
the O 0 2.310417634987516e-09
Dutch O 0 0.00015595470904372633
population O 0 7.307691873847943e-08
. O 0 8.697072217955792e-08

Germline O 0 0.0053932033479213715
mutations O 0 0.0022091034334152937
in O 0 6.292022902698591e-08
the O 0 3.4448504049322537e-09
ATM O 0 1.0958516583059463e-07
gene O 0 2.7628157539538734e-08
are O 0 4.968536138072466e-10
responsible O 0 5.3732547300455735e-09
for O 0 1.083354916886492e-08
the O 0 9.885100735118613e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 7.186581933638081e-05
A B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999841451644897
T I-Disease 1 0.9999986886978149
) O 0 4.7475668907281943e-07
. O 0 2.3304174590066395e-07

In O 0 3.9498328874287836e-07
our O 0 1.1645556519113143e-08
study O 0 3.5561682487639246e-09
, O 0 4.506214845712009e-10
we O 0 2.3148051531141078e-10
have O 0 5.852646700610364e-10
determined O 0 6.586777789863163e-09
the O 0 2.1422705276386012e-10
ATM O 0 7.277938607330725e-08
mutation O 0 9.29187962128708e-08
spectrum O 0 3.916923674296413e-08
in O 0 6.389065942968841e-10
19 O 0 9.934580269543858e-09
classical O 0 2.0065309058736602e-07
A B-Disease 1 0.9999969005584717
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 1 0.9349236488342285
, O 0 1.3277839938652392e-09
including O 0 1.838219992889023e-10
some O 0 1.586357045724185e-09
immigrant O 0 5.808668106510595e-07
populations O 0 5.2943307515818105e-09
, O 0 5.817056281109956e-10
as O 0 5.998069818602403e-10
well O 0 7.202669016770358e-10
as O 0 1.0456222554466876e-09
12 O 0 2.294229944910242e-10
of O 0 9.462779171354185e-11
Dutch O 0 2.323507715118467e-06
ethnic O 0 3.083307831275306e-08
origin O 0 6.986839906630848e-08
. O 0 1.4374096224401e-07

Both O 0 2.1155467777589365e-07
the O 0 3.4981313401516445e-09
protein O 0 1.866122900651135e-08
truncation O 0 2.2266813459737023e-07
test O 0 1.1274678257677806e-07
( O 0 1.9252928140645054e-09
PTT O 0 2.3480745880988252e-07
) O 0 4.6454814994767446e-10
and O 0 2.8740873569965686e-10
the O 0 2.3323065700964207e-10
restriction O 0 7.970446347371762e-08
endonuclease O 0 4.271224952390185e-06
fingerprinting O 0 6.29462761025934e-07
( O 0 1.7257325568564852e-09
REF O 0 7.918771984805062e-07
) O 0 5.261590607652522e-10
method O 0 4.817896304132319e-09
were O 0 2.192797943223468e-09
used O 0 5.977379036181674e-09
and O 0 3.446848362287369e-09
compared O 0 5.438646422106785e-09
for O 0 1.843957903036042e-10
their O 0 6.375578398554183e-10
detection O 0 9.339993667367708e-09
efficiency O 0 1.329355736601201e-08
, O 0 7.64271590458776e-10
identifying O 0 6.002982999575579e-09
76 O 0 3.555627259288485e-08
% O 0 3.3079158856530455e-10
and O 0 6.345963754483819e-10
60 O 0 4.027215450008725e-09
% O 0 1.3961093392467205e-10
of O 0 6.408187869233473e-11
the O 0 3.328334274854683e-09
mutations O 0 1.2833146456614486e-06
, O 0 1.9460129507820056e-08
respectively O 0 1.2943011995503184e-07
. O 0 1.5711400180862256e-07

Most O 0 1.7367148757330142e-05
patients O 0 0.00013804870832245797
were O 0 6.821786247002137e-09
found O 0 1.2624356005019877e-09
to O 0 3.757681721339168e-09
be O 0 2.6147436216206188e-08
compound O 0 1.3076402183287428e-06
heterozygote O 0 3.2822743378346786e-05
. O 0 4.2169793346147344e-07

Seventeen O 0 9.280900121666491e-05
mutations O 0 6.021497756591998e-05
were O 0 8.88619879901853e-08
distinct O 0 2.0387119548104238e-08
, O 0 1.3079767269275067e-09
of O 0 1.3393514075588087e-10
which O 0 1.197021060050929e-08
10 O 0 1.0560202712284195e-09
were O 0 8.746074975363172e-09
not O 0 2.759887429704122e-08
reported O 0 1.1145747436103193e-07
previously O 0 1.396825126676049e-07
. O 0 1.0297441122020246e-07

Mutations O 0 0.02471190132200718
are O 0 2.0150605450908188e-07
small O 0 2.596702763923986e-08
deletions O 0 4.2508725073275855e-07
or O 0 1.533076243731557e-08
point O 0 7.254184453131529e-08
mutations O 0 2.425667616989813e-06
frequently O 0 3.5129841080561164e-07
affecting O 0 1.3856960379143857e-07
splice O 0 5.807555226056138e-06
sites O 0 6.874905693621258e-07
. O 0 3.545882236721809e-07

Moreover O 0 2.8731627025990747e-05
, O 0 3.3491855333522835e-07
a O 0 4.14596769360287e-07
16 O 0 3.645338608748716e-07
. O 0 2.1000965944040217e-07

7 O 0 5.834579496877268e-06
- O 0 2.769548700598534e-06
kb O 0 1.8116400042345049e-06
genomic O 0 1.0845027276218389e-07
deletion O 0 1.3758356942616956e-07
of O 0 5.078373832567706e-10
the O 0 4.947825482659596e-10
3 O 0 8.797115258474264e-10
end O 0 7.655671652173623e-10
of O 0 6.882499431482003e-11
the O 0 2.64468502653159e-10
gene O 0 4.325328983867394e-09
, O 0 4.3015993544948117e-10
most O 0 5.091612687024849e-10
likely O 0 5.95215610132982e-09
a O 0 2.4411064281082417e-09
result O 0 2.4791511066268868e-09
of O 0 6.60862961576747e-11
recombination O 0 3.300644424442112e-09
between O 0 9.820819713013407e-10
two O 0 2.700224710494581e-09
LINE O 0 6.126798552941182e-07
elements O 0 1.92220426242784e-08
, O 0 5.245571088607903e-09
was O 0 8.566546512156492e-07
identified O 0 2.510276715383952e-07
. O 0 2.6283442977614868e-08

The O 0 1.270187510726828e-07
most O 0 3.5629863504027526e-08
frequently O 0 9.406252132748705e-08
found O 0 3.406153581408944e-08
mutation O 0 7.993236295078532e-08
, O 0 1.28088850637198e-09
identified O 0 1.416344730387209e-08
in O 0 3.4148736616224085e-10
three O 0 5.97206561980812e-10
unrelated O 0 2.786328145987227e-08
Turkish O 0 3.3390329917892814e-05
A B-Disease 1 0.9999760389328003
- I-Disease 1 0.999751627445221
T I-Disease 1 0.9999996423721313
individuals O 0 2.7418801451517538e-08
, O 0 2.377560148758562e-09
was O 0 2.6127975161216455e-07
previously O 0 1.9799863082425873e-08
described O 0 1.1998371185484302e-08
to O 0 5.541174741274801e-10
be O 0 1.140606942229283e-09
a O 0 1.489617318384262e-08
Turkish O 0 1.9172968677594326e-05
A B-Disease 1 0.9999668598175049
- I-Disease 1 0.9998948574066162
T I-Disease 1 0.999998927116394
founder O 0 0.00022503003128804266
mutation O 0 2.9458999506459804e-06
. O 0 5.989501516978635e-08

The O 0 8.399158701877241e-08
presence O 0 2.141676169742368e-08
of O 0 3.9656014583222543e-10
a O 0 1.2082931100110272e-08
founder O 0 7.299709068320226e-07
mutation O 0 1.3777672336345859e-07
among O 0 1.0871795685929442e-09
relatively O 0 2.7793152224120377e-09
small O 0 1.5358061489223473e-09
ethnic O 0 7.690874603838438e-09
population O 0 1.997056520153251e-09
groups O 0 4.489725813350276e-10
in O 0 3.963484263014294e-10
Western O 0 1.912344282928302e-09
Europe O 0 1.9898209746571638e-09
could O 0 1.8119955313977698e-08
indicate O 0 4.245003903946554e-09
a O 0 3.9816860919472674e-09
high O 0 2.130537168909541e-08
carrier O 0 1.4262195691117086e-07
frequency O 0 2.5074383458445482e-08
in O 0 5.919490453365484e-10
such O 0 2.289335387928304e-09
communities O 0 4.614955884107985e-08
. O 0 1.734412791165596e-07

In O 0 3.467229589659837e-06
patients O 0 1.5820807675481774e-05
of O 0 2.627641215724452e-09
Dutch O 0 6.047118858987233e-06
ethnic O 0 3.274935167496551e-08
origin O 0 7.792790412963768e-09
, O 0 3.580889140764043e-09
however O 0 8.260520267810989e-09
, O 0 1.2446758068662689e-09
no O 0 3.166277462440803e-09
significant O 0 3.7500349492347596e-09
founder O 0 2.0365243358355656e-07
effect O 0 1.0258312244104673e-07
could O 0 1.935593161306315e-07
be O 0 3.529047631900539e-08
identified O 0 3.3309783020740724e-07
. O 0 1.0567304542519196e-07

The O 0 4.3425504259175796e-07
observed O 0 5.233920887803833e-07
genetic O 0 1.2831246465339063e-07
heterogeneity O 0 3.6263372749090195e-07
including O 0 4.272231457491671e-09
the O 0 1.255361925522891e-09
relative O 0 9.201614403764324e-08
high O 0 4.4957971567782806e-08
percentage O 0 7.856292505437068e-09
of O 0 1.3508141827323072e-10
splice O 0 5.7564994904169e-07
- O 0 1.157431415776955e-05
site O 0 4.521445475802466e-07
mutations O 0 2.6796527663464076e-07
had O 0 8.683181818014418e-08
no O 0 3.1164932856597716e-09
reflection O 0 1.6036436178978875e-08
on O 0 1.3055472258827194e-08
the O 0 2.0492457508680673e-08
phenotype O 0 0.007016763091087341
. O 0 1.856367930486158e-07

All O 0 3.5864491110260133e-06
patients O 0 0.00021913781529292464
manifested O 0 1.9333251657371875e-06
classical O 0 5.821401600769605e-07
A B-Disease 1 0.9995757937431335
- I-Disease 1 0.99949049949646
T I-Disease 1 0.9999951124191284
and O 0 2.3534933291102789e-07
increased O 0 1.1130854460361661e-07
cellular O 0 2.612655691791588e-07
radioresistant O 0 2.6891145807894645e-06
DNA O 0 4.1537879269526456e-07
synthesis O 0 3.439449471898115e-07
. O 0 8.444730781320686e-08

Determination O 0 1.5190375052043237e-05
of O 0 8.26537416287465e-09
the O 0 1.1579038838860356e-09
genomic O 0 1.751288891682634e-08
structure O 0 7.563165205226596e-09
of O 0 1.9138467199919518e-10
the O 0 1.199436217014238e-09
COL4A4 O 0 3.33275579578185e-06
gene O 0 1.7825835030294e-08
and O 0 6.2590527205586e-10
of O 0 4.806612885488448e-10
novel O 0 1.4243603345676092e-06
mutations O 0 0.00014698469021823257
causing O 0 0.00017895203200168908
autosomal B-Disease 1 0.9999785423278809
recessive I-Disease 1 0.9999996423721313
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 7.642986929567996e-06

Autosomal B-Disease 1 0.9999957084655762
recessive I-Disease 1 0.9999997615814209
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.744200047454797e-06
a O 0 4.1104117372015025e-06
progressive O 1 0.6228487491607666
hematuric B-Disease 1 0.9988054037094116
glomerulonephritis I-Disease 1 0.9999996423721313
characterized O 0 0.017162121832370758
by O 0 2.707304531668342e-07
glomerular B-Disease 0 0.0013094721361994743
basement I-Disease 0 0.0012293461477383971
membrane I-Disease 0 0.004275107756257057
abnormalities I-Disease 1 0.9985252022743225
and O 0 8.581954347164356e-08
associated O 0 5.320350027204768e-08
with O 0 1.198339205643606e-08
mutations O 0 1.2696282283286564e-06
in O 0 2.2527766319058173e-09
either O 0 3.147238913925321e-09
the O 0 1.5972324574065055e-09
COL4A3 O 0 1.9784627511398867e-05
or O 0 1.925968717841897e-09
the O 0 1.4583020346847775e-09
COL4A4 O 0 6.211609616002534e-06
gene O 0 2.3686759220709064e-08
, O 0 4.832112487918039e-10
which O 0 3.6637926026372725e-10
encode O 0 2.1610429001839293e-09
the O 0 6.971858090842886e-10
alpha3 O 0 6.403951147149201e-07
and O 0 1.9045918620008706e-08
alpha4 O 0 5.349489583750255e-06
type O 0 8.665858331369236e-06
IV O 0 0.14002516865730286
collagen O 0 3.5218283301219344e-05
chains O 0 4.447610081115272e-06
, O 0 1.356666512464244e-08
respectively O 0 9.495136055193143e-08
. O 0 8.179342358971553e-08

To O 0 3.0563683139916975e-07
date O 0 8.729978873134314e-08
, O 0 5.0530810646876034e-09
mutation O 0 2.2117939479926463e-08
screening O 0 4.782856333207519e-09
in O 0 4.4461620496427656e-10
the O 0 2.022609163487843e-10
two O 0 8.919353589043055e-10
genes O 0 6.310745703785869e-09
has O 0 1.395262074765924e-07
been O 0 5.094775090697112e-08
hampered O 0 6.865654427201662e-07
by O 0 4.550855692286859e-09
the O 0 1.2565261053865129e-09
lack O 0 3.241994228631029e-09
of O 0 1.8673564083915295e-10
genomic O 0 2.637086637946595e-08
structure O 0 3.3742942662229325e-08
information O 0 6.961019316520378e-09
. O 0 6.062473545398461e-08

We O 0 6.177171485433064e-07
report O 0 2.202767568348918e-08
here O 0 3.251243718693786e-10
the O 0 1.1337890348794843e-10
complete O 0 1.4174899032326493e-09
characterization O 0 2.121979925107098e-08
of O 0 1.247503489398838e-10
the O 0 6.259697760135907e-10
48 O 0 9.837829217929084e-09
exons O 0 8.847128363242973e-09
of O 0 1.363903850970516e-10
the O 0 4.255508168071742e-10
COL4A4 O 0 2.1002979337936267e-06
gene O 0 1.4309780027588204e-08
, O 0 4.1417738683158234e-10
a O 0 1.413553385454236e-09
comprehensive O 0 1.1588435100406969e-08
gene O 0 1.9097866399420127e-08
screen O 0 6.476244038822188e-07
, O 0 9.366696307466782e-10
and O 0 5.57280221968881e-10
the O 0 2.104773716427033e-10
subsequent O 0 6.213404013521995e-09
detection O 0 2.8224691472900076e-09
of O 0 1.346960043502321e-10
10 O 0 1.1663556787055995e-09
novel O 0 2.4869146741934856e-08
mutations O 0 2.8898774928620696e-08
in O 0 1.1192562432427167e-09
eight O 0 2.4836492684698896e-07
patients O 0 0.0022394282277673483
diagnosed O 0 0.010523603297770023
with O 0 3.575244818421197e-06
autosomal B-Disease 1 0.9999880790710449
recessive I-Disease 1 0.9999997615814209
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 9.361518095829524e-06

Furthermore O 0 6.568853677890729e-06
, O 0 1.1078006956211084e-08
we O 0 1.5926571172997228e-09
identified O 0 1.8289670888904652e-09
a O 0 4.298343347919342e-10
glycine O 0 4.4584012037773846e-09
to O 0 2.5712356688245563e-09
alanine O 0 1.0342887435399462e-08
substitution O 0 2.5687505456062354e-09
in O 0 8.117865823997761e-10
the O 0 2.0798724964521398e-09
collagenous O 0 3.2023674521042267e-06
domain O 0 7.436074422884076e-09
that O 0 8.753180402720773e-10
is O 0 9.969368663931277e-10
apparently O 0 5.320390172869338e-08
silent O 0 8.49839238981076e-08
in O 0 5.96293681098814e-10
the O 0 7.777669619457583e-10
heterozygous O 0 1.89674381090299e-07
carriers O 0 1.4089028610442256e-08
, O 0 9.879926876621425e-10
in O 0 1.0483499623958892e-09
11 O 0 1.5552714671684953e-08
. O 0 6.65007462430367e-08

5 O 0 2.9376378734013997e-06
% O 0 2.5655007007685526e-08
of O 0 1.9176395193998275e-10
all O 0 3.247636881642535e-10
control O 0 8.371649329319553e-08
individuals O 0 1.1612324435361643e-09
, O 0 4.1921066618044733e-10
and O 0 7.634484155971677e-10
in O 0 4.330494018933706e-10
one O 0 2.241893337640022e-09
control O 0 2.6069256975347344e-08
individual O 0 6.125372986609534e-10
homozygous O 0 7.360917209098261e-09
for O 0 6.916518052735299e-11
this O 0 1.865274046330967e-10
glycine O 0 4.160828481758472e-08
substitution O 0 1.2812562033559516e-07
. O 0 1.462692296172463e-07

There O 0 1.1079887372034136e-06
has O 0 7.158683956731693e-08
been O 0 1.0329600286240748e-08
no O 0 3.49929929477355e-09
previous O 0 1.2926988368633374e-09
finding O 0 6.392577023284218e-10
of O 0 4.743793552419717e-11
a O 0 8.751910862692114e-10
glycine O 0 6.110893568944675e-09
substitution O 0 3.467705678161792e-09
that O 0 2.1996764409948355e-09
is O 0 2.77884870669709e-09
not O 0 2.2976205382718717e-09
associated O 0 1.359541035306222e-09
with O 0 2.932305787073375e-10
any O 0 2.652314146089907e-09
obvious O 0 1.225477490152116e-06
phenotype O 0 0.00029022697708569467
in O 0 1.7890004144760496e-08
homozygous O 0 3.6851340610155603e-06
individuals O 0 2.7517083722727875e-08
. O 0 5.4128602045011576e-08

Founder O 0 0.00026087721926160157
BRCA1 O 0 0.0012665758840739727
and O 0 7.702208790760778e-07
BRCA2 O 0 5.2372797654243186e-05
mutations O 0 2.1299210857250728e-06
in O 0 2.9815609536854026e-08
French O 0 6.735564966220409e-05
Canadian O 0 0.016663337126374245
breast B-Disease 1 0.9996906518936157
and I-Disease 1 0.9967758059501648
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 1.0866349384741625e-06
. O 0 1.8606199603254936e-07

We O 0 4.6916025553400686e-07
have O 0 4.121297081383091e-08
identified O 0 2.2780028530178242e-08
four O 0 1.6092684962387693e-09
mutations O 0 8.4008204837005e-09
in O 0 1.5628229266262395e-10
each O 0 1.49388654224758e-10
of O 0 2.2297683144323344e-10
the O 0 1.282226804733e-07
breast B-Disease 1 0.9994275569915771
cancer I-Disease 0 0.22646966576576233
- O 0 0.01608913019299507
susceptibility O 1 0.8118396997451782
genes O 0 7.514308322242869e-07
, O 0 2.1864011046091036e-08
BRCA1 O 0 3.755931629711995e-06
and O 0 1.4370121448337159e-07
BRCA2 O 0 8.276827429654077e-06
, O 0 3.021686456605721e-09
in O 0 2.834883661151366e-09
French O 0 4.668911060434766e-06
Canadian O 0 0.0008077268139459193
breast B-Disease 1 0.9869416356086731
cancer I-Disease 0 0.22638244926929474
and O 0 0.0017938259989023209
breast B-Disease 1 0.9999973773956299
/ I-Disease 1 0.9999988079071045
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.9769897789956303e-06
from O 0 8.109129367994683e-08
Quebec O 0 3.493635813356377e-05
. O 0 3.4986808827852656e-07

To O 0 1.364396553071856e-06
identify O 0 1.2688353763223859e-06
founder O 0 7.591603434775607e-07
effects O 0 8.7863219278006e-07
, O 0 9.632967312711571e-09
we O 0 1.732096910345149e-09
examined O 0 8.529685402436371e-08
independently O 0 2.9522931654923923e-08
ascertained O 0 8.016214536610278e-08
French O 0 2.165554491284638e-07
Canadian O 0 1.3412774251264636e-06
cancer B-Disease 0 2.9048540000076173e-06
families O 0 1.6591239493379817e-09
for O 0 2.1374135794616222e-10
the O 0 1.92439245094711e-10
distribution O 0 4.3531853122225073e-10
of O 0 1.333727711605448e-10
these O 0 5.305832440072322e-10
eight O 0 1.3476912918974904e-08
mutations O 0 6.240462084861065e-07
. O 0 7.230342191633099e-08

Mutations O 0 0.001009700819849968
were O 0 4.6573393319704337e-07
found O 0 2.7396426460768453e-08
in O 0 1.8446693061946462e-09
41 O 0 3.1253584609203244e-08
of O 0 9.087260943729802e-10
97 O 0 1.2775225854966266e-07
families O 0 1.2032616325541312e-07
. O 0 1.769140567375871e-07

Six O 0 5.589226930169389e-07
of O 0 3.5510712148578705e-09
eight O 0 1.2307669550182254e-08
mutations O 0 7.495142284597023e-08
were O 0 1.0264766814316317e-08
observed O 0 2.1065590161128966e-08
at O 0 3.554662786342533e-09
least O 0 2.800837428651448e-08
twice O 0 5.451599349726166e-07
. O 0 1.8572248450254847e-07

The O 0 1.0782835033751326e-06
BRCA1 O 0 5.3851952543482184e-05
C4446T O 0 7.5513730735110585e-06
mutation O 0 2.28798467105662e-06
was O 0 6.634352445189506e-08
the O 0 1.0368916836256403e-09
most O 0 5.304661154781343e-09
common O 0 3.1720336579610375e-08
mutation O 0 4.1658319105408737e-07
found O 0 2.4318783431453994e-08
, O 0 1.582482811457453e-09
followed O 0 5.326662666504944e-09
by O 0 2.0617945128975634e-09
the O 0 1.704824548198758e-08
BRCA2 O 0 5.9261583373881876e-05
8765delAG O 0 1.201397753902711e-05
mutation O 0 4.7467651711485814e-06
. O 0 2.3013416239336948e-07

Together O 0 7.5124455634068e-07
, O 0 1.6882182762856246e-08
these O 0 1.3460105252605103e-09
mutations O 0 2.1785666604046128e-08
were O 0 4.6324415414744635e-09
found O 0 3.80299125524175e-09
in O 0 1.0126093297202488e-09
28 O 0 6.505596061856522e-09
of O 0 2.47101117345494e-10
41 O 0 8.299785037024776e-08
families O 0 3.6734504327284867e-09
identified O 0 2.215618133405428e-09
to O 0 9.054492156046479e-10
have O 0 5.7986921930819335e-09
a O 0 9.95079787458053e-08
mutation O 0 2.986979552588309e-06
. O 0 8.63314397747672e-08

The O 0 1.1520549492161081e-07
odds O 0 5.805412115478248e-07
of O 0 6.614510050795275e-10
detection O 0 6.59940369018841e-09
of O 0 1.1362505381029564e-10
any O 0 3.101944534567025e-10
of O 0 5.6108864082693444e-11
the O 0 3.216542310280346e-10
four O 0 6.998801982405212e-09
BRCA1 O 0 6.294907507253811e-06
mutations O 0 6.222408615030872e-07
was O 0 4.6642284701192693e-07
18 O 0 1.0402501970929734e-07
. O 0 1.1616566553129815e-07

7x O 0 0.001327292062342167
greater O 0 1.8846877765099634e-06
if O 0 2.365804263604332e-08
one O 0 2.443291124976099e-09
or O 0 3.215977761872324e-10
more O 0 1.695355189568204e-09
cases O 0 9.798786493320222e-08
of O 0 3.151898681608145e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
were O 0 4.267689064363367e-07
also O 0 8.380435900789962e-08
present O 0 7.729193396421863e-10
in O 0 8.846128829453903e-10
the O 0 2.806568533131326e-09
family O 0 2.113048509500004e-07
. O 0 9.677629009274824e-08

The O 0 8.217308788971422e-08
odds O 0 3.1251144605448644e-07
of O 0 7.089947517968653e-10
detection O 0 2.2456507764445632e-09
of O 0 7.81193512655598e-11
any O 0 3.0217597868364976e-10
of O 0 1.0574589121015165e-10
the O 0 1.1362467633446727e-09
four O 0 3.644656842993754e-08
BRCA2 O 0 3.640056092990562e-05
mutations O 0 6.028049597261997e-07
was O 0 2.4305157353410323e-07
5 O 0 6.065492641482706e-08
. O 0 1.8236946175420599e-07

3x O 0 0.0001631800114409998
greater O 0 3.496599276786583e-07
if O 0 9.668326583778253e-09
there O 0 7.626014264516812e-10
were O 0 1.4019165828216273e-09
at O 0 1.3345063942793445e-10
least O 0 7.551630432089951e-10
five O 0 8.783584970473157e-10
cases O 0 4.3259067439294085e-09
of O 0 1.0795182525669134e-08
breast B-Disease 1 0.994712769985199
cancer I-Disease 0 0.002033588709309697
in O 0 3.637154799562836e-09
the O 0 9.218792840215428e-09
family O 0 3.571032323179679e-07
. O 0 1.3370382134780812e-07

Interestingly O 0 9.083062468562275e-05
, O 0 3.655392077916986e-08
the O 0 6.266195895499038e-10
presence O 0 1.6267046598628099e-09
of O 0 1.698558793616911e-10
a O 0 5.767082598140405e-07
breast B-Disease 1 0.9858614206314087
cancer I-Disease 0 0.0006538124871440232
case O 0 2.548689508330426e-07
< O 0 4.4782698438439184e-08
36 O 0 2.7327327956072622e-08
years O 0 1.1863490190222592e-09
of O 0 1.7485635162017843e-10
age O 0 1.0839418251862298e-08
was O 0 4.830661026744565e-08
strongly O 0 1.532418458793927e-08
predictive O 0 5.181541862242511e-09
of O 0 3.332548473289343e-11
the O 0 1.0206053363548406e-10
presence O 0 4.2017606061151014e-10
of O 0 1.6953438652933528e-11
any O 0 9.092405300892281e-11
of O 0 5.59851782988563e-11
the O 0 1.0945576667253931e-09
eight O 0 4.44732002335968e-08
mutations O 0 9.084095040634566e-07
screened O 0 4.0326008274860214e-06
. O 0 2.555012201810314e-07

Carriers O 0 2.3627030714123975e-06
of O 0 2.7809272662437934e-09
the O 0 1.7309114141994542e-09
same O 0 8.047554622692132e-09
mutation O 0 3.490615085866011e-08
, O 0 4.14494272238386e-10
from O 0 1.223113277326604e-10
different O 0 1.6724165108339406e-10
families O 0 1.5791903340556246e-09
, O 0 1.1931317045466017e-09
shared O 0 2.095513762512269e-09
similar O 0 5.933261437718329e-09
haplotypes O 0 6.64501499159087e-07
, O 0 1.930669180083555e-09
indicating O 0 5.997718766082016e-09
that O 0 3.972429607479455e-10
the O 0 6.232579036202779e-11
mutant O 0 2.2925002340912215e-08
alleles O 0 5.844038586388933e-09
were O 0 5.953030957073224e-09
likely O 0 2.2097443874713463e-08
to O 0 6.7690475447079734e-09
be O 0 3.7344765502211885e-08
identical O 0 2.3552604488941142e-07
by O 0 1.7423321674314707e-09
descent O 0 1.2863358733739005e-07
for O 0 5.925319124244766e-10
a O 0 2.6447834144960325e-08
mutation O 0 1.221877994339593e-07
in O 0 6.223554449569235e-10
the O 0 8.486980562771862e-10
founder O 0 5.418432351689262e-07
population O 0 2.2989631531800114e-08
. O 0 4.767448302800403e-08

The O 0 1.113830876420252e-07
identification O 0 5.394504043465531e-08
of O 0 2.4925121966390407e-09
common O 0 1.1039726643957692e-07
BRCA1 O 0 5.5870954383863136e-05
and O 0 1.167123855339014e-06
BRCA2 O 0 0.00022871112741995603
mutations O 0 9.521738206785813e-07
will O 0 1.0911813674852056e-08
facilitate O 0 7.750573516318582e-09
carrier O 0 2.42558343188648e-07
detection O 0 2.1860174115317932e-08
in O 0 2.5911797152389227e-09
French O 0 5.546833108382998e-06
Canadian O 0 0.00044363352935761213
breast B-Disease 1 0.9985072016716003
cancer I-Disease 0 0.35032913088798523
and O 0 0.007395617663860321
breast B-Disease 1 0.9999986886978149
/ I-Disease 1 0.9999983310699463
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 4.7334074224636424e-06
. O 0 1.194794549519429e-06

Are O 0 2.36031132772041e-06
Dp71 O 0 2.6423831513966434e-05
and O 0 2.821685711751343e-07
Dp140 O 0 2.3416385374730453e-05
brain O 0 0.00012635729217436165
dystrophin O 0 4.369718226371333e-05
isoforms O 0 5.887764586987032e-07
related O 0 6.012290043599933e-08
to O 0 4.8688544751485097e-08
cognitive B-Disease 0 0.0002686503285076469
impairment I-Disease 0 0.0048317937180399895
in O 0 3.733853645826457e-06
Duchenne B-Disease 1 0.9999674558639526
muscular I-Disease 1 0.9999922513961792
dystrophy I-Disease 1 0.9999936819076538
? O 0 0.0002295684244018048

Molecular O 0 2.3185752070276067e-05
study O 0 7.283159106918902e-07
and O 0 6.763758619854343e-08
neuropsychological O 0 1.5784313518452109e-06
analysis O 0 8.147543084646713e-09
were O 0 2.270012400273913e-09
performed O 0 6.8340151315737785e-09
concurrently O 0 7.126801815360295e-09
on O 0 2.5122542268718462e-08
49 O 0 5.178381343284855e-06
patients O 0 3.463333314357442e-06
with O 0 1.0116283419847605e-06
Duchenne B-Disease 1 0.9999833106994629
muscular I-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999996423721313
( O 0 7.717319931543898e-06
DMD B-Disease 1 0.9999997615814209
) O 0 2.2317530934401475e-08
in O 0 2.541609589457039e-09
order O 0 2.0421977442453e-09
to O 0 1.887521472454523e-09
find O 0 2.508609098228476e-09
a O 0 5.9863922707847905e-09
molecular O 0 5.240613631940505e-08
explanation O 0 1.3101446150187712e-08
for O 0 3.445328189410901e-10
the O 0 2.4215647265179996e-09
cognitive B-Disease 0 1.118714499170892e-05
impairment I-Disease 0 3.8012783534213668e-06
observed O 0 2.6664574548362907e-08
in O 0 7.214277175648931e-09
most O 0 7.593003374495311e-06
DMD B-Disease 1 1.0
patients O 1 0.9996963739395142
. O 0 8.301390721499047e-07

Complete O 0 1.3741288285018527e-06
analysis O 0 5.158696225748827e-08
of O 0 1.1492459206507988e-09
the O 0 2.8639381977058065e-09
dystrophin O 0 1.4921786259947112e-06
gene O 0 9.369955478177872e-08
was O 0 6.505536731538086e-08
performed O 0 1.1270351762959763e-08
to O 0 5.888432519363107e-10
define O 0 1.0984860132623453e-08
the O 0 9.294175429275242e-10
localization O 0 1.2934245674500744e-08
of O 0 2.966859813380296e-10
deletions O 0 4.131796771389418e-08
and O 0 2.7082709408432493e-09
duplications O 0 1.5891046700744482e-08
in O 0 6.69498234628918e-10
relation O 0 2.730485837432184e-09
to O 0 2.150082112351015e-09
the O 0 3.2948199724103233e-09
different O 0 6.352218662186715e-08
DMD B-Disease 1 0.9999985694885254
promoters O 0 0.00019532164151314646
. O 0 8.358324521395843e-07

Qualitative O 0 8.061766493483447e-06
analysis O 0 2.728353649672499e-07
of O 0 2.617047467623479e-09
the O 0 1.5963431687637808e-09
Dp71 O 0 1.135982756750309e-06
transcript O 0 4.2817697476493777e-07
and O 0 3.743088949903495e-09
testing O 0 1.3306996615725097e-09
for O 0 6.044211658950971e-11
the O 0 7.490930098441595e-11
specific O 0 1.3621151428999667e-10
first O 0 8.850803423499087e-10
exon O 0 5.666580982222058e-09
of O 0 1.6404787250845487e-10
Dp140 O 0 6.240057359718776e-08
were O 0 7.77954323183394e-09
also O 0 8.335159229488909e-09
carried O 0 3.196162268181979e-08
out O 0 1.964615314875573e-08
. O 0 6.550860121024016e-08

Neuropsychological O 0 0.0019862621556967497
analysis O 0 5.010614131606417e-06
assessed O 0 2.2685303520120215e-06
verbal O 0 5.235019102656224e-07
and O 0 2.6610312175989748e-08
visuospatial O 0 3.2243024179479107e-06
intelligence O 0 7.879841490421313e-08
, O 0 3.4811189486561034e-09
verbal O 0 1.411324035416328e-07
memory O 0 1.1692161479004426e-06
, O 0 9.063603201298065e-09
and O 0 2.1967005991996302e-08
reading O 0 2.5503209144517314e-07
skills O 0 1.6794608370673814e-07
. O 0 1.0991067256327369e-07

Comparison O 0 3.4984648209501756e-06
of O 0 1.5928096175343853e-08
molecular O 0 1.0474136047378124e-07
and O 0 1.3330220482998811e-08
psychometric O 0 1.423764160790597e-06
findings O 0 1.0479351431058603e-07
demonstrated O 0 3.202172749183774e-08
that O 0 9.077075202590379e-10
deletions O 0 1.8853203442859012e-08
and O 0 1.3343950389099746e-09
duplications O 0 1.1765584062572998e-08
that O 0 1.880481992344585e-09
were O 0 2.1605484068487613e-09
localized O 0 2.6700707422833148e-08
in O 0 9.173638515491689e-10
the O 0 6.248508377382223e-10
distal O 0 7.72303963003651e-07
part O 0 4.311244694576999e-09
of O 0 1.9349002955415529e-10
the O 0 5.126606361649522e-10
gene O 0 9.95299664907634e-09
seemed O 0 3.61491458988894e-08
to O 0 2.51657894523305e-09
be O 0 5.633400412818901e-09
preferentially O 0 4.044414652071282e-07
associated O 0 1.4707612017161864e-08
with O 0 2.09066808309899e-08
cognitive B-Disease 0 0.00012919794244226068
impairment I-Disease 0 0.000158335329615511
. O 0 2.3539445237474865e-07

Two O 0 1.1198929996680818e-06
altered O 0 4.625770088750869e-06
Dp71 O 0 5.465152298711473e-06
transcripts O 0 3.264804036007263e-07
and O 0 5.8119908885601035e-09
two O 0 1.0647901449445385e-09
deleted O 0 8.545806906568032e-08
Dp140 O 0 2.825557885444141e-07
DNA O 0 1.3246176600034687e-08
sequences O 0 3.0633406922220274e-09
were O 0 1.1956969858673006e-09
found O 0 6.893827730891644e-10
in O 0 2.756160022432397e-10
four O 0 3.008151239214385e-08
patients O 0 2.1446087430376792e-06
with O 0 1.1723955140041653e-07
severe O 1 0.9998818635940552
cerebral B-Disease 1 0.9999834299087524
dysfunction I-Disease 1 0.9973081350326538
. O 0 3.0648086521978257e-06

These O 0 2.8389280259943916e-07
findings O 0 1.5692650379151019e-07
suggest O 0 4.07619680231619e-08
that O 0 1.3794395625765787e-09
some O 0 2.618324446146403e-10
sequences O 0 9.493515973346689e-10
located O 0 6.352479098303832e-10
in O 0 3.203354526082336e-10
the O 0 4.759674876453346e-10
distal O 0 5.740480446547735e-07
part O 0 3.917280277931923e-09
of O 0 1.647895431222679e-10
the O 0 6.180247424936169e-10
gene O 0 5.570573335944573e-09
and O 0 2.396029152862411e-09
, O 0 5.549763426593302e-10
in O 0 2.402132104339927e-10
particular O 0 2.2140804745163223e-09
, O 0 3.3906797369809283e-09
some O 0 1.4945150894618564e-08
DMD B-Disease 1 0.9999986886978149
isoforms O 0 5.681376933353022e-07
expressed O 0 3.1906012054605526e-08
in O 0 5.780314560333011e-10
the O 0 1.6444613448740597e-09
brain O 0 3.2582422136329114e-05
may O 0 1.5410923026593082e-07
be O 0 1.0052754184641799e-09
related O 0 6.175710498546039e-10
to O 0 2.2068709082390114e-09
the O 0 2.0919525667295602e-08
cognitive B-Disease 0 0.018084010109305382
impairment I-Disease 0 0.006106802262365818
associated O 0 4.1545010276422545e-07
with O 0 1.1962653161390335e-06
DMD B-Disease 1 0.9999998807907104
. O 0 1.4661980003438657e-06
. O 0 3.2630546797918214e-07

I1307K O 0 0.00023008468269836158
APC O 0 2.9357139283092692e-05
and O 0 8.850963695294922e-08
hMLH1 O 0 1.12977488697652e-06
mutations O 0 2.610792648738425e-07
in O 0 1.2875583932370205e-09
a O 0 2.9234630716246102e-08
non O 0 2.7894069276612754e-08
- O 0 1.564062813486089e-06
Jewish O 0 5.4238874724887864e-08
family O 0 1.558936446599546e-08
with O 0 5.44819833692145e-09
hereditary B-Disease 1 0.8843477368354797
non I-Disease 0 0.0002482151612639427
- I-Disease 1 0.999994158744812
polyposis I-Disease 1 0.9999990463256836
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.4238064977689646e-05

We O 0 3.18387208153581e-07
describe O 0 2.921326256455359e-07
a O 0 8.525260852820793e-08
French O 0 1.0975184068229282e-06
Canadian O 0 2.690510200409335e-06
hereditary B-Disease 1 0.7719181776046753
non I-Disease 0 0.0006403290899470448
- I-Disease 1 0.9999985694885254
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 8.147543667291757e-06
HNPCC B-Disease 0 0.1314612776041031
) O 0 6.235620020333954e-08
kindred O 0 1.2248137863934971e-06
which O 0 1.6602832886292163e-08
carries O 0 6.416708941969773e-08
a O 0 2.333910842367004e-08
novel O 0 2.4799146558507346e-07
truncating O 0 9.350849268230377e-07
mutation O 0 1.0864659998333082e-06
in O 0 2.240470919900872e-08
hMLH1 O 0 1.077317756426055e-05
. O 0 5.297081315802643e-07

Interestingly O 0 8.201195305446163e-05
, O 0 7.926011846848269e-08
the O 0 5.225887722559719e-09
I1307K O 0 7.881628221184656e-07
APC O 0 1.0835697139555123e-06
polymorphism O 0 2.0028835933771916e-05
, O 0 6.9555508019902845e-09
associated O 0 1.7384782502460894e-09
with O 0 2.555603229037473e-10
an O 0 3.801830850136412e-09
increased O 0 9.680358061814331e-07
risk O 0 7.173917424552201e-07
of O 0 2.6940124371321872e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.9991162503174564e-07
is O 0 1.1233224128659458e-08
also O 0 1.034825469758971e-08
present O 0 9.37486421825895e-10
in O 0 5.487513221602569e-10
this O 0 4.374820505859134e-09
family O 0 2.62106340187529e-07
. O 0 5.9178933753401e-08

The O 0 6.238731202756753e-07
I1307K O 0 9.064123332791496e-06
polymorphism O 0 8.629054354969412e-05
has O 0 1.4517178215101012e-07
previously O 0 2.6081988124815325e-08
only O 0 1.2460463771901686e-09
been O 0 4.455162461169948e-09
identified O 0 7.975384797020979e-09
in O 0 2.367481211074107e-10
individuals O 0 1.3752907146447058e-10
of O 0 1.4860657149284862e-10
self O 0 4.8868946578295436e-06
- O 0 4.7351859393529594e-05
reported O 0 3.2507255127711687e-06
Ashkenazi O 0 3.0313924526126357e-07
Jewish O 0 1.979812580543694e-08
origins O 0 7.228866394370925e-08
. O 0 8.84392719058269e-08

In O 0 1.17150484868489e-07
addition O 0 5.8524820545358125e-09
, O 0 5.343450126815696e-10
in O 0 1.5434022115901058e-10
this O 0 7.833260706746614e-10
family O 0 1.461956689041699e-08
, O 0 4.5710354945605047e-10
there O 0 9.544407486572482e-10
appears O 0 2.5334651709840728e-08
to O 0 9.010938661901946e-10
be O 0 1.1629968099668986e-09
no O 0 6.741162072998463e-10
relationship O 0 6.64229837799013e-10
between O 0 2.146802596802999e-10
the O 0 8.551864771888518e-10
I1307K O 0 6.360929774018587e-07
polymorphism O 0 1.2633945516427048e-06
and O 0 8.200485290821291e-10
the O 0 1.9250825933347926e-10
presence O 0 2.2761601492504724e-09
or O 0 6.544609854053363e-10
absence O 0 1.7190743051287427e-08
of O 0 8.623463720880409e-09
cancer B-Disease 0 7.41050680517219e-05
. O 0 3.084460686864077e-08
. O 0 8.34720594866667e-08

Identification O 0 1.5482708022318548e-06
of O 0 1.1629442298044523e-08
a O 0 3.5782282026275425e-08
novel O 0 2.3512298241712415e-07
mutation O 0 9.641793496939499e-08
of O 0 6.69016952947743e-10
the O 0 3.977071560967715e-09
CPO O 0 1.3112617125443649e-06
gene O 0 1.689674355986881e-08
in O 0 8.31156365954655e-10
a O 0 1.695207352270245e-08
Japanese O 0 4.289032347060129e-07
hereditary B-Disease 0 0.3523831367492676
coproporphyria I-Disease 0 0.0008903730777092278
family O 0 1.8456930774846114e-06
. O 0 2.019473868131172e-07

Hereditary B-Disease 1 0.9999128580093384
coproporphyria I-Disease 1 0.9583742022514343
( O 0 1.3616247997561004e-05
HCP B-Disease 0 0.0010975019540637732
) O 0 2.691664313658748e-08
is O 0 1.0743297806925511e-08
an O 0 3.521798674910315e-08
autosomal B-Disease 1 0.9822260141372681
dominant I-Disease 1 0.9994538426399231
disease I-Disease 0 0.19408364593982697
characterized O 0 9.361964657728095e-06
by O 0 4.268861175660277e-08
a O 0 1.9283999790786766e-05
deficiency B-Disease 0 0.002639296930283308
of I-Disease 0 6.919137263139419e-09
coproporphyrinogen I-Disease 0 0.0002552596270106733
oxidase I-Disease 0 3.029394520126516e-06
( O 0 1.1133398203355682e-08
CPO O 0 4.932161118631484e-06
) O 0 5.354818366498648e-09
caused O 0 1.2074089283942158e-07
by O 0 2.1188160115315213e-09
a O 0 3.403653536793172e-08
mutation O 0 2.2233753327327577e-07
in O 0 1.5189240976098972e-09
the O 0 4.167044931335795e-09
CPO O 0 2.0239509467501193e-05
gene O 0 9.511192615718755e-07
. O 0 7.304932836404987e-08

Only O 0 9.408796586285462e-07
11 O 0 7.342956820366453e-08
mutations O 0 5.950025894208011e-08
of O 0 1.930027526686473e-10
the O 0 5.738001740418497e-10
gene O 0 2.547216126913554e-08
have O 0 1.7153666931335465e-08
been O 0 8.635318238248146e-08
reported O 0 1.831101172911076e-07
in O 0 2.458729042587038e-08
HCP B-Disease 1 0.9439563751220703
patients O 0 0.3236840069293976
. O 0 2.672919947599439e-07

We O 0 3.978766187628935e-07
report O 0 3.461370567947597e-08
another O 0 4.082886473355529e-09
mutation O 0 2.357336192915227e-08
in O 0 6.130246310576126e-10
a O 0 1.6276985093099938e-08
Japanese O 0 2.3344502153577196e-07
family O 0 2.1520796167351364e-07
. O 0 7.882081831667165e-08

Polymerase O 0 8.662345499033108e-05
chain O 0 1.597115806362126e-05
reaction O 0 1.220753347297432e-06
- O 0 4.86921749143221e-07
single O 0 6.220996340289275e-08
strand O 0 1.8937181778255763e-07
conformational O 0 1.3238047813501908e-07
polymorphism O 0 2.910155671997927e-06
and O 0 1.7190504575381738e-09
direct O 0 1.1464565963237305e-09
sequence O 0 3.1337255013141885e-09
analyses O 0 1.1071099592641076e-08
demonstrated O 0 1.1977336455970544e-08
a O 0 4.488118321432921e-09
C O 0 1.1595664872743328e-08
to O 0 3.059002606775607e-09
T O 0 5.828345450709094e-08
substitution O 0 2.5671833547846745e-09
in O 0 8.962430797510024e-10
exon O 0 1.137526695060842e-08
1 O 0 7.446743777173026e-10
of O 0 7.615719166409463e-11
the O 0 2.476484572966342e-10
CPO O 0 2.798205684939603e-07
gene O 0 7.731261852939042e-09
at O 0 2.3188485853697927e-10
nucleotide O 0 2.822307720862227e-09
position O 0 2.4734092107792094e-08
85 O 0 5.496314958719495e-09
, O 0 3.730727948791923e-10
which O 0 2.6664408458998423e-09
lies O 0 1.1841319036420828e-08
in O 0 3.361039779825603e-10
the O 0 3.872068776722415e-10
putative O 0 6.992132739469525e-08
presequence O 0 2.8343481517367763e-07
for O 0 6.171342326055651e-10
targeting O 0 7.47198747319544e-09
to O 0 2.4087137617812004e-08
mitochondria O 0 1.510982201580191e-06
. O 0 1.6340136710368824e-07

This O 0 2.2787162379245274e-07
mutation O 0 1.235567310686747e-06
changes O 0 1.2456857767517704e-08
the O 0 6.864319668231644e-10
codon O 0 6.747365777215464e-09
for O 0 2.358575001970564e-10
glutamine O 0 1.5326611091381892e-08
to O 0 2.4699287060059305e-09
a O 0 1.1565690627435288e-08
termination O 0 1.353338205944965e-07
codon O 0 2.5639451450842898e-08
at O 0 8.243359883586265e-10
amino O 0 6.960063636540781e-09
acid O 0 8.466680867513787e-08
position O 0 1.2389780579269427e-07
29 O 0 2.8620783609767386e-07
. O 0 5.000618585881966e-08

MaeI O 0 8.230433741118759e-05
restriction O 0 3.599713409130345e-06
analysis O 0 9.366488740170098e-08
showed O 0 1.0916855330833641e-07
two O 0 4.682005894096619e-10
other O 0 2.377644747753038e-10
carriers O 0 4.369083317357081e-09
in O 0 6.140427610823451e-10
the O 0 4.813588194707563e-09
family O 0 3.8754686215725087e-07
. O 0 1.193588019532399e-07

The O 0 1.8261360992255504e-06
C O 0 1.4760108570044395e-05
- O 0 0.00015081743185874075
T O 0 0.0003042371536139399
mutation O 0 5.349681373445492e-07
is O 0 3.9874468171774424e-09
located O 0 1.0793653748564225e-09
within O 0 1.8116481925734007e-10
a O 0 7.803811818973827e-09
recently O 0 5.809012293411797e-08
proposed O 0 6.4879874805967575e-09
putative O 0 4.37444747092286e-08
alternative O 0 6.875880309564764e-09
translation O 0 4.843260903442115e-09
initiation O 0 5.15968734404737e-09
codon O 0 3.593843445059974e-08
( O 0 1.983443853603717e-09
TIC O 0 1.673829359560841e-07
- O 0 1.790192385442424e-07
1 O 0 3.5999268011011054e-09
) O 0 3.7350142423342447e-10
, O 0 5.045104334300277e-10
supporting O 0 2.3371349300305155e-09
that O 0 2.95811442008187e-09
TIC O 0 1.6098994137792033e-07
- O 0 1.401171942916335e-07
1 O 0 2.459107806274119e-09
is O 0 5.328936181214772e-10
the O 0 1.1188266285655502e-10
real O 0 4.859778357513278e-09
TIC O 0 6.494428106407213e-08
rather O 0 6.059454271678533e-09
than O 0 2.915164776240431e-09
TIC O 0 1.850587949547844e-07
- O 0 2.1104446545905375e-07
2 O 0 1.461951093517655e-08
. O 0 6.512834715977078e-09
. O 0 4.129984176870494e-08

Human B-Disease 0 3.7418385545606725e-06
complement I-Disease 0 7.159255346778082e-06
factor I-Disease 0 0.000154032270074822
H I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9992741942405701
associated O 0 2.1345296772778966e-05
with O 0 0.0009018497075885534
hemolytic B-Disease 1 0.9999995231628418
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 2.1710169676225632e-05

This O 0 1.4107131107721216e-07
study O 0 1.041474639862372e-08
reports O 0 3.42519501650429e-09
on O 0 1.9571415599273223e-09
six O 0 5.239441325244343e-09
cases O 0 1.4949826265819866e-08
of O 0 9.130666001055943e-09
deficiency B-Disease 0 0.0001231404603458941
in I-Disease 0 1.2130169091406628e-09
the I-Disease 0 2.975110435787798e-10
human I-Disease 0 5.836593985897309e-10
complement I-Disease 0 2.718030911452729e-09
regulatory I-Disease 0 1.506742464130184e-08
protein I-Disease 0 2.3052068698348194e-08
Factor I-Disease 0 8.571550580427356e-08
H I-Disease 1 0.9997015595436096
( O 0 7.350506869840956e-09
FH O 0 4.3747832023655064e-06
) O 0 5.23272758456983e-10
in O 0 7.052503026017121e-11
the O 0 5.226380786482743e-11
context O 0 6.89760248917537e-10
of O 0 3.928067315861483e-10
an O 0 1.112307245421107e-06
acute B-Disease 1 0.9999902248382568
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 2.2422667825594544e-05

Five O 0 1.550859849430708e-07
of O 0 2.514870534042757e-09
the O 0 1.6439908323562236e-09
cases O 0 2.0154098834268552e-08
were O 0 2.7721323903051598e-08
observed O 0 2.445311153564944e-08
in O 0 4.0890668628890126e-09
children O 0 8.465227097076422e-08
presenting O 0 1.4731735120676603e-07
with O 0 1.4327253666124307e-05
idiopathic O 1 0.9999991655349731
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 7.19572271918878e-05
HUS B-Disease 1 0.999847412109375
) O 0 1.0685014331102138e-06
. O 0 1.317554392699094e-06

Two O 0 1.427263214281993e-07
of O 0 2.1294390695203447e-09
the O 0 1.7463513968252187e-09
children O 0 2.3375639202072307e-08
exhibited O 0 1.079644903256849e-06
a O 0 2.3049573428579606e-05
homozygous O 1 0.9854572415351868
deficiency O 0 0.08192844688892365
characterized O 0 2.775349798866955e-07
by O 0 1.388186676720693e-09
the O 0 4.98069030463455e-10
absence O 0 2.6283930587567284e-09
of O 0 5.6698291894807795e-11
the O 0 2.1961411855730972e-10
150 O 0 1.277828509671508e-09
- O 0 3.7207399827821064e-08
kD O 0 1.3850815605565003e-07
form O 0 2.059397097298188e-09
of O 0 2.7057500684435354e-10
Factor O 0 2.2633640739400107e-08
H O 1 0.9828890562057495
and O 0 4.251632379492776e-09
the O 0 2.764953266343184e-10
presence O 0 4.408208020834081e-09
, O 0 5.459867558066378e-10
upon O 0 5.146847947834488e-10
immunoblotting O 0 3.116607771858071e-08
, O 0 1.540713945313854e-10
of O 0 3.019004490845134e-11
the O 0 2.8909277749455953e-10
42 O 0 1.2444010266676742e-08
- O 0 5.2756448098989495e-08
kD O 0 1.0761096973510575e-06
Factor O 0 7.845813598805762e-08
H O 1 0.8079519271850586
- O 0 1.5066396485963196e-07
like O 0 7.793533818301057e-09
protein O 0 1.644506042453031e-08
1 O 0 7.144481450893636e-09
( O 0 1.0225270630215277e-09
FHL O 0 4.962569732924749e-07
- O 0 3.0824409691376786e-07
1 O 0 4.8658073126262025e-09
) O 0 4.479375759203208e-10
and O 0 3.4060807507785285e-09
other O 0 2.3160031670244052e-09
FH O 0 0.0005772319855168462
- O 0 5.5700725170027e-06
related O 0 5.550266379827917e-08
protein O 0 5.7867296732183604e-08
( O 0 2.185899461437657e-09
FHR O 0 1.545978079775523e-06
) O 0 4.163041023019787e-09
bands O 0 1.8976557214500644e-07
. O 0 1.234477338130091e-07

Southern O 0 7.90399280958809e-06
blot O 0 0.00010467755055287853
and O 0 5.883207165879867e-08
PCR O 0 8.368446060558199e-07
analysis O 0 4.18349799247153e-09
of O 0 7.074314745114663e-11
DNA O 0 2.4898798578476544e-09
of O 0 1.3576642587942445e-10
one O 0 5.5532600740093585e-09
patient O 0 1.5356830544988043e-06
with O 0 2.7018229431519103e-08
homozygous O 0 0.0021782023832201958
deficiency O 0 6.462128658313304e-05
ruled O 0 1.6258313451089634e-07
out O 0 4.234127715108116e-09
the O 0 3.007723792247674e-10
presence O 0 7.14852621541695e-10
of O 0 3.504679185750703e-11
a O 0 1.026329354836264e-09
large O 0 1.8256559597418232e-09
deletion O 0 3.5787195429293206e-08
of O 0 2.4374949281202873e-10
the O 0 2.412648525407235e-09
FH O 0 2.379590478085447e-05
gene O 0 2.7935920243749024e-08
as O 0 1.1804556221406415e-09
the O 0 4.0872555340243366e-10
underlying O 0 1.8610599283874762e-07
defect O 0 1.4931067653378705e-06
for O 0 8.20557488623308e-09
the O 0 5.808801120110729e-07
deficiency O 0 0.11349277943372726
. O 0 5.588912586063088e-07

The O 0 2.207167142387334e-07
other O 0 9.150209479003024e-09
four O 0 1.4111512847136964e-08
children O 0 2.3490954959015653e-08
presented O 0 1.4742212783858122e-08
with O 0 9.482666030180553e-08
heterozygous O 1 0.8803182244300842
deficiency O 0 0.00036514937528409064
and O 0 1.275968486424972e-08
exhibited O 0 8.859432227836805e-07
a O 0 3.8518603417969643e-08
normal O 0 4.90706035805033e-08
immunoblotting O 0 1.4349541288538603e-06
pattern O 0 3.294124084618488e-08
of O 0 1.0499703884114808e-10
proteins O 0 3.9822614650297794e-10
of O 0 2.277157906682703e-10
the O 0 1.4393020997260919e-08
FH O 0 0.011401638388633728
family O 0 6.435879527089128e-07
. O 0 1.2886762590369472e-07

Factor B-Disease 1 0.6035864353179932
H I-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9561473727226257
is O 0 3.127636460931171e-08
the O 0 5.305329509042167e-09
only O 0 1.8865381434807205e-06
complement B-Disease 1 0.999996542930603
deficiency I-Disease 1 0.9999998807907104
associated O 0 3.3555011214048136e-06
with O 0 4.649541551771108e-07
HUS B-Disease 1 0.9998714923858643
. O 0 6.151233264972689e-06

These O 0 1.4949291937682574e-07
observations O 0 3.0976025300333276e-07
suggest O 0 3.309212814883722e-08
a O 0 6.898553728262868e-09
role O 0 1.3931314768456105e-08
for O 0 1.4724790275977284e-08
FH O 0 8.022558904485777e-05
and O 0 1.2953360339906794e-07
/ O 0 2.528643392452068e-07
or O 0 1.6157096993651976e-08
FH O 0 8.833029278321192e-05
receptors O 0 2.395706530933239e-07
in O 0 4.039979017989026e-09
the O 0 5.564647853617544e-09
pathogenesis O 0 9.734683317219606e-07
of O 0 3.100362633290388e-08
idiopathic O 1 0.9910593628883362
HUS B-Disease 1 0.9999665021896362
. O 0 6.785608661630249e-07
. O 0 4.3429562879282457e-07

Further O 0 1.4687507245980669e-06
evidence O 0 4.3594379661726634e-08
for O 0 6.35589691988514e-10
a O 0 2.9980971039123006e-09
major O 0 5.447346573816958e-09
ancient O 0 4.941068709740648e-08
mutation O 0 0.00016452741692773998
underlying O 0 0.0035901416558772326
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
from O 0 2.7144375280840904e-07
linkage O 0 2.9226435799500905e-05
disequilibrium O 0 0.00011330458073643968
studies O 0 1.4365732603494052e-08
in O 0 3.495161660094226e-10
the O 0 7.085296793718499e-10
Japanese O 0 6.384564699146722e-08
population O 0 4.315096902018922e-08
. O 0 6.902610749648375e-08

The O 0 0.0006699487566947937
myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
( O 0 0.03555624932050705
DM B-Disease 1 0.9999998807907104
) O 0 7.681369424972218e-07
mutation O 0 4.7271187213482335e-06
is O 0 1.2230211510200206e-08
an O 0 2.8666775619967666e-08
unstable O 0 0.00047962882672436535
( O 0 7.17515336035035e-09
CTG O 0 9.997289680541144e-07
) O 0 1.0356108193221303e-09
n O 0 1.4030675288267958e-08
repeat O 0 2.6318458523633126e-08
, O 0 5.027352978359545e-10
present O 0 1.962478651806876e-10
at O 0 3.385661195842715e-11
a O 0 1.3541219257007242e-09
copy O 0 1.2497767265529092e-08
number O 0 5.080796339207438e-10
of O 0 1.2048330388925166e-10
5 O 0 2.3220629863374143e-09
- O 0 4.778490847456851e-07
37 O 0 4.786062035577743e-08
repeats O 0 5.5604250093210794e-09
on O 0 2.386401076748257e-09
normal O 0 2.2155843826254795e-09
chromosomes O 0 4.898566885458422e-09
but O 0 1.7772932014992193e-09
amplified O 0 5.709328476655173e-08
to O 0 4.395521280287085e-09
50 O 0 3.74553144055767e-09
- O 0 4.4303028801095934e-08
3000 O 0 1.1028799207224438e-08
copies O 0 2.0501486730495344e-08
on O 0 1.4937634773559694e-07
DM B-Disease 1 0.9999934434890747
chromosomes O 0 1.5541676475550048e-05
. O 0 4.83271605844493e-07

Previous O 0 3.280185183029971e-06
findings O 0 5.425474682851927e-07
in O 0 1.0262946048555932e-08
Caucasian O 0 7.182521812865161e-07
populations O 0 1.1797584242856374e-08
of O 0 8.393737371825694e-10
a O 0 6.003323051118059e-06
DM B-Disease 1 1.0
founder O 0 0.00017073385242838413
chromosome O 0 3.7127406358195003e-06
raise O 0 1.6948646930359246e-08
a O 0 2.97113089686718e-09
question O 0 2.2031361179841724e-09
about O 0 2.2395159338106652e-10
the O 0 2.0894941332727512e-10
molecular O 0 6.1539608964267245e-09
events O 0 5.535301106363022e-10
involved O 0 8.785193683635839e-10
in O 0 2.0125152933037072e-10
the O 0 9.451490701195553e-10
expansion O 0 9.88613706454089e-08
mutation O 0 3.681881025840994e-06
. O 0 1.0491150703728636e-07

To O 0 9.20008574212261e-07
investigate O 0 5.403101681622502e-07
whether O 0 1.9854773825045413e-08
a O 0 2.355268868825533e-08
founder O 0 3.4874213383773167e-07
chromosome O 0 5.698719860447454e-07
for O 0 1.9264829731469035e-09
the O 0 3.427614814199842e-08
DM B-Disease 1 1.0
mutation O 0 2.9375285521382466e-05
exists O 0 5.538958625095347e-09
in O 0 3.1311789272514545e-10
the O 0 2.1445638320738425e-10
Japanese O 0 1.4166743333987597e-08
population O 0 2.502697382666952e-09
, O 0 7.535990165230544e-10
we O 0 1.2633701862441171e-09
genotyped O 0 1.6256917945156601e-07
families O 0 1.5689345378433472e-09
using O 0 1.921272252403128e-09
polymorphic O 0 7.499045864278742e-07
markers O 0 5.305211061568116e-07
near O 0 2.7735868712852607e-08
the O 0 3.5149521071531353e-09
( O 0 2.9336890694509066e-09
CTG O 0 7.452419481523975e-07
) O 0 2.937446286210843e-09
n O 0 4.746470949612558e-08
repeat O 0 7.268643997804247e-08
region O 0 3.030848461094138e-08
and O 0 2.179215030650994e-08
constructed O 0 3.499445938359713e-06
haplotypes O 0 2.3465696358471178e-05
. O 0 1.493572483468597e-07

Six O 0 7.945641300466377e-07
different O 0 1.2385900305389441e-08
haplotypes O 0 1.1981811667283182e-06
were O 0 1.0231464386833977e-07
found O 0 8.312110821862007e-08
and O 0 1.0525168363528792e-06
DM B-Disease 1 0.9999998807907104
alleles O 0 3.437755731283687e-05
were O 0 4.847843229072168e-07
always O 0 5.317986051522894e-07
haplotype O 0 7.362243195530027e-05
A O 0 1.0600801942928229e-06
. O 0 6.975042765589023e-07

To O 0 5.081954554952972e-07
find O 0 9.912211851315078e-08
an O 0 2.9651017197096508e-09
origin O 0 1.1255973930701657e-09
of O 0 1.2139791949472567e-10
the O 0 7.871842622186875e-10
( O 0 1.16961940133109e-09
CTG O 0 3.100546450696129e-07
) O 0 5.487471588239146e-10
n O 0 1.5726174140695548e-08
repeat O 0 1.9516107840900077e-08
mutation O 0 2.3225426915018943e-08
and O 0 9.087607888424998e-10
to O 0 8.427666342569751e-10
investigate O 0 5.6076925325498905e-09
the O 0 3.3737634907993197e-10
mechanism O 0 8.715230204181523e-10
of O 0 4.813996423713718e-11
the O 0 6.809156710696485e-11
expansion O 0 1.4619112587155314e-09
mutation O 0 6.467872459836599e-09
in O 0 9.625518437861302e-11
the O 0 7.012451036514378e-11
Japanese O 0 2.4536823683973807e-09
population O 0 3.2096905688838717e-10
we O 0 1.6370185762504263e-10
have O 0 3.999479913918691e-10
studied O 0 2.5098869649298194e-09
90 O 0 2.9217110952828307e-09
Japanese O 0 1.4489044986021327e-07
DM B-Disease 1 0.9999963045120239
families O 0 4.22799679711261e-08
comprising O 0 2.1871506827864096e-09
190 O 0 2.0286421431592316e-08
affected O 0 2.0986504978282028e-08
and O 0 1.0768901326230207e-08
130 O 0 1.0808104633497351e-07
unaffected O 0 5.2154432523821015e-06
members O 0 3.738253440133121e-08
. O 0 1.1448680226067154e-07

The O 0 9.801646427831656e-08
results O 0 4.224297001087507e-08
suggest O 0 8.892145686445474e-09
that O 0 7.993488648772029e-10
a O 0 3.5058196345971737e-09
few O 0 2.861857639757659e-09
common O 0 2.119195929850548e-09
ancestral O 0 3.959000238751287e-08
mutations O 0 1.1880279515708025e-07
in O 0 1.0906979763802838e-09
both O 0 5.260349489333294e-09
Caucasian O 0 1.807453458013697e-07
and O 0 5.953984416606772e-09
Japanese O 0 2.048393810127891e-08
populations O 0 2.204413984685516e-09
have O 0 7.214906450059289e-10
originated O 0 5.130303404321523e-10
by O 0 7.089456799391769e-11
expansion O 0 3.5514624574517484e-10
of O 0 6.515710193610857e-11
an O 0 9.782065157892816e-10
ancestral O 0 1.5413208487302654e-08
n O 0 3.762115241556785e-08
= O 0 1.2354167466810395e-08
5 O 0 1.189582321536875e-09
repeat O 0 1.0899458224855607e-08
to O 0 1.518009717926816e-08
n O 0 1.949810695123233e-07
= O 0 7.40159364909232e-08
19 O 0 2.2143519018413826e-08
- O 0 2.767869489161967e-07
37 O 0 1.1921001430437173e-07
copies O 0 6.63688410895702e-08
. O 0 5.269801661711426e-08

These O 0 9.349282237280931e-08
data O 0 2.8212973290919763e-08
support O 0 5.297260408099191e-09
multistep O 0 4.947542606714705e-07
models O 0 6.038838051836137e-08
of O 0 9.756015995066036e-10
triplet O 0 6.677223041151592e-07
repeat O 0 1.8390494460618356e-08
expansion O 0 1.6432258886922568e-09
that O 0 1.5433441191703423e-09
have O 0 2.5776143441902377e-09
been O 0 4.673523346099273e-09
proposed O 0 2.9446713956104986e-09
for O 0 3.2433424834721336e-09
both O 0 4.279891925307311e-07
DM B-Disease 1 0.9999998807907104
and O 0 8.307170355692506e-05
Friedreichs B-Disease 0 0.034749627113342285
ataxia I-Disease 1 0.982714831829071
. O 0 2.502952156646643e-07
. O 0 2.9321950023586396e-07

The O 0 1.622330927375515e-07
molecular O 0 3.6902579836350924e-07
basis O 0 5.286836213258539e-08
of O 0 1.932044852992476e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
in O 0 1.7705136912127273e-08
the O 0 4.091734950861792e-09
western O 0 4.472755321671684e-08
Cape O 0 9.337573914081077e-08
, O 0 5.267306590894805e-09
South O 0 5.487746257415438e-09
Africa O 0 1.1810191047345597e-08
. O 0 5.8707090744292145e-08

Deficiency B-Disease 1 0.9275968670845032
of I-Disease 0 5.640843170340304e-08
the I-Disease 0 4.512891838004407e-09
sixth I-Disease 0 5.737635433433752e-08
component I-Disease 0 1.4162312211851713e-08
of I-Disease 0 7.680550639932449e-10
human I-Disease 0 2.735808468656842e-09
complement I-Disease 0 1.9807416151707002e-08
( O 0 5.200075481326394e-09
C6 O 0 4.859544333157828e-06
) O 0 1.2906244961641278e-09
has O 0 5.333985342304004e-08
been O 0 2.38729480628308e-08
reported O 0 4.4200874071975704e-09
in O 0 4.1713747039873184e-11
a O 0 8.879430524189047e-10
number O 0 2.628832984630236e-10
of O 0 6.699960725109477e-11
families O 0 9.85352355264979e-10
from O 0 1.1439179464778348e-10
the O 0 8.300538034688998e-10
western O 0 2.2867226334710722e-08
Cape O 0 8.344340329813349e-08
, O 0 4.618925242283467e-09
South O 0 5.707528671905493e-09
Africa O 0 1.4664697012278793e-08
. O 0 4.983517953860428e-08

Meningococcal B-Disease 1 0.999411940574646
disease I-Disease 1 0.8257398009300232
is O 0 2.707663782075542e-07
endemic O 0 6.864090096314612e-08
in O 0 3.624108346755861e-09
the O 0 2.5555071392346917e-09
Cape O 0 5.40524638381612e-08
and O 0 4.332314063049125e-09
almost O 0 8.140114693411249e-10
all O 0 1.277092043228123e-10
pedigrees O 0 2.2070908656246502e-08
of O 0 2.115440267402846e-09
total O 0 2.267326090077404e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
( O 0 3.80155711354746e-08
C6Q0 O 0 1.7390153516316786e-05
) O 0 1.6771320998643091e-09
have O 0 1.553184603153568e-08
been O 0 4.182447099765341e-08
ascertained O 0 9.655172306111126e-08
because O 0 3.436594564476536e-09
of O 0 2.351685512991253e-09
recurrent O 0 0.08857139199972153
disease O 0 0.01747884601354599
. O 0 6.154234029054351e-07

We O 0 3.8754131992391194e-07
have O 0 1.5882623216612046e-08
sequenced O 0 1.733971899398057e-08
the O 0 1.623765899516627e-09
expressed O 0 1.2319788744719062e-08
exons O 0 2.5753847054943435e-08
of O 0 2.6026797383948974e-10
the O 0 1.5476006032244527e-09
C6 O 0 2.5415272375539644e-06
gene O 0 1.8881092245237596e-08
from O 0 6.643793293292788e-10
selected O 0 1.994882703471035e-09
cases O 0 6.7725602903578874e-09
and O 0 9.679840040632826e-09
have O 0 4.2680472489564636e-08
found O 0 1.247852221553103e-08
three O 0 3.5235709905379053e-09
molecular O 0 1.7472926572281722e-07
defects O 0 0.0008426575222983956
leading O 0 2.8531333740033915e-08
to O 0 7.129958845553119e-08
total O 0 1.2534898132798844e-06
deficiency O 0 0.004848158452659845
879delG O 0 2.556884510340751e-06
, O 0 3.1084967933026064e-09
which O 0 2.0378128073872404e-09
is O 0 1.320230591517202e-09
the O 0 9.677897372384336e-10
common O 0 6.954264275549349e-09
defect O 0 9.497325095253473e-07
in O 0 1.7362216109262363e-09
the O 0 2.3324411291270053e-09
Cape O 0 8.469685042200581e-08
and O 0 2.908168816873058e-08
hitherto O 0 4.6480033688567346e-07
unreported O 0 7.983226879559879e-08
, O 0 1.253251724619986e-09
and O 0 2.0593262650692168e-09
1195delC O 0 2.478415410678281e-07
and O 0 1.0431565833357581e-08
1936delG O 0 1.6985579520678584e-07
, O 0 7.013872815875288e-10
which O 0 1.7642257654770788e-09
have O 0 3.998078312861253e-09
been O 0 8.508281190700018e-09
previously O 0 2.9470495377381667e-08
reported O 0 7.952978720027204e-09
in O 0 4.3456527265561817e-10
African O 0 3.0028071140719703e-09
- O 0 6.170242272673931e-07
Americans O 0 1.293632436727421e-07
. O 0 7.657942546757113e-08

We O 0 5.004702643418568e-07
also O 0 2.7174673178365083e-08
show O 0 1.3663839837363412e-08
that O 0 1.4332088849045022e-09
the O 0 9.808688306023328e-10
879delG O 0 1.2994180451642023e-06
and O 0 1.2144185745910363e-07
1195delC O 0 0.00037364009767770767
defects O 0 0.03893810510635376
are O 0 4.086447180640107e-09
associated O 0 9.285887614396415e-09
with O 0 1.2926205883445618e-08
characteristic O 0 0.0010937935439869761
C6 O 1 0.9571554660797119
/ O 0 0.00010565964475972578
C7 O 0 0.00011533739598235115
region O 0 1.1433655089376771e-07
DNA O 0 1.0252458650938934e-06
marker O 0 1.2748254448524676e-05
haplotypes O 0 6.628915343753761e-06
, O 0 5.734350327912807e-09
although O 0 2.962710521359213e-09
small O 0 1.0988961962610233e-09
variations O 0 6.220367509968128e-08
were O 0 5.410403502992267e-08
observed O 0 2.1446096809540904e-07
. O 0 6.938897456620907e-08

The O 0 5.128127895659418e-07
1936delG O 0 8.284669092972763e-06
defect O 0 5.3534345170191955e-06
was O 0 1.283748787272998e-07
observed O 0 1.5297347388809612e-08
only O 0 2.562496659308522e-09
once O 0 4.631513839115087e-09
in O 0 2.762950146451004e-10
the O 0 7.579524230472146e-10
Cape O 0 3.861467234855809e-08
, O 0 1.1498356711214797e-09
but O 0 1.4685683780157888e-09
its O 0 2.990569791805342e-09
associated O 0 1.0856534515824023e-07
haplotype O 0 2.524613773857709e-05
could O 0 1.6426290017079737e-07
be O 0 3.468402098860679e-08
deduced O 0 6.647956638516916e-07
. O 0 7.18649673103755e-08

The O 0 1.0519182325197107e-07
data O 0 1.2225081391648018e-08
from O 0 5.988170515003333e-10
the O 0 4.021080690641554e-10
haplotypes O 0 4.564488733649341e-07
indicate O 0 3.816174398707517e-08
that O 0 1.379587000194249e-09
these O 0 2.0775799136618645e-10
three O 0 7.757609554737144e-10
molecular O 0 1.1831841106868524e-07
defects O 0 0.0018893362721428275
account O 0 6.596484247722856e-09
for O 0 5.290189952766866e-10
the O 0 4.2592538385122225e-09
defects O 0 0.01267754752188921
in O 0 1.2649229441663579e-09
all O 0 1.3890547045924961e-10
the O 0 3.5492003780390746e-10
38 O 0 2.3335726240247823e-08
unrelated O 0 2.491429818007873e-08
C6Q0 O 0 7.751899829600006e-06
individuals O 0 2.4489974492780675e-09
we O 0 4.760564720207583e-10
have O 0 1.595439003132526e-09
studied O 0 4.266628383930993e-09
from O 0 3.3536565191560896e-10
the O 0 4.0693977076955434e-09
Cape O 0 8.160142215274391e-07
. O 0 3.2878915590117685e-07

We O 0 8.055611147028685e-07
have O 0 3.7034926236856336e-08
also O 0 5.4263988857883305e-09
observed O 0 4.548581955532427e-09
the O 0 3.7758421389533225e-10
879delG O 0 4.929212877868849e-07
defect O 0 5.24022368608712e-07
in O 0 3.0716429400001743e-09
two O 0 5.076596920616794e-08
Dutch O 1 0.9994188547134399
C6 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999808073043823
deficient I-Disease 1 0.9999997615814209
kindreds O 0 3.8183679862413555e-05
, O 0 3.6489744559276005e-09
but O 0 7.034397508931534e-10
the O 0 3.331768749781361e-10
879delG O 0 3.933443508685741e-07
defect O 0 3.3592493764444953e-07
in O 0 1.2859114884022915e-09
the O 0 7.045931615934364e-10
Cape O 0 2.1312116516014612e-08
probably O 0 3.781323343332588e-08
did O 0 3.9284588915222685e-09
not O 0 3.5668584752457377e-10
come O 0 3.3109456842872476e-10
from O 0 7.65638316635453e-11
The O 0 6.091433468746743e-10
Netherlands O 0 2.592047110283602e-07
. O 0 7.908929511302176e-09
. O 0 4.629599814620633e-08

Complement B-Disease 1 0.9963107705116272
C7 I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999998807907104
: O 0 1.1519122011804939e-07
seven O 0 1.8355274633563567e-08
further O 0 1.8537701151899455e-08
molecular O 0 6.747562110831495e-06
defects O 1 0.6004565358161926
and O 0 2.735914250706628e-08
their O 0 1.3881979121777022e-08
associated O 0 2.647464327765192e-07
marker O 0 6.564298382727429e-05
haplotypes O 0 0.00022488417744170874
. O 0 4.317624586747115e-07

Seven O 0 1.0729187351898872e-06
further O 0 5.485781429115377e-08
molecular O 0 1.6085840570667642e-07
bases O 0 1.2915910474475822e-07
of O 0 4.067483700964658e-07
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 2.153572182805874e-07
described O 0 5.229672296991339e-06
. O 0 2.832448444678448e-07

All O 0 1.2043268782235828e-07
these O 0 4.186531121774806e-09
new O 0 7.1263124290510405e-09
molecular O 0 4.4248810127101024e-07
defects O 0 0.0006590236444026232
involve O 0 8.53191028937772e-09
single O 0 4.325496050228139e-08
- O 0 1.01920413442258e-07
nucleotide O 0 1.3292087430727406e-08
events O 0 1.245383463022165e-09
, O 0 3.591681119186063e-10
deletions O 0 1.2082747247177394e-08
and O 0 1.759299705916817e-09
substitutions O 0 1.947004335534075e-08
, O 0 1.3326756365117376e-09
some O 0 1.6201547048400045e-10
of O 0 4.522443530774467e-11
which O 0 2.9470592632918624e-09
alter O 0 1.2025319051645056e-07
splice O 0 3.52633662714652e-07
sites O 0 1.5478523351930562e-08
, O 0 1.5966902244812786e-09
and O 0 2.2573702906925064e-09
others O 0 2.9875383944499845e-08
codons O 0 2.2097241014762403e-07
. O 0 7.17738686262237e-08

They O 0 9.017314255288511e-07
are O 0 1.1244242870134258e-08
distributed O 0 3.2596594312650495e-09
along O 0 1.4030507866635844e-09
the O 0 2.161109069476197e-09
C7 O 0 3.101249149040086e-06
gene O 0 3.446573870746761e-08
, O 0 1.4712570051145235e-09
but O 0 1.2476373267844565e-09
predominantly O 0 1.4732169928421968e-09
towards O 0 4.084496907363899e-10
the O 0 4.8629938964595e-10
3 O 0 7.228988074814424e-09
end O 0 4.561912092526654e-08
. O 0 2.1122869497958163e-07

All O 0 1.1253580112224881e-07
were O 0 1.2048273489995154e-08
found O 0 2.1754098522563936e-09
in O 0 1.128437121522552e-09
compound O 0 6.238052492335555e-07
heterozygous O 0 1.0393124284746591e-05
individuals O 0 2.868373094599974e-08
. O 0 9.393988165129485e-08

The O 0 5.538725417864043e-06
C6 O 0 0.19806523621082306
/ O 0 0.0006996638840064406
C7 O 0 0.0019177179783582687
marker O 0 0.00026342534692958
haplotypes O 0 0.00016021901683416218
associated O 0 3.1690950663687545e-07
with O 0 1.733680932147763e-08
most O 0 2.8028684937453363e-06
C7 B-Disease 1 0.9990332126617432
defects I-Disease 1 0.9991809725761414
are O 0 9.028494218910055e-08
tabulated O 0 7.512832667089242e-07
. O 0 3.1141002665435735e-08
. O 0 4.840446621301453e-08

A O 0 3.1460276659345254e-06
genome O 0 4.061855349846155e-07
- O 0 7.98503663190786e-07
wide O 0 5.980984951747814e-08
search O 0 1.397021787141739e-08
for O 0 5.2217927759556915e-09
chromosomal O 0 2.746308609857806e-06
loci O 0 2.5675231540844834e-07
linked O 0 3.6172434647596674e-06
to O 0 4.095597432751674e-06
mental O 1 0.9541661739349365
health O 0 2.874611482184264e-06
wellness O 0 1.4954324569771416e-06
in O 0 1.749612721368976e-08
relatives O 0 1.0601503674934065e-07
at O 0 1.6949091019569096e-09
high O 0 6.258306228801302e-08
risk O 0 1.6067212982306955e-07
for O 0 1.7618198455693346e-07
bipolar B-Disease 1 0.9999984502792358
affective I-Disease 1 0.9999732971191406
disorder I-Disease 1 0.997454822063446
among O 0 3.521180858001571e-08
the O 0 2.6494928473397295e-09
Old O 0 3.248960354085284e-07
Order O 0 4.194510339061708e-08
Amish O 0 4.72449573862832e-06
. O 0 1.3385437114266097e-07

Bipolar B-Disease 1 0.9999938011169434
affective I-Disease 1 0.9999791383743286
disorder I-Disease 1 0.9999946355819702
( O 0 0.00016589887673035264
BPAD B-Disease 1 0.9999988079071045
; O 0 0.0003907931095454842
manic B-Disease 1 0.9998781681060791
- I-Disease 1 0.9999849796295166
depressive I-Disease 1 0.9999992847442627
illness I-Disease 1 0.9925939440727234
) O 0 1.232749813340206e-08
is O 0 2.5915273482723933e-08
characterized O 0 1.36967756247941e-07
by O 0 5.1551425350737645e-09
episodes O 0 3.5449282620447775e-08
of O 0 1.078879652283149e-09
mania B-Disease 0 9.731724276207387e-06
and O 0 1.726761382769837e-07
/ O 0 1.5164779370024917e-06
or O 0 4.4479815386466726e-08
hypomania B-Disease 0 0.0003009862848557532
interspersed O 0 6.405276167242846e-07
with O 0 4.648062823520149e-09
periods O 0 2.8869303392298207e-08
of O 0 4.48175407896656e-09
depression B-Disease 0 2.0917923393426463e-05
. O 0 3.474322056717938e-07

Compelling O 0 4.5701668568653986e-05
evidence O 0 8.250971177403699e-07
supports O 0 5.2707669340179564e-08
a O 0 7.070962926292168e-09
significant O 0 5.91676219130477e-09
genetic O 0 1.62384719004649e-08
component O 0 4.626208305325008e-09
in O 0 5.522604595853409e-10
the O 0 3.6144784942848673e-09
susceptibility O 0 0.005947154946625233
to O 0 3.248017037549289e-06
develop O 0 7.473461300833151e-05
BPAD B-Disease 1 0.9999969005584717
. O 0 3.834411018033279e-06

To O 0 4.542636702353775e-07
date O 0 1.351643277303083e-07
, O 0 5.853598938898585e-09
however O 0 4.848889734176964e-09
, O 0 6.961122234194761e-10
linkage O 0 4.0530398592864e-08
studies O 0 1.8879822150097425e-09
have O 0 1.977818797627151e-09
attempted O 0 1.2766018642196286e-07
only O 0 2.0593300398275005e-09
to O 0 1.0362392055540681e-09
identify O 0 1.2097551405076956e-08
chromosomal O 0 5.497161623679858e-07
loci O 0 2.974330470806308e-08
that O 0 1.0278167650312753e-08
cause O 0 5.717130946436555e-08
or O 0 1.638550184424048e-09
increase O 0 3.470096388014099e-08
the O 0 1.6594821516946467e-08
risk O 0 1.0163078201230746e-07
of O 0 5.056744356579657e-09
developing O 0 6.747806082785246e-07
BPAD B-Disease 1 0.9999862909317017
. O 0 3.0665803478768794e-06

To O 0 2.7175300942872127e-07
determine O 0 1.0367540426159394e-07
whether O 0 7.677010138706919e-09
there O 0 2.2058019855109023e-09
could O 0 1.914085956400413e-08
be O 0 1.1457008675108682e-08
protective O 0 9.90106059362006e-07
alleles O 0 1.9277926810445933e-08
that O 0 9.938081468874316e-10
prevent O 0 3.6049081497679936e-09
or O 0 9.629746999806343e-10
reduce O 0 2.335999482738771e-08
the O 0 2.215795769089368e-09
risk O 0 1.2180835007313817e-08
of O 0 2.7346069852995925e-10
developing O 0 3.248903723829244e-08
BPAD B-Disease 1 0.9999967813491821
, O 0 5.4774460522821755e-09
similar O 0 1.563443818852761e-09
to O 0 1.042973041265327e-09
what O 0 4.4587988856648053e-10
is O 0 5.31892363486719e-10
observed O 0 1.8876942231571547e-09
in O 0 5.23115051276335e-10
other O 0 1.8099678200655944e-08
genetic B-Disease 1 0.9999964237213135
disorders I-Disease 1 0.9999997615814209
, O 0 2.4356014094450984e-08
we O 0 1.4660725966564314e-08
used O 0 1.1661909411486704e-05
mental O 1 0.7490872144699097
health O 0 3.194460987288039e-06
wellness O 0 1.895618652270059e-06
( O 0 9.632373787482607e-10
absence O 0 8.213622670893983e-09
of O 0 5.118145351978853e-10
any O 0 4.0271334000863135e-07
psychiatric B-Disease 1 0.9998749494552612
disorder I-Disease 0 0.03884502127766609
) O 0 1.328726351168541e-09
as O 0 1.0451840282144076e-08
the O 0 8.040712096146763e-09
phenotype O 0 0.0002688724489416927
in O 0 1.7621240022691609e-09
our O 0 6.627163262606928e-10
genome O 0 2.3610247090743997e-09
- O 0 6.148449216425433e-08
wide O 0 4.964448763189466e-08
linkage O 0 3.41978591222869e-07
scan O 0 2.613041942822747e-06
of O 0 3.3698402401860506e-10
several O 0 6.863927204392439e-10
large O 0 2.1745096834280275e-09
multigeneration O 0 4.813999225916632e-07
Old O 0 6.621622361535628e-08
Order O 0 7.381894207014739e-09
Amish O 0 2.5058636765606934e-07
pedigrees O 0 2.84898504787634e-07
exhibiting O 0 1.0599320177107074e-07
an O 0 4.466171876771341e-09
extremely O 0 9.629991382098524e-07
high O 0 3.2377247407566756e-06
incidence O 0 0.0010665180161595345
of O 0 1.1301440139277474e-07
BPAD B-Disease 1 0.9999982118606567
. O 0 4.38833831140073e-06

We O 0 7.092414762155386e-07
have O 0 2.4463609804570297e-08
found O 0 5.513324463635172e-09
strong O 0 1.7704561372511307e-08
evidence O 0 7.19781123592611e-09
for O 0 6.880009340015647e-10
a O 0 9.346140750210452e-09
locus O 0 7.242736899115698e-08
on O 0 3.105819601501025e-08
chromosome O 0 3.5802056572720176e-06
4p O 0 3.814417141256854e-06
at O 0 3.300392403815522e-09
D4S2949 O 0 1.3030921763856895e-07
( O 0 1.2022052242599557e-09
maximum O 0 1.3126815190389607e-07
GENEHUNTER O 0 1.1032419024559204e-05
- O 0 9.747597005116404e-07
PLUS O 0 1.0087432400496255e-07
nonparametric O 0 7.616455377501552e-07
linkage O 0 2.869052480036771e-07
score O 0 6.453088019497955e-08
= O 0 2.7928567902790746e-08
4 O 0 2.9217110952828307e-09
. O 0 8.347533220209868e-10
05 O 0 3.6479672615996606e-08
, O 0 4.268012609998095e-09
P O 0 1.0751582379953106e-07
= O 0 1.0420190932336482e-08
5 O 0 1.7727496137709409e-09
. O 0 3.3390529230459265e-10
22 O 0 2.1516000092702825e-09
x O 0 5.320897500382671e-08
10 O 0 1.4618666277499415e-09
( O 0 1.4499419720426232e-10
- O 0 8.1532682827401e-08
4 O 0 7.666182355592355e-09
) O 0 4.832305666724324e-10
; O 0 1.1021791257448399e-09
SIBPAL O 0 7.129550567697152e-07
Pempirical O 0 1.134173501782243e-07
value O 0 6.112336192742873e-10
< O 0 1.4538112935724712e-09
3 O 0 1.0531439054162206e-09
x O 0 9.432392289454583e-08
10 O 0 2.035283941381749e-09
( O 0 6.308948918842816e-10
- O 0 5.031161549595708e-07
5 O 0 5.068022446153009e-09
) O 0 2.506154450632181e-10
) O 0 5.286658888437046e-10
and O 0 5.590861107407363e-09
suggestive O 0 4.777697881763743e-07
evidence O 0 5.259396473888955e-09
for O 0 3.1659497246039336e-10
a O 0 1.3812517352107534e-08
locus O 0 1.9552162200398016e-07
on O 0 1.7391630535712466e-07
chromosome O 0 0.00017403962556272745
4q O 0 0.27666911482810974
at O 0 1.1689352596988556e-08
D4S397 O 0 4.112455940230575e-07
( O 0 1.7655824580131707e-09
maximum O 0 7.735793161600668e-08
GENEHUNTER O 0 4.120871381019242e-06
- O 0 3.764649818549515e-07
PLUS O 0 4.5975951934451587e-08
nonparametric O 0 2.828728611348197e-07
linkage O 0 2.2592284665279294e-07
score O 0 8.976244458835936e-08
= O 0 3.5713210166932186e-08
3 O 0 3.2686306994378356e-09
. O 0 1.3357039918560076e-09
29 O 0 1.7250160411208526e-08
, O 0 1.7461780910110747e-09
P O 0 1.1360527452097813e-07
= O 0 5.4484998734949386e-09
2 O 0 1.2943714988722377e-09
. O 0 6.769624860680779e-10
57 O 0 1.6192110763313394e-08
x O 0 8.839778331548587e-08
10 O 0 1.903559532223653e-09
( O 0 2.6509472395019884e-10
- O 0 1.2474694699449174e-07
3 O 0 8.410440344164272e-09
) O 0 9.46220546360621e-10
; O 0 2.612160265869079e-09
SIBPAL O 0 1.3932186675447156e-06
Pempirical O 0 1.995816916178228e-07
value O 0 1.9010342189318408e-09
< O 0 2.456398195960219e-09
1 O 0 1.0448825138453799e-09
x O 0 8.513659111031302e-08
10 O 0 2.4108084417662212e-09
( O 0 4.369356543243441e-10
- O 0 7.280714839907887e-07
3 O 0 1.0200069233690101e-08
) O 0 2.630713702433951e-10
) O 0 1.0028217145574558e-10
that O 0 4.947891540929561e-10
are O 0 5.068657715767699e-10
linked O 0 1.0436963293614099e-07
to O 0 4.757900740059995e-07
mental O 1 0.8984759449958801
health O 0 1.7072094124159776e-05
wellness O 0 5.682992559741251e-05
. O 0 5.037066443946969e-07

These O 0 3.4797668035935203e-07
findings O 0 2.9599397066704114e-07
are O 0 1.6793151313976296e-09
consistent O 0 3.8199608809463825e-08
with O 0 1.5052508128832187e-09
the O 0 1.9627979241931826e-09
hypothesis O 0 3.797875436362119e-08
that O 0 3.543869919742093e-10
certain O 0 2.672141674597839e-10
alleles O 0 9.726646155172602e-09
could O 0 4.52019932595249e-08
prevent O 0 1.0082081836060297e-08
or O 0 1.4205862042260264e-09
modify O 0 1.1722580950390693e-07
the O 0 7.190758211095272e-09
clinical O 0 4.569314171476435e-07
manifestations O 0 2.650991177688411e-07
of O 0 7.536050894429991e-09
BPAD B-Disease 1 0.9999966621398926
and O 0 8.003641482901003e-08
perhaps O 0 1.2577303643013238e-08
other O 0 1.3497202244749928e-09
related O 0 4.681983796217537e-07
affective B-Disease 1 0.9996465444564819
disorders I-Disease 1 0.9989369511604309
. O 0 1.4749701904293033e-06

Segregation O 0 0.0015404424630105495
distortion O 0 0.019378220662474632
in O 0 0.00017851231677923352
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999998807907104
. O 0 0.00017292075790464878

Myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
( O 1 0.9904041290283203
DM B-Disease 1 1.0
) O 0 4.957541364092322e-07
is O 0 7.957140013559183e-08
an O 0 3.419530969495099e-08
autosomal B-Disease 0 0.2410530298948288
dominant I-Disease 1 0.9685894250869751
disease I-Disease 0 0.0061219362542033195
which O 0 1.1109814579413069e-07
, O 0 1.8247507949098463e-09
in O 0 3.423443195593734e-10
the O 0 5.5717602753802e-10
typical O 0 8.389247341256123e-08
pedigree O 0 4.6610091430920875e-07
, O 0 9.205538553658243e-10
shows O 0 1.8447608995941778e-09
a O 0 9.375775711362166e-10
three O 0 8.284309904738052e-10
generation O 0 3.055126285289589e-08
anticipation O 0 5.348910647740013e-08
cascade O 0 8.030950198190112e-07
. O 0 1.0852290444063328e-07

This O 0 2.4382700303249294e-07
results O 0 2.9644820642715786e-07
in O 0 1.339978012993015e-07
infertility B-Disease 0 0.45357996225357056
and O 0 0.3632901906967163
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 3.6060253023606492e-06
CDM B-Disease 0 2.7421281629358418e-05
) O 0 7.190374073928751e-09
with O 0 1.1485730144755735e-09
the O 0 1.3304559676186045e-09
disappearance O 0 6.900333460180264e-08
of O 0 4.763219152437159e-09
DM B-Disease 1 0.9999997615814209
in O 0 9.212502760647112e-08
that O 0 8.021567765581494e-08
pedigree O 0 7.3442420216451865e-06
. O 0 2.549866167100845e-07

The O 0 3.538935899882745e-08
concept O 0 9.127914424311712e-09
of O 0 3.7747477366067983e-10
segregation O 0 8.315265631608781e-08
distortion O 0 1.3663400750374421e-05
, O 0 6.587091760934527e-09
where O 0 5.00170349582163e-09
there O 0 1.259148341148375e-09
is O 0 1.666176641101913e-09
preferential O 0 2.3047981301260734e-08
transmission O 0 3.6169421235854315e-08
of O 0 6.776610522729598e-11
the O 0 1.2344049393764323e-10
larger O 0 1.6763388455132144e-09
allele O 0 3.1292593405396474e-08
at O 0 2.8019564446424283e-10
the O 0 4.600277048183443e-09
DM B-Disease 1 0.9999996423721313
locus O 0 1.3211227269493975e-05
, O 0 1.8363925491371447e-08
has O 0 1.3642642571198849e-08
been O 0 4.625908101019149e-09
put O 0 5.306128425530687e-09
forward O 0 5.164826788472965e-09
to O 0 4.182907797911639e-09
explain O 0 3.055744102198332e-08
partially O 0 7.383390254744882e-08
the O 0 7.310124172654753e-10
maintenance O 0 2.0346405449345184e-08
of O 0 4.643729401010432e-09
DM B-Disease 1 0.999998927116394
in O 0 3.970858131197019e-08
the O 0 8.577499599482508e-09
population O 0 4.0284621860564584e-08
. O 0 1.030245115885009e-07

In O 0 3.5256638852843025e-07
a O 0 1.0607065803469595e-07
survey O 0 9.106840792583171e-08
of O 0 2.237147800343564e-09
DM B-Disease 1 0.9999969005584717
in O 0 1.6599958030383277e-07
Northern O 0 2.0580125692504225e-07
Ireland O 0 1.1532872434827368e-07
, O 0 8.39607938729614e-09
59 O 0 1.0548536977239564e-07
pedigrees O 0 2.828847414093616e-07
were O 0 1.1042569525443469e-07
ascertained O 0 2.2761323634767905e-06
. O 0 1.2370276181172812e-07

Sibships O 0 0.00016849457460921258
where O 0 3.210202521586325e-07
the O 0 1.986040665258315e-09
status O 0 1.232918434013186e-09
of O 0 4.796161384712505e-11
all O 0 6.829681958864242e-11
the O 0 1.0280098300397e-10
members O 0 3.100513179532527e-10
had O 0 1.2664155946140454e-08
been O 0 4.15396694819492e-09
identified O 0 9.627125763245203e-09
were O 0 2.340980520543212e-09
examined O 0 1.2517043401771843e-08
to O 0 1.4052630170624525e-09
determine O 0 3.1631506303142487e-09
the O 0 3.836268525070352e-10
transmission O 0 4.769294648099276e-08
of O 0 3.5669880937838627e-10
the O 0 1.4041866336356179e-08
DM B-Disease 1 0.9999958276748657
expansion O 0 9.678552004288576e-08
from O 0 2.8809441499078048e-09
affected O 0 1.7423529286020312e-08
parents O 0 1.1090246943012971e-08
to O 0 2.9312672289449893e-09
their O 0 1.7821108144744358e-08
offspring O 0 1.603315581633069e-06
. O 0 1.1700108615286808e-07

Where O 0 1.222841319759027e-06
the O 0 2.18678462005073e-08
transmitting O 0 4.2717445580819913e-07
parent O 0 1.9177007004600455e-07
was O 0 1.0565470631718199e-07
male O 0 4.7396409286193375e-07
, O 0 1.333540833314828e-08
58 O 0 4.6130548980727326e-07
. O 0 5.870070651781134e-08

3 O 0 1.5154978427744936e-06
% O 0 1.8805042856229193e-08
of O 0 2.5471505460394894e-10
the O 0 1.1387331078083207e-09
offspring O 0 1.6832160554258735e-07
were O 0 4.424593669227761e-08
affected O 0 7.908687926772018e-09
, O 0 7.589881501068874e-10
and O 0 1.149763284580274e-09
in O 0 4.952640519917395e-10
the O 0 3.1104702147288776e-10
case O 0 6.422547382811672e-09
of O 0 1.0339445272178338e-10
a O 0 2.7674781577502472e-08
female O 0 6.411708000086946e-06
transmitting O 0 5.595397851720918e-07
parent O 0 1.311152573180152e-07
, O 0 3.090289135698754e-09
68 O 0 1.9022506592136779e-07
. O 0 9.110559062719403e-08

7 O 0 1.011463155009551e-05
% O 0 2.898036655096803e-07
were O 0 6.785130324260535e-08
affected O 0 1.4423997640733432e-07
. O 0 2.8635525950448937e-07

Studies O 0 1.3167178849471384e-06
on O 0 9.879709494953204e-08
meiotic O 0 8.630902925688133e-07
drive O 0 2.401086192094226e-07
in O 0 3.381484248166089e-08
DM B-Disease 1 0.9999988079071045
have O 0 4.568025360640604e-06
shown O 0 1.6099529887014796e-07
increased O 0 1.0824502183481854e-08
transmission O 0 1.9237887727285852e-08
of O 0 7.994093581542572e-11
the O 0 2.9209074048353045e-10
larger O 0 5.716310091941068e-09
allele O 0 7.778107402600654e-08
at O 0 4.821386623277135e-10
the O 0 5.4249507108750095e-09
DM B-Disease 1 0.9999974966049194
locus O 0 5.383271400205558e-06
in O 0 4.681269061279636e-08
non O 0 5.736824846280797e-07
- O 1 0.538149356842041
DM O 1 0.9999997615814209
heterozygotes O 0 0.0005730501725338399
for O 0 2.3216441036311153e-07
CTGn O 0 3.885274054482579e-05
. O 0 4.971290081812185e-07

This O 0 2.7343864417161967e-07
study O 0 6.134743557595357e-08
provides O 0 8.404122731064945e-09
further O 0 3.197142328659197e-09
evidence O 0 3.6434175676447467e-09
that O 0 1.226248658170448e-09
the O 0 8.817377938896698e-09
DM B-Disease 1 0.9999948740005493
expansion O 0 2.3158614226304053e-07
tends O 0 5.294187417348439e-07
to O 0 1.2017610906411846e-08
be O 0 5.028125116268711e-08
transmitted O 0 1.8768799918689183e-06
preferentially O 0 2.248319333375548e-06
. O 0 1.9659785266412655e-07

Diagnosis O 1 0.9944930076599121
of O 0 1.0656302038114518e-05
hemochromatosis B-Disease 1 0.9999948740005493
. O 0 2.5454844944761135e-05

If O 0 4.774743865709752e-05
untreated O 0 0.018017644062638283
, O 0 1.0583789844531566e-06
hemochromatosis B-Disease 1 0.9999984502792358
can O 0 1.3253577890282031e-05
cause O 0 0.00011329519475111738
serious O 0 0.28324511647224426
illness O 1 0.9688931107521057
and O 0 1.5067487879605324e-07
early B-Disease 0 2.7522420964487537e-07
death I-Disease 0 0.0006611199351027608
, O 0 3.196617859302364e-09
but O 0 4.567656031184697e-09
the O 0 2.7859918816375284e-09
disease O 0 2.7131744673170033e-07
is O 0 6.713603895036613e-09
still O 0 1.9211420010378788e-07
substantially O 0 7.264720807143021e-07
under O 0 2.7978265393358015e-07
- O 1 0.5570949912071228
diagnosed O 1 0.9960142374038696
. O 0 3.3566041679478076e-07

The O 0 1.147317334471154e-07
cornerstone O 0 1.396658717567334e-07
of O 0 1.135232907678585e-09
screening O 0 2.1861591648075773e-08
and O 0 3.5538696430137406e-09
case O 0 6.061016932790153e-08
detection O 0 1.2049330422314597e-08
is O 0 5.308181116880917e-10
the O 0 9.504817072292226e-11
measurement O 0 1.3958658229284993e-08
of O 0 5.423664295456376e-10
serum O 0 2.430334973269055e-07
transferrin O 0 8.268561373370176e-07
saturation O 0 1.6424755244770495e-07
and O 0 2.4189519276518467e-09
the O 0 8.960140407410222e-10
serum O 0 7.731367190899618e-07
ferritin O 0 9.583684004610404e-06
level O 0 7.82559155254603e-08
. O 0 6.094146698387704e-08

Once O 0 3.3016585803125054e-06
the O 0 6.484723513722201e-08
diagnosis O 0 1.5647607142454945e-05
is O 0 1.3742877946754106e-08
suspected O 0 8.78280559390987e-08
, O 0 1.580128028422223e-08
physicians O 0 7.389306944105556e-08
must O 0 8.054557021353048e-09
use O 0 1.2838192731123854e-08
serum O 0 1.2386394701024983e-06
ferritin O 0 3.471252057352103e-05
levels O 0 3.3786864861440336e-08
and O 0 2.52699852154592e-08
hepatic O 0 2.0069104721187614e-05
iron O 0 0.007167408242821693
stores O 0 1.0250723647686755e-07
on O 0 1.5790892859968153e-07
liver O 0 2.1145548089407384e-05
biopsy O 0 0.0022817172575742006
specimens O 0 9.759765617900484e-08
to O 0 3.8280642655763586e-08
assess O 0 3.2642858514009276e-06
patients O 0 1.3379173651628662e-05
for O 0 7.698282011858737e-10
the O 0 3.565933659466225e-10
presence O 0 6.200582713944414e-09
of O 0 3.1207760819995656e-09
iron B-Disease 1 0.532063364982605
overload I-Disease 0 0.017994720488786697
. O 0 6.282087383624457e-07

Liver O 1 0.8962323069572449
biopsy O 0 0.21137292683124542
is O 0 1.1477540340365522e-07
also O 0 9.819400403898726e-09
used O 0 2.066700144354172e-09
to O 0 8.50373493843648e-10
establish O 0 1.144093042526606e-09
the O 0 5.512417744490961e-10
presence O 0 4.7501180766573725e-09
or O 0 1.17401788291005e-09
absence O 0 1.5263131203369085e-08
of O 0 2.4189148462028243e-09
cirrhosis B-Disease 0 0.0011160908034071326
, O 0 1.6352165843613875e-08
which O 0 2.196013682009834e-08
can O 0 1.8947514490719186e-07
affect O 0 2.0860929907939862e-06
prognosis O 0 0.19193744659423828
and O 0 1.0520707149908048e-07
management O 0 9.518055321677821e-08
. O 0 9.161703928839415e-08

A O 0 1.5640703168173786e-06
DNA O 0 7.943626201267762e-07
- O 0 1.632379735383438e-06
based O 0 6.400244956239476e-08
test O 0 6.720406897642306e-09
for O 0 2.504548790582817e-10
the O 0 9.139983214723202e-10
HFE O 0 1.20440085993323e-06
gene O 0 1.3376116214658396e-08
is O 0 1.112799963287614e-09
commercially O 0 7.5101365126784e-09
available O 0 6.7723759933358e-10
, O 0 1.660056814234423e-10
but O 0 2.4503135631626094e-10
its O 0 9.961532293489839e-11
place O 0 8.95173601911381e-10
in O 0 3.634809120356408e-10
the O 0 2.9735913731343544e-09
diagnosis O 0 5.175540718482807e-05
of O 0 1.605430810514008e-08
hemochromatosis B-Disease 1 1.0
is O 0 8.025406827982806e-07
still O 0 1.3746344507126196e-07
being O 0 4.569488609718064e-08
evaluated O 0 2.0409301271229197e-07
. O 0 6.823636766739583e-08

Currently O 0 2.310772742930567e-06
, O 0 9.19980447378066e-09
the O 0 4.0043041105164434e-10
most O 0 5.168095951191276e-10
useful O 0 1.0096047331487057e-09
role O 0 6.74345135287524e-10
for O 0 1.922107056850919e-10
this O 0 3.96757598997155e-10
test O 0 3.0660003424998195e-09
is O 0 4.203347947484559e-10
in O 0 5.603474628745886e-11
the O 0 1.3122139486121398e-10
detection O 0 1.0117680915300298e-08
of O 0 3.2259444004978377e-09
hemochromatosis B-Disease 1 0.9999998807907104
in O 0 1.8316281824581893e-08
the O 0 1.345502265159837e-09
family O 0 7.694293202575864e-09
members O 0 1.565502172340416e-10
of O 0 1.8929717515714373e-10
patients O 0 1.889116703068794e-07
with O 0 7.314447936224155e-10
a O 0 3.765144640510698e-08
proven O 0 8.536640621059632e-07
case O 0 1.4491582156495042e-08
of O 0 1.0439402675643805e-09
the O 0 4.743855441802225e-08
disease O 0 4.705090304923942e-06
. O 0 1.2700542129095993e-07

It O 0 1.234336082234222e-07
is O 0 9.921230059717345e-09
crucial O 0 3.249139624017516e-08
to O 0 9.809442644836963e-07
diagnose O 1 0.9999676942825317
hemochromatosis B-Disease 1 1.0
before O 0 0.00036724330857396126
hepatic B-Disease 1 0.9937713742256165
cirrhosis I-Disease 1 0.9337353110313416
develops O 0 3.198040940333158e-05
because O 0 2.2017347589553538e-07
phlebotomy O 0 4.8883786803344265e-05
therapy O 0 4.66775372842676e-06
can O 0 3.29342668692334e-08
avert O 0 1.4420203115150798e-05
serious O 1 0.9942014813423157
chronic O 1 0.9999995231628418
disease O 1 0.9748479127883911
and O 0 3.215420463220653e-07
can O 0 7.33065661506771e-08
even O 0 5.960302029706099e-09
lead O 0 2.2138069155630546e-08
to O 0 1.2158597684219785e-08
normal O 0 4.557233523883042e-08
life O 0 1.3316706315436022e-07
expectancy O 0 8.957428576650273e-07
. O 0 3.3504483631929816e-09
. O 0 3.3527385312481783e-08

Prevalence O 0 0.0006406792090274394
of O 0 4.115099372370423e-08
the O 0 1.582912467767983e-08
I1307K O 0 9.691923423815751e-07
APC B-Disease 0 2.706860584567039e-07
gene O 0 4.2266822930514536e-08
variant O 0 2.6961456001117767e-07
in O 0 2.2771633467755237e-09
Israeli O 0 2.8833787268922606e-07
Jews O 0 3.903303458230312e-09
of O 0 1.7083513770277392e-10
differing O 0 1.8965190307085322e-08
ethnic O 0 9.902325182054028e-09
origin O 0 1.7435398902421184e-08
and O 0 4.083005578081611e-08
risk O 0 1.0293754257872934e-06
for O 0 0.0003615238529164344
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.934094355732668e-06

BACKGROUND O 0 0.00025397303397767246
& O 0 3.010567752426141e-06
AIMS O 0 2.129436609266122e-07
Israeli O 0 4.4167444457343663e-07
Jews O 0 7.758767850418735e-09
of O 0 1.628206042214586e-10
European O 0 8.584668087507907e-09
birth O 0 1.90514114706275e-07
, O 0 2.94776203446645e-09
i O 0 1.0776092018716099e-08
. O 0 4.203395687074618e-10
e O 0 8.66629712437117e-10
. O 0 2.873654647572721e-10
, O 0 6.053605394740202e-10
Ashkenazim O 0 5.4027932350209085e-08
, O 0 4.690980381916177e-10
have O 0 3.2372116098855486e-09
the O 0 1.6367392774441214e-08
highest O 1 0.5143992304801941
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.0019222577102482319
of O 0 9.894655095266103e-10
any O 0 3.742603560397129e-09
Israeli O 0 5.577815613833081e-07
ethnic O 0 7.914213995263708e-08
group O 0 3.090632958446804e-07
. O 0 5.478336717601451e-08

The O 0 1.0177913054576493e-06
I1307K O 0 2.014757410506718e-05
APC B-Disease 0 5.226675511948997e-06
gene O 0 1.122498815675499e-06
variant O 0 1.0652064702298958e-05
was O 0 9.246193144463177e-07
found O 0 3.6690408933282015e-08
in O 0 7.511283151018233e-09
6 O 0 1.8221473396806687e-07
. O 0 2.7914757083635777e-07

1 O 0 5.680012122866174e-07
% O 0 1.241830815956746e-08
of O 0 2.420381395307203e-10
American O 0 4.51261605860509e-09
Jews O 0 2.464424220249839e-08
, O 0 1.5453235358009465e-09
28 O 0 9.070642015274188e-09
% O 0 8.834405429425374e-11
of O 0 8.482913677054782e-11
their O 0 3.9919700611790176e-07
familial O 1 0.9999936819076538
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.0008515801164321601
, O 0 7.881566510548055e-09
but O 0 2.6148123666303036e-09
not O 0 1.8414634261887386e-09
in O 0 6.806589181174161e-10
non O 0 1.4030836048561923e-08
- O 0 2.283463800267782e-06
Jews O 0 7.426955335176899e-07
. O 0 8.299959119995037e-08

We O 0 2.0279753698559944e-07
assessed O 0 1.8625530628924025e-07
the O 0 2.9337843265864194e-09
I1307K O 0 8.677856726535538e-07
prevalence O 0 2.091637725243345e-07
in O 0 1.145258887724765e-09
Israeli O 0 2.3376760793780704e-07
Jews O 0 7.871335583331529e-09
of O 0 1.5085151183757972e-10
differing O 0 1.7925460227274925e-08
ethnic O 0 1.0535985417448046e-08
origin O 0 8.767035986068095e-09
and O 0 4.5984808849652836e-08
risk O 0 1.2965017504029674e-06
for O 0 0.0004739878058899194
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.311118679353967e-06

METHODS O 0 1.1196026207471732e-05
DNA O 0 1.9853048343065893e-06
samples O 0 6.704955524128309e-08
from O 0 1.220149981051577e-09
500 O 0 1.7301191590490816e-09
unrelated O 0 4.6896939664975434e-09
Jews O 0 4.0145149426962234e-09
of O 0 1.2059664378227808e-10
European O 0 3.0462921074558835e-09
or O 0 3.681292159996019e-09
non O 0 8.08375411054385e-09
- O 0 6.148279680928681e-07
European O 0 2.6156415700029356e-08
origin O 0 7.273120328221694e-09
, O 0 5.224171095719043e-10
with O 0 1.8469216434002789e-10
or O 0 3.6441941131393207e-10
without O 0 4.783081708481518e-10
a O 0 4.157724386999462e-09
personal O 0 1.0680699347176414e-07
and O 0 3.480755239593236e-08
/ O 0 3.852962748851496e-08
or O 0 1.2228502654920703e-09
family O 0 2.7220048437470723e-09
history O 0 2.7704485927593225e-10
of O 0 3.2536134897398483e-10
neoplasia B-Disease 0 1.254964672625647e-06
, O 0 3.432611528353391e-09
were O 0 3.2784959191900498e-09
examined O 0 1.615746647587457e-08
for O 0 3.5680564058893083e-10
the O 0 6.264498919605899e-10
I1307K O 0 2.793603357531538e-07
variant O 0 2.4013107235987263e-07
by O 0 1.1211321870874258e-09
the O 0 8.443610810537905e-10
allele O 0 2.2586340264751925e-07
- O 0 2.2843211411327502e-07
specific O 0 2.9781338284351477e-08
oligonucleotide O 0 6.130607289378531e-06
( O 0 1.2797268134079332e-08
ASO O 0 7.263152838277165e-06
) O 0 7.09346759109053e-09
method O 0 2.9614702157232387e-07
. O 0 1.3509371399322845e-07

RESULTS O 0 8.467021871183533e-06
In O 0 2.2722444370515404e-08
persons O 0 6.6497300998946685e-09
at O 0 1.0698958385901847e-09
average O 0 3.823007688197322e-08
risk O 0 2.49994144496668e-07
for O 0 0.00022560103388968855
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.8317753358587652e-07
I1307K O 0 5.920659305047593e-07
was O 0 1.4476172793820297e-07
found O 0 3.2224021229154687e-09
in O 0 1.2365075630071942e-09
5 O 0 2.5804737902035413e-08
. O 0 4.419010579681526e-08

0 O 0 7.650870429642964e-06
% O 0 3.4610732058126814e-08
of O 0 8.220248370882643e-10
120 O 0 1.0877816869481194e-08
European O 0 1.0760031088352662e-08
and O 0 2.69498805494095e-08
1 O 0 6.834617494178019e-08
. O 0 1.2994115650144522e-07

6 O 0 4.3745826587837655e-06
% O 0 5.0234088888601036e-08
of O 0 1.3432944756530674e-09
188 O 0 3.169330398122838e-08
non O 0 2.076940042172737e-08
- O 0 6.414054496417521e-07
European O 0 8.967346332156012e-08
Jews O 0 9.892474395201134e-08
( O 0 3.32677285719285e-09
P O 0 7.275071993717575e-07
= O 0 7.016032554929552e-08
0 O 0 3.8956596171146884e-08
. O 0 2.9886824126634792e-09
08 O 0 3.441962448391678e-08
) O 0 6.070119518142292e-09
. O 0 2.8113007033425674e-08

It O 0 1.4132650676401681e-06
occurred O 0 3.860834567603888e-07
in O 0 1.6597702767739975e-08
15 O 0 6.998857315920759e-08
. O 0 8.549328356366459e-08

4 O 0 1.7257750641874736e-06
% O 0 1.3971444445814996e-08
of O 0 8.026182496401191e-10
52 O 0 1.5131307407045824e-07
Ashkenazi O 0 1.6677630583217251e-06
Israelis O 0 1.1797784509326448e-06
with O 0 8.969963261051817e-08
familial O 0 0.12980638444423676
cancer B-Disease 0 0.39048120379447937
( O 0 2.305374025013407e-08
P O 0 4.801184786629165e-06
= O 0 1.019616391317868e-07
0 O 0 1.885626055297962e-08
. O 0 1.4920079616231874e-09
02 O 0 9.538897671745872e-09
) O 0 7.546600844232643e-11
and O 0 4.986774326809496e-10
was O 0 4.5767979628408284e-08
not O 0 1.260356929932982e-09
detected O 0 9.243265708391846e-09
in O 0 6.741998070936006e-10
51 O 0 3.7004422637210155e-08
non O 0 2.3869610732418778e-09
- O 0 4.639500161829346e-08
European O 0 1.023235718378146e-08
Jews O 0 2.4109384710868653e-08
at O 0 3.5565617118038517e-09
increased O 0 3.157398396069766e-06
cancer B-Disease 0 0.00032863032538443804
risk O 0 5.879280706722056e-07
. O 0 1.2858292564033036e-07

Colorectal B-Disease 1 0.9985093474388123
neoplasia I-Disease 0 0.16715000569820404
occurred O 0 1.642274764890317e-05
personally O 0 3.0295998385554412e-06
or O 0 1.0049653553778626e-08
in O 0 6.532437923922885e-10
the O 0 4.5476250543075025e-10
families O 0 6.069108549056068e-10
of O 0 8.68104962914451e-11
13 O 0 8.980021726223697e-10
of O 0 8.60090124121804e-11
20 O 0 2.493539374981424e-09
Ashkenazi O 0 8.549328356366459e-08
I1307K O 0 1.9827230346436409e-07
carriers O 0 2.5079740950673113e-08
, O 0 3.683046090330322e-10
8 O 0 4.0571040971215666e-10
of O 0 2.588624592458899e-10
whom O 0 3.411381896967214e-07
also O 0 6.121371853851088e-08
had O 0 2.5562396643863394e-08
a O 0 1.960691164981654e-09
personal O 0 2.4120193842236404e-08
or O 0 3.1921152388036944e-09
family O 0 1.5220745552824155e-08
history O 0 5.387498891451514e-09
of O 0 1.0366310476683793e-08
noncolonic O 0 0.0002736948081292212
neoplasia B-Disease 0 0.00021251823636703193
. O 0 2.9374373866630776e-07

CONCLUSIONS O 0 2.374091673118528e-05
The O 0 1.24425440617415e-07
I1307K O 0 5.783568212791579e-06
APC O 0 3.400387868168764e-06
variant O 0 1.3301795661391225e-05
may O 0 2.3238990820573235e-07
represent O 0 3.5577150114818323e-09
a O 0 5.0142190843871504e-08
susceptibility O 0 0.005624277517199516
gene O 0 1.4428156873691478e-06
for O 0 2.342334028071491e-06
colorectal B-Disease 1 0.9999998807907104
, I-Disease 0 1.0511902104326509e-07
or I-Disease 0 1.473121513662079e-09
other I-Disease 0 1.213648737063977e-09
, I-Disease 0 3.253195046681867e-08
cancers I-Disease 0 2.4386923541896977e-05
in O 0 9.617013851936917e-09
Ashkenazi O 0 7.553850537078688e-06
Jews O 0 9.650202059674484e-08
, O 0 3.873548148902728e-09
and O 0 5.9994689216580355e-09
partially O 0 4.095770691492362e-07
explains O 0 1.9062708744854717e-08
the O 0 5.597377561450401e-10
higher O 0 1.8726835193660918e-08
incidence O 0 2.5954754164558835e-05
of O 0 1.6468324247398414e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 1.3312757118910667e-07
European O 0 1.8869812379307405e-07
Israelis O 0 6.866158400953282e-06
. O 0 1.5285861820757418e-07

Systematic O 0 1.0694642696762457e-05
analysis O 0 4.146758385559224e-07
of O 0 2.0906840703105445e-08
coproporphyrinogen O 0 1.6038497051340528e-05
oxidase O 0 9.973321539291646e-06
gene O 0 1.4521608136419673e-05
defects O 0 0.21218572556972504
in O 0 1.600219263764302e-07
hereditary B-Disease 1 0.997336208820343
coproporphyria I-Disease 0 0.18712462484836578
and O 0 1.2091643384337658e-06
mutation O 0 4.604326932167169e-06
update O 0 1.7516082380097941e-06
. O 0 1.9742699919333973e-07

Hereditary B-Disease 1 0.9997814297676086
coproporphyria I-Disease 1 0.6055555939674377
( O 0 4.158276624366408e-06
HC B-Disease 0 0.009524640627205372
) O 0 7.998819029353399e-08
is O 0 5.0333255785517395e-08
an O 0 1.3077698213237454e-06
acute O 1 0.9999363422393799
hepatic B-Disease 1 0.9999580383300781
porphyria I-Disease 1 0.9999755620956421
with O 0 2.328191294509452e-05
autosomal O 1 0.9928261041641235
dominant O 0 0.03552220016717911
inheritance O 0 0.0004239134141243994
caused O 0 7.00571108609438e-05
by O 0 4.761895411320438e-08
deficient B-Disease 0 1.0927622497547418e-05
activity I-Disease 0 7.743983232444407e-09
of I-Disease 0 2.204052274024093e-09
coproporphyrinogen I-Disease 0 0.00012610234261956066
III I-Disease 0 0.030496567487716675
oxidase I-Disease 0 4.6457707867375575e-06
( O 0 3.240301893470132e-08
CPO O 0 7.3680093919392675e-06
) O 0 8.446163946018714e-08
. O 0 1.5391859164992638e-07

Clinical O 0 0.00028942895005457103
manifestations O 0 3.6404505863174563e-06
of O 0 1.351122147497108e-08
the O 0 7.636136700739371e-08
disease O 0 5.6755948207865e-06
are O 0 8.244385618638717e-09
characterized O 0 2.4295061393786455e-06
by O 0 1.7406331664915342e-07
acute O 0 0.021408451721072197
attacks O 0 0.00012650943244807422
of O 0 1.0942079597953125e-07
neurological B-Disease 1 0.999783456325531
dysfunction I-Disease 1 0.770183265209198
often O 0 1.9218105080653913e-06
precipitated O 0 1.3097719602228608e-06
by O 0 3.911471591067084e-09
drugs O 0 6.482866687917976e-09
, O 0 2.676626920106173e-09
fasting O 0 3.346235288859134e-08
, O 0 2.1348887102590197e-09
cyclical O 0 1.0611674952087924e-06
hormonal O 0 1.8757184079731815e-05
changes O 0 3.68311994236592e-08
, O 0 1.0545172735021424e-08
or O 0 5.849717865658022e-08
infectious B-Disease 0 0.0001112416066462174
diseases I-Disease 0 0.00017739177565090358
. O 0 1.3717836964133312e-06

Skin O 1 0.999980092048645
photosensitivity O 1 0.9999077320098877
may O 0 0.00273373955860734
also O 0 3.6271049452807347e-07
be O 0 2.9463807393881325e-08
present O 0 6.409944575125337e-08
. O 0 2.7130349167237e-07

The O 0 9.861616234729809e-08
seven O 0 4.1784282700518816e-08
exons O 0 1.7931722595676547e-07
, O 0 2.0016670543299142e-09
the O 0 1.1224929874487088e-09
exon O 0 1.7260731510759797e-07
/ O 0 8.10422804420341e-08
intron O 0 1.3027980685365037e-06
boundaries O 0 2.4448354452033527e-08
and O 0 1.406804894799052e-09
part O 0 5.678663650421356e-10
of O 0 1.1242815706191678e-10
3 O 0 1.2640836155597412e-09
noncoding O 0 2.078941463423689e-08
sequence O 0 4.813153764438027e-10
of O 0 3.688837429960401e-11
the O 0 4.971342226767206e-10
CPO O 0 5.196296228859865e-07
gene O 0 1.432679397339598e-08
were O 0 6.302000699065502e-09
systematically O 0 5.450695894637647e-08
analyzed O 0 1.2061057041989898e-08
by O 0 2.374101193414191e-10
an O 0 6.640854532946605e-10
exon O 0 6.883651337830088e-08
- O 0 1.456038205560617e-07
by O 0 1.0987164955622575e-08
- O 0 1.5115371070351102e-06
exon O 0 4.140793407714227e-06
denaturing O 0 6.461728480644524e-05
gradient O 0 0.0005622762255370617
gel O 0 7.92807259131223e-05
electrophoresis O 0 5.347776095732115e-06
( O 0 6.626307058610337e-09
DGGE O 0 1.1341879826431978e-06
) O 0 3.4795191172776185e-09
strategy O 0 1.7181301714686015e-08
followed O 0 3.704649476077293e-09
by O 0 2.566016843452701e-10
direct O 0 7.05126901312525e-10
sequencing O 0 2.1753516765699032e-09
in O 0 1.0522444027216693e-09
seven O 0 4.172302059402e-09
unrelated O 0 7.159052728411552e-08
heterozygous O 0 1.3401009709923528e-05
HC B-Disease 0 0.013391254469752312
patients O 0 0.0030242702923715115
from O 0 6.88433132722821e-09
France O 0 1.234629735336057e-06
, O 0 3.973661577560961e-08
Holland O 0 2.804001951517421e-06
, O 0 5.536128000471763e-09
and O 0 1.8550647240545004e-08
Czech O 0 5.297356437949929e-06
Republic O 0 8.785318783566254e-08
. O 0 1.6537134683858312e-07

Seven O 0 3.633590267781983e-06
novel O 0 1.9603689906944055e-06
mutations O 0 1.0995665888913209e-06
and O 0 4.308498890992496e-09
two O 0 2.0803327949181494e-09
new O 0 1.6434775318430184e-08
polymorphisms O 0 2.3076499928720295e-06
were O 0 2.436958936868905e-07
detected O 0 3.4784638955898117e-06
. O 0 3.133545192213205e-07

Among O 0 2.4478554223605897e-06
these O 0 2.353041672620293e-08
mutations O 0 3.0768873671149777e-07
two O 0 2.0537445077906114e-09
are O 0 6.030905108644902e-09
missense O 0 5.560847512242617e-06
( O 0 4.881591575411903e-09
G197W O 0 5.20209312071529e-07
, O 0 5.095637245489115e-09
W427R O 0 1.0534381544857752e-07
) O 0 5.465848329500034e-10
, O 0 4.480333049006191e-10
two O 0 9.579917970015117e-10
are O 0 1.7228745097241926e-09
nonsense O 0 2.1931091964688676e-07
( O 0 8.317749267128249e-10
Q306X O 0 1.1760025131479779e-07
, O 0 2.6531947749930396e-09
Q385X O 0 5.189783536252435e-08
) O 0 2.845147450969421e-10
, O 0 1.5042196654935225e-10
two O 0 1.3658614517186862e-10
are O 0 2.2781743158617473e-10
small O 0 1.356158629839399e-09
deletions O 0 1.3576143942373164e-07
( O 0 3.2232259083997405e-09
662de14bp O 0 2.8351024639050593e-07
; O 0 1.5305452460978586e-09
1168del3bp O 0 8.170890453129687e-08
removing O 0 6.397129936885904e-09
a O 0 4.7242316725260025e-09
glycine O 0 1.7540502383894818e-08
at O 0 8.988451649649676e-10
position O 0 3.457661890138297e-08
390 O 0 2.2917657105381295e-08
) O 0 8.99476326754467e-10
, O 0 4.603513681367133e-10
and O 0 3.614538668372802e-10
one O 0 4.3171508035122486e-10
is O 0 5.111169820715133e-10
a O 0 6.2335008266245495e-09
splicing O 0 5.105056857246382e-07
mutation O 0 5.393988544710737e-07
( O 0 2.2199497795583056e-09
IVS1 O 0 5.573377166001592e-06
- O 0 1.672252437856514e-05
15c O 0 1.5839830666664056e-05
- O 0 4.580907898343867e-06
- O 0 1.7497617591288872e-05
> O 0 3.8600833818236424e-07
g O 0 4.899952728010248e-07
) O 0 2.808162591350083e-10
which O 0 1.1949605749350667e-09
creates O 0 7.97022980947304e-09
a O 0 5.984954309923296e-09
new O 0 6.652876471946456e-09
acceptor O 0 1.8163866855047672e-08
splice O 0 5.218131491346867e-07
site O 0 2.1249208259632724e-07
. O 0 9.01675747400077e-08

The O 0 2.4535157194804924e-07
pathological O 0 1.8233691889690817e-06
significance O 0 2.3447981334356882e-08
of O 0 8.344412383287647e-10
the O 0 1.7194407009313295e-09
point O 0 3.0359167624283145e-08
mutations O 0 2.8009554853269947e-07
G197W O 0 5.875581337022595e-07
, O 0 5.064746400051945e-09
W427R O 0 1.1146490663804798e-07
, O 0 8.225549130713716e-10
and O 0 4.289907040710972e-10
the O 0 2.1219939694283596e-10
in O 0 7.880796015768965e-10
- O 0 2.3349230104940943e-06
frame O 0 0.00363154080696404
deletion O 0 2.072264805974555e-06
390delGly O 0 6.044842848496046e-07
were O 0 1.573310370872605e-08
assessed O 0 8.229994463704315e-09
by O 0 3.477228227577456e-10
their O 0 2.9983529548083254e-10
respective O 0 1.0203332623248684e-09
expression O 0 5.296724836512112e-09
in O 0 3.215315513838135e-10
a O 0 3.0761808655910272e-09
prokaryotic O 0 5.599762431529598e-09
system O 0 2.0114494514444914e-09
using O 0 4.357241234487219e-09
site O 0 2.2283758838170797e-08
- O 0 1.3356796557673078e-07
directed O 0 8.300686431539361e-07
mutagenesis O 0 1.4310442566056736e-05
. O 0 2.569622381543013e-07

These O 0 3.362694940278743e-07
mutations O 0 2.4721955469431123e-06
resulted O 0 5.412385206682302e-08
in O 0 1.0721838972216347e-09
the O 0 5.267263847308357e-10
absence O 0 9.60927515336607e-09
or O 0 2.83962270364313e-10
a O 0 1.0894158464225256e-08
dramatic O 0 1.4784189943384263e-06
decrease O 0 6.202182021297631e-07
of O 0 2.3270998461555337e-09
CPO O 0 1.5160735529207159e-05
activity O 0 1.4978374451857235e-07
. O 0 9.160445557654384e-08

The O 0 1.4074181819978548e-07
two O 0 1.4515012303206731e-08
polymorphisms O 0 5.48536263522692e-07
were O 0 1.9061946687770615e-08
localized O 0 1.9289039698833221e-07
in O 0 7.59792495585998e-09
noncoding O 0 2.47053606017289e-07
part O 0 3.2366558322394212e-09
of O 0 1.6473862551880103e-10
the O 0 2.3560570161507144e-10
gene O 0 3.388100244805514e-09
1 O 0 6.888820069939072e-10
) O 0 1.998964882510279e-10
a O 0 2.714571323281234e-08
C O 0 1.353458515040984e-06
/ O 0 1.0479545835551107e-06
G O 0 0.0006204728269949555
polymorphism O 0 8.013041224330664e-06
in O 0 1.8379650024158423e-09
the O 0 1.7786496719907063e-09
promotor O 0 1.040546408148657e-06
region O 0 1.5896169713869313e-08
, O 0 1.3150710520548614e-09
142 O 0 6.2023217672901865e-09
bp O 0 1.4085810562391998e-07
upstream O 0 2.090196682402734e-09
from O 0 5.509765560463009e-11
the O 0 4.75857409032443e-11
transcriptional O 0 3.892478783740216e-09
initiation O 0 2.672525312163998e-09
site O 0 4.861540059408753e-09
( O 0 6.224598614323895e-10
- O 0 1.2899758417006524e-07
142C O 0 2.384171921221423e-06
/ O 0 2.070738531756433e-07
G O 0 4.0850263758329675e-06
) O 0 1.0111463888407002e-09
, O 0 7.270023472116804e-10
and O 0 5.707983530278682e-10
2 O 0 8.514446370178064e-10
) O 0 1.3418316457958213e-10
a O 0 4.44209558025932e-09
6 O 0 1.3613945526458338e-08
bp O 0 1.050481159836636e-06
deletion O 0 1.5751065518543328e-07
polymorphism O 0 6.997629498073366e-07
in O 0 7.568097259991191e-10
the O 0 7.106573107762415e-10
3 O 0 4.2938714805984546e-09
noncoding O 0 5.758850463166709e-08
part O 0 2.420114775247839e-09
of O 0 2.5724608554433814e-10
the O 0 1.7554215858694988e-09
CPO O 0 5.506532261279062e-07
gene O 0 2.6760003990489167e-08
, O 0 1.5780069473336766e-09
574 O 0 2.522736330945463e-08
bp O 0 1.8616847796693037e-07
downstream O 0 6.032837784886169e-09
of O 0 8.494231013012055e-11
the O 0 2.1760146462490582e-10
last O 0 7.288298409235949e-09
base O 0 3.3465781257291383e-09
of O 0 7.119458494964093e-11
the O 0 6.51275589014233e-10
normal O 0 3.566290729395405e-08
termination O 0 3.3951863542824867e-07
codon O 0 1.3185294278628135e-07
( O 0 5.166620020702339e-09
+ O 0 7.11288521415554e-08
574 O 0 2.2591983395159332e-07
delATTCTT O 0 1.1441937886047526e-06
) O 0 2.2983316583236046e-08
. O 0 6.197262791829417e-08

Five O 0 3.0721244002052117e-06
intragenic O 0 1.0844901225937065e-05
dimorphisms O 0 6.7360660978010856e-06
are O 0 8.323974398649625e-09
now O 0 4.544610021639528e-09
well O 0 2.352286587736785e-09
characterized O 0 1.0185453191979832e-07
and O 0 4.321255353545439e-09
the O 0 1.4585579410919536e-09
high O 0 9.048179094861553e-09
degree O 0 5.043096162893335e-09
of O 0 1.0168227371210037e-09
allelic O 0 1.0887821417782106e-06
heterogeneity O 0 5.5720488489896525e-06
in O 0 7.862306716788225e-08
HC B-Disease 0 0.0036981271114200354
is O 0 2.5299218009422475e-07
demonstrated O 0 9.852535498566795e-08
with O 0 6.325854284838783e-10
seven O 0 5.018615523155745e-10
new O 0 2.7381039102714055e-10
different O 0 1.5967167865671428e-10
mutations O 0 2.2309436520373538e-09
making O 0 2.449902503087742e-10
a O 0 2.0287611590674715e-09
total O 0 5.7091159577638e-10
of O 0 6.666718288528273e-10
nineteen O 0 1.8067125040488463e-07
CPO O 0 1.01270925370045e-05
gene B-Disease 0 1.626133553145337e-06
defects I-Disease 0 0.0030680247582495213
reported O 0 1.0195230260023891e-07
so O 0 6.254305962016815e-09
far O 0 2.3013761563106527e-08
. O 0 6.015396181169308e-09
. O 0 5.665838287427505e-08

Coincidence O 0 1.0722931619966403e-05
of O 0 3.3697151735623265e-08
two O 0 1.0728022026285089e-08
novel O 0 6.271402952506833e-08
arylsulfatase O 0 5.21140805176401e-07
A O 0 5.34184572131835e-08
alleles O 0 1.2424141004885314e-07
and O 0 3.4151767636103614e-08
mutation O 0 1.3232057654022356e-06
459 O 0 8.588191349190311e-07
+ O 0 3.0466284783869924e-07
1G O 0 4.206485391478054e-05
> O 0 1.2695976181475999e-07
A O 0 2.2663492416086228e-08
within O 0 6.191054335857871e-10
a O 0 3.0177137233522444e-08
family O 0 2.58335546732269e-07
with O 0 7.910099952823657e-07
metachromatic B-Disease 1 0.9999995231628418
leukodystrophy I-Disease 1 0.9999945163726807
: O 0 3.109967394721025e-09
molecular O 0 7.1266113010892695e-09
basis O 0 6.820338738222631e-10
of O 0 4.990685087413738e-10
phenotypic O 0 5.793934906250797e-05
heterogeneity O 0 0.0001885162782855332
. O 0 1.2592565781233134e-06

In O 0 3.3012321409842116e-07
a O 0 8.38763227761774e-08
family O 0 3.801136827519258e-08
with O 0 2.0753472274037676e-09
three O 0 9.333511741260736e-09
siblings O 0 3.0179273835528875e-07
, O 0 1.448334008280483e-09
one O 0 1.0339056277786085e-09
developed O 0 2.4731686920631546e-08
classical O 0 1.2149631345437228e-07
late O 0 5.4744273256801534e-06
infantile O 1 0.9969713687896729
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.999998927116394
( O 0 7.813852676008537e-07
MLD B-Disease 1 0.9998396635055542
) O 0 1.5005305442628014e-08
, O 0 7.3486985385784465e-09
fatal O 0 4.0154659473046195e-06
at O 0 3.0822362440119377e-09
age O 0 2.4377669660680112e-08
5 O 0 2.01176408864967e-09
years O 0 3.509512680466287e-09
, O 0 7.988336658826256e-10
with O 0 1.603135935113187e-08
deficient O 0 0.00011410182196414098
arylsulfatase O 0 4.634778179024579e-06
A O 0 2.662377198703325e-07
( O 0 2.5244051293782377e-09
ARSA O 0 1.9325730136188213e-06
) O 0 4.951658527652114e-10
activity O 0 1.126768123249633e-09
and O 0 3.89374132936382e-09
increased O 0 2.0783713239325152e-07
galactosylsulfatide O 0 0.000152781285578385
( O 0 6.298746768607089e-08
GS O 1 0.9996944665908813
) O 0 5.1917542265300654e-08
excretion O 0 1.02473757124244e-06
. O 0 1.6946067660228437e-07

The O 0 7.272429769500377e-08
two O 0 8.282623475963646e-09
other O 0 1.1626553053645239e-09
siblings O 0 6.700660293290639e-08
, O 0 2.9511824095607153e-09
apparently O 0 2.4780703711257956e-07
healthy O 0 5.441116002202762e-09
at O 0 2.749623029263404e-10
12 O 0 1.3055290182251156e-09
( O 0 3.0313249133051556e-10
1 O 0 1.922394021747209e-09
/ O 0 1.2714060915186565e-08
2 O 0 2.2935047194749814e-09
) O 0 3.8566350113455883e-10
and O 0 2.1269224159681244e-09
15 O 0 2.525748943327244e-09
years O 0 2.833148604608482e-09
, O 0 6.440711852739867e-10
respectively O 0 3.5653913155186956e-09
, O 0 5.181025608536061e-10
and O 0 1.0028069485912283e-09
their O 0 9.026902003661519e-10
father O 0 7.703590085839096e-07
, O 0 1.091651213869227e-09
apparently O 0 9.549422941290686e-08
healthy O 0 1.8889332320526364e-09
as O 0 3.59805102378985e-10
well O 0 1.1179184244980434e-09
, O 0 2.2200767890723228e-09
presented O 0 3.257945380141791e-08
ARSA O 0 5.1395483751548454e-05
and O 0 2.1116908044405136e-07
GS O 1 0.9940881729125977
values O 0 1.0696842522861516e-08
within O 0 2.2803654797787232e-10
the O 0 1.989857861817157e-10
range O 0 8.82471429264342e-09
of O 0 1.6013634862588333e-08
MLD B-Disease 1 0.999998927116394
patients O 1 0.9668977856636047
. O 0 3.7945670783301466e-07

Mutation O 0 0.00036585843190550804
screening O 0 1.7755730823409976e-06
and O 0 1.2199785182076539e-08
sequence O 0 5.6545426119214426e-09
analysis O 0 2.928060016671452e-09
disclosed O 0 8.635511861143641e-09
the O 0 1.7109308414475777e-10
involvement O 0 2.9669176004887277e-09
of O 0 8.664673145641899e-11
three O 0 2.233208507007589e-09
different O 0 2.9350717412057747e-09
ARSA O 0 4.701798388850875e-05
mutations O 0 2.4610710624983767e-07
being O 0 3.354131417054873e-09
the O 0 1.5465995151231482e-10
molecular O 0 8.027012832201308e-09
basis O 0 1.087482437434062e-09
of O 0 1.2732596088582682e-09
intrafamilial O 0 4.9770551413530484e-05
phenotypic O 0 0.0001377825392410159
heterogeneity O 0 5.9112691815244034e-05
. O 0 1.822847593757615e-06

The O 0 9.207177527059685e-07
late O 0 3.154578052999568e-06
infantile O 0 0.0501515194773674
patient O 0 0.06323374062776566
inherited O 0 5.3160656534601e-06
from O 0 2.3785169389611838e-09
his O 0 6.330978408186638e-08
mother O 0 2.9308000648597954e-07
the O 0 1.0957461604732543e-09
frequent O 0 3.2212429346145655e-07
0 O 0 1.4411789095447602e-07
- O 0 4.069822352903429e-06
type O 0 3.835728421108797e-05
mutation O 0 1.4517886484100018e-06
459 O 0 2.165137402698747e-07
+ O 0 8.460837364054896e-08
1G O 0 5.449808668345213e-06
> O 0 6.975934496722402e-08
A O 0 6.109008410248862e-08
, O 0 4.289557598013971e-09
and O 0 1.303110952477482e-09
from O 0 2.0655878396613758e-10
his O 0 1.9463470835034968e-08
father O 0 2.5566768613316526e-07
a O 0 6.3923732973591996e-09
novel O 0 1.3760557138198237e-08
, O 0 6.024739596099948e-10
single O 0 8.649358562706766e-09
basepair O 0 1.8418705849398975e-07
microdeletion O 0 4.299930367324123e-08
of O 0 1.1533758670356775e-10
guanine O 0 3.106564561150549e-09
at O 0 2.5416327376071024e-10
nucleotide O 0 3.0518285676350843e-09
7 O 0 2.0068202655210143e-09
in O 0 6.071969038679015e-10
exon O 0 1.8225817655093124e-07
1 O 0 2.0565719793808057e-08
( O 0 3.6771796718682026e-09
7delG O 0 1.5048632349135005e-06
) O 0 2.0535654954301208e-08
. O 0 6.303794464201928e-08

The O 0 1.6035005501180422e-07
two O 0 8.661513106744678e-08
clinically O 0 5.4513016948476434e-05
unaffected O 0 1.2122241059842054e-05
siblings O 0 6.634276132899686e-07
carried O 0 4.4546720090465897e-08
the O 0 3.3188631842762106e-09
maternal O 0 9.377083188155666e-06
mutation O 0 1.2974121545994421e-06
459 O 0 5.677542276316672e-07
+ O 0 1.8387343914127996e-07
1G O 0 1.6254083675448783e-05
> O 0 1.5704853240094963e-07
A O 0 6.243438832598258e-08
and O 0 8.81855566348122e-09
, O 0 1.1381446896052694e-09
on O 0 2.694354517274178e-09
their O 0 3.6316507578959545e-09
paternal O 0 7.307674422918353e-06
allele O 0 2.443251219119702e-07
, O 0 1.6646997114122541e-09
a O 0 9.527751032578635e-09
novel O 0 5.405266989555457e-08
cytosine O 0 3.546226778894379e-08
to O 0 3.468638487547082e-09
thymidine O 0 1.7302329524682136e-07
transition O 0 4.216405891099839e-09
at O 0 4.755083549135009e-10
nucleotide O 0 7.782110955645294e-09
2435 O 0 1.7406266294983652e-07
in O 0 2.340833304970147e-09
exon O 0 8.793281836005917e-08
8 O 0 6.384964112982061e-09
, O 0 8.030530684877135e-10
resulting O 0 3.912859369847865e-09
in O 0 2.361536799444508e-10
substitution O 0 2.1167803065935686e-09
of O 0 1.2014189643139161e-09
alanine O 0 5.95904850797524e-07
464 O 0 5.069780399935553e-07
by O 0 7.54956417381436e-08
valine O 0 3.771599585888907e-05
( O 0 2.2370635122115345e-08
A464V O 0 1.807003627618542e-06
) O 0 3.8087353715354766e-08
. O 0 1.504703988075562e-07

The O 0 9.588002285454422e-07
fathers O 0 4.405875188240316e-06
genotype O 0 1.6607556972303428e-05
thus O 0 1.0639911351972842e-07
was O 0 5.427146447800624e-07
7delG O 0 1.1593093404371757e-05
/ O 0 2.355081278437865e-06
A464V O 0 1.4100653970672283e-05
. O 0 3.0612048362854694e-07

Mutation O 0 0.0009505049092695117
A464V O 0 2.4642449716338888e-05
was O 0 4.728520934804692e-07
not O 0 6.842166833109786e-09
found O 0 4.458698743547984e-09
in O 0 2.1821837670188415e-09
18 O 0 1.09652908975022e-07
unrelated O 0 1.1341122444719076e-05
MLD B-Disease 1 0.9999996423721313
patients O 1 0.9748207926750183
and O 0 9.467937189810982e-08
50 O 0 8.471317158864622e-08
controls O 0 1.9957682525273412e-05
. O 0 4.441581040737219e-07

A464V O 0 0.0001363543706247583
, O 0 1.3532348930311855e-07
although O 0 2.8960688069901153e-08
clearly O 0 7.489369835411708e-08
modifying O 0 1.1510941533288133e-07
ARSA O 0 0.0001638287358218804
and O 0 1.4974818896007491e-06
GS O 1 0.99993896484375
levels O 0 1.3702106116397772e-07
, O 0 3.4565657003327033e-09
apparently O 0 1.1709529701420252e-07
bears O 0 2.9743532081738522e-08
little O 0 3.4440750251718555e-09
significance O 0 3.11849723821922e-09
for O 0 1.733104881829206e-09
clinical O 0 1.8489049580239225e-07
manifestation O 0 5.716246960218996e-07
of O 0 1.7662300066945136e-08
MLD B-Disease 1 0.9999631643295288
, O 0 2.5843945650194655e-08
mimicking O 0 1.897159904729051e-07
the O 0 7.168655891121034e-09
frequent O 0 4.098425961274188e-06
ARSA O 0 0.04620213061571121
pseudodeficiency O 0 0.00036372337490320206
allele O 0 2.5006833311636e-05
. O 0 3.8194878015929135e-07

Our O 0 8.903161869966425e-07
results O 0 1.449852646828731e-07
demonstrate O 0 1.6793416435234576e-08
that O 0 5.340566877620745e-10
in O 0 6.345358682935398e-10
certain O 0 4.5225427847128685e-09
genetic O 0 5.0034418563882355e-06
conditions O 0 0.005581383593380451
MLD B-Disease 1 0.9999939203262329
- O 0 0.0006441741716116667
like O 0 9.90242028819921e-07
ARSA O 0 0.00100888020824641
and O 0 5.571637871071289e-07
GS O 1 0.9988477230072021
values O 0 3.205986232046598e-08
need O 0 2.8161024623329922e-09
not O 0 1.5929487728882918e-09
be O 0 9.20134413107121e-10
paralleled O 0 6.073457115007841e-08
by O 0 2.5551281979119267e-08
clinical O 0 3.518417724990286e-05
disease O 0 4.1877183321048506e-06
, O 0 9.955687385598821e-10
a O 0 3.0413283003127844e-09
finding O 0 3.292294437073906e-09
with O 0 2.527647868788563e-09
serious O 0 8.458793558929756e-07
diagnostic O 0 1.2691170013567898e-05
and O 0 6.136112915555714e-07
prognostic O 0 0.05439284071326256
implications O 0 2.108667104039341e-06
. O 0 2.9866157547076e-07

Moreover O 0 2.7295734980725683e-05
, O 0 2.307418043301368e-07
further O 0 1.5920177531825175e-07
ARSA O 0 0.0006259020883589983
alleles O 0 1.6038875401136465e-06
functionally O 0 8.613068303020555e-07
similar O 0 1.9338910917099383e-08
to O 0 9.834301373246035e-09
A464V O 0 7.794248517711821e-07
might O 0 8.744110857605847e-08
exist O 0 1.9479986512749292e-09
which O 0 2.703337109721815e-09
, O 0 7.190397721679176e-10
together O 0 8.157647335416129e-10
with O 0 1.2671929061625065e-09
0 O 0 8.133231688134401e-08
- O 0 5.815357144456357e-05
type O 0 0.0026495440397411585
mutations O 0 5.300090379023459e-06
, O 0 1.1028104651700232e-08
may O 0 3.465764280008443e-07
cause O 0 5.55384019662597e-07
pathological O 0 0.0001209071560879238
ARSA O 0 0.46906861662864685
and O 0 4.568851363728754e-05
GS O 1 0.9999895095825195
levels O 0 6.288255605113591e-08
, O 0 6.316835943209753e-10
but O 0 9.671752287943036e-10
not O 0 4.123158259261572e-09
clinical O 0 3.747634025330626e-08
outbreak O 0 1.8756075803594285e-08
of O 0 7.619936348568501e-10
the O 0 3.3254419662398504e-08
disease O 0 6.20425680608605e-06
. O 0 2.7652935941091528e-08
. O 0 8.196693102036079e-08

Human O 0 0.0005493435310199857
MLH1 O 1 0.9989936947822571
deficiency O 1 0.9987090826034546
predisposes O 0 0.02185668610036373
to O 0 2.770820356090553e-05
hematological B-Disease 1 0.9697625637054443
malignancy I-Disease 0 0.3064030110836029
and O 0 6.335716989269713e-06
neurofibromatosis B-Disease 1 0.9857126474380493
type I-Disease 0 0.00012429016351234168
1 I-Disease 0 5.147560386831174e-07
. O 0 5.503167130882503e-07

Heterozygous O 0 0.0012170618865638971
germ O 0 5.442346082418226e-05
- O 0 0.00012561977200675756
line O 0 6.700520771119045e-06
mutations O 0 2.726683874243463e-07
in O 0 7.660944656429081e-10
the O 0 1.0782172932266576e-09
DNA O 0 2.492010366950126e-07
mismatch O 0 4.711420842795633e-06
repair O 0 2.311411890332238e-06
genes O 0 7.764870701976179e-08
lead O 0 7.884424348958419e-07
to O 0 9.76489536697045e-06
hereditary B-Disease 1 0.9999955892562866
nonpolyposis I-Disease 1 0.999998927116394
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.32062062525074e-06

The O 0 3.2058137549029198e-06
disease O 0 0.00022092608560342342
susceptibility O 0 0.0001027399703161791
of O 0 8.663954886856118e-09
individuals O 0 1.9394505557102093e-08
who O 0 5.2924333431292325e-06
constitutionally O 0 1.585131394676864e-05
lack O 0 4.593790947637899e-08
both O 0 4.896306027291075e-09
wild O 0 1.5867664515667457e-08
- O 0 9.38153789320495e-06
type O 0 1.2269192666281015e-05
alleles O 0 2.4628366190881934e-07
is O 0 4.253102758866589e-08
unknown O 0 2.21074003547983e-07
. O 0 7.119549394474234e-08

We O 0 3.574163542907627e-07
have O 0 2.793474784823502e-08
identified O 0 2.2461147608510146e-08
three O 0 7.957769998512276e-10
offspring O 0 1.2918811798101615e-08
in O 0 9.634486541898468e-10
a O 0 3.129243850708008e-06
hereditary B-Disease 1 0.9999936819076538
nonpolyposis I-Disease 1 0.9999994039535522
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.2676328778034076e-05
who O 0 8.049742973526008e-06
developed O 0 1.6355522802768974e-06
hematological B-Disease 0 0.0034006210044026375
malignancy I-Disease 0 7.042336164886365e-06
at O 0 5.202860919872876e-10
a O 0 6.192344859101695e-09
very O 0 1.321080134175645e-08
early O 0 4.092704841696104e-08
age O 0 1.3279011668032581e-08
, O 0 2.853952352221967e-10
and O 0 4.3904921365189864e-10
at O 0 1.0209635220581603e-10
least O 0 2.2641391539401923e-10
two O 0 5.540854580710075e-11
of O 0 2.6112509723952293e-11
them O 0 2.8323476897185174e-10
displayed O 0 1.7025239884560506e-08
signs O 0 4.940437037248557e-08
of O 0 2.674483523534832e-09
neurofibromatosis B-Disease 0 0.06535549461841583
type I-Disease 0 8.321600944327656e-06
1 I-Disease 0 6.698743248989558e-08
( O 0 1.982113673193453e-08
NF1 B-Disease 0 3.076409484492615e-05
) O 0 5.786056433976228e-08
. O 0 1.5588628343721211e-07

DNA O 0 5.6645958466106094e-06
sequence O 0 1.914718268380966e-07
analysis O 0 4.8352795545270055e-08
and O 0 5.391261215237364e-09
allele O 0 1.3705398771435284e-07
- O 0 6.565557697513213e-08
specific O 0 4.823320853830637e-09
amplification O 0 3.2169972996598517e-07
in O 0 2.2252317766202623e-09
two O 0 5.720520057650447e-09
siblings O 0 3.010809450643137e-07
revealed O 0 5.616355380766436e-08
a O 0 7.884427333237909e-08
homozygous O 0 2.829213372024242e-05
MLH1 O 0 0.0023735782597213984
mutation O 0 2.036587829934433e-06
( O 0 5.436966432625923e-09
C676T O 0 1.9023283357455512e-06
- O 0 2.071898961730767e-05
- O 0 0.00012282734678592533
> O 0 1.0867510127354763e-06
Arg226Stop O 0 6.5789977270469535e-06
) O 0 2.986928748782702e-08
. O 0 9.236536868684198e-08

Thus O 0 2.876569624277181e-06
, O 0 2.091473838561342e-08
a O 0 5.182473827858303e-08
homozygous O 0 3.2441041639685864e-06
germ O 0 2.8551176001201384e-06
- O 0 7.280405407072976e-05
line O 0 0.0001088333738152869
MLH1 O 0 0.007092948071658611
mutation O 0 2.8553381525853183e-06
and O 0 2.3924137337871798e-08
consequent O 0 2.1401103367679752e-05
mismatch O 0 0.2218170315027237
repair O 1 0.998136043548584
deficiency O 1 0.9885339140892029
results O 0 1.963716869113341e-07
in O 0 9.40325239895401e-09
a O 0 1.7096949704864528e-06
mutator O 1 0.9981960654258728
phenotype O 1 0.9871899485588074
characterized O 0 1.3351590496313293e-05
by O 0 1.0724297681008466e-06
leukemia B-Disease 1 0.7321857213973999
and O 0 4.388744400785072e-06
/ O 0 0.06676028668880463
or O 0 0.05701049417257309
lymphoma B-Disease 1 1.0
associated O 0 3.50710834027268e-05
with O 0 1.0487634654055e-06
neurofibromatosis B-Disease 1 0.9968674778938293
type I-Disease 0 5.4062355047790334e-05
1 I-Disease 0 2.2206791072676424e-08
. O 0 2.1130782457134956e-08
. O 0 1.0655793403202551e-07

Missense O 0 0.045856259763240814
mutations O 0 0.0010181482648476958
in O 0 4.794842567434898e-08
the O 0 1.989707287819442e-09
most O 0 1.0402373407103482e-09
ancient O 0 6.510060823750052e-10
residues O 0 1.917406677875988e-09
of O 0 1.0279314205385859e-10
the O 0 1.5923836693687576e-09
PAX6 O 0 2.04921088879928e-05
paired O 0 2.3675765703501384e-07
domain O 0 3.367414791455303e-08
underlie O 0 1.737680861424451e-07
a O 0 2.7068161045917805e-08
spectrum O 0 3.87335887808149e-07
of O 0 7.875991414607597e-09
human O 0 6.175573616928887e-06
congenital B-Disease 1 0.9999973773956299
eye I-Disease 1 0.9999934434890747
malformations I-Disease 1 0.9999809265136719
. O 0 1.318474460276775e-05

Mutations O 0 0.0003938841400668025
of O 0 4.669319864092358e-08
the O 0 1.4501535972044621e-08
human O 0 1.3090784989344684e-07
PAX6 O 0 0.0031975354067981243
gene O 0 0.0004177022201474756
underlie O 0 0.4843190312385559
aniridia B-Disease 1 0.9999997615814209
( O 0 1.265354785573436e-05
congenital B-Disease 1 0.9999643564224243
absence I-Disease 0 1.92594961845316e-06
of I-Disease 0 2.3305022356368e-09
the I-Disease 0 8.824899921933138e-09
iris I-Disease 0 0.00034315994707867503
) O 0 2.036145918538068e-09
, O 0 9.349150342785606e-10
a O 0 2.734777027058044e-08
rare O 0 1.7768113593774615e-06
dominant O 0 0.008920560590922832
malformation B-Disease 1 0.8267651200294495
of I-Disease 0 6.603155799922433e-09
the I-Disease 0 9.120451949229391e-08
eye I-Disease 0 0.07304245978593826
. O 0 1.500654207120533e-06

The O 0 3.6611035625355726e-07
spectrum O 0 1.110807261284208e-06
of O 0 9.918032617406425e-09
PAX6 O 0 0.00035500648664310575
mutations O 0 6.120179023128003e-05
in O 0 5.041420649831707e-07
aniridia B-Disease 1 0.9999997615814209
patients O 1 0.7930426001548767
is O 0 2.448830471735164e-08
highly O 0 2.5746674126025937e-08
biased O 0 4.503521608967276e-07
, O 0 7.129925538862381e-10
with O 0 5.271957870256472e-10
92 O 0 4.530608777031375e-08
% O 0 2.369202056762276e-10
of O 0 3.8185565820469947e-11
all O 0 5.940834491013902e-10
reported O 0 9.674048584429329e-08
mutations O 0 5.708402994741846e-08
leading O 0 6.011863007415741e-09
to O 0 1.32898554383587e-08
premature O 0 8.782869826973183e-07
truncation O 0 7.856085915136646e-08
of O 0 6.975183208801639e-10
the O 0 1.033365393254826e-09
protein O 0 1.526208315283384e-08
( O 0 3.541457682665339e-10
nonsense O 0 2.637101914615414e-08
, O 0 3.1221736307429637e-10
splicing O 0 1.2467245902314517e-08
, O 0 7.165016358001708e-10
insertions O 0 3.106921653284189e-08
and O 0 3.672525616948974e-09
deletions O 0 4.311929302502904e-08
) O 0 1.0225933433360979e-09
and O 0 2.3591701925340658e-09
just O 0 2.964937850791216e-09
2 O 0 2.934220866279702e-09
% O 0 5.696693672341269e-10
leading O 0 8.719969191162136e-10
to O 0 6.010553166291288e-10
substitution O 0 1.7654613326811841e-09
of O 0 1.826532675108794e-10
one O 0 2.7666533508607927e-09
amino O 0 3.1750098106186897e-09
acid O 0 2.7771438482204758e-08
by O 0 8.328353007236444e-10
another O 0 2.3254060010913236e-08
( O 0 1.4758727573394026e-08
missense O 0 5.01402701047482e-06
) O 0 4.043148749133252e-08
. O 0 1.3742753424139664e-07

The O 0 1.650833070243607e-07
extraordinary O 0 2.2193016491200979e-07
conservation O 0 1.099789948000307e-08
of O 0 1.6967550975355294e-10
the O 0 6.199704638554238e-10
PAX6 O 0 1.1703584732458694e-06
protein O 0 6.812268527056631e-09
at O 0 2.091264383885516e-10
the O 0 2.674828969428944e-10
amino O 0 3.96938704128047e-09
acid O 0 5.737416586271138e-08
level O 0 1.6705298255814682e-09
amongst O 0 2.2954258493967927e-09
vertebrates O 0 5.119885848614558e-09
predicts O 0 8.854814126380006e-08
that O 0 5.343065545559966e-09
pathological O 0 1.226279550792242e-06
missense O 0 3.31715309584979e-05
mutations O 0 9.428018188373244e-07
should O 0 1.2657491055279024e-08
in O 0 1.0901863856105365e-09
fact O 0 3.645155510767495e-09
be O 0 6.7231891165420166e-09
common O 0 1.415479733424263e-09
even O 0 8.074677815272935e-09
though O 0 5.672615266405501e-09
they O 0 1.1622585116555229e-09
are O 0 4.2546560719003423e-10
hardly O 0 1.0952641460448831e-08
ever O 0 1.0097438440936912e-08
seen O 0 7.762811549127946e-08
in O 0 3.456211672414611e-08
aniridia B-Disease 1 0.999997615814209
patients O 0 0.12996956706047058
. O 0 2.52191455274442e-07

This O 0 1.8304413629266492e-07
indicates O 0 5.73143346116467e-08
that O 0 2.4253825614550806e-09
there O 0 8.542458407312381e-10
is O 0 9.211510998419215e-10
a O 0 8.345992341673991e-09
heavy O 0 4.807352070201887e-06
ascertainment O 0 7.55841210775543e-06
bias O 0 8.556930879421998e-06
in O 0 3.6920347334934434e-10
the O 0 1.393172660568709e-10
selection O 0 1.7647207029014567e-09
of O 0 1.1175902425719642e-09
patients O 0 1.6583359183641733e-06
for O 0 4.549605581161131e-09
PAX6 O 0 0.0006299158558249474
mutation O 0 1.3724144309890107e-06
analysis O 0 3.929785385992091e-09
and O 0 1.173015240496511e-09
that O 0 1.6662021762314794e-09
the O 0 2.323835124329321e-09
missing O 0 2.825983926868503e-07
PAX6 O 0 0.0003111594123765826
missense O 0 0.00012031004735035822
mutations O 0 1.0249652405036613e-05
frequently O 0 3.4563743156468263e-06
may O 0 1.7873153410619125e-05
underlie O 0 0.000186088916962035
phenotypes O 0 0.0001502752274973318
distinct O 0 1.457344183108944e-07
from O 0 2.0643572185008452e-08
textbook O 0 0.00017013418255373836
aniridia B-Disease 1 0.9999691247940063
. O 0 2.2256376723817084e-06

Here O 0 8.271495062217582e-07
we O 0 1.3434412693413833e-08
present O 0 5.44242384492577e-09
four O 0 1.0388677473827101e-08
novel O 0 4.487187936774717e-07
PAX6 O 0 0.00017581514839548618
missense O 0 0.00010602711699903011
mutations O 0 5.005016646464355e-06
, O 0 4.09271860846161e-09
two O 0 2.737551962894713e-09
in O 0 2.5986683915846243e-09
association O 0 3.415689731056659e-09
with O 0 5.622108112390833e-09
atypical O 0 0.0007679251721128821
phenotypes O 0 0.01684262976050377
ectopia B-Disease 0 0.0002544446906540543
pupillae I-Disease 0 9.827093163039535e-05
( O 0 2.6900066174562198e-08
displaced B-Disease 0 4.661836214836512e-07
pupils I-Disease 0 2.3351940114935132e-07
) O 0 3.7526266538634445e-08
and O 0 6.442095036618412e-05
congenital B-Disease 1 0.9999980926513672
nystagmus I-Disease 1 0.8744849562644958
( O 0 1.207046906870346e-08
searching B-Disease 0 1.0652765780605478e-07
gaze I-Disease 0 8.959223123383708e-06
) O 0 1.0611933554116604e-09
, O 0 7.368442522803775e-10
and O 0 7.669131996124179e-10
two O 0 5.167248295911975e-10
in O 0 2.1717698750478576e-09
association O 0 1.0798555383217945e-09
with O 0 8.420645292162021e-10
more O 0 2.4285409239155342e-08
recognizable O 0 0.0038146967999637127
aniridia B-Disease 1 0.9999923706054688
phenotypes O 0 0.0007153131882660091
. O 0 3.789063498516043e-07

Strikingly O 0 0.0357675775885582
, O 0 2.0308105774802243e-07
all O 0 3.6101033273894245e-09
four O 0 5.091042254434797e-09
mutations O 0 5.12905664606933e-08
are O 0 8.869528445032415e-10
located O 0 4.261943686856284e-09
within O 0 8.471486845351706e-10
the O 0 3.531254400002126e-09
PAX6 O 0 3.261151505284943e-05
paired O 0 2.27414844289342e-07
domain O 0 1.360034573849589e-08
and O 0 3.1814963996623646e-09
affect O 0 5.653992829479648e-09
amino O 0 2.766537221532417e-09
acids O 0 1.4480827648100103e-09
which O 0 1.0020746454841856e-09
are O 0 2.1273433015167598e-10
highly O 0 1.5082224358309304e-09
conserved O 0 2.6847359890780353e-09
in O 0 3.108258095352312e-10
all O 0 1.3159735801071548e-10
known O 0 3.4056517606018133e-09
paired O 0 3.364423051266385e-08
domain O 0 2.856721792454664e-08
proteins O 0 1.371899305269153e-08
. O 0 4.240021667101246e-08

Our O 0 1.0769043683467316e-06
results O 0 1.657480623862284e-07
support O 0 4.4310102254030426e-09
the O 0 7.775207144788965e-10
hypothesis O 0 2.644556573727641e-08
that O 0 4.42402420253174e-10
the O 0 2.642869534330572e-10
under O 0 6.312852462997398e-09
- O 0 1.0523537241624581e-07
representation O 0 2.6040233080948383e-08
of O 0 1.1587323323070109e-09
missense O 0 1.3156096429156605e-05
mutations O 0 2.614784477827925e-07
is O 0 3.846645668659221e-09
caused O 0 4.8886846570894704e-08
by O 0 4.1250620697041995e-09
ascertainment O 0 6.346275768009946e-06
bias O 0 0.0006529786041937768
and O 0 2.8545104058252946e-08
suggest O 0 8.540035345561137e-09
that O 0 6.381868367100196e-10
a O 0 4.269933739919907e-09
substantial O 0 3.188538855170009e-08
burden O 0 1.2576483641169034e-06
of O 0 3.895984423962773e-09
PAX6 B-Disease 0 0.0017097831005230546
- I-Disease 0 0.0027013288345187902
related I-Disease 0 4.483565589907812e-06
disease I-Disease 0 1.1086545782745816e-05
remains O 0 3.719626420206623e-07
to O 0 4.939407105553073e-09
be O 0 8.37146973964309e-09
uncovered O 0 6.12143011835542e-08
. O 0 1.0853817400402477e-08
. O 0 4.6362181649328704e-08

The O 0 3.0352512681020016e-07
chromosomal O 0 8.257487024820875e-06
order O 0 1.6402957214722846e-08
of O 0 9.457478133967356e-10
genes O 0 1.6742149000492645e-08
controlling O 0 9.579852644492348e-08
the O 0 1.1302767610743558e-09
major O 0 4.46312364843493e-09
histocompatibility O 0 9.172682098324003e-07
complex O 0 4.924349639168213e-08
, O 0 3.360765665760823e-09
properdin O 0 5.926296466896019e-07
factor O 0 5.5186511360716395e-08
B O 0 2.3539983828868571e-07
, O 0 7.895875953067844e-09
and O 0 7.545934863628645e-07
deficiency B-Disease 0 2.814155095620663e-06
of I-Disease 0 4.907221504146797e-11
the I-Disease 0 2.0484659801756067e-10
second I-Disease 0 4.585087420849732e-09
component I-Disease 0 2.9152540381716108e-09
of I-Disease 0 3.906273082776579e-10
complement I-Disease 0 5.464936236876383e-08
. O 0 5.903373079263474e-08

The O 0 8.740141765883891e-08
relationship O 0 1.9773519710497567e-08
of O 0 3.5470279491356393e-10
the O 0 5.124611845985783e-10
genes O 0 3.0364537551008652e-09
coding O 0 2.756899064593199e-08
for O 0 2.010260402585118e-09
HLA O 0 3.8835449345242523e-07
to O 0 1.2700633433837538e-08
those O 0 8.511556459644964e-10
coding O 0 1.3757538219749677e-08
for O 0 8.387527894448965e-10
properdin O 0 3.3064938520510623e-07
Factor O 0 1.6397358137965057e-08
B O 0 9.667186873230094e-08
allotypes O 0 7.979600695762201e-07
and O 0 2.1221742585453285e-08
for O 0 1.561376450354146e-08
deficiency B-Disease 0 1.1773372534662485e-06
of I-Disease 0 1.5580489676203513e-10
the I-Disease 0 3.729511144356934e-10
second I-Disease 0 4.4139709665103055e-09
component I-Disease 0 4.028775091313719e-09
of I-Disease 0 3.2650773751363715e-10
complement I-Disease 0 1.820267669927489e-08
( O 0 3.4657221537059968e-09
C2 O 0 5.651526180372457e-07
) O 0 1.1311652725609633e-09
was O 0 4.4999321602290365e-08
studied O 0 3.4647307245450065e-09
in O 0 7.813324987004933e-10
families O 0 1.011995376387631e-09
of O 0 1.187841047745053e-09
patients O 0 1.2380499356368091e-05
with O 0 2.519779798149102e-07
connective O 1 0.9955002665519714
tissue O 1 0.9999136924743652
disorders O 1 0.9993662238121033
. O 0 1.7236762914762949e-06

Patients O 1 0.9255199432373047
were O 0 1.7546199160278775e-07
selected O 0 8.09948108582148e-09
because O 0 1.3189948022684916e-09
they O 0 1.192890564105653e-09
were O 0 5.299422678461951e-09
heterozygous O 0 2.9127389211680565e-07
or O 0 5.881005460395272e-09
homozygous O 0 1.8805543732014485e-05
for O 0 3.3266751415794715e-05
C2 B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999988079071045
. O 0 3.941918294003699e-06

12 O 0 1.4853835637040902e-06
families O 0 4.019397792376367e-08
with O 0 3.1138849276857172e-09
15 O 0 2.0216583962451296e-08
matings O 0 8.367508598894347e-06
informative O 0 2.995592012666748e-06
for O 0 0.00013828124792780727
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999990463256836
were O 0 1.3146022865839768e-06
found O 0 3.481064823063207e-07
. O 0 1.4523824631851312e-07

Of O 0 6.158813334877777e-07
57 O 0 1.7475072127126623e-06
informative O 0 2.473494760124595e-07
meioses O 0 1.4589894590244512e-06
, O 0 1.7584006473114755e-09
two O 0 3.6316627483046204e-10
crossovers O 0 2.8199522716931824e-08
were O 0 4.884013193873216e-09
noted O 0 9.842821668826218e-09
between O 0 3.5142080356820316e-09
the O 0 2.602321001177188e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999953508377075
gene O 0 6.050713352578896e-08
and O 0 3.0339355472364105e-09
the O 0 4.048463786432421e-09
HLA O 0 0.0001410761324223131
- O 0 0.0006505451165139675
B O 0 1.3146789115126012e-06
gene O 0 1.0190697175005425e-08
, O 0 1.7824321185688774e-10
with O 0 8.284906094502276e-11
a O 0 1.6979506689551727e-09
recombinant O 0 3.3152318668072667e-09
fraction O 0 1.1303440849985691e-08
of O 0 1.1704048841210124e-09
0 O 0 2.263377609779127e-07
. O 0 2.0671434697305813e-07

035 O 0 0.030871177092194557
. O 0 0.00010518876661080867

A O 0 6.556374046340352e-06
lod O 0 0.0002767818223219365
score O 0 9.256201138896358e-08
of O 0 1.163032448125989e-09
13 O 0 7.046446093283976e-09
was O 0 2.5313980245300627e-08
calculated O 0 1.9675065132673808e-08
for O 0 1.5271800490879173e-09
linkage O 0 9.696615052234847e-06
between O 0 0.00033588253427296877
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
and O 0 3.8564002124985564e-07
HLA O 0 1.441998392692767e-05
- O 0 3.912618922186084e-06
B O 0 1.278029628792865e-07
at O 0 1.9655203853385927e-10
a O 0 1.5105861006503574e-09
maximum O 0 1.381170111613983e-08
likelihood O 0 2.3348269984069248e-09
value O 0 9.116665061759122e-11
of O 0 1.1197313042055068e-11
the O 0 6.349810954819901e-11
recombinant O 0 3.2062903443375035e-09
fraction O 0 1.0689539919894742e-08
of O 0 9.83178316538158e-10
0 O 0 1.0698948216258941e-07
. O 0 6.234680682837279e-08

04 O 0 0.0031455126591026783
. O 0 1.357561177428579e-05

18 O 0 8.45565227791667e-06
families O 0 2.2636409369169996e-07
with O 0 5.943296521593311e-09
21 O 0 3.7067149349923056e-08
informative O 0 5.878272091308645e-08
matings O 0 1.319292096013669e-06
for O 0 6.421873699480329e-09
both O 0 5.039817008167802e-09
properdin O 0 5.299137910697027e-07
Factor O 0 4.187012336842599e-08
B O 0 1.1370596553206269e-07
allotype O 0 1.1869559557453613e-06
and O 0 6.983389511105997e-08
HLA O 0 1.4365012248163112e-05
- O 0 7.540717342635617e-05
B O 0 3.473547621979378e-06
were O 0 4.313270096645283e-08
found O 0 3.294444539392316e-08
. O 0 5.304583439169619e-08

Of O 0 7.6389619607653e-07
72 O 0 2.240183903268189e-06
informative O 0 7.742582397440856e-07
meioses O 0 4.9834029596240725e-06
, O 0 1.930578186204457e-08
three O 0 3.279208904416464e-09
recombinants O 0 8.815681553642207e-07
were O 0 2.2699095936218328e-08
found O 0 3.827200778516726e-09
, O 0 6.404867192166819e-10
giving O 0 6.736586843913983e-10
a O 0 1.2254677272949266e-09
recombinant O 0 5.054285434624717e-09
fraction O 0 1.0778681946987945e-08
of O 0 1.0817664541917793e-09
0 O 0 2.491615873623232e-07
. O 0 2.1005973849241855e-07

042 O 0 0.003006444778293371
. O 0 6.265096453716978e-05

A O 0 3.921658844774356e-06
lod O 0 0.00020315946312621236
score O 0 1.1146703826625526e-07
of O 0 1.4985162000158425e-09
16 O 0 7.012725511401641e-09
between O 0 2.0116797116997986e-09
HLA O 0 8.760428499954287e-06
- O 0 1.7988939362112433e-05
B O 0 1.473049877631638e-07
and O 0 2.71734656998035e-09
Factor O 0 6.145082220854192e-09
B O 0 2.0449975934866416e-08
allotypes O 0 7.381981959042605e-08
was O 0 8.7131732939838e-09
calculated O 0 4.490558591641047e-09
at O 0 1.2816869787712903e-10
a O 0 2.613779859217402e-09
maximum O 0 2.2195614235442918e-08
likelihood O 0 4.609991499648913e-09
value O 0 2.1419639673059265e-10
of O 0 1.9074027080012712e-11
the O 0 1.235196389615112e-10
recombinant O 0 4.544506104764423e-09
fraction O 0 2.0991230087474833e-08
of O 0 2.69381494888421e-09
0 O 0 1.4643265444647113e-07
. O 0 9.494157637846001e-08

04 O 0 0.009330658242106438
. O 0 1.5347548469435424e-05

A O 0 1.340747985523194e-06
crossover O 0 9.927856581271044e-07
was O 0 2.976993016545748e-07
shown O 0 1.4451172702933945e-08
to O 0 1.1838737767888574e-09
have O 0 1.9055792499500512e-09
occurred O 0 1.7465645596459467e-09
between O 0 1.1197531790685389e-10
genes O 0 1.4040493212519323e-09
for O 0 7.08962277773395e-10
Factor O 0 1.3020035716237999e-08
B O 0 9.76404805896891e-08
and O 0 2.67385225072303e-08
HLA O 0 1.0211426342721097e-05
- O 0 0.00017928403394762427
D O 0 3.0941388104110956e-05
, O 0 1.7932016982413757e-09
in O 0 8.938530471347406e-10
which O 0 4.124615671230458e-08
HLA O 0 5.3144965932006016e-05
- O 0 0.0009129028185270727
D O 0 4.333787728683092e-05
segregared O 0 8.879148367668677e-07
with O 0 5.319392926139699e-09
HLA O 0 1.6459297285109642e-06
- O 0 7.040443392725138e-07
A O 0 3.328431432692014e-07
and O 0 1.8758281328246085e-07
B O 0 1.4556788983099977e-06
. O 0 1.282136281588464e-07

These O 0 2.0675398104685883e-07
studies O 0 3.3379674135858295e-08
suggest O 0 1.0225119417839323e-08
that O 0 2.924977204887824e-10
the O 0 9.54970130750965e-11
genes O 0 6.719339529226431e-10
for O 0 3.835595729917429e-10
Factor O 0 2.2082151218683066e-08
B O 0 1.6240372133324854e-05
and O 0 0.10552896559238434
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999982118606567
are O 0 3.514456059505733e-09
located O 0 2.155132072800825e-09
outside O 0 2.764374507080447e-09
those O 0 4.020282995398361e-10
for O 0 1.1679407441178569e-09
HLA O 0 3.1114548164623557e-06
, O 0 3.2355820245300038e-09
that O 0 4.081381899112557e-10
the O 0 1.1694069323997525e-10
order O 0 4.457438029792371e-10
of O 0 3.944524429311258e-10
genese O 0 1.3088354080537101e-06
is O 0 3.573399354195317e-08
HLA O 0 1.8561656816018512e-06
- O 0 6.647817372140707e-07
A O 0 3.7158116583668743e-07
, O 0 9.714205440047863e-09
- O 0 3.6473207387643924e-07
B O 0 2.7451906703390705e-07
, O 0 2.7956479353719033e-09
- O 0 7.200216600722342e-07
D O 0 3.1675949685450178e-06
, O 0 1.8512535948644882e-09
Factor O 0 7.322995099201535e-09
B O 0 2.3997037601475313e-07
allotype O 0 0.00038700358709320426
, O 0 0.0005972838262096047
C2 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999977350234985
, O 0 6.074470926265008e-10
that O 0 1.0833744318317073e-10
the O 0 1.3648744634497945e-10
genes O 0 5.641152878155253e-09
coding O 0 6.02040358899103e-07
for O 0 6.817496796429623e-06
C2 B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999934434890747
and O 0 1.3866948478380436e-08
Factor O 0 2.514286734367488e-08
B O 0 1.0381550907823112e-07
allotypes O 0 2.840851038854453e-07
are O 0 1.1998159132886599e-09
approximately O 0 4.795935315549116e-10
3 O 0 1.8557362313487147e-09
- O 0 2.3375244495582592e-07
- O 0 2.245105406473158e-06
5 O 0 5.779512868286929e-09
centimorgans O 0 8.94969502951426e-08
from O 0 2.687209066376539e-10
the O 0 4.560115618446048e-10
HLA O 0 8.116106187117111e-07
- O 0 6.184145036058908e-07
A O 0 4.800873512067483e-07
and O 0 5.1806647860530575e-08
HLA O 0 4.840926521865185e-06
- O 0 9.344179488834925e-06
B O 0 3.0102583536972816e-07
loci O 0 8.436290777069644e-09
, O 0 3.4425104433744025e-10
and O 0 2.1432104702068244e-10
that O 0 4.196162306513429e-10
the O 0 4.738207604049194e-10
apparent O 0 4.3729210119636264e-07
lack O 0 7.068967189383102e-09
of O 0 2.2361226759137764e-10
recombinants O 0 1.273952960900715e-07
between O 0 3.6743874609612703e-10
the O 0 7.000547364022225e-10
Factor O 0 2.168170176730655e-08
B O 0 3.911780197540793e-07
gene O 0 8.718827189113654e-07
and O 0 0.049108829349279404
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
gene O 0 5.731159831157129e-07
suggests O 0 5.2843258657730985e-08
that O 0 1.3436635137864528e-09
these O 0 2.1725642118664013e-10
two O 0 3.7657299500892805e-10
genes O 0 4.431821576389439e-09
lie O 0 4.072979464808668e-08
in O 0 7.693071180092659e-10
close O 0 2.2799664378680973e-09
proximity O 0 1.0664532368309665e-08
to O 0 7.1673156298857066e-09
one O 0 6.375059147245565e-09
another O 0 4.519940688396673e-08
. O 0 5.061881225287834e-08

Distribution O 0 4.352293103693228e-07
of O 0 1.100062707592997e-08
emerin O 0 2.374550831518718e-06
and O 0 1.9846556398306348e-08
lamins O 0 2.215109361713985e-06
in O 0 1.1654395226656789e-09
the O 0 1.73836556260909e-09
heart O 0 9.720341722641024e-07
and O 0 3.645211243963331e-09
implications O 0 1.9568478393239275e-08
for O 0 1.2556114370454452e-08
Emery B-Disease 0 0.46554210782051086
- I-Disease 1 0.9985519051551819
Dreifuss I-Disease 1 0.9999796152114868
muscular I-Disease 1 0.9999268054962158
dystrophy I-Disease 1 0.999886155128479
. O 0 3.633666665336932e-06

Emerin O 0 0.00058599968906492
is O 0 4.022661812541628e-07
a O 0 5.20817842186716e-08
nuclear O 0 6.440840394361658e-08
membrane O 0 1.0509456416230023e-07
protein O 0 4.5837872164611326e-08
which O 0 4.504927986204166e-09
is O 0 2.800461862406678e-09
missing O 0 1.1719691883627092e-08
or O 0 1.904954416431792e-09
defective O 0 4.983003691449994e-06
in O 0 1.0967696795205484e-07
Emery B-Disease 1 0.9941481351852417
- I-Disease 1 0.999932050704956
Dreifuss I-Disease 1 0.9999984502792358
muscular I-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.9999977350234985
( O 0 2.7364471861801576e-06
EDMD B-Disease 1 0.9999914169311523
) O 0 2.138639700888234e-07
. O 0 2.038432569406723e-07

It O 0 8.353272846761683e-07
is O 0 2.382823005575574e-08
one O 0 1.6486507714574827e-09
member O 0 3.7837291633202597e-10
of O 0 6.233744076489245e-11
a O 0 6.182337752846934e-09
family O 0 1.6095823340833704e-08
of O 0 4.122645280713044e-10
lamina O 0 3.468406930551282e-06
- O 0 2.0464003682718612e-05
associated O 0 2.3730079234951518e-08
proteins O 0 6.928959628282882e-10
which O 0 3.4989520170114474e-09
includes O 0 4.5492409839198444e-09
LAP1 O 0 7.271982667589327e-06
, O 0 1.0674503947427638e-08
LAP2 O 0 1.1012993127224036e-05
and O 0 2.0170601544577949e-07
lamin O 0 0.0022561484947800636
B O 0 3.125313378404826e-05
receptor O 0 3.6788767374673625e-06
( O 0 8.906306447897805e-08
LBR O 0 0.00016066159878391773
) O 0 8.496836301219446e-08
. O 0 2.074907570204232e-07

A O 0 1.7662489426584216e-06
panel O 0 2.1473171329944307e-07
of O 0 4.001420084165375e-09
16 O 0 6.231874749573763e-08
monoclonal O 0 2.6422155769978417e-06
antibodies O 0 1.3989916851642192e-06
( O 0 9.051492000367034e-09
mAbs O 0 2.412346589153458e-07
) O 0 1.3921294117480443e-09
has O 0 1.0116078641431159e-08
been O 0 3.063048703566551e-09
mapped O 0 3.295185990737082e-08
to O 0 1.2528598158922932e-09
six O 0 3.156158112638252e-10
specific O 0 1.2919906811070803e-10
sites O 0 3.4743044552421054e-10
throughout O 0 1.4757334243498121e-10
the O 0 2.0086267371599575e-10
emerin O 0 9.727298078132662e-08
molecule O 0 8.660748562761e-09
using O 0 4.86584417203062e-09
phage O 0 1.4115676094661467e-07
- O 0 1.9609657897490251e-07
displayed O 0 3.330177023030956e-08
peptide O 0 4.1278402918010215e-09
libraries O 0 3.648930602118128e-10
and O 0 3.0947583384843824e-10
has O 0 2.5726241137391526e-09
been O 0 2.17023754522927e-09
used O 0 2.912125207643612e-09
to O 0 2.7193272078562813e-09
localize O 0 6.074720317883475e-07
emerin O 0 3.521756298141554e-06
in O 0 3.607886656098458e-09
human O 0 8.486887637104701e-09
and O 0 9.798487354828467e-08
rabbit O 0 7.608803571201861e-05
heart O 0 0.00029770206310786307
. O 0 4.384337444207631e-07

Several O 0 1.1873884204760543e-06
mAbs O 0 1.0841240509762429e-05
against O 0 4.596060421135917e-08
different O 0 5.267337233050284e-09
emerin O 0 2.131424707840779e-06
epitopes O 0 6.154941729619168e-06
did O 0 1.5251468710175686e-07
not O 0 4.619726823307246e-09
recognize O 0 1.0861729293765165e-08
intercalated O 0 3.832688832972053e-08
discs O 0 9.743860118760495e-07
in O 0 1.801738314100021e-09
the O 0 2.1326909127594718e-09
heart O 0 2.9447401175275445e-06
, O 0 5.366228794656536e-09
though O 0 5.619888554520003e-09
they O 0 1.3024796796656801e-09
recognized O 0 2.5126507541273213e-09
cardiomyocyte O 0 1.300046221786033e-07
nuclei O 0 3.64537982022739e-08
strongly O 0 4.8497803106783977e-08
, O 0 7.676097535380677e-10
both O 0 3.868776410342889e-10
at O 0 1.7556349429792562e-10
the O 0 4.572631162602647e-10
rim O 0 3.979608109716537e-08
and O 0 4.545823717450048e-09
in O 0 1.1420414613994012e-09
intranuclear O 0 6.804868917242857e-07
spots O 0 5.570204208993346e-08
or O 0 9.636770492704727e-09
channels O 0 2.0024458535772283e-07
. O 0 1.1731348337207237e-07

A O 0 1.2130602044635452e-05
polyclonal O 0 0.00010837418813025579
rabbit O 0 1.7952537746168673e-05
antiserum O 0 1.4243836631067097e-05
against O 0 1.773569806573505e-07
emerin O 0 7.086869572958676e-06
did O 0 1.6155438231635344e-07
recognize O 0 2.2921810227671813e-08
both O 0 2.6781077355764182e-09
nuclear O 0 1.2099812707333513e-08
membrane O 0 3.640626999867891e-08
and O 0 8.231423542781613e-09
intercalated O 0 5.923132917473595e-08
discs O 0 1.3098717772663804e-06
but O 0 1.2073025246195357e-08
, O 0 3.186730046511599e-10
after O 0 4.87001994287084e-10
affinity O 0 2.1760946378179824e-09
purification O 0 3.766478684497088e-09
against O 0 9.636544895386123e-10
a O 0 8.250127692122078e-09
pure O 0 1.2474381527738387e-08
- O 0 5.866007199983869e-07
emerin O 0 1.5596403954987181e-06
band O 0 3.0663763084248785e-08
on O 0 3.1955145196604917e-09
a O 0 1.6613316944358303e-08
western O 0 5.031578709235873e-08
blot O 0 0.00010320421279175207
, O 0 8.540832929782027e-09
it O 0 8.048475663713361e-09
stained O 0 2.7749417768063722e-06
only O 0 6.5487584244294794e-09
the O 0 2.1247976711435967e-09
nuclear O 0 1.0919166726353069e-07
membrane O 0 1.2653213161684107e-06
. O 0 1.742772610668908e-07

These O 0 6.911739660608873e-07
results O 0 8.08013425057652e-08
would O 0 7.368615051461802e-09
not O 0 1.503222324394926e-09
be O 0 1.1213781014873803e-09
expected O 0 1.6285058634935012e-08
if O 0 3.453468622183209e-09
immunostaining O 0 1.5425744948061038e-07
at O 0 3.361341205376789e-10
intercalated O 0 8.516139793357524e-09
discs O 0 5.31364662492706e-07
were O 0 1.4915078949684357e-08
due O 0 1.2031641238863244e-09
to O 0 9.162027803100159e-10
a O 0 3.524579073044265e-09
product O 0 1.8931172185432388e-09
of O 0 8.030374282208541e-11
the O 0 1.878777966535239e-10
emerin O 0 1.8232738341339427e-07
gene O 0 8.452219368848546e-09
and O 0 3.0008491247457414e-09
, O 0 1.5431468325388664e-09
therefore O 0 4.7901322908217026e-09
, O 0 6.639410132791568e-10
cast O 0 6.143760344912153e-08
some O 0 1.2694330031592926e-09
doubt O 0 1.3533273168775395e-08
upon O 0 5.472232111891628e-10
the O 0 4.1945699691403604e-10
hypothesis O 0 5.586344897778872e-08
that O 0 3.1612525930313495e-08
cardiac B-Disease 1 0.5168914794921875
defects I-Disease 1 0.9636731147766113
in O 0 4.212059820929426e-07
EDMD B-Disease 1 0.9999997615814209
are O 0 1.6255614809779217e-07
caused O 0 2.700849961456697e-07
by O 0 3.711594587230138e-09
absence O 0 2.4933218156775183e-08
of O 0 1.2499811186117427e-09
emerin O 0 4.375567641545786e-06
from O 0 7.202549223706001e-09
intercalated O 0 1.0278989748258027e-06
discs O 0 1.6899868569453247e-05
. O 0 4.2976918734893843e-07

Although O 0 8.641769454698078e-06
emerin O 0 2.1530358935706317e-05
was O 0 2.1272202843647392e-07
abundant O 0 7.917019040348805e-09
in O 0 8.691226627277615e-10
the O 0 6.843194344519077e-10
membranes O 0 2.5102808720589564e-08
of O 0 9.916892862449345e-10
cardiomyocyte O 0 9.82925826065184e-07
nuclei O 0 6.317661416233022e-08
, O 0 8.963302322584354e-10
it O 0 2.511007402006271e-09
was O 0 2.3929985104587104e-07
absent O 0 1.62384719004649e-08
from O 0 4.638522344002638e-10
many O 0 5.93668836312844e-10
non O 0 3.1902587238619162e-09
- O 0 7.69774430864345e-07
myocyte O 0 2.574423524492886e-05
cells O 0 4.854555868405441e-08
in O 0 1.3435610402012799e-09
the O 0 7.901059362325213e-09
heart O 0 1.3246462913230062e-05
. O 0 2.5251009105886624e-07

This O 0 1.7374225080857286e-07
distribution O 0 6.982934674937269e-09
of O 0 6.133661911711386e-10
emerin O 0 6.591932901756081e-07
was O 0 1.3649440688823233e-07
similar O 0 1.7725738654661427e-09
to O 0 1.3752521343946e-09
that O 0 1.242830172110132e-09
of O 0 3.471270770827317e-10
lamin O 0 6.268679499044083e-06
A O 0 2.9090463726788585e-07
, O 0 1.1480802974972448e-09
a O 0 4.3218819634205374e-09
candidate O 0 1.9574637022401475e-08
gene O 0 3.0966731401349534e-09
for O 0 4.0021735925321877e-10
an O 0 8.880315149895068e-09
autosomal O 0 0.00013262218271847814
form O 0 2.6968783117808925e-07
of O 0 7.595927797865443e-08
EDMD B-Disease 1 0.9999972581863403
. O 0 3.1868416954239365e-06

In O 0 1.0321780337108066e-06
contrast O 0 5.829718247696292e-06
, O 0 2.757467711944628e-07
lamin O 0 0.00015503512986470014
B1 O 0 0.00021298235515132546
was O 0 1.7569585679666488e-06
absent O 0 7.30993647835021e-08
from O 0 1.5723496948893967e-09
cardiomyocyte O 0 4.4265610199545335e-07
nuclei O 0 7.990370676225211e-08
, O 0 2.550939237622174e-09
showing O 0 5.253864188148327e-08
that O 0 2.638037521762726e-08
lamin O 0 0.0006268029101192951
B1 O 0 4.0607039409223944e-05
is O 0 6.382882222766284e-09
not O 0 1.29263222348186e-09
essential O 0 3.297748185637772e-10
for O 0 1.0599063293703637e-10
localization O 0 1.0811997519510896e-08
of O 0 6.060629775817006e-10
emerin O 0 3.8762891563237645e-07
to O 0 1.0283325302395951e-08
the O 0 4.359186345226362e-09
nuclear O 0 4.101082140550716e-07
lamina O 0 1.3512889381672721e-05
. O 0 5.893224965802801e-07

Lamin O 1 0.9580602645874023
B1 O 1 0.9321834444999695
is O 0 1.9364565559953917e-06
also O 0 7.027765036582423e-08
almost O 0 7.784263900134647e-09
completely O 0 7.43205035291794e-08
absent O 0 1.775526214942147e-07
from O 0 7.1921300026644985e-09
skeletal O 0 0.0004195518558844924
muscle O 0 0.0004456876195035875
nuclei O 0 1.7280530300922692e-05
. O 0 5.310323558660457e-07

In O 0 4.16704961025971e-06
EDMD B-Disease 1 0.9992437362670898
, O 0 1.3746102922596037e-08
the O 0 4.136239684093823e-10
additional O 0 2.1844908104640126e-09
absence O 0 1.7092983028987874e-08
of O 0 3.921855284971798e-09
lamin O 0 0.004615211393684149
B1 O 0 0.00028471631230786443
from O 0 1.1562646839990975e-08
heart O 0 3.7939623780403053e-06
and O 0 4.338965098327208e-08
skeletal O 0 0.00024878900148905814
muscle O 0 1.563381010782905e-05
nuclei O 0 4.4022362999385223e-07
which O 0 1.0278387208018103e-07
already O 0 2.968748731291271e-07
lack O 0 4.110738061058328e-08
emerin O 0 0.0001270872598979622
may O 0 7.510038813052233e-07
offer O 0 5.605415243081779e-09
an O 0 6.558354970209734e-10
alternative O 0 4.778370144009614e-09
explanation O 0 3.926324154690519e-09
of O 0 4.546391388360327e-11
why O 0 3.0208855417157565e-09
these O 0 3.342225940450305e-10
tissues O 0 7.467727769494559e-09
are O 0 4.984264112550818e-10
particularly O 0 1.4197147457650772e-08
affected O 0 3.553850902449085e-08
. O 0 1.2139364180541179e-08
. O 0 9.492275410138973e-08

Genetic O 0 4.557072315947153e-05
mapping O 0 7.147768315007852e-07
of O 0 5.243170342339454e-09
the O 0 7.560410963947106e-09
copper B-Disease 0 1.2164023246441502e-06
toxicosis I-Disease 0 1.3142040188540705e-05
locus O 0 3.86598543400396e-07
in O 0 1.217774503459168e-08
Bedlington O 0 1.6045944448705995e-06
terriers O 0 4.2632387931007543e-07
to O 0 2.5746086151912095e-08
dog O 0 4.9946697799896356e-06
chromosome O 0 2.7693160973285558e-06
10 O 0 3.3273757082952216e-09
, O 0 4.169078138271942e-10
in O 0 3.092834599538463e-10
a O 0 2.0363644992471563e-08
region O 0 1.822636797044197e-08
syntenic O 0 3.0841015359328594e-06
to O 0 1.688798079158005e-08
human O 0 2.4639213336286048e-08
chromosome O 0 5.909213086852105e-06
region O 0 9.890984387084245e-08
2p13 O 0 5.898752078792313e-06
- O 0 1.0705152817536145e-05
p16 O 0 1.0453501090523787e-05
. O 0 1.9180409083219274e-07

Abnormal O 1 0.8307910561561584
hepatic B-Disease 1 0.9941129088401794
copper I-Disease 0 6.371408380800858e-05
accumulation I-Disease 0 8.432302820438053e-07
is O 0 1.571361174512731e-08
recognized O 0 6.219000869833735e-09
as O 0 1.174217967303548e-08
an O 0 1.341862116532866e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
in O 0 2.603353834729205e-07
man O 0 0.00021070234652142972
, O 0 6.63589405647258e-09
mouse O 0 3.1146529977377213e-07
, O 0 3.6858589513855122e-09
rat O 0 2.2054596229281742e-06
and O 0 4.3664780235985745e-08
dog O 0 1.111292567657074e-05
. O 0 2.0220061003328738e-07

The O 0 1.7223702286628395e-07
major O 0 7.379729538570245e-08
cause O 0 5.53608799691574e-07
of O 0 1.5217842985748575e-08
hepatic B-Disease 0 0.002873521065339446
copper I-Disease 0 3.748943709069863e-05
accumulation I-Disease 0 1.8425961911816557e-07
in O 0 2.8850737354702005e-09
man O 0 7.690216534683714e-07
is O 0 3.5258163055829073e-09
a O 0 3.3040155500430046e-08
dysfunctional O 0 1.4318565035864594e-06
ATP7B O 0 2.705213955778163e-05
gene O 0 5.865727530363074e-07
, O 0 4.935096953317952e-08
causing O 0 9.276998753193766e-06
Wilson B-Disease 0 0.011190792545676231
disease I-Disease 0 0.001264146063476801
( O 0 1.229749102549249e-07
WD B-Disease 0 0.0025209684390574694
) O 0 2.184092409152072e-07
. O 0 3.4051996067319124e-07

Mutations O 0 0.00046815734822303057
in O 0 7.620278097419941e-08
the O 0 1.0581460152536692e-08
ATP7B O 0 2.888558128688601e-06
genes O 0 3.3760713336050685e-08
have O 0 1.9200863121682232e-08
also O 0 2.7302686333996462e-08
been O 0 3.587740948773899e-08
demonstrated O 0 4.19765555648155e-08
in O 0 2.142970467744476e-09
mouse O 0 9.249350796380895e-07
and O 0 2.541669914535305e-07
rat O 0 0.00020887012942694128
. O 0 5.570299208557117e-07

The O 0 5.856142024640576e-07
ATP7B O 0 9.446916010347195e-06
gene O 0 5.415342911874177e-07
has O 0 7.549218139502045e-08
been O 0 6.85655043852762e-09
excluded O 0 5.96806026820218e-09
in O 0 3.5799449515927506e-10
the O 0 4.1140593709521056e-10
much O 0 2.0110054066435623e-08
rarer O 0 2.800960601234692e-06
human O 0 7.326951845243457e-08
copper B-Disease 0 5.775487807113677e-05
overload I-Disease 0 0.09880082309246063
disease O 0 3.5582543205237016e-05
non B-Disease 0 8.138942320101705e-08
- I-Disease 0 4.046407866553636e-06
Indian I-Disease 0 3.940626243092993e-07
childhood I-Disease 0 4.583137069857912e-06
cirrhosis I-Disease 0 6.317814404610544e-05
, O 0 1.5663220054307203e-08
indicating O 0 1.8762129627702961e-07
genetic O 0 1.256806854144088e-06
heterogeneity O 0 6.147928797872737e-05
. O 0 1.208617845804838e-06

By O 0 3.0904530490261095e-07
investigating O 0 1.4403421744191292e-07
the O 0 1.0492307467302453e-08
common O 0 2.5999392505582364e-07
autosomal O 1 0.638500988483429
recessive O 1 0.998439371585846
copper B-Disease 0 0.45120546221733093
toxicosis I-Disease 0 0.12551583349704742
( O 0 6.326741441853301e-08
CT B-Disease 0 5.842137397849001e-05
) O 0 4.07687128500811e-09
in O 0 2.064434845294727e-09
Bedlington O 0 1.3024131249039783e-06
terriers O 0 6.546962936226919e-07
, O 0 1.231179602712018e-09
we O 0 4.2051598314607475e-10
have O 0 6.096710358782786e-10
identified O 0 2.278110367015529e-09
a O 0 6.344729186480436e-10
new O 0 1.8269169510531924e-09
locus O 0 4.8158771193129724e-08
involved O 0 5.609361419800507e-09
in O 0 2.0371569320332128e-08
progressive O 1 0.9989538192749023
liver B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
. O 0 6.009108346916037e-06

We O 0 7.821054168744013e-07
examined O 0 6.733367854394601e-07
whether O 0 2.7843890748613376e-08
the O 0 5.963554539079041e-09
WD B-Disease 0 3.659418143797666e-05
gene O 0 6.844518338766648e-07
ATP7B O 0 1.4213928807293996e-05
was O 0 6.441252367039851e-07
also O 0 1.3665247600158636e-08
causative O 0 4.575541012741269e-08
for O 0 2.553767641799709e-09
CT B-Disease 0 3.7841735320398584e-05
by O 0 1.6440284689167584e-09
investigating O 0 6.961178744546714e-09
the O 0 2.43021247570141e-09
chromosomal O 0 1.7205235053552315e-05
co O 0 4.064632321387762e-06
- O 0 7.962451604726084e-07
localization O 0 2.5078838916670065e-07
of O 0 1.386582959561622e-09
ATP7B O 0 6.184809535625391e-06
and O 0 1.7890483761107134e-08
C04107 O 0 1.2232945323376043e-07
, O 0 3.755472877120525e-10
using O 0 8.902714676572998e-10
fluorescence O 0 5.2961315333277525e-08
in O 0 2.0186290417001373e-09
situ O 0 1.6231805943789368e-07
hybridization O 0 4.426738087204285e-08
( O 0 2.3265229742719384e-09
FISH O 0 2.5456039054461144e-08
) O 0 9.447585824773341e-09
. O 0 3.9705252419253156e-08

C04107 O 0 0.00018663548689801246
is O 0 2.2802552734901838e-07
an O 0 1.4575185502962995e-08
anonymous O 0 6.134603580676412e-08
microsatellite O 0 4.127085503569106e-06
marker O 0 1.9611693460319657e-06
closely O 0 2.6347194648224104e-07
linked O 0 8.00260124833585e-07
to O 0 2.7848625450133113e-07
CT B-Disease 1 0.6060437560081482
. O 0 9.540199243929237e-07

However O 0 2.3270105884876102e-05
, O 0 4.045325283641432e-07
BAC O 0 1.1683729098876938e-05
clones O 0 2.219934600589113e-07
containing O 0 7.662296042099115e-08
ATP7B O 0 2.937542603831389e-06
and O 0 1.136425087366888e-08
C04107 O 0 1.0584007270608708e-07
mapped O 0 1.3321736958005204e-07
to O 0 4.90301621525191e-09
the O 0 2.428595324843741e-09
canine O 0 2.0530308120214613e-06
chromosome O 0 1.7916469005285762e-05
regions O 0 4.3360362411704045e-08
CFA22q11 O 0 4.107198492420139e-06
and O 0 1.6312975859023027e-08
CFA10q26 O 0 1.178874185825407e-06
, O 0 1.7735884982883476e-09
respectively O 0 3.2366436197861503e-09
, O 0 4.0571196402439114e-10
demonstrating O 0 2.6518791607088588e-09
that O 0 9.61721458025977e-09
WD B-Disease 0 3.309306066512363e-06
cannot O 0 6.368060923023222e-08
be O 0 1.1940970434665132e-09
homologous O 0 9.285692215144081e-09
to O 0 7.549218139502045e-08
CT B-Disease 0 0.11641246825456619
. O 0 4.2297713775951706e-07

The O 0 3.8213752873161866e-07
copper O 0 7.059376230245107e-07
transport O 0 9.057487915242746e-08
genes O 0 6.764274473880505e-08
CTR1 O 0 6.2265376072900835e-06
and O 0 6.81528646850893e-08
CTR2 O 0 1.9624676497187465e-05
were O 0 4.6436433365215635e-08
also O 0 2.0998959016083063e-08
excluded O 0 5.040730499672463e-09
as O 0 1.1591523296772266e-09
candidate O 0 1.1639428088017212e-08
genes O 0 2.94582291893164e-09
for O 0 1.6265029323392355e-09
CT B-Disease 0 0.0009303161059506238
since O 0 1.79082366713601e-08
they O 0 1.2736530718981953e-09
both O 0 3.1897096075539366e-10
mapped O 0 1.089663470565938e-07
to O 0 1.4735746844962705e-08
canine O 0 3.4376173516648123e-06
chromosome O 0 4.0334991354029626e-05
region O 0 3.115217452887009e-07
CFA11q22 O 0 7.184279093053192e-05
. O 0 4.484107876123744e-07

2 O 0 9.55406176217366e-06
- O 0 4.469100167625584e-05
22 O 0 3.6614947021007538e-06
. O 0 4.295024780276435e-07

5 O 0 1.970700941456016e-05
. O 0 3.1976032914826646e-06

A O 0 4.340155101090204e-06
transcribed O 0 1.1930831078643678e-06
sequence O 0 5.2568815078757325e-08
identified O 0 1.4496558620180622e-08
from O 0 1.9843093834737147e-10
the O 0 4.831927635784439e-10
C04107 O 0 2.81674942925747e-07
- O 0 7.72793214309786e-07
containing O 0 2.138403090157226e-07
BAC O 0 3.2316600027115783e-06
was O 0 7.072098640037439e-08
found O 0 1.6797380153477093e-09
to O 0 4.492192728910993e-10
be O 0 4.692304877984554e-10
homologous O 0 8.907962700810401e-10
to O 0 2.253541575569784e-09
a O 0 9.963557090486574e-09
gene O 0 2.5424883531854903e-08
expressed O 0 8.921722915999908e-09
from O 0 4.992341540166478e-10
human O 0 5.0955888397652416e-09
chromosome O 0 2.1027551611041417e-06
2p13 O 0 1.7401930563210044e-06
- O 0 6.96752977091819e-07
p16 O 0 3.8945159985814826e-07
, O 0 1.9969843556566502e-09
a O 0 3.921451607880044e-09
region O 0 4.890584826000577e-09
devoid O 0 1.2643037727855244e-08
of O 0 1.3237726192993904e-10
any O 0 7.022546433255172e-10
positional O 0 1.504699639554019e-06
candidate O 0 5.952374522166792e-07
genes O 0 3.208920134056825e-07
. O 0 1.8322943162729644e-07

Molecular O 0 1.2512823559518438e-05
analysis O 0 1.2734962240301684e-07
of O 0 1.6111173506416776e-09
the O 0 2.315402536368083e-09
APC B-Disease 0 1.2482810518577026e-07
gene O 0 1.9168663101254424e-08
in O 0 1.975081875826845e-09
205 O 0 2.5457687513608107e-08
families O 0 1.5774631378917547e-08
: O 0 3.228825207202135e-09
extended O 0 4.736961329854239e-07
genotype O 0 0.0016173842595890164
- O 0 8.564048766857013e-05
phenotype O 0 0.001228971523232758
correlations O 0 2.4233131057371793e-07
in O 0 2.5717263874014407e-09
FAP B-Disease 0 1.6122053239087109e-06
and O 0 4.4412168165308685e-08
evidence O 0 9.787557431195637e-09
for O 0 2.4928914488242526e-10
the O 0 3.410044191465289e-10
role O 0 2.2758217532725666e-09
of O 0 3.910261281436789e-10
APC B-Disease 0 1.0975523423439881e-07
amino O 0 9.66738600283179e-09
acid O 0 4.2544737510752384e-08
changes O 0 5.824900384254761e-08
in O 0 2.0207762645441107e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9980177879333496
. O 0 3.902192474924959e-06

BACKGROUND O 0 0.00011261692270636559
/ O 0 4.0540248846809845e-06
AIMS O 0 2.657410504980362e-07
The O 0 2.089160178186944e-09
development O 0 3.7046916645522288e-09
of O 0 1.2523703389888396e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.593244173316634e-07
a O 0 1.0287272544928783e-07
variable O 0 1.6246424650034896e-07
range O 0 5.695023563845325e-09
of O 0 6.502677285524783e-10
extracolonic O 0 1.83050779014593e-05
manifestations O 0 3.6328456189949065e-06
in O 0 1.1123040621896507e-06
familial B-Disease 1 0.9999994039535522
adenomatous I-Disease 1 0.9999825954437256
polyposis I-Disease 1 0.9999994039535522
( O 0 1.3115493402438005e-06
FAP B-Disease 0 3.2580246625002474e-05
) O 0 1.2823998751798626e-08
is O 0 3.457680142204822e-09
the O 0 3.766620626510786e-10
result O 0 1.3023754297236678e-09
of O 0 1.2574676022669706e-10
the O 0 2.0397996625121095e-09
dominant O 0 3.244555955461692e-06
inheritance O 0 1.0403497071820311e-05
of O 0 9.132356240115769e-07
adenomatous B-Disease 1 0.9999985694885254
polyposis I-Disease 1 0.9999667406082153
coli I-Disease 1 0.9999428987503052
( O 0 3.2058338206297776e-07
APC B-Disease 0 3.825696239800891e-06
) O 0 4.864807578996988e-08
gene O 0 1.2515250773503794e-06
mutations O 0 5.250886715657543e-06
. O 0 3.325220632177661e-07

In O 0 1.8184671546350728e-07
this O 0 4.316535129333943e-09
study O 0 2.8543565289140815e-09
, O 0 5.681404791069156e-10
direct O 0 6.2976273085268986e-09
mutation O 0 8.581103827509651e-08
analysis O 0 1.764367207890416e-09
of O 0 9.127452266222136e-11
the O 0 4.816460008605361e-10
APC B-Disease 0 5.702526451045742e-08
gene O 0 1.2646245828307201e-08
was O 0 3.5906985829115e-08
performed O 0 1.2365458879060043e-08
to O 0 3.851410301791702e-09
determine O 0 2.231064399893512e-07
genotype O 0 0.0005391323938965797
- O 0 0.0001488018751842901
phenotype O 0 0.0005069834878668189
correlations O 0 1.4638629863839014e-07
for O 0 4.726629310169983e-09
nine O 0 3.582325192041935e-08
extracolonic O 0 2.5290391931775957e-06
manifestations O 0 1.6000757341316785e-07
and O 0 3.3032137025656994e-09
to O 0 2.130190690508016e-09
investigate O 0 1.430134854984999e-08
the O 0 3.355257627291053e-09
incidence O 0 1.4165926813802798e-06
of O 0 1.1882761441484035e-09
APC B-Disease 0 2.038577576968237e-06
mutations O 0 6.540909112118243e-07
in O 0 1.4793533509305234e-08
non O 0 1.5069542769197142e-06
- O 1 0.999832272529602
FAP O 1 0.9999947547912598
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.5642255423008464e-05

METHODS O 0 3.335957899253117e-06
The O 0 2.6679632725290503e-08
APC B-Disease 0 3.082996613557043e-07
gene O 0 5.670356983955571e-08
was O 0 4.7328477137398295e-08
analysed O 0 4.221429605877347e-08
in O 0 1.4125615122040358e-09
190 O 0 1.4552685279056732e-08
unrelated O 0 5.0122494599236234e-08
FAP B-Disease 0 1.985388280445477e-06
and O 0 8.358453840173752e-08
15 O 0 4.6689994093185305e-08
non O 0 2.7220224296797824e-07
- O 1 0.9992842078208923
FAP O 1 0.9999973773956299
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.754021942615509
using O 0 2.9520799671445275e-07
denaturing O 0 0.0002477233938407153
gradient O 0 0.009998324327170849
gel O 0 4.0037564758677036e-05
electrophoresis O 0 7.481672810172313e-07
, O 0 1.3865142367563976e-09
the O 0 2.196371695628585e-10
protein O 0 4.947016130074644e-09
truncation O 0 6.902294558130961e-08
test O 0 6.007761754744934e-08
, O 0 1.426608720045408e-09
and O 0 1.1112432085624846e-09
direct O 0 2.5876646603251174e-08
sequencing O 0 3.8800357060608803e-07
. O 0 1.6968822080798418e-07

RESULTS O 0 2.836810381268151e-05
Chain O 0 2.638622163431137e-06
terminating O 0 3.145824791772611e-07
signals O 0 1.332384584884494e-07
were O 0 9.37372401921266e-09
only O 0 2.2620163520059577e-09
identified O 0 3.486136890273883e-08
in O 0 2.342222193973953e-09
patients O 0 3.064248232931277e-07
belonging O 0 1.2911562929929232e-09
to O 0 2.0473693851386088e-09
the O 0 5.0652393390748784e-09
FAP B-Disease 0 1.4949940123187844e-05
group O 0 3.0427287356360466e-07
( O 0 2.5220712185358707e-09
105 O 0 2.4901049755499116e-07
patients O 0 2.3991136913537048e-05
) O 0 1.5346033777063894e-08
. O 0 2.1224197155333968e-07

Amino O 0 7.697210094192997e-06
acid O 0 1.1394917009965866e-06
changes O 0 1.1759213158768489e-08
were O 0 4.680007936741504e-09
identified O 0 1.2972987128989644e-08
in O 0 1.5099004269103489e-09
four O 0 5.515462575544916e-08
patients O 0 1.649592604735517e-06
, O 0 5.150707083068085e-10
three O 0 2.8852484290631253e-10
of O 0 1.1118362480688759e-10
whom O 0 2.131561416263139e-08
belonged O 0 3.5627671923776916e-09
to O 0 3.679226645569855e-10
the O 0 3.8347616748701796e-10
non O 0 7.205915864005874e-09
- O 0 2.409813305348507e-06
FAP O 0 3.981968620792031e-05
group O 0 1.7755846783984452e-05
of O 0 4.873909347224981e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9973203539848328
. O 0 8.223217946579098e-07

Genotype O 1 0.9979637861251831
- O 1 0.9728009104728699
phenotype O 1 0.9472677111625671
correlations O 0 3.139289765385911e-05
identified O 0 9.825208735492197e-07
significant O 0 2.3594052933617604e-08
differences O 0 1.4448919216647482e-07
in O 0 2.7155537818401854e-09
the O 0 1.2962466655608296e-09
nature O 0 2.2625170625900637e-09
of O 0 1.0879051132173245e-10
certain O 0 1.8182193528559765e-09
extracolonic O 0 2.4199259769375203e-06
manifestations O 0 2.2748078265522054e-07
in O 0 1.9316241051114957e-08
FAP B-Disease 0 0.0008368666167370975
patients O 0 0.04445218667387962
belonging O 0 1.3383159469526618e-08
to O 0 1.5756828730673078e-08
three O 0 3.779924639957244e-08
mutation O 0 1.394202286064683e-06
subgroups O 0 4.867429765909037e-07
. O 0 1.020382924821206e-07

CONCLUSIONS O 0 0.00012170344416517764
Extended O 0 1.094796334655257e-05
genotype O 0 0.0060529387556016445
- O 0 0.0007942530792206526
phenotype O 0 0.008546225726604462
correlations O 0 3.714685021805053e-07
made O 0 2.4818113786295726e-08
in O 0 8.604269519096874e-10
this O 0 1.1428281654346506e-09
study O 0 5.449778406330097e-09
may O 0 2.461521120267207e-08
have O 0 7.597123485858503e-10
the O 0 1.4501576328651566e-10
potential O 0 3.9294459353023115e-10
to O 0 6.42993491783983e-10
determine O 0 1.0517468007620323e-09
the O 0 2.1232328395459632e-10
most O 0 4.5944081872306697e-10
appropriate O 0 1.0558390828308006e-09
surveillance O 0 6.239034178179281e-08
and O 0 1.3902965889656116e-08
prophylactic O 0 2.4053908418864012e-05
treatment O 0 0.003106215037405491
regimens O 0 2.1200335140747484e-06
for O 0 6.421530418521115e-09
those O 0 9.6357233303479e-09
patients O 0 5.420535558187112e-07
with O 0 7.565748028071084e-09
mutations O 0 9.131206297752215e-07
associated O 0 1.1506282149298386e-08
with O 0 1.0542920314549065e-08
life O 0 1.6483944591527688e-06
threatening O 0 3.827591353910975e-05
conditions O 0 7.66077937441878e-05
. O 0 6.453106493609084e-07

This O 0 3.575547395939793e-07
study O 0 8.10909810411431e-08
also O 0 1.559688911356716e-08
provided O 0 2.9391835631997765e-09
evidence O 0 3.4898675060901496e-09
for O 0 3.7832459387487916e-10
the O 0 1.2134889759707335e-09
pathological O 0 5.227715291766799e-07
nature O 0 3.898541933722299e-09
of O 0 1.3522423458756094e-10
amino O 0 4.650110962955978e-09
acid O 0 2.8084119918503347e-08
changes O 0 3.079767996183591e-09
in O 0 7.643051191941197e-10
APC O 0 2.2700790225371748e-07
associated O 0 4.643534445847308e-09
with O 0 9.17934450672675e-10
both O 0 6.726985635197025e-09
FAP B-Disease 0 2.17208753383602e-06
and O 0 8.116864478324715e-07
non O 0 1.5129245412026648e-06
- O 1 0.9993131160736084
FAP O 1 0.9999977350234985
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9997567534446716
. O 0 1.2324858289503027e-07
. O 0 1.6235165389844042e-07

Inherited B-Disease 1 0.999890923500061
colorectal I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.999916672706604
and O 1 0.7270696759223938
cancer B-Disease 1 0.9690120220184326
risk O 0 5.319477054399613e-07
of O 0 1.9021222374959734e-09
the O 0 1.3797561315698204e-08
APC O 0 1.1884095329151023e-05
I1307K O 0 2.0497815057751723e-05
polymorphism O 0 0.00019202013208996505
. O 0 5.253784820524743e-07

Germ O 0 0.0002465098223183304
- O 0 0.000146180740557611
line O 0 2.0048335045430576e-06
and O 0 1.122264503550241e-08
somatic O 0 2.894142312470649e-07
truncating O 0 1.3576004675996955e-06
mutations O 0 6.868254445180355e-07
of O 0 7.231107934657643e-10
the O 0 3.822327787617041e-09
APC B-Disease 0 2.5993421104431036e-07
gene O 0 1.978325236962064e-08
are O 0 5.399573566045035e-10
thought O 0 7.128582613091794e-09
to O 0 2.5266032821491535e-08
initiate O 0 0.00014945199654903263
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.3408719003200531
formation O 0 6.445793587772641e-07
in O 0 1.0973018333970685e-06
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 0.9999988079071045
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 7.798123260727152e-05
sporadic O 1 0.9505658745765686
colorectal O 1 1.0
carcinogenesis O 1 0.9273261427879333
, O 0 3.2091679713630583e-07
respectively O 0 2.9286209723977663e-07
. O 0 1.749088198721438e-07

Recently O 0 9.767410119820852e-06
, O 0 4.225731231599639e-08
an O 0 7.800314172357048e-09
isoleucine O 0 1.2949426491104532e-05
- O 0 5.621806394628948e-06
- O 0 3.795362135861069e-05
> O 0 3.8463548435174744e-07
lysine O 0 4.950237553202896e-07
polymorphism O 0 1.287013560613559e-06
at O 0 3.299889028696157e-09
codon O 0 1.0244175996376725e-07
1307 O 0 8.141765874825069e-07
( O 0 3.014916316601557e-09
I1307K O 0 9.829297908936496e-08
) O 0 4.43635267410869e-10
of O 0 8.028229470102843e-11
the O 0 8.331372258751912e-10
APC B-Disease 0 8.383217675600463e-08
gene O 0 1.4732262521022221e-08
has O 0 1.553412687371747e-08
been O 0 7.48072892520213e-09
identified O 0 6.0212737018616735e-09
in O 0 4.28054869328065e-10
6 O 0 4.7881956177775464e-09
% O 0 9.429559355567108e-10
- O 0 7.43702770478194e-08
7 O 0 2.721902525593123e-08
% O 0 6.407946395725617e-10
of O 0 5.1191776512249376e-11
the O 0 1.5039939293970406e-09
Ashkenazi O 0 7.299124149540148e-07
Jewish O 0 5.095591504300501e-08
population O 0 1.8586773009587887e-08
. O 0 6.909618122108441e-08

To O 0 7.498044851672603e-07
assess O 0 1.1385596963009448e-06
the O 0 5.827764493204768e-09
risk O 0 1.2149348194157028e-08
of O 0 1.3450858482588757e-10
this O 0 8.219057101577221e-10
common O 0 1.2179811825774323e-08
APC B-Disease 0 1.0759640645119362e-06
allelic O 0 2.5883859962050337e-06
variant O 0 0.0005030089523643255
in O 0 3.4778070130414562e-06
colorectal O 1 0.9999998807907104
carcinogenesis O 0 0.16993172466754913
, O 0 3.54222464693521e-08
we O 0 2.279809896421625e-09
have O 0 1.400294324938045e-09
analyzed O 0 2.795615960948794e-09
a O 0 1.3848703295238352e-09
large O 0 1.7083523484728858e-09
cohort O 0 3.8264143853439236e-08
of O 0 9.774362430547967e-10
unselected O 0 6.8130643740005326e-06
Ashkenazi O 0 1.3616720480058575e-06
Jewish O 0 2.981020585934857e-08
subjects O 0 4.027793565342108e-08
with O 0 1.8851837424449513e-08
adenomatous B-Disease 0 0.0001708419731585309
polyps I-Disease 0 0.0001944284449564293
and O 0 3.1713321391180216e-07
. O 0 2.89378647266858e-07
or O 0 0.024301273748278618
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 5.9167419408368005e-08
for O 0 2.1020307716668185e-09
the O 0 6.69139765818727e-09
APC O 0 7.4903637141687796e-06
I1307K O 0 1.1022176295227837e-05
polymorphism O 0 0.00010475282761035487
. O 0 4.0358187902711506e-07

The O 0 7.424186492244189e-07
APC O 0 3.9641495277464855e-06
I1307K O 0 4.1397429413336795e-06
allele O 0 1.7326482293356094e-06
was O 0 4.311312551408264e-08
identified O 0 1.2290684914262329e-08
in O 0 9.575605863787473e-10
48 O 0 2.2079749584236197e-08
( O 0 1.6422913029501274e-10
10 O 0 3.6514996581971104e-10
. O 0 2.1295842866919656e-10
1 O 0 1.573693730883008e-09
% O 0 5.865766761203872e-10
) O 0 1.3648615571071332e-10
of O 0 7.555823189342448e-10
476 O 0 6.719769316987367e-06
patients O 0 0.002472141059115529
. O 0 1.1271237809751256e-07

Compared O 0 9.47121861827327e-06
with O 0 9.766111475073558e-09
the O 0 7.445380423298786e-10
frequency O 0 2.8174900634780897e-08
in O 0 3.093070521931196e-10
two O 0 5.438135497470853e-10
separate O 0 2.1118966575528475e-09
population O 0 1.8351485886469732e-09
control O 0 4.519354490639671e-08
groups O 0 8.924492811424045e-10
, O 0 3.8680239566879493e-10
the O 0 6.834376953257504e-10
APC O 0 3.8535361568392545e-07
I1307K O 0 9.787613635126036e-07
allele O 0 4.1215491819457384e-07
is O 0 3.2365450319815636e-09
associated O 0 1.030161622672665e-09
with O 0 2.582543900953027e-10
an O 0 2.7478785913359616e-09
estimated O 0 9.600189088132538e-09
relative O 0 5.8687717796601646e-08
risk O 0 1.6536684910306576e-08
of O 0 5.375322964518148e-10
1 O 0 5.7744138359794306e-08
. O 0 2.111565891027567e-07

5 O 0 9.02893953025341e-06
- O 0 2.0994226360926405e-05
1 O 0 6.337574518511246e-07
. O 0 1.7686866726762673e-07

7 O 0 2.3311284166993573e-05
for O 0 3.725509259311366e-06
colorectal B-Disease 1 0.9999983310699463
neoplasia I-Disease 0 0.01669660024344921
( O 0 1.3328954651115055e-07
both O 0 1.890538641191597e-07
P O 0 2.9064640330034308e-05
= O 0 5.531306328521168e-07
. O 0 1.3146302713096247e-08
01 O 0 1.629127979185796e-07
) O 0 8.526509276407523e-09
. O 0 3.8134093216513065e-08

Furthermore O 0 3.237687633372843e-05
, O 0 7.873937590829883e-08
compared O 0 5.072512365700277e-08
with O 0 2.6292104049474574e-09
noncarriers O 0 2.519782356102951e-06
, O 0 7.516069544521997e-09
APC O 0 1.457877942812047e-07
I1307K O 0 2.7751593734137714e-07
carriers O 0 2.948005217717764e-08
had O 0 3.2018181883586294e-08
increased O 0 4.135310760489119e-09
numbers O 0 2.469372928359803e-09
of O 0 1.04480091245307e-09
adenomas B-Disease 0 2.2602707758778706e-05
and O 0 0.005714657250791788
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.999016523361206
per O 0 6.19010825175792e-06
patient O 0 0.0014989281771704555
( O 0 1.531316939917815e-08
P O 0 1.2136319128330797e-05
= O 0 8.484641256245595e-08
. O 0 1.5781603801556798e-09
03 O 0 1.0427030794346592e-08
) O 0 3.318747776592801e-10
, O 0 3.9306605192912514e-10
as O 0 9.769554054628315e-10
well O 0 5.068793718088216e-10
as O 0 7.069678176208072e-10
a O 0 2.2814814926164217e-08
younger O 0 1.632496491765778e-06
age O 0 1.0508690806432242e-08
at O 0 5.605447217504889e-09
diagnosis O 0 2.5151626687147655e-05
. O 0 2.3565320361740305e-07

We O 0 5.377778506954201e-07
conclude O 0 1.6255678758625436e-07
that O 0 3.175119056564313e-09
the O 0 1.361077028860791e-09
APC O 0 2.2905885543877957e-07
I1307K O 0 5.418168598225748e-07
variant O 0 1.5337832337536383e-06
leads O 0 1.0612145473487544e-07
to O 0 6.658032702944183e-08
increased O 0 2.5002613256219774e-05
adenoma B-Disease 1 0.9999911785125732
formation O 0 7.122048373275902e-08
and O 0 2.7575075556285356e-09
directly O 0 3.2001683525351154e-09
contributes O 0 4.658171626203966e-09
to O 0 1.851348852000001e-09
3 O 0 5.85859138979572e-09
% O 0 8.278054908217314e-10
- O 0 3.973873674567585e-08
4 O 0 1.3616334726407331e-08
% O 0 1.7327470014372182e-10
of O 0 4.8960960286059674e-11
all O 0 4.1564396369153656e-09
Ashkenazi O 0 7.793580880388618e-05
Jewish O 0 0.03206787630915642
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.720138354561641e-06

The O 0 2.259047562347405e-07
estimated O 0 8.494097869515826e-08
relative O 0 8.299991094418147e-08
risk O 0 2.6103487371642586e-08
for O 0 1.6047504436400573e-09
carriers O 0 7.359039244647647e-08
may O 0 5.006726766509928e-08
justify O 0 2.0867478411901175e-08
specific O 0 1.732136545307128e-09
clinical O 0 2.3700948759142193e-08
screening O 0 1.0267430461396998e-08
for O 0 2.701124601767191e-10
the O 0 1.8403213675188823e-10
360 O 0 3.433516937434433e-08
, O 0 1.8243958566088736e-09
000 O 0 1.3087877448469953e-09
Americans O 0 1.4943005721690383e-09
expected O 0 1.7612974412273275e-09
to O 0 2.339873406143056e-09
harbor O 0 9.985668469880693e-08
this O 0 1.0306568931639504e-09
allele O 0 4.303351630596808e-08
, O 0 5.841683803353703e-10
and O 0 1.1063895355434283e-09
genetic O 0 1.0841940678574247e-08
testing O 0 2.237062313170668e-09
in O 0 1.529202181549394e-10
the O 0 9.2549350128035e-11
setting O 0 9.174478399209818e-10
of O 0 3.650845181724094e-10
long O 0 3.778396262532624e-08
- O 0 6.821217084507225e-06
term O 0 1.7551353437283979e-07
- O 0 2.0586388416177215e-07
outcome O 0 1.2519168812730186e-08
studies O 0 1.1565575164240727e-09
may O 0 2.8654132400163235e-09
impact O 0 7.815862623772318e-09
significantly O 0 6.439086973841768e-06
on O 1 0.92386394739151
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.3813302075504907e-06
in O 0 6.0453593242471015e-09
this O 0 1.1160484980621277e-08
population O 0 4.3251660031273786e-08
. O 0 1.9594197908645583e-07

Localization O 0 2.3562726710224524e-05
of O 0 5.201983199754068e-08
human O 0 7.527908252313864e-08
BRCA1 O 0 2.630898052302655e-06
and O 0 1.0942242667510982e-08
its O 0 4.836808287222993e-09
loss O 0 4.145801426602702e-07
in O 0 9.406965872926776e-09
high O 0 2.448667544285854e-07
- O 0 7.001820904406486e-06
grade O 0 4.565559308389311e-08
, O 0 7.013126968047345e-09
non B-Disease 0 1.025127076559329e-07
- I-Disease 0 0.08482523262500763
inherited I-Disease 1 0.9946771860122681
breast I-Disease 1 0.9998577833175659
carcinomas I-Disease 1 0.9999983310699463
. O 0 1.850954686233308e-05

Although O 0 9.756412282513338e-07
the O 0 3.4530140968769274e-09
link O 0 2.561989553839794e-08
between O 0 1.8849024563394323e-09
the O 0 2.6655218476889786e-08
BRCA1 O 0 0.050845321267843246
tumour B-Disease 1 0.9999970197677612
- O 0 2.0315121219027787e-05
suppressor O 0 3.627124533522874e-05
gene O 0 3.8874358665452746e-07
and O 0 4.173701313447964e-07
hereditary B-Disease 1 0.9999576807022095
breast I-Disease 1 0.9999967813491821
and I-Disease 1 0.9999881982803345
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
is O 0 1.405218625905036e-07
established O 0 2.4505579787614806e-09
, O 0 2.3383198155535467e-10
the O 0 1.0513371423437334e-10
role O 0 2.5485658028401303e-09
, O 0 5.621794141319469e-10
if O 0 2.33233765634111e-10
any O 0 9.415949964175496e-11
, O 0 1.1677485367567186e-10
of O 0 1.2895878809260353e-10
BRCA1 O 0 2.665067313500913e-07
in O 0 3.83847398310877e-09
non B-Disease 0 1.0004999495549782e-07
- I-Disease 0 0.0038778712041676044
familial I-Disease 1 0.8884528875350952
cancers I-Disease 1 0.9621835947036743
is O 0 2.90871895458622e-07
unclear O 0 1.1749726809284766e-06
. O 0 9.12297437594134e-08

BRCA1 O 1 0.7063231468200684
mutations O 0 0.0013900541234761477
are O 0 7.995020467888025e-08
rare O 0 1.2915023717141594e-07
in O 0 3.012578275729538e-08
sporadic B-Disease 0 0.01591905578970909
cancers I-Disease 1 0.7801536321640015
, O 0 1.4741201148638083e-08
but O 0 1.9920245009075188e-08
loss O 0 6.912096495170772e-08
of O 0 2.6490987181659875e-09
BRCA1 O 0 8.486164006171748e-06
resulting O 0 1.8549344815710356e-07
from O 0 3.2338791644548337e-09
reduced O 0 1.6754358966863947e-07
expression O 0 3.966014006095975e-08
or O 0 1.8718042671395096e-09
incorrect O 0 1.4816016857821523e-07
subcellular O 0 5.633262958326668e-07
localization O 0 1.4959816496684653e-07
is O 0 6.060193680212933e-09
postulated O 0 5.8370897448867254e-08
to O 0 1.1814872413751232e-09
be O 0 1.0167160446883372e-09
important O 0 3.3570354829315363e-10
in O 0 1.3729143377716468e-09
non B-Disease 0 4.502198791556111e-08
- I-Disease 0 0.001465466571971774
familial I-Disease 1 0.8958168625831604
breast I-Disease 1 0.9999818801879883
and I-Disease 1 0.9980878233909607
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999992847442627
. O 0 6.426056643249467e-06

Epigenetic O 0 0.0017922803526744246
loss O 0 0.0032578459940850735
, O 0 2.1186541232509626e-07
however O 0 3.842042772816967e-08
, O 0 1.2823111461557346e-09
has O 0 9.828712954629282e-09
not O 0 1.9242649695883074e-09
received O 0 1.8129210355155578e-09
general O 0 8.469628332008483e-10
acceptance O 0 1.8433690129882052e-08
due O 0 4.854183277558377e-09
to O 0 4.923238705600852e-09
controversy O 0 3.948804305764497e-08
regarding O 0 6.291311915873621e-09
the O 0 1.4727927766244875e-09
subcellular O 0 2.486659411715664e-07
localization O 0 5.675182990216854e-08
of O 0 8.829288966616389e-10
BRCA1 O 0 1.5889264659563196e-07
proteins O 0 2.248041974795001e-09
, O 0 1.0249600057576913e-09
reports O 0 2.06638084421229e-09
of O 0 3.2255472598441415e-11
which O 0 4.925249097453843e-09
have O 0 9.680173107540213e-09
ranged O 0 2.431521117784996e-08
from O 0 1.156823872805468e-10
exclusively O 0 2.033235357856711e-09
nuclear O 0 5.258222746107322e-09
, O 0 2.5109486712082685e-10
to O 0 1.130043947306092e-09
conditionally O 0 3.1286631951843447e-07
nuclear O 0 8.9040943507257e-09
, O 0 2.0459123284410907e-10
to O 0 1.2414205219357655e-09
the O 0 3.1320523952160784e-09
ER O 0 6.595909781026421e-06
/ O 0 1.4462015940353012e-07
golgi O 0 6.378102170856437e-07
, O 0 4.555006594131328e-09
to O 0 4.000077158394788e-09
cytoplasmic O 0 9.559756364296845e-08
invaginations O 0 2.6557890464573575e-07
into O 0 1.2412524341698372e-09
the O 0 3.6029630390288503e-09
nucleus O 0 1.6410552916568122e-07
. O 0 1.2173093466572027e-07

In O 0 9.337092876648967e-08
an O 0 4.815874810049081e-09
attempt O 0 3.911361545760883e-08
to O 0 5.684670068006881e-09
resolve O 0 6.88224659484149e-08
this O 0 2.139984633942049e-09
issue O 0 1.9073766566179984e-08
, O 0 1.3619547711840596e-09
we O 0 1.1717674608391349e-09
have O 0 2.6603448333162305e-09
comprehensively O 0 1.524235017313913e-06
characterized O 0 4.898363954453089e-07
19 O 0 9.91495312518964e-08
anti O 0 1.2116391872041277e-06
- O 0 0.00023973872885107994
BRCA1 O 0 0.0002669394016265869
antibodies O 0 5.382219569582958e-06
. O 0 2.391050202277256e-07

These O 0 3.5911784834752325e-07
reagents O 0 7.756993340990448e-07
detect O 0 7.690084089517768e-07
a O 0 3.268925397037492e-08
220 O 0 5.789754453644491e-08
- O 0 2.97290227990743e-07
kD O 0 9.354291705676587e-07
protein O 0 3.29641807184089e-08
localized O 0 5.301022909520725e-08
in O 0 7.965514359220549e-10
discrete O 0 1.1482823580877266e-08
nuclear O 0 2.858629422064496e-08
foci O 0 3.27683210343821e-07
in O 0 2.3068860155461834e-09
all O 0 9.86209780506897e-10
epithelial O 0 2.6437051019456703e-06
cell O 0 0.00011288862151559442
lines O 0 1.099714381780359e-06
, O 0 1.6893642040827217e-09
including O 0 9.693175151426203e-10
those O 0 1.3764540618410592e-09
derived O 0 3.2128419036325795e-08
from O 0 3.074252674650779e-08
breast B-Disease 0 0.014367492869496346
malignancies I-Disease 0 0.00039995170664042234
. O 0 8.488977982779033e-07

Immunohistochemical O 0 0.004310871008783579
staining O 0 0.0002512830833438784
of O 0 2.1572147090864746e-07
human O 0 8.172588081833965e-07
breast O 0 0.005383342504501343
specimens O 0 9.060933052751352e-07
also O 0 2.3049261699270573e-07
revealed O 0 7.378616828646045e-07
BRCA1 O 0 1.1148229077662108e-06
nuclear O 0 5.8809185077279835e-08
foci O 0 1.1359524023646372e-06
in O 0 5.797379287741933e-08
benign O 0 0.01058026310056448
breast O 1 0.816877543926239
, O 0 5.750628133682767e-07
invasive B-Disease 0 0.0034348065964877605
lobular I-Disease 1 0.9998084902763367
cancers I-Disease 1 0.9981471300125122
and O 0 1.6224034879996907e-06
low B-Disease 0 4.6319666580529884e-05
- I-Disease 0 0.17702741920948029
grade I-Disease 0 7.691933569731191e-05
ductal I-Disease 1 0.9425403475761414
carcinomas I-Disease 1 0.9999991655349731
. O 0 9.937871254805941e-06

Conversely O 0 0.00010968248534481972
, O 0 3.0271456807895447e-07
BRCA1 O 0 9.703738214739133e-06
expression O 0 5.52207211512723e-07
was O 0 2.8627579240492196e-07
reduced O 0 4.796003949536498e-08
or O 0 4.741455672530037e-09
undetectable O 0 3.6577354478595225e-08
in O 0 5.772051725472238e-10
the O 0 3.0819757856903607e-10
majority O 0 1.1509992070557473e-08
of O 0 1.4969984973856043e-10
high O 0 5.5346209393292156e-08
- O 0 3.076327629969455e-05
grade O 0 3.024340742285858e-07
, O 0 8.556261832382006e-08
ductal B-Disease 0 0.128408282995224
carcinomas I-Disease 1 0.999998927116394
, O 0 6.539000452221444e-08
suggesting O 0 3.3808394306333867e-08
that O 0 1.6927121926357813e-09
absence O 0 6.0605178653361236e-09
of O 0 9.84890058397525e-10
BRCA1 O 0 3.764071834666538e-06
may O 0 1.211503501963307e-07
contribute O 0 1.4283513261048597e-09
to O 0 3.08871550558365e-09
the O 0 1.7433494647889347e-09
pathogenesis O 0 4.3301188412669944e-08
of O 0 9.81491554696845e-11
a O 0 2.8285913611370006e-09
significant O 0 5.4379620806344064e-09
percentage O 0 5.025342364461949e-09
of O 0 1.5054431035110838e-09
sporadic B-Disease 0 0.004119589924812317
breast I-Disease 1 0.9999042749404907
cancers I-Disease 1 0.7610756158828735
. O 0 8.776292048651158e-08
. O 0 1.9600011569309572e-07

